Comprehensive molecular characterization of human co

Nature

487, 330-337

DOI: 10.1038/nature11252

#	Article	IF	Citations
2	Colon Cancer Recurrence: Insights From the Interface Between Epidemiology, Laboratory Science, and Clinical Medicine. Journal of the National Cancer Institute, 2012, 104, 1697-1698.	3.0	0
3	Novel Wnt signaling and other pathway inhibitors in the colorectal cancer genomic landscape era. Future Oncology, 2012, 8, 1373-1376.	1.1	1
4	Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3659-67.	3.3	56
5	Interactions between epigenetics and metabolism in cancers. Frontiers in Oncology, 2012, 2, 163.	1.3	67
6	La formalisation de la GRH dans une PME comme enjeu d'une certification RSE. Revue De Gestion Des Ressources Humaines, 2012, NÂ° 83, 20-30.	0.1	8
7	Human Papillomavirus Vaccines for Cervical Cancer Prevention: Translating Possibility Into Reality. Journal of the National Cancer Institute, 2012, 104, 1698-1701.	3.0	3
8	AACR Cancer Progress Report 2012. Clinical Cancer Research, 2012, 18, S1-S100.	3.2	28
9	A Single-Nucleotide Substitution Mutator Phenotype Revealed by Exome Sequencing of Human Colon Adenomas. Cancer Research, 2012, 72, 6279-6289.	0.4	61
10	Patent controversies and court cases. Cancer Biology and Therapy, 2012, 13, 1229-1234.	1.5	10
11	Drug companies look to biomarkers to salvage cancer target. Nature Medicine, 2012, 18, 1312-1313.	15.2	5
12	<i>CDX2</i>is an amplified lineage-survival oncogene in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3196-205.	3.3	69
13	Effects of two monoclonal antibodies, MLS128 against Tn-antigen and 1H7 against insulin-like growth factor-I receptor, on the growth of colon cancer cells. BioScience Trends, 2012, , .	1.1	8
14	Medulloblastomics: the end of the beginning. Nature Reviews Cancer, 2012, 12, 818-834.	12.8	560
15	Aspirin â€" From Prevention to Targeted Therapy. New England Journal of Medicine, 2012, 367, 1650-1651.	13.9	13
16	The Unusual Case of Porcupine. Science, 2012, 337, 922-923.	6.0	66
17	Î²-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis. Cell, 2012, 151, 1457-1473.	13.5	647
18	Bioinformatics for cancer immunology and immunotherapy. Cancer Immunology, Immunotherapy, 2012, 61, 1885-1903.	2.0	40
19	A fast track to personalized medicine?. Cancer Cytopathology, 2012, 120, 283-284.	1.4	2

#	Article	IF	Citations
20	A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency. Journal of Pathology, 2012, 228, 586-595.	2.1	55
21	Revisiting Global Gene Expression Analysis. Cell, 2012, 151, 476-482.	13.5	526
22	What are we learning from the cancer genome?. Nature Reviews Clinical Oncology, 2012, 9, 621-630.	12.5	50
23	Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Medical Genomics, 2012, 5, 66.	0.7	202
24	Developmental pathways in colon cancer. Cell Cycle, 2012, 11, 4344-4351.	1.3	167
25	Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer. British Journal of Cancer, 2012, 107, 1761-1765.	2.9	105
26	Colon and Rectum. , 2012, , 185-201.		83
27	S-1 in colorectal cancer: a new standard of care?. Lancet Oncology, The, 2012, 13, 1068-1070.	5.1	0
28	MDM2 inhibition in liposarcoma: a step in the right direction. Lancet Oncology, The, 2012, 13, 1070-1071.	5.1	15
29	Cancer Biology: A New RING to Wnt Signaling. Current Biology, 2012, 22, R849-R851.	1.8	14
30	Alternative transcription and alternative splicing in cancer. , 2012, 136, 283-294.		107
31	Some Research Directions. Springer Briefs in Electrical and Computer Engineering, 2012, , 69-80.	0.3	0
32	The Role of the Insulin-like Growth Factor-1 Receptor (IGF-1R), Phosphatase and Tensin Homolog (PTEN), c-Met, and the PI3-Kinase Pathway in Colorectal Cancer. Current Colorectal Cancer Reports, 2012, 8, 243-253.	1.0	0
34	Integrative analysis of methylation and gene expression data in TCGA. , 2012, , .		1
35	DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer. Genome Biology, 2012, 13, R124.	13.9	247
36	Frequent Alteration of the Tumor Suppressor Gene APC in Sporadic Canine Colorectal Tumors. PLoS ONE, 2012, 7, e50813.	1.1	22
37	Epigenetic Changes in Basal Cell Carcinoma Affect SHH and WNT Signaling Components. PLoS ONE, 2012, 7, e51710.	1.1	38
38	Studies offer â€˜panoramic viewâ€™ of lung cancer. Nature, 2012, , .	13.7	0

#	Article	IF	Citations
39	From Reductionism to Holism: Systems-oriented Approaches in Cancer Research. Global Advances in Health and Medicine, 2012, 1, 68-77.	0.7	15
40	Integrated analysis of recurrent properties of cancer genes to identify novel drivers. Genome Biology, 2013, 14, R52.	13.9	33
41	Patchwork: allele-specific copy number analysis of whole-genome sequenced tumor tissue. Genome Biology, 2013, 14, R24.	13.9	65
42	Cancer heterogeneityâ€"a multifaceted view. EMBO Reports, 2013, 14, 686-695.	2.0	208
43	SAMHD1-dependent retroviral control and escape in mice. EMBO Journal, 2013, 32, 2454-2462.	3.5	141
44	Proteomics in colorectal cancer translational research: Biomarker discovery for clinical applications. Clinical Biochemistry, 2013, 46, 466-479.	0.8	80
45	BRAF: A Driver of the Serrated Pathway in Colon Cancer. Cancer Cell, 2013, 24, 1-2.	7.7	40
46	Association between X-ray repair cross-complementing group 1 Arg194Trp polymorphism and colorectal cancer risk. Tumor Biology, 2013, 34, 2529-2538.	0.8	9
47	Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. British Journal of Cancer, 2013, 109, 1004-1012.	2.9	97
48	Next generation sequencing in cancer research and clinical application. Biological Procedures Online, 2013, 15, 4.	1.4	102
49	Assessment of computational methods for predicting the effects of missense mutations in human cancers. BMC Genomics, 2013, 14, S7.	1.2	153
50	Revealing selection in cancer using the predicted functional impact of cancer mutations. Application to nomination of cancer drivers. BMC Genomics, 2013, 14, S8.	1.2	12
51	From single protein to colorectal cancer genome landscape and network biology-based biomarkers. Surgical Endoscopy and Other Interventional Techniques, 2013, 27, 3047-3048.	1.3	1
52	Functions and Clinical Implications of Autocrine VEGF Signaling in Colorectal Cancer. Current Colorectal Cancer Reports, 2013, 9, 270-277.	1.0	3
53	Signatures of mutational processes in human cancer. Nature, 2013, 500, 415-421.	13.7	8,060
54	Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment. Cell Host and Microbe, 2013, 14, 207-215.	5.1	1,913
55	DrGaP: A Powerful Tool for Identifying Driver Genes and Pathways in Cancer Sequencing Studies. American Journal of Human Genetics, 2013, 93, 439-451.	2.6	67
56	Next Generation Sequencing in Cancer Research. , 2013, , .		5

#	Article	IF	Citations
57	Technical and implementation issues in using next-generation sequencing of cancers in clinical practice. British Journal of Cancer, 2013, 109, 827-835.	2.9	91
58	Expression and localization of axin 2 in colorectal carcinoma and its clinical implication. International Journal of Colorectal Disease, 2013, 28, 1469-1478.	1.0	13
59	Identification of thresholds for dichotomizing DNA methylation data. Eurasip Journal on Bioinformatics and Systems Biology, 2013, 2013, 8.	1.4	12
60	The genomic landscape of oesophagogastric junctional adenocarcinoma. Journal of Pathology, 2013, 231, 301-310.	2.1	42
61	Germline and somatic polymerase Ïµ and Î´ mutations define a new class of hypermutated colorectal and endometrial cancers. Journal of Pathology, 2013, 230, 148-153.	2.1	242
62	<scp>BCL</scp>10 as a useful marker for pancreatic acinar cell carcinoma, especially using endoscopic ultrasound cytology specimens. Pathology International, 2013, 63, 176-182.	0.6	62
63	Integrative Annotation of Variants from 1092 Humans: Application to Cancer Genomics. Science, 2013, 342, 1235587.	6.0	341
64	Oncology Scanâ€"Treatment, Consequences, and Genomics in Gastrointestinal Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 86, 1-3.	0.4	17
65	Mutant N-RAS Protects Colorectal Cancer Cells from Stress-Induced Apoptosis and Contributes to Cancer Development and Progression. Cancer Discovery, 2013, 3, 294-307.	7.7	53
66	Evaluation of regorafenib in colorectal cancer and GIST. Lancet, The, 2013, 381, 273-275.	6.3	29
67	Paracrine Wnt signaling both promotes and inhibits human breast tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6991-6996.	3.3	69
68	The Exomes of the NCI-60 Panel: A Genomic Resource for Cancer Biology and Systems Pharmacology. Cancer Research, 2013, 73, 4372-4382.	0.4	239
69	Genome-wide association and sequencing studies on colorectal cancer. Seminars in Cancer Biology, 2013, 23, 502-511.	4.3	14
70	Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry. American Journal of Surgery, 2013, 205, 608-612.	0.9	8
71	Differences that matter in cancer genomics. Nature Biotechnology, 2013, 31, 892-893.	9.4	3
72	Inferring tumour purity and stromal and immune cell admixture from expression data. Nature Communications, 2013, 4, 2612.	5.8	5,788
73	Genetic Amplification of the NOTCH Modulator LNX2 Upregulates the WNT/Î²-Catenin Pathway in Colorectal Cancer. Cancer Research, 2013, 73, 2003-2013.	0.4	68
74	Identification of Novel Variants in Colorectal Cancer Families by High-Throughput Exome Sequencing. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1239-1251.	1.1	37

#	Article	IF	Citations
75	Cancer Genome Landscapes. Science, 2013, 339, 1546-1558.	6.0	6,507
76	Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed. Science, 2013, 339, 1563-1566.	6.0	142
77	<i>CCAT2</i>, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Research, 2013, 23, 1446-1461.	2.4	526
78	Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine. Modern Pathology, 2013, 26, 1413-1424.	2.9	35
79	Identification of Candidate Oncogenes in Human Colorectal Cancers With Microsatellite Instability. Gastroenterology, 2013, 145, 540-543.e22.	0.6	65
80	Essential Role for Dnmt1 in the Prevention and Maintenance of MYC-Induced T-Cell Lymphomas. Molecular and Cellular Biology, 2013, 33, 4321-4333.	1.1	55
81	The Regulation of SOX7 and Its Tumor Suppressive Role in Breast Cancer. American Journal of Pathology, 2013, 183, 1645-1653.	1.9	52
82	The Somatic Genomic Landscape of Glioblastoma. Cell, 2013, 155, 462-477.	13.5	3,979
83	Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis. British Journal of Cancer, 2013, 109, 2445-2452.	2.9	100
84	Can we deconstruct cancer, one patient at a time?. Trends in Genetics, 2013, 29, 6-10.	2.9	20
85	Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cells. Nature Communications, 2013, 4, 2610.	5.8	213
86	Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma. Cancer Research, 2013, 73, 5195-5205.	0.4	153
87	The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes. Cell, 2013, 155, 858-868.	13.5	311
88	From next-generation sequencing to nanopore sequencing technology: paving the way to personalized genomic medicine. Expert Review of Medical Devices, 2013, 10, 1-6.	1.4	76
89	Lineage tracing reveals multipotent stem cells maintain human adenomas and the pattern of clonal expansion in tumor evolution. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2490-9.	3.3	88
90	Pan-cancer patterns of somatic copy number alteration. Nature Genetics, 2013, 45, 1134-1140.	9.4	1,616
91	Network-based stratification of tumor mutations. Nature Methods, 2013, 10, 1108-1115.	9.0	698
92	Impact and Challenges in Assessing Tumor Purity by Next-Generation Sequencing. , 2013, , 359-371.		0

#	Article	IF	Citations
93	Mutational landscape and significance across 12 major cancer types. Nature, 2013, 502, 333-339.	13.7	3,695
94	Mutational Signature of Aristolochic Acid Exposure as Revealed by Whole-Exome Sequencing. Science Translational Medicine, 2013, 5, 197ra102.	5.8	220
95	Targeted Sequencing Strategies in Cancer Research. , 2013, , 137-163.		2
96	The causes and consequences of genetic heterogeneity in cancer evolution. Nature, 2013, 501, 338-345.	13.7	1,969
98	Anti-CEA-functionalized superparamagnetic iron oxide nanoparticles for examining colorectal tumors in vivo. Nanoscale Research Letters, 2013, 8, 413.	3.1	13
99	The Cancer Genome Atlas Pan-Cancer analysis project. Nature Genetics, 2013, 45, 1113-1120.	9.4	6,265
100	NPEBseq: nonparametric empirical bayesian-based procedure for differential expression analysis of RNA-seq data. BMC Bioinformatics, 2013, 14, 262.	1.2	28
101	Sister chromatid cohesion defects are associated with chromosome instability in Hodgkin lymphoma cells. BMC Cancer, 2013, 13, 391.	1.1	19
102	Characterization of aberrant pathways across human cancers. BMC Systems Biology, 2013, 7, S1.	3.0	11
103	Expression and potential role of apolipoprotein D on the deathâ€“survival balance of human colorectal cancer cells under oxidative stress conditions. International Journal of Colorectal Disease, 2013, 28, 751-766.	1.0	23
104	POMO - Plotting Omics analysis results for Multiple Organisms. BMC Genomics, 2013, 14, 918.	1.2	4
105	Viral expression associated with gastrointestinal adenocarcinomas in TCGA high-throughput sequencing data. Human Genomics, 2013, 7, 23.	1.4	55
106	Systematic genomic identification of colorectal cancer genes delineating advanced from early clinical stage and metastasis. BMC Medical Genomics, 2013, 6, 54.	0.7	34
107	Relative impact of multi-layered genomic data on gene expression phenotypes in serous ovarian tumors. BMC Systems Biology, 2013, 7, S9.	3.0	24
108	The chromatin remodelling component SMARCB1/INI1 influences the metastatic behavior of colorectal cancer through a gene signature mapping to chromosome 22. Journal of Translational Medicine, 2013, 11, 297.	1.8	22
109	Evaluation of read count based RNAseq analysis methods. BMC Genomics, 2013, 14, S2.	1.2	53
110	Systems biology of cancer: entropy, disorder, and selection-driven evolution to independence, invasion and â€œswarm intelligenceâ€. Cancer and Metastasis Reviews, 2013, 32, 403-421.	2.7	39
111	Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. Genome Medicine, 2013, 5, 91.	3.6	146

#	Article	IF	Citations
113	Emerging patterns of somatic mutations in cancer. Nature Reviews Genetics, 2013, 14, 703-718.	7.7	442
114	Integration of cancer genomics with treatment selection. Cancer, 2013, 119, 3914-3928.	2.0	15
115	Dissecting cancer heterogeneity â€“ An unsupervised classification approach. International Journal of Biochemistry and Cell Biology, 2013, 45, 2574-2579.	1.2	28
116	A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention. Cancer Cell, 2013, 24, 15-29.	7.7	183
117	Massivelyâ€parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. Journal of Pathology, 2013, 231, 413-423.	2.1	94
118	First Proteomic Exploration of Protein-Encoding Genes on Chromosome 1 in Human Liver, Stomach, and Colon. Journal of Proteome Research, 2013, 12, 67-80.	1.8	20
119	Genome-wide screening for understanding the role of DNA methylation in colorectal cancer. Epigenomics, 2013, 5, 569-581.	1.0	10
120	The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures. Immunity, 2013, 39, 11-26.	6.6	700
121	Associations Between Colorectal Cancer Molecular Markers and Pathways With Clinicopathologic Features in Older Women. Gastroenterology, 2013, 145, 348-356.e2.	0.6	49
122	Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis, 2013, 2, e71-e71.	2.1	658
123	Emerging landscape of oncogenic signatures across human cancers. Nature Genetics, 2013, 45, 1127-1133.	9.4	1,190
124	Molecular Origins of Colon and Rectal Cancer: Not a Wntâ€“Wnt Situation. Current Colorectal Cancer Reports, 2013, 9, 365-371.	1.0	3
125	Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nature Genetics, 2013, 45, 1483-1486.	9.4	275
126	A Novel Tankyrase Small-Molecule Inhibitor Suppresses <i>APC</i> Mutationâ€“Driven Colorectal Tumor Growth. Cancer Research, 2013, 73, 3132-3144.	0.4	282
127	Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!. Expert Opinion on Pharmacotherapy, 2013, 14, 2203-2220.	0.9	4
129	Nanoproteomic analysis of extracellular receptor kinaseâ€1/2 postâ€translational activation in microdissected human hyperplastic colon lesions. Proteomics, 2013, 13, 1428-1436.	1.3	14
130	Tumor subtype identification with weighted sparse non-negative matrix factorization for multiple heterogeneous data integration. , 2013, , .		2
131	Visualizing multidimensional cancer genomics data. Genome Medicine, 2013, 5, 9.	3.6	79

#	Article	IF	Citations
132	Pattern discovery and cancer gene identification in integrated cancer genomic data. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4245-4250.	3.3	361
133	<i>customProDB</i>: an R package to generate customized protein databases from RNA-Seq data for proteomics search. Bioinformatics, 2013, 29, 3235-3237.	1.8	138
134	Deep Sequencing in Cancer Research. Japanese Journal of Clinical Oncology, 2013, 43, 110-115.	0.6	19
135	Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer. Science, 2013, 339, 543-548.	6.0	691
136	Genomic Medicine: New Frontiers and New Challenges. Clinical Chemistry, 2013, 59, 158-167.	1.5	59
137	Qualitative and Quantitative Expression Status of the Human Chromosome 20 Genes in Cancer Tissues and the Representative Cell Lines. Journal of Proteome Research, 2013, 12, 151-161.	1.8	19
138	<i><scp>RNF43</scp></i> is a tumour suppressor gene mutated in mucinous tumours of the ovary. Journal of Pathology, 2013, 229, 469-476.	2.1	102
139	<i>SMAD2</i>, <i>SMAD3</i> and <i>SMAD4</i> Mutations in Colorectal Cancer. Cancer Research, 2013, 73, 725-735.	0.4	260
140	WNT signalling pathways as therapeutic targets in cancer. Nature Reviews Cancer, 2013, 13, 11-26.	12.8	1,665
141	Single-Molecule Genomic Data Delineate Patient-Specific Tumor Profiles and Cancer Stem Cell Organization. Cancer Research, 2013, 73, 41-49.	0.4	68
142	Intersection of Hippo/YAP and Wnt/β-catenin signaling pathways. Acta Biochimica Et Biophysica Sinica, 2013, 45, 71-79.	0.9	62
143	Development of PI3K inhibitors: lessons learned from early clinical trials. Nature Reviews Clinical Oncology, 2013, 10, 143-153.	12.5	694
144	Developing proteomicsâ€based biomarkers for colorectal neoplasms for clinical practice: Opportunities and challenges. Proteomics - Clinical Applications, 2013, 7, 30-41.	0.8	21
145	Revisiting landmark trials and identifying new therapies. Nature Reviews Clinical Oncology, 2013, 10, 71-72.	12.5	6
146	<i>MLH1</i>â€silenced and nonâ€silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes. Journal of Pathology, 2013, 229, 99-110.	2.1	67
147	Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. Journal of Pathology, 2013, 229, 441-448.	2.1	80
148	Genome-wide sequencing to identify the cause of hereditary cancer syndromes: With examples from familial pancreatic cancer. Cancer Letters, 2013, 340, 227-233.	3.2	19
149	Tight junction proteins: From barrier to tumorigenesis. Cancer Letters, 2013, 337, 41-48.	3.2	178

#	Article	IF	Citations
150	Molecular biomarkers as predictors of response to neoadjuvant chemoradiation therapy in rectal cancer. Seminars in Colon and Rectal Surgery, 2013, 24, 119-124.	0.2	5
151	More than two decades of Apc modeling in rodents. Biochimica Et Biophysica Acta: Reviews on Cancer, 2013, 1836, 80-89.	3.3	36
152	Rhabdoid Tumors: An Initial Clue to the Role of Chromatin Remodeling in Cancer. Brain Pathology, 2013, 23, 200-205.	2.1	25
153	Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. Blood, 2013, 122, 999-1006.	0.6	156
154	Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. American Journal of Gastroenterology, 2013, 108, 1785-1793.	0.2	120
155	Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma. Gynecologic Oncology, 2013, 128, 349-355.	0.6	37
156	Human Pol É›-dependent replication errors and the influence of mismatch repair on their correction. DNA Repair, 2013, 12, 954-963.	1.3	18
157	Distinct molecular features of colorectal cancer in Ghana. Cancer Epidemiology, 2013, 37, 556-561.	0.8	31
158	Adjuvant chemotherapy. European Journal of Cancer, Supplement, 2013, 11, 72-79.	2.2	1
159	Cancer genome sequencing: Understanding malignancy as a disease of the genome, its conformation, and its evolution. Cancer Letters, 2013, 340, 152-160.	3.2	21
160	Colorectal cancer liver metastases: advances in minimally invasive surgery and genome sequencing-based discoveries. Surgical Endoscopy and Other Interventional Techniques, 2013, 27, 1848-1850.	1.3	0
161	Diagnosis of sessile serrated polyps/adenomas: what does this mean for the pathologist, gastroenterologist and patient?. Journal of Clinical Pathology, 2013, 66, 265-268.	1.0	20
162	Applying ecological and evolutionary theory to cancer: a long and winding road. Evolutionary Applications, 2013, 6, 1-10.	1.5	70
163	Analysis of colorectal cancers in British Bangladeshi identifies early onset, frequent mucinous histotype and a high prevalence of RBFOX1 deletion. Molecular Cancer, 2013, 12, 1.	7.9	154
164	A cyclin without cyclin-dependent kinases: cyclin F controls genome stability through ubiquitin-mediated proteolysis. Trends in Cell Biology, 2013, 23, 135-140.	3.6	82
165	Molecular Dissection of Microsatellite Instable Colorectal Cancer. Cancer Discovery, 2013, 3, 502-511.	7.7	91
166	Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nature Biotechnology, 2013, 31, 213-219.	9.4	3,934
167	Comprehensive genome sequencing of the liver cancer genome. Cancer Letters, 2013, 340, 234-240.	3.2	48

#	Article	IF	Citations
168	Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2916-2921.	3.3	275
169	Integrated analysis of genomeâ€wide copy number alterations and gene expression in microsatellite stable, CpG island methylator phenotypeâ€negative colon cancer. Genes Chromosomes and Cancer, 2013, 52, 450-466.	1.5	51
170	Interplay between the Cancer Genome and Epigenome. Cell, 2013, 153, 38-55.	13.5	733
171	The burden of faulty proofreading in colon cancer. Nature Genetics, 2013, 45, 121-122.	9.4	25
172	Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Modern Pathology, 2013, 26, 465-484.	2.9	193
173	The future of epigenetic therapy in solid tumoursâ€"lessons from the past. Nature Reviews Clinical Oncology, 2013, 10, 256-266.	12.5	299
174	Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nature Genetics, 2013, 45, 478-486.	9.4	671
175	Identification of differentially methylated regions using streptavidin bisulfite ligand methylation enrichment (SuBLiME), a new method to enrich for methylated DNA prior to deep bisulfite genomic sequencing. Epigenetics, 2013, 8, 113-127.	1.3	7
176	A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nature Medicine, 2013, 19, 619-625.	15.2	831
177	The war on cancer: are we winning?. Tumor Biology, 2013, 34, 1275-1284.	0.8	42
178	Identification of serum microRNA profiles in colon cancer. British Journal of Cancer, 2013, 108, 1712-1719.	2.9	76
179	Computational solutions for omics data. Nature Reviews Genetics, 2013, 14, 333-346.	7.7	288
180	Cancer genome-sequencing study design. Nature Reviews Genetics, 2013, 14, 321-332.	7.7	100
181	Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nature Genetics, 2013, 45, 136-144.	9.4	851
182	Interplay between SOX9, Î²-catenin and PPARÎ³ activation in colorectal cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 1853-1865.	1.9	36
183	Genomics and epigenomics of colorectal cancer. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2013, 5, 205-219.	6.6	34
184	Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management. OncoTargets and Therapy, 2013, 6, 223.	1.0	38
185	Using MEMo to Discover Mutual Exclusivity Modules in Cancer. Current Protocols in Bioinformatics, 2013, 41, Unit 8.17.	25.8	29

#	Article	IF	Citations
186	Targeted therapy for colorectal cancer resistance to EGF receptor antibodies and new trends. Expert Review of Gastroenterology and Hepatology, 2013, 7, 5-8.	1.4	3
187	Epigenetic regulation of colon cancer and intestinal stem cells. Current Opinion in Cell Biology, 2013, 25, 177-183.	2.6	80
188	Existing and Emerging Technologies for Tumor Genomic Profiling. Journal of Clinical Oncology, 2013, 31, 1815-1824.	0.8	129
189	Genomic sequencing in cancer. Cancer Letters, 2013, 340, 161-170.	3.2	28
190	Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nature Medicine, 2013, 19, 614-618.	15.2	656
191	Integrated genomic characterization of endometrial carcinoma. Nature, 2013, 497, 67-73.	13.7	4,075
192	Understanding genomic alterations in cancer genomes using an integrative network approach. Cancer Letters, 2013, 340, 261-269.	3.2	70
193	Antibody-based therapy in colorectal cancer. Immunotherapy, 2013, 5, 533-545.	1.0	31
194	Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Science Signaling, 2013, 6, pl1.	1.6	11,344
195	End-joining, translocations and cancer. Nature Reviews Cancer, 2013, 13, 443-454.	12.8	311
196	Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nature Reviews Cancer, 2013, 13, 497-510.	12.8	490
197	Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 2013, 499, 214-218.	13.7	4,761
198	Applying systems biology in drug discovery and development. Drug Metabolism and Drug Interactions, 2013, 28, 67-78.	0.3	10
199	Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity. Journal of Human Genetics, 2013, 58, 346-352.	1.1	52
200	Oncogenic ERBB3 Mutations in Human Cancers. Cancer Cell, 2013, 23, 603-617.	7.7	318
201	Colon cancer cells adopt an invasive phenotype without mesenchymal transition in 3-D but not 2-D culture upon combined stimulation with EGF and crypt growth factors. BMC Cancer, 2013, 13, 221.	1.1	20
202	KRAS, BRAF, and TP53 Deep Sequencing for Colorectal Carcinoma Patient Diagnostics. Journal of Molecular Diagnostics, 2013, 15, 299-311.	1.2	27
203	The mutational landscape of adenoid cystic carcinoma. Nature Genetics, 2013, 45, 791-798.	9.4	394

#	Article	IF	Citations
204	Serrated polyps of the large intestine: current understanding of diagnosis, pathogenesis, and clinical management. Journal of Gastroenterology, 2013, 48, 287-302.	2.3	144
205	Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nature Genetics, 2013, 45, 592-601.	9.4	1,082
206	Replication stress links structural and numerical cancer chromosomal instability. Nature, 2013, 494, 492-496.	13.7	694
207	Bacterial oncogenesis in the colon. Future Microbiology, 2013, 8, 445-460.	1.0	72
208	Brush border myosin Ia inactivation in gastric but not endometrial tumors. International Journal of Cancer, 2013, 132, 1790-1799.	2.3	21
209	Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Modern Pathology, 2013, 26, 825-834.	2.9	126
210	Do mutator mutations fuel tumorigenesis?. Cancer and Metastasis Reviews, 2013, 32, 353-361.	2.7	64
211	Molecular Mechanisms and Functions of DNA Mismatch Repair. , 2013, , 25-45.		1
212	Biopsies: next-generation biospecimens for tailoring therapy. Nature Reviews Clinical Oncology, 2013, 10, 437-450.	12.5	110
213	Wholeâ€genome methylation analysis of benign and malignant colorectal tumours. Journal of Pathology, 2013, 229, 697-704.	2.1	76
214	Integrated molecular analysis of clear-cell renal cell carcinoma. Nature Genetics, 2013, 45, 860-867.	9.4	955
215	Improving outcomes in colorectal cancer: Where do we go from here?. European Journal of Cancer, 2013, 49, 2476-2485.	1.3	43
216	PPP1R13L variant associated with prognosis for patients with rectal cancer. Journal of Cancer Research and Clinical Oncology, 2013, 139, 465-473.	1.2	9
217	ROS Production and NF-ÎºB Activation Triggered by RAC1 Facilitate WNT-Driven Intestinal Stem Cell Proliferation and Colorectal Cancer Initiation. Cell Stem Cell, 2013, 12, 761-773.	5.2	340
218	The Hippo superhighway: signaling crossroads converging on the Hippo/Yap pathway in stem cells and development. Current Opinion in Cell Biology, 2013, 25, 247-253.	2.6	194
219	Functional proteomics, human genetics and cancer biology of GIPC family members. Experimental and Molecular Medicine, 2013, 45, e26-e26.	3.2	69
220	DNA repair genes are selectively mutated in diffuse large B cell lymphomas. Journal of Experimental Medicine, 2013, 210, 1729-1742.	4.2	87
221	Genomics-Driven Oncology: Framework for an Emerging Paradigm. Journal of Clinical Oncology, 2013, 31, 1806-1814.	0.8	315

#	Article	IF	Citations
222	Patterns and Mutational Signatures of Tandem Base Substitutions Causing Human Inherited Disease. Human Mutation, 2013, 34, 1119-1130.	1.1	34
223	Directional genomic hybridization for chromosomal inversion discovery and detection. Chromosome Research, 2013, 21, 165-174.	1.0	28
224	Amplification of the <i>MET</i> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. Cancer Discovery, 2013, 3, 658-673.	7.7	585
225	Assessing colorectal cancer heterogeneity: one step closer to tailored medicine. Journal of Applied Biomedicine, 2013, 11, 115-129.	0.6	2
226	From human genome to cancer genome: The first decade. Genome Research, 2013, 23, 1054-1062.	2.4	132
228	Molecular therapies of colorectal cancer: where will we go from here?. Memo - Magazine of European Medical Oncology, 2013, 6, 215-219.	0.3	1
229	MicroRNA-31 Predicts the Presence of Lymph Node Metastases and Survival in Patients with Lung Adenocarcinoma. Clinical Cancer Research, 2013, 19, 5423-5433.	3.2	98
230	A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Investigational New Drugs, 2013, 31, 1257-1264.	1.2	59
231	Toggling a conformational switch in Wnt/Î²â€catenin signaling: Regulation of Axin phosphorylation. BioEssays, 2013, 35, 1063-1070.	1.2	26
232	Notch3 Functions as a Tumor Suppressor by Controlling Cellular Senescence. Cancer Research, 2013, 73, 3451-3459.	0.4	93
233	Synthetic Lethal Targeting of Superoxide Dismutase 1 Selectively Kills <i>RAD54B</i>-Deficient Colorectal Cancer Cells. Genetics, 2013, 195, 757-767.	1.2	47
234	Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer. Clinical Cancer Research, 2013, 19, 4149-4162.	3.2	61
235	Harnessing massively parallel DNA sequencing for the personalization of cancer management. Personalized Medicine, 2013, 10, 183-190.	0.8	2
236	Cancer heterogeneity and signaling network-based drug target. Pharmacogenomics, 2013, 14, 1243-1246.	0.6	2
237	Identification of driver genes in microsatellite-unstable colorectal cancers. Colorectal Cancer, 2013, 2, 515-523.	0.8	0
238	Colorectal Cancer: Basic and Translational Research. Gastrointestinal Tumors, 2013, 1, 18-24.	0.3	0
239	Oncogenic mutations in adenomatous polyposis coli (<i>Apc</i>) activate mechanistic target of rapamycin complex 1 (mTORC1)in mice and zebrafish. DMM Disease Models and Mechanisms, 2014, 7, 63-71.	1.2	25
240	Challenges and strategies for identifying biomarkers for colorectal cancer. Colorectal Cancer, 2013, 2, 487-489.	0.8	1

#	Article	IF	Citations
241	Integrated clinical genomics: new horizon for diagnostic and biomarker discoveries in cancer. Expert Review of Molecular Diagnostics, 2013, 13, 1-4.	1.5	9
242	Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. Genome Research, 2013, 23, 228-235.	2.4	124
243	Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Annals of Oncology, 2013, 24, 2554-2559.	0.6	83
244	An evolutionary perspective on anti-tumor immunity. Frontiers in Oncology, 2012, 2, 202.	1.3	15
245	QPLOT: A Quality Assessment Tool for Next Generation Sequencing Data. BioMed Research International, 2013, 2013, 1-4.	0.9	17
246	Multi-Layered Cancer Chromosomal Instability Phenotype. Frontiers in Oncology, 2013, 3, 302.	1.3	32
247	A Case Report and Genetic Characterization of a Massive Acinic Cell Carcinoma of the Parotid with Delayed Distant Metastases. Case Reports in Oncological Medicine, 2013, 2013, 1-7.	0.2	5
248	Vitamin D Is a Multilevel Repressor of Wnt/b-Catenin Signaling in Cancer Cells. Cancers, 2013, 5, 1242-1260.	1.7	116
249	A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells. Journal of Visualized Experiments, 2013, , e50369.	0.2	6
250	Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value. PLoS Medicine, 2013, 10, e1001453.	3.9	1,064
251	Dominant Mutations in S. cerevisiae PMS1 Identify the Mlh1-Pms1 Endonuclease Active Site and an Exonuclease 1-Independent Mismatch Repair Pathway. PLoS Genetics, 2013, 9, e1003869.	1.5	52
252	Simultaneous Identification of Multiple Driver Pathways in Cancer. PLoS Computational Biology, 2013, 9, e1003054.	1.5	231
253	SOX9 directly regulates <i>IGFBP-4</i> in the intestinal epithelium. American Journal of Physiology - Renal Physiology, 2013, 305, G74-G83.	1.6	29
254	The Scientific Drunk and the Lamppost: Massive Sequencing Efforts in Cancer Discovery and Treatment. Science Signaling, 2013, 6, pe13.	1.6	64
255	Nuclear Expression of Î²-Catenin Promotes RB Stability and Resistance to TNF-Induced Apoptosis in Colon Cancer Cells. Molecular Cancer Research, 2013, 11, 207-218.	1.5	26
256	Frameshift mutations of axon guidance genes ROBO1 and ROBO2 in gastric and colorectal cancers with microsatellite instability. Pathology, 2013, 45, 645-650.	0.3	22
257	Low-copy <i>piggyBac</i> transposon mutagenesis in mice identifies genes driving melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E3640-9.	3.3	28
258	Pathways of Colorectal Carcinogenesis. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 97-102.	0.6	100

#	Article	IF	Citations
259	Targeted therapies of solid cancers. Current Opinion in Oncology, 2013, 25, 296-304.	1.1	21
260	N-Glycoprotein SRMAtlas. Molecular and Cellular Proteomics, 2013, 12, 1005-1016.	2.5	48
261	DETECTING STATISTICAL INTERACTION BETWEEN SOMATIC MUTATIONAL EVENTS AND GERMLINE VARIATION FROM NEXT-GENERATION SEQUENCE DATA. , 2013, , .		3
262	Î²-Cateninâ€"dependent lysosomal targeting of internalized tumor necrosis factor-Î± suppresses caspase-8 activation in apoptosis-resistant colon cancer cells. Molecular Biology of the Cell, 2013, 24, 465-473.	0.9	12
263	Protein Kinase C-Î´â€"Mediated Recycling of Active KIT in Colon Cancer. Clinical Cancer Research, 2013, 19, 4961-4971.	3.2	22
264	Differential Effects of Aspirin Before and After Diagnosis of Colorectal Cancer. JAMA - Journal of the American Medical Association, 2013, 309, 2598.	3.8	9
266	Mutation Rates, Spectra, and Genome-Wide Distribution of Spontaneous Mutations in Mismatch Repair Deficient Yeast. G3: Genes, Genomes, Genetics, 2013, 3, 1453-1465.	0.8	113
267	COHCAP: an integrative genomic pipeline for single-nucleotide resolution DNA methylation analysis. Nucleic Acids Research, 2013, 41, e117-e117.	6.5	101
268	TSGene: a web resource for tumor suppressor genes. Nucleic Acids Research, 2013, 41, D970-D976.	6.5	295
269	Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08. Journal of the National Cancer Institute, 2013, 105, 989-992.	3.0	56
270	ER stress transcription factor Xbp1 suppresses intestinal tumorigenesis and directs intestinal stem cells. Journal of Experimental Medicine, 2013, 210, 2041-2056.	4.2	120
272	GBP-1 acts as a tumor suppressor in colorectal cancer cells. Carcinogenesis, 2013, 34, 153-162.	1.3	85
273	Biomarkers in precision therapy in colorectal cancer. Gastroenterology Report, 2013, 1, 166-183.	0.6	86
274	The UCSC Interaction Browser: multidimensional data views in pathway context. Nucleic Acids Research, 2013, 41, W218-W224.	6.5	20
275	Henryin, an ent-kaurane Diterpenoid, Inhibits Wnt Signaling through Interference with Î²-Catenin/TCF4 Interaction in Colorectal Cancer Cells. PLoS ONE, 2013, 8, e68525.	1.1	36
276	<i>RAS, BRAF,</i> and <i>TP53</i> Gene Mutations in Taiwanese Colorectal Cancer Patients. Oncology Research and Treatment, 2013, 36, 719-724.	0.8	17
277	Impact of Molecular Alterations and Targeted Therapy in Appendiceal Adenocarcinomas. Oncologist, 2013, 18, 1270-1277.	1.9	41
278	The mutational landscape of chromatin regulatory factors across 4,623 tumor samples. Genome Biology, 2013, 14, r106.	13.9	102

#	Article	IF	Citations
279	Gene expression â€˜signatureâ€™ limitations and genome architecture-based perspectives for robust cancer biomarkers. Biomarkers in Medicine, 2013, 7, 79-82.	0.6	1
280	BRAF Mutation and Microsatellite Instability Status in Colonic and Rectal Carcinoma: Context Really Does Matter. Journal of the National Cancer Institute, 2013, 105, 1075-1077.	3.0	16
281	A Prospective Study of Duration of Smoking Cessation and Colorectal Cancer Risk by Epigenetics-related Tumor Classification. American Journal of Epidemiology, 2013, 178, 84-100.	1.6	81
282	Precise inference of copy number alterations in tumor samples from SNP arrays. Bioinformatics, 2013, 29, 2964-2970.	1.8	12
283	Genetic reconstitution of tumorigenesis in primary intestinal cells. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11127-11132.	3.3	100
284	Phosphotyrosine Signaling Proteins that Drive Oncogenesis Tend to be Highly Interconnected. Molecular and Cellular Proteomics, 2013, 12, 1204-1213.	2.5	31
285	SomamiR: a database for somatic mutations impacting microRNA function in cancer. Nucleic Acids Research, 2013, 41, D977-D982.	6.5	87
286	Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models. Clinical Cancer Research, 2013, 19, 6219-6229.	3.2	53
287	Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and <i>PIK3CA</i> Mutations. Molecular Cancer Therapeutics, 2013, 12, 2857-2863.	1.9	42
288	The era of genomic medicine. Clinical Medicine, 2013, 13, 594-601.	0.8	14
289	An APC:WNT Counter-Current-Like Mechanism Regulates Cell Division Along the Human Colonic Crypt Axis: A Mechanism That Explains How APC Mutations Induce Proliferative Abnormalities That Drive Colon Cancer Development. Frontiers in Oncology, 2013, 3, 244.	1.3	48
290	Review of Biological Network Data and Its Applications. Genomics and Informatics, 2013, 11, 200.	0.4	79
291	Genome-scale analysis of DNA methylation in colorectal cancer using Infinium HumanMethylation450 BeadChips. Epigenetics, 2013, 8, 921-934.	1.3	130
292	<scp>PTEN</scp> expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. Cancer Medicine, 2013, 2, 496-506.	1.3	43
293	Acceleration in colorectal carcinogenesis: the hare, the tortoise or myth?: TableÂ1. Gut, 2013, 62, 657-659.	6.1	4
294	Inhibiting the RASâ€“PI3K Pathway in Cancer Therapy. The Enzymes, 2013, 34 Pt. B, 107-136.	0.7	20
295	<scp><i>IRS2</i></scp> is a candidate driver oncogene on 13q34 in colorectal cancer. International Journal of Experimental Pathology, 2013, 94, 203-211.	0.6	49
296	Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. Journal of Pathology, 2013, 231, 63-76.	2.1	331

#	Article	IF	Citations
297	A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells. Clinical Cancer Research, 2013, 19, 6787-6801.	3.2	80
298	Mixed Lineage Kinase MLK4 Is Activated in Colorectal Cancers Where It Synergistically Cooperates with Activated RAS Signaling in Driving Tumorigenesis. Cancer Research, 2013, 73, 1912-1921.	0.4	15
299	AP4 is a mediator of epithelialâ€“mesenchymal transition and metastasis in colorectal cancer. Journal of Experimental Medicine, 2013, 210, 1331-1350.	4.2	136
300	<i>PIK3CA</i> and <i>PTEN</i> Gene and Exon Mutation-Specific Clinicopathologic and Molecular Associations in Colorectal Cancer. Clinical Cancer Research, 2013, 19, 3285-3296.	3.2	107
301	Clinical Cancer Advances 2012: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2013, 31, 131-161.	0.8	40
302	The role of personalized medicine in metastatic colorectal cancer: an evolving landscape. Therapeutic Advances in Gastroenterology, 2013, 6, 381-395.	1.4	33
303	The FAT epidemic: A gene family frequently mutated across multiple human cancer types. Cell Cycle, 2013, 12, 1011-1012.	1.3	28
304	Recurrent patterns of DNA methylation in the<i>ZNF154,</i><i>CASP8</i>, and<i>VHL</i>promoters across a wide spectrum of human solid epithelial tumors and cancer cell lines. Epigenetics, 2013, 8, 1355-1372.	1.3	52
305	The mutational landscape of phosphorylation signaling in cancer. Scientific Reports, 2013, 3, 2651.	1.6	149
307	A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. British Journal of Cancer, 2013, 109, 1085-1092.	2.9	54
308	Epigenetic silencing of monoallelically methylated miRNA loci in precancerous colorectal lesions. Oncogenesis, 2013, 2, e56-e56.	2.1	43
309	Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas. Nature Genetics, 2013, 45, 1121-1126.	9.4	102
310	DNA polymerase É› and Î´ exonuclease domain mutations in endometrial cancer. Human Molecular Genetics, 2013, 22, 2820-2828.	1.4	319
312	Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1999-2004.	3.3	348
313	Mouse Models of Kras-Mutant Colorectal Cancer: Valuable GEMMs for Drug Testing?. Clinical Cancer Research, 2013, 19, 2794-2796.	3.2	2
314	Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4762-9.	3.3	99
315	From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development. Journal of the National Cancer Institute, 2013, 105, 1441-1456.	3.0	51
317	A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes and Development, 2013, 27, 1462-1472.	2.7	74

#	Article	IF	Citations
319	Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. Scientific Reports, 2013, 3, 3544.	1.6	45
320	Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers. Cancer Discovery, 2013, 3, 770-781.	7.7	484
321	Comprehensive whole-genome sequencing of an early-stage primary myelofibrosis patient defines low mutational burden and non-recurrent candidate genes. Haematologica, 2013, 98, 1689-1696.	1.7	10
322	Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status. International Journal of Oncology, 2013, 42, 1644-1653.	1.4	30
323	CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. Blood, 2013, 121, 975-983.	0.6	130
324	Monitoring of Technical Variation in Quantitative High-Throughput Datasets. Cancer Informatics, 2013, 12, CIN.S12862.	0.9	47
325	Regulation of stem cell self-renewal and differentiation by Wnt and Notch are conserved throughout the adenoma-carcinoma sequence in the colon. Molecular Cancer, 2013, 12, 126.	7.9	50
326	ATHENA: Identifying interactions between different levels of genomic data associated with cancer clinical outcomes using grammatical evolution neural network. BioData Mining, 2013, 6, 23.	2.2	64
327	Principles for Combining Radioembolisation with Systemic Chemotherapy for Metastatic Colorectal Cancer. Medical Radiology, 2013, , 129-139.	0.0	0
328	Multidisciplinary Management of Locally Advanced Rectal Cancer: Neoadjuvant Approaches. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 548-557.	2.3	5
329	Genetics and Genomics Nursing Has Arrived!. Oncology Nursing Forum, 2013, 40, 20-21.	0.5	5
330	Emerging Treatments in Recurrent and Metastatic Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, S-18-S-27.	2.3	9
331	The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin. BMC Cancer, 2013, 13, 521.	1.1	17
332	Comprehensive molecular characterization of human colon and rectal cancer. Yearbook of Pathology and Laboratory Medicine, 2013, 2013, 295-296.	0.0	3
333	An explorative analysis of ERCC1-19q13 copy number aberrations in a chemonaive stage III colorectal cancer cohort. BMC Cancer, 2013, 13, 489.	1.1	5
334	The real informatics challenges of personalized medicine: not just about the number of central processing units. Personalized Medicine, 2013, 10, 639-645.	0.8	3
335	Computation as the Mechanistic Bridge Between Precision Medicine and Systems Therapeutics. Clinical Pharmacology and Therapeutics, 2013, 93, 117-128.	2.3	37
336	Intertumoral and Intratumoral Heterogeneity as a Barrier for Effective Treatment of Medulloblastoma. Neurosurgery, 2013, 60, 57-63.	0.6	13

#	Article	IF	Citations
337	Listening to the Brain. Neurosurgery, 2013, 60, 64-69.	0.6	7
338	A decision-theoretic approach for segmental classification. Annals of Applied Statistics, 2013, 7, .	0.5	11
339	New and emerging treatment options for biliary tract cancer. OncoTargets and Therapy, 2013, 6, 1545.	1.0	17
340	The Interactions of microRNA and Epigenetic Modifications in Prostate Cancer. Cancers, 2013, 5, 998-1019.	1.7	33
341	Issues in Screening and Surveillance Colonoscopy. , 2013, , .		3
342	DNA Damage, DNA Repair and Cancer. , 0, , .		40
344	Era of universal testing of microsatellite instability in colorectal cancer. World Journal of Gastrointestinal Oncology, 2013, 5, 12.	0.8	58
345	Positional Mapping and Candidate Gene Analysis of the Mouse Ccs3 Locus That Regulates Differential Susceptibility to Carcinogen-Induced Colorectal Cancer. PLoS ONE, 2013, 8, e58733.	1.1	5
346	FOXQ1, a Novel Target of the Wnt Pathway and a New Marker for Activation of Wnt Signaling in Solid Tumors. PLoS ONE, 2013, 8, e60051.	1.1	55
347	Intra-Tumoral Heterogeneity in Metastatic Potential and Survival Signaling between Iso-Clonal HCT116 and HCT116b Human Colon Carcinoma Cell Lines. PLoS ONE, 2013, 8, e60299.	1.1	21
348	Whole Genome and Transcriptome Sequencing of a B3 Thymoma. PLoS ONE, 2013, 8, e60572.	1.1	28
349	ARID1A Alterations Are Associated with FGFR3-Wild Type, Poor-Prognosis, Urothelial Bladder Tumors. PLoS ONE, 2013, 8, e62483.	1.1	52
350	An Ensemble Prognostic Model for Colorectal Cancer. PLoS ONE, 2013, 8, e63494.	1.1	14
351	Targeted Sequencing of Cancer-Related Genes in Colorectal Cancer Using Next-Generation Sequencing. PLoS ONE, 2013, 8, e64271.	1.1	71
352	Oncogenic Actions of the Nuclear Receptor Corepressor (NCOR1) in a Mouse Model of Thyroid Cancer. PLoS ONE, 2013, 8, e67954.	1.1	20
353	Boolean Network Model for Cancer Pathways: Predicting Carcinogenesis and Targeted Therapy Outcomes. PLoS ONE, 2013, 8, e69008.	1.1	148
354	Targeted Re-Sequencing Identified rs3106189 at the 5â€² UTR of TAPBP and rs1052918 at the 3â€² UTR of TCF3 to Be Associated with the Overall Survival of Colorectal Cancer Patients. PLoS ONE, 2013, 8, e70307.	1.1	8
355	Unique Haploinsufficient Role of the MicroRNA-Processing Molecule Dicer1 in a Murine Colitis-Associated Tumorigenesis Model. PLoS ONE, 2013, 8, e71969.	1.1	19

#	Article	IF	Citations
356	Ensemble of Gene Signatures Identifies Novel Biomarkers in Colorectal Cancer Activated through PPARÎ³ and TNFÎ± Signaling. PLoS ONE, 2013, 8, e72638.	1.1	33
357	Whole Transcriptome Sequencing Enables Discovery and Analysis of Viruses in Archived Primary Central Nervous System Lymphomas. PLoS ONE, 2013, 8, e73956.	1.1	9
358	Somatic Point Mutation Calling in Low Cellularity Tumors. PLoS ONE, 2013, 8, e74380.	1.1	67
359	CIP2A Influences Survival in Colon Cancer and Is Critical for Maintaining Myc Expression. PLoS ONE, 2013, 8, e75292.	1.1	36
360	Enu Mutagenesis Identifies a Novel Platelet Phenotype in a Loss-Of-Function Jak2 Allele. PLoS ONE, 2013, 8, e75472.	1.1	2
361	Phenotypic and Transcriptional Fidelity of Patient-Derived Colon Cancer Xenografts in Immune-Deficient Mice. PLoS ONE, 2013, 8, e79874.	1.1	34
362	Comprehensive Analysis of Long Non-Coding RNAs in Ovarian Cancer Reveals Global Patterns and Targeted DNA Amplification. PLoS ONE, 2013, 8, e80306.	1.1	90
363	WNT5A Encodes Two Isoforms with Distinct Functions in Cancers. PLoS ONE, 2013, 8, e80526.	1.1	49
364	Effectors of Epidermal Growth Factor Receptor Pathway: The Genetic Profiling of KRAS, BRAF, PIK3CA, NRAS Mutations in Colorectal Cancer Characteristics and Personalized Medicine. PLoS ONE, 2013, 8, e81628.	1.1	86
365	Exome Sequencing Identifies Early Gastric Carcinoma as an Early Stage of Advanced Gastric Cancer. PLoS ONE, 2013, 8, e82770.	1.1	36
366	Two Distinct Categories of Focal Deletions in Cancer Genomes. PLoS ONE, 2013, 8, e66264.	1.1	34
367	Genome-wide multi-omics profiling of colorectal cancer identifies immune determinants strongly associated with relapse. Frontiers in Genetics, 2013, 4, 236.	1.1	31
368	Portraying the Expression Landscapes of B-CellLymphoma-Intuitive Detection of Outlier Samples and of Molecular Subtypes. Biology, 2013, 2, 1411-1437.	1.3	17
369	Synthetic Genetic Targeting of Genome Instability in Cancer. Cancers, 2013, 5, 739-761.	1.7	31
370	Computational methods for detecting copy number variations in cancer genome using next generation sequencing: principles and challenges. Oncotarget, 2013, 4, 1868-1881.	0.8	77
371	Using Aptamers for Cancer Biomarker Discovery. Journal of Nucleic Acids, 2013, 2013, 1-7.	0.8	47
372	Establishment and Validation of an Orthotopic Metastatic Mouse Model of Colorectal Cancer. ISRN Hepatology, 2013, 2013, 1-9.	0.9	13
374	An Introduction to The Cancer Genome Atlas. , 0, , 31-53.		1

#	Article	IF	Citations
375	Epigenetics, Probiotic Metabolites and Colon Cancer Prevention: An Overview of Progress, Opportunities and Challenges. Medical Epigenetics, 2013, 1, 60-69.	262.3	5
376	Optimal management of endemic Burkitt lymphoma: a holistic approach mindful of limited resources. Blood and Lymphatic Cancer: Targets and Therapy, 2014, , 91.	1.2	8
377	Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management. Cancer Management and Research, 2014, 6, 93.	0.9	18
378	Gastrointestinal Polyposis Syndromes: Early Tumor Evolution Through the Looking Glass. , 2014, , 1319-1331.		0
379	Chromosomal Copy Number Aberrations in Colorectal Metastases Resemble Their Primary Counterparts and Differences Are Typically Non-Recurrent. PLoS ONE, 2014, 9, e86833.	1.1	21
380	Immunohistochemistry for Myc Predicts Survival in Colorectal Cancer. PLoS ONE, 2014, 9, e87456.	1.1	38
381	High Frequency of Fusion Transcripts Involving TCF7L2 in Colorectal Cancer: Novel Fusion Partner and Splice Variants. PLoS ONE, 2014, 9, e91264.	1.1	26
382	Microsatellite Stable Colorectal Cancers Stratified by the BRAF V600E Mutation Show Distinct Patterns of Chromosomal Instability. PLoS ONE, 2014, 9, e91739.	1.1	15
383	Integrated Analysis of Copy Number Variation and Genome-Wide Expression Profiling in Colorectal Cancer Tissues. PLoS ONE, 2014, 9, e92553.	1.1	43
384	S-Score: A Scoring System for the Identification and Prioritization of Predicted Cancer Genes. PLoS ONE, 2014, 9, e94147.	1.1	8
385	Fusion Transcript Discovery in Formalin-Fixed Paraffin-Embedded Human Breast Cancer Tissues Reveals a Link to Tumor Progression. PLoS ONE, 2014, 9, e94202.	1.1	16
386	Crystal Structure of Yeast DNA Polymerase Îµ Catalytic Domain. PLoS ONE, 2014, 9, e94835.	1.1	42
387	Identification of Druggable Cancer Driver Genes Amplified across TCGA Datasets. PLoS ONE, 2014, 9, e98293.	1.1	105
388	Influence of Race on Microsatellite Instability and CD8+ T Cell Infiltration in Colon Cancer. PLoS ONE, 2014, 9, e100461.	1.1	84
389	Mutations of C-Reactive Protein (CRP) -286 SNP, APC and p53 in Colorectal Cancer: Implication for a CRP-Wnt Crosstalk. PLoS ONE, 2014, 9, e102418.	1.1	22
390	Activation of c-Myc and Cyclin D1 by JCV T-Antigen and Î²-Catenin in Colon Cancer. PLoS ONE, 2014, 9, e106257.	1.1	47
391	SOX9 Regulates Multiple Genes in Chondrocytes, Including Genes Encoding ECM Proteins, ECM Modification Enzymes, Receptors, and Transporters. PLoS ONE, 2014, 9, e107577.	1.1	86
392	Genomic Instability and Radiation Risk in Molecular Pathways to Colon Cancer. PLoS ONE, 2014, 9, e111024.	1.1	27

#	Article	IF	Citations
393	RADIA: RNA and DNA Integrated Analysis for Somatic Mutation Detection. PLoS ONE, 2014, 9, e111516.	1.1	90
394	Dual Pharmacological Targeting of the MAP Kinase and PI3K/mTOR Pathway in Preclinical Models of Colorectal Cancer. PLoS ONE, 2014, 9, e113037.	1.1	40
395	CREB Targets Define the Gene Expression Signature of Malignancies Having Reduced Levels of the Tumor Suppressor Tristetraprolin. PLoS ONE, 2014, 9, e115517.	1.1	29
396	Time-Intensity Curve Parameters in Rectal Cancer Measured Using Endorectal Ultrasonography with Sterile Coupling Gels Filling the Rectum: Correlations with Tumor Angiogenesis and Clinicopathological Features. BioMed Research International, 2014, 2014, 1-7.	0.9	22
397	Single Nucleotide Polymorphisms in MicroRNA Binding Sites: Implications in Colorectal Cancer. Scientific World Journal, The, 2014, 2014, 1-10.	0.8	24
398	Mammalian MYC Proteins and Cancer. New Journal of Science, 2014, 2014, 1-27.	1.0	170
399	Epidemiological transition of colorectal cancer in developing countries: Environmental factors, molecular pathways, and opportunities for prevention. World Journal of Gastroenterology, 2014, 20, 6055.	1.4	203
400	From Genotype to Functional Phenotype: Unraveling the Metabolomic Features of Colorectal Cancer. Genes, 2014, 5, 536-560.	1.0	39
401	Toward a systematic understanding of cancers: a survey of the pan-cancer study. Frontiers in Genetics, 2014, 5, 194.	1.1	22
402	Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. OncoTargets and Therapy, 2014, 7, 1001.	1.0	96
403	Mechanisms of Base Substitution Mutagenesis in Cancer Genomes. Genes, 2014, 5, 108-146.	1.0	49
404	Potential of antibody–drug conjugates and novel therapeutics in breast cancer management. OncoTargets and Therapy, 2014, 7, 491.	1.0	19
405	Translating Mismatch Repair Mechanism into Cancer Care. Current Drug Targets, 2014, 15, 53-64.	1.0	13
406	Differences in carcinoembryonic antigen levels between colon and rectal cancer. Molecular and Clinical Oncology, 2014, 2, 618-622.	0.4	16
408	Targeting metastatic colorectal cancer – present and emerging treatment options. Pharmacogenomics and Personalized Medicine, 2014, 7, 137.	0.4	14
409	Chemopreventive drugs: Mechanisms<i>via</i>inhibition of cancer stem cells in colorectal cancer. World Journal of Gastroenterology, 2014, 20, 3835.	1.4	14
410	Prospects of â€˜Omics Based Molecular Approaches in Colorectal Cancer Diagnosis and Treatment in the Developing World: A Case Study in Cape Town, South Africa. , 0, , .		1
411	A 5-gene classifier from the carcinoma-associated fibroblast transcriptomic profile and clinical outcome in colorectal cancer. Oncotarget, 2014, 5, 6437-6452.	0.8	30

#	Article	IF	Citations
413	The Evolution of Our Molecular Understanding of Colorectal Cancer: What We Are Doing Now, What the Future Holds, and How Tumor Profiling Is Just the Beginning. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 91-99.	1.8	27
414	Molecular profiling in colorectal cancer: current state of play and future directions. Colorectal Cancer, 2014, 3, 41-56.	0.8	1
415	Prediction of individualized therapeutic vulnerabilities in cancer from genomic profiles. Bioinformatics, 2014, 30, 2051-2059.	1.8	30
416	Compact variantâ€rich customized sequence database and a fast and sensitive database search for efficient proteogenomic analyses. Proteomics, 2014, 14, 2742-2749.	1.3	27
417	Insights into cancer biology through next-generation sequencing. Clinical Medicine, 2014, 14, s71-s77.	0.8	3
418	Concomitant Notch activation and p53 deletion trigger epithelial-to-mesenchymal transition and metastasis in mouse gut. Nature Communications, 2014, 5, 5005.	5.8	114
419	Past, current and future approaches to querying MAPK pathway activation: status and clinical implications. Personalized Medicine, 2014, 11, 745-760.	0.8	0
420	Personalized Cancer Therapy. , 2014, , 671-824.		1
421	Cancer <i>In Silico</i> Drug Discovery: A Systems Biology Tool for Identifying Candidate Drugs to Target Specific Molecular Tumor Subtypes. Molecular Cancer Therapeutics, 2014, 13, 3230-3240.	1.9	21
422	CDC42 Inhibition Suppresses Progression of Incipient Intestinal Tumors. Cancer Research, 2014, 74, 5480-5492.	0.4	48
423	A Functional Cancer Genomics Screen Identifies a Druggable Synthetic Lethal Interaction between <i>MSH3</i> and <i>PRKDC</i>. Cancer Discovery, 2014, 4, 592-605.	7.7	60
424	The emerging roles of ARID1A in tumor suppression. Cancer Biology and Therapy, 2014, 15, 655-664.	1.5	200
425	Aberrant SOX2 expression in colorectal cancers does not correlate with mucinous differentiation and gastric mucin MUC5AC expression. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 395-400.	1.4	4
427	The impact of pyrvinium pamoate on colon cancer cell viability. International Journal of Colorectal Disease, 2014, 29, 1189-1198.	1.0	29
428	Epigenetic inactivation of the novel candidate tumor suppressor gene<i>ITIH5</i>in colon cancer predicts unfavorable overall survival in the CpG island methylator phenotype. Epigenetics, 2014, 9, 1290-1301.	1.3	29
429	Next-generation sequencing in precision oncology: challenges and opportunities. Expert Review of Molecular Diagnostics, 2014, 14, 635-637.	1.5	22
430	Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biology, 2014, 15, 454.	3.8	296
431	Characterization of age signatures of DNA methylation in normal and cancer tissues from multiple studies. BMC Genomics, 2014, 15, 997.	1.2	20

#	Article	IF	Citations
432	MicroRNA-31 contributes to colorectal cancer development by targeting factor inhibiting HIF-1Î± (FIH-1). Cancer Biology and Therapy, 2014, 15, 516-523.	1.5	50
433	Large differences in global transcriptional regulatory programs of normal and tumor colon cells. BMC Cancer, 2014, 14, 708.	1.1	31
434	Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X. Nature Communications, 2014, 5, 5191.	5.8	51
435	Overview of Genetically Engineered Mouse Models of Colorectal Carcinoma to Enable Translational Biology and Drug Development. Current Protocols in Pharmacology, 2014, 65, 14.29.1-10.	4.0	2
436	Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin. Molecular Cancer Therapeutics, 2014, 13, 399-409.	1.9	83
437	Chromosome 20 Aberrations at the Diploid-Aneuploid Transition in Sporadic Colorectal Cancer. Cytogenetic and Genome Research, 2014, 144, 9-14.	0.6	7
438	Oncogenic mutations in intestinal adenomas regulate Bim-mediated apoptosis induced by TGF-Î². Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2229-36.	3.3	52
439	Bioinformatics in otolaryngology research. Part two: other high-throughput platforms in genomics and epigenetics. Journal of Laryngology and Otology, 2014, 128, 942-947.	0.4	1
440	KLF5 Regulates the Integrity and Oncogenicity of Intestinal Stem Cells. Cancer Research, 2014, 74, 2882-2891.	0.4	66
441	Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity. Cell Death and Disease, 2014, 5, e1108-e1108.	2.7	89
442	RNA editing in <i>RHOQ</i> promotes invasion potential in colorectal cancer. Journal of Experimental Medicine, 2014, 211, 613-621.	4.2	97
443	Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. British Journal of Cancer, 2014, 111, 25-32.	2.9	41
444	The confounding effects of tumour heterogeneity and cellular plasticity on personalized surgical management of colorectal cancer. Colorectal Disease, 2014, 16, 329-331.	0.7	2
445	Epidermal growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic biomarkers for patients with resected colorectal cancer liver metastases. British Journal of Cancer, 2014, 111, 749-755.	2.9	25
446	Potential of fecal microbiota for earlyâ€stage detection of colorectal cancer. Molecular Systems Biology, 2014, 10, 766.	3.2	991
447	A germline missense mutation in COQ6 is associated with susceptibility to familial schwannomatosis. Genetics in Medicine, 2014, 16, 787-792.	1.1	20
448	The expression level of small nonâ€coding <scp>RNA</scp> s derived from the first exon of proteinâ€coding genes is predictive of cancer status. EMBO Reports, 2014, 15, 402-410.	2.0	13
449	Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Research, 2014, 24, 743-750.	2.4	534

#	Article	IF	Citations
450	Reduced LIMK2 expression in colorectal cancer reflects its role in limiting stem cell proliferation. Gut, 2014, 63, 480-493.	6.1	26
451	Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations. Science Signaling, 2014, 7, ra114.	1.6	98
452	Characterization of the Usage of the Serine Metabolic Network in Human Cancer. Cell Reports, 2014, 9, 1507-1519.	2.9	136
453	Identification of candidate susceptibility genes for colorectal cancer through eQTL analysis. Carcinogenesis, 2014, 35, 2039-2046.	1.3	60
454	Flavonoids and Wnt/Î²-Catenin Signaling: Potential Role in Colorectal Cancer Therapies. International Journal of Molecular Sciences, 2014, 15, 12094-12106.	1.8	63
455	Integrative Pathway Analysis Using Graph-Based Learning with Applications to TCGA Colon and Ovarian Data. Cancer Informatics, 2014, 13s4, CIN.S13634.	0.9	6
456	Genotoxic Anti-Cancer Agents and Their Relationship to DNA Damage, Mitosis, and Checkpoint Adaptation in Proliferating Cancer Cells. International Journal of Molecular Sciences, 2014, 15, 3403-3431.	1.8	155
457	Attempt at a systemic outlook on aging and carcinogenesis. Bio-Algorithms and Med-Systems, 2014, 10, 101-115.	1.0	1
458	Comparative gene expression profiling of normal and human colorectal adenomatous tissues. Oncology Letters, 2014, 8, 2081-2085.	0.8	3
459	Independent Component Analysis Uncovers the Landscape of the Bladder Tumor Transcriptome and Reveals Insights into Luminal and Basal Subtypes. Cell Reports, 2014, 9, 1235-1245.	2.9	181
460	Prostate cancer incidence in males with Lynch syndrome. Genetics in Medicine, 2014, 16, 553-557.	1.1	88
461	Occult progression by<i>Apc</i>-deficient intestinal crypts as a target for chemoprevention. Carcinogenesis, 2014, 35, 237-246.	1.3	27
462	Immune Escape Mechanisms in Colorectal Cancer Pathogenesis and Liver Metastasis. Journal of Immunology Research, 2014, 2014, 1-11.	0.9	86
463	RAS Transformation Requires CUX1-Dependent Repair of Oxidative DNA Damage. PLoS Biology, 2014, 12, e1001807.	2.6	51
464	Abnormal Dosage of Ultraconserved Elements Is Highly Disfavored in Healthy Cells but Not Cancer Cells. PLoS Genetics, 2014, 10, e1004646.	1.5	22
465	The Protective Role of Symmetric Stem Cell Division on the Accumulation of Heritable Damage. PLoS Computational Biology, 2014, 10, e1003802.	1.5	26
466	â€˜Druggableâ€™ alterations detected by Ion Torrent in metastatic colorectal cancer patients. Oncology Letters, 2014, 7, 1761-1766.	0.8	10
467	Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing. PLoS Genetics, 2014, 10, e1004271.	1.5	157

#	Article	IF	Citations
468	Hydroxymethylated Cytosines Are Associated with Elevated C to G Transversion Rates. PLoS Genetics, 2014, 10, e1004585.	1.5	31
469	A Massively Parallel Pipeline to Clone DNA Variants and Examine Molecular Phenotypes of Human Disease Mutations. PLoS Genetics, 2014, 10, e1004819.	1.5	47
470	Increased and Imbalanced dNTP Pools Symmetrically Promote Both Leading and Lagging Strand Replication Infidelity. PLoS Genetics, 2014, 10, e1004846.	1.5	71
471	Differences in telomerase activity between colon and rectal cancer. Canadian Journal of Surgery, 2014, 57, 199-208.	0.5	17
472	Identification of Drivers from Cancer Genome Diversity in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2014, 15, 11142-11160.	1.8	47
473	Physiological expression of the PI3K-activating mutation <i>Pik3ca</i>H1047R combines with <i>Apc</i> loss to promote development of invasive intestinal adenocarcinomas in mice. Biochemical Journal, 2014, 458, 251-258.	1.7	20
474	RidgeRace: ridge regression for continuous ancestral character estimation on phylogenetic trees. Bioinformatics, 2014, 30, i527-i533.	1.8	28
475	Culturing intestinal stem cells: applications for colorectal cancer research. Frontiers in Genetics, 2014, 5, 169.	1.1	8
476	Tumour-associated mutations of PA-TM-RING ubiquitin ligases RNF167/RNF13 identify the PA domain as a determinant for endosomal localization. Biochemical Journal, 2014, 459, 27-36.	1.7	20
477	Microbial Contamination in Next Generation Sequencing: Implications for Sequence-Based Analysis of Clinical Samples. PLoS Pathogens, 2014, 10, e1004437.	2.1	159
478	Genomic landscape of metastatic colorectal cancer. Nature Communications, 2014, 5, 5457.	5.8	61
479	Cross-species analysis of genetically engineered mouse models of MAPK driven colorectal cancer identifies hallmarks of human disease. DMM Disease Models and Mechanisms, 2014, 7, 613-23.	1.2	5
480	Unsupervised analyses reveal molecular subtypes associated to prognosis and response to therapy in colorectal cancer. Colorectal Cancer, 2014, 3, 277-288.	0.8	2
481	The molecular background of mucinous carcinoma beyond MUC2. The Clinical Journal of Pathology, 2014, , n/a-n/a.	0.0	1
482	Protein kinase C Î² inhibition by enzastaurin leads to mitotic missegregation and preferential cytotoxicity toward colorectal cancer cells with chromosomal instability (CIN). Cell Cycle, 2014, 13, 2697-2706.	1.3	8
483	Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics, 2014, 15, 190.	1.2	334
484	Gene module based regulator inference identifying miR-139 as a tumor suppressor in colorectal cancer. Molecular BioSystems, 2014, 10, 3249-3254.	2.9	13
485	Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nature Communications, 2014, 5, 4988.	5.8	219

#	Article	IF	Citations
486	A global profile of gene promoter methylation in treatment-naÃ¯ve urothelial cancer. Epigenetics, 2014, 9, 760-773.	1.3	31
487	What is the potential of using PI3K inhibitors in the management of breast cancer in the clinic?. Breast Cancer Management, 2014, 3, 345-357.	0.2	0
488	Inhibition of C-terminal binding protein attenuates transcription factor 4 signaling to selectively target colon cancer stem cells. Cell Cycle, 2014, 13, 3506-3518.	1.3	26
489	Methylation epigenotypes and genetic features in colorectal laterally spreading tumors. International Journal of Cancer, 2014, 135, 1586-1595.	2.3	24
490	Novel Lys63-linked ubiquitination of IKKÎ² induces STAT3 signaling. Cell Cycle, 2014, 13, 3964-3976.	1.3	20
491	<i>Isocitrate dehydrogenase 1</i>R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype. Epigenetics, 2014, 9, 1454-1460.	1.3	20
492	Exome sequencing reveals frequent inactivating mutations in<i>ARID1A, ARID1B, ARID2</i>and<i>ARID4A</i>in microsatellite unstable colorectal cancer. International Journal of Cancer, 2014, 135, 611-623.	2.3	107
493	Genome-wide analysis of the human p53 transcriptional network unveils a lncRNA tumour suppressor signature. Nature Communications, 2014, 5, 5812.	5.8	172
494	Fbxw7 hotspot mutations and human colon cancer: mechanistic insights from new mouse models. Gut, 2014, 63, 707-709.	6.1	16
495	Discovery of biclonal origin and a novel oncogene SLC12A5 in colon cancer by single-cell sequencing. Cell Research, 2014, 24, 701-712.	5.7	123
496	Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency. International Journal of Cancer, 2014, 134, 2342-2351.	2.3	51
497	Reconciliation of classification systems defining molecular subtypes of colorectal cancer. Cell Cycle, 2014, 13, 353-357.	1.3	69
498	Boveri at 100: Theodor Boveri and genetic predisposition to cancer. Journal of Pathology, 2014, 234, 142-145.	2.1	18
499	Immunohistochemical detection of ARID1A in colorectal carcinoma: loss of staining is associated with sporadic microsatellite unstable tumors with medullary histology and high TNM stage. Human Pathology, 2014, 45, 2430-2436.	1.1	41
500	The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function. Cancer Cell, 2014, 26, 923-937.	7.7	851
501	Cancer beyond organ and tissue specificity: Nextâ€generationâ€sequencing gene mutation data reveal complex genetic similarities across major cancers. International Journal of Cancer, 2014, 135, 2362-2369.	2.3	36
502	Extrachromosomal driver mutations in glioblastoma and low-grade glioma. Nature Communications, 2014, 5, 5690.	5.8	74
503	Systems-level perspective of sudden infant death syndrome. Pediatric Research, 2014, 76, 220-229.	1.1	10

#	Article	IF	Citations
504	A Novel Method for Detecting Association Between DNA Methylation and Diseases Using Spatial Information. Genetic Epidemiology, 2014, 38, 714-721.	0.6	3
505	Inactivation of the tumor suppressor <i>WTX</i> in a subset of pediatric tumors. Genes Chromosomes and Cancer, 2014, 53, 67-77.	1.5	5
506	High-throughput screening of extended RAS mutations based on high-resolution melting analysis for prediction of anti-EGFR treatment efficacy in colorectal carcinoma. Clinical Biochemistry, 2014, 47, 340-343.	0.8	9
507	<i>CHFR</i> silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer. International Journal of Cancer, 2014, 134, 596-605.	2.3	20
508	Outcomes in nonâ€metastatic colorectal cancer. Journal of Surgical Oncology, 2014, 110, 518-526.	0.8	5
509	RHOA inactivation enhances Wnt signalling and promotes colorectal cancer. Nature Communications, 2014, 5, 5458.	5.8	95
510	Geneâ€dosage dependent overexpression at the 13q amplicon identifies <i>DIS3</i> as candidate oncogene in colorectal cancer progression. Genes Chromosomes and Cancer, 2014, 53, 339-348.	1.5	31
511	Oncogenic activity of the regulatory subunit p85Î² of phosphatidylinositol 3-kinase (PI3K). Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16826-16829.	3.3	36
512	Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing?. European Respiratory Journal, 2014, 44, 1011-1022.	3.1	63
513	Mutational and expressional analysis ofSMC2gene in gastric and colorectal cancers with microsatellite instability. Apmis, 2014, 122, 499-504.	0.9	13
514	Emerging Research and Clinical Development Trends of Liposome and Lipid Nanoparticle Drug Delivery Systems. Journal of Pharmaceutical Sciences, 2014, 103, 29-52.	1.6	437
515	Insights into Wild-Type and Mutant p53 Functions Provided by Genetically Engineered Mice. Human Mutation, 2014, 35, 715-727.	1.1	27
516	Effects of <i><scp>TP53</scp></i> mutational status on gene expression patterns across 10 human cancer types. Journal of Pathology, 2014, 232, 522-533.	2.1	65
517	Hypermutation in human cancer genomes: footprints and mechanisms. Nature Reviews Cancer, 2014, 14, 786-800.	12.8	354
518	A novel reannotation strategy for dissecting DNA methylation patterns of human long intergenic non-coding RNAs in cancers. Nucleic Acids Research, 2014, 42, 8258-8270.	6.5	40
519	Molecular Pathways: SWI/SNF (BAF) Complexes Are Frequently Mutated in Cancerâ€"Mechanisms and Potential Therapeutic Insights. Clinical Cancer Research, 2014, 20, 21-27.	3.2	166
520	Tumor cellâ€specific inhibition of <scp>MYC</scp> function using small molecule inhibitors of the <scp>HUWE</scp>1 ubiquitin ligase. EMBO Molecular Medicine, 2014, 6, 1525-1541.	3.3	92
521	Managing Advanced Colorectal Cancer: Have We Reached the PEAK With Current Therapies?. Journal of Clinical Oncology, 2014, 32, 2200-2202.	0.8	6

#	Article	IF	Citations
522	Microbiota organization is a distinct feature of proximal colorectal cancers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 18321-18326.	3.3	572
523	Contribution of cyclin D1 (CCND1) and E-cadherin (CDH1) alterations to colorectal cancer susceptibility: a caseâ€“control study. Tumor Biology, 2014, 35, 12059-12067.	0.8	22
524	Genome network medicine: innovation to overcome huge challenges in cancer therapy. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2014, 6, 201-208.	6.6	8
525	Microsatellite Instability Detection by Next Generation Sequencing. Clinical Chemistry, 2014, 60, 1192-1199.	1.5	333
526	<i>MLH1</i>constitutional and somatic methylation in patients with MLH1 negative tumors fulfilling the revised Bethesda criteria. Epigenetics, 2014, 9, 1431-1438.	1.3	22
527	Sequencing HNC: Emergence of Notch Signaling. , 2014, , 303-323.		0
528	FISH Oracle 2: a web server for integrative visualization of genomic data in cancer research. Journal of Clinical Bioinformatics, 2014, 4, 5.	1.2	5
529	Survival regression by data fusion. Systems Biomedicine (Austin, Tex), 2014, 2, 47-53.	0.7	3
530	Understanding Cancer at the Genomic Level. , 2014, , 89-112.		0
531	Biomarkers in Metastatic Colorectal Cancer. , 2014, , 1-25.		0
532	Expression QTL-based analyses reveal the mechanisms underlying colorectal cancer predisposition. Tumor Biology, 2014, 35, 12607-12611.	0.8	2
533	Population dynamics inside cancer biomass driven by repeated hypoxiaâ€reoxygenation cycles. Quantitative Biology, 2015, 2, 85-99.	0.3	12
534	Proteomics, genomics and transcriptomics: their emerging roles in the discovery and validation of colorectal cancer biomarkers. Expert Review of Proteomics, 2014, 11, 179-205.	1.3	31
535	iGPSe: A visual analytic system for integrative genomic based cancer patient stratification. BMC Bioinformatics, 2014, 15, 203.	1.2	20
536	1p36 deletion is a marker for tumour dissemination in microsatellite stable stage II-III colon cancer. BMC Cancer, 2014, 14, 872.	1.1	13
537	Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel. BMC Medical Genomics, 2014, 7, 62.	0.7	25
538	Levels of human replication factor C4, a clamp loader, correlate with tumor progression and predict the prognosis for colorectal cancer. Journal of Translational Medicine, 2014, 12, 320.	1.8	39
539	Onco-STS: a web-based laboratory information management system for sample and analysis tracking in oncogenomic experiments. Source Code for Biology and Medicine, 2014, 9, 25.	1.7	3

#	Article	IF	Citations
540	Deep sequencing of the X chromosome reveals the proliferation history of colorectal adenomas. Genome Biology, 2014, 15, 437.	3.8	1
541	A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma. Genome Medicine, 2014, 6, 105.	3.6	106
542	Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. Acta Neuropathologica Communications, 2014, 2, 167.	2.4	65
543	SMO Expression in Colorectal Cancer: Associations with Clinical, Pathological, and Molecular Features. Annals of Surgical Oncology, 2014, 21, 4164-4173.	0.7	24
544	Gamma Interferon-Induced Guanylate Binding Protein 1 Is a Novel Actin Cytoskeleton Remodeling Factor. Molecular and Cellular Biology, 2014, 34, 196-209.	1.1	67
545	Proteogenomic Analysis Reveals Unanticipated Adaptations of Colorectal Tumor Cells to Deficiencies in DNA Mismatch Repair. Cancer Research, 2014, 74, 387-397.	0.4	46
546	Machine learning methods in the computational biology of cancer. Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences, 2014, 470, 20140081.	1.0	23
547	Rapid Diagnosis and Staging of Colorectal Cancer via High-Resolution Magic Angle Spinning Nuclear Magnetic Resonance (HR-MAS NMR) Spectroscopy of Intact Tissue Biopsies. Annals of Surgery, 2014, 259, 1138-1149.	2.1	67
548	Polymerase Proofreading-Associated Polyposis. Diseases of the Colon and Rectum, 2014, 57, 396-397.	0.7	42
549	Morphologic and Molecular Characterization of Traditional Serrated Adenomas of the Distal Colon and Rectum. American Journal of Surgical Pathology, 2014, 38, 1290-1297.	2.1	60
550	Practicing Pathology in the Era of Big Data and Personalized Medicine. Applied Immunohistochemistry and Molecular Morphology, 2014, 22, 1-9.	0.6	47
551	DNA polymerases Î¶ and Rev1 mediate error-prone bypass of non-B DNA structures. Nucleic Acids Research, 2014, 42, 290-306.	6.5	93
552	NCG 4.0: the network of cancer genes in the era of massive mutational screenings of cancer genomes. Database: the Journal of Biological Databases and Curation, 2014, 2014, bau015.	1.4	50
553	The eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing data. Nucleic Acids Research, 2014, 42, e172-e172.	6.5	33
554	Genomic organization and evolution of double minutes/homogeneously staining regions with<i>MYC</i>amplification in human cancer. Nucleic Acids Research, 2014, 42, 9131-9145.	6.5	91
555	DNA Replication Error-Induced Extinction of Diploid Yeast. Genetics, 2014, 196, 677-691.	1.2	45
556	Optimal Time Intervals between Pre-Operative Radiotherapy or Chemoradiotherapy and Surgery in Rectal Cancer?. Frontiers in Oncology, 2014, 4, 50.	1.3	43
557	Changing the paradigm: circulating tumor DNA as a â€˜liquid biopsyâ€™ for clinical biomarker assessments. Clinical Investigation, 2014, 4, 1083-1093.	0.0	1

#	Article	IF	Citations
558	Wellness and Health Omics Linked to the Environment: The WHOLE Approach to Personalized Medicine. Advances in Experimental Medicine and Biology, 2014, 799, 1-14.	0.8	8
559	Ion channel TRPV1-dependent activation of PTP1B suppresses EGFR-associated intestinal tumorigenesis. Journal of Clinical Investigation, 2014, 124, 3793-3806.	3.9	63
560	Genome-wide analysis associates familial colorectal cancer with increases in copy number variations and a rare structural variation at 12p12.3. Carcinogenesis, 2014, 35, 315-323.	1.3	31
561	Colorectal Cancers. , 2014, , 593-610.		2
562	Clinical Application of Whole-Genome Sequencing. JAMA - Journal of the American Medical Association, 2014, 311, 1017.	3.8	54
563	Updating the Wnt pathways. Bioscience Reports, 2014, 34, .	1.1	67
564	Inhibitory effects of Dendrobium candidum Wall ex Lindl. on azoxymethane- and dextran sulfate sodium-induced colon carcinogenesis in C57BL/6 mice. Oncology Letters, 2014, 7, 493-498.	0.8	30
565	Spatial and temporal cancer evolution: causes and consequences of tumour diversity. Clinical Medicine, 2014, 14, s33-s37.	0.8	23
566	Tumor LINE-1 Methylation Level and Microsatellite Instability in Relation to Colorectal Cancer Prognosis. Journal of the National Cancer Institute, 2014, 106, .	3.0	58
567	Sequencing in Cancer. , 2014, , 33-61.		0
568	The TCF C-clamp DNA binding domain expands the Wnt transcriptome via alternative target recognition. Nucleic Acids Research, 2014, 42, 13615-13632.	6.5	34
569	Opposite variation tendencies of serum CA724 levels in patients with colon and rectal carcinoma. Molecular and Clinical Oncology, 2014, 2, 139-145.	0.4	5
570	STAT3: An Anti-Invasive Factor in Colorectal Cancer?. Cancers, 2014, 6, 1394-1407.	1.7	11
571	Prognostic Significance of ÃŽÂ²-Catenin, E-Cadherin, and SOX9 in Colorectal Cancer: Results from a Large Population-Representative Series. Frontiers in Oncology, 2014, 4, 118.	1.3	63
572	Whole exome sequencing for cancer – is there evidence of clinical utility?. Advances in Genomics and Genetics, 2014, , 115.	0.8	2
573	Aberrant gene expression in mucosa adjacent to tumor reveals a molecular crosstalk in colon cancer. Molecular Cancer, 2014, 13, 46.	7.9	108
574	Structure-based predictions broadly link transcription factor mutations to gene expression changes in cancers. Nucleic Acids Research, 2014, 42, 12973-12983.	6.5	5
575	Reprogramming of the human intestinal epigenome by surgical tissue transposition. Genome Research, 2014, 24, 545-553.	2.4	16

#	Article	IF	Citations
576	Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer. Cancer Letters, 2014, 342, 159-166.	3.2	33
577	Colorectal Carcinomas With CpG Island Methylator Phenotype 1 Frequently Contain Mutations in Chromatin Regulators. Gastroenterology, 2014, 146, 530-538.e5.	0.6	76
578	Differential expression of microRNA-320a, -145, andÂ-192 along the continuum of normal mucosa to high-grade dysplastic adenomas of the colorectum. American Journal of Surgery, 2014, 207, 717-722.	0.9	11
579	The APC Network Regulates the Removal of Mutated Cells from Colonic Crypts. Cell Reports, 2014, 7, 94-103.	2.9	19
580	Colon carcinogenesis: Influence of Western diet-induced obesity and targeting stem cells using dietary bioactive compounds. Nutrition, 2014, 30, 1242-1256.	1.1	49
581	Differences in DNA Methylation Signatures Reveal Multiple Pathways of Progression From Adenoma to Colorectal Cancer. Gastroenterology, 2014, 147, 418-429.e8.	0.6	170
582	Personalizing Therapy for Colorectal Cancer. Clinical Gastroenterology and Hepatology, 2014, 12, 139-144.	2.4	25
583	Activating Mutations in PTPN3 Promote Cholangiocarcinoma Cell Proliferation and Migration and Are Associated With Tumor Recurrence in Patients. Gastroenterology, 2014, 146, 1397-1407.	0.6	111
584	MicroRNA-135b Promotes Cancer Progression by Acting as a Downstream Effector of Oncogenic Pathways in Colon Cancer. Cancer Cell, 2014, 25, 469-483.	7.7	267
585	Lack of anti-tumor activity with the Î²-catenin expression inhibitor EZN-3892 in the C57BL/6J Min/+ model of intestinal carcinogenesis. Biochemical and Biophysical Research Communications, 2014, 444, 283-289.	1.0	1
586	Frequent POLE1 p.S297F mutation in Chinese patients with ovarian endometrioid carcinoma. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2014, 761, 49-52.	0.4	24
587	Adjuvant chemotherapy for rectal cancer. Lancet Oncology, The, 2014, 15, e194-e195.	5.1	4
588	Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelialâ€toâ€mesenchymal transition. International Journal of Cancer, 2014, 134, 552-562.	2.3	286
589	Gene-centric content management system. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 77-81.	1.1	7
590	Familial Colorectal Cancer, Beyond Lynch Syndrome. Clinical Gastroenterology and Hepatology, 2014, 12, 1059-1068.	2.4	70
591	Omics-based nanomedicine: The future of personalized oncology. Cancer Letters, 2014, 352, 126-136.	3.2	75
592	Distinct patterns of DNA methylation in conventional adenomas involving the right and left colon. Modern Pathology, 2014, 27, 145-155.	2.9	40
593	Strategies in the Multidisciplinary Management of Synchronous Colorectal Cancer and Resectable Liver Metastases. Current Colorectal Cancer Reports, 2014, 10, 227-238.	1.0	1

#	Article	IF	Citations
594	Germline CDH1 mutations in bilateral lobular carcinoma in situ. British Journal of Cancer, 2014, 110, 1053-1057.	2.9	70
595	Replicative DNA polymerase mutations in cancer. Current Opinion in Genetics and Development, 2014, 24, 107-113.	1.5	92
596	Stressâ€induced cellular adaptive strategies: Ancient evolutionarily conserved programs as new anticancer therapeutic targets. BioEssays, 2014, 36, 552-560.	1.2	9
597	Masking Epistasis Between MYC and TGF-Î² Pathways in Antiangiogenesis-Mediated Colon Cancer Suppression. Journal of the National Cancer Institute, 2014, 106, dju043.	3.0	15
598	The impact of germline mutations on targeted therapy. Journal of Pathology, 2014, 232, 230-243.	2.1	7
599	<scp>DNA</scp> content analysis of colorectal cancer defines a distinct â€˜microsatellite and chromosome stableâ€™ group but does not predict response to radiotherapy. International Journal of Experimental Pathology, 2014, 95, 16-23.	0.6	7
600	Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Current Opinion in Genetics and Development, 2014, 24, 52-60.	1.5	393
601	Cancer Systems Biology: a peek into the future of patient care?. Nature Reviews Clinical Oncology, 2014, 11, 167-176.	12.5	159
602	Profiling proteoforms: promising follow-up of proteomics for biomarker discovery. Expert Review of Proteomics, 2014, 11, 121-129.	1.3	44
603	Integrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls. Nature Biotechnology, 2014, 32, 246-251.	9.4	722
604	Detection of a Recurrent <i>DNAJB1-PRKACA</i> Chimeric Transcript in Fibrolamellar Hepatocellular Carcinoma. Science, 2014, 343, 1010-1014.	6.0	388
605	NOTCH1 Mutations Occur Early during Cutaneous Squamous Cell Carcinogenesis. Journal of Investigative Dermatology, 2014, 134, 2630-2638.	0.3	287
606	Parallel states of pathological Wnt signaling in neonatal brain injury and colon cancer. Nature Neuroscience, 2014, 17, 506-512.	7.1	98
607	Genetic unraveling of colorectal cancer. Tumor Biology, 2014, 35, 5067-5082.	0.8	17
608	Genetic variation in vitamin D-related genes and risk of colorectal cancer in African Americans. Cancer Causes and Control, 2014, 25, 561-570.	0.8	46
609	Aberrant DNA methylation reprogramming during induced pluripotent stem cell generation is dependent on the choice of reprogramming factors. Cell Regeneration, 2014, 3, 3:4.	1.1	22
610	A panel of genes methylated with high frequency in colorectal cancer. BMC Cancer, 2014, 14, 54.	1.1	138
611	TP53 alterations and colorectal cancer predisposition in south Indian population: A case-control study. Tumor Biology, 2014, 35, 2303-2311.	0.8	17

#	Article	IF	Citations
612	Mouse models of cancer: Sleeping Beauty transposons for insertional mutagenesis screens and reverse genetic studies. Seminars in Cell and Developmental Biology, 2014, 27, 86-95.	2.3	22
613	Predictive utility of cyclo-oxygenase-2 expression by colon and rectal cancer. American Journal of Surgery, 2014, 207, 712-716.	0.9	12
614	RET revisited: expanding the oncogenic portfolio. Nature Reviews Cancer, 2014, 14, 173-186.	12.8	414
615	<i>KRAS</i> Codon 12 and 13 Mutations in Relation to Disease-Free Survival in <i>BRAF</i>â€"Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance). Clinical Cancer Research, 2014, 20, 3033-3043.	3.2	129
617	Laying a solid foundation for Manhattan â€" â€˜setting the functional basis for the post-GWAS eraâ€™. Trends in Genetics, 2014, 30, 140-149.	2.9	84
618	Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature, 2014, 506, 445-450.	13.7	521
619	MicroRNAâ€31 expression in relation to <i>BRAF</i> mutation, CpG island methylation and colorectal continuum in serrated lesions. International Journal of Cancer, 2014, 135, 2507-2515.	2.3	45
620	Thymine DNA Glycosylase Is a Positive Regulator of Wnt Signaling in Colorectal Cancer. Journal of Biological Chemistry, 2014, 289, 8881-8890.	1.6	22
621	Up-regulation of Neutrophil Gelatinase-Associated Lipocalin in Colorectal Cancer Predicts Poor Patient Survival. World Journal of Surgery, 2014, 38, 2160-2167.	0.8	17
622	Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nature Reviews Clinical Oncology, 2014, 11, 260-271.	12.5	218
623	Hypermutable DNA chronicles the evolution of human colon cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E1889-98.	3.3	35
624	Cancer Cell Lines for Drug Discovery and Development. Cancer Research, 2014, 74, 2377-2384.	0.4	324
625	HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome. European Journal of Cancer, 2014, 50, 656-662.	1.3	43
626	From Breaking Bad to Worse: Exploiting Homologous DNA Repair Deficiency in Cancer. Cancer Discovery, 2014, 4, 516-518.	7.7	7
627	Wnt of the Two Horizons: Putting Stem Cell Self-Renewal and Cell Fate Determination into Context. Stem Cells and Development, 2014, 23, 1975-1990.	1.1	9
628	Molecular Testing in Cancer. , 2014, , .		2
629	Obesity, Rather Than Diet, Drives Epigenomic Alterations in Colonic Epithelium Resembling Cancer Progression. Cell Metabolism, 2014, 19, 702-711.	7.2	61
630	Pharmacogenomics and Personalized Medicines in Cancer Treatment. , 2014, , 55-90.		0

#	Article	IF	Citations
631	Rectal cancer genomics. Seminars in Colon and Rectal Surgery, 2014, 25, 13-18.	0.2	1
632	Genomics of Colorectal Cancer. , 2014, , 247-264.		2
633	Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. Nature Genetics, 2014, 46, 613-617.	9.4	211
634	Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients. Clinical Cancer Research, 2014, 20, 265-272.	3.2	36
635	Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nature Genetics, 2014, 46, 573-582.	9.4	895
636	Up-regulation of NEK2 by MicroRNA-128 Methylation is Associated with Poor Prognosis in Colorectal Cancer. Annals of Surgical Oncology, 2014, 21, 205-212.	0.7	70
637	TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade. Human Mutation, 2014, 35, 672-688.	1.1	294
639	The potential of targeting Wnt/Î²-catenin in colon cancer. Expert Opinion on Therapeutic Targets, 2014, 18, 611-615.	1.5	198
640	Large-scale genetic study in East Asians identifies six new loci associated with colorectal cancer risk. Nature Genetics, 2014, 46, 533-542.	9.4	212
641	Colorectal cancer risk and patientsâ€™ survival: influence of polymorphisms in genes somatically mutated in colorectal tumors. Cancer Causes and Control, 2014, 25, 759-769.	0.8	15
642	RSPO2â€“LGR5 signaling has tumour-suppressive activity in colorectal cancer. Nature Communications, 2014, 5, 3149.	5.8	101
643	Transcriptomes and shRNA Suppressors in a <i>TP53</i> Alleleâ€“Specific Model of Early-Onset Colon Cancer in African Americans. Molecular Cancer Research, 2014, 12, 1029-1041.	1.5	15
644	A Common Cancer-Associated DNA Polymerase Ïµ Mutation Causes an Exceptionally Strong Mutator Phenotype, Indicating Fidelity Defects Distinct from Loss of Proofreading. Cancer Research, 2014, 74, 1895-1901.	0.4	113
645	STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy <i>in vitro</i> and <i>in vivo</i>. International Journal of Cancer, 2014, 134, 997-1007.	2.3	111
646	Emerging roles of the microbiome in cancer. Carcinogenesis, 2014, 35, 249-255.	1.3	202
647	Reduced expression of the chromatin remodeling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcription. Carcinogenesis, 2014, 35, 867-876.	1.3	107
648	Palliative Treatment of Metastatic Colorectal Cancer: What is the Optimal Approach?. Current Oncology Reports, 2014, 16, 363.	1.8	9
649	DNA Testing and Molecular Screening for Colon Cancer. Clinical Gastroenterology and Hepatology, 2014, 12, 377-381.	2.4	32

#	Article	IF	Citations
650	The molecular rationale of Src inhibition in colorectal carcinomas. International Journal of Cancer, 2014, 134, 2019-2029.	2.3	43
651	AmphoraNet: The webserver implementation of the AMPHORA2 metagenomic workflow suite. Gene, 2014, 533, 538-540.	1.0	98
652	Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nature Reviews Cancer, 2014, 14, 135-146.	12.8	925
653	Mining cancer methylomes: prospects and challenges. Trends in Genetics, 2014, 30, 75-84.	2.9	180
654	MicroRNA-29a promotes colorectal cancer metastasis by regulating matrix metalloproteinase 2 and E-cadherin via KLF4. British Journal of Cancer, 2014, 110, 450-458.	2.9	159
655	The evolution of the unstable cancer genome. Current Opinion in Genetics and Development, 2014, 24, 61-67.	1.5	62
656	Genomic insights into WNT/Î²-catenin signaling. Trends in Pharmacological Sciences, 2014, 35, 103-109.	4.0	99
657	Age-related epigenetic drift in the pathogenesis of MDS and AML. Genome Research, 2014, 24, 580-591.	2.4	76
658	Targeting the Wnt pathway in zebrafish as a screening method to identify novel therapeutic compounds. Experimental Biology and Medicine, 2014, 239, 169-176.	1.1	10
659	Wnt signaling in adult intestinal stem cells and cancer. Cellular Signalling, 2014, 26, 570-579.	1.7	307
660	Molecularly targeted cancer therapy: some lessons from the past decade. Trends in Pharmacological Sciences, 2014, 35, 41-50.	4.0	255
661	Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncology, The, 2014, 15, e8-e21.	5.1	413
662	Simultaneous identification and prioritization of variants in familial, de novo, and somatic genetic disorders with VariantMaster. Genome Research, 2014, 24, 349-355.	2.4	36
663	Adenomatous polyposis coli (<scp>APC</scp>) membrane recruitmentÂ3, a member of the <scp>APC</scp> membrane recruitment family of <scp>APC</scp>â€binding proteins, is a positive regulator of <scp>Wnt</scp>â€“Î²â€catenin signalling. FEBS Journal, 2014, 281, 787-801.	2.2	19
664	Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer. Pharmacogenomics, 2014, 15, 1043-1052.	0.6	16
665	Somatic mutation as a mechanism of Wnt/Î²-catenin pathway activation in CLL. Blood, 2014, 124, 1089-1098.	0.6	65
666	Epigenetic mechanisms in the pathogenesis ofÂLynch syndrome. Clinical Genetics, 2014, 85, 403-412.	1.0	44
667	A Genome-wide View of Microsatellite Instability: Old Stories of Cancer Mutations Revisited with New Sequencing Technologies. Cancer Research, 2014, 74, 6377-6382.	0.4	17

#	Article	IF	Citations
668	Clinical Significance of CTNNB1 Mutation and Wnt Pathway Activation in Endometrioid Endometrial Carcinoma. Journal of the National Cancer Institute, 2014, 106, .	3.0	182
669	Tubulin glycylases are required for primary cilia, control of cell proliferation and tumor development in colon. EMBO Journal, 2014, 33, 2247-2260.	3.5	82
670	Sequential expression of <scp>miR</scp>â€182 and <scp>miR</scp>â€503 cooperatively targets <scp>FBXW7</scp>, contributing to the malignant transformation of colon adenoma to adenocarcinoma. Journal of Pathology, 2014, 234, 488-501.	2.1	59
671	The TPM3â€NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Molecular Oncology, 2014, 8, 1495-1507.	2.1	128
672	A nineteen geneâ€based risk score classifier predicts prognosis of colorectal cancer patients. Molecular Oncology, 2014, 8, 1653-1666.	2.1	136
673	The Role of Predictive Molecular Biomarkers for the Treatment of Metastatic Colorectal Cancer. Current Colorectal Cancer Reports, 2014, 10, 395-402.	1.0	4
674	A randomized, phase II study of the antiâ€insulinâ€like growth factor receptor type 1 (IGFâ€1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer. Cancer Medicine, 2014, 3, 988-997.	1.3	22
675	High Frequency of<i>RPL22</i>Mutations in Microsatellite-Unstable Colorectal and Endometrial Tumors. Human Mutation, 2014, 35, 1442-1445.	1.1	38
676	Optimization of Anti-EGFR Treatment of Advanced Colorectal Cancer. Current Colorectal Cancer Reports, 2014, 10, 263-271.	1.0	1
677	Analysis of protein partners of the human nucleolar protein SURF6 in HeLa cells by a GST pull-down assay. Russian Journal of Bioorganic Chemistry, 2014, 40, 390-400.	0.3	1
678	Validation of the 12-Gene Colon Cancer Recurrence Score as a Predictor of Recurrence Risk in Stage II and III Rectal Cancer Patients. Journal of the National Cancer Institute, 2014, 106, .	3.0	17
679	Scoring the Recurrence Score in Rectal Cancer. Journal of the National Cancer Institute, 2014, 106, dju295-dju295.	3.0	0
680	So Much Effort, So Little Progress?. Journal of the National Cancer Institute, 2014, 106, .	3.0	5
681	AXIN1 and AXIN2 variants in gastrointestinal cancers. Cancer Letters, 2014, 355, 1-8.	3.2	109
682	BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer, 2014, 120, 2316-2324.	2.0	170
683	A Role for the Mitochondrial Pyruvate Carrier as a Repressor of the Warburg Effect and Colon Cancer Cell Growth. Molecular Cell, 2014, 56, 400-413.	4.5	294
684	Opposing activities of the <scp>R</scp> as and <scp>H</scp> ippo pathways converge on regulation of <scp>YAP</scp> protein turnover. EMBO Journal, 2014, 33, 2447-2457.	3.5	102
685	DNA methylation changes in genes frequently mutated in sporadic colorectal cancer and in the DNA repair and Wnt/Î²-catenin signaling pathway genes. Epigenomics, 2014, 6, 179-191.	1.0	55

#	Article	IF	Citations
686	MultiNotch MS3 Enables Accurate, Sensitive, and Multiplexed Detection of Differential Expression across Cancer Cell Line Proteomes. Analytical Chemistry, 2014, 86, 7150-7158.	3.2	1,130
687	Pan-cancer patterns of DNA methylation. Genome Medicine, 2014, 6, 66.	3.6	149
688	Germline Mutation of RPS20, Encoding a Ribosomal Protein, Causes Predisposition to Hereditary Nonpolyposis Colorectal Carcinoma Without DNA Mismatch Repair Deficiency. Gastroenterology, 2014, 147, 595-598.e5.	0.6	143
689	Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication. Genome Research, 2014, 24, 1740-1750.	2.4	244
690	VDI healthcare management: Surgical oncology, management model and formalization of knowledge: Case studies CRC (colorectal cancer). , 2014, , .		0
691	Iro/IRX transcription factors negatively regulate <scp>D</scp>pp/<scp>TGF</scp>â€Î² pathway activity during intestinal tumorigenesis. EMBO Reports, 2014, 15, 1210-1218.	2.0	28
692	Tumor Suppression by the Fbw7ÂUbiquitin Ligase: Mechanisms and Opportunities. Cancer Cell, 2014, 26, 455-464.	7.7	303
693	How Can Next-Generation Sequencing (Genomics) Help Us in Treating Colorectal Cancer?. Current Colorectal Cancer Reports, 2014, 10, 372-379.	1.0	6
694	Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. Genome Medicine, 2014, 6, 5.	3.6	186
695	Advancing clinical oncology through genome biology and technology. Genome Biology, 2014, 15, 427.	3.8	9
696	RNF43 is frequently mutated in colorectal and endometrial cancers. Nature Genetics, 2014, 46, 1264-1266.	9.4	388
697	Human embryonic stem cells show low-grade microsatellite instability. Molecular Human Reproduction, 2014, 20, 981-989.	1.3	10
698	Functional annotation of colon cancer risk SNPs. Nature Communications, 2014, 5, 5114.	5.8	98
699	Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors. Cancer Letters, 2014, 354, 12-20.	3.2	98
700	Endogenous Retroviruses and the Development of Cancer. Journal of Immunology, 2014, 192, 1343-1349.	0.4	156
701	SWI/SNF chromatin remodeling complexes and cancer. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2014, 166, 350-366.	0.7	155
702	HD Chromoendoscopy Coupled with DNA Mass Spectrometry Profiling Identifies Somatic Mutations in Microdissected Human Proximal Aberrant Crypt Foci. Molecular Cancer Research, 2014, 12, 823-829.	1.5	15
703	B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies. Haematologica, 2014, 99, 222-231.	1.7	52

#	Article	IF	Citations
704	Directions for the drivers. Nature, 2014, 512, 31-32.	13.7	3
705	Excess of Proximal Microsatellite-Stable Colorectal Cancer in African Americans from a Multiethnic Study. Clinical Cancer Research, 2014, 20, 4962-4970.	3.2	42
706	Novel Drug Candidates for the Treatment of Metastatic Colorectal Cancer through Global Inverse Gene-Expression Profiling. Cancer Research, 2014, 74, 5690-5699.	0.4	142
708	Inducible loss of one <i>Apc</i> allele in Lrig1-expressing progenitor cells results in multiple distal colonic tumors with features of familial adenomatous polyposis. American Journal of Physiology - Renal Physiology, 2014, 307, G16-G23.	1.6	53
709	Altered regulation of DNA ligase IV activity by aberrant promoter DNA methylation and gene amplification in colorectal cancer. Human Molecular Genetics, 2014, 23, 2043-2054.	1.4	15
710	Cancer driverâ€“passenger distinction via sporadic human and dog cancer comparison: a proof-of-principle study with colorectal cancer. Oncogene, 2014, 33, 814-822.	2.6	35
711	ArhGAP30 promotes p53 acetylation and function in colorectal cancer. Nature Communications, 2014, 5, 4735.	5.8	55
712	Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nature Reviews Cancer, 2014, 14, 455-467.	12.8	683
713	Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nature Medicine, 2014, 20, 769-777.	15.2	349
714	PCNA and Msh2-Msh6 Activate an Mlh1-Pms1 Endonuclease Pathway Required for Exo1-Independent Mismatch Repair. Molecular Cell, 2014, 55, 291-304.	4.5	89
715	Similarity network fusion for aggregating data types on a genomic scale. Nature Methods, 2014, 11, 333-337.	9.0	1,392
716	Progress Against GI Cancer During the American Society of Clinical Oncology's First 50 Years. Journal of Clinical Oncology, 2014, 32, 1521-1530.	0.8	36
717	Lean Big Data integration in systems biology and systems pharmacology. Trends in Pharmacological Sciences, 2014, 35, 450-460.	4.0	85
718	A Conserved Isoleucine Maintains the Inactive State of Bruton's Tyrosine Kinase. Journal of Molecular Biology, 2014, 426, 3656-3669.	2.0	10
719	Human symptomsâ€“disease network. Nature Communications, 2014, 5, 4212.	5.8	557
720	Cancer-associated Isocitrate Dehydrogenase 1 (IDH1) R132H Mutation and d-2-Hydroxyglutarate Stimulate Glutamine Metabolism under Hypoxia. Journal of Biological Chemistry, 2014, 289, 23318-23328.	1.6	81
721	KRAS and Cancer Stem Cells in APC-Mutant Colorectal Cancer. Journal of the National Cancer Institute, 2014, 106, djt444-djt444.	3.0	13
722	Seminal plasma as a diagnostic fluid for male reproductive system disorders. Nature Reviews Urology, 2014, 11, 278-288.	1.9	159

#	Article	IF	Citations
723	Mutations in POLE and survival of colorectal cancer patients â€“ link to disease stage and treatment. Cancer Medicine, 2014, 3, 1527-1538.	1.3	56
724	Wnt-induced transcriptional activation is exclusively mediated by TCF/LEF. EMBO Journal, 2014, 33, 146-156.	3.5	157
725	Putative cis-regulatory drivers in colorectal cancer. Nature, 2014, 512, 87-90.	13.7	136
726	Comprehensive molecular characterization of gastric adenocarcinoma. Nature, 2014, 513, 202-209.	13.7	5,055
727	Proteogenomic characterization of human colon and rectal cancer. Nature, 2014, 513, 382-387.	13.7	1,219
728	Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. Science, 2014, 345, 1251343.	6.0	348
729	Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends in Genetics, 2014, 30, 326-339.	2.9	230
730	Transcriptional Dynamics in Colorectal Carcinogenesis: New Insights into the Role of c-Myc and miR17 in Benign to Cancer Transformation. Cancer Research, 2014, 74, 5532-5540.	0.4	19
731	TP53, MSH4, and LATS1 Germline Mutations in a Family with Clustering of Nervous System Tumors. American Journal of Pathology, 2014, 184, 2374-2381.	1.9	22
732	Ischemia in Tumors Induces Early and Sustained Phosphorylation Changes in Stress Kinase Pathways but Does Not Affect Global Protein Levels. Molecular and Cellular Proteomics, 2014, 13, 1690-1704.	2.5	323
733	Mutational Signatures in Helicobacter pyloriâ€“induced Gastric Cancer: Lessons From New Sequencing Technologies. Gastroenterology, 2014, 147, 267-269.	0.6	11
734	WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 188-200.	3.3	89
735	Alzheimer's disease under strain. Nature, 2014, 512, 32-34.	13.7	32
736	Role of DNA damage response pathways in preventing carcinogenesis caused by intrinsic replication stress. Oncogene, 2014, 33, 3688-3695.	2.6	19
737	Epiviz: interactive visual analytics for functional genomics data. Nature Methods, 2014, 11, 938-940.	9.0	59
738	Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. Cell, 2014, 158, 929-944.	13.5	1,242
739	Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Annals of Oncology, 2014, 25, 1995-2001.	0.6	498
740	Cancer Genomics and Inherited Risk. Journal of Clinical Oncology, 2014, 32, 687-698.	0.8	121

#	Article	IF	Citations
741	Profiling Cancer Gene Mutations in Clinical Formalin-Fixed, Paraffin-Embedded Colorectal Tumor Specimens Using Targeted Next-Generation Sequencing. Oncologist, 2014, 19, 336-343.	1.9	52
742	Progress and Opportunities in Molecular Pathological Epidemiology of Colorectal Premalignant Lesions. American Journal of Gastroenterology, 2014, 109, 1205-1214.	0.2	55
743	Patterns of somatic alterations between matched primary and metastatic colorectal tumors characterized by whole-genome sequencing. Genomics, 2014, 104, 234-241.	1.3	58
744	The Biology of YAP/TAZ: Hippo Signaling and Beyond. Physiological Reviews, 2014, 94, 1287-1312.	13.1	1,336
745	CUX1, a haploinsufficient tumour suppressor gene overexpressed in advanced cancers. Nature Reviews Cancer, 2014, 14, 673-682.	12.8	100
746	Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution. Cancer Discovery, 2014, 4, 1269-1280.	7.7	415
747	Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer-associated cryptic promoters and somatically acquired regulatory elements. Nature Communications, 2014, 5, 4361.	5.8	72
748	Gene network-based analysis identifies two potential subtypes of small intestinal neuroendocrine tumors. BMC Genomics, 2014, 15, 595.	1.2	33
749	Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study. BMC Cancer, 2014, 14, 486.	1.1	76
750	Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver. BMC Cancer, 2014, 14, 518.	1.1	204
751	Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Molecular Cancer, 2014, 13, 141.	7.9	24
752	Whole genome sequencing reveals potential targets for therapy in patients with refractory KRASmutated metastatic colorectal cancer. BMC Medical Genomics, 2014, 7, 36.	0.7	18
753	Returning individual research results for genome sequences of pancreatic cancer. Genome Medicine, 2014, 6, 42.	3.6	25
754	Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin. Genome Medicine, 2014, 6, 43.	3.6	94
755	KeyPathwayMiner 4.0: condition-specific pathway analysis by combining multiple omics studies and networks with Cytoscape. BMC Systems Biology, 2014, 8, 99.	3.0	59
756	Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer. Genome Biology, 2014, 15, 429.	3.8	179
757	SeqControl: process control for DNA sequencing. Nature Methods, 2014, 11, 1071-1075.	9.0	10
758	Long non-coding RNAs in colorectal cancer: implications for pathogenesis and clinical application. Modern Pathology, 2014, 27, 1310-1320.	2.9	101

#	Article	IF	Citations
759	Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack. Biotechnology Journal, 2014, 9, 1104-1114.	1.8	43
760	Next-generation sequencing technologies: breaking the sound barrier of human genetics. Mutagenesis, 2014, 29, 303-310.	1.0	106
761	Cancer: Evolution Within a Lifetime. Annual Review of Genetics, 2014, 48, 215-236.	3.2	196
762	Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study. British Journal of Cancer, 2014, 110, 2728-2737.	2.9	20
763	Mouse knockout models for HIV-1 restriction factors. Cellular and Molecular Life Sciences, 2014, 71, 3749-3766.	2.4	16
764	High-resolution analysis of DNA copy number alterations in rectal cancer. Strahlentherapie Und Onkologie, 2014, 190, 1028-1036.	1.0	4
766	Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. Journal of Molecular Medicine, 2014, 92, 709-722.	1.7	75
767	The first mouse mutants of D14Abb1e (Fam208a) show that it is critical for early development. Mammalian Genome, 2014, 25, 293-303.	1.0	30
768	Combined analysis of biomarkers of proliferation and apoptosis in colon cancer: an immunohistochemistry-based study using tissue microarray. International Journal of Colorectal Disease, 2014, 29, 1043-1052.	1.0	9
769	A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck. Investigational New Drugs, 2014, 32, 1197-1203.	1.2	22
770	Biological significance of the CpG island methylator phenotype. Biochemical and Biophysical Research Communications, 2014, 455, 35-42.	1.0	86
771	Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisited. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 201-215.	3.3	89
772	Where cancer genomics should go next: a clinician's perspective. Human Molecular Genetics, 2014, 23, R69-R75.	1.4	13
773	IGF2 DMR0 Methylation, Loss of Imprinting, and Patient Prognosis in Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2014, 21, 1166-1174.	0.7	20
774	Clinical Relevance of Alterations in Quantity and Quality of Plasma DNA in Colorectal Cancer Patients: Based on the Mutation Spectra Detected in Primary Tumors. Annals of Surgical Oncology, 2014, 21, 680-686.	0.7	60
775	Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway. British Journal of Cancer, 2014, 110, 946-957.	2.9	87
776	Epigenetic modifications in colorectal cancer: Molecular insights and therapeutic challenges. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 971-980.	1.8	98
777	A de novo germline mutation of APC for inheritable colon cancer in a Chinese family using multigene next generation sequencing. Biochemical and Biophysical Research Communications, 2014, 447, 503-507.	1.0	10

#	Article	IF	Citations
778	A new generation of companion diagnostics: cobasBRAF, KRASandEGFRmutation detection tests. Expert Review of Molecular Diagnostics, 2014, 14, 517-524.	1.5	22
779	Recent advances in personalized colorectal cancer research. Cancer Letters, 2014, 347, 15-21.	3.2	50
780	Stem Cells in Cancer: Should We Believe or Not?. , 2014, , .		2
781	Sinonasal carcinoma: clinical, pathological, genetic and therapeutic advances. Nature Reviews Clinical Oncology, 2014, 11, 460-472.	12.5	200
782	Inferring primary tumor sites from mutation spectra: a meta-analysis of histology-specific aberrations in cancer-derived cell lines. Human Molecular Genetics, 2014, 23, 1527-1537.	1.4	19
783	Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer. Cancer Letters, 2014, 347, 204-211.	3.2	36
784	Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nature Biotechnology, 2014, 32, 644-652.	9.4	257
785	A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC) Tj ETQq1 1 0.784314 rgBT /Over Journal of Cancer, 2014, 110, 2178-2186.	2.9	27
786	Whole genome gene copy number profiling of gastric cancer identifies <i>PAK1</i> and <i>KRAS</i> gene amplification as therapy targets. Genes Chromosomes and Cancer, 2014, 53, 883-894.	1.5	69
787	The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes. Nature Communications, 2014, 5, 3963.	5.8	143
788	Expanding the computational toolbox for mining cancer genomes. Nature Reviews Genetics, 2014, 15, 556-570.	7.7	166
789	Statistical Analysis of Next Generation Sequencing Data. , 2014, , .		20
790	Prognosis and Therapeutic Implications for Emerging Colorectal Cancer Subtypes. Current Colorectal Cancer Reports, 2014, 10, 55-61.	1.0	4
791	Environmental Exposure and Tumor Heterogeneity in Colorectal Cancer Risk and Outcomes. Current Colorectal Cancer Reports, 2014, 10, 94-104.	1.0	11
792	Can We Predict Response and/or Resistance to Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer?. Current Colorectal Cancer Reports, 2014, 10, 164-172.	1.0	4
793	Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1. Molecular Cancer, 2014, 13, 103.	7.9	102
794	Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Molecular Cancer, 2014, 13, 135.	7.9	121
795	Patterns and processes of somatic mutations in nine major cancers. BMC Medical Genomics, 2014, 7, 11.	0.7	57

#	Article	IF	Citations
796	MicroRNA expression signatures for the prediction of BRCA1/2 mutationâ€associated hereditary breast cancer in paraffinâ€embedded formalinâ€fixed breast tumors. International Journal of Cancer, 2015, 136, 593-602.	2.3	43
797	Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway. Carcinogenesis, 2014, 35, 776-783.	1.3	94
798	Whole-exome sequencing of endometriosis identifies frequent alterations in genes involved in cell adhesion and chromatin-remodeling complexes. Human Molecular Genetics, 2014, 23, 6008-6021.	1.4	59
799	The Disparate Twins: A Comparative Study of CXCR4 and CXCR7 in SDF-1Î±â€"Induced Gene Expression, Invasion and Chemosensitivity of Colon Cancer. Clinical Cancer Research, 2014, 20, 604-616.	3.2	47
800	Mechanisms underlying mutational signatures in human cancers. Nature Reviews Genetics, 2014, 15, 585-598.	7.7	703
801	Mutations in Exon 1 Highlight the Role of<i>MED12</i>in Uterine Leiomyomas. Human Mutation, 2014, 35, 1136-1141.	1.1	67
802	c-Src drives intestinal regeneration and transformation. EMBO Journal, 2014, 33, 1474-91.	3.5	56
803	An analysis of genetic factors related to risk of inflammatory bowel disease and colon cancer. Cancer Epidemiology, 2014, 38, 583-590.	0.8	26
804	FXR silencing in human colon cancer by DNA methylation and KRAS signaling. American Journal of Physiology - Renal Physiology, 2014, 306, G48-G58.	1.6	64
805	Colon and Endometrial Cancers With Mismatch Repair Deficiency Can Arise From Somatic, Rather Than Germline, Mutations. Gastroenterology, 2014, 147, 1308-1316.e1.	0.6	328
806	Genome-wide analysis of DNA methylation in UVB- and DMBA/TPA-induced mouse skin cancer models. Life Sciences, 2014, 113, 45-54.	2.0	20
808	Animal models of gastrointestinal and liver diseases. New mouse models for studying dietary prevention of colorectal cancer. American Journal of Physiology - Renal Physiology, 2014, 307, G249-G259.	1.6	8
809	Sestrins Function as Guanine Nucleotide Dissociation Inhibitors for Rag GTPases to Control mTORC1 Signaling. Cell, 2014, 159, 122-133.	13.5	194
810	Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04. Journal of Clinical Oncology, 2014, 32, 1927-1934.	0.8	373
811	SLAP displays tumour suppressor functions in colorectal cancer via destabilization of the SRC substrate EPHA2. Nature Communications, 2014, 5, 3159.	5.8	32
812	A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nature Communications, 2014, 5, 3887.	5.8	456
813	miRâ€203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. Molecular Oncology, 2014, 8, 83-92.	2.1	156
814	PHLPP Is a Negative Regulator of RAF1, Which Reduces Colorectal Cancer Cell Motility and Prevents Tumor Progression in Mice. Gastroenterology, 2014, 146, 1301-1312.e10.	0.6	82

#	Article	IF	Citations
815	Expression of Lgr5, a marker of intestinal stem cells, in colorectal cancer and its clinicopathological significance. Biomedicine and Pharmacotherapy, 2014, 68, 507-513.	2.5	58
816	Stratification and delineation of gastric cancer signaling by in vitro transcription factor activity profiling and integrative genomics. Cellular Signalling, 2014, 26, 880-894.	1.7	11
817	An integrative framework identifies alternative splicing events in colorectal cancer development. Molecular Oncology, 2014, 8, 129-141.	2.1	43
818	ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma. European Journal of Cancer, 2014, 50, 1740-1746.	1.3	79
819	Decoding complex patterns of genomic rearrangement in hepatocellular carcinoma. Genomics, 2014, 103, 189-203.	1.3	49
820	Incorporating inter-relationships between different levels of genomic data into cancer clinical outcome prediction. Methods, 2014, 67, 344-353.	1.9	30
821	Colorectal cancer progression: Lessons from Drosophila?. Seminars in Cell and Developmental Biology, 2014, 28, 70-77.	2.3	25
822	Collection, integration and analysis of cancer genomic profiles: from data to insight. Current Opinion in Genetics and Development, 2014, 24, 92-98.	1.5	22
823	Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer, 2014, 120, 1482-1490.	2.0	63
824	Novel somatic and germline mutations in intracranial germ cell tumours. Nature, 2014, 511, 241-245.	13.7	181
825	The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis. Annals of Surgical Oncology, 2014, 21, 4195-4201.	0.7	141
826	Molecular Pathways: Targeting <i>NRAS</i> in Melanoma and Acute Myelogenous Leukemia. Clinical Cancer Research, 2014, 20, 4186-4192.	3.2	61
827	Colorectal Cancer Cell Lines Are Representative Models of the Main Molecular Subtypes of Primary Cancer. Cancer Research, 2014, 74, 3238-3247.	0.4	317
828	Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3110-3115.	3.3	736
829	Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia. Cancer Discovery, 2014, 4, 348-361.	7.7	135
830	DNA polymerase Îµ and its roles in genome stability. IUBMB Life, 2014, 66, 339-351.	1.5	70
831	Immune Escape and Survival Mechanisms in Circulating Tumor Cells of Colorectal Cancer. Cancer Research, 2014, 74, 1694-1704.	0.4	205
833	DNA Replication and Oncogene-Induced Replicative Stress. Current Biology, 2014, 24, R435-R444.	1.8	320

#	Article	IF	Citations
834	The <scp>MAPK</scp> pathway across different malignancies: A new perspective. Cancer, 2014, 120, 3446-3456.	2.0	752
835	Germline Mutations in Oncogene-Induced Senescence Pathways Are Associated With Multiple Sessile Serrated Adenomas. Gastroenterology, 2014, 146, 520-529.e6.	0.6	121
836	From genomes to societies: a holistic view of determinants of human health. Current Opinion in Biotechnology, 2014, 28, 134-142.	3.3	7
837	ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene, 2014, 33, 1828-1839.	2.6	145
838	PIK3CA and APC mutations are synergistic in the development of intestinal cancers. Oncogene, 2014, 33, 2245-2254.	2.6	56
839	Inactivation of TGF-Î² signaling and loss of PTEN cooperate to induce colon cancer in vivo. Oncogene, 2014, 33, 1538-1547.	2.6	66
840	Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene, 2014, 33, 1590-1600.	2.6	76
841	Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene, 2014, 33, 2949-2955.	2.6	114
842	PELO negatively regulates HER receptor signalling and metastasis. Oncogene, 2014, 33, 1190-1197.	2.6	13
843	Cripto haploinsufficiency affects in vivo colon tumor development. International Journal of Oncology, 2014, 45, 31-40.	1.4	10
845	Characterizing DNA methylation alterations from The Cancer Genome Atlas. Journal of Clinical Investigation, 2014, 124, 17-23.	3.9	162
846	Harnessing the potential of epigenetic therapy to target solid tumors. Journal of Clinical Investigation, 2014, 124, 56-63.	3.9	130
847	Vitamin D and colon cancer. World Journal of Gastrointestinal Oncology, 2014, 6, 430.	0.8	70
848	TCGA divides gastric cancer into four molecular subtypes: implications for individualized therapeutics. Chinese Journal of Cancer, 2014, 33, 469-70.	4.9	35
849	Expression profiles of 507 proteins from a biotin label-based antibody array in human colorectal cancer. Oncology Reports, 2014, 31, 1277-1281.	1.2	12
851	Management of colorectal cancer. F1000prime Reports, 2014, 6, 108.	5.9	86
852	A mutation in POLE predisposing to a multi-tumour phenotype. International Journal of Oncology, 2014, 45, 77-81.	1.4	61
853	Should mismatch repair status be determined in all stage II and III colon cancer patients?. Colorectal Cancer, 2014, 3, 321-329.	0.8	0

#	Article	IF	Citations
854	Differential expression of miRNAs in colon cancer between African and Caucasian Americans: Implications for cancer racial health disparities. International Journal of Oncology, 2014, 45, 587-594.	1.4	61
857	Predictive Biomarkers for Anti-Epidermal Growth Factor Receptor Therapy: BeyondKRASTesting. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1433-1442.	2.3	6
858	A new model of time scheme for progression of colorectal cancer. BMC Systems Biology, 2014, 8, S2.	3.0	22
859	Biomarker-driven Studies in Metastatic Colorectal Cancer (mCRC): Challenges and Opportunities. The Journal of Oncopathology, 2014, 2, 37-45.	0.1	0
860	The biological and clinical challenge of liver cancer heterogeneity. Hepatic Oncology, 2014, 1, 349-353.	4.2	34
861	Comprehensive genomic analyses of a metastatic colon cancer to the lung by whole exome sequencing and gene expression analysis. International Journal of Oncology, 2014, 44, 211-221.	1.4	30
862	KRAS, NRAS, BRAF mutations and high counts of poorly differentiated clusters of neoplastic cells in colorectal cancer: observational analysis of 175 cases. Pathology, 2015, 47, 551-556.	0.3	27
863	Inhibition of autophagy exerts anti-colon cancer effects via apoptosis induced by p53 activation and ER stress. BMC Cancer, 2015, 15, 795.	1.1	38
864	Inferring regulatory element landscapes and transcription factor networks from cancer methylomes. Genome Biology, 2015, 16, 105.	13.9	178
865	MEK and PI3K inhibition in solid tumors: rationale and evidence to date. Therapeutic Advances in Medical Oncology, 2015, 7, 170-180.	1.4	105
866	The loss of MiR-139-5p promotes colitis-associated tumorigenesis by mediating PI3K/AKT/Wnt signaling. International Journal of Biochemistry and Cell Biology, 2015, 69, 153-161.	1.2	33
867	Protein phosphatase methylesteraseâ€1 (<scp>PME</scp>â€1) expression predicts a favorable clinical outcome in colorectal cancer. Cancer Medicine, 2015, 4, 1798-1808.	1.3	14
868	Mouse models of colorectal cancer as preclinical models. BioEssays, 2015, 37, 909-920.	1.2	59
869	The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer. Journal of Internal Medicine, 2015, 278, 545-570.	2.7	46
870	MicroRNA-144 inhibits migration and proliferation in rectal cancer by downregulating ROCK-1. Molecular Medicine Reports, 2015, 12, 7396-7402.	1.1	44
872	Phosphoproteomic profiling of tumor tissues identifies HSP27 Ser82 phosphorylation as a robust marker of early ischemia. Scientific Reports, 2015, 5, 13660.	1.6	11
873	Analysis of AC3-33 gene expression in multiple organ cancer and adjacent normal tissue by RNA in situ hybridization. Oncology Letters, 2015, 9, 2795-2798.	0.8	2
875	Colorectal cancer. Nature Reviews Disease Primers, 2015, 1, 15065.	18.1	1,104

#	Article	IF	Citations
877	Prediction of colorectal cancer diagnosis based onÂcirculating plasma proteins. EMBO Molecular Medicine, 2015, 7, 1166-1178.	3.3	80
878	Tumour-promoting role of SOCS1 in colorectal cancer cells. Scientific Reports, 2015, 5, 14301.	1.6	28
879	Eâ€cadherin can limit the transforming properties of activating Î²â€catenin mutations. EMBO Journal, 2015, 34, 2321-2333.	3.5	83
880	An evidence-based knowledgebase of metastasis suppressors to identify key pathways relevant to cancer metastasis. Scientific Reports, 2015, 5, 15478.	1.6	19
881	Lentivirus-mediated knockdown of rhomboid domain containing 1 inhibits colorectal cancer cell growth. Molecular Medicine Reports, 2015, 12, 377-381.	1.1	8
882	Proteomic analysis of colon and rectal carcinoma using standard and customized databases. Scientific Data, 2015, 2, 150022.	2.4	22
883	MSIseq: Software for Assessing Microsatellite Instability from Catalogs of Somatic Mutations. Scientific Reports, 2015, 5, 13321.	1.6	113
884	Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. Scientific Reports, 2015, 5, 17369.	1.6	35
885	Cancer typeâ€dependent genetic interactions between cancer driver alterations indicate plasticity of epistasis across cell types. Molecular Systems Biology, 2015, 11, 824.	3.2	54
886	Combined Mapping of Multiple clUsteriNg ALgorithms (COMMUNAL): A Robust Method for Selection of Cluster Number, K. Scientific Reports, 2015, 5, 16971.	1.6	16
887	Quantitative Proteomic Analysis of Meningiomas for the Identification of Surrogate Protein Markers. Scientific Reports, 2014, 4, 7140.	1.6	61
888	Analyzing Combinations of Somatic Mutations in Cancer Genomes. , 0, , 337-361.		0
889	HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1061-1064.	2.3	70
890	Nonâ€invasive prognostic protein biomarker signatures associated with colorectal cancer. EMBO Molecular Medicine, 2015, 7, 1153-1165.	3.3	49
891	An NGS Workflow Blueprint for DNA Sequencing Data and Its Application in Individualized Molecular Oncology. Cancer Informatics, 2015, 14s5, CIN.S30793.	0.9	10
892	Epiviz: a view inside the design of an integrated visual analysis software for genomics. BMC Bioinformatics, 2015, 16, S4.	1.2	3
893	Integrating heterogeneous genomic data to accurately identify disease subtypes. BMC Medical Genomics, 2015, 8, 78.	0.7	3
894	A functional connectome: regulation of Wnt/TCF-dependent transcription by pairs of pathway activators. Molecular Cancer, 2015, 14, 206.	7.9	15

#	Article	IF	Citations
895	Preferential occurrence of RHOA mutation in gastric and colorectal cancers. Pathology, 2015, 47, 598-599.	0.3	5
896	Spiral bodies in pulse granulomas are remnant plant vascular structures. Pathology, 2015, 47, 599-601.	0.3	4
897	Abrupt Loss of MLH1 and PMS2 Expression in Endometrial Carcinoma. American Journal of Surgical Pathology, 2015, 39, 993-999.	2.1	41
898	Bioinformatics analysis of thousands of TCGA tumors to determine the involvement of epigenetic regulators in human cancer. BMC Genomics, 2015, 16, S5.	1.2	29
899	Computational methods and resources for the interpretation of genomic variants in cancer. BMC Genomics, 2015, 16, S7.	1.2	18
900	Methylome profiling reveals functions and genes which are differentially methylated in serrated compared to conventional colorectal carcinoma. Clinical Epigenetics, 2015, 7, 101.	1.8	21
901	Structural analysis of tumor-related single amino acid mutations in human MxA protein. Chinese Journal of Cancer, 2015, 34, 583-93.	4.9	9
902	Functional and protein-protein interaction network analysis of colorectal cancer induced by ulcerative colitis. Molecular Medicine Reports, 2015, 12, 4947-4958.	1.1	4
903	Activin and TGFÎ² use diverging mitogenic signaling in advanced colon cancer. Molecular Cancer, 2015, 14, 182.	7.9	52
904	Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. Journal of Translational Medicine, 2015, 13, 217.	1.8	36
905	Neuron navigator 2 overexpression indicates poor prognosis of colorectal cancer and promotes invasion through the SSH1L/cofilin-1 pathway. Journal of Experimental and Clinical Cancer Research, 2015, 34, 117.	3.5	27
906	Aberrant DNA methylation profiles of inherited and sporadic colorectal cancer. Clinical Epigenetics, 2015, 7, 131.	1.8	45
907	Comprehensive data resources and analytical tools for pathological association of aminoacyl tRNA synthetases with cancer. Database: the Journal of Biological Databases and Curation, 2015, 2015, bav022-bav022.	1.4	4
908	Somatic MMR Gene Mutations as a Cause for MSI-H Sebaceous Neoplasms in Muir-Torre Syndrome-Like Patients. Human Mutation, 2015, 36, 292-295.	1.1	20
909	Chrysinâ€"organogermanium (IV) complex induced Colo205 cell apoptosisâ€associated mitochondrial function and antiâ€angiogenesis. Scanning, 2015, 37, 246-257.	0.7	13
910	Network-based stratification analysis of 13 major cancer types using mutations in panels of cancer genes. BMC Genomics, 2015, 16, S7.	1.2	27
911	Assaying Carcinoembryonic Antigens by Normalized Saturation Magnetization. Nanoscale Research Letters, 2015, 10, 964.	3.1	2
912	A survey of tandem repeat instabilities and associated gene expression changes in 35 colorectal cancers. BMC Genomics, 2015, 16, 702.	1.2	27

#	Article	IF	Citations
913	Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients. BMC Cancer, 2015, 15, 808.	1.1	54
914	Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology. BMC Systems Biology, 2015, 9, 70.	3.0	13
915	Regulation of deoxynucleotide metabolism in cancer: novel mechanisms and therapeutic implications. Molecular Cancer, 2015, 14, 176.	7.9	93
916	Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2015, 34, 108.	3.5	54
917	Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion. Breast Cancer Research, 2015, 17, 128.	2.2	43
918	The utility of transposon mutagenesis for cancer studies in the era of genome editing. Genome Biology, 2015, 16, 229.	3.8	28
919	ENVE: a novel computational framework characterizes copy-number mutational landscapes in colorectal cancers from African American patients. Genome Medicine, 2015, 7, 69.	3.6	2
920	FBXW7 Mutation Analysis and its Correlation with Clinicopathological Features and Prognosis in Colorectal Cancer Patients. International Journal of Biological Markers, 2015, 30, 88-95.	0.7	32
921	The Histone Acetyltransferase GCN5 Expression Is Elevated and Regulated by c-Myc and E2F1 Transcription Factors in Human Colon Cancer. Gene Expression, 2015, 16, 187-196.	0.5	64
922	The Effects of miRâ€20a on p21: Two Mechanisms Blocking Growth Arrest in TGFâ€Î²â€Responsive Colon Carcinoma. Journal of Cellular Physiology, 2015, 230, 3105-3114.	2.0	46
923	Genetic analysis of colon tumors induced by a dietary carcinogen PhIP in CYP1A humanized mice: Identification of mutation of Î²â€catenin/Ctnnb1 as the driver gene for the carcinogenesis. Molecular Carcinogenesis, 2015, 54, 1264-1274.	1.3	16
924	Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions?. Oncologist, 2015, 20, 1448-1456.	1.9	3
925	Severe radiotoxicity in an allogeneic transplant recipient with a heterozygous <i><scp>ATM</scp></i> mutation. European Journal of Haematology, 2015, 95, 90-92.	1.1	6
926	Elevated CA19-9 as the Most Significant Prognostic Factor in Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiotherapy. Medicine (United States), 2015, 94, e1793.	0.4	24
927	Identification of diagnostic markers in colorectal cancer via integrative epigenomics and genomics data. Oncology Reports, 2015, 34, 22-32.	1.2	44
928	Clinicopathological and genetic differences between lowâ€grade and highâ€grade colorectal mucinous adenocarcinomas. Cancer, 2015, 121, 4359-4368.	2.0	16
929	Cd11b+ myeloid cells support hepatic metastasis through downâ€regulation of angiopoietinâ€like 7 in cancer cells. Hepatology, 2015, 62, 521-533.	3.6	45
930	Mitogenâ€activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelialâ€mesenchymal transition. Hepatology, 2015, 62, 1804-1816.	3.6	33

#	Article	IF	Citations
931	Incidence of Second Primary Malignancies Following Colorectal Cancer. Medicine (United States), 2015, 94, e1079.	0.4	27
932	Distinctive Spatiotemporal Stability of Somatic Mutations in Metastasized Microsatellite-stable Colorectal Cancer. American Journal of Surgical Pathology, 2015, 39, 1140-1147.	2.1	35
933	Microsatellite Instability Use in Mismatch Repair Gene Sequence Variant Classification. Genes, 2015, 6, 150-162.	1.0	7
934	Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. OncoTargets and Therapy, 2016, 9, 75.	1.0	5
935	Hypothesis: Obesity Is Associated with a Lower Mutation Threshold in Colon Cancer. Journal of Cancer, 2015, 6, 825-831.	1.2	21
936	Targeting SOD1 induces synthetic lethal killing in<i>BLM- and CHEK2</i>-deficient colorectal cancer cells. Oncotarget, 2015, 6, 27907-27922.	0.8	34
937	Epigenetic Reduction of DNA Repair in Progression to Cancer. , 2015, , .		0
938	Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. Oncotarget, 2015, 6, 20785-20800.	0.8	112
939	A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. OncoTargets and Therapy, 2015, 8, 3561.	1.0	9
940	Review Computational characterisation of cancer molecular profiles derived using next generation sequencing. Wspolczesna Onkologia, 2015, 1A, 78-91.	0.7	4
941	Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer. World Journal of Gastroenterology, 2015, 21, 9253.	1.4	154
942	Somatic<i>MED12</i>mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. Oncotarget, 2015, 6, 1884-1888.	0.8	49
943	FAK/PYK2 promotes the Wnt/Î²-catenin pathway and intestinal tumorigenesis by phosphorylating GSK3Î². ELife, 2015, 4, .	2.8	93
944	EMAST is a Form of Microsatellite Instability That is Initiated by Inflammation and Modulates Colorectal Cancer Progression. Genes, 2015, 6, 185-205.	1.0	86
945	Gliotoxin Inhibits Proliferation and Induces Apoptosis in Colorectal Cancer Cells. Marine Drugs, 2015, 13, 6259-6273.	2.2	25
946	Exome sequencing of a colorectal cancer family reveals shared mutation pattern and predisposition circuitry along tumor pathways. Frontiers in Genetics, 2015, 6, 288.	1.1	11
947	Molecular and Pathogenetic Aspects of Tumor Budding in Colorectal Cancer. Frontiers in Medicine, 2015, 2, 11.	1.2	74
948	The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy. Frontiers in Oncology, 2015, 5, 230.	1.3	144

#	Article	IF	Citations
949	SPARCoC: A New Framework for Molecular Pattern Discovery and Cancer Gene Identification. PLoS ONE, 2015, 10, e0117135.	1.1	6
950	Derricin and Derricidin Inhibit Wnt/Î²-Catenin Signaling and Suppress Colon Cancer Cell Growth In Vitro. PLoS ONE, 2015, 10, e0120919.	1.1	33
951	Molecular Subtypes in Stage II-III Colon Cancer Defined by Genomic Instability: Early Recurrence-Risk Associated with a High Copy-Number Variation and Loss of RUNX3 and CDKN2A. PLoS ONE, 2015, 10, e0122391.	1.1	27
952	Classifying Ten Types of Major Cancers Based on Reverse Phase Protein Array Profiles. PLoS ONE, 2015, 10, e0123147.	1.1	58
953	YKL-40/c-Met Expression in Rectal Cancer Biopsies Predicts Tumor Regression following Neoadjuvant Chemoradiotherapy: A Multi-Institutional Study. PLoS ONE, 2015, 10, e0123759.	1.1	14
954	PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines. PLoS ONE, 2015, 10, e0123830.	1.1	29
955	ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer. PLoS ONE, 2015, 10, e0126898.	1.1	24
956	Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Wspolczesna Onkologia, 2015, 1A, 68-77.	0.7	2,410
957	Comparison of the Prognostic Utility of the Diverse Molecular Data among lncRNA, DNA Methylation, microRNA, and mRNA across Five Human Cancers. PLoS ONE, 2015, 10, e0142433.	1.1	14
958	Genome Modeling System: A Knowledge Management Platform for Genomics. PLoS Computational Biology, 2015, 11, e1004274.	1.5	83
959	An Evolutionary Approach for Identifying Driver Mutations in Colorectal Cancer. PLoS Computational Biology, 2015, 11, e1004350.	1.5	25
960	A Pan-Cancer Catalogue of Cancer Driver Protein Interaction Interfaces. PLoS Computational Biology, 2015, 11, e1004518.	1.5	122
961	Canine Spontaneous Head and Neck Squamous Cell Carcinomas Represent Their Human Counterparts at the Molecular Level. PLoS Genetics, 2015, 11, e1005277.	1.5	37
962	Let-7 Represses Carcinogenesis and a Stem Cell Phenotype in the Intestine via Regulation of Hmga2. PLoS Genetics, 2015, 11, e1005408.	1.5	68
963	Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations. PLoS ONE, 2015, 10, e0128202.	1.1	8
964	Combined Targeted DNA Sequencing in Non-Small Cell Lung Cancer (NSCLC) Using UNCseq and NGScopy, and RNA Sequencing Using UNCqeR for the Detection of Genetic Aberrations in NSCLC. PLoS ONE, 2015, 10, e0129280.	1.1	36
965	High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort. PLoS ONE, 2015, 10, e0131046.	1.1	91
966	Chlorinated Water Modulates the Development of Colorectal Tumors with Chromosomal Instability and Gut Microbiota in Apc-Deficient Mice. PLoS ONE, 2015, 10, e0132435.	1.1	33

#	Article	IF	Citations
967	Oncogenic Role of miR-15a-3p in 13q Amplicon-Driven Colorectal Adenoma-to-Carcinoma Progression. PLoS ONE, 2015, 10, e0132495.	1.1	22
968	A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona. PLoS ONE, 2015, 10, e0132831.	1.1	9
969	Comprehensive DNA Methylation Analysis Reveals a Common Ten-Gene Methylation Signature in Colorectal Adenomas and Carcinomas. PLoS ONE, 2015, 10, e0133836.	1.1	42
970	A Pan-GTPase Inhibitor as a Molecular Probe. PLoS ONE, 2015, 10, e0134317.	1.1	30
971	Cancer-Testis Antigen Expression in Serous Endometrial Cancer with Loss of X Chromosome Inactivation. PLoS ONE, 2015, 10, e0137476.	1.1	12
972	A Case of Six Synchronous Primary Colorectal Cancers Showing Multiple Oncogenic Mechanisms at the Same Time. Nihon Daicho Komonbyo Gakkai Zasshi, 2015, 68, 544-551.	0.1	0
973	Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. ELife, 2015, 4, e06907.	2.8	140
974	Nonsynonymous Single-Nucleotide Variations on Some Posttranslational Modifications of Human Proteins and the Association with Diseases. Computational and Mathematical Methods in Medicine, 2015, 2015, 1-12.	0.7	5
976	Induction of KIAA1199/CEMIP is associated with colon cancer phenotype and poor patient survival. Oncotarget, 2015, 6, 30500-30515.	0.8	62
977	Reduced rate of copy number aberrations in mucinous colorectal carcinoma. Oncotarget, 2015, 6, 25715-25725.	0.8	11
978	Structural variation discovery in the cancer genome using next generation sequencing: Computational solutions and perspectives. Oncotarget, 2015, 6, 5477-5489.	0.8	33
979	Role of the Wnt/Î²-catenin pathway in gastric cancer: An in-depth literature review. World Journal of Experimental Medicine, 2015, 5, 84.	0.9	246
980	Integrating Colon Cancer Microarray Data: Associating Locus-Specific Methylation Groups to Gene Expression-Based Classifications. Microarrays (Basel, Switzerland), 2015, 4, 630-646.	1.4	3
981	Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform. Oncotarget, 2015, 6, 2549-2561.	0.8	96
982	Expression profile of innate immune receptors, NLRs and AIM2, in human colorectal cancer: correlation with cancer stages and inflammasome components. Oncotarget, 2015, 6, 33456-33469.	0.8	101
983	Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients. World Journal of Gastroenterology, 2015, 21, 1457.	1.4	98
984	Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type. Oncotarget, 2015, 6, 17764-17776.	0.8	136
985	Implications of NQO1 in cancer therapy. BMB Reports, 2015, 48, 609-617.	1.1	125

#	Article	IF	Citations
986	Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention. World Journal of Clinical Oncology, 2015, 6, 133.	0.9	83
987	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine, 2015, 372, 2509-2520.	13.9	7,696
988	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nature Medicine, 2015, 21, 795-801.	15.2	809
989	Aberrant RSPO3-LGR4 signaling in Keap1-deficient lung adenocarcinomas promotes tumor aggressiveness. Oncogene, 2015, 34, 4692-4701.	2.6	59
990	SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair. Oncogene, 2015, 34, 5699-5708.	2.6	147
991	Quantifying the contributions of base selectivity, proofreading and mismatch repair to nuclear DNA replication in Saccharomyces cerevisiae. DNA Repair, 2015, 31, 41-51.	1.3	51
992	Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nature Reviews Cancer, 2015, 15, 334-346.	12.8	486
993	The emerging complexity of gene fusions in cancer. Nature Reviews Cancer, 2015, 15, 371-381.	12.8	544
994	Frequency and distribution of Notch mutations in tumor cell lines. BMC Cancer, 2015, 15, 311.	1.1	15
995	Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity. Clinical Cancer Research, 2015, 21, 4461-4472.	3.2	157
996	Colorectal Adenomas Contain Multiple Somatic Mutations That Do Not Coincide with Synchronous Adenocarcinoma Specimens. PLoS ONE, 2015, 10, e0119946.	1.1	11
997	RasGRP1 opposes proliferative EGFRâ€“SOS1â€“Ras signals and restricts intestinal epithelial cell growth. Nature Cell Biology, 2015, 17, 804-815.	4.6	54
998	Simultaneous Inference of Cancer Pathways and Tumor Progression from Cross-Sectional Mutation Data. Journal of Computational Biology, 2015, 22, 510-527.	0.8	28
999	The Cancer Cell Map Initiative: Defining the Hallmark Networks of Cancer. Molecular Cell, 2015, 58, 690-698.	4.5	117
1001	Drug development: Mix and match. Nature, 2015, 521, S12-S14.	13.7	7
1002	<i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. Clinical Cancer Research, 2015, 21, 3347-3355.	3.2	249
1003	Implications of EpithelialÃ¢â‚¬â€œMesenchymal Plasticity for Heterogeneity in Colorectal Cancer. Frontiers in Oncology, 2015, 5, 13.	1.3	27
1004	Diagnostic value of preoperative CT scan to stratify colon cancer for neoadjuvant therapy. International Journal of Colorectal Disease, 2015, 30, 1067-1073.	1.0	16

#	Article	IF	Citations
1005	A perspective on the current treatment strategies for locally advanced rectal cancer. International Journal of Biochemistry and Cell Biology, 2015, 65, 192-196.	1.2	3
1006	Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer. Current Treatment Options in Oncology, 2015, 16, 30.	1.3	309
1007	Single nucleotide polymorphism array profiling identifies distinct chromosomal aberration patterns across colorectal adenomas and carcinomas. Genes Chromosomes and Cancer, 2015, 54, 303-314.	1.5	14
1008	Oncotator: Cancer Variant Annotation Tool. Human Mutation, 2015, 36, E2423-E2429.	1.1	448
1009	Towards a Mechanistic Understanding of Epigenetic Dynamics. Translational Bioinformatics, 2015, , 141-160.	0.0	2
1010	Molecular markers for colorectal cancer screening. Gut, 2015, 64, 1485-1494.	6.1	100
1011	Special Series: Advances in GI Cancer. Journal of Clinical Oncology, 2015, 33, 1717-1720.	0.8	13
1012	Usp28 Counteracts Fbw7 in Intestinal Homeostasis and Cancer. Cancer Research, 2015, 75, 1181-1186.	0.4	60
1013	Personalized Therapy of Cancer. , 2015, , 199-381.		1
1014	MAGI: visualization and collaborative annotation of genomic aberrations. Nature Methods, 2015, 12, 483-484.	9.0	25
1015	Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations. Cytokine and Growth Factor Reviews, 2015, 26, 425-449.	3.2	125
1016	Exome Capture and Capturing Technologies in Cancer Research. , 2015, , 279-302.		0
1018	LIN28 cooperates with WNT signaling to drive invasive intestinal and colorectal adenocarcinoma in mice and humans. Genes and Development, 2015, 29, 1074-1086.	2.7	92
1019	Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies. Clinical Cancer Research, 2015, 21, 3377-3383.	3.2	34
1020	Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma. International Journal of Gynecological Cancer, 2015, 25, 1187-1193.	1.2	31
1021	BRAF Mutations in Non-Metastatic Colorectal Cancer: Current Relevance and Future Implications. Current Colorectal Cancer Reports, 2015, 11, 303-310.	1.0	0
1022	Assessment of cytotoxicity and genotoxicity of stem bark extracts from Canarium odontophyllum Miq. (dabai) against HCT 116 human colorectal cancer cell line. BMC Complementary and Alternative Medicine, 2015, 16, 36.	3.7	23
1023	Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials. Current Colorectal Cancer Reports, 2015, 11, 275-280.	1.0	115

#	Article	IF	Citations
1024	Progress of cancer genomics. Thoracic Cancer, 2015, 6, 557-560.	0.8	1
1025	Virulence genes are a signature of the microbiome in the colorectal tumor microenvironment. Genome Medicine, 2015, 7, 55.	3.6	197
1026	The molecular background of mucinous carcinoma beyond MUC2. Journal of Pathology: Clinical Research, 2015, 1, 3-17.	1.3	69
1027	Potent antitumor activity of cabozantinib, a câ€<scp>MET</scp> and <scp>VEGFR</scp>2 inhibitor, in a colorectal cancer patientâ€derived tumor explant model. International Journal of Cancer, 2015, 136, 1967-1975.	2.3	47
1028	Semiconductorâ€Based Sequencing of Formalinâ€Fixed, Paraffinâ€Embedded Colorectal Cancer Samples. Oncologist, 2015, 20, e10-1.	1.9	10
1029	An Optimization-Based Framework for the Transformation of Incomplete Biological Knowledge into a Probabilistic Structure and Its Application to the Utilization of Gene/Protein Signaling Pathways in Discrete Phenotype Classification. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2015, 12, 1304-1321.	1.9	15
1030	Activation of Saccharomyces cerevisiae Mlh1-Pms1 Endonuclease in a Reconstituted Mismatch Repair System. Journal of Biological Chemistry, 2015, 290, 21580-21590.	1.6	29
1031	Differences in genome-wide repeat sequence instability conferred by proofreading and mismatch repair defects. Nucleic Acids Research, 2015, 43, 4067-4074.	6.5	28
1032	Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). OncoImmunology, 2015, 4, e1049804.	2.1	51
1033	Highly sensitive, non-invasive detection of colorectal cancer mutations using single molecule, third generation sequencing. Applied & Translational Genomics, 2015, 7, 32-39.	2.1	16
1034	Microsatellite instability detected in tumor-related genes in C57BL/6J mice with thymic lymphoma induced by N -methyl- N -nitrosourea. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 782, 7-16.	0.4	4
1035	Treatment Individualization in Colorectal Cancer. Current Colorectal Cancer Reports, 2015, 11, 335-344.	1.0	17
1036	Differential flux balance analysis of quantitative proteomic data on protein interaction networks. , 2015, , .		0
1037	microRNAs in the Malignant Transformation Process. Advances in Experimental Medicine and Biology, 2015, 889, 1-21.	0.8	4
1038	Elevated RNA Editing Activity Is a Major Contributor to Transcriptomic Diversity in Tumors. Cell Reports, 2015, 13, 267-276.	2.9	262
1039	Regulation of cancer cell death by a novel compound, C604, in a c-Myc-overexpressing cellular environment. European Journal of Pharmacology, 2015, 769, 257-265.	1.7	3
1040	Transcriptional modulator ZBED6 affects cell cycle and growth of human colorectal cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7743-7748.	3.3	26
1041	DNA hypermethylation and decreased mRNA expression of MAL, PRIMA1, PTGDR and SFRP1 in colorectal adenoma and cancer. BMC Cancer, 2015, 15, 736.	1.1	53

#	Article	IF	Citations
1042	Thyroid genomics: refining diagnosis, prognosis and treatment. International Journal of Endocrine Oncology, 2015, 2, 105-107.	0.4	0
1043	BCL9/9L-Î²-catenin Signaling is Associated With Poor Outcome in Colorectal Cancer. EBioMedicine, 2015, 2, 1932-1943.	2.7	58
1044	SASS6 overexpression is associated with mitotic chromosomal abnormalities and a poor prognosis in patients with colorectal cancer. Oncology Reports, 2015, 34, 727-738.	1.2	13
1045	SOX15 Governs Transcription in Human Stratified Epithelia and a Subset of Esophageal Adenocarcinomas. Cellular and Molecular Gastroenterology and Hepatology, 2015, 1, 598-609.e6.	2.3	14
1046	MicroRNAâ€“mRNA interactions underlying colorectal cancer molecular subtypes. Nature Communications, 2015, 6, 8878.	5.8	65
1047	HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. Breast Cancer Research, 2015, 17, 149.	2.2	42
1048	Circadian gene hClock enhances proliferation and inhibits apoptosis of human colorectal carcinoma cells in vitro and in vivo. Molecular Medicine Reports, 2015, 11, 4204-4210.	1.1	23
1049	Colon and Rectal Cancer. , 2015, , 499-514.e2.		0
1050	Target-Enriched Next-Generation Sequencing Reveals Differences between Primary and Secondary Ovarian Tumors in Formalin-Fixed, Paraffin-Embedded Tissue. Journal of Molecular Diagnostics, 2015, 17, 193-200.	1.2	8
1051	Cancer Stem Cells: Biology and Potential Therapeutic Applications. , 2015, , 151-176.		1
1052	Identifying Predictive Features in Drug Response Using Machine Learning: Opportunities and Challenges. Annual Review of Pharmacology and Toxicology, 2015, 55, 15-34.	4.2	64
1053	WIPI proteins: essential PtdIns3<i>P</i> effectors at the nascent autophagosome. Journal of Cell Science, 2015, 128, 207-17.	1.2	214
1054	Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer. Cancer Immunology, Immunotherapy, 2015, 64, 99-104.	2.0	32
1055	Transposon mutagenesis identifies genes and evolutionary forces driving gastrointestinal tract tumor progression. Nature Genetics, 2015, 47, 142-150.	9.4	101
1056	TRKing Down an Old Oncogene in a New Era of Targeted Therapy. Cancer Discovery, 2015, 5, 25-34.	7.7	509
1057	Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. Pharmacogenomics Journal, 2015, 15, 354-362.	0.9	41
1058	Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development. Cancer Treatment Reviews, 2015, 41, 129-135.	3.4	14
1059	IGF2 signaling and regulation in cancer. Cytokine and Growth Factor Reviews, 2015, 26, 371-377.	3.2	92

#	Article	IF	Citations
1060	Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies. Langenbeck's Archives of Surgery, 2015, 400, 129-143.	0.8	14
1061	A Big Bang model of human colorectal tumor growth. Nature Genetics, 2015, 47, 209-216.	9.4	867
1062	A leak pathway for luminal protons in endosomes drives oncogenic signalling in glioblastoma. Nature Communications, 2015, 6, 6289.	5.8	82
1063	Signaling-Mediated Regulation of MicroRNA Processing. Cancer Research, 2015, 75, 783-791.	0.4	46
1064	Somatic Diseases (Cancer). , 2015, , 343-360.		0
1065	mTOR Signaling in Endometrial Cancer: From a Molecular and Therapeutic Point of View. Current Obstetrics and Gynecology Reports, 2015, 4, 1-10.	0.3	11
1066	Role of MYC-Regulated Long Noncoding RNAs in Cell Cycle Regulation and Tumorigenesis. Journal of the National Cancer Institute, 2015, 107, .	3.0	139
1067	<i>j</i>NMFMA: a joint non-negative matrix factorization meta-analysis of transcriptomics data. Bioinformatics, 2015, 31, 572-580.	1.8	46
1068	Molecular Markers Predictive of Chemotherapy Response in Colorectal Cancer. Current Gastroenterology Reports, 2015, 17, 431.	1.1	13
1069	Milestones of Lynch syndrome: 1895â€"2015. Nature Reviews Cancer, 2015, 15, 181-194.	12.8	603
1070	Review on adjuvant chemotherapy for rectal cancer â€" why do treatment guidelines differ so much?. Acta OncolÃ³gica, 2015, 54, 437-446.	0.8	42
1071	Combined methylation of p16 and hMLH1 (CMETH2) discriminates a subpopulation with better prognosis in colorectal cancer patients with microsatellite instability tumors. Tumor Biology, 2015, 36, 3853-3861.	0.8	7
1072	Association of HPV with genetic and epigenetic alterations in colorectal adenocarcinoma from Indian population. Tumor Biology, 2015, 36, 4661-4670.	0.8	10
1073	Integrative genomics identifies YY1AP1 as an oncogenic driver in EpCAM+ AFP+ hepatocellular carcinoma. Oncogene, 2015, 34, 5095-5104.	2.6	57
1074	SNAIL1 combines competitive displacement of ASCL2 andÂepigenetic mechanisms to rapidly silence the EPHB3 tumor suppressor in colorectal cancer. Molecular Oncology, 2015, 9, 335-354.	2.1	34
1075	Identification of HPV Integration and Gene Mutation in HeLa Cell Line by Integrated Analysis of RNA-Seq and MS/MS Data. Journal of Proteome Research, 2015, 14, 1678-1686.	1.8	16
1076	Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors. Clinical Chemistry, 2015, 61, 544-553.	1.5	85
1077	Novel molecular insights from routine genotyping of colorectal carcinomas. Human Pathology, 2015, 46, 507-513.	1.1	22

#	Article	IF	Citations
1078	Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. British Journal of Cancer, 2015, 112, 1088-1097.	2.9	123
1079	The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC. Annals of Oncology, 2015, 26, 935-942.	0.6	54
1080	Junk DNA and the long non-coding RNA twist in cancer genetics. Oncogene, 2015, 34, 5003-5011.	2.6	293
1081	Emerging critical roles of Feâ€"S clusters in DNA replication and repair. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 1253-1271.	1.9	187
1082	Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers. , 2015, 149, 139-149.		27
1083	Twist1 and AP-1 cooperatively upregulate integrin Î±5 expression to induce invasion and the epithelialâ€"mesenchymal transition. Carcinogenesis, 2015, 36, 327-337.	1.3	47
1084	Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nature Genetics, 2015, 47, 257-262.	9.4	306
1085	Association of the Colorectal CpG Island Methylator Phenotype with Molecular Features, Risk Factors, and Family History. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 512-519.	1.1	71
1086	Plasma methylated septin 9: a colorectal cancer screening marker. Expert Review of Molecular Diagnostics, 2015, 15, 171-184.	1.5	45
1087	Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncology, The, 2015, 16, 200-207.	5.1	461
1088	Intrinsic cancer subtypes-next steps into personalized medicine. Cellular Oncology (Dordrecht), 2015, 38, 3-16.	2.1	24
1089	Identification of a Functional SNP in the 3â€²UTR of CXCR2 That Is Associated with Reduced Risk of Lung Cancer. Cancer Research, 2015, 75, 566-575.	0.4	53
1090	Novel recurrently mutated genes in African American colon cancers. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1149-1154.	3.3	118
1091	Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nature Genetics, 2015, 47, 180-185.	9.4	299
1092	Understanding and Using Information about Cancer Genomes. , 2015, , 357-368.e3.		0
1093	Novel genotype-phenotype associations in human cancers enabled by advanced molecular platforms and computational analysis of whole slide images. Laboratory Investigation, 2015, 95, 366-376.	1.7	54
1094	KrÃ¼ppel-Like Factor 5 Is Required for Proper Maintenance of Adult Intestinal Crypt Cellular Proliferation. Digestive Diseases and Sciences, 2015, 60, 86-100.	1.1	11
1095	Tissue-based map of the human proteome. Science, 2015, 347, 1260419.	6.0	10,802

#	Article	IF	Citations
1096	Augmented Pentose Phosphate Pathway Plays Critical Roles in Colorectal Carcinomas. Oncology, 2015, 88, 309-319.	0.9	22
1097	Identifying gene disruptions in novel balanced de novo constitutional translocations in childhood cancer patients by whole-genome sequencing. Genetics in Medicine, 2015, 17, 831-835.	1.1	7
1098	Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer: an update. Expert Review of Molecular Diagnostics, 2015, 15, 399-414.	1.5	8
1099	Comprehensive screening for mutations associated with colorectal cancer in unselected cases reveals penetrant and nonpenetrant mutations. International Journal of Cancer, 2015, 136, E559-68.	2.3	21
1100	Inherited Susceptibility to Pancreatic Cancer in the Era of Next-Generation Sequencing. Gastroenterology, 2015, 148, 496-498.	0.6	3
1101	A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Oral Oncology, 2015, 51, 383-388.	0.8	74
1102	Colorectal Cancer Heterogeneity and Targeted Therapy: A Case for Molecular Disease Subtypes. Cancer Research, 2015, 75, 245-249.	0.4	163
1103	Microsatellite instability: an update. Archives of Toxicology, 2015, 89, 899-921.	1.9	182
1104	Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2015, 107, .	3.0	385
1105	Big Bang and context-driven collapse. Nature Genetics, 2015, 47, 196-197.	9.4	20
1106	Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer. Nucleic Acids Research, 2015, 43, 1345-1356.	6.5	157
1107	Avalanching mutations in biallelic mismatch repair deficiency syndrome. Nature Genetics, 2015, 47, 194-196.	9.4	4
1108	Evaluating Patient-Derived Colorectal Cancer Xenografts as Preclinical Models by Comparison with Patient Clinical Data. Cancer Research, 2015, 75, 1560-1566.	0.4	117
1109	Suppressing TGFÎ² Signaling in Regenerating Epithelia in an Inflammatory Microenvironment Is Sufficient to Cause Invasive Intestinal Cancer. Cancer Research, 2015, 75, 766-776.	0.4	80
1110	Systems oncology: toward the clinical application of cancer systems biology. Future Oncology, 2015, 11, 553-555.	1.1	4
1111	Capture Hi-C identifies the chromatin interactome of colorectal cancer risk loci. Nature Communications, 2015, 6, 6178.	5.8	186
1112	Identification of novel mutations by exome sequencing in African American colorectal cancer patients. Cancer, 2015, 121, 34-42.	2.0	36
1113	Differential DNA mismatch repair underlies mutation rate variation across the human genome. Nature, 2015, 521, 81-84.	13.7	310

#	Article	IF	Citations
1114	Modeling colorectal cancer using CRISPR-Cas9â€"mediated engineering of human intestinal organoids. Nature Medicine, 2015, 21, 256-262.	15.2	887
1115	The Cancer Genomics Resource List 2014. Archives of Pathology and Laboratory Medicine, 2015, 139, 989-1008.	1.2	18
1116	Therapeutic opportunities within the DNA damage response. Nature Reviews Cancer, 2015, 15, 166-180.	12.8	442
1117	Stromal contribution to the colorectal cancer transcriptome. Nature Genetics, 2015, 47, 312-319.	9.4	520
1118	Going for broke: targeting the human cancer pseudokinome. Biochemical Journal, 2015, 465, 195-211.	1.7	31
1119	The landscape of precision cancer medicine clinical trials in the United States. Cancer Treatment Reviews, 2015, 41, 385-390.	3.4	57
1121	Toward recreating colon cancer in human organoids. Nature Medicine, 2015, 21, 215-216.	15.2	19
1122	Is it all Lynch syndrome?: An assessment of family history in individuals with mismatch repairâ€"deficient tumors. Genetics in Medicine, 2015, 17, 476-484.	1.1	9
1123	Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer. Cell, 2015, 161, 1539-1552.	13.5	432
1124	Towards a Molecular Classification of Colorectal Cancer. Frontiers in Oncology, 2015, 5, 46.	1.3	5
1125	A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Annals of Oncology, 2015, 26, 556-561.	0.6	79
1126	Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics, 2015, 47, 888-897.	9.4	78
1127	Whole Exome Sequencing of a Patient with Metastatic Hidradenocarcinoma and Review of the Literature. Rare Tumors, 2015, 7, 29-33.	0.3	11
1128	Personalised medicine in veterinary oncology: One to cure just one. Veterinary Journal, 2015, 205, 128-135.	0.6	17
1129	Current controversies in the management of metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 659-677.	1.1	17
1130	Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer. Gastroenterology, 2015, 149, 1177-1190.e3.	0.6	337
1131	ERBB2 Emerges as a New Target for Colorectal Cancer. Cancer Discovery, 2015, 5, 799-801.	7.7	21
1132	Epigenetic regulation of the intestinal epithelium. Cellular and Molecular Life Sciences, 2015, 72, 4139-4156.	2.4	35

#	Article	IF	Citations
1133	Locally Advanced Rectal Cancer: What Does the Local Treatment Response Tell Us About the Global Picture?. International Journal of Radiation Oncology Biology Physics, 2015, 92, 498-500.	0.4	0
1134	HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment. Cancer Discovery, 2015, 5, 832-841.	7.7	250
1135	Diagnostic yield of targeted next generation sequencing in various cancer types: An information-theoretic approach. Cancer Genetics, 2015, 208, 441-447.	0.2	9
1136	Radiotherapy in the Era of Precision Medicine. Seminars in Radiation Oncology, 2015, 25, 227-236.	1.0	29
1137	Polymerase Slippage Restoration of Frameshifted TGFBR2 in Colorectal Cancer: A Novel Paradigm. Gastroenterology, 2015, 148, 1276-1279.	0.6	6
1138	NKD1 marks intestinal and liver tumors linked to aberrant Wnt signaling. Cellular Signalling, 2015, 27, 245-256.	1.7	19
1139	Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: Opportunities for signaling-adapted therapies. Critical Reviews in Oncology/Hematology, 2015, 95, 114-124.	2.0	15
1140	Structure, Dynamics, and Functionality of Tankyrase Inhibitor-Induced Degradasomes. Molecular Cancer Research, 2015, 13, 1487-1501.	1.5	38
1141	Clinical Implications of Intestinal Stem Cell Markers in Colorectal Cancer. Clinical Colorectal Cancer, 2015, 14, 63-71.	1.0	34
1142	FOXQ1 mediates the crosstalk between TGF-Î² and Wnt signaling pathways in the progression of colorectal cancer. Cancer Biology and Therapy, 2015, 16, 1099-1109.	1.5	72
1143	<i>TP53</i>mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer. Nucleic Acids Research, 2015, 43, 6945-6958.	6.5	46
1144	Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. Cancer and Metastasis Reviews, 2015, 34, 479-496.	2.7	101
1145	Genetics and Genetic Testing in Hereditary Colorectal Cancer. Gastroenterology, 2015, 149, 1191-1203.e2.	0.6	57
1146	Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. Science Advances, 2015, 1, e1500447.	4.7	627
1147	An AXIN2 Mutant Allele Associated With Predisposition to Colorectal Neoplasia Has Context-Dependent Effects on AXIN2 Protein Function. Neoplasia, 2015, 17, 463-472.	2.3	12
1148	Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis. British Journal of Cancer, 2015, 113, 500-509.	2.9	112
1149	Surgery in the era of the 'omics revolution. British Journal of Surgery, 2015, 102, e29-e40.	0.1	9
1150	Frequency of mitogen-activated protein kinase and phosphoinositide 3-kinase signaling pathway pathogenic alterations in EUS-FNA sampled malignant lymph nodes in rectal cancer with theranostic potential. Gastrointestinal Endoscopy, 2015, 82, 550-556.e1.	0.5	7

#	Article	IF	Citations
1151	Volatility of Mutator Phenotypes at Single Cell Resolution. PLoS Genetics, 2015, 11, e1005151.	1.5	15
1152	The role of DNA methylation in directing the functional organization of the cancer epigenome. Genome Research, 2015, 25, 467-477.	2.4	90
1153	Genetic mutations in human rectal cancers detected by targeted sequencing. Journal of Human Genetics, 2015, 60, 589-596.	1.1	25
1154	Advanced Proteogenomic Analysis Reveals Multiple Peptide Mutations and Complex Immunoglobulin Peptides in Colon Cancer. Journal of Proteome Research, 2015, 14, 3555-3567.	1.8	36
1155	Genome-wide association study of colorectal cancer identifies six new susceptibility loci. Nature Communications, 2015, 6, 7138.	5.8	138
1156	DRO1/CCDC80: a Novel Tumor Suppressor of Colorectal Carcinogenesis. Current Colorectal Cancer Reports, 2015, 11, 200-208.	1.0	2
1157	Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer. Cancer Prevention Research, 2015, 8, 702-711.	0.7	47
1158	Systems approach for the selection of micro-RNAs as therapeutic biomarkers of anti-EGFR monoclonal antibody treatment in colorectal cancer. Scientific Reports, 2015, 5, 8013.	1.6	6
1159	Colorectal Cancer: Personalized Therapy. Gastrointestinal Tumors, 2014, 1, 209-220.	0.3	6
1160	Exome Sequencing Reveals <i>AMER1</i> as a Frequently Mutated Gene in Colorectal Cancer. Clinical Cancer Research, 2015, 21, 4709-4718.	3.2	52
1161	OMICS for Tumor Biomarker Research. Biomarkers in Disease, 2015, , 3-30.	0.0	3
1162	p53-Regulated Networks of Protein, mRNA, miRNA, and lncRNA Expression Revealed by Integrated Pulsed Stable Isotope Labeling With Amino Acids in Cell Culture (pSILAC) and Next Generation Sequencing (NGS) Analyses. Molecular and Cellular Proteomics, 2015, 14, 2609-2629.	2.5	59
1163	An overview of new biomolecular pathways in pathogen-related cancers. Future Oncology, 2015, 11, 1625-1639.	1.1	12
1164	Comprehensive genomic profiles of small cell lung cancer. Nature, 2015, 524, 47-53.	13.7	1,634
1165	Reserve stem cells: Differentiated cells reprogram to fuel repair, metaplasia, and neoplasia in the adult gastrointestinal tract. Science Signaling, 2015, 8, re8.	1.6	111
1166	Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer. Expert Review of Molecular Diagnostics, 2015, 15, 1033-1048.	1.5	0
1167	Understanding next generation sequencing in oncology: A guide for oncologists. Critical Reviews in Oncology/Hematology, 2015, 96, 463-474.	2.0	38
1168	Germline Mutations in FAN1 Cause Hereditary Colorectal Cancer by Impairing DNA Repair. Gastroenterology, 2015, 149, 563-566.	0.6	94

#	Article	IF	Citations
1169	Association of Somatic Mutations of<i>ADAMTS</i>Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. JAMA Oncology, 2015, 1, 486.	3.4	32
1170	The bone marrow metastasis niche in retinoblastoma. Cellular Oncology (Dordrecht), 2015, 38, 253-263.	2.1	16
1171	The cancer COMPASS: navigating the functions of MLL complexes in cancer. Cancer Genetics, 2015, 208, 178-191.	0.2	122
1172	Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic ColorectalÂCancer. Clinical Colorectal Cancer, 2015, 14, 203-218.	1.0	25
1173	Publisher's Note: Abstraction for data integration: Fusing mammalian molecular, cellular and phenotype big datasets for better knowledge extraction. Computational Biology and Chemistry, 2015, 58, 104-119.	1.1	4
1174	Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treatment Reviews, 2015, 41, 653-659.	3.4	49
1175	The WTX Tumor Suppressor Interacts with the Transcriptional Corepressor TRIM28. Journal of Biological Chemistry, 2015, 290, 14381-14390.	1.6	16
1176	Colorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology Approach. International Journal of Molecular Sciences, 2015, 16, 13610-13632.	1.8	47
1177	Fatal Congenital Hypertrophic Cardiomyopathy and a Pancreatic Nodule Morphologically Identical to Focal Lesion of Congenital Hyperinsulinism in an Infant with Costello Syndrome: Case Report and Review of the Literature. Pediatric and Developmental Pathology, 2015, 18, 237-244.	0.5	14
1178	Rectal and colon cancer: Not just a different anatomic site. Cancer Treatment Reviews, 2015, 41, 671-679.	3.4	239
1179	Accurate Computation of Survival Statistics in Genome-Wide Studies. PLoS Computational Biology, 2015, 11, e1004071.	1.5	24
1180	Protein Domain-Level Landscape of Cancer-Type-Specific Somatic Mutations. PLoS Computational Biology, 2015, 11, e1004147.	1.5	59
1181	Select Biomarkers for Tumors of the Gastrointestinal Tract: Present and Future. Archives of Pathology and Laboratory Medicine, 2015, 139, 457-468.	1.2	9
1182	The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nature Communications, 2015, 6, 7002.	5.8	251
1183	Colon cancer-associated mutator DNA polymerase Î´ variant causes expansion of dNTP pools increasing its own infidelity. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E2467-76.	3.3	58
1184	Enterobacteria-secreted particles induce production of exosome-like S1P-containing particles by intestinal epithelium to drive Th17-mediated tumorigenesis. Nature Communications, 2015, 6, 6956.	5.8	67
1185	Screening in GI Cancers: The Role of Genetics. Journal of Clinical Oncology, 2015, 33, 1721-1728.	0.8	26
1186	Candidate colorectal cancer predisposing gene variants in Chinese early-onset and familial cases. World Journal of Gastroenterology, 2015, 21, 4136.	1.4	10

#	Article	IF	Citations
1187	Metastatic Colorectal Cancer: Current State and Future Directions. Journal of Clinical Oncology, 2015, 33, 1809-1824.	0.8	418
1188	Sequential cancer mutations in cultured human intestinal stem cells. Nature, 2015, 521, 43-47.	13.7	853
1189	Tumor Vessel Up-Regulation of INSR Revealed by Single-Cell Expression Analysis of the Tyrosine Kinome and Phosphatome in Human Cancers. American Journal of Pathology, 2015, 185, 1600-1609.	1.9	24
1190	Identifying Molecular Targets to Improve Immune Function in Alcoholic Hepatitis. Gastroenterology, 2015, 148, 498-501.	0.6	12
1191	Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance. Molecular Oncology, 2015, 9, 1169-1185.	2.1	91
1192	Pan-cancer transcriptome analysis reveals long noncoding RNAs with conserved function. RNA Biology, 2015, 12, 628-642.	1.5	85
1193	Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nature Medicine, 2015, 21, 449-456.	15.2	1,592
1194	miR-1269 promotes metastasis and forms a positive feedback loop with TGF-Î². Nature Communications, 2015, 6, 6879.	5.8	110
1195	Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: Evaluation of concordance between genomic and transcriptional profiles. European Journal of Cancer, 2015, 51, 791-799.	1.3	83
1196	HER3 protein expression in relation to HER2 positivity in patients with primary colorectal cancer: clinical relevance and prognostic value. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 645-654.	1.4	15
1197	A novel POLE mutation associated with cancers of colon, pancreas, ovaries and small intestine. Familial Cancer, 2015, 14, 437-448.	0.9	67
1198	Translational Considerations on the Outlook of Immunotherapy for Colorectal Cancer. Current Colorectal Cancer Reports, 2015, 11, 92-97.	1.0	6
1199	Crosstalk between Wnt/Î²-catenin and Hedgehog/Gli signaling pathways in colon cancer and implications for therapy. Cancer Biology and Therapy, 2015, 16, 1-7.	1.5	98
1200	Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer. Expert Review of Molecular Diagnostics, 2015, 15, 647-664.	1.5	40
1201	ENCAPP: elastic-net-based prognosis prediction and biomarker discovery for human cancers. BMC Genomics, 2015, 16, 263.	1.2	30
1202	Methylation and expression of the tumour suppressor, PRDM5, in colorectal cancer and polyp subgroups. BMC Cancer, 2015, 15, 20.	1.1	14
1203	Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer. BMC Cancer, 2015, 15, 125.	1.1	35
1204	Improved survival among colon cancer patients with increased differentially expressed pathways. BMC Medicine, 2015, 13, 75.	2.3	18

#	Article	IF	Citations
1205	Altered pathways and colorectal cancer prognosis. BMC Medicine, 2015, 13, 76.	2.3	8
1206	Identification of rare germline copy number variations over-represented in five human cancer types. Molecular Cancer, 2015, 14, 25.	7.9	32
1207	5-hydroxymethylcytosine marks promoters in colon that resist DNA hypermethylation in cancer. Genome Biology, 2015, 16, 69.	3.8	60
1208	Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations. Genome Biology, 2015, 16, 45.	3.8	145
1209	CopywriteR: DNA copy number detection from off-target sequence data. Genome Biology, 2015, 16, 49.	3.8	183
1210	Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biology, 2015, 16, 64.	3.8	433
1211	TET proteins and the control of cytosine demethylation in cancer. Genome Medicine, 2015, 7, 9.	3.6	176
1212	The next steps in next-gen sequencing of cancer genomes. Journal of Clinical Investigation, 2015, 125, 462-468.	3.9	34
1213	C/EBP-Î²-activated microRNA-223 promotes tumour growth through targeting RASA1 in human colorectal cancer. British Journal of Cancer, 2015, 112, 1491-1500.	2.9	55
1214	IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. Science Translational Medicine, 2015, 7, 272ra12.	5.8	100
1215	The Molecular Taxonomy of Colorectal Cancer: Whatâ€™s New?. Current Colorectal Cancer Reports, 2015, 11, 118-124.	1.0	2
1216	A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nature Genetics, 2015, 47, 668-671.	9.4	311
1217	Highly Expressed Genes in Rapidly Proliferating Tumor Cells as New Targets for Colorectal Cancer Treatment. Clinical Cancer Research, 2015, 21, 3695-3704.	3.2	25
1218	An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy. OncoImmunology, 2015, 4, e976052.	2.1	92
1219	dNTP pool levels modulate mutator phenotypes of error-prone DNA polymerase Îµ variants. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E2457-66.	3.3	47
1220	Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer. Journal of Clinical Pathology, 2015, 68, 341-345.	1.0	37
1221	Chronic Inflammation Induces a Novel Epigenetic Program That Is Conserved in Intestinal Adenomas and in Colorectal Cancer. Cancer Research, 2015, 75, 2120-2130.	0.4	91
1222	Concomitant mutation and epimutation of the MLH1 gene in a Lynch syndrome family. Carcinogenesis, 2015, 36, 452-458.	1.3	32

#	Article	IF	Citations
1223	Molecular Pathways: Aspirin and Wnt Signalingâ€"A Molecularly Targeted Approach to Cancer Prevention and Treatment. Clinical Cancer Research, 2015, 21, 1543-1548.	3.2	74
1224	DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. Oncogene, 2015, 34, 5869-5878.	2.6	195
1225	Textbook of Personalized Medicine. , 2015, , .		27
1226	Current and future trends in biomarker discovery and development of companion diagnostics for arthritis. Expert Review of Molecular Diagnostics, 2015, 15, 219-234.	1.5	15
1227	Next Generation Sequencing in Cancer Research, Volume 2. , 2015, , .		4
1228	Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein. Clinical Cancer Research, 2015, 21, 2359-2366.	3.2	125
1229	Targeting Translation Initiation Bypasses Signaling Crosstalk Mechanisms That Maintain High MYC Levels in Colorectal Cancer. Cancer Discovery, 2015, 5, 768-781.	7.7	86
1230	Targeting Wnts at the Sourceâ€"New Mechanisms, New Biomarkers, New Drugs. Molecular Cancer Therapeutics, 2015, 14, 1087-1094.	1.9	94
1231	Exonuclease 1-dependent and independent mismatch repair. DNA Repair, 2015, 32, 24-32.	1.3	115
1232	BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers. Nucleic Acids Research, 2015, 43, e19-e19.	6.5	161
1233	Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients. Cell, 2015, 161, 933-945.	13.5	1,710
1234	Stem cell and progenitor fate in the mammalian intestine: Notch and lateral inhibition in homeostasis and disease. EMBO Reports, 2015, 16, 571-581.	2.0	148
1235	The phosphoinositide 3-kinase pathway and therapy resistance in cancer. F1000prime Reports, 2015, 7, 13.	5.9	91
1236	Frameshift mutations of TAF1C gene, a core component for transcription by RNA polymerase I, and its regional heterogeneity in gastric and colorectal cancers. Pathology, 2015, 47, 101-104.	0.3	10
1237	Sporadic Microsatellite Instability-High Colon Cancers Rarely Display Immunohistochemical Evidence of Wnt Signaling Activation. American Journal of Surgical Pathology, 2015, 39, 313-317.	2.1	29
1238	Somatic<i>POLE</i>mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis. Neuro-Oncology, 2015, 17, 1356-1364.	0.6	94
1239	CMPD: cancer mutant proteome database. Nucleic Acids Research, 2015, 43, D849-D855.	6.5	13
1240	HES5 silencing is an early and recurrent change in prostate tumourigenesis. Endocrine-Related Cancer, 2015, 22, 131-144.	1.6	10

#	Article	IF	Citations
1241	Methionine to isothreonine conversion as a source of false discovery identifications of genetically encoded variants in proteogenomics. Journal of Proteomics, 2015, 120, 169-178.	1.2	24
1242	The Promise of Multi-Omics and Clinical Data Integration to Identify and Target Personalized Healthcare Approaches in Autism Spectrum Disorders. OMICS A Journal of Integrative Biology, 2015, 19, 197-208.	1.0	84
1243	Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. Annals of Oncology, 2015, 26, 1710-1714.	0.6	120
1244	Genetics of the Serrated Pathway to Colorectal Cancer. Clinical and Translational Gastroenterology, 2015, 6, e84.	1.3	22
1245	KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer. Molecular Oncology, 2015, 9, 1341-1347.	2.1	37
1246	Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies. Biomarkers in Medicine, 2015, 9, 363-375.	0.6	11
1247	The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. Cancer Cell, 2015, 28, 515-528.	7.7	426
1248	Genotyping concordance in DNA extracted from formalinâ€fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses. Molecular Oncology, 2015, 9, 1868-1876.	2.1	29
1250	MicroRNA Involvement in Intestinal Tumorigenesis. , 2015, , 169-188.		0
1251	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in <i>BRAF</i> V600â€"Mutant Colorectal Cancer. Journal of Clinical Oncology, 2015, 33, 4023-4031.	0.8	430
1252	Genomic alterations in <i>BCL2L1</i> and <i>DLC1</i> contribute to drug sensitivity in gastric cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 12492-12497.	3.3	46
1253	Biobanking for Personalized Medicine. Advances in Experimental Medicine and Biology, 2015, 864, 55-68.	0.8	41
1254	Intron retention is a widespread mechanism of tumor-suppressor inactivation. Nature Genetics, 2015, 47, 1242-1248.	9.4	322
1255	Right- and left-sided colorectal cancers respond differently to cetuximab. Chinese Journal of Cancer, 2015, 34, 384-93.	4.9	63
1256	MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by<i>TP53</i>Mutation in Preclinical Models of Colorectal Cancer. Clinical Cancer Research, 2015, 21, 5499-5510.	3.2	18
1257	Elucidating the molecular aspects of colorectal cancer and their clinical importance. Colorectal Cancer, 2015, 4, 175-183.	0.8	0
1258	The RYK Receptor Family. , 2015, , 685-741.		6
1259	Machine Learning-based Classification of Diffuse Large B-cell Lymphoma Patients by Their Protein Expression Profiles. Molecular and Cellular Proteomics, 2015, 14, 2947-2960.	2.5	73

#	Article	IF	Citations
1260	Immune checkpoints and immunotherapy for colorectal cancer. Gastroenterology Report, 2015, 3, gov053.	0.6	80
1261	Detection of Clonal and Subclonal Copy-Number Variants in Cell-Free DNA from Patients with Breast Cancer Using a Massively Multiplexed PCR Methodology. Translational Oncology, 2015, 8, 407-416.	1.7	43
1262	Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages. BMC Cancer, 2015, 15, 340.	1.1	61
1263	Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in<i>MET</i>-Amplified Esophagogastric Cancer. Cancer Discovery, 2015, 5, 1271-1281.	7.7	162
1264	ATM rs189037 (G>A) polymorphism and risk of lung cancer and head and neck cancer: A meta-analysis. Meta Gene, 2015, 6, 42-48.	0.3	12
1265	Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas. BMC Cancer, 2015, 15, 32.	1.1	34
1266	Markers in Colorectal Cancer and Clinical Trials Based Upon Them. Current Colorectal Cancer Reports, 2015, 11, 317-325.	1.0	0
1267	Molecular and Histologic Considerations in the Assessment of Serrated Polyps. Archives of Pathology and Laboratory Medicine, 2015, 139, 730-741.	1.2	40
1268	Identification of Colorectal Cancer Candidate Genes Based on Subnetwork Extraction Algorithm. Lecture Notes in Computer Science, 2015, , 706-712.	1.0	0
1269	The Personalization of Therapy: Molecular Profiling Technologies and Their Application. Seminars in Oncology, 2015, 42, 775-787.	0.8	6
1270	Transcriptomic characterization of fibrolamellar hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5916-25.	3.3	103
1271	BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis. Molecular Cancer Therapeutics, 2015, 14, 2762-2772.	1.9	18
1272	Mitochondrial DNA copy number in colorectal cancer: between tissue comparisons, clinicopathological characteristics and survival. Carcinogenesis, 2015, 36, bgv151.	1.3	36
1273	Clinical and prognostic value of MET gene copy number gain and chromosome 7 polysomy in primary colorectal cancer patients. Tumor Biology, 2015, 36, 9813-9821.	0.8	8
1274	The path to routine use of genomic biomarkers in the cancer clinic. Genome Research, 2015, 25, 1508-1513.	2.4	35
1275	Type I IFN induces protein ISGylation to enhance cytokine expression and augments colonic inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14313-14318.	3.3	41
1276	Pan-Cancer Analysis of Mutation Hotspots in Protein Domains. Cell Systems, 2015, 1, 197-209.	2.9	94
1277	Precision medicine in oncology drug development: a pharma perspective. Drug Discovery Today, 2015, 20, 1455-1463.	3.2	24

#	Article	IF	Citations
1278	Durable recurrence-free survival after pneumonectomy for late lung metastasis from rectal cancer: case report with genetic and epigenetic analyses. BMC Cancer, 2015, 15, 567.	1.1	0
1279	Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). Clinical Cancer Research, 2015, 21, 5294-5304.	3.2	70
1280	Prognostic and Predictive Biomarkers in Colorectal Cancer: Implications for the Clinical Surgeon. Annals of Surgical Oncology, 2015, 22, 3433-3450.	0.7	24
1281	ERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer Development. Cancer Cell, 2015, 28, 183-197.	7.7	67
1282	SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer. Cell Research, 2015, 25, 445-458.	5.7	36
1283	Pan-cancer stratification of solid human epithelial tumors and cancer cell lines reveals commonalities and tissue-specific features of the CpG island methylator phenotype. Epigenetics and Chromatin, 2015, 8, 14.	1.8	42
1284	Expression quantitative trait locus analysis for translational medicine. Genome Medicine, 2015, 7, 60.	3.6	69
1285	Differential Effects of Hepatocyte Nuclear Factor 4Î± Isoforms on Tumor Growth and T-Cell Factor 4/AP-1 Interactions in Human Colorectal Cancer Cells. Molecular and Cellular Biology, 2015, 35, 3471-3490.	1.1	57
1286	Modulation of LSD1 phosphorylation by CK2/WIP1 regulates RNF168-dependent 53BP1 recruitment in response to DNA damage. Nucleic Acids Research, 2015, 43, 5936-5947.	6.5	63
1287	Targeting Wnt signaling in colorectal cancer. A Review in the Theme: Cell Signaling: Proteins, Pathways and Mechanisms. American Journal of Physiology - Cell Physiology, 2015, 309, C511-C521.	2.1	276
1288	Deficient mismatch repair in colorectal cancer: current perspectives on patient management and future directions. Colorectal Cancer, 2015, 4, 69-83.	0.8	0
1289	Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers. Journal of Molecular Diagnostics, 2015, 17, 487-495.	1.2	53
1290	Eukaryotic Mismatch Repair in Relation to DNA Replication. Annual Review of Genetics, 2015, 49, 291-313.	3.2	342
1291	Comprehensive assessment of cancer missense mutation clustering in protein structures. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5486-95.	3.3	195
1292	Racial Disparities in Colorectal Cancer Survival: Is Elimination of Variation in Care the Cure?. Journal of the National Cancer Institute, 2015, 107, djv229.	3.0	12
1293	Limited evidence that cancer susceptibility regions are preferential targets for somatic mutation. Genome Biology, 2015, 16, 193.	3.8	19
1294	Genetic Variants That Predispose to DNA Double-Strand Breaks in Lymphocytes From a Subset of Patients With Familial Colorectal Carcinomas. Gastroenterology, 2015, 149, 1872-1883.e9.	0.6	31
1295	Integrated transcriptional profiling and genomic analyses reveal RPN2 and HMGB1 as promising biomarkers in colorectal cancer. Cell and Bioscience, 2015, 5, 53.	2.1	29

#	Article	IF	Citations
1296	Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Modern Pathology, 2015, 28, 1481-1491.	2.9	226
1297	The consensus molecular subtypes of colorectal cancer. Nature Medicine, 2015, 21, 1350-1356.	15.2	3,596
1298	The mini-driver model of polygenic cancer evolution. Nature Reviews Cancer, 2015, 15, 680-685.	12.8	104
1299	The E3 ligase RNF43 inhibits Wnt signaling downstream of mutated Î²-catenin by sequestering TCF4 to the nuclear membrane. Science Signaling, 2015, 8, ra90.	1.6	67
1300	TFF2â€"CXCR4 Axis Is Associated with <i>BRAF</i> V600E Colon Cancer. Cancer Prevention Research, 2015, 8, 614-619.	0.7	9
1301	Patterns of Chromosomal Aberrations in Solid Tumors. Recent Results in Cancer Research, 2015, 200, 115-142.	1.8	44
1303	Reprint of â€œAbstraction for data integration: Fusing mammalian molecular, cellular and phenotype big datasets for better knowledge extractionâ€. Computational Biology and Chemistry, 2015, 59, 123-138.	1.1	14
1304	Endoplasmic reticulum ribosome-binding protein 1, RRBP1, promotes progression of colorectal cancer and predicts an unfavourable prognosis. British Journal of Cancer, 2015, 113, 763-772.	2.9	39
1305	How to Identify the Right Patients for the Right Treatment in Metastatic Colorectal Cancer (mCRC). Current Colorectal Cancer Reports, 2015, 11, 151-159.	1.0	2
1306	Genetic Landscape of Primary Versus Metastatic Colorectal Cancer: to What Extent Are They Concordant?. Current Colorectal Cancer Reports, 2015, 11, 217-224.	1.0	1
1307	LncRNAs: emerging biomarkers in gastric cancer. Future Oncology, 2015, 11, 2427-2441.	1.1	92
1308	Cancer Genetics and Implications for Clinical Management. Surgical Clinics of North America, 2015, 95, 919-934.	0.5	6
1309	Genomic Characterization of Upper Tract Urothelial Carcinoma. European Urology, 2015, 68, 970-977.	0.9	202
1310	Colon Tumors with the Simultaneous Induction of Driver Mutations in <i>APC</i>, <i>KRAS</i>, and <i>PIK3CA</i> Still Progress through the Adenoma-to-carcinoma Sequence. Cancer Prevention Research, 2015, 8, 952-961.	0.7	22
1311	Assessment of the <i>In Vivo</i> Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer. Molecular Cancer Therapeutics, 2015, 14, 2175-2186.	1.9	12
1312	Predicting Future Scientific Discoveries Based on a Networked Analysis of the Past Literature. , 2015, , .		22
1313	Current and future molecular profiling of cancer by next-generation sequencing: Table 1.. Japanese Journal of Clinical Oncology, 2015, 45, 895-899.	0.6	12
1314	Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification. Case Reports in Oncology, 2015, 8, 83-87.	0.3	24

#	Article	IF	Citations
1315	Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer. Drug Discovery Today, 2015, 20, 1391-1397.	3.2	74
1316	Whole-Genome Sequencing of Growth Hormone (GH)-Secreting Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3918-3927.	1.8	96
1317	Patterns of somatic uniparental disomy identify novel tumor suppressor genes in colorectal cancer. Carcinogenesis, 2015, 36, 1103-1110.	1.3	18
1318	Lipid Cooperativity as a General Membrane-Recruitment Principle for PH Domains. Cell Reports, 2015, 12, 1519-1530.	2.9	59
1319	Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer. British Journal of Cancer, 2015, 113, 979-988.	2.9	35
1320	Emerging drugs in refractory colorectal cancer. Future Medicinal Chemistry, 2015, 7, 1491-1501.	1.1	3
1321	Inferred miRNA activity identifies miRNA-mediated regulatory networks underlying multiple cancers. Bioinformatics, 2016, 32, 96-105.	1.8	31
1322	Impact of Biomarkers on Personalized Medicine. Handbook of Experimental Pharmacology, 2015, 232, 285-311.	0.9	11
1323	Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2. Drugs, 2015, 75, 1739-1756.	4.9	6
1324	Empowering biologists with multi-omics data: colorectal cancer as a paradigm. Bioinformatics, 2015, 31, 1436-1443.	1.8	22
1325	Identification of recurrent regulated alternative splicing events across human solid tumors. Nucleic Acids Research, 2015, 43, 5130-5144.	6.5	137
1326	Knowledge boosting: a graph-based integration approach with multi-omics data and genomic knowledge for cancer clinical outcome prediction. Journal of the American Medical Informatics Association: JAMIA, 2015, 22, 109-120.	2.2	79
1327	KRAS mutations in microsatellite instable gastric tumours: impact of targeted treatment and intratumoural heterogeneity. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 383-392.	1.4	6
1328	SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression. Oncogenesis, 2015, 4, e162-e162.	2.1	50
1329	Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. Cancer Research, 2015, 75, 4790-4802.	0.4	127
1330	An integrative pan-cancer-wide analysis of epigenetic enzymes reveals universal patterns of epigenomic deregulation in cancer. Genome Biology, 2015, 16, 140.	3.8	60
1331	Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus. Future Oncology, 2015, 11, 2711-2719.	1.1	5
1332	Potential of DNA methylation in rectal cancer as diagnostic and prognostic biomarkers. British Journal of Cancer, 2015, 113, 1035-1045.	2.9	25

#	Article	IF	Citations
1333	Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nature Genetics, 2015, 47, 1194-1199.	9.4	221
1334	Molecular phenotypes of colorectal cancer and potential clinical applications. Gastroenterology Report, 2015, 3, gov046.	0.6	105
1335	Epstein-Barr Virus-Associated Gastric Carcinoma: Use of Host Cell Machineries and Somatic Gene Mutations. Pathobiology, 2015, 82, 212-223.	1.9	46
1336	The molecular landscape of premenopausal breast cancer. Breast Cancer Research, 2015, 17, 104.	2.2	56
1337	Bisulfite-Based DNA Methylation Analysis from Recent and Archived Formalin-Fixed, Paraffin Embedded Colorectal Tissue Samples. Pathology and Oncology Research, 2015, 21, 1149-1156.	0.9	10
1338	FIRE-3 and C80405: Is There a Best Choice for Initial Treatment of Metastatic Colorectal Cancer?. Current Colorectal Cancer Reports, 2015, 11, 298-302.	1.0	0
1339	Bevacizumab beyond first disease progression in metastatic colorectal cancer: a review of recent clinical trial data. Colorectal Cancer, 2015, 4, 13-25.	0.8	0
1340	Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale. Current Opinion in Genetics and Development, 2015, 30, 1-6.	1.5	57
1341	Comprehensive functional characterization of cancerâ€"testis antigens defines obligate participation in multiple hallmarks of cancer. Nature Communications, 2015, 6, 8840.	5.8	94
1342	Therapeutic targets in the Wnt signaling pathway: Feasibility of targeting TNIK in colorectal cancer. , 2015, 156, 1-9.		64
1343	The mathematics of cancer: integrating quantitative models. Nature Reviews Cancer, 2015, 15, 730-745.	12.8	539
1344	The Cancer Genome Atlas Clinical Explorer: a web and mobile interface for identifying clinicalâ€"genomic driver associations. Genome Medicine, 2015, 7, 112.	3.6	80
1345	Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Molecular Oncology, 2015, 9, 1936-1965.	2.1	64
1346	Frequency and phenotypic spectrum of germline mutations in <scp><i>POLE</i></scp> and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. International Journal of Cancer, 2015, 137, 320-331.	2.3	121
1347	Only three driver gene mutations are required for the development of lung and colorectal cancers. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 118-123.	3.3	325
1348	Global DNA Methylation Profiling Technologies and the Ovarian Cancer Methylome. Methods in Molecular Biology, 2015, 1238, 653-675.	0.4	22
1349	Heterogeneous DNA methylation contributes to tumorigenesis through inducing the loss of coexpression connectivity in colorectal cancer. Genes Chromosomes and Cancer, 2015, 54, 110-121.	1.5	15
1350	ATM and ATR as therapeutic targets in cancer. , 2015, 149, 124-138.		487

#	Article	IF	Citations
1351	Snowball: resampling combined with distance-based regression to discover transcriptional consequences of a driver mutation. Bioinformatics, 2015, 31, 84-93.	1.8	5
1352	MicroRNAs: new players in IBD. Gut, 2015, 64, 504-513.	6.1	223
1353	Development of a robust classifier for quality control of reverse-phase protein arrays. Bioinformatics, 2015, 31, 912-918.	1.8	43
1354	Molecular Subtyping of Colorectal Cancer: Time to Explore BothÂIntertumoral and Intratumoral Heterogeneity toÂEvaluateÂPatient Outcome. Gastroenterology, 2015, 148, 10-13.	0.6	27
1355	Translational control by oncogenic signaling pathways. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2015, 1849, 753-765.	0.9	40
1356	Colorectal serrated pathway cancers and precursors. Histopathology, 2015, 66, 49-65.	1.6	88
1357	Polymorphisms in microRNA genes as predictors of clinical outcomes in colorectal cancer patients. Carcinogenesis, 2015, 36, 82-86.	1.3	47
1358	Vanno: A Visualization-Aided Variant Annotation Tool. Human Mutation, 2015, 36, 167-174.	1.1	6
1359	Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients. Clinical Cancer Research, 2015, 21, 357-364.	3.2	127
1360	Rectal cancer profiling identifies distinct subtypes in India based on age at onset, genetic, epigenetic and clinicopathological characteristics. Molecular Carcinogenesis, 2015, 54, 1786-1795.	1.3	12
1361	Portrait of the PI3K/AKT pathway in colorectal cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1855, 104-121.	3.3	205
1363	TRAF2 is an NF-Î°B-activating oncogene in epithelial cancers. Oncogene, 2015, 34, 209-216.	2.6	54
1364	The AMP-activated protein kinase (AMPK) and cancer: Many faces of a metabolic regulator. Cancer Letters, 2015, 356, 165-170.	3.2	289
1365	Gut microbiome and anticancer immune response: really hot Sh*t!. Cell Death and Differentiation, 2015, 22, 199-214.	5.0	100
1366	Driver and Passenger Mutations in Cancer. Annual Review of Pathology: Mechanisms of Disease, 2015, 10, 25-50.	9.6	291
1367	SWI/SNF Chromatin Remodeling and Human Malignancies. Annual Review of Pathology: Mechanisms of Disease, 2015, 10, 145-171.	9.6	242
1368	Recent Therapeutic Advances in the Treatment of Colorectal Cancer. Annual Review of Medicine, 2015, 66, 83-95.	5.0	162
1369	Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. Pharmacogenomics Journal, 2015, 15, 69-76.	0.9	25

#	Article	IF	Citations
1370	Germline variants in POLE are associated with early onset mismatch repair deficient colorectal cancer. European Journal of Human Genetics, 2015, 23, 1080-1084.	1.4	101
1371	Molecular markers for colon diagnosis, prognosis and targeted therapy. Journal of Surgical Oncology, 2015, 111, 96-102.	0.8	50
1372	Cumulative effects of genetic markers and the detection of advanced colorectal neoplasias by population screening. Clinical Genetics, 2015, 88, 234-240.	1.0	5
1373	IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo. Nature, 2015, 517, 626-630.	13.7	117
1374	Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Modern Pathology, 2015, 28, 505-514.	2.9	180
1375	GSK-3 modulates cellular responses to a broad spectrum of kinase inhibitors. Nature Chemical Biology, 2015, 11, 58-63.	3.9	28
1376	Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer. Gut, 2015, 64, 636-645.	6.1	163
1377	<scp><i>POLE</i></scp> mutations as an alternative pathway for microsatellite instability in endometrial cancer: Implications for <scp>L</scp>ynch syndrome testing. Cancer, 2015, 121, 331-334.	2.0	17
1378	Defining the genomic landscape of head and neck cancers through nextâ€generation sequencing. Oral Diseases, 2015, 21, e11-24.	1.5	23
1379	Comparison of gene expression patterns across 12 tumor types identifies a cancer supercluster characterized by TP53 mutations and cell cycle defects. Oncogene, 2015, 34, 2732-2740.	2.6	46
1380	<scp>L</scp>ynchâ€like syndrome: Characterization and comparison with EPCAM deletion carriers. International Journal of Cancer, 2015, 136, 1568-1578.	2.3	40
1381	Transgenic expression of oncogenic BRAF induces loss of stem cells in the mouse intestine, which is antagonized by Î²-catenin activity. Oncogene, 2015, 34, 3164-3175.	2.6	36
1382	Polymerase É› (<scp><i>POLE</i></scp>) mutations in endometrial cancer: Clinical outcomes and implications for <scp>L</scp>ynch syndrome testing. Cancer, 2015, 121, 386-394.	2.0	142
1383	Affinity proteomics led identification of vimentin as a potential biomarker in colon cancers: insights from serological screening and computational modelling. Molecular BioSystems, 2015, 11, 159-169.	2.9	23
1384	Frameshift Mutations of Cadherin Genes DCHS2, CDH10 and CDH24 Genes in Gastric and Colorectal Cancers with High Microsatellite Instability. Pathology and Oncology Research, 2015, 21, 181-185.	0.9	31
1385	We are all individualsâ€¦ bioinformatics in the personalized medicine era. Cellular Oncology (Dordrecht), 2015, 38, 29-37.	2.1	5
1386	Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene, 2015, 34, 3617-3626.	2.6	211
1387	Genomic Applications in Pathology. , 2015, , .		1

#	Article	IF	Citations
1388	Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. Oncotarget, 2016, 7, 66595-66605.	0.8	78
1389	Two subtypes of colorectal tumor with distinct molecular features in familial adenomatous polyposis. Oncotarget, 2016, 7, 84003-84016.	0.8	5
1390	The Emerging Role of NOD-like Receptors in Colorectal Cancer. Journal of Neoplasm, 2016, 01, .	0.1	1
1391	CoGAPS matrix factorization algorithm identifies transcriptional changes in AP-2alpha target genes in feedback from therapeutic inhibition of the EGFR network. Oncotarget, 2016, 7, 73845-73864.	0.8	16
1393	Microsatellite Instability and its Significance to Hereditary and Sporadic Cancer. , 0, , .		6
1394	Mining Datasets for Molecular Subtyping in Cancer. Journal of Data Mining in Genomics & Proteomics, 2016, 07, .	0.5	1
1395	Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget, 2016, 7, 67495-67506.	0.8	42
1396	Recurrent, truncating <i>SOX9</i> mutations are associated with SOX9 overexpression, <i>KRAS</i> mutation, and <i>TP53</i> wild type status in colorectal carcinoma. Oncotarget, 2016, 7, 50875-50882.	0.8	26
1397	Diet- and Genetically-induced Obesity Produces Alterations in the Microbiome, Inflammation and <i>Wnt </i>Pathway in the Intestine of Apc^{+/1638N} Mice: Comparisons and Contrasts. Journal of Cancer, 2016, 7, 1780-1790.	1.2	61
1398	IGF-2 Growth Factor Expression in Human Rectal Adenocarcinoma. , 2016, 6, .		3
1399	Genomics of Colorectal Cancer in African Americans. Journal of Next Generation Sequencing & Applications, 2016, 3, .	0.3	9
1400	Mutations of <i>KRAS/NRAS/BRAF</i> predict cetuximab resistance in metastatic colorectal cancer patients. Oncotarget, 2016, 7, 22257-22270.	0.8	109
1401	Important molecular genetic markers of colorectal cancer. Oncotarget, 2016, 7, 53959-53983.	0.8	91
1402	Mutation analysis of 13 driver genes of colorectal cancer-related pathways in Taiwanese patients. World Journal of Gastroenterology, 2016, 22, 2314-2325.	1.4	28
1403	HOXB7 and Hsa-miR-222 as the Potential Therapeutic Candidates for Metastatic Colorectal Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2016, 11, 434-443.	0.8	13
1404	MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a <i>de novo</i> phenomenon. Oncotarget, 2016, 7, 54627-54631.	0.8	53
1405	Characterization of novel low passage primary and metastatic colorectal cancer cell lines. Oncotarget, 2016, 7, 14499-14509.	0.8	11
1406	Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy. OncoTargets and Therapy, 2016, Volume 9, 4695-4703.	1.0	12

#	Article	IF	Citations
1407	What is the Current Role of Immunotherapy for Colon Cancer?. Reviews on Recent Clinical Trials, 2016, 11, 93-98.	0.4	4
1408	New trends in molecular and cellular biomarker discovery for colorectal cancer. World Journal of Gastroenterology, 2016, 22, 5678.	1.4	69
1409	The somatic <i>POLE</i> P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy. Oncotarget, 2016, 7, 68638-68649.	0.8	59
1410	HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. Oncotarget, 2016, 7, 69060-69074.	0.8	29
1411	The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. Journal of Gastrointestinal Oncology, 2016, 7, 771-788.	0.6	84
1412	Mouse models for the discovery of colorectal cancer driver genes. World Journal of Gastroenterology, 2016, 22, 815.	1.4	8
1413	Genomic and epigenomic heterogeneity in molecular subtypes of gastric cancer. World Journal of Gastroenterology, 2016, 22, 1190.	1.4	57
1414	Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine. Oncotarget, 2016, 7, 52493-52516.	0.8	15
1415	LGALS3 and AXIN1 gene variants playing role in the Wnt/ Î²-catenin signaling pathway are associated with mucinous component and tumor size in colorectal cancer. Bosnian Journal of Basic Medical Sciences, 2016, 16, 108-13.	0.6	6
1416	Role of Biologics in First-Line Treatment of Colorectal Cancer. Journal of Oncology Practice, 2016, 12, 1219-1228.	2.5	32
1417	Exploring cancer genomic data from the cancer genome atlas project. BMB Reports, 2016, 49, 607-611.	1.1	64
1418	TNFRSF10C copy number variation is associated with metastatic colorectal cancer. Journal of Gastrointestinal Oncology, 2016, 7, 306-314.	0.6	14
1419	Mutation profiles of synchronous colorectal cancers from a patient with Lynch syndrome suggest distinct oncogenic pathways. Journal of Gastrointestinal Oncology, 2016, 7, E64-E71.	0.6	6
1420	RAS and BRAF in metastatic colorectal cancer management. Journal of Gastrointestinal Oncology, 2016, 7, 687-704.	0.6	56
1421	Beyond RAS and BRAF: a target rich disease that is ripe for picking. Journal of Gastrointestinal Oncology, 2016, 7, 705-712.	0.6	2
1422	Tumoral heterogeneity of breast cancer. Annales De Biologie Clinique, 2016, 74, 653-660.	0.2	53
1423	Increased PTP1B expression and phosphatase activity in colorectal cancer results in a more invasive phenotype and worse patient outcome. Oncotarget, 2016, 7, 21922-21938.	0.8	59
1424	Mutations of Chromatin Structure Regulating Genes in Human Malignancies. Current Protein and Peptide Science, 2016, 17, 411-437.	0.7	25

#	Article	IF	Citations
1425	Enumeration and targeted analysis of <i>KRAS</i>, <i>BRAF</i> and <i>PIK3CA</i> mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer. Oncotarget, 2016, 7, 85349-85364.	0.8	79
1426	An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts. Molecules and Cells, 2016, 39, 77-86.	1.0	110
1427	Abnormal Expressions of DNA Glycosylase Genes NEIL1, NEIL2, and NEIL3 Are Associated with Somatic Mutation Loads in Human Cancer. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-10.	1.9	39
1428	The Role of Chromosomal Instability and Epigenetics in Colorectal Cancers Lacking<i>Î²</i>-Catenin/TCF Regulated Transcription. Gastroenterology Research and Practice, 2016, 2016, 1-11.	0.7	17
1429	Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. BioMed Research International, 2016, 2016, 1-12.	0.9	19
1430	Tumor suppressive role of sestrin2 during colitis and colon carcinogenesis. ELife, 2016, 5, e12204.	2.8	74
1431	Differentially expressed long non-coding RNAs and the prognostic potential in colorectal cancer. Neoplasma, 2016, 63, 977-983.	0.7	100
1432	Wnt Drug Discovery: Weaving Through the Screens, Patents and Clinical Trials. Cancers, 2016, 8, 82.	1.7	38
1433	How the Lab is Changing Our View of Colorectal Cancer. Tumori, 2016, 102, 541-547.	0.6	15
1434	Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. OncoTargets and Therapy, 2016, 9, 1899.	1.0	44
1435	Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer. Oncotarget, 2016, 7, 60807-60822.	0.8	23
1436	Networks and Consortia for Epigenetic Drug Discovery. , 2016, , 143-166.		1
1437	The Integrative Network of Gene Expression, MicroRNA, Methylation and Copy Number Variation in Colon and Rectal Cancer. Current Bioinformatics, 2016, 11, 59-65.	0.7	17
1438	ROMA: Representation and Quantification of Module Activity from Target Expression Data. Frontiers in Genetics, 2016, 7, 18.	1.1	44
1439	Computational Identification of Key Regulators in Two Different Colorectal Cancer Cell Lines. Frontiers in Genetics, 2016, 7, 42.	1.1	10
1440	Immunological Landscape and Clinical Management of Rectal Cancer. Frontiers in Immunology, 2016, 7, 61.	2.2	14
1441	The Emergence of Pan-Cancer CIMP and Its Elusive Interpretation. Biomolecules, 2016, 6, 45.	1.8	22
1442	Frizzled7: A Promising Achillesâ€™ Heel for Targeting the Wnt Receptor Complex to Treat Cancer. Cancers, 2016, 8, 50.	1.7	73

#	Article	IF	Citations
1443	TCF/LEF Transcription Factors: An Update from the Internet Resources. Cancers, 2016, 8, 70.	1.7	111
1444	The Role of Chemokines in Promoting Colorectal Cancer Invasion/Metastasis. International Journal of Molecular Sciences, 2016, 17, 643.	1.8	97
1445	Clinical Application of Targeted Next Generation Sequencing for Colorectal Cancers. International Journal of Molecular Sciences, 2016, 17, 2117.	1.8	13
1446	Analysing multiple types of molecular profiles simultaneously: connecting the needles in the haystack. BMC Bioinformatics, 2016, 17, 77.	1.2	2
1447	Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells. BMC Cancer, 2016, 16, 531.	1.1	6
1449	Individualized Mutation Detection in Circulating Tumor DNA for Monitoring Colorectal Tumor Burden Using a Cancer-Associated Gene Sequencing Panel. PLoS ONE, 2016, 11, e0146275.	1.1	43
1450	Identifying Cancer Subtypes from miRNA-TF-mRNA Regulatory Networks and Expression Data. PLoS ONE, 2016, 11, e0152792.	1.1	59
1451	Mutational Profiles Reveal an Aberrant TGF-Î²-CEA Regulated Pathway in Colon Adenomas. PLoS ONE, 2016, 11, e0153933.	1.1	17
1452	Computational Framework for Prediction of Peptide Sequences That May Mediate Multiple Protein Interactions in Cancer-Associated Hub Proteins. PLoS ONE, 2016, 11, e0155911.	1.1	5
1453	The Characteristics and Prognostic Effect of E-Cadherin Expression in Colorectal Signet Ring Cell Carcinoma. PLoS ONE, 2016, 11, e0160527.	1.1	26
1454	The MYC 3â€² Wnt-Responsive Element Drives Oncogenic MYC Expression in Human Colorectal Cancer Cells. Cancers, 2016, 8, 52.	1.7	11
1455	Pan-cancer methylation and expression profiling of adenocarcinomas revealed epigenetic silencing in the WNT signaling pathway. Neoplasma, 2016, 63, 208-14.	0.7	8
1456	The DNA mismatch repair pathway. , 2016, , 151-177.		2
1457	Drug Discovery via Human-Derived Stem Cell Organoids. Frontiers in Pharmacology, 2016, 7, 334.	1.6	68
1458	Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives. Frontiers in Pharmacology, 2016, 7, 395.	1.6	131
1459	Cross Talk between the Calcium-Sensing Receptor and the Vitamin D System in Prevention of Cancer. Frontiers in Physiology, 2016, 7, 451.	1.3	21
1460	Pathophysiological role of guanylate-binding proteins in gastrointestinal diseases. World Journal of Gastroenterology, 2016, 22, 6434.	1.4	41
1461	MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer. Oncotarget, 2016, 7, 6476-6505.	0.8	93

#	Article	IF	Citations
1462	The State of the Art in Colorectal Cancer Molecular Biomarker Testing. Advances in Anatomic Pathology, 2016, 23, 92-103.	2.4	9
1463	A recellularized human colon model identifies cancer driver genes. Nature Biotechnology, 2016, 34, 845-851.	9.4	91
1464	Activating<i>KRAS</i>mutations are characteristic of oncocytic sinonasal papilloma and associated sinonasal squamous cell carcinoma. Journal of Pathology, 2016, 239, 394-398.	2.1	55
1465	Phosphoproteome analysis of the MAPK pathway reveals previously undetected feedback mechanisms. Proteomics, 2016, 16, 1998-2004.	1.3	6
1466	RES-529. Anti-Cancer Drugs, 2016, 27, 475-487.	0.7	30
1467	Mps1 kinase regulates tumor cell viability via its novel role in mitochondria. Cell Death and Disease, 2016, 7, e2292-e2292.	2.7	14
1468	Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. Clinical Cancer Research, 2016, 22, 4309-4321.	3.2	182
1469	Genomeâ€wide <scp>DNA</scp> methylation profiling of peripheral blood mononuclear cells in irritable bowel syndrome. Neurogastroenterology and Motility, 2016, 28, 410-422.	1.6	29
1470	Next steps for adolescent and young adult oncology workshop: An update on progress and recommendations for the future. Cancer, 2016, 122, 988-999.	2.0	158
1471	Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma. Cancer, 2016, 122, 1017-1028.	2.0	106
1472	From amino acid sequence to bioactivity: The biomedical potential of antitumor peptides. Protein Science, 2016, 25, 1084-1095.	3.1	55
1473	KPNA2 overâ€expression is a potential marker of prognosis and therapeutic sensitivity in colorectal cancer patients. Journal of Surgical Oncology, 2016, 113, 213-217.	0.8	19
1474	Frequent<i>PTPRK-RSPO3</i>fusions and<i>RNF43</i>mutations in colorectal traditional serrated adenoma. Journal of Pathology, 2016, 239, 133-138.	2.1	99
1475	Genetic and epigenetic alterations of micro<scp>RNA</scp>s and implications for human cancers and other diseases. Genes Chromosomes and Cancer, 2016, 55, 193-214.	1.5	52
1476	mutation3D: Cancer Gene Prediction Through Atomic Clustering of Coding Variants in the Structural Proteome. Human Mutation, 2016, 37, 447-456.	1.1	94
1477	Rapid and quantitative discrimination of tumour cells on tissue slices. Nanotechnology, 2016, 27, 235101.	1.3	2
1478	Translating colorectal cancer genetics into clinically useful biomarkers. Colorectal Disease, 2016, 18, 749-762.	0.7	4
1479	Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas. Archives of Pathology and Laboratory Medicine, 2016, 140, 529-535.	1.2	16

#	Article	IF	Citations
1480	Stem Cells Antigen-1 Enriches for a Cancer Stem Cell-Like Subpopulation in Mouse Gastric Cancer. Stem Cells, 2016, 34, 1177-1187.	1.4	21
1481	Discovering potential cancer driver genes by an integrated network-based approach. Molecular BioSystems, 2016, 12, 2921-2931.	2.9	27
1482	Detection of <scp><i>PIK3CA</i></scp> mutations, including a novel mutation of <scp>V344G</scp> in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 <scp>FNA</scp> cases. Cancer Cytopathology, 2016, 124, 485-492.	1.4	6
1483	Wholeâ€exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/Î²â€catenin signaling pathway mutations. Cancer, 2016, 122, 1689-1696.	2.0	20
1484	Increased incidence of <i>FBXW7</i> and <i>POLE</i> proofreading domain mutations in young adult colorectal cancers. Cancer, 2016, 122, 2828-2835.	2.0	41
1485	Singleâ€cell profiling approaches to probing tumor heterogeneity. International Journal of Cancer, 2016, 139, 243-255.	2.3	52
1486	New paradigms in clonal evolution: punctuated equilibrium in cancer. Journal of Pathology, 2016, 240, 126-136.	2.1	69
1487	Quantitative phosphoproteomic analysis of the PI3K-regulated signaling network. Proteomics, 2016, 16, 1992-1997.	1.3	4
1488	Frameshift mutations of a tumor suppressor gene <i><scp>ZNF</scp>292</i> in gastric and colorectal cancers with high microsatellite instability. Apmis, 2016, 124, 556-560.	0.9	15
1489	Integrated genomic profiling identifies micro<scp>RNA</scp>â€92a regulation of <scp>IQGAP</scp>2 in locally advanced rectal cancer. Genes Chromosomes and Cancer, 2016, 55, 311-321.	1.5	9
1490	Inhibition of DNA Methylation at the <i>MLH1</i> Promoter Region Using Pyrroleâ€“Imidazole Polyamide. ACS Omega, 2016, 1, 1164-1172.	1.6	8
1491	TGFÎ² signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype. EMBO Molecular Medicine, 2016, 8, 745-760.	3.3	119
1492	Community detection from genomic datasets across human cancers. , 2016, , .		3
1493	H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-Î²-Catenin Signaling in Colorectal Cancer. EBioMedicine, 2016, 13, 113-124.	2.7	106
1494	Stratification of Digestive Cancers with Different Pathological Features and Survival Outcomes by MicroRNA Expression. Scientific Reports, 2016, 6, 24466.	1.6	35
1495	Functional exploration of colorectal cancer genomes using Drosophila. Nature Communications, 2016, 7, 13615.	5.8	82
1496	The space of enzyme regulation in HeLa cells can be inferred from its intracellular metabolome. Scientific Reports, 2016, 6, 28415.	1.6	15
1497	Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia. Genome Biology, 2016, 17, 140.	3.8	67

#	Article	IF	Citations
1498	The gut microbiota in conventional and serrated precursors of colorectal cancer. Microbiome, 2016, 4, 69.	4.9	206
1499	Pristimerin demonstrates anticancer potential in colorectal cancer cells by inducing G1 phase arrest and apoptosis and suppressing various pro-survival signaling proteins. Oncology Reports, 2016, 35, 1091-1100.	1.2	29
1500	How Cancer Genomics Drives Cancer Biology: Does Synthetic Lethality Explain Mutually Exclusive Oncogenic Mutations?. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 247-255.	2.0	19
1501	Fbxw7-associated drug resistance is reversed by induction of terminal differentiation in murine intestinal organoid culture. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16024.	1.8	31
1502	Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. Journal of Clinical Pathology, 2016, 69, 767-771.	1.0	75
1503	Low expression of centrosomal protein 78 (CEP78) is associated with poor prognosis of colorectal cancer patients. Chinese Journal of Cancer, 2016, 35, 62.	4.9	8
1504	Hypoxia-driven splicing into noncoding isoforms regulates the DNA damage response. Npj Genomic Medicine, 2016, 1, 16020.	1.7	22
1505	Regulation of functional KCNQ1OT1 lncRNA by Î²-catenin. Scientific Reports, 2016, 6, 20690.	1.6	66
1506	Comprehensive site-specific whole genome profiling of stromal and epithelial colonic gene signatures in human sigmoid colon and rectal tissue. Physiological Genomics, 2016, 48, 651-659.	1.0	12
1507	SEPT9 and SHOX2 DNA methylation status and its utility in the diagnosis of colonic adenomas and colorectal adenocarcinomas. Clinical Epigenetics, 2016, 8, 100.	1.8	46
1508	A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC. Nature Communications, 2016, 7, 11743.	5.8	170
1509	A gene browser of colorectal cancer with literature evidence and pre-computed regulatory information to identify key tumor suppressors and oncogenes. Scientific Reports, 2016, 6, 30624.	1.6	3
1510	Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine. Genome Medicine, 2016, 8, 136.	3.6	64
1511	Expression of metastasis suppressor gene <i><scp>AES</scp></i> driven by a Yin Yang (<scp>YY</scp>) element in a CpG island promoter and transcription factor <scp>YY</scp>2. Cancer Science, 2016, 107, 1622-1631.	1.7	17
1513	Identification of cancer-driver genes in focal genomic alterations from whole genome sequencing data. Scientific Reports, 2016, 6, 25582.	1.6	4
1514	Targeting the Microenvironment in Advanced Colorectal Cancer. Trends in Cancer, 2016, 2, 495-504.	3.8	80
1515	DNA Methylation Identifies Loci Distinguishing Hereditary Nonpolyposis Colorectal Cancer Without Germ-Line MLH1/MSH2 Mutation from Sporadic Colorectal Cancer. Clinical and Translational Gastroenterology, 2016, 7, e208.	1.3	14
1516	NQO1 inhibits proteasome-mediated degradation of HIF-1Î±. Nature Communications, 2016, 7, 13593.	5.8	125

#	Article	IF	Citations
1517	Spectrum of Gene Mutations in Colorectal Cancer. Cancer Journal (Sudbury, Mass), 2016, 22, 149-155.	1.0	22
1518	A weighted exact test for mutually exclusive mutations in cancer. Bioinformatics, 2016, 32, i736-i745.	1.8	46
1519	Differential Radiographic Appearance ofBRAFV600Eâ€"Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1536-1543.	2.3	17
1520	Immunotherapy Progress in Mismatch Repairâ€"Deficient Colorectal Cancer and Future Therapeutic Challenges. Cancer Journal (Sudbury, Mass), 2016, 22, 190-195.	1.0	20
1522	Report of a case with gallbladder carcinoma: P53 expression of the peritumor epithelium might predict biliary tract recurrence. International Journal of Surgery Case Reports, 2016, 28, 325-329.	0.2	2
1523	Evaluation of frozen tissue-derived prognostic gene expression signatures in FFPE colorectal cancer samples. Scientific Reports, 2016, 6, 33273.	1.6	11
1524	An integrative and comparative study of pan-cancer transcriptomes reveals distinct cancer common and specific signatures. Scientific Reports, 2016, 6, 33398.	1.6	31
1525	Data integration to prioritize drugs using genomics and curated data. BioData Mining, 2016, 9, 21.	2.2	14
1526	RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres. BMC Cancer, 2016, 16, 825.	1.1	30
1527	Molecular Basis of Colorectal Cancer and Overview of Inherited Colorectal Cancer Syndromes. , 2016, , 383-415.		0
1528	Colorectal Cancer: Surveillance After Curative-Intent Therapy. , 2016, , 555-570.		0
1529	A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes. Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 681-691.	2.2	46
1530	A review of gigaxonin mutations in giant axonal neuropathy (GAN) and cancer. Human Genetics, 2016, 135, 675-684.	1.8	17
1531	Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer. Annals of Oncology, 2016, 27, 801-806.	0.6	39
1532	Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. Clinical Cancer Research, 2016, 22, 2659-2667.	3.2	39
1533	Recent discoveries in the molecular genetics of Lynch syndrome. Familial Cancer, 2016, 15, 395-403.	0.9	18
1534	SETD7 Controls Intestinal Regeneration and Tumorigenesis by Regulating Wnt/Î²-Catenin and Hippo/YAP Signaling. Developmental Cell, 2016, 37, 47-57.	3.1	87
1535	Gene Signature in Sessile Serrated Polyps Identifies Colon Cancer Subtype. Cancer Prevention Research, 2016, 9, 456-465.	0.7	40

#	Article	IF	Citations
1536	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. Journal of Clinical Oncology, 2016, 34, 2141-2147.	0.8	204
1537	Endoplasmic reticulum stress, unfolded protein response and development of colon adenocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 145-154.	1.4	10
1538	Deregulated ERK1/2 MAP kinase signaling promotes aneuploidy by a Fbxw7Î²-Aurora A pathway. Cell Cycle, 2016, 15, 1631-1642.	1.3	5
1539	Genomic Landscape of Colorectal Mucosa and Adenomas. Cancer Prevention Research, 2016, 9, 417-427.	0.7	65
1540	Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. Annals of Oncology, 2016, 27, 1456-1466.	0.6	51
1541	Loss of INI1 expression in colorectal carcinoma is associated with high tumor grade, poor survival, BRAFV600E mutation, and mismatch repair deficiency. Human Pathology, 2016, 55, 83-90.	1.1	20
1542	The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?. Targeted Oncology, 2016, 11, 593-603.	1.7	14
1543	Genomics of SCC: Tumor Formation, Progression, and Future Therapeutic Implications for High-Risk Cutaneous Squamous Cell Carcinoma. , 2016, , 67-102.		1
1544	A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during Tumorigenesis. Cell Stem Cell, 2016, 18, 827-838.	5.2	593
1545	The UVB1 Vitamin D analogue inhibits colorectal carcinoma progression. Journal of Steroid Biochemistry and Molecular Biology, 2016, 163, 193-205.	1.2	10
1546	Understanding mutagenesis through delineation of mutational signatures in human cancer. Carcinogenesis, 2016, 37, 531-540.	1.3	90
1547	Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications. Expert Review of Clinical Pharmacology, 2016, 9, 1091-1108.	1.3	9
1548	<i>BRAF</i> V600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAFâ€"MEK Combination Therapy. Cancer Discovery, 2016, 6, 594-600.	7.7	75
1549	TGF-Î² signaling in liver and gastrointestinal cancers. Cancer Letters, 2016, 379, 166-172.	3.2	113
1550	Epithelial calcineurin controls microbiota-dependent intestinal tumor development. Nature Medicine, 2016, 22, 506-515.	15.2	93
1551	Transgenic Mouse Models of SV40-Induced Cancer. ILAR Journal, 2016, 57, 44-54.	1.8	11
1552	A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma. Clinical Colorectal Cancer, 2016, 15, 337-344.e2.	1.0	33
1553	DNA Methylation and Cancer. , 2016, , 103-134.		4

#	Article	IF	Citations
1554	Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease. Gastroenterology, 2016, 151, 278-287.e6.	0.6	147
1555	Diagnosis and Management of Hereditary Pancreatic Cancer. Recent Results in Cancer Research, 2016, 205, 61-83.	1.8	2
1556	The role of neoantigens in response to immune checkpoint blockade. International Immunology, 2016, 28, 411-419.	1.8	148
1557	Multifaceted enrichment analysis of RNAâ€"RNA crosstalk reveals cooperating micro-societies in human colorectal cancer. Nucleic Acids Research, 2016, 44, 4025-4036.	6.5	14
1558	Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Reports, 2016, 15, 857-865.	2.9	671
1559	Comparative analysis of copy number variations in ulcerative colitis associated and sporadic colorectal neoplasia. BMC Cancer, 2016, 16, 271.	1.1	17
1560	Translocation and deletion breakpoints in cancer genomes are associated with potential non-B DNA-forming sequences. Nucleic Acids Research, 2016, 44, 5673-5688.	6.5	117
1561	Bioinformatic exploration of MTA1-regulated gene networks in colon cancer. Frontiers of Medicine, 2016, 10, 178-182.	1.5	5
1562	Processing ribonucleotides incorporated during eukaryotic DNA replication. Nature Reviews Molecular Cell Biology, 2016, 17, 350-363.	16.1	152
1563	Human Cancers Express a Mutator Phenotype: Hypothesis, Origin, and Consequences. Cancer Research, 2016, 76, 2057-2059.	0.4	84
1564	A new molecular signature method for prediction of driver cancer pathways from transcriptional data. Nucleic Acids Research, 2016, 44, e110-e110.	6.5	15
1565	Zfp703 Is a Wnt/Î²-Catenin Feedback Suppressor Targeting the Î²-Catenin/Tcf1 Complex. Molecular and Cellular Biology, 2016, 36, 1793-1802.	1.1	13
1566	Overexpression of GRO-Î² is associated with an unfavorable outcome in colorectal cancer. Oncology Letters, 2016, 11, 2391-2397.	0.8	5
1567	Opportunities for immunotherapy in microsatellite instable colorectal cancer. Cancer Immunology, Immunotherapy, 2016, 65, 1249-1259.	2.0	67
1568	Inulin: Properties, health benefits and food applications. Carbohydrate Polymers, 2016, 147, 444-454.	5.1	495
1569	Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nature Genetics, 2016, 48, 500-509.	9.4	596
1570	Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer. Clinical Cancer Research, 2016, 22, 4095-4104.	3.2	135
1571	Label-free nanoplasmonic sensing of tumor-associate autoantibodies for early diagnosis of colorectal cancer. Analytica Chimica Acta, 2016, 930, 31-38.	2.6	58

#	Article	IF	Citations
1572	A multidimensional network approach reveals microRNAs as determinants of the mesenchymal colorectal cancer subtype. Oncogene, 2016, 35, 6026-6037.	2.6	49
1573	Suppression of intestinal tumors by targeting the mitotic spindle of intestinal stem cells. Oncogene, 2016, 35, 6109-6119.	2.6	8
1574	High-Risk Cutaneous Squamous Cell Carcinoma. , 2016, , .		5
1575	Driver Gene Mutations in Stools of Colorectal Carcinoma Patients Detected by Targeted Next-Generation Sequencing. Journal of Molecular Diagnostics, 2016, 18, 471-479.	1.2	10
1576	The Immune Biology of Microsatellite-Unstable Cancer. Trends in Cancer, 2016, 2, 121-133.	3.8	193
1577	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 738-746.	5.1	778
1578	Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles. Nature Medicine, 2016, 22, 685-691.	15.2	64
1579	Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. Cancer Discovery, 2016, 6, 703-713.	7.7	92
1580	Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival. BMC Cancer, 2016, 16, 219.	1.1	17
1581	Integrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activity. BMC Systems Biology, 2016, 10, 16.	3.0	24
1582	Carcinoma of the colon and rectum with deregulation of insulin-like growth factor 2 signaling: clinical and molecular implications. Journal of Gastroenterology, 2016, 51, 971-984.	2.3	19
1583	Mismatch Repair and Colon Cancer: Mechanisms and Therapies Explored. Trends in Molecular Medicine, 2016, 22, 274-289.	3.5	136
1584	<i>WRN</i> Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy. Clinical Cancer Research, 2016, 22, 4612-4622.	3.2	9
1585	Impacts of somatic mutations on gene expression: an association perspective. Briefings in Bioinformatics, 2017, 18, bbw037.	3.2	40
1586	Phosphatidylinositol-3 kinase-dependent translational regulation of Id1 involves the PPM1G phosphatase. Oncogene, 2016, 35, 5807-5816.	2.6	13
1587	In vivo overexpression of Emi1 promotes chromosome instability and tumorigenesis. Oncogene, 2016, 35, 5446-5455.	2.6	51
1588	A hot L1 retrotransposon evades somatic repression and initiates human colorectal cancer. Genome Research, 2016, 26, 745-755.	2.4	233
1589	Focusing the Spotlight on the Zebrafish Intestine to Illuminate Mechanisms of Colorectal Cancer. Advances in Experimental Medicine and Biology, 2016, 916, 411-437.	0.8	11

#	Article	IF	Citations
1590	Olfactomedin 4 expression and functions in innate immunity, inflammation, and cancer. Cancer and Metastasis Reviews, 2016, 35, 201-212.	2.7	91
1591	Two-Step Forward Genetic Screen in Mice Identifies RalÂGTPase-Activating Proteins as Suppressors of HepatocellularÂCarcinoma. Gastroenterology, 2016, 151, 324-337.e12.	0.6	27
1592	Effects of mutations in Wnt/Î²-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activityâ€"Diverse effects on cell growth, metabolism and cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 2942-2976.	1.9	137
1593	Interplay Between Transcription Factors and MicroRNAs Regulating Epithelial-Mesenchymal Transitions in Colorectal Cancer. Advances in Experimental Medicine and Biology, 2016, 937, 71-92.	0.8	30
1594	The use of an artificial nucleotide for polymerase-based recognition of carcinogenic<i>O⁶</i>-alkylguanine DNA adducts. Nucleic Acids Research, 2016, 44, 6564-6573.	6.5	20
1595	Wnt-signalling pathways and microRNAs network in carcinogenesis: experimental and bioinformatics approaches. Molecular Cancer, 2016, 15, 56.	7.9	55
1596	Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer. Cancer Letters, 2016, 382, 32-43.	3.2	25
1597	Major milestones in translational oncology. BMC Medicine, 2016, 14, 110.	2.3	15
1598	The Greater Genomic Landscape: The Heterogeneous Evolution of Cancer. Cancer Research, 2016, 76, 5605-5609.	0.4	25
1599	A practical approach to liver metastasis from unknown primary cancer: What surgeons need to know. Cancer Genetics, 2016, 209, 559-566.	0.2	13
1600	Colorectal Cancer Subtypes: Developmental Origin and Microenvironmental Regulation. Trends in Cancer, 2016, 2, 505-518.	3.8	51
1601	Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in Î²-Catenin-Active Cancers. Cell Systems, 2016, 3, 302-316.e4.	2.9	55
1604	Integrated Genetic, Epigenetic, and Transcriptional Profiling Identifies Molecular Pathways in the Development of Laterally Spreading Tumors. Molecular Cancer Research, 2016, 14, 1217-1228.	1.5	20
1605	Epigenetics, Energy Balance, and Cancer. Energy Balance and Cancer, 2016, , .	0.2	2
1606	Epigenetics, Obesity, and Colon Cancer. Energy Balance and Cancer, 2016, , 211-233.	0.2	0
1607	Optimization of cell lines as tumour models by integrating multi-omics data. Briefings in Bioinformatics, 2016, 18, bbw082.	3.2	14
1608	Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. Oncologist, 2016, 21, 1306-1314.	1.9	36
1609	Up-regulation of GTPBP4 in colorectal carcinoma is responsible for tumor metastasis. Biochemical and Biophysical Research Communications, 2016, 480, 48-54.	1.0	21

#	Article	IF	Citations
1610	EphA3 promotes malignant transformation of colorectal epithelial cells by upregulating oncogenic pathways. Cancer Letters, 2016, 383, 195-203.	3.2	16
1611	Single cell lineage tracing reveals a role for TgfÎ²R2 in intestinal stem cell dynamics and differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12192-12197.	3.3	19
1612	Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. The Lancet Gastroenterology and Hepatology, 2016, 1, 207-216.	3.7	227
1613	DNA copy number alterations, gene expression changes and disease-free survival in patients with colorectal cancer: a 10 year follow-up. Cellular Oncology (Dordrecht), 2016, 39, 545-558.	2.1	22
1614	Identifying cancer type specific oncogenes and tumor suppressors using limited size data. Journal of Bioinformatics and Computational Biology, 2016, 14, 1650031.	0.3	9
1615	The genomic landscape of schwannoma. Nature Genetics, 2016, 48, 1339-1348.	9.4	124
1616	Genetic predisposition to colorectal cancer: Implications for treatment and prevention. Seminars in Oncology, 2016, 43, 536-542.	0.8	14
1617	High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells. Cancer Research, 2016, 76, 6950-6963.	0.4	30
1618	Expression and prognostic value of E2F activators in NSCLC and subtypes: a research based on bioinformatics analysis. Tumor Biology, 2016, 37, 14979-14987.	0.8	17
1619	The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers. Seminars in Cell and Developmental Biology, 2016, 58, 108-117.	2.3	10
1620	Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer. Cell, 2016, 166, 1041-1054.	13.5	206
1621	Prognostic value of 5-microRNA based signature in T2-T3N0 colon cancer. Clinical and Experimental Metastasis, 2016, 33, 765-773.	1.7	52
1622	The miR-17 â^¼ 92 microRNA Cluster Is a Global Regulator of Tumor Metabolism. Cell Reports, 2016, 16, 1915-1928.	2.9	58
1623	Genetics and epigenetics in small intestinal neuroendocrine tumours. Journal of Internal Medicine, 2016, 280, 584-594.	2.7	31
1624	A novel somatic MAPK1 mutation in primary ovarian mixed germ cell tumors. Oncology Reports, 2016, 35, 725-730.	1.2	8
1625	Advancements in Modeling Colorectal Cancer in Rodents. Current Colorectal Cancer Reports, 2016, 12, 274-280.	1.0	0
1626	Somatic mutation profiles in primary colorectal cancers and matching ovarian metastases: Identification of driver and passenger mutations. Journal of Pathology: Clinical Research, 2016, 2, 166-174.	1.3	12
1627	Molecular differences in the microsatellite stable phenotype between leftâ€sided and rightâ€sided colorectal cancer. International Journal of Cancer, 2016, 139, 2493-2501.	2.3	31

#	Article	IF	Citations
1628	The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026930.	2.9	309
1629	Methylglyoxal suppresses human colon cancer cell lines and tumor growth in a mouse model by impairing glycolytic metabolism of cancer cells associated with down-regulation of c-Myc expression. Cancer Biology and Therapy, 2016, 17, 955-965.	1.5	17
1630	Sterol Regulatory Element Binding Protein Regulates the Expression and Metabolic Functions of Wild-Type and Oncogenic <i>IDH1</i>. Molecular and Cellular Biology, 2016, 36, 2384-2395.	1.1	25
1631	Inflammatory response in serrated precursor lesions of the colon classified according to WHO entities, clinical parameters and phenotypeâ€"genotype correlation. Journal of Pathology: Clinical Research, 2016, 2, 113-124.	1.3	18
1632	<scp>W</scp>nt Signaling Inhibition Deprives Small Intestinal Stem Cells of Clonogenic Capacity. Genesis, 2016, 54, 101-114.	0.8	12
1633	A<i>NOTCH1</i>gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer. International Journal of Cancer, 2016, 138, 195-205.	2.3	35
1634	Genetic and epigenetic aberrations occurring in colorectal tumors associated with serrated pathway. International Journal of Cancer, 2016, 138, 1634-1644.	2.3	41
1635	Mouse models of intestinal cancer. Journal of Pathology, 2016, 238, 141-151.	2.1	109
1636	Phosphoproteome Characterization of Human Colorectal Cancer SW620 Cell-Derived Exosomes and New Phosphosite Discovery for C-HPP. Journal of Proteome Research, 2016, 15, 4060-4072.	1.8	31
1637	Pathology of premalignant colorectal neoplasia. Digestive Endoscopy, 2016, 28, 312-323.	1.3	19
1638	Distribution of the câ€‹<scp>MYC</scp> gene product in colorectal neoplasia. Histopathology, 2016, 69, 222-229.	1.6	13
1639	Mass spectrometry based translational proteomics for biomarker discovery and application in colorectal cancer. Proteomics - Clinical Applications, 2016, 10, 503-515.	0.8	15
1640	<scp>TP</scp>53 mutation at early stage of colorectal cancer progression from two types of laterally spreading tumors. Cancer Science, 2016, 107, 820-827.	1.7	18
1641	A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics. British Journal of Cancer, 2016, 115, 848-857.	2.9	108
1642	Testing <i>ERBB2</i> p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer. Journal of Physical Education and Sports Management, 2016, 2, a001016.	0.5	5
1643	Targeted molecular profiling of rare genetic alterations in colorectal cancer using next-generation sequencing. Medical Oncology, 2016, 33, 106.	1.2	23
1644	Colorectal Cancer with Residual Polyp of Origin: A Model of Malignant Transformation. Translational Oncology, 2016, 9, 280-286.	1.7	9
1645	Higher Order Chromatin Modulator Cohesin SA1 Is an Early Biomarker for Colon Carcinogenesis: Race-Specific Implications. Cancer Prevention Research, 2016, 9, 844-854.	0.7	11

#	Article	IF	Citations
1646	The Genomic Fabric Perspective on the Transcriptome Between Universal Quantifiers and Personalized Genomic Medicine. Biological Theory, 2016, 11, 123-137.	0.8	16
1647	The multi-omic landscape of transcription factor inactivation in cancer. Genome Medicine, 2016, 8, 89.	3.6	26
1648	Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Molecular Cancer, 2016, 15, 55.	7.9	212
1649	Colorectal Cancer. Gastroenterology Clinics of North America, 2016, 45, 459-476.	1.0	40
1650	The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms. Clinics in Colon and Rectal Surgery, 2016, 29, 232-238.	0.5	17
1651	Heritable Gastrointestinal Cancer Syndromes. Gastroenterology Clinics of North America, 2016, 45, 509-527.	1.0	15
1652	Olfactomedin 1 negatively regulates <scp>NFâ€ÎºB</scp> signalling and suppresses the growth and metastasis of colorectal cancer cells. Journal of Pathology, 2016, 240, 352-365.	2.1	31
1653	Iron Uptake via DMT1 Integrates Cell Cycle with JAK-STAT3 Signaling to Promote Colorectal Tumorigenesis. Cell Metabolism, 2016, 24, 447-461.	7.2	168
1654	Unexpected frequency of genomic alterations in histologically normal colonic tissue from colon cancer patients. Tumor Biology, 2016, 37, 13831-13842.	0.8	8
1655	Systems medicine in colorectal cancer: from a mathematical model toward a new type of clinical trial. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2016, 8, 314-336.	6.6	11
1656	Molecular Evaluation of Colorectal Adenocarcinoma. Surgical Pathology Clinics, 2016, 9, 427-439.	0.7	16
1657	How Many Lymph Nodes Are Enough? Assessing the Adequacy of Lymph Node Yield for Papillary Thyroid Cancer. Journal of Clinical Oncology, 2016, 34, 3434-3439.	0.8	85
1658	An Evolutionary Genetic Perspective on Cancer Biology. Annual Review of Ecology, Evolution, and Systematics, 2016, 47, 25-49.	3.8	10
1659	Targeted nanoparticles for colorectal cancer. Nanomedicine, 2016, 11, 2443-2456.	1.7	117
1660	Epigenome-wide analysis of DNA methylation reveals a rectal cancer-specific epigenomic signature. Epigenomics, 2016, 8, 1193-1207.	1.0	22
1661	Advances in Biomarkers: Going Beyond the Carcinoembryonic Antigen. Clinics in Colon and Rectal Surgery, 2016, 29, 196-204.	0.5	10
1662	Stem cell competition in the gut: insights from multi-scale computational modelling. Journal of the Royal Society Interface, 2016, 13, 20160218.	1.5	18
1663	A genetic network that suppresses genome rearrangements in Saccharomyces cerevisiae and contains defects in cancers. Nature Communications, 2016, 7, 11256.	5.8	36

#	Article	IF	Citations
1665	In-depth comparison of somatic point mutation callers based on different tumor next-generation sequencing depth data. Scientific Reports, 2016, 6, 36540.	1.6	99
1666	Leveraging premalignant biology for immune-based cancer prevention. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10750-10758.	3.3	57
1667	Transcriptome analysis of paired primary colorectal carcinoma and liver metastases reveals fusion transcripts and similar gene expression profiles in primary carcinoma and liver metastases. BMC Cancer, 2016, 16, 539.	1.1	30
1668	Cancer cells that survive checkpoint adaptation contain micronuclei that harbor damaged DNA. Cell Cycle, 2016, 15, 3131-3145.	1.3	47
1669	Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. Oncologist, 2016, 21, 1200-1211.	1.9	211
1670	Clinical and Molecular Characteristics of Post-Colonoscopy Colorectal Cancer: A Population-based Study. Gastroenterology, 2016, 151, 870-878.e3.	0.6	53
1671	MonoSeq Variant Caller Reveals Novel Mononucleotide Run Indel Mutations in Tumors with Defective DNA Mismatch Repair. Human Mutation, 2016, 37, 1004-1012.	1.1	6
1672	Cancer Stem Cell-Based Models of Colorectal Cancer Reveal Molecular Determinants of Therapy Resistance. Stem Cells Translational Medicine, 2016, 5, 511-523.	1.6	48
1673	Small-molecule binding sites to explore proteinâ€"protein interactions in the cancer proteome. Molecular BioSystems, 2016, 12, 3067-3087.	2.9	15
1674	A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy. Molecular Cell, 2016, 63, 514-525.	4.5	140
1676	High frequency of KRAS mutation in early onset colorectal adenocarcinoma: implications for pathogenesis. Human Pathology, 2016, 56, 163-170.	1.1	33
1677	The Role of Stem Cell DNA Methylation in Colorectal Carcinogenesis. Stem Cell Reviews and Reports, 2016, 12, 573-583.	5.6	16
1678	Comparative pan-cancer DNA methylation analysis reveals cancer common and specific patterns. Briefings in Bioinformatics, 2016, 18, bbw063.	3.2	119
1679	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <i>BRAF</i>V600E Mutation. Cancer Discovery, 2016, 6, 1352-1365.	7.7	192
1680	Increased global transcription activity as a mechanism of replication stress in cancer. Nature Communications, 2016, 7, 13087.	5.8	232
1681	Posterior Contraction Rates of the Phylogenetic Indian Buffet Processes. Bayesian Analysis, 2016, 11, 477-497.	1.6	6
1682	Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR. Cancer Treatment Reviews, 2016, 51, 54-62.	3.4	24
1683	Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence. British Journal of Cancer, 2016, 115, 1565-1574.	2.9	34

#	Article	IF	Citations
1684	Colon cancer subtypes: concordance, effect on survival and selection of the most representative preclinical models. Scientific Reports, 2016, 6, 37169.	1.6	23
1685	Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7769-E7777.	3.3	145
1686	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Science Translational Medicine, 2016, 8, 346ra92.	5.8	1,036
1687	Impaired coordination between signaling pathways is revealed in human colorectal cancer using single-cell mass cytometry of archival tissue blocks. Science Signaling, 2016, 9, rs11.	1.6	22
1688	Molecular Classification of Colon Cancer: Perspectives for Personalized Adjuvant Therapy. Current Colorectal Cancer Reports, 2016, 12, 296-302.	1.0	1
1689	A genetic basis for the variation in the vulnerability of cancer to DNA damage. Nature Communications, 2016, 7, 11428.	5.8	136
1690	Computational Approaches to Accelerating Novel Medicine and Better Patient Care from Bedside to Benchtop. Advances in Protein Chemistry and Structural Biology, 2016, 102, 147-179.	1.0	2
1691	The alternatively-included 11a sequence modifies the effects of Mena on actin cytoskeletal organization and cell behavior. Scientific Reports, 2016, 6, 35298.	1.6	22
1692	Is sidedness prognostically important across all stages of colorectal cancer?. Lancet Oncology, The, 2016, 17, 1480-1482.	5.1	15
1693	A novel gene delivery composite system based on biodegradable folate-poly (ester amine) polymer and thermosensitive hydrogel for sustained gene release. Scientific Reports, 2016, 6, 21402.	1.6	36
1694	Characterization of cytokinome landscape for clinical responses in human cancers. OncoImmunology, 2016, 5, e1214789.	2.1	21
1695	Comprehensive evaluation and validation of targeted next-generation sequencing performance in two clinical laboratories. International Journal of Oncology, 2016, 49, 235-242.	1.4	9
1697	Epigenetic inactivation of the p53-induced long noncoding RNA TP53 target 1 in human cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7535-E7544.	3.3	140
1698	TNIK inhibition abrogates colorectal cancer stemness. Nature Communications, 2016, 7, 12586.	5.8	117
1699	Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases. Molecular Oncology, 2016, 10, 1575-1584.	2.1	61
1700	Stromal Hedgehog signalling is downregulated in colon cancer and its restoration restrains tumour growth. Nature Communications, 2016, 7, 12321.	5.8	113
1701	Mouse Crumbs3 sustains epithelial tissue morphogenesis in vivo. Scientific Reports, 2016, 5, 17699.	1.6	46
1702	A novel TP53 pathway influences the HGS-mediated exosome formation in colorectal cancer. Scientific Reports, 2016, 6, 28083.	1.6	45

#	Article	IF	Citations
1703	TCF7L1 Modulates Colorectal Cancer Growth by Inhibiting Expression of the Tumor-Suppressor Gene EPHB3. Scientific Reports, 2016, 6, 28299.	1.6	42
1704	SOX9-regulated cell plasticity in colorectal metastasis is attenuated by rapamycin. Scientific Reports, 2016, 6, 32350.	1.6	39
1705	An empirical likelihood ratio test robust to individual heterogeneity for differential expression analysis of RNA-seq. Briefings in Bioinformatics, 2018, 19, bbw103.	3.2	3
1706	Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer. BMC Medical Genomics, 2016, 9, 65.	0.7	21
1707	Basic Principles of Carcinogenesis. , 2016, , 1-17.		1
1708	Patients with genetically heterogeneous synchronous colorectal cancer carry rare damaging germline mutations in immune-related genes. Nature Communications, 2016, 7, 12072.	5.8	49
1709	Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells. Nature Methods, 2016, 13, 1036-1042.	9.0	378
1710	ROR2 is epigenetically inactivated in the early stages of colorectal neoplasia and is associated with proliferation and migration. BMC Cancer, 2016, 16, 508.	1.1	29
1711	Prognostic value of pigment epithelium-derived factor for neoadjuvant radiation therapy in patients with locally advanced rectal carcinoma. International Journal of Oncology, 2016, 49, 1415-1426.	1.4	9
1713	Network-Based Enriched Gene Subnetwork Identification: A Game-Theoretic Approach. Biomedical Engineering and Computational Biology, 2016, 7s2, BECB.S38244.	0.8	12
1714	Function of Deubiquitinating Enzyme USP14 as Oncogene in Different Types of Cancer. Cellular Physiology and Biochemistry, 2016, 38, 993-1002.	1.1	33
1715	Multiple differential expression networks identify key genes in rectal cancer. Cancer Biomarkers, 2016, 16, 435-444.	0.8	3
1716	Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. Scientific Reports, 2016, 6, 19649.	1.6	15
1717	Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies. Journal of Visualized Experiments, 2016, , .	0.2	15
1718	Molecular profiles to biology and pathways: a systems biology approach. Chinese Journal of Cancer, 2016, 35, 53.	4.9	6
1719	Integrating gene set analysis and nonlinear predictive modeling of disease phenotypes using a Bayesian multitask formulation. BMC Bioinformatics, 2016, 17, 0.	1.2	5
1720	Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening. BMC Cancer, 2016, 16, 536.	1.1	5
1721	Prediction of chemo-response in serous ovarian cancer. Molecular Cancer, 2016, 15, 66.	7.9	33

#	Article	IF	Citations
1722	Therapeutic Approaches to RAS Mutation. Cancer Journal (Sudbury, Mass), 2016, 22, 165-174.	1.0	14
1723	Molecular Triage Trials in Colorectal Cancer. Cancer Journal (Sudbury, Mass), 2016, 22, 218-222.	1.0	0
1724	Transcriptome analysis of copper homeostasis genes reveals coordinated upregulation of <i><scp>SLC</scp>31A1</i>,<i><scp>SCO</scp></i>1, and <i><scp>COX</scp>11</i> in colorectal cancer. FEBS Open Bio, 2016, 6, 794-806.	1.0	68
1725	Genetic heterogeneity in synchronous colorectal cancers impacts genotyping approaches and therapeutic strategies. Genes Chromosomes and Cancer, 2016, 55, 268-277.	1.5	28
1726	Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology. Genes Chromosomes and Cancer, 2016, 55, 505-521.	1.5	34
1727	Clinicopathogenomic analysis of mismatch repair proficient colorectal adenocarcinoma uncovers novel prognostic subgroups with differing patterns of genetic evolution. International Journal of Cancer, 2016, 139, 1546-1556.	2.3	23
1728	Molecular Subtypes of Colorectal Cancer and Their Clinicopathologic Features, With an Emphasis on the Serrated Neoplasia Pathway. Archives of Pathology and Laboratory Medicine, 2016, 140, 406-412.	1.2	75
1729	An enduring role for quiescent stem cells. Developmental Dynamics, 2016, 245, 718-726.	0.8	17
1730	Efficacy of cetuximab-based chemotherapy in metastatic colorectal cancer according to RAS and BRAF mutation subgroups: A meta-analysis. Molecular and Clinical Oncology, 2016, 4, 1017-1024.	0.4	8
1731	Network-based analysis for identification of candidate genes for colorectal cancer progression. Biochemical and Biophysical Research Communications, 2016, 476, 534-540.	1.0	12
1732	Copy number analysis of whole-genome data using BIC-seq2 and its application to detection of cancer susceptibility variants. Nucleic Acids Research, 2016, 44, 6274-6286.	6.5	117
1733	Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms. Nature Reviews Clinical Oncology, 2016, 13, 691-705.	12.5	47
1734	Stromal CCR6 drives tumor growth in a murine transplantable colon cancer through recruitment of tumor-promoting macrophages. OncoImmunology, 2016, 5, e1189052.	2.1	54
1735	KSR1 and EPHB4 Regulate Myc and PGC1Î² To Promote Survival of Human Colon Tumors. Molecular and Cellular Biology, 2016, 36, 2246-2261.	1.1	30
1736	The genetic heterogeneity of colorectal cancer predisposition - guidelines for gene discovery. Cellular Oncology (Dordrecht), 2016, 39, 491-510.	2.1	34
1737	Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. British Journal of Cancer, 2016, 114, 1352-1361.	2.9	81
1738	An interplay of the base excision repair and mismatch repair pathways in active DNA demethylation. Nucleic Acids Research, 2016, 44, 3713-3727.	6.5	54
1739	PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia. Nature Cell Biology, 2016, 18, 803-813.	4.6	95

#	Article	IF	Citations
1740	Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nature Medicine, 2016, 22, 792-799.	15.2	322
1741	Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2016, 34, 3062-3068.	0.8	141
1742	Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature. Pharmacological Research, 2016, 111, 290-302.	3.1	156
1743	Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection. British Journal of Cancer, 2016, 114, 1387-1394.	2.9	43
1744	Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer. Molecular and Cellular Proteomics, 2016, 15, 2924-2938.	2.5	79
1745	A Positive Regulatory Loop between a Wnt-Regulated Non-coding RNA and ASCL2 Controls Intestinal Stem Cell Fate. Cell Reports, 2016, 15, 2588-2596.	2.9	47
1746	Molecular pathological classification of colorectal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 125-134.	1.4	276
1747	POLD1: Central mediator of DNA replication and repair, and implication in cancer and other pathologies. Gene, 2016, 590, 128-141.	1.0	98
1748	Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter. Oncogene, 2016, 35, 6403-6415.	2.6	58
1749	Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. Journal of the National Cancer Institute, 2016, 108, djw144.	3.0	271
1750	Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026211.	2.9	105
1751	Rad51C-ATXN7 fusion gene expression in colorectal tumors. Molecular Cancer, 2016, 15, 47.	7.9	10
1752	Epigenetic silencing of TPM2 contributes to colorectal cancer progression upon RhoA activation. Tumor Biology, 2016, 37, 12477-12483.	0.8	31
1753	IGF2 knockdown in two colorectal cancer cell lines decreases survival, adhesion and modulates survival-associated genes. Tumor Biology, 2016, 37, 12485-12495.	0.8	9
1754	Development and clinical application of an integrative genomic approach to personalized cancer therapy. Genome Medicine, 2016, 8, 62.	3.6	71
1755	Copy number variants associated with 18p11.32, DCC and the promoter 1B region of APC in colorectal polyposis patients. Meta Gene, 2016, 7, 95-104.	0.3	7
1756	Mutation spectra of RAS gene family in colorectal cancer. American Journal of Surgery, 2016, 212, 537-544.e3.	0.9	38
1757	Association of a let-7 miRNA binding region of<i>TGFBR1</i>with hereditary mismatch repair proficient colorectal cancer (MSS HNPCC). Carcinogenesis, 2016, 37, 751-758.	1.3	16

#	Article	IF	Citations
1758	Aberrant DNA methylation of WNT pathway genes in the development and progression of CIMP-negative colorectal cancer. Epigenetics, 2016, 11, 588-602.	1.3	67
1759	Subcellular compartmentalization of docking protein-1 contributes to progression in colorectal cancer. EBioMedicine, 2016, 8, 159-172.	2.7	15
1760	Current targeted therapies in the treatment of advanced colorectal cancer: a review. Therapeutic Advances in Medical Oncology, 2016, 8, 276-293.	1.4	72
1761	Promoter methylation of ITF2, but not APC, is associated with microsatellite instability in two populations of colorectal cancer patients. BMC Cancer, 2016, 16, 113.	1.1	7
1762	Integrating mutation and gene expression cross-sectional data to infer cancer progression. BMC Systems Biology, 2016, 10, 12.	3.0	24
1763	ELF5 isoform expression is tissue-specific and significantly altered in cancer. Breast Cancer Research, 2016, 18, 4.	2.2	37
1764	A holistic view of cancer bioenergetics: mitochondrial function and respiration play fundamental roles in the development and progression of diverse tumors. Clinical and Translational Medicine, 2016, 5, 3.	1.7	65
1765	Molecular pathogenesis of sporadic colorectal cancers. Chinese Journal of Cancer, 2016, 35, 4.	4.9	105
1766	Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in <i>BRAF</i>-Mutant Colorectal Cancer. Cancer Research, 2016, 76, 4504-4515.	0.4	91
1767	Survival of Patients with Gastrointestinal Cancers Can Be Predicted by a Surrogate microRNA Signature for Cancer Stemâ€“like Cells Marked by DCLK1 Kinase. Cancer Research, 2016, 76, 4090-4099.	0.4	30
1768	Aberrant Methylation of FOXE1 Contributes to a Poor Prognosis for Patients with Colorectal Cancer. Annals of Surgical Oncology, 2016, 23, 3948-3955.	0.7	12
1770	Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict <i>KRAS</i> mutations before surgery. Molecular Oncology, 2016, 10, 1221-1231.	2.1	78
1771	Block-Constraint Robust Principal Component Analysis and its Application to Integrated Analysis of TCGA Data. IEEE Transactions on Nanobioscience, 2016, 15, 510-516.	2.2	17
1772	How should whole-genome sequencing be implemented in children? A consideration of the current limitations. Personalized Medicine, 2016, 13, 33-42.	0.8	1
1773	The PI3K/Akt pathway is involved in procyanidinâ€mediated suppression of human colorectal cancer cell growth. Molecular Carcinogenesis, 2016, 55, 2196-2209.	1.3	33
1774	Integrative methods for analyzing big data in precision medicine. Proteomics, 2016, 16, 741-758.	1.3	149
1775	Algorithmic methods to infer the evolutionary trajectories in cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E4025-34.	3.3	80
1776	Targeting the serrated pathway of colorectal cancer with mutation in BRAF. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1866, 51-63.	3.3	8

#	Article	IF	Citations
1777	Methylation status of long interspersed element-1 in advanced gastric cancer and its prognostic implication. Gastric Cancer, 2016, 19, 98-106.	2.7	19
1778	PAC exhibits potent antiâ€colon cancer properties through targeting cyclin D1 and suppressing epithelialâ€toâ€mesenchymal transition. Molecular Carcinogenesis, 2016, 55, 233-244.	1.3	20
1779	Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene, 2016, 35, 691-701.	2.6	40
1780	Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut, 2016, 65, 625-634.	6.1	381
1781	DUSP10 regulates intestinal epithelial cell growth and colorectal tumorigenesis. Oncogene, 2016, 35, 206-217.	2.6	33
1782	Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. Gut, 2016, 65, 1296-1305.	6.1	65
1783	An in vivo molecular response analysis of colorectal cancer treated with Astragalus membranaceus extract. Oncology Reports, 2016, 35, 659-668.	1.2	25
1784	SOCS1 in cancer: An oncogene and a tumor suppressor. Cytokine, 2016, 82, 87-94.	1.4	47
1785	Colorectal clinical trials: what is on the horizon?. Future Oncology, 2016, 12, 525-531.	1.1	1
1786	Identifying molecular subtypes in human colon cancer using gene expression and DNA methylation microarray data. International Journal of Oncology, 2016, 48, 690-702.	1.4	21
1787	Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence. Nucleic Acids Research, 2016, 44, 4105-4122.	6.5	38
1788	A panoply of errors: polymerase proofreading domain mutations in cancer. Nature Reviews Cancer, 2016, 16, 71-81.	12.8	292
1789	The kinome 'at large' in cancer. Nature Reviews Cancer, 2016, 16, 83-98.	12.8	226
1790	Adjuvant Chemotherapy in Rectal Cancer after Chemoradiotherapy. Clinical Oncology, 2016, 28, 140-145.	0.6	15
1791	From Molecular Biology to Clinical Trials: Toward Personalized Colorectal Cancer Therapy. Clinical Colorectal Cancer, 2016, 15, 104-115.	1.0	20
1792	Integrative Omics Analysis Reveals Post-Transcriptionally Enhanced Protective Host Response in Colorectal Cancers with Microsatellite Instability. Journal of Proteome Research, 2016, 15, 766-776.	1.8	10
1793	Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma. Cancer Cell, 2016, 29, 229-240.	7.7	147
1794	Investigation of FIH-1 and SOCS3 expression in KRAS mutant and wild-type patients with colorectal cancer. Tumor Biology, 2016, 37, 8841-8848.	0.8	12

#	Article	IF	Citations
1795	Microsatellite Alterations With Allelic Loss at 9p24.2 SignifyÂLess-Aggressive Colorectal Cancer Metastasis. Gastroenterology, 2016, 150, 944-955.	0.6	34
1796	Identification of neutral tumor evolution across cancer types. Nature Genetics, 2016, 48, 238-244.	9.4	525
1797	CrossHub: a tool for multi-way analysis of The Cancer Genome Atlas (TCGA) in the context of gene expression regulation mechanisms. Nucleic Acids Research, 2016, 44, e62-e62.	6.5	41
1798	Role of Intestinal HIF-2Î± in Health and Disease. Annual Review of Physiology, 2016, 78, 301-325.	5.6	60
1799	RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2016, 15, 95-103.	1.0	30
1800	Large-scale profiling of microRNAs for The Cancer Genome Atlas. Nucleic Acids Research, 2016, 44, e3-e3.	6.5	125
1801	Identification of large-scale genomic variation in cancer genomes using<i>in silico</i>reference models. Nucleic Acids Research, 2016, 44, e5-e5.	6.5	4
1802	Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography. Journal of Clinical Oncology, 2016, 34, 91-101.	0.8	146
1803	The Clinicopathologic Significance of BAF250a (ARID1A) Expression in Hepatocellular Carcinoma. Pathology and Oncology Research, 2016, 22, 453-459.	0.9	31
1804	Phenotypic differentiation does not affect tumorigenicity of primary human colon cancer initiating cells. Cancer Letters, 2016, 371, 326-333.	3.2	11
1805	Molecular Taxonomy and Tumourigenesis of Colorectal Cancer. Clinical Oncology, 2016, 28, 73-82.	0.6	5
1806	Systematic discovery of complex insertions and deletions in human cancers. Nature Medicine, 2016, 22, 97-104.	15.2	93
1807	Rare RAS Mutations in Metastatic Colorectal Cancer Detected During Routine RAS Genotyping Using Next Generation Sequencing. Targeted Oncology, 2016, 11, 363-370.	1.7	20
1808	Targeting <i>BRAF</i> aberrations in advanced colorectal carcinoma: from bench to bedside. Future Oncology, 2016, 12, 25-30.	1.1	4
1809	DNA Methylation Microarrays. , 2016, , 19-46.		2
1810	Deficiency of IL-17A, but not the prototypical Th17 transcription factor RORÎ³t, decreases murine spontaneous intestinal tumorigenesis. Cancer Immunology, Immunotherapy, 2016, 65, 13-24.	2.0	10
1811	Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis. Cancer Research, 2016, 76, 724-735.	0.4	36
1812	Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. Immunity, 2016, 44, 698-711.	6.6	814

#	Article	IF	Citations
1813	Olfactomedin 4 deletion induces colon adenocarcinoma in ApcMin/+ mice. Oncogene, 2016, 35, 5237-5247.	2.6	64
1814	Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell, 2016, 165, 35-44.	13.5	2,437
1815	p53MutaGene: an online tool to estimate the effect of p53 mutational status on gene regulation in cancer. Cell Death and Disease, 2016, 7, e2148-e2148.	2.7	9
1816	Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer. Molecular Cancer Research, 2016, 14, 563-573.	1.5	19
1817	Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer. Genome Biology, 2016, 17, 11.	3.8	184
1818	Proteomic identification of potential cancer markers in human urine using subtractive analysis. International Journal of Oncology, 2016, 48, 1921-1932.	1.4	12
1819	Technical Validation of a Next-Generation Sequencing Assay for Detecting Actionable Mutations in Patients with Gastrointestinal Cancer. Journal of Molecular Diagnostics, 2016, 18, 416-424.	1.2	11
1820	Identification of the CIMP-like subtype and aberrant methylation of members of the chromosomal segregation and spindle assembly pathways in esophageal adenocarcinoma. Carcinogenesis, 2016, 37, 356-365.	1.3	46
1821	Thermodynamic measures of cancer: Gibbs free energy and entropy of proteinâ€“protein interactions. Journal of Biological Physics, 2016, 42, 339-350.	0.7	42
1822	Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. Cell Reports, 2016, 14, 907-919.	2.9	107
1823	Network-Based Method for Inferring Cancer Progression at the Pathway Level from Cross-Sectional Mutation Data. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2016, 13, 1036-1044.	1.9	8
1824	Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. Advances in Immunology, 2016, 130, 95-190.	1.1	160
1825	High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine. Familial Cancer, 2016, 15, 405-412.	0.9	105
1826	Distinct Subtypes of Gastric Cancer Defined by Molecular Characterization Include Novel Mutational Signatures with Prognostic Capability. Cancer Research, 2016, 76, 1724-1732.	0.4	120
1827	Organoids as Model Systems for Gastrointestinal Diseases: Tissue Engineering Meets Genetic Engineering. Current Pathobiology Reports, 2016, 4, 1-9.	1.6	25
1828	Update on Lynch syndrome genomics. Familial Cancer, 2016, 15, 385-393.	0.9	127
1829	Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma. Radiotherapy and Oncology, 2016, 118, 350-358.	0.3	62
1830	KRAS insertion mutations are oncogenic and exhibit distinct functional properties. Nature Communications, 2016, 7, 10647.	5.8	15

#	Article	IF	Citations
1831	Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. Clinical Gastroenterology and Hepatology, 2016, 14, 651-658.	2.4	99
1832	Microsatellite Instability as a Biomarker for PD-1 Blockade. Clinical Cancer Research, 2016, 22, 813-820.	3.2	698
1833	Chromosomal microarray provides enhanced targetable gene aberration detection when paired with next generation sequencing panel in profiling lung and colorectal tumors. Cancer Genetics, 2016, 209, 119-129.	0.2	7
1834	Exosomal microRNA Biomarkers: Emerging Frontiers in Colorectal and Other Human Cancers. Expert Review of Molecular Diagnostics, 2016, 16, 553-567.	1.5	64
1835	Mechanisms and Consequences of Cancer Genome Instability: Lessons from Genome Sequencing Studies. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 283-312.	9.6	106
1836	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nature Medicine, 2016, 22, 298-305.	15.2	1,193
1837	A network-based analysis of colon cancer splicing changes reveals a tumorigenesis-favoring regulatory pathway emanating from ELK1. Genome Research, 2016, 26, 541-553.	2.4	45
1838	Next-Generation Sequencing for the Analysis of Cancer Specimens. , 2016, , 911-931.		0
1839	Maternal plasma folate impacts differential DNA methylation in an epigenome-wide meta-analysis of newborns. Nature Communications, 2016, 7, 10577.	5.8	219
1840	Genomic Alteration During Metastasis of Lung Adenocarcinoma. Cellular Physiology and Biochemistry, 2016, 38, 469-486.	1.1	23
1841	Rare cancers: a sea of opportunity. Lancet Oncology, The, 2016, 17, e52-e61.	5.1	76
1842	Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. Molecular Cell, 2016, 61, 520-534.	4.5	142
1843	Manganese-superoxide dismutase (Mn-SOD) overexpression is a common event in colorectal cancers with mitochondrial microsatellite instability. Tumor Biology, 2016, 37, 10357-10364.	0.8	15
1844	SOX9 expression predicts relapse of stage II colon cancer patients. Human Pathology, 2016, 52, 38-46.	1.1	24
1845	Haplotyping germline and cancer genomes with high-throughput linked-read sequencing. Nature Biotechnology, 2016, 34, 303-311.	9.4	617
1846	Combination of Novel Agents with Radiotherapy to Treat Rectal Cancer. Clinical Oncology, 2016, 28, 116-139.	0.6	17
1847	Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nature Reviews Genetics, 2016, 17, 284-299.	7.7	679
1848	Molecular Pathology of Solid Tumors. , 2016, , 557-594.		0

#	Article	IF	Citations
1849	The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Science Translational Medicine, 2016, 8, 327ra26.	5.8	360
1850	Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer. Cell Death and Disease, 2016, 7, e2120-e2120.	2.7	65
1851	Organoids as Models for Neoplastic Transformation. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 199-220.	9.6	64
1852	Application of next-generation sequencing in gastrointestinal and liver tumors. Cancer Letters, 2016, 374, 187-191.	3.2	14
1853	The possibility of clinical sequencing in the management of cancer. Japanese Journal of Clinical Oncology, 2016, 46, 399-406.	0.6	26
1854	SynTarget: an online tool to test the synergetic effect of genes on survival outcome in cancer. Cell Death and Differentiation, 2016, 23, 912-912.	5.0	46
1855	Oncogenic <i>ALK</i> Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target. Clinical Cancer Research, 2016, 22, 3831-3840.	3.2	99
1856	On Predicting lung cancer subtypes using â€˜omicâ€™ data from tumor and tumor-adjacent histologically-normal tissue. BMC Cancer, 2016, 16, 184.	1.1	10
1857	Molecular evolution of colorectal cancer: from multistep carcinogenesis to the big bang. Cancer and Metastasis Reviews, 2016, 35, 63-74.	2.7	29
1858	Are Gene Signatures Ready for Use in the Selection of Patients for Adjuvant Treatment?. Current Colorectal Cancer Reports, 2016, 12, 18-26.	1.0	1
1859	Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse. Cancer Research, 2016, 76, 2197-2205.	0.4	133
1860	Smad4 sensitizes colorectal cancer to 5-fluorouracil through cell cycle arrest by inhibiting the PI3K/Akt/CDC2/survivin cascade. Oncology Reports, 2016, 35, 1807-1815.	1.2	23
1861	The Innate Immune Receptor NLRX1 Functions as a Tumor Suppressor by Reducing Colon Tumorigenesis and Key Tumor-Promoting Signals. Cell Reports, 2016, 14, 2562-2575.	2.9	59
1862	Association of Wnt signaling pathway genetic variants in gallbladder cancer susceptibility and survival. Tumor Biology, 2016, 37, 8083-8095.	0.8	23
1863	On the Sample Complexity of Cancer Pathways Identification. Journal of Computational Biology, 2016, 23, 30-41.	0.8	6
1864	The colorectal cancer immune paradox revisited. OncoImmunology, 2016, 5, e1078058.	2.1	12
1865	Beyond the exome: the role of non-coding somatic mutations in cancer. Annals of Oncology, 2016, 27, 240-248.	0.6	31
1866	Whole-Exome Sequencing Analyses of Inflammatory Bowel Diseaseâ^'Associated Colorectal Cancers. Gastroenterology, 2016, 150, 931-943.	0.6	208

#	Article	IF	Citations
1867	moCluster: Identifying Joint Patterns Across Multiple Omics Data Sets. Journal of Proteome Research, 2016, 15, 755-765.	1.8	88
1868	Mismatch repair defects and Lynch syndrome: The role of the basic scientist in the battle against cancer. DNA Repair, 2016, 38, 127-134.	1.3	46
1869	Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotypeâ€“high colorectal cancers?. Human Pathology, 2016, 47, 85-94.	1.1	8
1870	Approaches to diagnose DNA mismatch repair gene defects in cancer. DNA Repair, 2016, 38, 147-154.	1.3	26
1871	Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer. Advances in Experimental Medicine and Biology, 2016, 890, 123-136.	0.8	44
1872	Natural coordinate descent algorithm for L1-penalised regression in generalised linear models. Computational Statistics and Data Analysis, 2016, 97, 60-70.	0.7	4
1873	Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function. Nature, 2016, 529, 97-100.	13.7	203
1874	TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Research, 2016, 44, e71-e71.	6.5	2,519
1875	p53 genes function to restrain mobile elements. Genes and Development, 2016, 30, 64-77.	2.7	174
1876	Highly multiplexed targeted DNA sequencing from single nuclei. Nature Protocols, 2016, 11, 214-235.	5.5	49
1877	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nature Biotechnology, 2016, 34, 155-163.	9.4	634
1878	Genetic Progression of High Grade Prostatic Intraepithelial Neoplasia to Prostate Cancer. European Urology, 2016, 69, 823-830.	0.9	39
1879	Intra-tumor genetic heterogeneity in rectal cancer. Laboratory Investigation, 2016, 96, 4-15.	1.7	72
1880	Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to<i>KRAS</i>Mutation Status. Journal of the National Cancer Institute, 2016, 108, djv363.	3.0	37
1881	Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers. Oncogene, 2016, 35, 2011-2019.	2.6	83
1882	Distinct Profiles for Mitochondrial t-RNAs and Small Nucleolar RNAs in Locally Invasive and Metastatic Colorectal Cancer. Clinical Cancer Research, 2016, 22, 773-784.	3.2	28
1883	Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling. Gastroenterology, 2016, 150, 513-525.e10.	0.6	78
1884	Adenoma development in familial adenomatous polyposis and <i><scp>MUTYH</scp></i>â€associated polyposis: somatic landscape and driver genes. Journal of Pathology, 2016, 238, 98-108.	2.1	39

#	Article	IF	Citations
1885	ccmGDB: a database for cancer cell metabolism genes. Nucleic Acids Research, 2016, 44, D959-D968.	6.5	41
1886	Genome-wide CpG island methylation and intergenic demethylation propensities vary among different tumor sites. Nucleic Acids Research, 2016, 44, 1105-1117.	6.5	44
1887	Colorectal cancer atlas: An integrative resource for genomic and proteomic annotations from colorectal cancer cell lines and tissues. Nucleic Acids Research, 2016, 44, D969-D974.	6.5	55
1888	Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer. Clinical Cancer Research, 2016, 22, 1489-1498.	3.2	9
1889	Mismatch repair proteins recruit DNA methyltransferase 1 to sites of oxidative DNA damage. Journal of Molecular Cell Biology, 2016, 8, 244-254.	1.5	63
1890	Sporadic colorectal cancer: Studying ways to an end. United European Gastroenterology Journal, 2016, 4, 288-296.	1.6	3
1891	Mutation Spectra of Common Cancer-Associated Genes in Different Phenotypes of Colorectal Carcinoma Without Distant Metastasis. Annals of Surgical Oncology, 2016, 23, 849-855.	0.7	26
1892	Targeting the Wnt signaling pathway in colorectal cancer. Expert Opinion on Therapeutic Targets, 2016, 20, 419-429.	1.5	54
1893	Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelialâ€"mesenchymal transition and metastasis in a YAP-independent manner. Oncogene, 2016, 35, 2789-2800.	2.6	110
1894	A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome. Clinical Cancer Research, 2016, 22, 734-745.	3.2	43
1895	JRK is a positive regulator of Î²-catenin transcriptional activity commonly overexpressed in colon, breast and ovarian cancer. Oncogene, 2016, 35, 2834-2841.	2.6	20
1896	DNA copy number profiling reveals different patterns of chromosomal instability within colorectal cancer according to the age of onset. Molecular Carcinogenesis, 2016, 55, 705-716.	1.3	30
1897	New Wnt/Î²-catenin target genes promote experimental metastasis and migration of colorectal cancer cells through different signals. Gut, 2016, 65, 1690-1701.	6.1	149
1898	Disruption of NCOA2 by recurrent fusion with LACTB2 in colorectal cancer. Oncogene, 2016, 35, 187-195.	2.6	22
1899	Tankyrase Inhibition Blocks Wnt/Î²-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clinical Cancer Research, 2016, 22, 644-656.	3.2	143
1900	Consumption of Red/Processed Meat and Colorectal Carcinoma: Possible Mechanisms Underlying the Significant Association. Critical Reviews in Food Science and Nutrition, 2016, 56, 614-634.	5.4	30
1901	Opportunities and challenges provided by crosstalk between signalling pathways in cancer. Oncogene, 2016, 35, 1073-1079.	2.6	39
1902	The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. Gut, 2016, 65, 977-989.	6.1	111

#	Article	IF	Citations
1903	Clinicopathological and molecular features of sessile serrated adenomas with dysplasia or carcinoma. Gut, 2017, 66, 97-106.	6.1	161
1904	Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients withFGF9upregulation may be resistant to anti-EGFR therapies. Molecular Carcinogenesis, 2017, 56, 106-117.	1.3	19
1905	Aberrant BLM cytoplasmic expression associates with DNA damage stress and hypersensitivity to DNA-damaging agents in colorectal cancer. Journal of Gastroenterology, 2017, 52, 327-340.	2.3	16
1906	Association of mitochondrial displacement loop polymorphisms with risk of colorectal cancer in south Indian population. Mitochondrial DNA Part A: DNA Mapping, Sequencing, and Analysis, 2017, 28, 632-637.	0.7	12
1907	Sparse Multi-Dimensional Graphical Models: A Unified Bayesian Framework. Journal of the American Statistical Association, 2017, 112, 779-793.	1.8	12
1908	Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer. Clinical Cancer Research, 2017, 23, 159-170.	3.2	65
1909	Reduced expression of the DNA glycosylase gene MUTYH is associated with an increased number of somatic mutations via a reduction in the DNA repair capacity in prostate adenocarcinoma. Molecular Carcinogenesis, 2017, 56, 781-788.	1.3	9
1910	Genomeâ€wide analysis of DNA copy number alterations in early and advanced gastric cancers. Molecular Carcinogenesis, 2017, 56, 527-537.	1.3	23
1911	Dysregulation of MicroRNA-543 expression in colorectal cancer promotes tumor migration and invasion. Molecular Carcinogenesis, 2017, 56, 250-257.	1.3	22
1912	<i>BRAF</i>â€ˆ<i>V600E</i> Mutant Colorectal Cancer Subtypes Based on Gene Expression. Clinical Cancer Research, 2017, 23, 104-115.	3.2	167
1913	RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation. Gut, 2017, 66, 1645-1656.	6.1	157
1914	Order Matters: The Order of Somatic Mutations Influences Cancer Evolution. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a027060.	2.9	46
1915	Antibody Drug and Radionuclide Conjugates for GI Cancers. , 2017, , 79-99.		1
1916	Common risk variants for colorectal cancer: an evaluation of associations with age at cancer onset. Scientific Reports, 2017, 7, 40644.	1.6	19
1917	A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs. Journal of Oncology Practice, 2017, 13, e108-e119.	2.5	80
1918	Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas. Modern Pathology, 2017, 30, 610-619.	2.9	131
1919	<i> <scp>HUWE</scp> 1 </i> is a critical colonic tumour suppressor gene that prevents <scp>MYC</scp> signalling, <scp>DNA</scp> damage accumulation and tumour initiation. EMBO Molecular Medicine, 2017, 9, 181-197.	3.3	63
1920	KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. Medical Oncology, 2017, 34, 26.	1.2	94

#	Article	IF	Citations
1921	Pan-Cancer Analysis of Genomic Sequencing Among the Elderly. International Journal of Radiation Oncology Biology Physics, 2017, 98, 726-732.	0.4	11
1922	BCL9L Dysfunction Impairs Caspase-2 Expression Permitting Aneuploidy Tolerance in Colorectal Cancer. Cancer Cell, 2017, 31, 79-93.	7.7	83
1923	APC/C Dysfunction Limits Excessive Cancer Chromosomal Instability. Cancer Discovery, 2017, 7, 218-233.	7.7	87
1924	Translating genomic profiling to gastrointestinal cancer treatment. Future Oncology, 2017, 13, 919-934.	1.1	7
1925	E3 ubiquitin ligase Mule targets Î²-catenin under conditions of hyperactive Wnt signaling. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E1148-E1157.	3.3	40
1927	Epigenomic landscape of 5-hydroxymethylcytosine reveals its transcriptional regulation of lncRNAs in colorectal cancer. British Journal of Cancer, 2017, 116, 658-668.	2.9	38
1928	Multiregion ultraâ€deep sequencing reveals early intermixing and variable levels of intratumoral heterogeneity in colorectal cancer. Molecular Oncology, 2017, 11, 124-139.	2.1	38
1929	Benzimidazole inhibitors from the Niclosamide chemotype inhibit Wnt/Î²-catenin signaling with selectivity over effects on ATP homeostasis. Bioorganic and Medicinal Chemistry, 2017, 25, 1804-1816.	1.4	19
1930	Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis. Clinical Colorectal Cancer, 2017, 16, e153-e163.	1.0	110
1931	Pancancer modelling predicts the context-specific impact of somatic mutations on transcriptional programs. Nature Communications, 2017, 8, 14249.	5.8	52
1932	Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells. Cancer Prevention Research, 2017, 10, 208-218.	0.7	31
1933	The Heterocellular Emergence of Colorectal Cancer. Trends in Cancer, 2017, 3, 79-88.	3.8	26
1934	Erythropoietic protoporphyria a clinical and molecular study from Lebanon: Ferrochelatase a potential tumor suppressor gene in colon cancer. Clinical Genetics, 2017, 92, 495-502.	1.0	5
1935	The novel fusion transcript NR5A2â€KLHL29FT is generated by an insertion at the KLHL29 locus. Cancer, 2017, 123, 1507-1515.	2.0	4
1936	Dietary phytochemical PEITC restricts tumor development via modulation of epigenetic writers and erasers. Scientific Reports, 2017, 7, 40569.	1.6	29
1937	Determinants of metastatic competency in colorectal cancer. Molecular Oncology, 2017, 11, 97-119.	2.1	180
1938	ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt. Experimental and Molecular Pathology, 2017, 102, 78-85.	0.9	14
1939	Somatic Ephrin Receptor Mutations Are Associated with Metastasis in Primary Colorectal Cancer. Cancer Research, 2017, 77, 1730-1740.	0.4	29

#	Article	IF	Citations
1940	A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance. Molecular Cancer Research, 2017, 15, 382-394.	1.5	10
1941	DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer. Nature Communications, 2017, 8, 14093.	5.8	85
1942	The Global Relationship between Chromatin Physical Topology, Fractal Structure, and Gene Expression. Scientific Reports, 2017, 7, 41061.	1.6	64
1943	Mutational signature analysis identifies <i><scp>MUTYH</scp></i> deficiency in colorectal cancers and adrenocortical carcinomas. Journal of Pathology, 2017, 242, 10-15.	2.1	130
1944	Decoding transcriptional states in cancer. Current Opinion in Genetics and Development, 2017, 43, 82-92.	1.5	7
1945	YAPâ€"IL-6ST autoregulatory loop activated on APC loss controls colonic tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1643-1648.	3.3	85
1946	Regulation of pairing between broken DNA-containing chromatin regions by Ku80, DNA-PKcs, ATM, and 53BP1. Scientific Reports, 2017, 7, 41812.	1.6	15
1947	miRâ€506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing <scp>MDR</scp>1/Pâ€gp expression. Cell Proliferation, 2017, 50, .	2.4	92
1949	Mining Cancer Transcriptomes: Bioinformatic Tools and the Remaining Challenges. Molecular Diagnosis and Therapy, 2017, 21, 249-258.	1.6	13
1950	TarSeqQC: Quality control on targeted sequencing experiments in R. Human Mutation, 2017, 38, 494-502.	1.1	6
1951	Rectal and Colon Cancer: Background and Clinical Evidence. , 2017, , 155-169.		0
1952	Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. British Journal of Cancer, 2017, 116, 923-929.	2.9	114
1953	T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes. Gut, 2017, 66, 454-463.	6.1	48
1954	Molecular Stratification of Colorectal Cancer: Moving from the Laboratory to Clinical Practice. Current Colorectal Cancer Reports, 2017, 13, 81-90.	1.0	0
1955	Molecular alterations in colorectal adenomas and intramucosal adenocarcinomas defined by high-density single-nucleotide polymorphism arrays. Journal of Gastroenterology, 2017, 52, 1158-1168.	2.3	14
1956	Alternative splicing of the <i>OCC-1</i> gene generates three splice variants and a novel exonic microRNA, which regulate the Wnt signaling pathway. Rna, 2017, 23, 70-85.	1.6	23
1957	Neighbours of cancer-related proteins have key influence on pathogenesis and could increase the drug target space for anticancer therapies. Npj Systems Biology and Applications, 2017, 3, 2.	1.4	24
1958	Expression of angiogenic growth factors VEGF, bFGF and ANG1 in colon cancer after bevacizumab treatment in vitro: A potential self-regulating mechanism. Oncology Reports, 2017, 37, 601-607.	1.2	26

#	Article	IF	Citations
1959	Precision medicine driven by cancer systems biology. Cancer and Metastasis Reviews, 2017, 36, 91-108.	2.7	38
1960	Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system. British Journal of Cancer, 2017, 116, 1012-1020.	2.9	40
1961	Oncogenic retinoic acid receptor Î³ knockdown reverses multi-drug resistance of human colorectal cancer via Wnt/Î²-catenin pathway. Cell Cycle, 2017, 16, 685-692.	1.3	33
1962	Identification of Genomic Somatic Variants in Cancer. Advances in Clinical Chemistry, 2017, 78, 123-162.	1.8	2
1963	Gastric Cancer Genomics: Advances and FutureÂDirections. Cellular and Molecular Gastroenterology and Hepatology, 2017, 3, 211-217.	2.3	60
1964	Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin. Neoplasia, 2017, 19, 301-309.	2.3	33
1965	HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy. Clinical Colorectal Cancer, 2017, 16, 247-251.	1.0	32
1966	Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naÃ¯ve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic ColorectalÂCancer. Clinical Colorectal Cancer, 2017, 16, 158-163.	1.0	13
1967	Genomic variants in mouse model induced by azoxymethane and dextran sodium sulfate improperly mimic human colorectal cancer. Scientific Reports, 2017, 7, 25.	1.6	37
1968	High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis. Cancer Research, 2017, 77, 2464-2475.	0.4	93
1969	A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nature Medicine, 2017, 23, 461-471.	15.2	379
1970	CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype. Molecular Cancer Research, 2017, 15, 696-707.	1.5	39
1971	Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors. Neoplasia, 2017, 19, 196-206.	2.3	22
1972	SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026468.	2.9	60
1973	Immune Checkpoint Inhibitors in Malignancies with Mismatch Repair Deficiency: A Review of the State of the Current Knowledge. Journal of Investigative Medicine, 2017, 65, 754-758.	0.7	37
1974	The importance of regulatory ubiquitination in cancer and metastasis. Cell Cycle, 2017, 16, 634-648.	1.3	134
1975	DNA Hypomethylating Drugs in Cancer Therapy. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026948.	2.9	104
1976	The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas. Clinical Cancer Research, 2017, 23, 3859-3870.	3.2	129

#	Article	IF	Citations
1977	The loss-of-function mutations and down-regulated expression of ASB3 gene promote the growth and metastasis of colorectal cancer cells. Chinese Journal of Cancer, 2017, 36, 11.	4.9	23
1978	Microsatellite Instability Pathway and EMAST in Colorectal Cancer. Current Colorectal Cancer Reports, 2017, 13, 73-80.	1.0	51
1979	Clonal evolution of colorectal cancer in IBD. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 218-229.	8.2	124
1980	Investigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer. Scientific Reports, 2017, 7, 41576.	1.6	9
1981	KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior. Human Pathology, 2017, 65, 21-30.	1.1	27
1982	Identification of microRNA-487b as a negative regulator of liver metastasis by regulation of KRAS in colorectal cancer. International Journal of Oncology, 2017, 50, 487-496.	1.4	24
1983	Somatic cancer mutations in the <scp>MLL</scp>1 histone methyltransferase modulate its enzymatic activity and dependence on the <scp>WDR</scp>5/<scp>RBBP</scp>5/<scp>ASH</scp>2L complex. Molecular Oncology, 2017, 11, 373-387.	2.1	16
1984	Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions. Cellular and Molecular Gastroenterology and Hepatology, 2017, 3, 163-173.	2.3	220
1985	Caspase-mediated proteolysis of the sorting nexin 2 disrupts retromer assembly and potentiates Met/hepatocyte growth factor receptor signaling. Cell Death Discovery, 2017, 3, 16100.	2.0	12
1986	MicroRNAs in the etiology of colorectal cancer: pathways and clinical implications. DMM Disease Models and Mechanisms, 2017, 10, 197-214.	1.2	113
1987	Tissue-specific tumorigenesis: context matters. Nature Reviews Cancer, 2017, 17, 239-253.	12.8	234
1988	Historical Perspective on Familial Gastric Cancer. Cellular and Molecular Gastroenterology and Hepatology, 2017, 3, 192-200.	2.3	31
1989	Hypermutated Colorectal Cancer and Neoantigen Load. , 2017, , 187-215.		3
1990	The emergence of TNIK as a therapeutic target for colorectal cancer. Expert Opinion on Therapeutic Targets, 2017, 21, 353-355.	1.5	9
1991	<i>APC</i> Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer. Molecular Cancer Therapeutics, 2017, 16, 752-762.	1.9	67
1992	Comprehensive Proteomic Characterization of the Human Colorectal Carcinoma Reveals Signature Proteins and Perturbed Pathways. Scientific Reports, 2017, 7, 42436.	1.6	25
1993	<i>MED12</i>is recurrently mutated in Middle Eastern colorectal cancer. Gut, 2018, 67, gutjnl-2016-313334.	6.1	12
1994	Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival. Molecular Cancer Research, 2017, 15, 708-713.	1.5	24

#	Article	IF	Citations
1995	Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nature Communications, 2017, 8, 14262.	5.8	260
1996	Systematic analysis of the achaete-scute complex-like gene signature in clinical cancer patients. Molecular and Clinical Oncology, 2017, 6, 7-18.	0.4	23
1997	The non-coding variant rs1800734 enhances DCLK3 expression through long-range interaction and promotes colorectal cancer progression. Nature Communications, 2017, 8, 14418.	5.8	48
1998	Stem Cells, Cancer, and MUSASHI in Blood and Guts. Trends in Cancer, 2017, 3, 347-356.	3.8	39
2001	Molecular subtypes in cancers of the gastrointestinal tract. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 333-342.	8.2	99
2002	Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. Annals of Oncology, 2017, 28, 958-968.	0.6	107
2003	Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer. Molecular Cancer, 2017, 16, 33.	7.9	48
2004	Integrative epigenetic and genetic pan-cancer somatic alteration portraits. Epigenetics, 2017, 12, 561-574.	1.3	18
2005	Mapping clinicopathological entities within colorectal mucinous adenocarcinomas: a hierarchical clustering approach. Modern Pathology, 2017, 30, 1177-1189.	2.9	19
2006	Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer. International Journal of Clinical Oncology, 2017, 22, 690-697.	1.0	20
2007	Recommendations on surveillance and management of biallelic mismatch repair deficiency (BMMRD) syndrome: a consensus statement by the US Multi-Society Task Force on ColorectalÂCancer. Gastrointestinal Endoscopy, 2017, 85, 873-882.	0.5	2
2008	Identification of <scp>FERM</scp> domainâ€containing protein 5 as a novel target of Î²â€catenin/<scp>TCF</scp>7L2 complex. Cancer Science, 2017, 108, 612-619.	1.7	8
2009	Combining Click Chemistry-Based Proteomics With Dox-Inducible Gene Expression. Methods in Enzymology, 2017, 585, 295-327.	0.4	1
2010	miR-15a-5p, A Novel Prognostic Biomarker, Predicting Recurrent Colorectal Adenocarcinoma. Molecular Diagnosis and Therapy, 2017, 21, 453-464.	1.6	40
2011	WNT Signaling and Colorectal Cancer. Current Colorectal Cancer Reports, 2017, 13, 101-110.	1.0	222
2012	Intrinsic Molecular Processes: Impact on Mutagenesis. Trends in Cancer, 2017, 3, 357-371.	3.8	4
2013	Locoregional Effects of Microbiota in a Preclinical Model of Colon Carcinogenesis. Cancer Research, 2017, 77, 2620-2632.	0.4	195
2014	Knowledge about the presence or absence of miRNA isoforms (isomiRs) can successfully discriminate amongst 32 TCGA cancer types. Nucleic Acids Research, 2017, 45, 2973-2985.	6.5	158

#	Article	IF	Citations
2015	Single and Combination Drug Screening with Aqueous Biphasic Tumor Spheroids. SLAS Discovery, 2017, 22, 507-515.	1.4	16
2016	Future perspectives of circulating tumor DNA in colorectal cancer. Tumor Biology, 2017, 39, 101042831770574.	0.8	16
2017	Cellâ€free <scp>DNA</scp> copy number variations in plasma from colorectal cancer patients. Molecular Oncology, 2017, 11, 1099-1111.	2.1	48
2018	With me or against me: Tumor suppressor and drug resistance activities of SAMHD1. Experimental Hematology, 2017, 52, 32-39.	0.2	43
2019	A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer. Cancer Research, 2017, 77, 3814-3822.	0.4	76
2020	Colorectal cancer subtypes: Translation to routine clinical pathology. Cancer Treatment Reviews, 2017, 57, 1-7.	3.4	36
2022	Asymmetrical barcode adapter-assisted recovery of duplicate reads and error correction strategy to detect rare mutations in circulating tumor DNA. Scientific Reports, 2017, 7, 46678.	1.6	6
2023	The genetics and molecular biology of colonic neoplasia. Current Opinion in Gastroenterology, 2017, 33, 47-52.	1.0	4
2024	A three-caller pipeline for variant analysis of cancer whole-exome sequencing data. Molecular Medicine Reports, 2017, 15, 2489-2494.	1.1	16
2025	Synthetic lethal targeting of RNF20 through PARP1 silencing and inhibition. Cellular Oncology (Dordrecht), 2017, 40, 281-292.	2.1	10
2026	In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. Nature Biotechnology, 2017, 35, 569-576.	9.4	248
2027	Visualization of tumor heterogeneity by in situ padlock probe technology in colorectal cancer. Histochemistry and Cell Biology, 2017, 148, 105-115.	0.8	16
2028	TCF7L1 recruits CtBP and HDAC1 to repress DICKKOPF4 gene expression in human colorectal cancer cells. Biochemical and Biophysical Research Communications, 2017, 487, 716-722.	1.0	24
2029	Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2. Nature Communications, 2017, 8, 14755.	5.8	96
2030	Emergence of <scp>TNIK</scp> inhibitors in cancer therapeutics. Cancer Science, 2017, 108, 818-823.	1.7	36
2031	DNA Polymerase Îµ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity. Oncologist, 2017, 22, 497-502.	1.9	24
2032	Discovering DNA methylation patterns for long non-coding RNAs associated with cancer subtypes. Computational Biology and Chemistry, 2017, 69, 164-170.	1.1	27
2033	Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2. Scientific Reports, 2017, 7, 1502.	1.6	20

#	Article	IF	Citations
2034	Regression of apoptosis-resistant colorectal tumors by induction of necroptosis in mice. Journal of Experimental Medicine, 2017, 214, 1655-1662.	4.2	60
2035	Antagonistic Effects of p53 and HIF1A on microRNA-34a Regulation of PPP1R11 and STAT3 and Hypoxia-induced Epithelial to Mesenchymal Transition in Colorectal Cancer Cells. Gastroenterology, 2017, 153, 505-520.	0.6	127
2036	Oncogenic Î²-catenin and PIK3CA instruct network states and cancer phenotypes in intestinal organoids. Journal of Cell Biology, 2017, 216, 1567-1577.	2.3	29
2037	Transcriptional Regulator CNOT3 Defines an Aggressive Colorectal Cancer Subtype. Cancer Research, 2017, 77, 766-779.	0.4	21
2038	ADNP Is a Therapeutically Inducible Repressor of WNT Signaling in Colorectal Cancer. Clinical Cancer Research, 2017, 23, 2769-2780.	3.2	24
2039	Oncogenic retinoic acid receptor Î± promotes human colorectal cancer growth through simultaneously regulating p21 transcription and GSK3Î²/Î²-catenin signaling. Cancer Letters, 2017, 388, 118-129.	3.2	4
2040	Non-heme dioxygenases in tumor hypoxia: Theyâ€™re all bound with the same fate. DNA Repair, 2017, 49, 21-25.	1.3	8
2041	Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell, 2017, 169, 1327-1341.e23.	13.5	1,794
2042	Replicative DNA polymerase defects in human cancers: Consequences, mechanisms, and implications for therapy. DNA Repair, 2017, 56, 16-25.	1.3	84
2043	Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with <i>BRAF</i> or <i>KRAS</i> Mutations. Clinical Cancer Research, 2017, 23, 5547-5560.	3.2	40
2044	A Novel Combination Treatment Targeting BCL-XL and MCL1 for <i>KRAS/BRAF</i>-mutated and <i>BCL2L1</i>-amplified Colorectal Cancers. Molecular Cancer Therapeutics, 2017, 16, 2178-2190.	1.9	17
2045	Comprehensive Evaluation of Protein Coding Mononucleotide Microsatellites in Microsatellite-Unstable Colorectal Cancer. Cancer Research, 2017, 77, 4078-4088.	0.4	18
2046	Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity. Gastroenterology, 2017, 153, 1082-1095.	0.6	55
2047	A formalin-fixed paraffin-embedded (FFPE)-based prognostic signature to predict metastasis in clinically low risk stage I/II microsatellite stable colorectal cancer. Cancer Letters, 2017, 403, 13-20.	3.2	16
2048	Enhanced Rate of Acquisition of Point Mutations in Mouse Intestinal Adenomas Compared to Normal Tissue. Cell Reports, 2017, 19, 2185-2192.	2.9	18
2049	TGFÎ² pathway limits dedifferentiation following WNT and MAPK pathway activation to suppress intestinal tumourigenesis. Cell Death and Differentiation, 2017, 24, 1681-1693.	5.0	48
2050	RNA-seq implicates deregulation of the immune system in the pathogenesis of diverticulitis. American Journal of Physiology - Renal Physiology, 2017, 313, G277-G284.	1.6	20
2051	The emerging role of Wnt signaling dysregulation in the understanding and modification of age-associated diseases. Ageing Research Reviews, 2017, 37, 135-145.	5.0	51

#	Article	IF	Citations
2052	Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation. Oncogene, 2017, 36, 5885-5896.	2.6	56
2053	Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer. Cancer, 2017, 123, 3513-3523.	2.0	50
2054	In silico pathway analysis and tissue specific cis-eQTL for colorectal cancer GWAS risk variants. BMC Genomics, 2017, 18, 381.	1.2	20
2055	Detection of an <i>ALK</i> Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA. Oncologist, 2017, 22, 774-779.	1.9	16
2056	Targeted sequencing-based analyses of candidate gene variants in ulcerative colitis-associated colorectal neoplasia. British Journal of Cancer, 2017, 117, 136-143.	2.9	29
2057	<i>KIF11</i> silencing and inhibition induces chromosome instability that may contribute to cancer. Genes Chromosomes and Cancer, 2017, 56, 668-680.	1.5	35
2058	AXL. , 2017, , 661-671.		0
2059	Biomarker correlation network in colorectal carcinoma by tumor anatomic location. BMC Bioinformatics, 2017, 18, 304.	1.2	18
2060	Population-based study of effectiveness of neoadjuvant radiotherapy on survival in US rectal cancer patients according to age. Scientific Reports, 2017, 7, 3471.	1.6	8
2061	DNA Damage and Repair Biomarkers of Immunotherapy Response. Cancer Discovery, 2017, 7, 675-693.	7.7	519
2062	<i>P53</i> Mutation and Epigenetic Imprinted <i>IGF2/H19</i> Gene Analysis in Mesenchymal Stem Cells Derived from Amniotic Fluid, Amnion, Endometrium, and Wharton's Jelly. Stem Cells and Development, 2017, 26, 1344-1354.	1.1	7
2063	Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing. Acta Neuropathologica, 2017, 134, 691-703.	3.9	131
2064	Early-onset Colorectal Cancer is Distinct From Traditional Colorectal Cancer. Clinical Colorectal Cancer, 2017, 16, 293-299.e6.	1.0	117
2065	Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors. British Journal of Cancer, 2017, 117, 306-314.	2.9	26
2066	Prognostic and Predictive Ability of Tumor Sidedness. JAMA Oncology, 2017, 3, 1314.	3.4	7
2067	Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancer. Lancet Oncology, The, 2017, 18, e354-e363.	5.1	89
2068	A Specific Mutational Signature Associated with DNA 8-Oxoguanine Persistence in MUTYH-defective Colorectal Cancer. EBioMedicine, 2017, 20, 39-49.	2.7	170
2069	Origin of Somatic Mutations in Î²-Catenin versus Adenomatous Polyposis Coli in Colon Cancer: Random Mutagenesis in Animal Models versus Nonrandom Mutagenesis in Humans. Chemical Research in Toxicology, 2017, 30, 1369-1375.	1.7	11

#	Article	IF	Citations
2070	A molecular portrait of microsatellite instability across multiple cancers. Nature Communications, 2017, 8, 15180.	5.8	480
2071	Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance. Nature Communications, 2017, 8, 15617.	5.8	38
2072	Conditional knockout of microRNA-31 promotes the development of colitis associated cancer. Biochemical and Biophysical Research Communications, 2017, 490, 62-68.	1.0	20
2073	Adiponectin: Its role in obesity-associated colon and prostate cancers. Critical Reviews in Oncology/Hematology, 2017, 116, 125-133.	2.0	34
2074	The Transcriptional Landscape of p53 Signalling Pathway. EBioMedicine, 2017, 20, 109-119.	2.7	47
2075	Precise integration of inducible transcriptional elements (PrIITE) enables absolute control of gene expression. Nucleic Acids Research, 2017, 45, e123-e123.	6.5	18
2076	Mismatch Repair Proteins Initiate Epigenetic Alterations during Inflammation-Driven Tumorigenesis. Cancer Research, 2017, 77, 3467-3478.	0.4	46
2077	Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms. Oncogene, 2017, 36, 5341-5355.	2.6	63
2078	Metformin Inhibits Cellular Proliferation and Bioenergetics in Colorectal Cancer Patientâ€"Derived Xenografts. Molecular Cancer Therapeutics, 2017, 16, 2035-2044.	1.9	29
2079	Single-cell DNA sequencing reveals a late-dissemination model in metastatic colorectal cancer. Genome Research, 2017, 27, 1287-1299.	2.4	189
2080	Mismatch repair deficiency commonly precedes adenoma formation in Lynch Syndrome-Associated colorectal tumorigenesis. Modern Pathology, 2017, 30, 1144-1151.	2.9	56
2081	Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 411-419.	2.3	261
2082	Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma. Modern Pathology, 2017, 30, 1133-1143.	2.9	44
2083	Genomic analysis of oesophageal squamous-cell carcinoma identifies alcohol drinking-related mutation signature and genomic alterations. Nature Communications, 2017, 8, 15290.	5.8	195
2084	Gender-related prognostic value and genomic pattern of intra-tumor heterogeneity in colorectal cancer. Carcinogenesis, 2017, 38, 837-846.	1.3	30
2085	Clinical application of a cancer genomic profiling assay to guide precision medicine decisions. Personalized Medicine, 2017, 14, 309-325.	0.8	22
2086	Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a<i>POLE</i>Mutation. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 142-147.	2.3	182
2087	An Expanding Role for Immunotherapy in Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 401-410.	2.3	47

#	Article	IF	Citations
2089	Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients. Medicine (United States), 2017, 96, e6931.	0.4	3
2090	Comprehensive characterization of <i><scp>RSPO</scp></i> fusions in colorectal traditional serrated adenomas. Histopathology, 2017, 71, 601-609.	1.6	35
2091	Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 235-242.	1.4	6
2092	Early detection: the impact of genomics. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 165-173.	1.4	10
2093	Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification. Nature Communications, 2017, 8, 15657.	5.8	70
2094	Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer. Nature Communications, 2017, 8, 15107.	5.8	213
2095	Genetic and epigenetic markers in colorectal cancer screening: recent advances. Expert Review of Molecular Diagnostics, 2017, 17, 665-685.	1.5	22
2096	Genetic subclone architecture of tumor clone-initiating cells in colorectal cancer. Journal of Experimental Medicine, 2017, 214, 2073-2088.	4.2	30
2097	Translational Genomics: Practical Applications of the Genomic Revolution in Breast Cancer. Clinical Cancer Research, 2017, 23, 2630-2639.	3.2	30
2098	AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discovery, 2017, 7, 818-831.	7.7	1,235
2099	Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer. Clinical Cancer Research, 2017, 23, 5437-5445.	3.2	232
2100	Mucosa-associated microbiota signature in colorectal cancer. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 2073-2083.	1.3	91
2101	Significance of positive and inhibitory regulators in the TGF-Î² signaling pathway in colorectal cancers. Human Pathology, 2017, 66, 34-39.	1.1	11
2102	Elastic-Fluid Model for DNA Damage and Mutation from Nuclear Fluid Segregation Due to Cell Migration. Biophysical Journal, 2017, 112, 2271-2279.	0.2	21
2103	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	183
2104	Analysis of mutant allele fractions in driver genes in colorectal cancer â€“ biological and clinical insights. Molecular Oncology, 2017, 11, 1263-1272.	2.1	26
2105	Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency. Critical Reviews in Oncology/Hematology, 2017, 113, 242-248.	2.0	68
2106	<i>miR-34a</i> and <i>miR-34b/c</i> Suppress Intestinal Tumorigenesis. Cancer Research, 2017, 77, 2746-2758.	0.4	78

#	Article	IF	Citations
2107	Biologically-based mechanistic models of radiation-related carcinogenesis applied to epidemiological data. International Journal of Radiation Biology, 2017, 93, 1093-1117.	1.0	59
2108	PathwayMapper: a collaborative visual web editor for cancer pathways and genomic data. Bioinformatics, 2017, 33, 2238-2240.	1.8	50
2109	Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. Nature Reviews Clinical Oncology, 2017, 14, 562-576.	12.5	150
2110	Nucleotide selectivity defect and mutator phenotype conferred by a colon cancer-associated DNA polymerase Î´ mutation in human cells. Oncogene, 2017, 36, 4427-4433.	2.6	22
2111	Targeting Tankyrase to Fight <scp>WNT</scp>â€dependent Tumours. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 81-88.	1.2	23
2112	<scp>DNA</scp> methylation epigenotype and clinical features of <i>NRAS</i>â€mutation(+) colorectal cancer. Cancer Medicine, 2017, 6, 1023-1035.	1.3	22
2113	Sessile Serrated Polyps and Colon Cancer Prevention. Cancer Prevention Research, 2017, 10, 270-278.	0.7	31
2114	Loss of AXIN1 drives acquired resistance to <scp>WNT</scp> pathway blockade in colorectal cancer cells carrying <scp>RSPO</scp> 3 fusions. EMBO Molecular Medicine, 2017, 9, 293-303.	3.3	54
2115	PML nuclear bodies contribute to the basal expression of the mTOR inhibitor DDIT4. Scientific Reports, 2017, 7, 45038.	1.6	15
2116	A covalently bound inhibitor triggers <scp>EZH</scp>2 degradation through <scp>CHIP</scp>â€mediated ubiquitination. EMBO Journal, 2017, 36, 1243-1260.	3.5	67
2117	Descriptive characteristics of colon and rectal cancer recurrence in a Danish population-based study. Acta OncolÃ³gica, 2017, 56, 1111-1119.	0.8	18
2118	miR-330-5p suppresses glioblastoma cell proliferation and invasiveness through targeting ITGA5. Bioscience Reports, 2017, 37, .	1.1	65
2119	Molecular subtypes of colorectal cancers determined by <scp>PCR</scp>â€based analysis. Cancer Science, 2017, 108, 427-434.	1.7	13
2120	The <scp>PD</scp>â€1 expressing immune phenotype of T cell exhaustion is prominent in the â€˜immunoreactiveâ€™ microenvironment of colorectal carcinoma. Histopathology, 2017, 71, 366-374.	1.6	20
2121	Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer. Handbook of Experimental Pharmacology, 2017, 249, 145-159.	0.9	1
2122	Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer. Annals of Oncology, 2017, 28, 1243-1249.	0.6	25
2123	Molecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular network. Scientific Reports, 2017, 7, 738.	1.6	12
2124	Recommendations on Surveillance and Management of Biallelic Mismatch Repair Deficiency (BMMRD) Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2017, 112, 682-690.	0.2	6

#	Article	IF	Citations
2125	Recommendations on Surveillance and Management of Biallelic Mismatch Repair Deficiency (BMMRD) Syndrome: A Consensus Statement by the US Multi-Society Task Force on ColorectalÂCancer. Gastroenterology, 2017, 152, 1605-1614.	0.6	46
2126	Comprehensive somatic genome alterations of urachal carcinoma. Journal of Medical Genetics, 2017, 54, 572-578.	1.5	30
2127	A comprehensive analysis of cancer-driving mutations and genes in kidney cancer. Oncology Letters, 2017, 13, 2151-2160.	0.8	4
2128	Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer. Human Pathology, 2017, 66, 1-9.	1.1	31
2129	DNA methylation aberrancies as a guide for surveillance and treatment of human cancers. Epigenetics, 2017, 12, 416-432.	1.3	98
2130	Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma. Journal of Neuro-Oncology, 2017, 132, 359-372.	1.4	8
2131	Colorectal adenoma and carcinoma specific miRNA profiles in biopsy and their expression in plasma specimens. Clinical Epigenetics, 2017, 9, 22.	1.8	40
2132	The dynamic DNA methylation landscape of the mutL homolog 1 shore is altered by MLH1-93G>A polymorphism in normal tissues and colorectal cancer. Clinical Epigenetics, 2017, 9, 26.	1.8	9
2133	The enigmatic oncogene and tumor suppressorâ€like properties of RAD54B: Insights into genome instability and cancer. Genes Chromosomes and Cancer, 2017, 56, 513-523.	1.5	16
2134	Bone morphogenetic protein and Notch signalling crosstalk in poorâ€prognosis, mesenchymalâ€subtype colorectal cancer. Journal of Pathology, 2017, 242, 178-192.	2.1	36
2135	CD95 ligand induces senescence in mismatch repair-deficient human colon cancer via chronic caspase-mediated induction of DNA damage. Cell Death and Disease, 2017, 8, e2669-e2669.	2.7	10
2136	Characterization of a novel <i>POLD1</i> missense founder mutation in a Spanish population. Journal of Gene Medicine, 2017, 19, e2951.	1.4	4
2137	Precision surgery for colorectal liver metastases: Opportunities and challenges of omics-based decision making. European Journal of Surgical Oncology, 2017, 43, 875-883.	0.5	32
2138	Bioinformatic approaches to interrogating vitamin D receptor signaling. Molecular and Cellular Endocrinology, 2017, 453, 3-13.	1.6	11
2139	No back seat for a progression eventâ€"K-RAS as a therapeutic target in CRC. Genes and Development, 2017, 31, 333-335.	2.7	7
2140	Pan-cancer analysis distinguishes transcriptional changes of aneuploidy from proliferation. Genome Research, 2017, 27, 501-511.	2.4	52
2141	Clinical relevance of colorectal cancer molecular subtypes. Critical Reviews in Oncology/Hematology, 2017, 109, 9-19.	2.0	109
2142	From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nature Reviews Clinical Oncology, 2017, 14, 235-246.	12.5	466

#	Article	IF	Citations
2143	<i>GPX3</i> promoter methylation predicts platinum sensitivity in colorectal cancer. Epigenetics, 2017, 12, 540-550.	1.3	43
2144	A critical discussion on diet, genomic mutations and repair mechanisms in colon carcinogenesis. Toxicology Letters, 2017, 265, 106-116.	0.4	13
2145	Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery. Cancer Immunology Research, 2017, 5, 29-41.	1.6	321
2146	Molecular Markers Beyond Microsatellite Instability for Assessing Prognosis in Early-Stage Colorectal Cancer. JAMA Oncology, 2017, 3, 481.	3.4	1
2147	Association of DNA Mismatch Repair and Mutations in <i>BRAF</i> and <i>KRAS</i> With Survival After Recurrence in Stage III Colon Cancers. JAMA Oncology, 2017, 3, 472.	3.4	82
2148	HER3 as a Therapeutic Target in Cancer. BioDrugs, 2017, 31, 63-73.	2.2	29
2149	Cornerstones of CRISPRâ€"Cas in drug discovery and therapy. Nature Reviews Drug Discovery, 2017, 16, 89-100.	21.5	370
2150	Copy number alterations unmasked as enhancer hijackers. Nature Genetics, 2017, 49, 5-6.	9.4	40
2151	Copy number variations in <i>DCC/</i>18q and <i>ERBB2/</i>17q are associated with diseaseâ€free survival in microsatellite stable colon cancer. International Journal of Cancer, 2017, 140, 1653-1661.	2.3	10
2152	Integrative genomic approaches to dissect clinically-significant relationships between the VDR cistrome and gene expression in primary colon cancer. Journal of Steroid Biochemistry and Molecular Biology, 2017, 173, 130-138.	1.2	14
2154	Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. Cancer Treatment Reviews, 2017, 53, 61-69.	3.4	118
2155	Exogenous expression of SAMHD1 inhibits proliferation and induces apoptosis in cutaneous T-cell lymphoma-derived HuT78 cells. Cell Cycle, 2017, 16, 179-188.	1.3	26
2156	Upregulated miR-16 expression is an independent indicator of relapse and poor overall survival of colorectal adenocarcinoma patients. Clinical Chemistry and Laboratory Medicine, 2017, 55, 737-747.	1.4	33
2157	Patient-derived xenografts of gastrointestinal cancers are susceptible to rapid and delayed B-lymphoproliferation. International Journal of Cancer, 2017, 140, 1356-1363.	2.3	26
2158	Ex Vivo Engineering of the Tumor Microenvironment. Cancer Drug Discovery and Development, 2017, , .	0.2	4
2159	Advancing Techniques and Insights in Circulating Tumor Cell (CTC) Research. Cancer Drug Discovery and Development, 2017, , 71-94.	0.2	2
2160	Smarca4 ATPase mutations disrupt direct eviction of PRC1 from chromatin. Nature Genetics, 2017, 49, 282-288.	9.4	165
2161	ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice. Nature Genetics, 2017, 49, 296-302.	9.4	260

#	Article	IF	Citations
2162	Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nature Reviews Cancer, 2017, 17, 79-92.	12.8	686
2164	Phytochemical Investigations of Three <i>Rhodocodon</i> (Hyacinthaceae Sensu APG II) Species. Journal of Natural Products, 2017, 80, 30-37.	1.5	11
2165	Integrated genomic characterization of oesophageal carcinoma. Nature, 2017, 541, 169-175.	13.7	1,448
2166	Immunological profiling of molecularly classified high-risk endometrial cancers identifies <i>POLE</i>-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. OncoImmunology, 2017, 6, e1264565.	2.1	102
2167	Phosphoproteomics of colon cancer metastasis: comparative mass spectrometric analysis of the isogenic primary and metastatic cell lines SW480 and SW620. Analytical and Bioanalytical Chemistry, 2017, 409, 1749-1763.	1.9	18
2168	CIB1 contributes to oncogenic signalling by Ras via modulating the subcellular localisation of sphingosine kinase 1. Oncogene, 2017, 36, 2619-2627.	2.6	28
2169	Evolution and heterogeneity of non-hereditary colorectal cancer revealed by single-cell exome sequencing. Oncogene, 2017, 36, 2857-2867.	2.6	61
2170	Different in vivo and in vitro transformation of intestinal stem cells in mismatch repair deficiency. Oncogene, 2017, 36, 2750-2761.	2.6	12
2171	Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphologyâ€"molecular associations: clinical and biological implications. Modern Pathology, 2017, 30, 599-609.	2.9	74
2172	Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. European Journal of Cancer, 2017, 86, 305-317.	1.3	22
2173	Deletion of 3p13-14 locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis. Nature Communications, 2017, 8, 1081.	5.8	16
2174	Pteisolic acid G, a novel entâ€'kaurane diterpenoid, inhibits viability and induces apoptosis in human colorectal carcinoma cells. Oncology Letters, 2017, 14, 5540-5548.	0.8	5
2175	<i><scp>POLE</scp></i> somatic mutations in advanced colorectal cancer. Cancer Medicine, 2017, 6, 2966-2971.	1.3	43
2177	Circadian gene hCLOCK contributes to progression of colorectal carcinoma and is directly regulated by tumor-suppressive microRNA-124. Molecular Medicine Reports, 2017, 16, 7923-7930.	1.1	5
2178	Chromosome-scale mega-haplotypes enable digital karyotyping of cancer aneuploidy. Nucleic Acids Research, 2017, 45, e162-e162.	6.5	28
2179	PI3K-Akt and Ras-Raf-MAPK signaling in colorectal cancer â€" Comparison of activity in primary tumor tissues and primary tumour â€" Derived human colorectal cancer cell lines. Porto Biomedical Journal, 2017, 2, 215-216.	0.4	1
2180	PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients. Clinical Cancer Research, 2017, 23, 7225-7231.	3.2	17
2181	Pan-cancer analysis reveals presence of pronounced DNA methylation drift in CpG island methylator phenotype clusters. Epigenomics, 2017, 9, 1341-1352.	1.0	12

#	Article	IF	Citations
2182	Network-Based Coverage of Mutational Profiles Reveals Cancer Genes. Cell Systems, 2017, 5, 221-229.e4.	2.9	40
2183	Vitamin D Receptor Signaling and Cancer. Endocrinology and Metabolism Clinics of North America, 2017, 46, 1009-1038.	1.2	52
2184	Molecular testing of gastrointestinal tumours. Diagnostic Histopathology, 2017, 23, 442-449.	0.2	1
2185	Molecular Profiling in Colon Cancer: Where Are We Now?. Current Colorectal Cancer Reports, 2017, 13, 362-369.	1.0	0
2186	Molecular stratification of colorectal cancer populations and its use in directing precision medicine. Expert Review of Precision Medicine and Drug Development, 2017, 2, 205-215.	0.4	3
2187	Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients. Cancer Genetics, 2017, 218-219, 51-57.	0.2	14
2188	Sample Size Calculation for Differential Expression Analysis of RNA-Seq Data. , 2017, , 359-379.		0
2190	Molecular Testing of Colorectal Cancer in the Modern Era. Surgical Pathology Clinics, 2017, 10, 1009-1020.	0.7	4
2191	The dose-dependent effect of SOX9 and its incidence in colorectal cancer. European Journal of Cancer, 2017, 86, 150-157.	1.3	33
2192	A plasma lipidomics strategy reveals perturbed lipid metabolic pathways and potential lipid biomarkers of human colorectal cancer. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1068-1069, 41-48.	1.2	63
2193	Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric. Cancer Research, 2017, 77, 6415-6428.	0.4	206
2194	The number of key carcinogenic events can be predicted from cancer incidence. Scientific Reports, 2017, 7, 12170.	1.6	35
2195	Interethnic DNA methylation difference and its implications in pharmacoepigenetics. Epigenomics, 2017, 9, 1437-1454.	1.0	18
2196	Tubulin-binding anticancer polysulfides induce cell death via mitotic arrest and autophagic interference in colorectal cancer. Cancer Letters, 2017, 410, 139-157.	3.2	21
2197	Onco-proteogenomics: Multi-omics level data integration for accurate phenotype prediction. Critical Reviews in Clinical Laboratory Sciences, 2017, 54, 414-432.	2.7	16
2198	Chemoprevention by artesunate in a preclinical model of colorectal cancer involves down regulation of Î²-catenin, suppression of angiogenesis, cellular proliferation and induction of apoptosis. Chemico-Biological Interactions, 2017, 278, 84-91.	1.7	33
2199	USP7 Is a Tumor-Specific WNT Activator for APC -Mutated Colorectal Cancer by Mediating Î²-Catenin Deubiquitination. Cell Reports, 2017, 21, 612-627.	2.9	118
2200	Widespread Post-transcriptional Attenuation of Genomic Copy-Number Variation in Cancer. Cell Systems, 2017, 5, 386-398.e4.	2.9	102

#	Article	IF	Citations
2201	Cancer Precision Medicine: Why More Is More and DNA Is Not Enough. Public Health Genomics, 2017, 20, 70-80.	0.6	30
2202	Comprehensive Analysis of Hypermutation in Human Cancer. Cell, 2017, 171, 1042-1056.e10.	13.5	596
2203	Adaptive Multiview Nonnegative Matrix Factorization Algorithm for Integration of Multimodal Biomedical Data. Cancer Informatics, 2017, 16, 117693511772572.	0.9	6
2204	The Antibody Repertoire of Colorectal Cancer. Molecular and Cellular Proteomics, 2017, 16, 2111-2124.	2.5	8
2205	Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING caseâ€“control study. Annals of Oncology, 2017, 28, 3009-3014.	0.6	72
2206	A novel approach for data integration and disease subtyping. Genome Research, 2017, 27, 2025-2039.	2.4	139
2207	A Review of Compounds for Prevention of Colorectal Cancer. Current Pharmacology Reports, 2017, 3, 221-231.	1.5	5
2208	Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity. OncoImmunology, 2017, 6, e1356150.	2.1	32
2209	Cancer bypasses the lymph nodes. Science, 2017, 357, 35-36.	6.0	7
2210	A material-basis study of Aloe vera on the wnt/Î²-catenin signaling pathway using a knockin/knockout method with high-speed countercurrent chromatography. RSC Advances, 2017, 7, 38819-38829.	1.7	5
2211	Whole exome sequencing identifies a KCNJ12 mutation as a cause of familial dilated cardiomyopathy. Medicine (United States), 2017, 96, e7727.	0.4	10
2212	Cancer Biology: APC Delivers Kiss of Death to Focal Adhesions. Current Biology, 2017, 27, R805-R807.	1.8	1
2213	Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 2017, 17, 951-964.	1.1	2
2214	<i>FGFR2</i> amplification in colorectal adenocarcinoma. Journal of Physical Education and Sports Management, 2017, 3, a001495.	0.5	19
2215	The colorectal cancer immune microenvironment and approach to immunotherapies. Future Oncology, 2017, 13, 1633-1647.	1.1	76
2216	Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine. European Journal of Cancer, 2017, 84, 290-303.	1.3	112
2217	Ethnopharmacological use of Cymbopogon citratus (DC.) Stapf and Cymbopogon schoenanthus (L.) Spreng.: Anti-inflammatory potential of phenol-rich extracts. Porto Biomedical Journal, 2017, 2, 216-217.	0.4	4
2218	Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer. Scientific Reports, 2017, 7, 11590.	1.6	173

#	Article	IF	Citations
2219	Overexpression of transcription factor activating enhancer binding protein 4 (TFAP4) predicts poor prognosis for colorectal cancer patients. Experimental and Therapeutic Medicine, 2017, 14, 3057-3061.	0.8	11
2220	<i>In Silico</i> Modeling of Immunotherapy and Stroma-Targeting Therapies in Human Colorectal Cancer. Cancer Research, 2017, 77, 6442-6452.	0.4	90
2221	DNA Methylation Changes in Cancer. Cancer Drug Discovery and Development, 2017, , 75-96.	0.2	1
2222	The role of the hypoxic tumor microenvironment on the macrophage-tumor cell interplay. Porto Biomedical Journal, 2017, 2, 216.	0.4	0
2223	A Genome-wide Association Study of Dupuytren Disease Reveals 17 Additional Variants Implicated in Fibrosis. American Journal of Human Genetics, 2017, 101, 417-427.	2.6	67
2224	Differences of protein expression profiles, KRAS and BRAF mutation, and prognosis in right-sided colon, left-sided colon and rectal cancer. Scientific Reports, 2017, 7, 7882.	1.6	53
2225	MIER3 suppresses colorectal cancer progression by down-regulating Sp1, inhibiting epithelial-mesenchymal transition. Scientific Reports, 2017, 7, 11000.	1.6	21
2226	Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. Cancer Treatment Reviews, 2017, 60, 109-119.	3.4	45
2227	Analysis of somatic microsatellite indels identifies driver events in human tumors. Nature Biotechnology, 2017, 35, 951-959.	9.4	106
2228	Network-based machine learning and graph theory algorithms for precision oncology. Npj Precision Oncology, 2017, 1, 25.	2.3	74
2229	Aberrant DNA Methylation in Colorectal Cancer: What Should We Target?. Trends in Cancer, 2017, 3, 698-712.	3.8	85
2230	<i>VHL</i> Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma. Cancer Discovery, 2017, 7, 1284-1305.	7.7	111
2231	Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome. Nature Communications, 2017, 8, 14400.	5.8	93
2232	Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer. Clinical Cancer Research, 2017, 23, 7209-7216.	3.2	72
2233	Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. Annals of Surgical Oncology, 2017, 24, 4051-4058.	0.7	32
2234	Genomic landscape of human erythroleukemia K562 cell line, as determined by next-generation sequencing and cytogenetics. Acta Haematologica Polonica, 2017, 48, 343-349.	0.1	3
2235	Towards personalized medicine of colorectal cancer. Critical Reviews in Oncology/Hematology, 2017, 118, 70-78.	2.0	42
2236	Molecular Signatures for Tumor Classification. Journal of Molecular Diagnostics, 2017, 19, 881-891.	1.2	22

#	Article	IF	Citations
2237	An Optimal Mean Based Block Robust Feature Extraction Method to Identify Colorectal Cancer Genes with Integrated Data. Scientific Reports, 2017, 7, 8584.	1.6	5
2238	geneSurv: An interactive web-based tool for survival analysis in genomics research. Computers in Biology and Medicine, 2017, 89, 487-496.	3.9	4
2239	Mutational heterogeneity in non-serous ovarian cancers. Scientific Reports, 2017, 7, 9728.	1.6	35
2240	Copy number rather than epigenetic alterations are the major dictator of imprinted methylation in tumors. Nature Communications, 2017, 8, 467.	5.8	27
2241	DNA and Histone Methylation in Colon Cancer. Cancer Drug Discovery and Development, 2017, , 461-487.	0.2	0
2242	Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials. Oncologist, 2017, 22, 1169-1177.	1.9	14
2243	Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis. Annals of Oncology, 2017, 28, 2135-2141.	0.6	92
2244	Genomic and transcriptomic heterogeneity of colorectal tumours arising in Lynch syndrome. Journal of Pathology, 2017, 243, 242-254.	2.1	69
2245	Long Noncoding RNA BC032913 as a Novel Therapeutic Target for Colorectal Cancer that Suppresses Metastasis by Upregulating TIMP3. Molecular Therapy - Nucleic Acids, 2017, 8, 469-481.	2.3	29
2246	The whole-genome landscape of medulloblastoma subtypes. Nature, 2017, 547, 311-317.	13.7	787
2247	The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy. Molecular Cancer Therapeutics, 2017, 16, 2223-2233.	1.9	24
2248	UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia, 2017, 19, 649-658.	2.3	4,166
2249	BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives. Annals of Oncology, 2017, 28, 2648-2657.	0.6	227
2250	BRAF mutations are associated with increased iron regulatory proteinâ€2 expression in colorectal tumorigenesis. Cancer Science, 2017, 108, 1135-1143.	1.7	42
2251	A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution. Cell Reports, 2017, 20, 999-1015.	2.9	77
2252	Molecular genetics and targeted therapy of WNT-related human diseases (Review). International Journal of Molecular Medicine, 2017, 40, 587-606.	1.8	144
2253	High-fat diet induced leptin and Wnt expression: RNA-sequencing and pathway analysis of mouse colonic tissue and tumors. Carcinogenesis, 2017, 38, 302-311.	1.3	34
2254	Genetic and epigenetic drivers of neuroendocrine tumours (NET). Endocrine-Related Cancer, 2017, 24, R315-R334.	1.6	94

#	Article	IF	Citations
2255	Tandem repeat variation near the <i>HIC1</i> (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatinâ€based chemotherapy in patients with metastatic colorectal cancer. Cancer, 2017, 123, 4506-4514.	2.0	8
2256	Genomic approaches to accelerate cancer interception. Lancet Oncology, The, 2017, 18, e494-e502.	5.1	43
2257	Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies. Cancer Cell, 2017, 32, 155-168.e6.	7.7	93
2258	Formalin-fixed paraffin-embedded sample conditions for deep next generation sequencing. Journal of Surgical Research, 2017, 220, 125-132.	0.8	45
2259	Evidence for genetic association between chromosome 1q loci and predisposition to colorectal neoplasia. British Journal of Cancer, 2017, 117, 1215-1223.	2.9	10
2260	Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. Clinical Cancer Research, 2017, 23, 4441-4449.	3.2	342
2261	Inhibition of nuclear Wnt signalling: challenges of an elusive target for cancer therapy. British Journal of Pharmacology, 2017, 174, 4589-4599.	2.7	48
2262	Bidirectional reporter assay using <i>HAL</i> promoter and TOPFLASH improves specificity in highâ€throughput screening of Wnt inhibitors. Biotechnology and Bioengineering, 2017, 114, 2868-2882.	1.7	9
2263	Development of a Whole Organism Platform for Phenotype-Based Analysis of IGF1R-PI3K-Akt-Tor Action. Scientific Reports, 2017, 7, 1994.	1.6	13
2264	Activin signaling is an essential component of the TGF-Î² induced pro-metastatic phenotype in colorectal cancer. Scientific Reports, 2017, 7, 5569.	1.6	55
2265	Porcine familial adenomatous polyposis model enables systematic analysis of early events in adenoma progression. Scientific Reports, 2017, 7, 6613.	1.6	22
2266	ctPath: Demixing pathway crosstalk effect from transcriptomics data for differential pathway identification. Journal of Biomedical Informatics, 2017, 73, 104-114.	2.5	9
2267	Precision Oncology: Present Status and Perspectives. Current Clinical Pathology, 2017, , 7-26.	0.0	0
2268	Recent developments in the treatment of metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2017, 9, 551-564.	1.4	82
2269	Inflammation and Colorectal Cancer. Current Colorectal Cancer Reports, 2017, 13, 341-351.	1.0	111
2270	Improving Hierarchical Models Using Historical Data with Applications in High-Throughput Genomics Data Analysis. Statistics in Biosciences, 2017, 9, 73-90.	0.6	1
2271	Burden and Profile of Somatic Mutation in Duodenal Adenomas from Patients with Familial Adenomatous- and <i>MUTYH</i>-associated Polyposis. Clinical Cancer Research, 2017, 23, 6721-6732.	3.2	24
2272	Oncologic outcomes of single-incision laparoscopic surgery for right colon cancer: A propensity score-matching analysis. International Journal of Surgery, 2017, 45, 125-130.	1.1	16

#	Article	IF	Citations
2273	In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E7301-E7310.	3.3	88
2274	Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/Î²-catenin Signaling. Molecular Cancer Research, 2017, 15, 1481-1490.	1.5	105
2275	Multiplexed Liquid Chromatography-Multiple Reaction Monitoring Mass Spectrometry Quantification of Cancer Signaling Proteins. Methods in Molecular Biology, 2017, 1647, 19-45.	0.4	5
2276	Inference for multimarker adaptive enrichment trials. Statistics in Medicine, 2017, 36, 4083-4093.	0.8	15
2277	TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer. OncoImmunology, 2017, 6, e1356143.	2.1	79
2278	Defining key concepts of intestinal and epithelial cancer biology through the use of mouse models. Carcinogenesis, 2017, 38, 953-965.	1.3	5
2279	Myeloid Cell-Derived Reactive Oxygen Species Induce Epithelial Mutagenesis. Cancer Cell, 2017, 32, 869-883.e5.	7.7	232
2280	CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models. Scientific Reports, 2017, 7, 16618.	1.6	229
2281	Non-Canonical Hedgehog Signaling Is a Positive Regulator of the WNT Pathway and Is Required for the Survival of Colon Cancer Stem Cells. Cell Reports, 2017, 21, 2813-2828.	2.9	105
2282	Heterogeneity of colon cancer: from bench to bedside. ESMO Open, 2017, 2, e000218.	2.0	36
2283	Analysis of <i>Fusobacterium</i> persistence and antibiotic response in colorectal cancer. Science, 2017, 358, 1443-1448.	6.0	983
2284	Transmembrane helix connectivity in Orai1 controls two gates for calcium-dependent transcription. Science Signaling, 2017, 10, .	1.6	68
2285	The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors. Targeted Oncology, 2017, 12, 757-774.	1.7	1
2286	Tumor-Suppressor Inactivation of GDF11 Occurs by Precursor Sequestration in Triple-Negative Breast Cancer. Developmental Cell, 2017, 43, 418-435.e13.	3.1	62
2287	MicroRNAs and their role for T stage determination and lymph node metastasis in early colon carcinoma. Clinical and Experimental Metastasis, 2017, 34, 431-440.	1.7	13
2288	The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation. Scientific Reports, 2017, 7, 14992.	1.6	110
2289	Structural basis for the selective incorporation of an artificial nucleotide opposite a DNA adduct by a DNA polymerase. Chemical Communications, 2017, 53, 12704-12707.	2.2	9
2290	Beyond cancer genes: colorectal cancer as robust intrinsic states formed by molecular interactions. Open Biology, 2017, 7, 170169.	1.5	17

#	Article	IF	Citations
2291	A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2017, 23, 5981-5992.	3.2	107
2292	DNA mismatch repair and its many roles in eukaryotic cells. Mutation Research - Reviews in Mutation Research, 2017, 773, 174-187.	2.4	135
2293	Somatic mutations in ZFHX4 gene are associated with poor overall survival of Chinese esophageal squamous cell carcinoma patients. Scientific Reports, 2017, 7, 4951.	1.6	46
2294	Immune checkpoint inhibitors for patients with colorectal cancer: mismatch repair deficiency and perspectives. Colorectal Cancer, 2017, 6, 23-31.	0.8	1
2295	Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 355-362.	1.4	11
2296	Normally lethal amino acid substitutions suppress an ultramutator DNA Polymerase Î´ variant. Scientific Reports, 2017, 7, 46535.	1.6	5
2297	Comprehensive analysis of copy number aberrations in microsatellite stable colon cancer in view of stromal component. British Journal of Cancer, 2017, 117, 421-431.	2.9	125
2298	Spectral clustering using NystrÃ¶m approximation for the accurate identification of cancer molecular subtypes. Scientific Reports, 2017, 7, 4896.	1.6	2
2299	Recommendations on Surveillance and Management of Biallelic Mismatch Repair Deficiency (BMMRD) Syndrome. Journal of Pediatric Gastroenterology and Nutrition, 2017, 64, 836-843.	0.9	5
2300	Targeting the Wnt Pathway in Cancer: A Review of Novel Therapeutics. Targeted Oncology, 2017, 12, 623-641.	1.7	47
2301	Interaction of tankyrase and peroxiredoxin II is indispensable for the survival of colorectal cancer cells. Nature Communications, 2017, 8, 40.	5.8	37
2302	Multilevel genomics of colorectal cancers with microsatellite instabilityâ€"clinical impact of JAK1 mutations and consensus molecular subtype 1. Genome Medicine, 2017, 9, 46.	3.6	71
2303	ISOWN: accurate somatic mutation identification in the absence of normal tissue controls. Genome Medicine, 2017, 9, 59.	3.6	44
2304	Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples. BMC Cancer, 2017, 17, 139.	1.1	22
2305	Objective response to mTOR inhibition in a metastatic collision tumor of the liver composed of melanoma and adenocarcinoma with TSC1 loss: a case report. BMC Cancer, 2017, 17, 197.	1.1	5
2306	Genome-wide methylation analysis identifies a core set of hypermethylated genes in CIMP-H colorectal cancer. BMC Cancer, 2017, 17, 228.	1.1	32
2307	Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT). BMC Cancer, 2017, 17, 282.	1.1	13
2308	The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients. BMC Cancer, 2017, 17, 403.	1.1	28

#	Article	IF	Citations
2309	Analysis of the DNA methylation level of cancer-related genes in colorectal cancer and the surrounding normal mucosa. Clinical Epigenetics, 2017, 9, 55.	1.8	35
2310	The NF1 somatic mutational landscape in sporadic human cancers. Human Genomics, 2017, 11, 13.	1.4	203
2311	Current applications of molecular pathology in colorectal carcinoma. Applied Cancer Research, 2017, 37, .	1.0	8
2312	Inactivation of the Kinase Domain of CDK10 Prevents Tumor Growth in a Preclinical Model of Colorectal Cancer, and Is Accompanied by Downregulation of Bcl-2. Molecular Cancer Therapeutics, 2017, 16, 2292-2303.	1.9	14
2313	Genomic profiling of colorectal cancers and the future of personalized treatment. Colorectal Cancer, 2017, 6, 11-22.	0.8	1
2314	Baseline MAPK signaling activity confers intrinsic radioresistance to KRAS-mutant colorectal carcinoma cells by rapid upregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K). Cancer Letters, 2017, 385, 160-167.	3.2	18
2315	Transposon mutagenesis identifies candidate genes that cooperate with loss of transforming growth factorâ€beta signaling in mouse intestinal neoplasms. International Journal of Cancer, 2017, 140, 853-863.	2.3	19
2316	Analysis of the interplay between methylation and expression reveals its potential role in cancer aetiology. Functional and Integrative Genomics, 2017, 17, 53-68.	1.4	14
2317	Cancer predisposition syndromes: lessons for truly precision medicine. Journal of Pathology, 2017, 241, 226-235.	2.1	13
2318	Colorectal Cancer Prognosis Following Obesity Surgery in a Population-Based Cohort Study. Obesity Surgery, 2017, 27, 1233-1239.	1.1	29
2319	Proteome Profiling Outperforms Transcriptome Profiling for Coexpression Based Gene Function Prediction. Molecular and Cellular Proteomics, 2017, 16, 121-134.	2.5	111
2320	Measuring cancer evolution from the genome. Journal of Pathology, 2017, 241, 183-191.	2.1	93
2321	Neomorphic mutations create therapeutic challenges in cancer. Oncogene, 2017, 36, 1607-1618.	2.6	24
2322	Rationale for <i>RAS</i> mutation-tailored therapies. Future Oncology, 2017, 13, 263-271.	1.1	16
2323	Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. JAMA Oncology, 2017, 3, 774.	3.4	221
2324	Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAFV600E In Vivo. Molecular Imaging and Biology, 2017, 19, 421-428.	1.3	17
2325	Transforming Growth Factor Î² Superfamily Signaling inÂDevelopment of Colorectal Cancer. Gastroenterology, 2017, 152, 36-52.	0.6	181
2326	Natural Selection in Cancer Biology: From Molecular Snowflakes to Trait Hallmarks. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a029652.	2.9	48

#	Article	IF	Citations
2327	Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer. Indian Journal of Surgical Oncology, 2017, 8, 580-590.	0.3	2
2328	Comparison of biomarker expression between proximal and distal colorectal adenomas: The Tennesseeâ€"Indiana Adenoma Recurrence Study. Molecular Carcinogenesis, 2017, 56, 761-773.	1.3	4
2329	CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy. Pharmacogenomics Journal, 2017, 17, 543-550.	0.9	11
2330	Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions. Expert Review of Clinical Immunology, 2017, 13, 235-245.	1.3	26
2331	Clinicopathological characteristics of serrated polyps as precursors to colorectal cancer: Current status and management. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 358-367.	1.4	42
2332	Wnt3A Induces GSKâ€3Î² Phosphorylation and Î²â€Catenin Accumulation Through RhoA/ROCK. Journal of Cellular Physiology, 2017, 232, 1104-1113.	2.0	41
2333	In-depth mutational analyses of colorectal neuroendocrine carcinomas with adenoma or adenocarcinoma components. Modern Pathology, 2017, 30, 95-103.	2.9	84
2334	Validation of specificity of antibodies for immunohistochemistry: the case of ROR2. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 99-108.	1.4	13
2335	A copy number variation in <i>PKD1L2</i> is associated with colorectal cancer predisposition in korean population. International Journal of Cancer, 2017, 140, 86-94.	2.3	11
2336	Radiosensitivity of Colon and Rectal Lung Oligometastasis Treated With Stereotactic Ablative Radiotherapy. Clinical Colorectal Cancer, 2017, 16, e211-e220.	1.0	33
2337	Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p. Oncogene, 2017, 36, 1339-1350.	2.6	39
2338	The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer. Clinical Cancer Research, 2017, 23, 2027-2037.	3.2	59
2339	<i><scp>MIIP</scp></i> haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer. Journal of Pathology, 2017, 241, 67-79.	2.1	13
2340	Chasing the personalized medicine dream through biomarker validation in colorectal cancer. Drug Discovery Today, 2017, 22, 111-119.	3.2	22
2341	Colorectal carcinomas with submucosal invasion (pT1): analysis of histopathological and molecular factors predicting lymph node metastasis. Modern Pathology, 2017, 30, 113-122.	2.9	29
2342	Recent Discoveries in the Genetics of Familial Colorectal CancerÂand Polyposis. Clinical Gastroenterology and Hepatology, 2017, 15, 809-819.	2.4	66
2343	CONUT: a novel independent predictive score for colorectal cancer patients undergoing potentially curative resection. International Journal of Colorectal Disease, 2017, 32, 99-106.	1.0	108
2344	Bioinformatics exploration of PAK1 (P21-activated kinase-1) revealed potential network gene elements in breast invasive carcinoma. Journal of Biomolecular Structure and Dynamics, 2017, 35, 2269-2279.	2.0	7

#	Article	IF	Citations
2345	Natural products from <i>Cuscuta reflexa</i> Roxb<i>.</i> with antiproliferation activities in HCT116 colorectal cell lines. Natural Product Research, 2017, 31, 583-587.	1.0	21
2346	Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry. Clinical Cancer Research, 2017, 23, 387-398.	3.2	128
2347	Overproduction of IGF-2 drives a subset of colorectal cancer cells, which specifically respond to an anti-IGF therapeutic antibody and combination therapies. Oncogene, 2017, 36, 797-806.	2.6	29
2348	Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. Nature Genetics, 2017, 49, 65-74.	9.4	326
2349	Hypermutation In Pancreatic Cancer. Gastroenterology, 2017, 152, 68-74.e2.	0.6	174
2350	Epigenetic Biomarkers in Colorectal Cancer. Molecular Diagnosis and Therapy, 2017, 21, 153-165.	1.6	21
2351	Metastatic Anal Cancer and Novel Agents. Surgical Oncology Clinics of North America, 2017, 26, 133-142.	0.6	7
2352	Molecular pathways driving disease-specific alterations of intestinal epithelial cells. Cellular and Molecular Life Sciences, 2017, 74, 803-826.	2.4	12
2353	Disruption of the RP-MDM2-p53 pathway accelerates APC loss-induced colorectal tumorigenesis. Oncogene, 2017, 36, 1374-1383.	2.6	28
2354	Fucosylation Deficiency in Mice Leads to Colitis andÂAdenocarcinoma. Gastroenterology, 2017, 152, 193-205.e10.	0.6	48
2355	Gene heterogeneity in metastasis of colorectal cancer to the lung. Seminars in Cell and Developmental Biology, 2017, 64, 58-64.	2.3	15
2356	Usability and Suitability of the Omics-Integrating Analysis Platform tranSMART for Translational Research and Education. Applied Clinical Informatics, 2017, 08, 1173-1183.	0.8	7
2357	Cell-free DNA as a post-treatment surveillance strategy: current status. Seminars in Oncology, 2017, 44, 330-346.	0.8	20
2358	Differential network analysis via lasso penalized D-trace loss. Biometrika, 2017, 104, 755-770.	1.3	49
2359	Upregulated HOXA9 expression is associated with lymph node metastasis in colorectal cancer. Oncology Letters, 2018, 15, 2756-2762.	0.8	17
2360	Degree of Tissue Differentiation Dictates Susceptibility to BRAF-Driven Colorectal Cancer. Cell Reports, 2017, 21, 3833-3845.	2.9	52
2361	Lifestyle, Diet, and Colorectal Cancer Risk According to (Epi)genetic Instability: Current Evidence and Future Directions of Molecular Pathological Epidemiology. Current Colorectal Cancer Reports, 2017, 13, 455-469.	1.0	91
2362	Guanylate-binding protein 2 regulates Drp1-mediated mitochondrial fission to suppress breast cancer cell invasion. Cell Death and Disease, 2017, 8, e3151-e3151.	2.7	56

#	Article	IF	Citations
2363	Increased Frequency of KRAS Mutations in African Americans Compared with Caucasians in Sporadic Colorectal Cancer. Clinical and Translational Gastroenterology, 2017, 8, e124.	1.3	35
2364	Fibrolamellar hepatocellular carcinoma: Exploring molecular mechanisms and differentiation pathways to better understand disease outcomes and prognosis. Liver Research, 2017, 1, 187-192.	0.5	5
2365	circlncRNAnet: An integrated web-based resource for mapping functional networks of long or circular forms of non-coding RNAs. GigaScience, 2018, 7, 1-10.	3.3	75
2366	Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2017, 28, iv22-iv40.	0.6	1,126
2368	<i>TBX19</i> is overexpressed in colorectal cancer and associated with lymph node metastasis. Fukushima Journal of Medical Sciences, 2017, 63, 141-151.	0.1	11
2369	Epigenetic and genetic deregulation in cancer target distinct signaling pathway domains. Nucleic Acids Research, 2017, 45, 583-596.	6.5	18
2370	Identification and validation of PSAT1 as a potential prognostic factor for predicting clinical outcomes in patients with colorectal carcinoma. Oncology Letters, 2017, 14, 8014-8020.	0.8	23
2371	RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutations. Scientific Reports, 2017, 7, 15270.	1.6	32
2372	digitâ€"a tool fordetection andidentification ofgenomicinterchromosomaltranslocations. Nucleic Acids Research, 2017, 45, gkx010.	6.5	0
2373	Tissue-Agnostic Drug Development. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 222-230.	1.8	25
2374	Transcriptional response profiles of paired tumor-normal samples offer novel perspectives in pan-cancer analysis. Oncotarget, 2017, 8, 41334-41347.	0.8	22
2375	<i>NOMO-1</i> gene is deleted in early-onset colorectal cancer. Oncotarget, 2017, 8, 24429-24436.	0.8	17
2376	Identification of potential long non-coding RNA biomarkers associated with the progression of colon cancer. Oncotarget, 2017, 8, 75834-75843.	0.8	17
2377	Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience. Oncotarget, 2017, 8, 42198-42213.	0.8	49
2378	Microsatellite Instability Testing Using Next-Generation Sequencing Data and Therapy Implications. JCO Precision Oncology, 2017, 1, 1-4.	1.5	8
2379	Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2â€"Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine. JCO Precision Oncology, 2017, 1, 1-6.	1.5	5
2380	Molecular Characterization of Somatic Alterations in Dukesâ€™ B and C Colorectal Cancers by Targeted Sequencing. Frontiers in Pharmacology, 2017, 8, 465.	1.6	8
2381	FH535 Inhibits Proliferation and Motility of Colon Cancer Cells by Targeting Wnt/Î²-catenin Signaling Pathway. Journal of Cancer, 2017, 8, 3142-3153.	1.2	32

#	Article	IF	Citations
2382	Potential roles of microRNAs and ROS in colorectal cancer: diagnostic biomarkers and therapeutic targets. Oncotarget, 2017, 8, 17328-17346.	0.8	50
2383	Primary Tumor Location as a Predictive Factor for First-line Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients. Journal of Cancer, 2017, 8, 388-394.	1.2	24
2384	Current and future biomarkers in colorectal cancer. Annals of Gastroenterology, 2017, 30, 613-621.	0.4	88
2385	An integrated lncRNA, microRNA and mRNA signature to improve prognosis prediction of colorectal cancer. Oncotarget, 2017, 8, 85463-85478.	0.8	33
2386	Molecular classification of esophagogastric junction carcinoma correlated with prognosis. OncoTargets and Therapy, 2017, Volume 10, 4765-4772.	1.0	5
2387	Molecular and Clinicopathological Differences by Age at the Diagnosis of Colorectal Cancer. International Journal of Molecular Sciences, 2017, 18, 1441.	1.8	24
2388	PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence. Gastrointestinal Cancer: Targets and Therapy, 2017, Volume 7, 1-11.	5.5	49
2389	G2/M-Phase Checkpoint Adaptation and Micronuclei Formation as Mechanisms That Contribute to Genomic Instability in Human Cells. International Journal of Molecular Sciences, 2017, 18, 2344.	1.8	61
2390	Detecting Disease Specific Pathway Substructures through an Integrated Systems Biology Approach. Non-coding RNA, 2017, 3, 20.	1.3	25
2391	A transcriptome-based protein network that identifies new therapeutic targets in colorectal cancer. BMC Genomics, 2017, 18, 758.	1.2	5
2392	EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?. International Journal of Molecular Sciences, 2017, 18, 1172.	1.8	73
2393	2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications. Oncotarget, 2017, 8, 18456-18485.	0.8	134
2394	To Wnt or Lose: The Missing Non-Coding Linc in Colorectal Cancer. International Journal of Molecular Sciences, 2017, 18, 2003.	1.8	48
2395	Immunotherapy for Colorectal Cancer. Cancers, 2017, 9, 50.	1.7	125
2396	MicroRNAs as Biomarkers in Colorectal Cancer. Cancers, 2017, 9, 124.	1.7	94
2397	Genomic Destabilization Triggered by Replication Stress during Senescence. Cancers, 2017, 9, 159.	1.7	4
2398	Ubiquitin Specific Peptidase 22 Regulates Histone H2B Mono-Ubiquitination and Exhibits Both Oncogenic and Tumor Suppressor Roles in Cancer. Cancers, 2017, 9, 167.	1.7	43
2399	Risks at the DNA Replication Fork: Effects upon Carcinogenesis and Tumor Heterogeneity. Genes, 2017, 8, 46.	1.0	27

#	Article	IF	Citations
2400	MYC Deregulation in Primary Human Cancers. Genes, 2017, 8, 151.	1.0	281
2401	Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. International Journal of Molecular Sciences, 2017, 18, 197.	1.8	888
2402	Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. International Journal of Molecular Sciences, 2017, 18, 308.	1.8	353
2403	Multifaceted Interpretation of Colon Cancer Stem Cells. International Journal of Molecular Sciences, 2017, 18, 1446.	1.8	52
2404	Cofactors As Metabolic Sensors Driving Cell Adaptation in Physiology and Disease. Frontiers in Endocrinology, 2017, 8, 304.	1.5	19
2405	Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy. Frontiers in Immunology, 2017, 8, 1679.	2.2	171
2406	Breaking Ties in Weighted Interactomes. , 2017, , .		0
2407	Signal Transduction Networks Analysis: The Reverse Phase Protein Array. , 2017, , .		0
2408	Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future. BioMed Research International, 2017, 2017, 1-10.	0.9	6
2409	Prediction and Validation of Hub Genes Associated with Colorectal Cancer by Integrating PPI Network and Gene Expression Data. BioMed Research International, 2017, 2017, 1-12.	0.9	30
2410	Negative Correlation between miR-200c and Decorin Plays an Important Role in the Pathogenesis of Colorectal Carcinoma. BioMed Research International, 2017, 2017, 1-8.	0.9	8
2411	Patterns of Sociodemographic and Clinicopathologic Characteristics of Stages II and III Colorectal Cancer Patients by Age: Examining Potential Mechanisms of Young-Onset Disease. Journal of Cancer Epidemiology, 2017, 2017, 1-10.	0.5	20
2412	Upregulation of circadian gene 'hClock' contribution to metastasis of colorectal cancer. International Journal of Oncology, 2017, 50, 2191-2199.	1.4	28
2413	BRAFV600E cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis. ELife, 2017, 6, .	2.8	73
2414	The ESRP1-GPR137 axis contributes to intestinal pathogenesis. ELife, 2017, 6, .	2.8	24
2415	Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers. ELife, 2017, 6, .	2.8	138
2416	Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer. International Journal of Biological Sciences, 2017, 13, 1163-1171.	2.6	39
2417	Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center. Theranostics, 2017, 7, 2914-2923.	4.6	31

#	Article	IF	Citations
2418	Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS. Oncotarget, 2017, 8, 7452-7463.	0.8	232
2419	Vascular Invasion and Stromal S100A4 Expression at the Invasive Front of Colorectal Cancer are Novel Determinants and Tumor Prognostic Markers. Journal of Cancer, 2017, 8, 1552-1561.	1.2	19
2420	Hedgehog signaling pathway in colorectal cancer: function, mechanism, and therapy. OncoTargets and Therapy, 2017, Volume 10, 3249-3259.	1.0	62
2421	The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer. PLoS ONE, 2017, 12, e0179979.	1.1	38
2422	A novel isoform of IL-33 revealed by screening for transposable element promoted genes in human colorectal cancer. PLoS ONE, 2017, 12, e0180659.	1.1	17
2423	Methylation associated transcriptional repression of ELOVL5 in novel colorectal cancer cell lines. PLoS ONE, 2017, 12, e0184900.	1.1	10
2424	NRG1-ErbB Lost in Translation: A New Paradigm for Lung Cancer?. Current Medicinal Chemistry, 2017, 24, 4213-4228.	1.2	19
2425	Effects of FGFR2 kinase activation loop dynamics on catalytic activity. PLoS Computational Biology, 2017, 13, e1005360.	1.5	10
2426	Construction of a combinatorial pipeline using two somatic variantÂ callingÂ methodsÂ for whole exome sequence data of gastric cancer. Journal of Medical Investigation, 2017, 64, 233-240.	0.2	0
2427	Clinical baseline and prognostic difference of platelet lymphocyte ratio (PLR) in right-sided and let-sided colon cancers. BMC Cancer, 2017, 17, 873.	1.1	13
2428	Multi-region and single-cell sequencing reveal variable genomic heterogeneity in rectal cancer. BMC Cancer, 2017, 17, 787.	1.1	30
2429	Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies. Molecular Cancer, 2017, 16, 116.	7.9	232
2430	CLCA1 suppresses colorectal cancer aggressiveness via inhibition of the Wnt/beta-catenin signaling pathway. Cell Communication and Signaling, 2017, 15, 38.	2.7	48
2431	Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer. Journal of Translational Medicine, 2017, 15, 167.	1.8	13
2432	Association of a novel point mutation in MSH2 gene with familial multiple primary cancers. Journal of Hematology and Oncology, 2017, 10, 158.	6.9	4
2433	Predicting cancer type from tumour DNA signatures. Genome Medicine, 2017, 9, 104.	3.6	40
2434	Molecular features that predict the response to antimetabolite chemotherapies. Cancer & Metabolism, 2017, 5, 8.	2.4	13
2435	Quantitation of putative colorectal cancer biomarker candidates in serum extracellular vesicles by targeted proteomics. Scientific Reports, 2017, 7, 12782.	1.6	47

#	Article	IF	Citations
2436	A regulation probability model-based meta-analysis of multiple transcriptomics data sets for cancer biomarker identification. BMC Bioinformatics, 2017, 18, 375.	1.2	0
2437	Investigating MicroRNA and transcription factor co-regulatory networks in colorectal cancer. BMC Bioinformatics, 2017, 18, 388.	1.2	35
2438	CIRH1A augments the proliferation of RKO colorectal cancer cells. Oncology Reports, 2017, 37, 2375-2381.	1.2	8
2439	BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stageÃ¯Â¿Â½IV colorectal cancer. Oncology Letters, 2017, 15, 2195-2201.	0.8	6
2440	Upregulated solute carrier family 37 member 1 in colorectal cancer is associated with poor patient outcome and metastasis. Oncology Letters, 2017, 15, 2065-2072.	0.8	6
2441	DEXseq and Cuffdiff approaches weighing differential spliced genes exons modulation in estrogen receptor (Er) breast cancer cells. African Journal of Biotechnology, 2017, 16, 1404-1427.	0.3	0
2442	Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. Oncotarget, 2017, 8, 90532-90544.	0.8	89
2443	BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations. Oncotarget, 2017, 8, 39945-39962.	0.8	29
2444	Distinctive DNA mismatch repair and APC rare variants in African Americans with colorectal neoplasia. Oncotarget, 2017, 8, 99966-99977.	0.8	7
2445	Clinical relevance of the transcriptional signature regulated by CDC42 in colorectal cancer. Oncotarget, 2017, 8, 26755-26770.	0.8	12
2446	<i>SAMMSON</i> drives the self-renewal of liver tumor initiating cells through EZH2-dependent Wnt/Î²-catenin activation. Oncotarget, 2017, 8, 103785-103796.	0.8	16
2447	Identification of lung adenocarcinoma specific dysregulated genes with diagnostic and prognostic value across 27 TCGA cancer types. Oncotarget, 2017, 8, 87292-87306.	0.8	16
2448	Human DNA polymerase delta double-mutant D316A;E318A interferes with DNA mismatch repair in vitro. Nucleic Acids Research, 2017, 45, 9427-9440.	6.5	4
2449	Clinical course and outcome of patients with high-level microsatellite instability cancers in a real-life setting: a retrospective analysis. OncoTargets and Therapy, 2017, Volume 10, 1889-1896.	1.0	20
2450	<i>POLE</i>and<i>POLD1</i>screening in 155 patients with multiple polyps and early-onset colorectal cancer. Oncotarget, 2017, 8, 26732-26743.	0.8	40
2451	Molecular Testing for Gastrointestinal Cancer. Journal of Pathology and Translational Medicine, 2017, 51, 103-121.	0.4	54
2452	Nuclear Expression of GS28 Protein: A Novel Biomarker that Predicts Prognosis in Colorectal Cancers. International Journal of Medical Sciences, 2017, 14, 515-522.	1.1	8
2453	Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget, 2017, 8, 86356-86368.	0.8	147

#	Article	IF	Citations
2454	A panel of microRNA signature in serum for colorectal cancer diagnosis. Oncotarget, 2017, 8, 17081-17091.	0.8	111
2455	Exome and transcriptome sequencing identifies loss of PDLIM2 in metastatic colorectal cancers. Cancer Management and Research, 2017, Volume 9, 581-589.	0.9	19
2456	Identification of novel mutations in endometrial cancer patients by whole-exome sequencing. International Journal of Oncology, 2017, 50, 1778-1784.	1.4	43
2457	Molecular Prognostic Factors in Gastric Cancer. , 2017, , .		0
2458	AF1q Mediates Tumor Progression in Colorectal Cancer by Regulating AKT Signaling. International Journal of Molecular Sciences, 2017, 18, 987.	1.8	10
2459	Sphingosine Kinase 1 and Sphingosine-1-Phosphate Signaling in Colorectal Cancer. International Journal of Molecular Sciences, 2017, 18, 2109.	1.8	35
2460	Construction of a multiplex mutation hot spot PCR panel: the first step towards colorectal cancer genotyping on the GS Junior platform. Journal of Cancer, 2017, 8, 162-173.	1.2	7
2461	MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines. Journal of Cancer, 2017, 8, 2263-2268.	1.2	6
2462	Sequencing of Lynch syndrome tumors reveals the importance of epigenetic alterations. Oncotarget, 2017, 8, 108020-108030.	0.8	18
2463	Genomics of peritoneal surface malignancies. Journal of Peritoneum (and Other Serosal Surfaces), 2017, , .	0.1	1
2464	<i>APC</i> hypermethylation for early diagnosis of colorectal cancer: a meta-analysis and literature review. Oncotarget, 2017, 8, 46468-46479.	0.8	51
2465	Hypermutation and microsatellite instability in gastrointestinal cancers. Oncotarget, 2017, 8, 112103-112115.	0.8	69
2466	OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology, 2017, 2017, 1-16.	1.5	1,266
2467	To Treat or Not to Treat: Adjuvant Therapy for Stage II Colon Cancer in the Era of Precision Oncology. Journal of Oncology Practice, 2017, 13, 242-244.	2.5	3
2468	Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precision Oncology, 2017, 2017, 1-15.	1.5	796
2469	Not All BRAF-Mutant Metastatic Colorectal Cancers Are Identical: Distinct Clinical Consequences of non-V600BRAF Mutations. Journal of Clinical Oncology, 2017, 35, 2598-2599.	0.8	4
2470	Exceptional Chemotherapy Response in Metastatic Colorectal Cancer Associated With Hyper-Indelâ€“Hypermutated Cancer Genome and Comutation of <i>POLD1</i> and <i>MLH1</i>. JCO Precision Oncology, 2017, 2017, 1-12.	1.5	3
2471	CpG Island Methylator Phenotype-High Colorectal Cancers and Their Prognostic Implications and Relationships with the Serrated Neoplasia Pathway. Gut and Liver, 2017, 11, 38-46.	1.4	34

#	Article	IF	Citations
2472	Expression analysis of microRNA as prognostic biomarkers in colorectal cancer. Oncotarget, 2017, 8, 52403-52412.	0.8	49
2473	Genome-wide DNA methylation analysis reveals molecular subtypes of pancreatic cancer. Oncotarget, 2017, 8, 28990-29012.	0.8	72
2474	Comprehensive Molecular Characterization of Urachal Adenocarcinoma Reveals Commonalities With Colorectal Cancer, Including a Hypermutable Phenotype. JCO Precision Oncology, 2017, 1, 1-12.	1.5	17
2475	The DNA repair function of<i>CUX1</i>contributes to radioresistance. Oncotarget, 2017, 8, 19021-19038.	0.8	21
2476	Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer. Oncotarget, 2017, 8, 93567-93579.	0.8	26
2477	Novel strategies for comprehensive mutation screening of the APC gene. Neoplasma, 2017, 64, 338-343.	0.7	13
2478	Tumor Heterogeneity. , 2017, , 37-55.		7
2479	Molecular landscape and sub-classification of gastrointestinal cancers: a review of literature. Journal of Gastrointestinal Oncology, 2017, 8, 379-386.	0.6	19
2480	Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. Journal of Gastrointestinal Oncology, 2017, 8, 199-212.	0.6	26
2481	Next generation sequencing identifies â€˜interactomeâ€™ signatures in relapsed and refractory metastatic colorectal cancer. Journal of Gastrointestinal Oncology, 2017, 8, 20-31.	0.6	14
2482	Correlation of tumor mutational burden and treatment outcomes in patients with colorectal cancer. Journal of Gastrointestinal Oncology, 2017, 8, 858-866.	0.6	37
2483	<i>PTEN</i> Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. JCO Precision Oncology, 2017, 1, 1-15.	1.5	275
2485	SUV39H2 promotes colorectal cancer proliferation and metastasis via tri-methylation of the SLIT1 promoter. Cancer Letters, 2018, 422, 56-69.	3.2	38
2486	The path to metastatic mouse models of colorectal cancer. Oncogene, 2018, 37, 2481-2489.	2.6	20
2487	Interaction between Wnt/Î²-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of Î²-catenin and RAS by targeting the Wnt/Î²-catenin pathway. Npj Precision Oncology, 2018, 2, 5.	2.3	138
2488	Inherited DNA-Repair Defects in Colorectal Cancer. American Journal of Human Genetics, 2018, 102, 401-414.	2.6	89
2489	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, 2018, 359, 920-926.	6.0	1,199
2490	Adjuvant Chemotherapy. , 2018, , 97-109.		0

#	Article	IF	Citations
2491	The Immunome of Colon Cancer: Functional In Silico Analysis of Antigenic Proteins Deduced from IgG Microarray Profiling. Genomics, Proteomics and Bioinformatics, 2018, 16, 73-84.	3.0	21
2492	Membranous or Cytoplasmic HER2 Expression in Colorectal Carcinoma: Evaluation of Prognostic Value Using Both IHC & BDISH. Cancer Investigation, 2018, 36, 129-140.	0.6	6
2493	Molecular characterization of <i>ERBB2</i>-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases. Journal of Physical Education and Sports Management, 2018, 4, a002535.	0.5	16
2494	Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Cancer Discovery, 2018, 8, 730-749.	7.7	367
2495	Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer. Clinical Cancer Research, 2018, 24, 3867-3877.	3.2	47
2496	Fidelity of DNA replicationâ€"a matter of proofreading. Current Genetics, 2018, 64, 985-996.	0.8	109
2497	The crucial role of multiomic approach in cancer research and clinically relevant outcomes. EPMA Journal, 2018, 9, 77-102.	3.3	184
2498	Prospective patient stratification into robust cancerâ€cell intrinsic subtypes from colorectal cancer biopsies. Journal of Pathology, 2018, 245, 19-28.	2.1	49
2499	Extracellular Matrix Remodeling in Intestinal Homeostasis and Disease. Advances in Stem Cells and Their Niches, 2018, 2, 99-140.	0.1	5
2500	Single Nucleotide Polymorphism Facilitated Down-Regulation of the Cohesin Stromal Antigen-1: Implications for Colorectal Cancer Racial Disparities. Neoplasia, 2018, 20, 289-294.	2.3	7
2501	Identification, isolation, and characterization of human LGR5-positive colon adenoma cells. Development (Cambridge), 2018, 145, .	1.2	70
2502	Co-inhibition of BET proteins and NF-Î°B as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions. Cell Death and Disease, 2018, 9, 315.	2.7	33
2503	Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer. Current Treatment Options in Oncology, 2018, 19, 11.	1.3	3
2504	Dysbiosis of gut microbiota in promoting the development of colorectal cancer. Gastroenterology Report, 2018, 6, 1-12.	0.6	192
2505	The association between copy number aberration, DNA methylation and gene expression in tumor samples. Nucleic Acids Research, 2018, 46, 3009-3018.	6.5	51
2506	Genomic Profiling and Metabolic Homeostasis in Primary Liver Cancers. Trends in Molecular Medicine, 2018, 24, 395-411.	3.5	58
2507	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. Molecular Cancer Research, 2018, 16, 805-812.	1.5	169
2508	Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 342-351.	1.3	13

#	Article	IF	Citations
2509	Recent progress in Lynch syndrome and other familial colorectal cancer syndromes. Ca-A Cancer Journal for Clinicians, 2018, 68, 217-231.	157.7	117
2510	Data processing, multi-omic pathway mapping, and metabolite activity analysis using XCMS Online. Nature Protocols, 2018, 13, 633-651.	5.5	207
2511	Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers. Molecular Cancer Therapeutics, 2018, 17, 1123-1132.	1.9	19
2512	Colorectal Tumors Require NUAK1 for Protection from Oxidative Stress. Cancer Discovery, 2018, 8, 632-647.	7.7	57
2513	Early onset sporadic colorectal cancer: Worrisome trends and oncogenic features. Digestive and Liver Disease, 2018, 50, 521-532.	0.4	65
2514	Genomics and emerging biomarkers for immunotherapy of colorectal cancer. Seminars in Cancer Biology, 2018, 52, 189-197.	4.3	112
2515	Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes. Blood, 2018, 131, 2402-2405.	0.6	30
2516	Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience. Oncologist, 2018, 23, 1083-1091.	1.9	39
2517	Organoids in cancer research. Nature Reviews Cancer, 2018, 18, 407-418.	12.8	1,096
2518	Non-canonical functions of the RB protein in cancer. Nature Reviews Cancer, 2018, 18, 442-451.	12.8	138
2519	A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer. Cancer Cell, 2018, 33, 817-828.e7.	7.7	172
2520	Toll-like receptor 2 stimulation promotes colorectal cancer cell growth via PI3K/Akt and NF-ÎºB signaling pathways. International Immunopharmacology, 2018, 59, 375-383.	1.7	33
2521	The clinical significance of PD-L1 in advanced gastric cancer is dependent on<i>ARID1A</i>mutations and ATM expression. OncoImmunology, 2018, 7, e1457602.	2.1	11
2522	Mutational signatures of DNA mismatch repair deficiency in <i>C. elegans</i> and human cancers. Genome Research, 2018, 28, 666-675.	2.4	112
2523	Colon cancers carrying BRAF V600E and Î²-catenin T41A activating mutations are resistant to numerous common anticancer drugs. Oncology Letters, 2018, 15, 4471-4476.	0.8	2
2524	Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. JAMA Oncology, 2018, 4, 1085.	3.4	62
2525	Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. Clinical Colorectal Cancer, 2018, 17, e471-e488.	1.0	12
2526	DNA mismatch repair in cancer. , 2018, 189, 45-62.		356

#	Article	IF	Citations
2527	NIPS, a 3D network-integrated predictor of deleterious protein SAPs, and its application in cancer prognosis. Scientific Reports, 2018, 8, 6021.	1.6	1
2528	Emerging Systemic Therapies for Colorectal Cancer. Clinics in Colon and Rectal Surgery, 2018, 31, 179-191.	0.5	26
2529	â€œAre There New Chemotherapy Drugs Behind the Corner?â€•, 2018, , 355-358.		0
2530	Are There Biochemical and Molecular Biological Factors to Distinguish the Rectal Cancer by the Colon Cancer?. , 2018, , 503-507.		0
2531	Analysis of DNA methylation in cancer: location revisited. Nature Reviews Clinical Oncology, 2018, 15, 459-466.	12.5	486
2532	<scp>P</scp>athogenic and targetable genetic alterations in 70 urachal adenocarcinomas. International Journal of Cancer, 2018, 143, 1764-1773.	2.3	44
2533	A Designed Peptide Targets Two Types of Modifications of p53 with Anti-cancer Activity. Cell Chemical Biology, 2018, 25, 761-774.e5.	2.5	17
2534	Biomarkers in colorectal liver metastases. British Journal of Surgery, 2018, 105, 618-627.	0.1	59
2535	Resistance of Colorectal Tumors to Anti-EGFR Antibodies. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 1-27.	0.1	1
2536	Mutation analysis of adenomas and carcinomas of the colon: Early and late drivers. Genes Chromosomes and Cancer, 2018, 57, 366-376.	1.5	50
2537	BRAF^{wild} papillary thyroid carcinoma has two distinct mRNA expression patterns with different clinical behaviors. Head and Neck, 2018, 40, 1707-1718.	0.9	3
2538	Somatic <i>POLE</i> exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. Journal of Pathology, 2018, 245, 283-296.	2.1	71
2539	Is primary sidedness a prognostic factor in patients with resected colon cancer liver metastases (CLM)?. Journal of Surgical Oncology, 2018, 117, 858-863.	0.8	20
2540	Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell, 2018, 173, 321-337.e10.	13.5	2,111
2541	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Reports, 2018, 23, 239-254.e6.	2.9	801
2542	Genomic profile of appendiceal goblet cell carcinoid is distinct compared to appendiceal neuroendocrine tumor and conventional adenocarcinoma. Human Pathology, 2018, 77, 166-174.	1.1	35
2543	Update on Sporadic Colorectal Cancer Genetics. Clinics in Colon and Rectal Surgery, 2018, 31, 147-152.	0.5	19
2544	Development of Preclinical Models to Understand and Treat Colorectal Cancer. Clinics in Colon and Rectal Surgery, 2018, 31, 199-204.	0.5	6

#	Article	IF	Citations
2545	Impact of <i>Nrf2</i> on tumour growth and drug sensitivity in oncogenic K-ras-transformed cells <i>in vitro</i> and <i>in vivo</i>. Free Radical Research, 2018, 52, 661-671.	1.5	13
2546	Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Annals of Oncology, 2018, 29, 1108-1119.	0.6	177
2547	Intra-tumour diversification in colorectal cancer at the single-cell level. Nature, 2018, 556, 457-462.	13.7	406
2548	Characterization of magnetic relaxation when biofunctionalized magnetic nano-particles are associated with biomarkers in the liquid state in biomedical applications. RSC Advances, 2018, 8, 4057-4062.	1.7	4
2549	Nanocarrier Composed of Magnetite Core Coated with Three Polymeric Shells Mediates LCS-1 Delivery for Synthetic Lethal Therapy of BLM-Defective Colorectal Cancer Cells. Biomacromolecules, 2018, 19, 803-815.	2.6	39
2550	Î²-catenin-independent regulation of Wnt target genes by RoR2 and ATF2/ATF4 in colon cancer cells. Scientific Reports, 2018, 8, 3178.	1.6	45
2551	Molecular characterization of colorectal adenomas with and without malignancy reveals distinguishing genome, transcriptome and methylome alterations. Scientific Reports, 2018, 8, 3161.	1.6	35
2552	Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C. Oncogene, 2018, 37, 2444-2455.	2.6	31
2553	15. Iron and Its Role in Cancer Defense: A Double-Edged Sword. , 2018, 18, 437-468.		24
2554	PBX3 Is Part of an EMT Regulatory Network and Indicates Poor Outcome in Colorectal Cancer. Clinical Cancer Research, 2018, 24, 1974-1986.	3.2	37
2555	Tumour spheres with inverted polarity drive the formation of peritoneal metastases in patients with hypermethylated colorectal carcinomas. Nature Cell Biology, 2018, 20, 296-306.	4.6	88
2556	Pristimerin exhibits in vitro and in vivo anticancer activities through inhibition of nuclear factor-ĐºB signaling pathway in colorectal cancer cells. Phytomedicine, 2018, 40, 140-147.	2.3	32
2557	The inflammatory microenvironment that promotes gastrointestinal cancer development and invasion. Advances in Biological Regulation, 2018, 68, 39-45.	1.4	32
2558	TGFÎ² drives immune evasion in genetically reconstituted colon cancer metastasis. Nature, 2018, 554, 538-543.	13.7	1,296
2559	Classification of gene signatures for their information value and functional redundancy. Npj Systems Biology and Applications, 2018, 4, 2.	1.4	50
2560	Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in <i>BRAF</i>V600E Colorectal Cancer. Cancer Discovery, 2018, 8, 417-427.	7.7	61
2561	Bioimpedimetric analysis in conjunction with growth dynamics to differentiate aggressiveness of cancer cells. Scientific Reports, 2018, 8, 783.	1.6	35
2562	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. ESMO Open, 2018, 3, e000299.	2.0	29

#	Article	IF	Citations
2563	miR-508 Defines the Stem-like/Mesenchymal Subtype in Colorectal Cancer. Cancer Research, 2018, 78, 1751-1765.	0.4	30
2564	Colorectal Carcinomas With Isolated Loss of PMS2 Staining by Immunohistochemistry. Archives of Pathology and Laboratory Medicine, 2018, 142, 523-528.	1.2	22
2565	RNF6 Promotes Colorectal Cancer by Activating the Wnt/Î²-Catenin Pathway via Ubiquitination of TLE3. Cancer Research, 2018, 78, 1958-1971.	0.4	67
2566	Correlation between circulating endothelial progenitor cells and serum carcinoembryonic antigen level in colorectal cancer. Acta Biochimica Et Biophysica Sinica, 2018, 50, 307-312.	0.9	5
2567	ERADâ€dependent control of the Wnt secretory factor Evi. EMBO Journal, 2018, 37, .	3.5	42
2568	Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers. Therapeutic Advances in Medical Oncology, 2018, 10, 175883401774604.	1.4	11
2569	Intratumoral morphological heterogeneity can be an indicator of genetic heterogeneity in colorectal cancer. Experimental and Molecular Pathology, 2018, 104, 76-81.	0.9	6
2570	Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer. Cancer Biology and Therapy, 2018, 19, 335-345.	1.5	19
2571	Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in <i>ERBB2</i> and <i>ERBB3</i>. Cancer, 2018, 124, 1358-1373.	2.0	151
2572	BMI1 activates WNT signaling in colon cancer by negatively regulating the WNT antagonist IDAX. Biochemical and Biophysical Research Communications, 2018, 496, 468-474.	1.0	19
2573	Mutational landscape of goblet cell carcinoids and adenocarcinoma ex goblet cell carcinoids of the appendix is distinct from typical carcinoids and colorectal adenocarcinomas. Modern Pathology, 2018, 31, 989-996.	2.9	42
2574	Three molecular pathways model colorectal carcinogenesis in <scp>L</scp>ynch syndrome. International Journal of Cancer, 2018, 143, 139-150.	2.3	129
2575	Mutational signatures and chromosome alteration profiles of squamous cell carcinomas of the vulva. Experimental and Molecular Medicine, 2018, 50, e442-e442.	3.2	43
2576	Wnt Signaling in Adult Epithelial Stem Cells and Cancer. Progress in Molecular Biology and Translational Science, 2018, 153, 21-79.	0.9	30
2577	Integrative expression quantitative trait locusâ€"based analysis of colorectal cancer identified a functional polymorphism regulating SLC22A5 expression. European Journal of Cancer, 2018, 93, 1-9.	1.3	47
2578	CRISPR-Cas9: a promising genetic engineering approach in cancer research. Therapeutic Advances in Medical Oncology, 2018, 10, 175883401875508.	1.4	31
2579	Epigenetic and epitranscriptomic changes in colorectal cancer: Diagnostic, prognostic, and treatment implications. Cancer Letters, 2018, 419, 84-95.	3.2	52
2580	The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell, 2018, 33, 244-258.e10.	7.7	270

#	Article	IF	Citations
2581	A qualitative signature for predicting pathological response to neoadjuvant chemoradiation in locally advanced rectal cancers. Radiotherapy and Oncology, 2018, 129, 149-153.	0.3	20
2582	DKK2 imparts tumor immunity evasion through Î²-catenin-independent suppression of cytotoxic immune-cell activation. Nature Medicine, 2018, 24, 262-270.	15.2	106
2583	Pancancer analysis identifies prognostic high-APOBEC1 expression level implicated in cancer in-frame insertions and deletions. Carcinogenesis, 2018, 39, 327-335.	1.3	17
2584	Functional Analysis of Cancer-Associated DNA Polymerase Îµ Variants in<i>Saccharomyces cerevisiae</i>. G3: Genes, Genomes, Genetics, 2018, 8, 1019-1029.	0.8	49
2585	Hybrid Captureâ€“Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. Clinical Cancer Research, 2018, 24, 1881-1890.	3.2	59
2586	CM-viewer: Visualizing interaction network of co-mutated and mutually exclusively mutated cancer genes. BioSystems, 2018, 166, 37-42.	0.9	0
2587	Functional significance and therapeutic implication of ring-type E3 ligases in colorectal cancer. Oncogene, 2018, 37, 148-159.	2.6	49
2588	Combined Mutation of <i>Apc, Kras</i>, and <i>Tgfbr2</i> Effectively Drives Metastasis of Intestinal Cancer. Cancer Research, 2018, 78, 1334-1346.	0.4	106
2589	PanCancer insights from The Cancer Genome Atlas: the pathologist's perspective. Journal of Pathology, 2018, 244, 512-524.	2.1	144
2590	Dual role of autophagy in hallmarks of cancer. Oncogene, 2018, 37, 1142-1158.	2.6	403
2591	Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. Gut, 2018, 67, 179-193.	6.1	73
2592	Predictors of Response to Immune Checkpoint Blockade. , 2018, , 525-544.		0
2593	Prediagnostic Antibodies to Serum p53 and Subsequent Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 219-223.	1.1	19
2594	Appendiceal goblet cell carcinoids and adenocarcinomas ex-goblet cell carcinoid are genetically distinct from primary colorectal-type adenocarcinoma of the appendix. Modern Pathology, 2018, 31, 829-839.	2.9	44
2595	Precision Molecular Pathology of Bladder Cancer. Molecular Pathology Library, 2018, , .	0.1	0
2596	A RNA-Sequencing approach for the identification of novel long non-coding RNA biomarkers in colorectal cancer. Scientific Reports, 2018, 8, 575.	1.6	80
2597	Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With <i>BRAF</i> -Mutated High-Grade Glioma. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 4-10.	2.3	60
2598	Proteome Heterogeneity in Colorectal Cancer. Proteomics, 2018, 18, 1700169.	1.3	13

#	Article	IF	Citations
2599	Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models. Cell Death and Differentiation, 2018, 25, 616-633.	5.0	137
2600	Perturbation-response genes reveal signaling footprints in cancer gene expression. Nature Communications, 2018, 9, 20.	5.8	436
2601	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer Cell, 2018, 33, 125-136.e3.	7.7	589
2602	Characterizing the Killer Colorectal Carcinomas. Cancer Cell, 2018, 33, 7-9.	7.7	14
2603	Genomic heterogeneity in primary colorectal carcinomas and their metastases: born bad or brought up a villain?. Human Pathology, 2018, 74, 54-63.	1.1	13
2604	The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine. Cancer, 2018, 124, 1650-1659.	2.0	32
2605	Treatment Paradigms in Bladder Cancer: Clinical Implications of Histological and Molecular Analysis. Molecular Pathology Library, 2018, , 85-101.	0.1	0
2606	Two Months of Therapy: A Case of Pathologic Complete Response to Chemoimmunotherapy in a Patient With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, e229-e232.	1.0	3
2607	Phenotypic characteristics of colorectal cancer in BRCA1/2 mutation carriers. European Journal of Human Genetics, 2018, 26, 382-386.	1.4	11
2608	Functions of the APC tumor suppressor protein dependent and independent of canonical WNT signaling: implications for therapeutic targeting. Cancer and Metastasis Reviews, 2018, 37, 159-172.	2.7	125
2609	Alterations in cancer stem-cell marker CD44 expression predict oncologic outcome in soft-tissue sarcomas. Journal of Surgical Research, 2018, 223, 207-214.	0.8	20
2610	Determinants and clinical implications of chromosomal instability in cancer. Nature Reviews Clinical Oncology, 2018, 15, 139-150.	12.5	272
2611	Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution. Nature Communications, 2018, 9, 32.	5.8	193
2612	Combining gene essentiality with feature selection method to explore multi-cancer biomarkers. Chemometrics and Intelligent Laboratory Systems, 2018, 172, 241-247.	1.8	3
2613	Multi-scale modeling of APC and $$eta $$Î²-catenin regulation in the human colonic crypt. Journal of Mathematical Biology, 2018, 76, 1797-1830.	0.8	3
2614	The burgeoning role of cytochrome P450-mediated vitamin D metabolites against colorectal cancer. Pharmacological Research, 2018, 133, 9-20.	3.1	14
2615	Distinct mutational signatures characterize concurrent loss of polymerase proofreading and mismatch repair. Nature Communications, 2018, 9, 1746.	5.8	142
2616	Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nature Communications, 2018, 9, 1777.	5.8	245

#	Article	IF	Citations
2617	Smad4/DPC4. Journal of Clinical Pathology, 2018, 71, 661-664.	1.0	47
2618	Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer. BMC Cancer, 2018, 18, 136.	1.1	13
2619	Differential networking meta-analysis of gastric cancer across Asian and American racial groups. BMC Systems Biology, 2018, 12, 51.	3.0	7
2620	Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1. Molecular Cancer, 2018, 17, 81.	7.9	27
2621	Cytoplasmic TrkA Expression as a Screen for Detecting NTRK1 Fusions in Colorectal Cancer. Translational Oncology, 2018, 11, 764-770.	1.7	8
2622	Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nature Communications, 2018, 9, 1793.	5.8	188
2623	Targeted therapy according to next generation sequencing-based panel sequencing. Fukushima Journal of Medical Sciences, 2018, 64, 9-14.	0.1	17
2624	Validating the concept of mutational signatures with isogenic cell models. Nature Communications, 2018, 9, 1744.	5.8	128
2625	<scp>G</scp>ene expression differences among different <scp>MSI</scp> statuses in colorectal cancer. International Journal of Cancer, 2018, 143, 1731-1740.	2.3	137
2626	Molecular Landscape of<i>ERBB2/ERBB3</i>Mutated Colorectal Cancer. Journal of the National Cancer Institute, 2018, 110, 1409-1417.	3.0	53
2627	Mutation load estimation model as a predictor of the response to cancer immunotherapy. Npj Genomic Medicine, 2018, 3, 12.	1.7	55
2628	BRAF-mutant colorectal cancer, a different breed evolving. Expert Review of Molecular Diagnostics, 2018, 18, 499-512.	1.5	19
2629	Precision Medicine Based on Next-Generation Sequencing and Master Controllers. , 2018, , 1577-1611.		1
2630	Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer. Oncologist, 2018, 23, 1310-1318.	1.9	40
2631	Evaluation of Cancer-Associated DNA Copy Number Events in Colorectal (Advanced) Adenomas. Cancer Prevention Research, 2018, 11, 403-412.	0.7	15
2632	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell, 2018, 33, 721-735.e8.	7.7	396
2633	Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor. International Journal of Cancer, 2018, 143, 907-920.	2.3	41
2634	Exome sequencing reveals the genetic landscape and frequent inactivation of <i>PCDHB3</i> in Chinese rectal cancers. Journal of Pathology, 2018, 245, 222-234.	2.1	9

#	Article	IF	Citations
2635	Integrative Analysis of Omics Big Data. Methods in Molecular Biology, 2018, 1754, 109-135.	0.4	54
2636	SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases. European Journal of Surgical Oncology, 2018, 44, 684-692.	0.5	61
2637	Clinical Trials and Progress in Metastatic Colon Cancer. Surgical Oncology Clinics of North America, 2018, 27, 349-365.	0.6	64
2638	DEAD-box helicase 27 promotes colorectal cancer growth and metastasis and predicts poor survival in CRC patients. Oncogene, 2018, 37, 3006-3021.	2.6	46
2639	Impaired Secretion of Glucagon-Like Peptide 1 in Patients with Colorectal Adenoma after an Oral Glucose Load. Digestion, 2018, 97, 324-332.	1.2	5
2640	Classification of miRNA-related sequence variations. Epigenomics, 2018, 10, 463-481.	1.0	34
2641	Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview. Methods in Molecular Biology, 2018, 1765, 281-297.	0.4	12
2642	Significance of PITX2 Promoter Methylation in Colorectal Carcinoma Prognosis. Clinical Colorectal Cancer, 2018, 17, e385-e393.	1.0	10
2643	Aqueous extract of Sanguisorba officinalis blocks the Wnt/Î²-catenin signaling pathway in colorectal cancer cells. RSC Advances, 2018, 8, 10197-10206.	1.7	10
2644	Precision Medicine for CRC Patients in the Veteran Population: State-of-the-Art, Challenges and Research Directions. Digestive Diseases and Sciences, 2018, 63, 1123-1138.	1.1	9
2645	The molecular landscape of synchronous colorectal cancer reveals genetic heterogeneity. Carcinogenesis, 2018, 39, 708-718.	1.3	28
2646	Subtypes of the Type II Pit Pattern Reflect Distinct Molecular Subclasses in the Serrated Neoplastic Pathway. Digestive Diseases and Sciences, 2018, 63, 1920-1928.	1.1	9
2647	CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. Gut, 2018, 67, 903-917.	6.1	64
2648	The novel role of pyrvinium in cancer therapy. Journal of Cellular Physiology, 2018, 233, 2871-2881.	2.0	57
2649	Regularized Non-Negative Matrix Factorization for Identifying Differentially Expressed Genes and Clustering Samples: A Survey. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2018, 15, 974-987.	1.9	52
2650	The somatic mutation landscape of premalignant colorectal adenoma. Gut, 2018, 67, 1299-1305.	6.1	52
2651	Targeting the tumor microenvironment as a potential therapeutic approach in colorectal cancer: Rational and progress. Journal of Cellular Physiology, 2018, 233, 2928-2936.	2.0	35
2652	The Application of CRISPR/Cas Technology to Efficiently Model Complex Cancer Genomes in Stem Cells. Journal of Cellular Biochemistry, 2018, 119, 134-140.	1.2	13

#	Article	IF	Citations
2653	Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment. Gut, 2018, 67, 447-455.	6.1	27
2654	Total Neoadjuvant Therapy: A Shifting Paradigm in Locally Advanced Rectal Cancer Management. Clinical Colorectal Cancer, 2018, 17, 1-12.	1.0	90
2655	Microbial Interactions and Interventions in Colorectal Cancer. Microbiology Spectrum, 2017, 5, .	1.2	35
2656	Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing. Genes Chromosomes and Cancer, 2018, 57, 51-60.	1.5	83
2657	A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. Oncologist, 2018, 23, 25-34.	1.9	63
2658	Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study. Clinical Colorectal Cancer, 2018, 17, e69-e76.	1.0	44
2659	CUX1 stimulates APE1 enzymatic activity and increases the resistance of glioblastoma cells to the mono-alkylating agent temozolomide. Neuro-Oncology, 2018, 20, 484-493.	0.6	32
2660	Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. Clinical Colorectal Cancer, 2018, 17, 73-79.	1.0	17
2661	Small molecule promotes Î²-catenin citrullination and inhibits Wnt signaling in cancer. Nature Chemical Biology, 2018, 14, 94-101.	3.9	105
2662	Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-Î² Pathway. Gastroenterology, 2018, 154, 195-210.	0.6	105
2663	A Molecularly Annotated Model of Patient-Derived Colon Cancer Stemâ€"Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy. Clinical Cancer Research, 2018, 24, 807-820.	3.2	23
2664	Mechanisms of DNA damage repair in adult stem cells and implications for cancer formation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 89-101.	1.8	40
2665	â€˜MCCâ€™ protein interacts with E-cadherin and Î²-catenin strengthening cellâ€"cell adhesion of HCT116 colon cancer cells. Oncogene, 2018, 37, 663-672.	2.6	25
2666	Heterogeneous Reciprocal Graphical Models. Biometrics, 2018, 74, 606-615.	0.8	16
2667	DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies. Oncogene, 2018, 37, 566-577.	2.6	65
2668	A Practical Approach to Tumor Heterogeneity in Clinical Research and Diagnostics. Pathobiology, 2018, 85, 7-17.	1.9	13
2669	Oncogenic RAS-induced CK1Î± drives nuclear FOXO proteolysis. Oncogene, 2018, 37, 363-376.	2.6	22
2670	Cumulative evidence for relationships between multiple variants in the <i>VTI1A</i> and <i>TCF7L2</i> genes and cancer incidence. International Journal of Cancer, 2018, 142, 498-513.	2.3	15

#	Article	IF	Citations
2671	RCC2 is a novel p53 target in suppressing metastasis. Oncogene, 2018, 37, 8-17.	2.6	15
2672	Early genetic aberrations in patients with sporadic colorectal cancer. Molecular Carcinogenesis, 2018, 57, 114-124.	1.3	23
2673	Characterization of genome-wide copy number aberrations in colonic mixed adenoneuroendocrine carcinoma and neuroendocrine carcinoma reveals recurrent amplification of PTGER4 and MYC genes. Human Pathology, 2018, 73, 16-25.	1.1	19
2674	The Role of the Surgical Pathologist in the Diagnosis of Gastrointestinal Polyposis Syndromes. Advances in Anatomic Pathology, 2018, 25, 1-13.	2.4	22
2675	Pathology and genetics of hereditary colorectal cancer. Pathology, 2018, 50, 49-59.	0.3	119
2676	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clinical Cancer Research, 2018, 24, 1062-1072.	3.2	225
2677	Structural analyses of key features in the KANK1Â·KIF21A complex yield mechanistic insights into the cross-talk between microtubules and the cell cortex. Journal of Biological Chemistry, 2018, 293, 215-225.	1.6	18
2678	Colorectal Cancers Developed from Proximal and Distal Tumor Location Belong to theÂDistinct Genetic Entity and Show Different Oncologic Behavior. Current Human Cell Research and Applications, 2018, , 81-91.	0.1	0
2679	Exome sequencing of synchronously resected primary colorectal tumours and colorectal liver metastases to inform oncosurgical management. European Journal of Surgical Oncology, 2018, 44, 115-121.	0.5	4
2680	Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes. Cancer Research, 2018, 78, 451-462.	0.4	22
2682	Revisiting the thiosemicarbazonecopper(II) reaction with glutathione. Activity against colorectal carcinoma cell lines. Journal of Inorganic Biochemistry, 2018, 180, 69-79.	1.5	13
2683	Molecular profiling and genomeâ€wide analysis based on somatic copy number alterations in advanced colorectal cancers. Molecular Carcinogenesis, 2018, 57, 451-461.	1.3	13
2684	Integrated Molecular Characterization of the Lethal Pediatric Cancer Pancreatoblastoma. Cancer Research, 2018, 78, 865-876.	0.4	25
2685	Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer. Molecular Cancer Research, 2018, 16, 378-389.	1.5	99
2686	Individual Susceptibility Analysis Using Patient-derived Slice Cultures of Colorectal Carcinoma. Clinical Colorectal Cancer, 2018, 17, e189-e199.	1.0	24
2687	Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. Clinical Cancer Research, 2018, 24, 794-806.	3.2	177
2688	A mutational comparison of adult and adolescent and young adult (AYA) colon cancer. Cancer, 2018, 124, 1070-1082.	2.0	42
2689	Ribosome biogenesis in cancer: new players and therapeutic avenues. Nature Reviews Cancer, 2018, 18, 51-63.	12.8	524

#	Article	IF	Citations
2690	Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. Cancer Discovery, 2018, 8, 164-173.	7.7	243
2691	Multi-omics Approach Reveals Distinct Differences in Left- and Right-Sided Colon Cancer. Molecular Cancer Research, 2018, 16, 476-485.	1.5	47
2692	Molecular Markers and Mutational Analysis. , 2018, , 295-312.		1
2693	DACT2 Epigenetic Stimulator Exerts Dual Efficacy for Colorectal Cancer Prevention and Treatment. Pharmacological Research, 2018, 129, 318-328.	3.1	31
2694	Immunotherapeutic Biomarkers and Selection Strategies. Current Cancer Research, 2018, , 69-114.	0.2	0
2695	Whole exome sequencing reveals intertumor heterogeneity and distinct genetic origins of sporadic synchronous colorectal cancer. International Journal of Cancer, 2018, 142, 927-939.	2.3	21
2696	A look into centrosome abnormalities in colon cancer cells, how they arise and how they might be targeted therapeutically. Biochemical Pharmacology, 2018, 147, 1-8.	2.0	14
2697	Decoding colorectal cancer epigenomics. Cancer Genetics, 2018, 220, 49-76.	0.2	42
2698	DNA polymerase Î· mutational signatures are found in a variety of different types of cancer. Cell Cycle, 2018, 17, 348-355.	1.3	32
2699	The role of APC in WNT pathway activation in serrated neoplasia. Modern Pathology, 2018, 31, 495-504.	2.9	43
2700	Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part Iâ€”Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications. Archives of Pathology and Laboratory Medicine, 2018, 142, 17-25.	1.2	34
2701	Primary Tumor Location and Survival in the General Population With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, e201-e206.	1.0	17
2702	The predictive value of primary tumor location in patients with metastatic colorectal cancer: A systematic review. Critical Reviews in Oncology/Hematology, 2018, 121, 1-10.	2.0	45
2703	Ca2+/nuclear factor of activated T cells signaling is enriched in early-onset rectal tumors devoid of canonical Wnt activation. Journal of Molecular Medicine, 2018, 96, 135-146.	1.7	13
2704	Characterization of genetic intratumor heterogeneity in colorectal cancer and matching patientâ€derived spheroid cultures. Molecular Oncology, 2018, 12, 132-147.	2.1	49
2705	Molecular criteria for mutagenesis by DNA methylation: Some computational elucidations. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2018, 807, 10-20.	0.4	5
2706	Fetal-type gastrointestinal adenocarcinoma: a morphologically distinct entity with unfavourable prognosis. Journal of Clinical Pathology, 2018, 71, 221-227.	1.0	22
2707	Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. Gut, 2018, 67, 1484-1492.	6.1	59

#	Article	IF	Citations
2708	The competing risks Cox model with auxiliary case covariates under weaker missing-at-random cause of failure. Lifetime Data Analysis, 2018, 24, 425-442.	0.4	13
2709	Biological Validation of RNA Sequencing Data From Formalin-Fixed Paraffin-Embedded Primary Melanomas. JCO Precision Oncology, 2018, 2018, 1-19.	1.5	19
2710	Collaborating genomic, transcriptomic and microbiomic alterations lead to canine extreme intestinal polyposis. Oncotarget, 2018, 9, 29162-29179.	0.8	16
2711	Ampulla of Vater carcinoma: Molecular landscape and clinical implications. World Journal of Gastrointestinal Oncology, 2018, 10, 370-380.	0.8	34
2712	D3Oncoprint: Stand-Alone Software to Visualize and Dynamically Explore Annotated Genomic Mutation Files. JCO Clinical Cancer Informatics, 2018, 2, 1-9.	1.0	4
2713	Aberrant glycosylation in colorectal cancer with genomic and epigenomic alterations. Oncotarget, 2018, 9, 35609-35610.	0.8	1
2714	ERBB3-Activating Mutations in Small Bowel Adenocarcinomas. JCO Precision Oncology, 2018, 2, 1-9.	1.5	1
2715	<i>Flavius Josephus: Translation and Commentary</i>. Volume 6a: <i>Judean Antiquities 11</i>. By <scp>Paul Spilsbury</scp> and <scp>Chris Seeman</scp>. Journal of Theological Studies, 2018, 69, 781-784.	0.0	0
2716	Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 231-238.	1.8	46
2717	Reciprocal Graphical Models for Integrative Gene Regulatory Network Analysis. Bayesian Analysis, 2018, 13, .	1.6	6
2718	Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. Journal of Clinical Oncology, 2018, 36, 2052-2060.	0.8	26
2719	Phosphatidylinositol 3-Kinase Î±â€"Selective Inhibition With Alpelisib (BYL719) in <i>PIK3CA</i>-Altered Solid Tumors: Results From the First-in-Human Study. Journal of Clinical Oncology, 2018, 36, 1291-1299.	0.8	298
2720	Long noncoding RNAs regulate malignant phenotypes in colorectal cancer. Biotarget, 0, 2, 4-4.	0.5	6
2721	Effect of oxaliplatin combined with 5-fluorouracil on treatment efficacy of radiotherapy in the treatment of elderly patients with rectal cancer. Experimental and Therapeutic Medicine, 2018, 17, 1517-1522.	0.8	1
2722	Recurrent Mutations in APC and CTNNB1 and Activated Wnt/Î²-catenin Signaling in Intraductal Papillary Neoplasms of the Bile Duct. American Journal of Surgical Pathology, 2018, 42, 1674-1685.	2.1	45
2723	DLAD4U: deriving and prioritizing disease lists from PubMed literature. BMC Bioinformatics, 2018, 19, 495.	1.2	2
2724	Low prevalence of deficient mismatch repair (dMMR) protein in locally advanced rectal cancers (LARC) and treatment outcomes. Journal of Gastrointestinal Oncology, 2018, 10, 19-29.	0.6	12
2725	The landscape of somatic mutation in sporadic Chinese colorectal cancer. Oncotarget, 2018, 9, 27412-27422.	0.8	26

#	Article	IF	Citations
2726	Caveolin-1 Inhibits Proliferation, Migration, and Invasion of Human Colorectal Cancer Cells by Suppressing Phosphorylation of Epidermal Growth Factor Receptor. Medical Science Monitor, 2018, 24, 332-341.	0.5	24
2727	Gene pair based prognostic signature for colorectal colon cancer. Medicine (United States), 2018, 97, e12788.	0.4	10
2728	UEG Week 2018 Oral Presentations. United European Gastroenterology Journal, 2018, 6, A1.	1.6	5
2729	Identification of recurrent and novel mutations by wholeâ€'genome sequencing of colorectal tumors from the Han population in Shanghai, eastern China. Molecular Medicine Reports, 2018, 18, 5361-5370.	1.1	9
2730	Datalog Extensions for Bioinformatic Data Analysis. , 2018, 2018, 1303-1306.		0
2731	Liquid Biopsy for Colorectal Cancer Screening, A Modern Approach for Patients Stratification and Monitoring. , 2018, , .		0
2732	Clinical Importance of Myc Family Oncogene Aberrations in Epithelial Ovarian Cancer. JNCI Cancer Spectrum, 2018, 2, pky047.	1.4	11
2733	MiR-192, miR-200c and miR-17 are fibroblast-mediated inhibitors of colorectal cancer invasion. Oncotarget, 2018, 9, 35559-35580.	0.8	26
2734	Actionable Gene Alterations in an Asian Population With Triple-Negative Breast Cancer. JCO Precision Oncology, 2018, 2, 1-13.	1.5	3
2735	Targeted Therapy for Colorectal Cancers With Non-V600 BRAF Mutations: Perspectives for Precision Oncology. JCO Precision Oncology, 2018, 2, 1-12.	1.5	10
2736	Sustainable Response of a Patient With Metastasized Pancreatic Cancer and a Hypermutational Phenotype to Immunotherapy. New Therapeutic Concept for a Rare Subtype?. JCO Precision Oncology, 2018, 2, 1-6.	1.5	1
2737	Recent advances in understanding colorectal cancer. F1000Research, 2018, 7, 1528.	0.8	14
2738	Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer. Current Drug Targets, 2018, 19, 1731-1737.	1.0	12
2739	6 Colorectal Cancer. , 2018, , .		0
2740	Genetic Susceptibility. Molecular Pathology Library, 2018, , 57-78.	0.1	0
2741	Pathway-based subnetworks enable cross-disease biomarker discovery. Nature Communications, 2018, 9, 4746.	5.8	30
2742	A 15-lncRNA signature predicts survival and functions as a ceRNA in patients with colorectal cancer. Cancer Management and Research, 2018, Volume 10, 5799-5806.	0.9	56
2743	SAMHD1 inhibits epithelial cell transformation in vitro and affects leukemia development in xenograft mice. Cell Cycle, 2018, 17, 2564-2576.	1.3	4

#	Article	IF	Citations
2744	DNA Polymerase Epsilon Deficiency Causes IMAGe Syndrome with Variable Immunodeficiency. American Journal of Human Genetics, 2018, 103, 1038-1044.	2.6	71
2745	Novel insight into the function of tankyrase (Review). Oncology Letters, 2018, 16, 6895-6902.	0.8	52
2747	Epigenetic Heterogeneity in Human Colorectal Tumors Reveals Preferential Conservation And Evidence of Immune Surveillance. Scientific Reports, 2018, 8, 17292.	1.6	17
2748	Molecular characterization of sessile serrated adenoma/polyps with dysplasia/carcinoma based on immunohistochemistry, next-generation sequencing, and microsatellite instability testing: a case series study. Diagnostic Pathology, 2018, 13, 88.	0.9	26
2749	Colorectal Cancer and Metabolism. Current Colorectal Cancer Reports, 2018, 14, 226-241.	1.0	88
2750	Active Kâ€‹<scp>RAS</scp> induces the coherent rotation of epithelial cells: A model for collective cell invasion in vitro. Cancer Science, 2018, 109, 4045-4055.	1.7	13
2751	The prognostic efficacy of cell-free DNA hypermethylation in colorectal cancer. Oncotarget, 2018, 9, 7010-7022.	0.8	13
2752	Bcl-2-dependent synthetic lethal interaction of the IDF-11774 with the V0 subunit C of vacuolar ATPase (ATP6V0C) in colorectal cancer. British Journal of Cancer, 2018, 119, 1347-1357.	2.9	18
2753	Whole genome sequencing puts forward hypotheses on metastasis evolution and therapy in colorectal cancer. Nature Communications, 2018, 9, 4782.	5.8	103
2754	Deletion of C9orf53 promotes the growth of head and neck squamous cell carcinoma and is associated with poor prognosis of patients with head and neck squamous cell carcinoma. Oncology Letters, 2018, 17, 1223-1228.	0.8	1
2755	Gene expression profiles in genome instability-based classes of colorectal cancer. BMC Cancer, 2018, 18, 1265.	1.1	12
2756	Tumor suppressor RARRES1- A novel regulator of fatty acid metabolism in epithelial cells. PLoS ONE, 2018, 13, e0208756.	1.1	21
2757	A potential common role of the Jumonji C domainâ€'containing 1A histone demethylase and chromatin remodeler ATRX in promoting colon cancer. Oncology Letters, 2018, 16, 6652-6662.	0.8	16
2758	Therapy Implications of DNA Mismatch Repair Deficiency, Microsatellite Instability, and Tumor Mutation Burden. Advances in Molecular Pathology, 2018, 1, 193-208.	0.2	5
2759	Targeting Colon Cancers with Mutated BRAF and Microsatellite Instability. Advances in Experimental Medicine and Biology, 2018, 1110, 7-21.	0.8	6
2760	CUX2 functions as an oncogene in papillary thyroid cancer. OncoTargets and Therapy, 2019, Volume 12, 217-224.	1.0	7
2761	MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5â€'fluorouracil in MEK1 Q56Pâ€'mutant colorectal cancer cells. Molecular Medicine Reports, 2018, 19, 1092-1100.	1.1	6
2762	New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles. Oncotarget, 2018, 9, 10635-10649.	0.8	41

#	Article	IF	Citations
2763	<i>KRAS</i>, <i>NRAS</i> and <i>BRAF</i> mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy. Oncotarget, 2018, 9, 26279-26290.	0.8	20
2764	Targeting PTEN in Colorectal Cancers. Advances in Experimental Medicine and Biology, 2018, 1110, 55-73.	0.8	24
2765	Targeted Therapy of Colorectal Cancer Subtypes. Advances in Experimental Medicine and Biology, 2018, , .	0.8	0
2766	Colorectal Cancer Subtypes â€" The Current Portrait. Advances in Experimental Medicine and Biology, 2018, 1110, 1-6.	0.8	2
2767	Wnt Signalling-Targeted Therapy in the CMS2 Tumour Subtype: A New Paradigm in CRC Treatment?. Advances in Experimental Medicine and Biology, 2018, 1110, 75-100.	0.8	7
2768	Clinical and Genetic Factors to Inform Reducing Colorectal Cancer Disparitites in African Americans. Frontiers in Oncology, 2018, 8, 531.	1.3	37
2769	How the<i>BRAF</i>V600E Mutation Defines a Distinct Subgroup of Colorectal Cancer: Molecular and Clinical Implications. Gastroenterology Research and Practice, 2018, 2018, 1-14.	0.7	34
2770	RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective. Cancers, 2018, 10, 518.	1.7	10
2771	Adolescent and Young Adult Cancer Biology. Cancer Journal (Sudbury, Mass), 2018, 24, 267-274.	1.0	45
2772	Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles. Molecular Cancer, 2018, 17, 177.	7.9	80
2773	Sulforaphane inhibits growth and blocks Wnt/Î²-catenin signaling of colorectal cancer cells. Oncotarget, 2018, 9, 33982-33994.	0.8	23
2774	Organoid Modeling of the Tumor Immune Microenvironment. Cell, 2018, 175, 1972-1988.e16.	13.5	870
2775	Biology of Nodal Spread in Colon Cancer: Insights from Molecular and Genetic Studies. European Surgical Research, 2018, 59, 361-370.	0.6	12
2776	Survival marker genes of colorectal cancer derived from consistent transcriptomic profiling. BMC Genomics, 2018, 19, 857.	1.2	48
2777	Hypermethylation of DMTN promotes the metastasis of colorectal cancer cells by regulating the actin cytoskeleton through Rac1 signaling activation. Journal of Experimental and Clinical Cancer Research, 2018, 37, 299.	3.5	32
2778	G-quadruplexes formation in the 5â€™UTRs of mRNAs associated with colorectal cancer pathways. PLoS ONE, 2018, 13, e0208363.	1.1	8
2780	Single-cell multiomics sequencing and analyses of human colorectal cancer. Science, 2018, 362, 1060-1063.	6.0	256
2781	Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?. International Journal of Molecular Sciences, 2018, 19, 3733.	1.8	147

#	Article	IF	Citations
2782	Clonality and heterogeneity of metachronous colorectal cancer. Molecular Carcinogenesis, 2018, 58, 447-457.	1.3	3
2783	Altered mRNA expression levels of the major components of sphingolipid metabolism, ceramide synthases and their clinical implication in colorectal cancer. Oncology Reports, 2018, 40, 3489-3500.	1.2	20
2784	Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature, 2018, 564, 268-272.	13.7	742
2785	MSIpred: a python package for tumor microsatellite instability classification from tumor mutation annotation data using a support vector machine. Scientific Reports, 2018, 8, 17546.	1.6	41
2786	Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream. Cancer Management and Research, 2018, Volume 10, 5895-5908.	0.9	18
2787	Lupeol inhibits growth and migration in two human colorectal cancer cell lines by suppression of Wnt–β-catenin pathway. OncoTargets and Therapy, 2018, Volume 11, 7987-7999.	1.0	33
2788	DeltaNp63-dependent super enhancers define molecular identity in pancreatic cancer by an interconnected transcription factor network. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E12343-E12352.	3.3	69
2789	Molecular Lesions of Insulator CTCF and Its Paralogue CTCFL (BORIS) in Cancer: An Analysis from Published Genomic Studies. High-Throughput, 2018, 7, 30.	4.4	8
2790	Positive Caricature Transcriptomic Effects Associated with Broad Genomic Aberrations in Colorectal Cancer. Scientific Reports, 2018, 8, 14826.	1.6	14
2791	SRSF3, a Splicer of the PKM Gene, Regulates Cell Growth and Maintenance of Cancer-Specific Energy Metabolism in Colon Cancer Cells. International Journal of Molecular Sciences, 2018, 19, 3012.	1.8	72
2792	Continuity of transcriptomes among colorectal cancer subtypes based on meta-analysis. Genome Biology, 2018, 19, 142.	3.8	20
2793	Studying cellular heterogeneity and drug sensitivity in colorectal cancer using organoid technology. Current Opinion in Genetics and Development, 2018, 52, 117-122.	1.5	54
2794	Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature. Gastroenterology Research, 2018, 11, 264-273.	0.4	294
2795	Genomeâ€wide DNA methylation profiling of primary colorectal laterally spreading tumors identifies diseaseâ€specific epimutations on common pathways. International Journal of Cancer, 2018, 143, 2488-2498.	2.3	18
2796	Lack of<i>APC</i>somatic mutation is associated with early-onset colorectal cancer in African Americans. Carcinogenesis, 2018, 39, 1331-1341.	1.3	34
2797	Proteogenomic characterization and comprehensive integrative genomic analysis of human colorectal cancer liver metastasis. Molecular Cancer, 2018, 17, 139.	7.9	62
2798	The long noncoding RNA SNHG1 regulates colorectal cancer cell growth through interactions with EZH2 and miR-154-5p. Molecular Cancer, 2018, 17, 141.	7.9	259
2799	Downregulation of Lgr6 inhibits proliferation and invasion and increases apoptosis in human colorectal cancer. International Journal of Molecular Medicine, 2018, 42, 625-632.	1.8	7

#	Article	IF	Citations
2800	Overview of Microsatellite Instability and Immune Checkpoint Inhibitors in Colorectal Cancer. Current Colorectal Cancer Reports, 2018, 14, 167-174.	1.0	0
2801	Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer. Cancer Management and Research, 2018, Volume 10, 3569-3577.	0.9	100
2802	Colon-specific eQTL analysis to inform on functional SNPs. British Journal of Cancer, 2018, 119, 971-977.	2.9	25
2803	Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. Nature Communications, 2018, 9, 4112.	5.8	55
2804	Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy. Cancer Immunology Research, 2018, 6, 1401-1416.	1.6	28
2805	Genome-Wide Network-Based Analysis of Colorectal Cancer Identifies Novel Prognostic Factors and an Integrative Prognostic Index. Cellular Physiology and Biochemistry, 2018, 49, 1703-1716.	1.1	52
2806	Different Anatomical Subsites of Colon Cancer and Mortality: A Population-Based Study. Gastroenterology Research and Practice, 2018, 2018, 1-9.	0.7	11
2807	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-Î² Superfamily. Cell Systems, 2018, 7, 422-437.e7.	2.9	134
2808	Colonic Lysine Homocysteinylation Induced by High-Fat Diet Suppresses DNA Damage Repair. Cell Reports, 2018, 25, 398-412.e6.	2.9	70
2809	Typing tumors using pathways selected by somatic evolution. Nature Communications, 2018, 9, 4159.	5.8	19
2810	Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis. World Journal of Surgical Oncology, 2018, 16, 200.	0.8	3
2811	Personalized Integrated Network Modeling of the Cancer Proteome Atlas. Scientific Reports, 2018, 8, 14924.	1.6	14
2812	Association rule mining algorithms on high-dimensional datasets. Artificial Life and Robotics, 2018, 23, 420-427.	0.7	18
2813	A Bioinformatic Profile of Gene Expression of Colorectal Carcinoma Derived Organoids. BioMed Research International, 2018, 2018, 1-12.	0.9	3
2814	Prognostic Values of EPDR1 Hypermethylation and Its Inhibitory Function on Tumor Invasion in Colorectal Cancer. Cancers, 2018, 10, 393.	1.7	21
2815	Prediction of smoking by multiplex bisulfite PCR with long amplicons considering allele-specific effects on DNA methylation. Clinical Epigenetics, 2018, 10, 130.	1.8	11
2816	Association analysis using somatic mutations. PLoS Genetics, 2018, 14, e1007746.	1.5	8
2817	Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors. Cell Reports, 2018, 25, 1066-1080.e8.	2.9	239

#	Article	IF	Citations
2818	Breakthrough cancer genome analysis in time and space: novel oncotargets and early drug development. Pharmacogenomics, 2018, 19, 1303-1310.	0.6	0
2819	BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase IIâ€“DNA complexes. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E10642-E10651.	3.3	75
2820	Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer. Cell, 2018, 175, 1244-1258.e26.	13.5	182
2821	<scp>RK</scp>â€287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model. Cancer Science, 2018, 109, 4003-4014.	1.7	60
2822	Microbiome and Colorectal Cancer. Current Colorectal Cancer Reports, 2018, 14, 217-225.	1.0	5
2823	Downregulation of Activin A Receptor Type 2A Is Associated with Metastatic Potential and Poor Prognosis of Colon Cancer. Journal of Cancer, 2018, 9, 3626-3633.	1.2	10
2824	Pan-cancer analysis of tumor metabolic landscape associated with genomic alterations. Molecular Cancer, 2018, 17, 150.	7.9	21
2825	Whole-genome sequencing of esophageal adenocarcinoma in Chinese patients reveals distinct mutational signatures and genomic alterations. Communications Biology, 2018, 1, 174.	2.0	6
2826	Predominance of triple wild-type and IGF2R mutations in mucosal melanomas. BMC Cancer, 2018, 18, 1054.	1.1	15
2827	LncRNA NEAT1 promotes colorectal cancer cell proliferation and migration via regulating glial cell-derived neurotrophic factor by sponging miR-196a-5p. Acta Biochimica Et Biophysica Sinica, 2018, 50, 1190-1199.	0.9	28
2828	Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Research, 2018, 28, 1747-1756.	2.4	2,614
2829	Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells. Cancers, 2018, 10, 386.	1.7	11
2830	Mutational interactions define novel cancer subgroups. Nature Communications, 2018, 9, 4353.	5.8	26
2831	Transposon mutagenesis screen in mice identifies TM9SF2 as a novel colorectal cancer oncogene. Scientific Reports, 2018, 8, 15327.	1.6	17
2832	Local delivery of macromolecules to treat diseases associated with the colon. Advanced Drug Delivery Reviews, 2018, 136-137, 2-27.	6.6	72
2833	CRAD as a cytoskeletal tumour suppressor. Nature Cell Biology, 2018, 20, 1232-1233.	4.6	2
2834	Atypical matrix adhesions guide cell division. Nature Cell Biology, 2018, 20, 1233-1235.	4.6	7
2835	Prediction of Target Genes and Pathways Associated With Cetuximab Insensitivity in Colorectal Cancer. Technology in Cancer Research and Treatment, 2018, 17, 153303381880690.	0.8	11

#	Article	IF	Citations
2836	Quantitative assessment of cell population diversity in single-cell landscapes. PLoS Biology, 2018, 16, e2006687.	2.6	40
2837	Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets. Frontiers in Genetics, 2018, 9, 427.	1.1	88
2838	A panâ€cancer atlas of cancer hallmarkâ€associated candidate driver lnc<scp>RNA</scp>s. Molecular Oncology, 2018, 12, 1980-2005.	2.1	20
2839	Promoter capture Hi-C-based identification of recurrent noncoding mutations in colorectal cancer. Nature Genetics, 2018, 50, 1375-1380.	9.4	49
2840	A novel panel of short mononucleotide repeats linked to informative polymorphisms enabling effective high volume low cost discrimination between mismatch repair deficient and proficient tumours. PLoS ONE, 2018, 13, e0203052.	1.1	14
2841	Differences in clinical characteristics and mutational pattern between synchronous and metachronous colorectal liver metastases. Cancer Management and Research, 2018, Volume 10, 2871-2881.	0.9	11
2842	Role of Microbiome in Carcinogenesis Process and Epigenetic Regulation of Colorectal Cancer. Methods in Molecular Biology, 2018, 1856, 35-55.	0.4	26
2843	Ap4 is rate limiting for intestinal tumor formation by controlling the homeostasis of intestinal stem cells. Nature Communications, 2018, 9, 3573.	5.8	18
2844	A machine learning approach for somatic mutation discovery. Science Translational Medicine, 2018, 10, .	5.8	80
2845	Structural Basis for Regulation of METTL16, an S-Adenosylmethionine Homeostasis Factor. Molecular Cell, 2018, 71, 1001-1011.e4.	4.5	146
2846	MiR-384 inhibits the proliferation of colorectal cancer by targeting AKT3. Cancer Cell International, 2018, 18, 124.	1.8	34
2847	The evolutionary landscape of colorectal tumorigenesis. Nature Ecology and Evolution, 2018, 2, 1661-1672.	3.4	99
2848	Metformin blocks <scp>MYC</scp> protein synthesis in colorectal cancer via m<scp>TOR</scp>â€4<scp>EBP</scp>â€<scp>IF</scp>4E and MNK1â€<scp>IF</scp>4Gâ€<scp>IF</scp>4E signaling. Molecular Oncology, 2018, 12, 1856-1870.	2.1	31
2849	Genome-wide methylation analysis identifies novel prognostic methylation markers in colon adenocarcinoma. Biomedicine and Pharmacotherapy, 2018, 108, 288-296.	2.5	14
2850	Identification of DK419, a potent inhibitor of Wnt/Î²-catenin signaling and colorectal cancer growth. Bioorganic and Medicinal Chemistry, 2018, 26, 5435-5442.	1.4	10
2851	Tissue and plasma proteomics for early stage cancer detection. Molecular Omics, 2018, 14, 405-423.	1.4	28
2852	Evolving Tissue and Circulating Biomarkers as Prognostic and Predictive Tools in Colorectal Cancer. Current Colorectal Cancer Reports, 2018, 14, 138-151.	1.0	0
2853	Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. Nature Communications, 2018, 9, 3787.	5.8	112

#	Article	IF	Citations
2854	Proliferative and Invasive Colorectal Tumors in Pet Dogs Provide Unique Insights into Human Colorectal Cancer. Cancers, 2018, 10, 330.	1.7	21
2855	KIF14 promotes cell proliferation via activation of Akt and is directly targeted by miR-200c in colorectal cancer. International Journal of Oncology, 2018, 53, 1939-1952.	1.4	32
2856	Advanced microRNA-based cancer diagnostics using amplified time-gated FRET. Chemical Science, 2018, 9, 8046-8055.	3.7	32
2857	Contribution of allelic imbalance to colorectal cancer. Nature Communications, 2018, 9, 3664.	5.8	25
2858	PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients. Cancers, 2018, 10, 314.	1.7	32
2859	Wnt Effector TCF4 Is Dispensable for Wnt Signaling in Human Cancer Cells. Genes, 2018, 9, 439.	1.0	31
2860	Pan-cancer inference of intra-tumor heterogeneity reveals associations with different forms of genomic instability. PLoS Genetics, 2018, 14, e1007669.	1.5	72
2861	Brain Organoids: Expanding Our Understanding of Human Development and Disease. Results and Problems in Cell Differentiation, 2018, 66, 183-206.	0.2	16
2862	Tales from the crypt: intestinal niche signals in tissue renewal, plasticity and cancer. Open Biology, 2018, 8, .	1.5	96
2863	Genetic Alterations of TRAF Proteins in Human Cancers. Frontiers in Immunology, 2018, 9, 2111.	2.2	67
2864	POLE gene hotspot mutations in advanced pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2161-2166.	1.2	15
2865	Regulation of Transcription Factor SP1 by the <i>Î²</i>-Catenin Destruction Complex Modulates Wnt Response. Molecular and Cellular Biology, 2018, 38, .	1.1	21
2866	SEG - A Software Program for Finding Somatic Copy Number Alterations in Whole Genome Sequencing Data of Cancer. Computational and Structural Biotechnology Journal, 2018, 16, 335-341.	1.9	7
2867	Report from the 19th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29â€“30 September 2017. Current Oncology, 2018, 25, 275-284.	0.9	3
2868	Tumorâ€stroma interactions differentially alter drug sensitivity based on the origin of stromal cells. Molecular Systems Biology, 2018, 14, e8322.	3.2	25
2869	Genomeâ€scale analysis to identify potential prognostic microRNA biomarkers for predicting overall survival in patients with colon adenocarcinoma. Oncology Reports, 2018, 40, 1947-1958.	1.2	25
2870	Analysis of key genes and signaling pathways involved in <i>Helicobacter pylori</i>â€associated gastric cancer based on The Cancer Genome Atlas database and <scp>RNA</scp> sequencing data. Helicobacter, 2018, 23, e12530.	1.6	31
2871	Identification of Key Genes and Pathways in Triple-Negative Breast Cancer by Integrated Bioinformatics Analysis. BioMed Research International, 2018, 2018, 1-10.	0.9	59

#	Article	IF	Citations
2872	Peroxiredoxin II Regulates Cancer Stem Cells and Stemness-Associated Properties of Cancers. Cancers, 2018, 10, 305.	1.7	25
2873	Immunological-based approaches for cancer therapy. Clinics, 2018, 73, e429s.	0.6	7
2874	Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing. Clinical Chemistry, 2018, 64, 1626-1635.	1.5	46
2875	Prevalence and characteristics of colonic adenoma in mainland China. Cancer Management and Research, 2018, Volume 10, 2743-2755.	0.9	14
2876	Analysis and visualization of linked molecular and clinical cancer data by using Oncoscape. Nature Genetics, 2018, 50, 1203-1204.	9.4	10
2877	Ancillary studies in cytology: Secondary or necessary?. Cancer Cytopathology, 2018, 126, 584-589.	1.4	1
2878	Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneity. Cell Death and Disease, 2018, 9, 894.	2.7	34
2879	Role of HOX Genes in Stem Cell Differentiation and Cancer. Stem Cells International, 2018, 2018, 1-15.	1.2	125
2880	Microbial Interactions and Interventions in Colorectal Cancer. , 2018, , 99-130.		1
2881	Computational modeling and confirmation of leukemia-associated minor histocompatibility antigens. Blood Advances, 2018, 2, 2052-2062.	2.5	24
2883	Quantification of subclonal selection in cancer from bulk sequencing data. Nature Genetics, 2018, 50, 895-903.	9.4	222
2884	FAM188B enhances cell survival via interaction with USP7. Cell Death and Disease, 2018, 9, 633.	2.7	11
2885	Bim regulates the survival and suppressive capability of CD8+ FOXP3+ regulatory T cells during murine GVHD. Blood, 2018, 132, 435-447.	0.6	31
2886	Targeting tumor cell plasticity by combined inhibition of NOTCH and MAPK signaling in colon cancer. Journal of Experimental Medicine, 2018, 215, 1693-1708.	4.2	31
2887	Roles for selenium and selenoprotein P in the development, progression, and prevention of intestinal disease. Free Radical Biology and Medicine, 2018, 127, 26-35.	1.3	69
2888	Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses. Gynecologic Oncology, 2018, 150, 127-135.	0.6	41
2889	Distinct Histopathologic and Molecular Alterations in Inflammatory Bowel Disease-Associated Intestinal Adenocarcinoma: c-MYC Amplification is Common and Associated with Mucinous/Signet Ring Cell Differentiation. Inflammatory Bowel Diseases, 2018, 24, 1780-1790.	0.9	14
2890	Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation. Cancer Research, 2018, 78, 4627-4641.	0.4	56

#	Article	IF	Citations
2891	Centrosome Linkerâ€"induced Tetraploid Segregation Errors Link Rhabdoid Phenotypes and Lethal Colorectal Cancers. Molecular Cancer Research, 2018, 16, 1385-1395.	1.5	13
2892	Colorectal Cancer: Why Does Side Matter?. Drugs, 2018, 78, 789-798.	4.9	41
2893	Individualized predictive signatures for 5â€fluorouracilâ€based chemotherapy in rightâ€and leftâ€sided colon cancer. Cancer Science, 2018, 109, 1939-1948.	1.7	13
2894	Molecular Diagnostics in the Neoplasms of Small Intestine and Appendix. Clinics in Laboratory Medicine, 2018, 38, 343-355.	0.7	7
2895	Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. Medical Oncology, 2018, 35, 101.	1.2	6
2896	Glycosyltransferase Gene Expression Identifies a Poor Prognostic Colorectal Cancer Subtype Associated with Mismatch Repair Deficiency and Incomplete Glycan Synthesis. Clinical Cancer Research, 2018, 24, 4468-4481.	3.2	31
2897	Spatial mutation patterns as markers of early colorectal tumor cell mobility. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 5774-5779.	3.3	43
2898	Methylation and Gene Expression of <i>BCAT1</i> and <i>IKZF1</i> in Colorectal Cancer Tissues. Clinical Medicine Insights: Oncology, 2018, 12, 117955491877506.	0.6	19
2899	Impact of lossâ€ofâ€function mutations at the <i>RNF43</i> locus on colorectal cancer development and progression. Journal of Pathology, 2018, 245, 445-455.	2.1	39
2900	The Immune Biology of Microsatellite Unstable Cancer. , 2018, , 367-384.		4
2901	Aurora kinase A (AURKA) interaction with Wnt and Ras-MAPK signalling pathways in colorectal cancer. Scientific Reports, 2018, 8, 7522.	1.6	38
2902	Pre-clinical Profile and Expectations for Pharmacological ATM Inhibition. Cancer Drug Discovery and Development, 2018, , 155-183.	0.2	0
2903	Host MICA Polymorphism as a Potential Predictive Marker in Response to Chemotherapy for Colorectal Liver Metastases. Digestive Diseases, 2018, 36, 437-445.	0.8	2
2904	Epithelial Smad4 Deletion Up-Regulates Inflammation and Promotes Inflammation-Associated Cancer. Cellular and Molecular Gastroenterology and Hepatology, 2018, 6, 257-276.	2.3	50
2906	Prognostic role of FUT8 expression in relation to p53 status in stage II and III colorectal cancer. PLoS ONE, 2018, 13, e0200315.	1.1	29
2907	Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. The Lancet Gastroenterology and Hepatology, 2018, 3, 635-643.	3.7	60
2908	Is Î²-Catenin a Druggable Target for Cancer Therapy?. Trends in Biochemical Sciences, 2018, 43, 623-634.	3.7	101
2909	Dynamics of Genome Alterations in Crohn's Diseaseâ€"Associated Colorectal Carcinogenesis. Clinical Cancer Research, 2018, 24, 4997-5011.	3.2	22

#	Article	IF	Citations
2910	Wnt Ligands as a Part of the Stem Cell Niche in the Intestine and the Liver. Progress in Molecular Biology and Translational Science, 2018, 153, 1-19.	0.9	8
2911	Mutational Analysis Identifies Therapeutic Biomarkers in Inflammatory Bowel Diseaseâ€"Associated Colorectal Cancers. Clinical Cancer Research, 2018, 24, 5133-5142.	3.2	26
2912	Surface microstructures are associated with mutational intratumoral heterogeneity in colorectal tumors. Journal of Gastroenterology, 2018, 53, 1241-1252.	2.3	5
2913	Meta-analysis of the prognostic value of CpG island methylator phenotype in rectal cancer. International Journal of Colorectal Disease, 2018, 33, 995-1000.	1.0	5
2914	Data science vs. statistics: two cultures?. Japanese Journal of Statistics and Data Science, 2018, 1, 117-138.	0.7	25
2915	Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, 258-273.	1.0	41
2916	Role of RNF20 in cancer development and progression â€" a comprehensive review. Bioscience Reports, 2018, 38, .	1.1	34
2917	p190 RhoGAP promotes contact inhibition in epithelial cells by repressing YAP activity. Journal of Cell Biology, 2018, 217, 3183-3201.	2.3	21
2918	Prevalence and prognostic relevance of BrafV600E mutation in colorectal carcinomas from Kashmir (North India) valley. Mutagenesis, 2018, 33, 225-230.	1.0	5
2919	Chemical Modulation of WNT Signaling in Cancer. Progress in Molecular Biology and Translational Science, 2018, 153, 245-269.	0.9	20
2920	Uncovering pseudotemporal trajectories with covariates from single cell and bulk expression data. Nature Communications, 2018, 9, 2442.	5.8	80
2921	PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation. Scientific Reports, 2018, 8, 9296.	1.6	23
2922	Optimized base editors enable efficient editing in cells, organoids and mice. Nature Biotechnology, 2018, 36, 888-893.	9.4	269
2923	The stress response gene ATF3 is a direct target of the Wnt/Î²-catenin pathway and inhibits the invasion and migration of HCT116 human colorectal cancer cells. PLoS ONE, 2018, 13, e0194160.	1.1	36
2924	Consensus molecular subtype classification of colorectal adenomas. Journal of Pathology, 2018, 246, 266-276.	2.1	60
2925	Predictive Value of Epigenetic Signatures. , 2018, , 275-311.		0
2926	Mechanisms of Gastrointestinal Malignancies. , 2018, , 1615-1642.		3
2927	Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma. Modern Pathology, 2018, 31, 1882-1890.	2.9	49

#	Article	IF	Citations
2928	Integrative analysis of oncogenic fusion genes and their functional impact in colorectal cancer. British Journal of Cancer, 2018, 119, 230-240.	2.9	27
2929	Two critical positions in zinc finger domains are heavily mutated in three human cancer types. PLoS Computational Biology, 2018, 14, e1006290.	1.5	31
2930	The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy (Review). Oncology Letters, 2018, 16, 9-18.	0.8	147
2931	Trimodal distribution of arylamine N-acetyltransferase 1 mRNA in breast cancer tumors: association with overall survival and drug resistance. BMC Genomics, 2018, 19, 513.	1.2	24
2932	Manic Fringe deficiency imposes Jagged1 addiction to intestinal tumor cells. Nature Communications, 2018, 9, 2992.	5.8	23
2933	Explaining cancer type specific mutations with transcriptomic and epigenomic features in normal tissues. Scientific Reports, 2018, 8, 11456.	1.6	11
2934	RECK isoforms have opposing effects on cell migration. Molecular Biology of the Cell, 2018, 29, 1825-1838.	0.9	20
2935	IDH1â€mutant cancer cells are sensitive to cisplatin and an IDH1â€mutant inhibitor counteracts this sensitivity. FASEB Journal, 2018, 32, 6344-6352.	0.2	28
2936	Colorectal Cancer, Pathology and Genetics. , 2018, , 428-428.		0
2937	Vitamin D and Colon Cancer. , 2018, , 837-862.		6
2938	Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Cancer Cell, 2018, 34, 211-224.e6.	7.7	623
2939	Discovering novel valid biomarkers and drugs in patient-centric genomic trials: the new epoch of precision surgical oncology. Drug Discovery Today, 2018, 23, 1848-1872.	3.2	12
2940	Clinical Significance of BRAF Non-V600E Mutations in Colorectal Cancer: A Retrospective Study of Two Institutions. Journal of Surgical Research, 2018, 232, 72-81.	0.8	19
2941	Stepwise approach to SNP-set analysis illustrated with the Metabochip and colorectal cancer in Japanese Americans of the Multiethnic Cohort. BMC Genomics, 2018, 19, 524.	1.2	5
2942	Biomarkers of response to immune checkpoint blockade in cancer treatment. Critical Reviews in Oncology/Hematology, 2018, 130, 108-120.	2.0	61
2943	Mutational Signatures in Cancer (MuSiCa): a web application to implement mutational signatures analysis in cancer samples. BMC Bioinformatics, 2018, 19, 224.	1.2	77
2944	Combination of a six microRNA expression profile with four clinicopathological factors for response prediction of systemic treatment in patients with advanced colorectal cancer. PLoS ONE, 2018, 13, e0201809.	1.1	20
2945	Colorectal cancer immunotherapy. Rad Hrvatske Akademije Znanosti I Umjetnosti Medicinske Znanosti, 2018, 533, 127-138.	0.1	0

#	Article	IF	Citations
2946	Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nature Communications, 2018, 9, 3114.	5.8	122
2947	Evaluating the prognostic value and functional roles of transcription factor AP4 in colorectal cancer. Oncology Letters, 2018, 15, 7545-7554.	0.8	11
2948	Overexpression of dedicator of cytokinesis 2 correlates with good prognosis in colorectal cancer associated with more prominent CD8 + lymphocytes infiltration: a colorectal cancer analysis. Journal of Cellular Biochemistry, 2018, 119, 8962-8970.	1.2	6
2949	Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression. Breast Cancer Research, 2018, 20, 74.	2.2	25
2950	Nano-Diamino-Tetrac (NDAT) Enhances Resveratrol-Induced Antiproliferation by Action on the RRM2 Pathway in Colorectal Cancers. Hormones and Cancer, 2018, 9, 349-360.	4.9	22
2951	The NK1 receptor antagonist NKP608 inhibits proliferation of human colorectal cancer cells via Wnt signaling pathway. Biological Research, 2018, 51, 14.	1.5	11
2952	Quality control of single amino acid variations detected by tandem mass spectrometry. Journal of Proteomics, 2018, 187, 144-151.	1.2	10
2953	Emerging treatment options for BRAF-mutant colorectal cancer. Gastrointestinal Cancer: Targets and Therapy, 2018, Volume 8, 13-23.	5.5	55
2954	Inference of Crosstalk Effects between DNA Methylation and lncRNA Regulation in NSCLC. BioMed Research International, 2018, 2018, 1-6.	0.9	13
2955	A genomeâ€wide analysis of colorectal cancer in a child with Noonan syndrome. Pediatric Blood and Cancer, 2018, 65, e27362.	0.8	1
2956	A temporal shift of the evolutionary principle shaping intratumor heterogeneity in colorectal cancer. Nature Communications, 2018, 9, 2884.	5.8	82
2957	Epigenetic and transcriptional dysregulation of VWA2 associated with a MYC-driven oncogenic program in colorectal cancer. Scientific Reports, 2018, 8, 11097.	1.6	7
2958	Discovering mutated driver genes through a robust and sparse co-regularized matrix factorization framework with prior information from mRNA expression patterns and interaction network. BMC Bioinformatics, 2018, 19, 214.	1.2	24
2959	Clinical, Pathological, and Molecular Characteristics of CpG Island Methylator Phenotype in Colorectal Cancer: A Systematic Review and Meta-analysis. Translational Oncology, 2018, 11, 1188-1201.	1.7	57
2960	Inflammation-induced DNA methylation of DNA polymerase gamma alters the metabolic profile of colon tumors. Cancer & Metabolism, 2018, 6, 9.	2.4	15
2961	Tensorial blind source separation for improved analysis of multi-omic data. Genome Biology, 2018, 19, 76.	3.8	20
2962	An Integrated Approach for Identifying Molecular Subtypes in Human Colon Cancer Using Gene Expression Data. Genes, 2018, 9, 397.	1.0	6
2963	Differential Integration of Transcriptome and Proteome Identifies Pan-Cancer Prognostic Biomarkers. Frontiers in Genetics, 2018, 9, 205.	1.1	14

#	Article	IF	Citations
2964	Combining Pathway Identification and Breast Cancer Survival Prediction via Screening-Network Methods. Frontiers in Genetics, 2018, 9, 206.	1.1	10
2965	Overview on Clinical Relevance of Intra-Tumor Heterogeneity. Frontiers in Medicine, 2018, 5, 85.	1.2	182
2966	Significance of Streptococcus gallolyticus subsp. gallolyticus Association With Colorectal Cancer. Frontiers in Microbiology, 2018, 9, 614.	1.5	96
2967	Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. Cancers, 2018, 10, 17.	1.7	21
2968	Colorectal Cancers: An Update on Their Molecular Pathology. Cancers, 2018, 10, 26.	1.7	128
2969	The Glucose-Regulated MiR-483-3p Influences Key Signaling Pathways in Cancer. Cancers, 2018, 10, 181.	1.7	35
2970	Understanding Intratumor Heterogeneity and Evolution in NSCLC and Potential New Therapeutic Approach. Cancers, 2018, 10, 212.	1.7	17
2971	Wnt, RSPO and Hippo Signalling in the Intestine and Intestinal Stem Cells. Genes, 2018, 9, 20.	1.0	49
2972	Protein Phosphatase 2A in the Regulation of Wnt Signaling, Stem Cells, and Cancer. Genes, 2018, 9, 121.	1.0	52
2973	Applying Expression Profile Similarity for Discovery of Patient-Specific Functional Mutations. High-Throughput, 2018, 7, 6.	4.4	3
2974	Performance comparison of three DNA extraction kits on human whole-exome data from formalin-fixed paraffin-embedded normal and tumor samples. PLoS ONE, 2018, 13, e0195471.	1.1	39
2975	Validation Strategy for Ultrasensitive Mutation Detection. Molecular Diagnosis and Therapy, 2018, 22, 603-611.	1.6	0
2976	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. Cancer Cell, 2018, 34, 148-162.e7.	7.7	129
2977	Transcriptome profiling reveals an integrated mRNAâ€"lncRNA signature with predictive value of early relapse in colon cancer. Carcinogenesis, 2018, 39, 1235-1244.	1.3	46
2978	Wingless/Wnt Signaling in Intestinal Development, Homeostasis, Regeneration and Tumorigenesis: A Drosophila Perspective. Journal of Developmental Biology, 2018, 6, 8.	0.9	33
2979	Colorectal Cancer: Genetic Abnormalities, Tumor Progression, Tumor Heterogeneity, Clonal Evolution and Tumor-Initiating Cells. Medical Sciences (Basel, Switzerland), 2018, 6, 31.	1.3	167
2980	Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 903-908.	2.3	10
2981	Probing the colorectal cancer proteome for biomarkers: Current status and perspectives. Journal of Proteomics, 2018, 187, 93-105.	1.2	46

#	Article	IF	Citations
2982	The risk of developing a mismatch repair deficient colorectal cancer after undergoing cholecystectomy. Scandinavian Journal of Gastroenterology, 2018, 53, 972-975.	0.6	2
2983	Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. Gastroenterology Research and Practice, 2018, 2018, 1-21.	0.7	60
2984	Genomic characterization of colitis-associated colorectal cancer. World Journal of Surgical Oncology, 2018, 16, 121.	0.8	37
2985	Negative selection in tumor genome evolution acts on essential cellular functions and the immunopeptidome. Genome Biology, 2018, 19, 67.	3.8	81
2986	Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth. PLoS ONE, 2018, 13, e0200163.	1.1	6
2987	Germline and somatic variations influence the somatic mutational signatures of esophageal squamous cell carcinomas in a Chinese population. BMC Genomics, 2018, 19, 538.	1.2	19
2988	Gene promoter and exon DNA methylation changes in colon cancer development â€" mRNA expression and tumor mutation alterations. BMC Cancer, 2018, 18, 695.	1.1	45
2989	SMAD4 Suppresses WNT-Driven Dedifferentiation and Oncogenesis in the Differentiated Gut Epithelium. Cancer Research, 2018, 78, 4878-4890.	0.4	56
2990	Targeted Sequencing of Circulating Tumor DNA to Monitor Genetic Variants and Therapeutic Response in Metastatic Colorectal Cancer. Molecular Cancer Therapeutics, 2018, 17, 2238-2247.	1.9	31
2991	In Silico Studies on Colon Cancer. , 2018, , 145-158.		0
2992	A Pan-Cancer Compendium of Genes Deregulated by Somatic Genomic Rearrangement across More Than 1,400 Cases. Cell Reports, 2018, 24, 515-527.	2.9	70
2993	The TGFÎ²-signaling pathway and colorectal cancer: associations between dysregulated genes and miRNAs. Journal of Translational Medicine, 2018, 16, 191.	1.8	35
2994	Modeling APC mutagenesis and familial adenomatous polyposis using human iPS cells. PLoS ONE, 2018, 13, e0200657.	1.1	29
2995	Advantage of <i>HSP110</i> (T17) marker inclusion for microsatellite instability (MSI) detection in colorectal cancer patients. Oncotarget, 2018, 9, 28691-28701.	0.8	46
2996	Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. Clinical Colorectal Cancer, 2018, 17, e699-e709.	1.0	34
2997	Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer. Oncogenesis, 2018, 7, 55.	2.1	12
2998	Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance. Genome Medicine, 2018, 10, 55.	3.6	37
2999	Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing. BMC Cancer, 2018, 18, 752.	1.1	29

#	Article	IF	Citations
3000	SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients. BMC Cancer, 2018, 18, 479.	1.1	34
3001	Chromatin 3D â€" will it make understanding of cancer transformation finally possible?. Bio-Algorithms and Med-Systems, 2018, 14, .	1.0	0
3002	ARID1A loss in cancer: Towards a mechanistic understanding. , 2018, 190, 15-23.		97
3003	Robotic Total Mesorectal Excision and Sphincter-Saving Operation. , 2018, , 163-177.		0
3004	Promising New Agents for Colorectal Cancer. Current Treatment Options in Oncology, 2018, 19, 29.	1.3	46
3005	VAReporter: variant reporter for cancer research of massive parallel sequencing. BMC Genomics, 2018, 19, 86.	1.2	2
3006	Clinicopathological significance of G9A expression in colorectal carcinoma. Oncology Letters, 2018, 15, 8611-8619.	0.8	11
3007	Molecular Basis of Colorectal Cancer: Tumor Biology. , 2018, , 23-34.		0
3008	Nine primary malignant neoplasms-involving the esophagus, stomach, colon, rectum, prostate, and external ear canal-without microsatellite instability: a case report. BMC Cancer, 2018, 18, 24.	1.1	3
3009	Accuracy of four mononucleotide-repeat markers for the identification of DNA mismatch-repair deficiency in solid tumors. Journal of Translational Medicine, 2018, 16, 5.	1.8	21
3010	Linking FOXO3, NCOA3, and TCF7L2 to Ras pathway phenotypes through a genome-wide forward genetic screen in human colorectal cancer cells. Genome Medicine, 2018, 10, 2.	3.6	6
3011	<i>Fusobacterium nucleatum</i> Infection in Colorectal Cancer: Linking Inflammation, DNA Mismatch Repair and Genetic and Epigenetic Alterations. Journal of the Anus, Rectum and Colon, 2018, 2, 37-46.	0.4	48
3012	Knockdown of Uba2 inhibits colorectal cancer cell invasion and migration through downregulation of the Wnt/Î²â€catenin signaling pathway. Journal of Cellular Biochemistry, 2018, 119, 6914-6925.	1.2	18
3013	Molecular Characterization of Colorectal Signet-Ring Cell Carcinoma Using Whole-Exome and RNA Sequencing. Translational Oncology, 2018, 11, 836-844.	1.7	14
3014	Integrated analysis highlights APC11 protein expression as a likely new independent predictive marker for colorectal cancer. Scientific Reports, 2018, 8, 7386.	1.6	12
3015	Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer. BMC Cancer, 2018, 18, 541.	1.1	6
3016	Adenomatous Polyposis Syndromes: Polymerase Proofreading-Associated Polyposis. , 2018, , 113-134.		4
3017	Atypical Cadherin Dachsous1b Interacts with Ttc28 and Aurora B to Control Microtubule Dynamics in Embryonic Cleavages. Developmental Cell, 2018, 45, 376-391.e5.	3.1	15

#	Article	IF	Citations
3018	Establishment and Characterization of Paired Primary and Peritoneal Seeding Human Colorectal Cancer Cell Lines: Identification of Genes That Mediate Metastatic Potential. Translational Oncology, 2018, 11, 1232-1243.	1.7	34
3019	Family A and B DNA Polymerases in Cancer: Opportunities for Therapeutic Interventions. Biology, 2018, 7, 5.	1.3	3
3020	Differential expression of Cosmc, T-synthase and mucins in Tn-positive colorectal cancers. BMC Cancer, 2018, 18, 827.	1.1	42
3021	Synthetic Lethality: From Research to Precision Cancer Nanomedicine. Current Cancer Drug Targets, 2018, 18, 337-346.	0.8	17
3022	Genetic and epigenetic alterations of colorectal cancer. Intestinal Research, 2018, 16, 327.	1.0	100
3023	Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells. Nature Communications, 2018, 9, 3212.	5.8	97
3024	Current and future therapies for targeting HER2 mutations in gastrointestinal cancer. Expert Review of Anticancer Therapy, 2018, 18, 1085-1092.	1.1	8
3025	Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets. Biomedicines, 2018, 6, 32.	1.4	41
3026	Integrated Genomic Analysis of HÃ¼rthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. Cancer Cell, 2018, 34, 256-270.e5.	7.7	195
3027	Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion. Cancer Cell, 2018, 34, 298-314.e7.	7.7	162
3028	The association between fecal microbiota and different types of colorectal polyp as precursors of colorectal cancer. Microbial Pathogenesis, 2018, 124, 244-249.	1.3	95
3029	Three distinct genomic subtypes of head and neck squamous cell carcinoma associated with clinical outcomes. Oral Oncology, 2018, 85, 44-51.	0.8	11
3030	Frequent Mutations in Natural Killer/T Cell Lymphoma. Cellular Physiology and Biochemistry, 2018, 49, 1-16.	1.1	29
3031	FBW7 suppresses metastasis of colorectal cancer by inhibiting HIF1Î±/CEACAM5 functional axis. International Journal of Biological Sciences, 2018, 14, 726-735.	2.6	18
3032	Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2. Annals of Oncology, 2018, 29, 2061-2067.	0.6	35
3033	Recurrence-Associated Long Non-coding RNA Signature for Determining the Risk of Recurrence in Patients with Colon Cancer. Molecular Therapy - Nucleic Acids, 2018, 12, 518-529.	2.3	139
3034	PTEN deficiency confers colorectal cancer cell resistance to dual inhibitors of FLT3 and aurora kinase A. Cancer Letters, 2018, 436, 28-37.	3.2	10
3035	HER2: An emerging target in colorectal cancer. Current Problems in Cancer, 2018, 42, 560-571.	1.0	67

#	Article	IF	Citations
3036	Comprehensive evaluation of coding region point mutations in microsatelliteâ€unstable colorectal cancer. EMBO Molecular Medicine, 2018, 10, .	3.3	10
3037	Global Inequities in Precision Medicine and Molecular Cancer Research. Frontiers in Oncology, 2018, 8, 346.	1.3	44
3038	Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. Theranostics, 2018, 8, 3932-3948.	4.6	494
3039	Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. Cell, 2018, 174, 1586-1598.e12.	13.5	644
3040	Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells. Scientific Reports, 2018, 8, 11879.	1.6	30
3041	Silencing non-SMC chromosome-associated polypeptide G inhibits proliferation and induces apoptosis in hepatocellular carcinoma cells. Canadian Journal of Physiology and Pharmacology, 2018, 96, 1246-1254.	0.7	29
3042	Transcriptome analysis reveals an altered expression profile of zinc transporters in colorectal cancer. Journal of Cellular Biochemistry, 2018, 119, 9707-9719.	1.2	42
3043	Lynch Syndromeâ€"Associated Colorectal Cancer. New England Journal of Medicine, 2018, 379, 764-773.	13.9	183
3044	TRIM14 promotes chemoresistance in gliomas by activating Wnt/Î²-catenin signaling via stabilizing Dvl2. Oncogene, 2018, 37, 5403-5415.	2.6	52
3045	The Genetic Evolution of Melanoma. , 2018, , 105-114.		0
3046	The Human Transcriptome. , 2018, , 135-164.		4
3047	Molecular Basis of Diseases of the Gastrointestinal Tract. , 2018, , 387-415.		1
3048	Potential of memory T cells in bridging preoperative chemoradiation and immunotherapy in rectal cancer. Radiotherapy and Oncology, 2018, 127, 361-369.	0.3	4
3049	Tissue-specific DNA methylation loss during ageing and carcinogenesis is linked to chromosome structure, replication timing and cell division rates. Nucleic Acids Research, 2018, 46, 7022-7039.	6.5	33
3050	Multilevel omic data clustering reveals variable contribution of methylator phenotype to integrative cancer subtypes. Epigenomics, 2018, 10, 1289-1299.	1.0	4
3051	Mitophagy in Intestinal Epithelial Cells Triggers Adaptive Immunity during Tumorigenesis. Cell, 2018, 174, 88-101.e16.	13.5	93
3052	Cell-of-Origin DNA Methylation Signatures Are Maintained during Colorectal Carcinogenesis. Cell Reports, 2018, 23, 3407-3418.	2.9	66
3053	Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. Nature Communications, 2018, 9, 2287.	5.8	18

#	Article	IF	Citations
3054	Tumor mutational burden analysis of 2,000 Japanese cancer genomes using whole exome and targeted gene panel sequencing . Biomedical Research, 2018, 39, 159-167.	0.3	32
3055	The Emerging Potential for Network Analysis to Inform Precision Cancer Medicine. Journal of Molecular Biology, 2018, 430, 2875-2899.	2.0	72
3056	A feasibility study of colorectal cancer diagnosis via circulating tumor DNA derived CNV detection. PLoS ONE, 2018, 13, e0196826.	1.1	22
3057	Oncogenic BRAF^{V600E} drives expression of MGL ligands in the colorectal cancer cell line HT29 through <i>N</i>-acetylgalactosamine-transferase 3. Biological Chemistry, 2018, 399, 649-659.	1.2	16
3058	Wnt signaling in development and tissue homeostasis. Development (Cambridge), 2018, 145, .	1.2	528
3059	Molecular profiling and sequential somatic mutation shift in hypermutator tumours harbouring POLE mutations. Scientific Reports, 2018, 8, 8700.	1.6	26
3060	Landscaping the epigenetic landscape of cancer. Progress in Biophysics and Molecular Biology, 2018, 140, 155-174.	1.4	13
3061	Autonomous Multimodal Metabolomics Data Integration for Comprehensive Pathway Analysis and Systems Biology. Analytical Chemistry, 2018, 90, 8396-8403.	3.2	24
3062	CRISPR therapeutic tools for complex genetic disorders and cancer (Review). International Journal of Oncology, 2018, 53, 443-468.	1.4	28
3063	Association between expression of random gene sets and survival is evident in multiple cancer types and may be explained by sub-classification. PLoS Computational Biology, 2018, 14, e1006026.	1.5	21
3064	Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. Developmental Cell, 2018, 45, 738-752.e6.	3.1	27
3065	SAMHD1 modulates <i>in vitro</i> proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis. Cell Cycle, 2018, 17, 1124-1137.	1.3	18
3066	Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment. Precision Clinical Medicine, 2018, 1, 29-48.	1.3	79
3067	Subtypes of Barrettâ€™s oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis. Gut, 2019, 68, 389-399.	6.1	37
3068	PIK3CA mutations in colorectal and breast cancer: impact on oncogenesis and response to nonsteroidal anti-inflammatory drugs. , 2019, , 123-144.		2
3069	Identification of cancer subtypes by integrating multiple types of transcriptomics data with deep learning in breast cancer. Neurocomputing, 2019, 324, 20-30.	3.5	68
3070	Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities. Seminars in Cancer Biology, 2019, 55, 37-52.	4.3	125
3071	Impaired Wnt Signaling in the Prefrontal Cortex of Alzheimerâ€™s Disease. Molecular Neurobiology, 2019, 56, 873-891.	1.9	82

#	Article	IF	Citations
3072	Mechanisms of action of vitamin D in colon cancer. Journal of Steroid Biochemistry and Molecular Biology, 2019, 185, 1-6.	1.2	94
3073	CI-SNF: Exploiting contextual information to improve SNF based information retrieval. Information Fusion, 2019, 52, 175-186.	11.7	6
3074	Mutation heterogeneity between primary gastric cancers and their matched lymph node metastases. Gastric Cancer, 2019, 22, 323-334.	2.7	17
3075	Alternative splicing expands the prognostic impact of <i>KRAS</i> in microsatellite stable primary colorectal cancer. International Journal of Cancer, 2019, 144, 841-847.	2.3	26
3076	Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracilâ€based adjuvant chemotherapy benefit. FASEB Journal, 2019, 33, 151-162.	0.2	29
3077	ELF3 is an antagonist of oncogenic-signalling-induced expression of EMT-TF ZEB1. Cancer Biology and Therapy, 2019, 20, 90-100.	1.5	20
3078	A comparison of mechanistic signaling pathway activity analysis methods. Briefings in Bioinformatics, 2019, 20, 1655-1668.	3.2	33
3079	PRSS8 suppresses colorectal carcinogenesis and metastasis. Oncogene, 2019, 38, 497-517.	2.6	24
3080	Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. Oncologist, 2019, 24, 319-326.	1.9	29
3081	Evolutionary history of human colitis-associated colorectal cancer. Gut, 2019, 68, 985-995.	6.1	97
3082	The impact of tumor location on the biological and oncological differences of colon cancer: Multi-institutional propensity score-matched study. American Journal of Surgery, 2019, 217, 46-52.	0.9	13
3083	MUC13 promotes the development of colitis-associated colorectal tumors via Î²-catenin activity. Oncogene, 2019, 38, 7294-7310.	2.6	28
3084	The landscape of genomic copy number alterations in colorectal cancer and their consequences on gene expression levels and disease outcome. Molecular Aspects of Medicine, 2019, 69, 48-61.	2.7	40
3085	Genomic profiles of colorectal carcinoma with liver metastases and newly identified fusion genes. Cancer Science, 2019, 110, 2973-2981.	1.7	23
3086	Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage. British Journal of Cancer, 2019, 121, 474-482.	2.9	41
3087	Coâ€expression Network Analysis Identified Key Proteins in Association With Hepatic Metastatic Colorectal Cancer. Proteomics - Clinical Applications, 2019, 13, e1900017.	0.8	16
3088	TP53 DNA Binding Domain Mutations Predict Progression-Free Survival of Bevacizumab Therapy in Metastatic Colorectal Cancer. Cancers, 2019, 11, 1079.	1.7	6
3089	Genomic alterations in signet ring and mucinous patterned colorectal carcinoma. Pathology Research and Practice, 2019, 215, 152566.	1.0	9

#	Article	IF	Citations
3090	Maternal transmission of an Igf2r domain 11: IGF2 binding mutant allele (Igf2rI1565A) results in partial lethality, overgrowth and intestinal adenoma progression. Scientific Reports, 2019, 9, 11388.	1.6	8
3091	Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients. Nature Communications, 2019, 10, 3722.	5.8	131
3092	Comprehensive assessment of HER2 alteration in a colorectal cancer cohort: from next-generation sequencing to clinical significance . Cancer Management and Research, 2019, Volume 11, 7867-7875.	0.9	7
3093	Disparities in colon and rectal cancer queried individually between Hispanics and Whites. Journal of Gastrointestinal Oncology, 2019, 10, 632-640.	0.6	5
3094	Epigenome Mapping Identifies Tumor-Specific Gene Expression in Primary Rectal Cancer. Cancers, 2019, 11, 1142.	1.7	10
3095	An enhanced genetic model of colorectal cancer progression history. Genome Biology, 2019, 20, 168.	3.8	34
3096	Xenopus: Driving the Discovery of Novel Genes in Patient Disease and Their Underlying Pathological Mechanisms Relevant for Organogenesis. Frontiers in Physiology, 2019, 10, 953.	1.3	15
3097	p21 in Cancer Research. Cancers, 2019, 11, 1178.	1.7	215
3098	BRAFV600E-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts. Oncogene, 2019, 38, 6752-6766.	2.6	52
3099	Epigenetic Biomarkers and Their Therapeutic Applications in Colorectal Cancer. , 2019, , .		0
3100	Mechanically and chemically defined hydrogel matrices for patient-derived colorectal tumor organoid culture. Biomaterials, 2019, 219, 119400.	5.7	60
3101	Every which way? On predicting tumor evolution using cancer progression models. PLoS Computational Biology, 2019, 15, e1007246.	1.5	27
3102	The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer. EBioMedicine, 2019, 46, 94-104.	2.7	24
3103	Increased glucocorticoid receptor activity and proliferation in metastatic colon cancer. Scientific Reports, 2019, 9, 11257.	1.6	30
3104	A Hallmark-Based Six-Gene Expression Signature to Assess Colorectal Cancer and Its Recurrence Risk. Genetic Testing and Molecular Biomarkers, 2019, 23, 557-564.	0.3	3
3105	Integrated Molecular Analysis of Papillary Renal Cell Carcinoma and Precursor Lesions Unfolds Evolutionary Process from Kidney Progenitor-Like Cells. American Journal of Pathology, 2019, 189, 2046-2060.	1.9	6
3106	Discovery and Optimization of 2-Arylquinazolin-4-ones into a Potent and Selective Tankyrase Inhibitor Modulating Wnt Pathway Activity. Journal of Medicinal Chemistry, 2019, 62, 7897-7909.	2.9	26
3107	Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. Clinical Cancer Research, 2019, 25, 6243-6259.	3.2	42

#	Article	IF	Citations
3108	Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin. Clinical Cancer Research, 2019, 25, 6141-6147.	3.2	98
3109	The impact of DNA methylation on the cancer proteome. PLoS Computational Biology, 2019, 15, e1007245.	1.5	9
3110	Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 364.	3.5	63
3111	Inferring novel genes related to colorectal cancer via random walk with restart algorithm. Gene Therapy, 2019, 26, 373-385.	2.3	3
3112	Emergence of <i>ERBB2</i> Mutation as a Biomarker and an Actionable Target in Solid Cancers. Oncologist, 2019, 24, e1303-e1314.	1.9	64
3113	Lysophosphatidic Acid and Autotaxin-associated Effects on the Initiation and Progression of Colorectal Cancer. Cancers, 2019, 11, 958.	1.7	19
3114	Diabetes Mellitus and Colon Carcinogenesis: Expectation for Inhibition of Colon Carcinogenesis by Oral Hypoglycemic Drugs. Gastrointestinal Disorders, 2019, 1, 273-289.	0.4	1
3115	Genomic signatures reveal DNA damage response deficiency in colorectal cancer brain metastases. Nature Communications, 2019, 10, 3190.	5.8	64
3116	Patient-specific cancer genes contribute to recurrently perturbed pathways and establish therapeutic vulnerabilities in esophageal adenocarcinoma. Nature Communications, 2019, 10, 3101.	5.8	34
3117	Regulation of CD137 expression through Kâ€Ras signaling in pancreatic cancer cells. Cancer Communications, 2019, 39, 1-11.	3.7	14
3118	Integrative genomic analysis identifies associations of molecular alterations to APOBEC and BRCA1/2 mutational signatures in breast cancer. Molecular Genetics & Genomic Medicine, 2019, 7, e810.	0.6	7
3119	Sleeping beauty genetic screen identifies miR-23b::BTBD7 gene interaction as crucial for colorectal cancer metastasis. EBioMedicine, 2019, 46, 79-93.	2.7	13
3120	CRISPR-Cas9â€“mediated gene knockout in intestinal tumor organoids provides functional validation for colorectal cancer driver genes. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15635-15644.	3.3	100
3121	Cancer driver gene discovery in transcriptional regulatory networks using influence maximization approach. Computers in Biology and Medicine, 2019, 114, 103362.	3.9	13
3122	Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nature Communications, 2019, 10, 2978.	5.8	91
3123	Metagenomics and transcriptomics data from human colorectal cancer. Scientific Data, 2019, 6, 116.	2.4	7
3124	Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. Cancer Cell, 2019, 36, 35-50.e9.	7.7	179
3125	Methylated SEPTIN9 plasma test for colorectal cancer detection may be applicable to Lynch syndrome. BMJ Open Gastroenterology, 2019, 6, e000299.	1.1	9

#	Article	IF	Citations
3126	A systematic approach to orient the human proteinâ€"protein interaction network. Nature Communications, 2019, 10, 3015.	5.8	39
3127	Î²-Catenin/TCF4 Complex-Mediated Induction of the NRF3 (NFE2L3) Gene in Cancer Cells. International Journal of Molecular Sciences, 2019, 20, 3344.	1.8	25
3128	Prognostic value of DLGAP5 in colorectal cancer. International Journal of Colorectal Disease, 2019, 34, 1455-1465.	1.0	32
3129	Anti-apoptotic effect by the suppression of IRF1 as a downstream of Wnt/Î²-catenin signaling in colorectal cancer cells. Oncogene, 2019, 38, 6051-6064.	2.6	26
3130	Reproduction of molecular subtypes of gastric adenocarcinoma by transcriptome sequencing of archival tissue. Scientific Reports, 2019, 9, 9675.	1.6	7
3131	Colorectal cancer mutations are associated with survival and recurrence after pulmonary metastasectomy. Journal of Surgical Oncology, 2019, 120, 729-735.	0.8	20
3132	Genomeâ€wide DNA methylation analysis of colorectal adenomas with and without recurrence reveals an association between cytosineâ€phosphateâ€guanine methylation and histological subtypes. Genes Chromosomes and Cancer, 2019, 58, 783-797.	1.5	26
3133	Integration and Analysis of CPTAC Proteomics Data in the Context of Cancer Genomics in the cBioPortal. Molecular and Cellular Proteomics, 2019, 18, 1893-1898.	2.5	106
3134	Oncogenic MYC Induces the Impaired Ribosome Biogenesis Checkpoint and Stabilizes p53 Independent of Increased Ribosome Content. Cancer Research, 2019, 79, 4348-4359.	0.4	24
3135	L1TD1 - a prognostic marker for colon cancer. BMC Cancer, 2019, 19, 727.	1.1	11
3136	Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis. Cell, 2019, 178, 714-730.e22.	13.5	806
3137	Synergistic Inhibition of Kinase Pathways Overcomes Resistance of Colorectal Cancer Spheroids to Cyclic Targeted Therapies. ACS Pharmacology and Translational Science, 2019, 2, 275-284.	2.5	9
3138	Genetic Aberration Analysis in Thai Colorectal Adenoma and Early-Stage Adenocarcinoma Patients by Whole-Exome Sequencing. Cancers, 2019, 11, 977.	1.7	10
3139	Uncovering Potential Therapeutic Targets in Colorectal Cancer by Deciphering Mutational Status and Expression of Druggable Oncogenes. Cancers, 2019, 11, 983.	1.7	14
3140	Deep single-cell RNA sequencing data of individual T cells from treatment-naÃ¯ve colorectal cancer patients. Scientific Data, 2019, 6, 131.	2.4	49
3141	BRAF Mutation and Its Importance in Colorectal Cancer. , 0, , .		11
3142	Distinct Colorectal Cancerâ€"Associated APC Mutations Dictate Response to Tankyrase Inhibition. Cancer Discovery, 2019, 9, 1358-1371.	7.7	54
3143	Cimp-Positive Status is More Representative in Multiple Colorectal Cancers than in Unique Primary Colorectal Cancers. Scientific Reports, 2019, 9, 10516.	1.6	17

#	Article	IF	Citations
3144	Correlation between circulating endothelial progenitor cells and serum carcinoembryonic antigen level in colorectal cancer. Acta Biochimica Et Biophysica Sinica, 2019, 51, 1304-1304.	0.9	1
3145	Stromal iodothyronine deiodinase 2 (<scp>DIO</scp>2) promotes the growth of intestinal tumors in <i>Apc</i>^{Î”716} mutant mice. Cancer Science, 2019, 110, 2520-2528.	1.7	17
3146	Systematic analysis of the intersection of disease mutations with protein modifications. BMC Medical Genomics, 2019, 12, 109.	0.7	16
3147	Intestinal PPARÎ± Protects Against Colon Carcinogenesis via Regulation of Methyltransferases DNMT1 and PRMT6. Gastroenterology, 2019, 157, 744-759.e4.	0.6	111
3148	Serum PlGF and EGF are independent prognostic markers in non-metastatic colorectal cancer. Scientific Reports, 2019, 9, 10921.	1.6	7
3149	Salinomycin exerts antiâ€colorectal cancer activity by targeting the Î²â€catenin/Tâ€cell factor complex. British Journal of Pharmacology, 2019, 176, 3390-3406.	2.7	30
3150	Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer. Clinical Cancer Research, 2019, 25, 5852-5858.	3.2	116
3151	Oncogenic Pathways and Loss of the Rab11 GTPase Synergize To Alter Metabolism in Drosophila. Genetics, 2019, 212, 1227-1239.	1.2	12
3152	Genomics and metagenomics of colorectal cancer. Journal of Gastrointestinal Oncology, 2019, 10, 1164-1170.	0.6	28
3153	Intercellular Transfer of Oncogenic KRAS via Tunneling Nanotubes Introduces Intracellular Mutational Heterogeneity in Colon Cancer Cells. Cancers, 2019, 11, 892.	1.7	43
3154	Dual Regulatory Mechanisms of Expression and Mutation Involving Metabolism-Related Genes FDFT1 and UQCR5 during CLM. Molecular Therapy - Oncolytics, 2019, 14, 172-178.	2.0	17
3155	Evolving neoantigen profiles in colorectal cancers with DNA repair defects. Genome Medicine, 2019, 11, 42.	3.6	42
3156	Comprehensive elaboration of database resources utilized in next-generation sequencing-based tumor somatic mutation detection. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1872, 122-137.	3.3	5
3157	Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies. Clinical Cancer Research, 2019, 25, 6899-6908.	3.2	76
3158	The Role of Wnt and R-spondin in the Stomach During Health and Disease. Biomedicines, 2019, 7, 44.	1.4	22
3159	Circulating miRâ€'141â€'3p, miRâ€'143â€'3p and miRâ€'200câ€'3p are differentially expressed in colorectal cancer and advanced adenomas. Molecular and Clinical Oncology, 2019, 11, 201-207.	0.4	28
3160	Associations Between Loss of ARID1A Expression and Clinicopathologic and Genetic Variables in T1 Early Colorectal Cancer. American Journal of Clinical Pathology, 2019, 152, 463-470.	0.4	14
3161	DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. Clinical Cancer Research, 2019, 25, 5608-5622.	3.2	17

#	Article	IF	Citations
3162	Genomic data analysis workflows for tumors from patient-derived xenografts (PDXs): challenges and guidelines. BMC Medical Genomics, 2019, 12, 92.	0.7	29
3163	Mutational burden and signatures in 4000 Japanese cancers provide insights into tumorigenesis and response to therapy. Cancer Science, 2019, 110, 2620-2628.	1.7	27
3164	Mutational profiling and immunohistochemical analysis of a surgical series of ampullary carcinomas. Journal of Clinical Pathology, 2019, 72, 762-770.	1.0	11
3165	ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal Cancer. Cells, 2019, 8, 678.	1.8	73
3166	Expression and Clinical Relevance of SOX9 in Gastric Cancer. Disease Markers, 2019, 2019, 1-11.	0.6	18
3167	Is the Mirror Image Method Really Useful in Tumor Tissue Bank Quality Control?. Biopreservation and Biobanking, 2019, 17, 539-545.	0.5	0
3168	Microsatellite Instability assessment in Black South African Colorectal Cancer patients reveal an increased incidence of suspected Lynch syndrome. Scientific Reports, 2019, 9, 15019.	1.6	5
3169	Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab. Expert Opinion on Biological Therapy, 2019, 19, 1247-1263.	1.4	29
3170	Synergistic Anti-Tumor Effect of mTOR Inhibitors with Irinotecan on Colon Cancer Cells. Cancers, 2019, 11, 1581.	1.7	26
3171	Insulin-Like Growth Factor 2 (IGF2) Signaling in Colorectal Cancerâ€"from Basic Research to Potential Clinical Applications. International Journal of Molecular Sciences, 2019, 20, 4915.	1.8	49
3172	Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer. BMC Cancer, 2019, 19, 964.	1.1	20
3173	The critical role of calcineurin/NFAT (C/N) pathways and effective antitumor prospect for colorectal cancers. Journal of Cellular Biochemistry, 2019, 120, 19254-19273.	1.2	11
3174	Variations in AXIN2 predict risk and prognosis of colorectal cancer. BDJ Open, 2019, 5, 13.	0.8	20
3175	Cancer classification of single-cell gene expression data by neural network. Bioinformatics, 2020, 36, 1360-1366.	1.8	39
3176	Integrated Biobanking and Tumor Model Establishment of Human Colorectal Carcinoma Provides Excellent Tools for Preclinical Research. Cancers, 2019, 11, 1520.	1.7	31
3177	Machine Learning in Biology and Medicine. Advances in Molecular Pathology, 2019, 2, 143-152.	0.2	13
3178	Somatic substitution signature as an innovative tool in lung cancer diagnosis. Scientific Reports, 2019, 9, 14561.	1.6	2
3179	Unraveling the role of peroxisome proliferator-activated receptor-Î²/Î´ (PPARÎ²/Î´) expression in colon carcinogenesis. Npj Precision Oncology, 2019, 3, 26.	2.3	8

#	Article	IF	Citations
3180	GLTSCR1 Negatively Regulates BRD4â€Dependent Transcription Elongation and Inhibits CRC Metastasis. Advanced Science, 2019, 6, 1901114.	5.6	14
3181	Dickkopfâ€4 gene expression is associated with differentiation and lymph node metastasis in colorectal cancer. JGH Open, 2019, 3, 409-416.	0.7	2
3182	Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution. Critical Reviews in Oncology/Hematology, 2019, 143, 153-163.	2.0	49
3183	Joyce and the Law. Ed. by Jonathan Goldman. Forum for Modern Language Studies, 2019, 55, 246-246.	0.2	1
3184	Is microsatellite instability-high really a favorable prognostic factor for advanced colorectal cancer? A meta-analysis. World Journal of Surgical Oncology, 2019, 17, 169.	0.8	25
3185	Lynch syndromeâ€"associated ultra-hypermutated pediatric glioblastoma mimicking a constitutional mismatch repair deficiency syndrome. Journal of Physical Education and Sports Management, 2019, 5, a003863.	0.5	21
3186	Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease. Journal of Physical Education and Sports Management, 2019, 5, a004408.	0.5	34
3187	A hierarchical integration deep flexible neural forest framework for cancer subtype classification by integrating multi-omics data. BMC Bioinformatics, 2019, 20, 527.	1.2	69
3188	BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights. International Journal of Molecular Sciences, 2019, 20, 5369.	1.8	88
3189	Hypoxiaâ€induced HIFâ€1Î± and ZEB1 are critical for the malignant transformation of ameloblastoma via TGFâ€Î²â€dependent EMT. Cancer Medicine, 2019, 8, 7822-7832.	1.3	41
3192	VEGF-A drives TOX-dependent T cell exhaustion in antiâ€"PD-1â€"resistant microsatellite stable colorectal cancers. Science Immunology, 2019, 4, .	5.6	148
3193	Enhancer of Zeste Homolog 2 in Colorectal Cancer Development and Progression. Digestion, 2021, 102, 227-235.	1.2	19
3194	KH-Type Splicing Regulatory Protein Controls Colorectal Cancer Cell Growth and Modulates the Tumor Microenvironment. American Journal of Pathology, 2019, 189, 1916-1932.	1.9	8
3195	Wnt Signaling in the Regulation of Immune Cell and Cancer Therapeutics. Cells, 2019, 8, 1380.	1.8	76
3196	NFE2L3 Controls Colon Cancer Cell Growth through Regulation of DUX4, a CDK1 Inhibitor. Cell Reports, 2019, 29, 1469-1481.e9.	2.9	62
3197	Drug Design Targeting T-Cell Factor-Driven Epithelialâ€"Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer. Journal of Medicinal Chemistry, 2019, 62, 10182-10203.	2.9	12
3198	Telomere Length Maintenance and Its Transcriptional Regulation in Lynch Syndrome and Sporadic Colorectal Carcinoma. Frontiers in Oncology, 2019, 9, 1172.	1.3	46
3199	The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications. European Journal of Cancer, 2019, 123, 118-129.	1.3	50

#	Article	IF	Citations
3200	A MYCâ€“GCN2â€“eIF2Î± negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer. Nature Cell Biology, 2019, 21, 1413-1424.	4.6	65
3201	PRODIGY: personalized prioritization of driver genes. Bioinformatics, 2020, 36, 1831-1839.	1.8	32
3202	Uncovering the subtype-specific temporal order of cancer pathway dysregulation. PLoS Computational Biology, 2019, 15, e1007451.	1.5	6
3203	Lower LINE-1 methylation is associated with promoter hypermethylation and distinct molecular features in gastric cancer. Epigenomics, 2019, 11, 1651-1659.	1.0	4
3204	RBP7 is a clinically prognostic biomarker and linked to tumor invasion and EMT in colon cancer. Journal of Cancer, 2019, 10, 4883-4891.	1.2	20
3205	Genome landscapes of rectal cancer before and after preoperative chemoradiotherapy. Theranostics, 2019, 9, 6856-6866.	4.6	27
3206	Loss of ARID1A expression is associated with DNA mismatch repair protein deficiency and favorable prognosis in advanced stage surgically resected esophageal adenocarcinoma. Human Pathology, 2019, 94, 1-10.	1.1	6
3207	Serrated Colorectal Cancer: The Road Less Travelled?. Trends in Cancer, 2019, 5, 742-754.	3.8	32
3208	Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma. Frontiers in Genetics, 2019, 10, 986.	1.1	22
3209	RBBP6, a RING finger-domain E3 ubiquitin ligase, induces epithelialâ€“mesenchymal transition and promotes metastasis of colorectal cancer. Cell Death and Disease, 2019, 10, 833.	2.7	29
3210	Genome-wide expression profiling in colorectal cancer focusing on lncRNAs in the adenoma-carcinoma transition. BMC Cancer, 2019, 19, 1059.	1.1	36
3211	DNA repair capacity and response to treatment of colon cancer. Pharmacogenomics, 2019, 20, 1225-1233.	0.6	11
3212	Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients. Scientific Reports, 2019, 9, 16894.	1.6	8
3213	PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target. Cancers, 2019, 11, 1765.	1.7	54
3214	Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells. Neoplasia, 2019, 21, 1110-1120.	2.3	40
3215	Clonal selection confers distinct evolutionary trajectories in BRAF-driven cancers. Nature Communications, 2019, 10, 5143.	5.8	15
3216	Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients. Scientific Reports, 2019, 9, 15365.	1.6	54
3217	Hypermethylation Of ADHFE1 Promotes The Proliferation Of Colorectal Cancer Cell Via Modulating Cell Cycle Progression . OncoTargets and Therapy, 2019, Volume 12, 8105-8115.	1.0	19

#	Article	IF	Citations
3218	Downregulation of Wnt3 Suppresses Colorectal Cancer Development Through Inhibiting Cell Proliferation and Migration. Frontiers in Pharmacology, 2019, 10, 1110.	1.6	23
3219	Genomic-Destabilization-Associated Mutagenesis and Clonal Evolution of Cells with Mutations in Tumor-Suppressor Genes. Cancers, 2019, 11, 1643.	1.7	12
3220	Identification of a novel large EPCAM-MSH2 duplication, concurrently with LOHs in chromosome 20 and X, in a family with Lynch syndrome. International Journal of Colorectal Disease, 2019, 34, 1999-2002.	1.0	0
3221	Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis and therapeutics. Human Pathology, 2019, 94, 58-63.	1.1	6
3222	Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden. Lung Cancer, 2019, 138, 35-42.	0.9	53
3223	The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab. Biomolecules, 2019, 9, 629.	1.8	10
3224	Diagnostic and Prognostic Value of B4GALT1 Hypermethylation and Its Clinical Significance as a Novel Circulating Cell-Free DNA Biomarker in Colorectal Cancer. Cancers, 2019, 11, 1598.	1.7	35
3225	Dockingâ€based approach for identification of mutations that disrupt binding between Bclâ€2 and Bax proteins: Inducing apoptosis in cancer cells. Molecular Genetics & Genomic Medicine, 2019, 7, e910.	0.6	30
3226	Colorectal cancer. Lancet, The, 2019, 394, 1467-1480.	6.3	2,462
3227	Recent advances in Lynch syndrome. Familial Cancer, 2019, 18, 211-219.	0.9	70
3228	lncRNA SNHG6 regulates EZH2 expression by sponging miR-26a/b and miR-214 in colorectal cancer. Journal of Hematology and Oncology, 2019, 12, 3.	6.9	175
3229	Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 713-732.	8.2	1,399
3230	Targeting c-MYC through Interference with NAMPT and SIRT1 and Their Association to Oncogenic Drivers in Murine Serrated Intestinal Tumorigenesis. Neoplasia, 2019, 21, 974-988.	2.3	9
3231	Advances in Molecular Subclassification of Colorectal Cancer. , 2019, , .		0
3232	Comprehensive characterization of circular RNAs in ~â€‰1000 human cancer cell lines. Genome Medicine, 2019, 11, 55.	3.6	116
3233	Capture and Detection of Circulating Glioma Cells Using the Recombinant VAR2CSA Malaria Protein. Cells, 2019, 8, 998.	1.8	49
3234	Replication stress triggers microsatellite destabilization and hypermutation leading to clonal expansion in vitro. Nature Communications, 2019, 10, 3925.	5.8	36
3235	Comprehensive intra-individual genomic and transcriptional heterogeneity: Evidence-based Colorectal Cancer Precision Medicine. Cancer Treatment Reviews, 2019, 80, 101894.	3.4	37

#	Article	IF	Citations
3236	Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction. Immunity, 2019, 51, 766-779.e17.	6.6	187
3237	Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer. BMC Cancer, 2019, 19, 880.	1.1	13
3238	WNT5B governs the phenotype of basal-like breast cancer by activating WNT signaling. Cell Communication and Signaling, 2019, 17, 109.	2.7	45
3239	Estrogen receptor 1 mutations in 260 cervical cancer samples from Chinese patients. Oncology Letters, 2019, 18, 2771-2776.	0.8	4
3240	The molecular origin and taxonomy of mucinous ovarian carcinoma. Nature Communications, 2019, 10, 3935.	5.8	110
3241	Transcriptome analyses of tumor-adjacent somatic tissues reveal genes co-expressed with transposable elements. Mobile DNA, 2019, 10, 39.	1.3	21
3242	Identification of Transcriptional Markers and microRNAâ€"mRNA Regulatory Networks in Colon Cancer by Integrative Analysis of mRNA and microRNA Expression Profiles in Colon Tumor Stroma. Cells, 2019, 8, 1054.	1.8	29
3243	An aggregon in conductin/axin2 regulates Wnt/Î²-catenin signaling and holds potential for cancer therapy. Nature Communications, 2019, 10, 4251.	5.8	22
3244	Digitaldlsorter: Deep-Learning on scRNA-Seq to Deconvolute Gene Expression Data. Frontiers in Genetics, 2019, 10, 978.	1.1	22
3245	Knockdown of long non-coding RNA TINCR decreases radioresistance in colorectal cancer cells. Pathology Research and Practice, 2019, 215, 152622.	1.0	13
3246	Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis. Cancer Cell, 2019, 36, 319-336.e7.	7.7	278
3247	Proteogenomic Network Analysis of Context-Specific KRAS Signaling in Mouse-to-Human Cross-Species Translation. Cell Systems, 2019, 9, 258-270.e6.	2.9	44
3248	Rectal cancer sub-clones respond differentially to neoadjuvant therapy. Neoplasia, 2019, 21, 1051-1062.	2.3	21
3249	Discovery of Aberrant Alteration of Genome in Colorectal Cancer by Exome Sequencing. American Journal of the Medical Sciences, 2019, 358, 340-349.	0.4	18
3250	An Efficient and Flexible Method for Deconvoluting Bulk RNA-Seq Data with Single-Cell RNA-Seq Data. Cells, 2019, 8, 1161.	1.8	17
3251	Mutation profiling of cancer drivers in Brazilian colorectal cancer. Scientific Reports, 2019, 9, 13687.	1.6	31
3252	Purine-Metabolising Enzymes and Apoptosis in Cancer. Cancers, 2019, 11, 1354.	1.7	54
3253	Matched Whole-Genome Sequencing (WGS) and Whole-Exome Sequencing (WES) of Tumor Tissue with Circulating Tumor DNA (ctDNA) Analysis: Complementary Modalities in Clinical Practice. Cancers, 2019, 11, 1399.	1.7	27

#	Article	IF	Citations
3254	WiNTRLINC1/ASCL2/c-Myc Axis Characteristics of Colon Cancer with Differentiated Histology at Young Onset and Essential for Cell Viability. Annals of Surgical Oncology, 2019, 26, 4826-4834.	0.7	6
3255	The Effects of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancerâ€"The Impact in Intratumoral Heterogeneity. Frontiers in Oncology, 2019, 9, 974.	1.3	20
3256	A prognostic index based on an eleven gene signature to predict systemic recurrences in colorectal cancer. Experimental and Molecular Medicine, 2019, 51, 1-12.	3.2	21
3257	RPL22L1 induction in colorectal cancer is associated with poor prognosis and 5-FU resistance. PLoS ONE, 2019, 14, e0222392.	1.1	19
3258	Prognostic significance of primary tumor sidedness in patients undergoing liver resection for metastatic colorectal cancer. Hpb, 2019, 21, 1667-1675.	0.1	7
3259	A systems mechanism for KRAS mutant alleleâ€"specific responses to targeted therapy. Science Signaling, 2019, 12, .	1.6	42
3260	Complete and Prolonged Response to Immune Checkpoint Blockade in <i>POLE</i>-Mutated Colorectal Cancer. JCO Precision Oncology, 2019, 3, 1-5.	1.5	20
3261	Cancer-Specific Thresholds Adjust for Whole Exome Sequencingâ€"Based Tumor Mutational Burden Distribution. JCO Precision Oncology, 2019, 3, 1-12.	1.5	21
3262	DLIC 1 , but not DLIC 2 , is upregulated in colon cancer and this contributes to proliferative overgrowth and migratory characteristics of cancer cells. FEBS Journal, 2019, 286, 803-820.	2.2	8
3263	Unstable Genome and Transcriptome Dynamics during Tumor Metastasis Contribute to Therapeutic Heterogeneity in Colorectal Cancers. Clinical Cancer Research, 2019, 25, 2821-2834.	3.2	12
3264	Serine Threonine Kinase 17A Maintains the Epithelial State in Colorectal Cancer Cells. Molecular Cancer Research, 2019, 17, 882-894.	1.5	10
3265	Blood vessel epicardial substance reduces LRP6 receptor and cytoplasmic Î²-catenin levels to modulate Wnt signaling and intestinal homeostasis. Carcinogenesis, 2019, 40, 1086-1098.	1.3	11
3266	A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer. Cancers, 2019, 11, 147.	1.7	15
3267	Outcome of chemotherapy with or without targeted agents in metastatic colorectal cancer patients with deficient DNA mismatch repair: A single center, cohort study. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 128-135.	0.7	4
3268	Back to the Colorectal Cancer Consensus Molecular Subtype Future. Current Gastroenterology Reports, 2019, 21, 5.	1.1	50
3269	The lysineâ€specific methyltransferase <scp>KMT</scp> 2C/ <scp>MLL</scp> 3 regulates <scp>DNA</scp> repair components in cancer. EMBO Reports, 2019, 20, .	2.0	93
3270	Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy. Annals of Oncology, 2019, 30, 439-446.	0.6	18
3271	KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib. Bioscience Reports, 2019, 39, .	1.1	6

#	Article	IF	Citations
3272	Predicting survival from colorectal cancer histology slides using deep learning: A retrospective multicenter study. PLoS Medicine, 2019, 16, e1002730.	3.9	563
3273	Identification of key genes and pathways involved in microsatellite instability in colorectal cancer. Molecular Medicine Reports, 2019, 19, 2065-2076.	1.1	25
3274	Landscape of Big Medical Data: A Pragmatic Survey on Prioritized Tasks. IEEE Access, 2019, 7, 15590-15611.	2.6	2
3275	Treatment sequencing in metastatic colorectal cancer. European Journal of Cancer, 2019, 109, 70-83.	1.3	215
3276	Colorectal Cancer in Young Adults. Current Treatment Options in Gastroenterology, 2019, 17, 89-98.	0.3	38
3277	Structural consequence of the most frequently recurring cancer-associated substitution in DNA polymerase Îµ. Nature Communications, 2019, 10, 373.	5.8	40
3278	Development of somatic mutation signatures for risk stratification and prognosis in lung and colorectal adenocarcinomas. BMC Medical Genomics, 2019, 12, 24.	0.7	9
3279	Exploiting <scp>DNA</scp> repair defects in colorectal cancer. Molecular Oncology, 2019, 13, 681-700.	2.1	90
3280	Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasia. Human Pathology, 2019, 87, 103-114.	1.1	18
3281	Predicting responses to platin chemotherapy agents with biochemically-inspired machine learning. Signal Transduction and Targeted Therapy, 2019, 4, 1.	7.1	202
3282	Somatic mutational signatures in polyposis and colorectal cancer. Molecular Aspects of Medicine, 2019, 69, 62-72.	2.7	14
3283	Targeted next generation sequencing reveals a common genetic pathway for colorectal cancers with chromosomal instability and those with microsatellite and chromosome stability. Pathology Research and Practice, 2019, 215, 152445.	1.0	3
3284	Scarcity of Recurrent Regulatory Driver Mutations in Colorectal Cancer Revealed by Targeted Deep Sequencing. JNCI Cancer Spectrum, 2019, 3, pkz012.	1.4	2
3285	Loss of PTPN4 activates STAT3 to promote the tumor growth in rectal cancer. Cancer Science, 2019, 110, 2258-2272.	1.7	18
3286	Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma. American Journal of Clinical Pathology, 2019, 152, 97-108.	0.4	36
3287	Bacterial biofilms as a potential contributor to mucinous colorectal cancer formation. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1872, 74-79.	3.3	35
3288	Role of Microbiome in Modulating Immune Responses in Cancer. Mediators of Inflammation, 2019, 2019, 1-7.	1.4	25
3289	CHASMplus Reveals the Scope of Somatic Missense Mutations Driving Human Cancers. Cell Systems, 2019, 9, 9-23.e8.	2.9	83

#	Article	IF	Citations
3290	Quantitative evidence for early metastatic seeding in colorectal cancer. Nature Genetics, 2019, 51, 1113-1122.	9.4	315
3291	Targeted Gene Sequencing Panels: Applicability for Neoantigen Profiling of Colon and Rectal Adenocarcinoma. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2019, 13, 146-153.	0.2	1
3292	Immunohistochemical expression of mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) in prostate cancer: correlation with grade groups (WHO 2016) and ERG and PTEN status. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 223-231.	1.4	18
3293	InÂvivo effects of chemotherapy on oncogenic pathways in colorectal cancer. Cancer Science, 2019, 110, 2529-2539.	1.7	13
3294	Establishment and characterization of a novel cell line (ccâ€'006cpm8) of moderately/poorly differentiated colorectal adenocarcinoma derived from a primary tumor of a patient. International Journal of Oncology, 2019, 55, 243-256.	1.4	1
3295	Effects of somatic alterations at pathway level are more mechanismâ€explanatory and clinically applicable to quantity of liver metastases of colorectal cancer. Cancer Medicine, 2019, 8, 4732-4742.	1.3	1
3296	Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repairâ€"Deficient Colorectal Cancer. Cancer Immunology Research, 2019, 7, 1230-1236.	1.6	59
3297	V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer. Cancer Discovery, 2019, 9, 1182-1191.	7.7	27
3298	BioTarget: A Computational Framework Identifying Cancer Type Specific Transcriptional Targets of Immune Response Pathways. Scientific Reports, 2019, 9, 9029.	1.6	7
3299	Identification of a Novel Fusion Gene, FAM174A-WWC1, in Early-Onset Colorectal Cancer: Establishment and Characterization of Four Human Cancer Cell Lines from Early-Onset Colorectal Cancers. Translational Oncology, 2019, 12, 1185-1195.	1.7	5
3300	Multi-omics Characterization of Interaction-mediated Control of Human Protein Abundance levels. Molecular and Cellular Proteomics, 2019, 18, S114-S125.	2.5	16
3301	Clinicopathological and mutational analyses of colorectal cancer with mutations in the <i>POLE</i> gene. Cancer Medicine, 2019, 8, 4587-4597.	1.3	23
3303	From parts to mechanisms: research heuristics for addressing heterogeneity in cancer genetics. History and Philosophy of the Life Sciences, 2019, 41, 27.	0.6	3
3304	Circulating Tumor DNA Analysis: Clinical Implications for Colorectal Cancer Patients. A Systematic Review. JNCI Cancer Spectrum, 2019, 3, pkz042.	1.4	22
3305	Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication. Journal of Clinical Medicine, 2019, 8, 903.	1.0	13
3306	RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues. Science, 2019, 364, .	6.0	369
3307	LncRNA H19 regulates PI3Kâ€"Akt signal pathway by functioning as a ceRNA and predicts poor prognosis in colorectal cancer: integrative analysis of dysregulated ncRNA-associated ceRNA network. Cancer Cell International, 2019, 19, 148.	1.8	60
3308	Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing. Journal of Translational Medicine, 2019, 17, 189.	1.8	80

#	Article	IF	Citations
3309	Study of Promoter Methylation Patterns of HOXA2, HOXA5, and HOXA6 and Its Clinicopathological Characteristics in Colorectal Cancer. Frontiers in Oncology, 2019, 9, 394.	1.3	29
3310	Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic Response. Frontiers in Genetics, 2019, 10, 470.	1.1	29
3311	ResMarkerDB: a database of biomarkers of response to antibody therapy in breast and colorectal cancer. Database: the Journal of Biological Databases and Curation, 2019, 2019, .	1.4	10
3312	<scp>RASSF</scp> 1A is required for the maintenance of nuclear actin levels. EMBO Journal, 2019, 38, e101168.	3.5	37
3313	Dissecting the Dual Nature of Hyaluronan in the Tumor Microenvironment. Frontiers in Immunology, 2019, 10, 947.	2.2	111
3314	Molecular characterization of colorectal cancer using wholeâ€exome sequencing in a Taiwanese population. Cancer Medicine, 2019, 8, 3738-3747.	1.3	18
3315	Identifying Epistasis in Cancer Genomes: A Delicate Affair. Cell, 2019, 177, 1375-1383.	13.5	81
3316	Trp53 null and R270H mutant alleles have comparable effects in regulating invasion, metastasis, and gene expression in mouse colon tumorigenesis. Laboratory Investigation, 2019, 99, 1454-1469.	1.7	18
3318	Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer. Cancer Letters, 2019, 459, 41-49.	3.2	35
3319	Development and validation of a prognostic nomogram for early-onset colon cancer. Bioscience Reports, 2019, 39, .	1.1	16
3320	Targeted mutational analysis of inflammatory bowel diseaseâ€“associated colorectal cancers. Human Pathology, 2019, 89, 44-50.	1.1	21
3321	Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nature Medicine, 2019, 25, 1054-1056.	15.2	773
3322	Primary tumour location affects survival after resection of colorectal liver metastases: A two-institutional cohort study with international validation, systematic meta-analysis and a clinical risk score. PLoS ONE, 2019, 14, e0217411.	1.1	36
3323	Solid Tumors Challenges and New Insights of CAR T Cell Engineering. Stem Cell Reviews and Reports, 2019, 15, 619-636.	1.7	71
3324	Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy. Molecular Aspects of Medicine, 2019, 69, 123-129.	2.7	30
3325	Clinicopathological features, diagnosis, and treatment of sessile serrated adenoma/polyp with dysplasia/carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1685-1695.	1.4	28
3326	Circulating biomarkers for early detection and clinical management of colorectal cancer. Molecular Aspects of Medicine, 2019, 69, 107-122.	2.7	214
3327	Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer. British Journal of Surgery, 2019, 106, 1381-1392.	0.1	40

#	Article	IF	Citations
3328	Colorectal Cancer Research: A State of theÂArt. Hot Topics in Acute Care Surgery and Trauma, 2019, , 1-13.	0.1	1
3329	A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer. Science Advances, 2019, 5, eaav6528.	4.7	74
3330	Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy. BMC Cancer, 2019, 19, 421.	1.1	2
3331	UHRF1 depletion and HDAC inhibition reactivate epigenetically silenced genes in colorectal cancer cells. Clinical Epigenetics, 2019, 11, 70.	1.8	27
3332	DNA methylation of shelf, shore and open sea CpG positions distinguish high microsatellite instability from low or stable microsatellite status colon cancer stem cells. Epigenomics, 2019, 11, 587-604.	1.0	29
3333	Molecular classification of colorectal cancer using the gene expression profile of tumor samples. Experimental Biology and Medicine, 2019, 244, 1005-1016.	1.1	5
3334	Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer. Oncogenesis, 2019, 8, 35.	2.1	19
3335	BRIP-1 germline mutation and its role in colon cancer: presentation of two case reports and review of literature. BMC Medical Genetics, 2019, 20, 75.	2.1	21
3336	Emerging Roles of C-Myc in Cancer Stem Cell-Related Signaling and Resistance to Cancer Chemotherapy: A Potential Therapeutic Target Against Colorectal Cancer. International Journal of Molecular Sciences, 2019, 20, 2340.	1.8	165
3337	MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer. Nature Communications, 2019, 10, 2197.	5.8	126
3338	Genetics of rectal cancer and novel therapies: primer for radiologists. Abdominal Radiology, 2019, 44, 3743-3750.	1.0	10
3340	Stemness underpinning all steps of human colorectal cancer defines the core of effective therapeutic strategies. EBioMedicine, 2019, 44, 346-360.	2.7	11
3341	Development of an MSI-positive colon tumor with aberrant DNA methylation in a PPAP patient. Journal of Human Genetics, 2019, 64, 729-740.	1.1	7
3342	Magnetic Resonance Imaging Is More Sensitive Than PET for Detecting Treatment-Induced Cell Deathâ€"Dependent Changes in Glycolysis. Cancer Research, 2019, 79, 3557-3569.	0.4	36
3343	F-Box/WD Repeat Domain-Containing 7 Induces Chemotherapy Resistance in Colorectal Cancer Stem Cells. Cancers, 2019, 11, 635.	1.7	4
3344	Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer. Prostaglandins and Other Lipid Mediators, 2019, 144, 106338.	1.0	79
3345	Accurate differential analysis of transcription factor activity from gene expression. Bioinformatics, 2019, 35, 5018-5029.	1.8	3
3346	A Short SOX9 Peptide Mimics SOX9 Tumor Suppressor Activity and Is Sufficient to Inhibit Colon Cancer Cell Growth. Molecular Cancer Therapeutics, 2019, 18, 1386-1395.	1.9	10

#	Article	IF	Citations
3347	Genomic Profiling of the Steroidogenic Acute Regulatory Protein in Breast Cancer: In Silico Assessments and a Mechanistic Perspective. Cancers, 2019, 11, 623.	1.7	10
3348	National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer. Cancer, 2019, 125, 2732-2746.	2.0	19
3349	Integrative Genome-Scale DNA Methylation Analysis of a Large and Unselected Cohort Reveals 5 Distinct Subtypes of Colorectal Adenocarcinomas. Cellular and Molecular Gastroenterology and Hepatology, 2019, 8, 269-290.	2.3	42
3350	Metabolic profiling of cancer cells reveals genome-wide crosstalk between transcriptional regulators and metabolism. Nature Communications, 2019, 10, 1841.	5.8	108
3351	Development and validation of an immune-related gene pairs signature in colorectal cancer. OncoImmunology, 2019, 8, e1596715.	2.1	70
3352	Epigeneticâ€based therapy for colorectal cancer: Prospect and involved mechanisms. Journal of Cellular Physiology, 2019, 234, 19366-19383.	2.0	12
3353	Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities. Cell, 2019, 177, 1035-1049.e19.	13.5	498
3354	ZFR promotes cell proliferation and tumor development in colorectal and liver cancers. Biochemical and Biophysical Research Communications, 2019, 513, 1027-1034.	1.0	9
3355	Parsimonious Gene Correlation Network Analysis (PGCNA): a tool to define modular gene co-expression for refined molecular stratification in cancer. Npj Systems Biology and Applications, 2019, 5, 13.	1.4	22
3356	Gene Expression Signature in Surgical Tissues and Endoscopic Biopsies Identifies High-Risk T1 Colorectal Cancers. Gastroenterology, 2019, 156, 2338-2341.e3.	0.6	37
3357	A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer. Clinical Cancer Research, 2019, 25, 4431-4442.	3.2	40
3358	Genomeâ€wide expression profilingâ€based copy number variations and colorectal cancer risk in Chinese. Molecular Carcinogenesis, 2019, 58, 1324-1333.	1.3	4
3359	State of the Art and Future Direction for the Analysis of Cell-Free Circulating DNA. , 2019, , 133-188.		2
3360	Mutation analysis of POLE gene in patients with early-onset colorectal cancer revealed a rare silent variant within the endonuclease domain with potential effect on splicing. Clinical and Experimental Medicine, 2019, 19, 393-400.	1.9	9
3361	Ongoing chromosomal instability and karyotype evolution in human colorectal cancer organoids. Nature Genetics, 2019, 51, 824-834.	9.4	162
3362	Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival. JCO Precision Oncology, 2019, 3, 1-16.	1.5	30
3363	High-Dimensional Data Approaches to Understanding Nuclear Hormone Receptor Signaling. Methods in Molecular Biology, 2019, 1966, 291-311.	0.4	1
3364	APC/C Ubiquitin Ligase: Coupling Cellular Differentiation to G1/G0 Phase in Multicellular Systems. Trends in Cell Biology, 2019, 29, 591-603.	3.6	17

#	Article	IF	Citations
3365	CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. , 2019, 7, 101.		65
3366	Engineering Multidimensional Evolutionary Forces to Combat Cancer. Cancer Discovery, 2019, 9, 587-604.	7.7	13
3367	Genes CEP55, FOXD3, FOXF2, GNAO1, GRIA4, and KCNA5 as potential diagnostic biomarkers in colorectal cancer. BMC Medical Genomics, 2019, 12, 54.	0.7	39
3368	Passenger mutations accurately classify human tumors. PLoS Computational Biology, 2019, 15, e1006953.	1.5	39
3369	Implication of DNA repair genes in Lynch-like syndrome. Familial Cancer, 2019, 18, 331-342.	0.9	25
3370	Differentially mutated subnetworks discovery. Algorithms for Molecular Biology, 2019, 14, 10.	0.3	7
3371	Selecting treatment options in refractory metastatic colorectal cancer . OncoTargets and Therapy, 2019, Volume 12, 2271-2278.	1.0	20
3372	Repurposing EGFR Inhibitor Utility in Colorectal Cancer in Mutant <i>APC</i> and <i>TP53</i> Subpopulations. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1141-1152.	1.1	15
3373	An update on the morphology and molecular pathology of serrated colorectal polyps and associated carcinomas. Modern Pathology, 2019, 32, 1390-1415.	2.9	73
3374	Differences in gene expression profiling and biomarkers between histological colorectal carcinoma subsets from the serrated pathway. Histopathology, 2019, 75, 496-507.	1.6	6
3375	Exome and immune cell score analyses reveal great variation within synchronous primary colorectal cancers. British Journal of Cancer, 2019, 120, 922-930.	2.9	4
3376	Visual Analytics of Genomic and Cancer Data: A Systematic Review. Cancer Informatics, 2019, 18, 117693511983554.	0.9	18
3377	IFN/STAT signaling controls tumorigenesis and the drug response in colorectal cancer. Cancer Science, 2019, 110, 1293-1305.	1.7	13
3378	The BAF complex in development and disease. Epigenetics and Chromatin, 2019, 12, 19.	1.8	155
3379	Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy. BMC Cancer, 2019, 19, 255.	1.1	16
3380	KRAS mutations in the parental tumour accelerate in vitro growth of tumoroids established from colorectal adenocarcinoma. International Journal of Experimental Pathology, 2019, 100, 12-18.	0.6	7
3381	Combined Menin and EGFR Inhibitors Synergize to Suppress Colorectal Cancer via EGFR-Independent and Calcium-Mediated Repression of SKP2 Transcription. Cancer Research, 2019, 79, 2195-2207.	0.4	19
3382	A novel 4-gene prognostic signature for hypermutated colorectal cancer . Cancer Management and Research, 2019, Volume 11, 1985-1996.	0.9	12

#	Article	IF	Citations
3383	Molecular Diagnostics in Colorectal Cancer. , 2019, , 143-155.		2
3384	Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance. Cancer Cell, 2019, 35, 347-367.	7.7	533
3385	Update on genetic predisposition to colorectal cancer and polyposis. Molecular Aspects of Medicine, 2019, 69, 10-26.	2.7	113
3386	Immunotherapy in colorectal cancer: rationale, challenges and potential. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 361-375.	8.2	1,039
3387	Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review. Current Colorectal Cancer Reports, 2019, 15, 61-69.	1.0	27
3388	Paracrine Induction of Epithelial-Mesenchymal Transition Between Colorectal Cancer Cells and its Suppression by a p53/miR-192/215/NID1 Axis. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 783-802.	2.3	19
3389	Deep convolutional neural networks for accurate somatic mutation detection. Nature Communications, 2019, 10, 1041.	5.8	81
3390	The atypical RhoU/Wrch1 Rho GTPase controls cell proliferation and apoptosis in the gut epithelium. Biology of the Cell, 2019, 111, 121-141.	0.7	11
3391	Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study. British Journal of Cancer, 2019, 120, 697-702.	2.9	19
3392	Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. Scientific Reports, 2019, 9, 2858.	1.6	38
3393	I-Boost: an integrative boosting approach for predicting survival time with multiple genomics platforms. Genome Biology, 2019, 20, 52.	3.8	7
3394	Enhanced anticancer potency by combination chemotherapy of HT-29 cells with biodegradable, pH-sensitive nanoparticles for co-delivery of hydroxytyrosol and doxorubicin. Journal of Drug Delivery Science and Technology, 2019, 51, 721-735.	1.4	25
3395	TET1 suppresses colon cancer proliferation by impairing Î²â€catenin signal pathway. Journal of Cellular Biochemistry, 2019, 120, 12559-12565.	1.2	21
3396	Overexpression of the cohesin-core subunit SMC1A contributes to colorectal cancer development. Journal of Experimental and Clinical Cancer Research, 2019, 38, 108.	3.5	34
3397	Interplay between bile acids and the gut microbiota promotes intestinal carcinogenesis. Molecular Carcinogenesis, 2019, 58, 1155-1167.	1.3	81
3398	Urachal cancerâ€"current concepts of aÂrare cancer. Der Pathologe, 2019, 40, 31-39.	0.7	15
3399	Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer. Oncogene, 2019, 38, 5076-5090.	2.6	26
3400	Mutational Signatures in Mandibular Ameloblastoma Correlate with Smoking. Journal of Dental Research, 2019, 98, 652-658.	2.5	14

#	Article	IF	Citations
3401	Clinical implications of the genetics of sporadic colorectal cancer. ANZ Journal of Surgery, 2019, 89, 1224-1229.	0.3	25
3402	Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. Clinical Colorectal Cancer, 2019, 18, 116-124.	1.0	7
3403	Factors affecting KRAS mutation detection in colorectal cancer tissue. Pathology Research and Practice, 2019, 215, 1071-1075.	1.0	1
3404	Clinical and molecular characterization of earlyâ€onset colorectal cancer. Cancer, 2019, 125, 2002-2010.	2.0	212
3405	Colon Cancer Tumor Location Defined by Gene Expression May Disagree With Anatomic Tumor Location. Clinical Colorectal Cancer, 2019, 18, 149-158.	1.0	7
3406	The Molecular Organization of Human cGMP Specific Phosphodiesterase 6 (PDE6): Structural Implications of Somatic Mutations in Cancer and Retinitis Pigmentosa. Computational and Structural Biotechnology Journal, 2019, 17, 378-389.	1.9	20
3407	New insights into niclosamide action: autophagy activation in colorectal cancer. Biochemical Journal, 2019, 476, 779-781.	1.7	13
3408	Clinicopathological and molecular differences in colorectal cancer according to location. International Journal of Biological Markers, 2019, 34, 47-53.	0.7	32
3409	Deep Learning With Sampling in Colon Cancer Histology. Frontiers in Bioengineering and Biotechnology, 2019, 7, 52.	2.0	54
3410	Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Recent Advances and Future Strategies. Current Colorectal Cancer Reports, 2019, 15, 53-60.	1.0	4
3411	Cancer mutational burden is shaped by G4 DNA, replication stress and mitochondrial dysfunction. Progress in Biophysics and Molecular Biology, 2019, 147, 47-61.	1.4	35
3412	Kaiso is required for MTG16-dependent effects on colitis-associated carcinoma. Oncogene, 2019, 38, 5091-5106.	2.6	10
3413	Impact of laterality and mucinous histology on relapse-free and overall survival in a registry-based colon cancer series. Scientific Reports, 2019, 9, 3668.	1.6	7
3414	miRNA-148a-3p Regulates Immunosuppression in DNA Mismatch Repairâ€"Deficient Colorectal Cancer by Targeting PD-L1. Molecular Cancer Research, 2019, 17, 1403-1413.	1.5	89
3415	Molecular Subtypes Are Frequently Discordant Between Lesions in Patients With Synchronous Colorectal Cancer: Molecular Analysis of 59 Patients. Anticancer Research, 2019, 39, 1425-1432.	0.5	2
3416	Integrative analysis identifies DNMTs against immune-infiltrating neutrophils and dendritic cells in colorectal cancer. Epigenetics, 2019, 14, 392-404.	1.3	12
3417	From the magic bullet to the magic target: exploiting the diverse roles of DDX3X in viral infections and tumorigenesis. Future Medicinal Chemistry, 2019, 11, 1357-1381.	1.1	22
3418	Selected Aspects of Chemoresistance Mechanisms in Colorectal Carcinomaâ€"A Focus on Epithelial-to-Mesenchymal Transition, Autophagy, and Apoptosis. Cells, 2019, 8, 234.	1.8	46

#	Article	IF	Citations
3419	Discrimination of low- and high-grade appendiceal mucinous neoplasms by targeted sequencing of cancer-related variants. Modern Pathology, 2019, 32, 1197-1209.	2.9	13
3420	Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers. JCO Precision Oncology, 2019, 3, 1-14.	1.5	12
3421	Class 1, 2, and 3 <i>BRAF</i>-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. Clinical Cancer Research, 2019, 25, 3954-3961.	3.2	67
3422	The CIMP-high phenotype is associated with energy metabolism alterations in colon adenocarcinoma. BMC Medical Genetics, 2019, 20, 52.	2.1	20
3423	Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms. Journal of Hematology and Oncology, 2019, 12, 38.	6.9	66
3424	Update on systemic therapy for colorectal cancer: biologics take sides. Translational Gastroenterology and Hepatology, 2019, 4, 9-9.	1.5	22
3425	Combinatorial Detection of Conserved Alteration Patterns for Identifying Cancer Subnetworks. GigaScience, 2019, 8, .	3.3	9
3426	Successful treatment with nivolumab for SMARCA4â€deficient nonâ€small cell lung carcinoma with a high tumor mutation burden: A case report. Thoracic Cancer, 2019, 10, 1285-1288.	0.8	58
3427	TRIM47 is up-regulated in colorectal cancer, promoting ubiquitination and degradation of SMAD4. Journal of Experimental and Clinical Cancer Research, 2019, 38, 159.	3.5	69
3428	A reinforcing HNF4â€"SMAD4 feed-forward module stabilizes enterocyte identity. Nature Genetics, 2019, 51, 777-785.	9.4	110
3429	RAC1b Overexpression Confers Resistance to Chemotherapy Treatment in Colorectal Cancer. Molecular Cancer Therapeutics, 2019, 18, 957-968.	1.9	32
3430	Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures. PLoS Genetics, 2019, 15, e1008076.	1.5	59
3431	Chasing the FOXO3: Insights into Its New Mitochondrial Lair in Colorectal Cancer Landscape. Cancers, 2019, 11, 414.	1.7	19
3432	Systems Biology Analyses Show Hyperactivation of Transforming Growth Factor-Î² and JNK Signaling Pathways in Esophageal Cancer. Gastroenterology, 2019, 156, 1761-1774.	0.6	38
3433	Amplification-free SERS analysis of DNA mutation in cancer cells with single-base sensitivity. Nanoscale, 2019, 11, 7781-7789.	2.8	37
3434	Approaches to functionally validate candidate genetic variants involved in colorectal cancer predisposition. Molecular Aspects of Medicine, 2019, 69, 27-40.	2.7	5
3435	Phenotype of POLE-mutated endometrial cancer. PLoS ONE, 2019, 14, e0214318.	1.1	53
3436	DNA methylation inhibitor attenuates polyglutamineâ€induced neurodegeneration by regulating Hes5. EMBO Molecular Medicine, 2019, 11, .	3.3	16

#	Article	IF	Citations
3437	Defining UHRF1 Domains that Support Maintenance of Human Colon Cancer DNA Methylation and Oncogenic Properties. Cancer Cell, 2019, 35, 633-648.e7.	7.7	89
3438	Prevalence and role of HER2 mutations in cancer. , 2019, 199, 188-196.		44
3439	Functional Analysis of Somatic Mutations Affecting Receptor Tyrosine Kinase Family in Metastatic Colorectal Cancer. Molecular Cancer Therapeutics, 2019, 18, 1137-1148.	1.9	0
3440	Somatic mutation of DNAH genes implicated higher chemotherapy response rate in gastric adenocarcinoma patients. Journal of Translational Medicine, 2019, 17, 109.	1.8	18
3441	Tissue-Specific Oncogenic Activity of KRASA146T. Cancer Discovery, 2019, 9, 738-755.	7.7	127
3442	High <i>KCNQ1OT1</i> expression might independently predict shorter survival of colon adenocarcinoma. Future Oncology, 2019, 15, 1085-1095.	1.1	25
3443	Inherited Colorectal Cancer and the Genetics of Colorectal Cancer. , 2019, , 1959-1980.		2
3444	BRAF V600E and SRC mutations as molecular markers for predicting prognosis and conversion surgery in Stage IV colorectal cancer. Scientific Reports, 2019, 9, 2466.	1.6	16
3445	Context mattersâ€"consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials. Annals of Oncology, 2019, 30, 520-527.	0.6	80
3446	Association of genetic ancestry with colorectal tumor location in Puerto Rican Latinos. Human Genomics, 2019, 13, 12.	1.4	10
3447	BCL-3 promotes a cancer stem cell phenotype by enhancing Î²-catenin signalling in colorectal tumour cells. DMM Disease Models and Mechanisms, 2019, 12, .	1.2	24
3448	Targeting cancer stem cells as therapeutic approach in the treatment of colorectal cancer. International Journal of Biochemistry and Cell Biology, 2019, 110, 75-83.	1.2	33
3449	Cytoplasmic Asporin promotes cell migration by regulating TGF-Î²/Smad2/3 pathway and indicates a poor prognosis in colorectal cancer. Cell Death and Disease, 2019, 10, 109.	2.7	39
3450	Meeting report from the joint IARCâ€"NCI international cancer seminar series: a focus on colorectal cancer. Annals of Oncology, 2019, 30, 510-519.	0.6	42
3451	Systems analysis identifies potential target genes to overcome cetuximab resistance in colorectal cancer cells. FEBS Journal, 2019, 286, 1305-1318.	2.2	31
3452	Comprehensive Genetic Search to Clarify the Molecular Mechanism of Drug Resistance Identifies ASCL2-LEF1/TSPAN8 Axis in Colorectal Cancer. Annals of Surgical Oncology, 2019, 26, 1401-1411.	0.7	13
3453	A Guide to PIN1 Function and Mutations Across Cancers. Frontiers in Pharmacology, 2018, 9, 1477.	1.6	12
3454	Interaction between IGF2â€PI3K axis and cancerâ€associatedâ€fibroblasts promotes anal squamous carcinogenesis. International Journal of Cancer, 2019, 145, 1852-1859.	2.3	13

#	Article	IF	Citations
3455	Biomarker concordance between primary colorectal cancer and its metastases. EBioMedicine, 2019, 40, 363-374.	2.7	75
3456	Msx1 loss suppresses formation of the ectopic crypts developed in the Apc-deficient small intestinal epithelium. Scientific Reports, 2019, 9, 1629.	1.6	10
3457	Stratifin Inhibits SCFFBW7 Formation and Blocks Ubiquitination of Oncoproteins during the Course of Lung Adenocarcinogenesis. Clinical Cancer Research, 2019, 25, 2809-2820.	3.2	19
3458	Tumor classification and biomarker discovery based on the 5â€™isomiR expression level. BMC Cancer, 2019, 19, 127.	1.1	12
3459	The Developing Story of Predictive Biomarkers in Colorectal Cancer. Journal of Personalized Medicine, 2019, 9, 12.	1.1	111
3460	Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry Study. Frontiers in Oncology, 2019, 9, 76.	1.3	33
3461	POLE proofreading defects: Contributions to mutagenesis and cancer. DNA Repair, 2019, 76, 50-59.	1.3	44
3462	Loss of Forkhead Box O3 Facilitates Inflammatory Colon Cancer: Transcriptome Profiling of the Immune Landscape and Novel Targets. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 391-408.	2.3	28
3463	Mechanisms of PTEN loss in cancer: Itâ€™s all about diversity. Seminars in Cancer Biology, 2019, 59, 66-79.	4.3	214
3464	Non-invasive markers to detect colorectal cancer in asymptomatic population. Minerva Biotecnologica, 2019, 31, .	1.2	6
3465	Aging-like Spontaneous Epigenetic Silencing Facilitates Wnt Activation, Stemness, and BrafV600E-Induced Tumorigenesis. Cancer Cell, 2019, 35, 315-328.e6.	7.7	107
3466	The role of dePARylation in DNA damage repair and cancer suppression. DNA Repair, 2019, 76, 20-29.	1.3	7
3467	Molecular characterization of â€œsessile serratedâ€•adenoma to carcinoma transition in six early colorectal cancers. Pathology Research and Practice, 2019, 215, 957-962.	1.0	11
3468	Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer. Scientific Reports, 2019, 9, 1482.	1.6	25
3469	TRAF6 inhibits colorectal cancer metastasis through regulating selective autophagic CTNNB1/Î²-catenin degradation and is targeted for GSK3B/GSK3Î²-mediated phosphorylation and degradation. Autophagy, 2019, 15, 1506-1522.	4.3	90
3470	HOXA9 mediates and marks premalignant compartment size expansion in colonic adenomas. Carcinogenesis, 2019, 40, 1514-1524.	1.3	5
3471	SH3BP4 Regulates Intestinal Stem Cells and Tumorigenesis by Modulating Î²-Catenin Nuclear Localization. Cell Reports, 2019, 26, 2266-2273.e4.	2.9	21
3472	Differential genomic destabilisation in human cells with pathogenic MSH2 mutations introduced by genome editing. Experimental Cell Research, 2019, 377, 24-35.	1.2	12

#	Article	IF	Citations
3473	BHLHA15-Positive Secretory Precursor Cells Can Give Rise to Tumors in Intestine and Colon in Mice. Gastroenterology, 2019, 156, 1066-1081.e16.	0.6	34
3474	Radiogenomic Analysis of F-18-Fluorodeoxyglucose Positron Emission Tomography and Gene Expression Data Elucidates the Epidemiological Complexity of Colorectal Cancer Landscape. Computational and Structural Biotechnology Journal, 2019, 17, 177-185.	1.9	51
3475	Large-Scale Genome-Wide Association Study of East Asians Identifies Loci Associated With Risk for Colorectal Cancer. Gastroenterology, 2019, 156, 1455-1466.	0.6	111
3476	Establishment of multiple diagnosis models for colorectal cancer with artificial neural networks. Oncology Letters, 2019, 17, 3314-3322.	0.8	11
3477	Towards a data-integrated cell. Nature Communications, 2019, 10, 805.	5.8	37
3478	Drug Sensitivity Screening and Targeted Pathway Analysis Reveal a Multi-Driver Proliferative Mechanism and Suggest a Strategy of Combination Targeted Therapy for Colorectal Cancer Cells. Molecules, 2019, 24, 623.	1.7	7
3479	Epigenome-Wide Analysis of DNA Methylation in Colorectal Cancer. , 2019, , 289-310.		2
3480	Human colon organoids reveal distinct physiologic and oncogenic Wnt responses. Journal of Experimental Medicine, 2019, 216, 704-720.	4.2	49
3481	Characteristics of mismatch repair deficiency in sarcomas. Modern Pathology, 2019, 32, 977-987.	2.9	49
3482	Loss of BCL9/9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer. Nature Communications, 2019, 10, 723.	5.8	64
3483	DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers. Gastroenterology, 2019, 156, 890-903.	0.6	48
3484	Significant Strain Variation in the Mutation Spectra of Inbred Laboratory Mice. Molecular Biology and Evolution, 2019, 36, 865-874.	3.5	23
3485	Firstâ€line therapy for metastatic colorectal cancer: Current perspectives and future directions. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 3-14.	0.7	4
3486	Shortcuts to intestinal carcinogenesis by genetic engineering in organoids. Cancer Science, 2019, 110, 858-866.	1.7	25
3487	Right versus left sided metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 136-143.	0.7	12
3489	Identifying Structural Changes in Correlation Networks Models of Cancer Gene Expression by Stage. , 2019, , .		3
3490	Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer. ESMO Open, 2019, 4, e000523.	2.0	11
3491	Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer. ESMO Open, 2019, 4, e000474.	2.0	34

#	Article	IF	Citations
3492	Germline <i>POLE</i> mutation in a child with hypermutated medulloblastoma and features of constitutional mismatch repair deficiency. Journal of Physical Education and Sports Management, 2019, 5, a004499.	0.5	19
3493	A case of class 3 MEK1 mutated metastatic colorectal cancer with a non-durable tumor marker response to MEK and ERK inhibitors. Journal of Gastrointestinal Oncology, 2019, 10, 1140-1143.	0.6	7
3494	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. Oncologist, 2019, 24, 1395-1402.	1.9	95
3495	Gains of Chromosome 1p and 15q are Associated with Poor Survival After Cytoreductive Surgery and HIPEC for Treating Colorectal Peritoneal Metastases. Annals of Surgical Oncology, 2019, 26, 4835-4842.	0.7	5
3496	Predictive and prognostic implications of microsatellite instability and mismatch repair deficiency in carcinomas of the gastrointestinal tract, liver, and pancreas. Precision Cancer Medicine, 2019, 2, 36-36.	1.8	1
3497	Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics. Molecular Cancer Therapeutics, 2019, 18, 1852-1862.	1.9	22
3498	Distinct clinical and biological implications of CUX1 in myeloid neoplasms. Blood Advances, 2019, 3, 2164-2178.	2.5	26
3499	High predictability for identifying Lynch syndrome via microsatellite instability testing or immunohistochemistry in all Lynch-associated tumor types. Translational Cancer Research, 2019, 8, S559-S563.	0.4	8
3500	Integrative subspace clustering by common and specific decomposition for applications on cancer subtype identification. BMC Medical Genomics, 2019, 12, 191.	0.7	4
3501	The evolving treatment paradigm for BRAF V600 mutant colorectal cancer. Annals of Translational Medicine, 2019, 7, S257-S257.	0.7	1
3502	Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. , 2019, 7, 309.		112
3503	The Landscape of Actionable Gene Fusions in Colorectal Cancer. International Journal of Molecular Sciences, 2019, 20, 5319.	1.8	34
3504	Mapping the Mutation Landscape of Colorectal Cancer. American Journal of the Medical Sciences, 2019, 358, 313-314.	0.4	1
3505	Recognizing Novel Tumor Suppressor Genes Using a Network Machine Learning Strategy. IEEE Access, 2019, 7, 155002-155013.	2.6	33
3506	Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR. BMC Medical Genomics, 2019, 12, 162.	0.7	17
3507	The Role and Therapeutic Potential of miRNAs in Colorectal Liver Metastasis. Scientific Reports, 2019, 9, 15803.	1.6	12
3508	MRTFB suppresses colorectal cancer development through regulating SPDL1 and MCAM. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23625-23635.	3.3	22
3509	28 Drug Development in the 21st Century: Monoclonal Antibodies and Immunotherapy. , 2019, , .		0

#	Article	IF	Citations
3510	Importance of Feature Weighing in Cervical Cancer Subtypes Identification. , 2019, , .		0
3511	Validation of <i>HER2</i> Amplification as a Predictive Biomarker for Antiâ€"Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. JCO Precision Oncology, 2019, 3, 1-13.	1.5	46
3512	Elevated Microsatellite Alterations at Selected Tetranucleotides (EMAST) Is Not Attributed to MSH3 Loss in Stage I-III Colon cancer: An Automated, Digitalized Assessment by Immunohistochemistry of Whole Slides and Hot Spots. Translational Oncology, 2019, 12, 1583-1588.	1.7	7
3513	Inflammation-Associated Microsatellite Alterations Caused by MSH3 Dysfunction Are Prevalent in Ulcerative Colitis and Increase With Neoplastic Advancement. Clinical and Translational Gastroenterology, 2019, 10, e00105.	1.3	22
3514	Tankyrase inhibition sensitizes cells to CDK4 blockade. PLoS ONE, 2019, 14, e0226645.	1.1	6
3515	DNA methylation instability by BRAF-mediated TET silencing and lifestyle-exposure divides colon cancer pathways. Clinical Epigenetics, 2019, 11, 196.	1.8	22
3516	Identification of Common and Subtype-Specific Mutated Sub-Pathways for a Cancer. Frontiers in Genetics, 2019, 10, 1228.	1.1	6
3517	A network view of microRNA and gene interactions in different pathological stages of colon cancer. BMC Medical Genomics, 2019, 12, 158.	0.7	5
3518	Tumor diversity and the trade-off between universal cancer tasks. Nature Communications, 2019, 10, 5423.	5.8	53
3519	In-Depth Characterization of Mass Spectrometry-Based Proteomic Profiles Revealed Novel Signature Proteins Associated with Liver Metastatic Colorectal Cancers. Analytical Cellular Pathology, 2019, 2019, 1-9.	0.7	7
3520	FGF Signalling in the Self-Renewal of Colon Cancer Organoids. Scientific Reports, 2019, 9, 17365.	1.6	32
3521	Mutation Profiling of Premalignant Colorectal Neoplasia. Gastroenterology Research and Practice, 2019, 2019, 1-9.	0.7	5
3522	Systematic mutation analysis in rare colorectal cancer presenting ovarian metastases. Scientific Reports, 2019, 9, 16990.	1.6	4
3523	Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer. Scientific Reports, 2019, 9, 17358.	1.6	67
3524	Immune checkpoint inhibitors in gastrointestinal malignancies: what can we learn from experience with other tumors?. Translational Gastroenterology and Hepatology, 2019, 4, 73-73.	1.5	4
3525	Transforming Growth Factor-Î² Signaling Pathway in Colorectal Cancer and Its Tumor Microenvironment. International Journal of Molecular Sciences, 2019, 20, 5822.	1.8	147
3526	Bulk and Single-Cell Next-Generation Sequencing: Individualizing Treatment for Colorectal Cancer. Cancers, 2019, 11, 1809.	1.7	17
3527	Pyrazole-4-Carboxamide (YW2065): A Therapeutic Candidate for Colorectal Cancer via Dual Activities of Wnt/Î²-Catenin Signaling Inhibition and AMP-Activated Protein Kinase (AMPK) Activation. Journal of Medicinal Chemistry, 2019, 62, 11151-11164.	2.9	28

#	Article	IF	Citations
3528	Molecular subtyping improves prognostication of Stage 2 colorectal cancer. BMC Cancer, 2019, 19, 1155.	1.1	13
3529	Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors. International Journal of Molecular Sciences, 2019, 20, 5999.	1.8	64
3530	Multigene panel predicting survival of patients with colon cancer. Journal of Cancer, 2019, 10, 6792-6800.	1.2	0
3531	Signaling pathways involved in colorectal cancer progression. Cell and Bioscience, 2019, 9, 97.	2.1	226
3532	Activating Structural Alterations in MAPK Genes Are Distinct Genetic Drivers in a Unique Subgroup Of Spitzoid Neoplasms. American Journal of Surgical Pathology, 2019, 43, 538-548.	2.1	41
3533	The Pathologic and Genetic Characteristics of the Intestinal Subtype of Intraductal Papillary Neoplasms of the Bile Duct. American Journal of Surgical Pathology, 2019, 43, 1212-1220.	2.1	13
3534	Identification of Differently Expressed Genes Associated With Prognosis and Growth in Colon Adenocarcinoma Based on Integrated Bioinformatics Analysis. Frontiers in Genetics, 2019, 10, 1245.	1.1	36
3535	Recurrent Extradural Myxopapillary Ependymoma With Oligometastatic Spread. Frontiers in Oncology, 2019, 9, 1322.	1.3	11
3536	Germline POLE and POLD1 proofreading domain mutations in endometrial carcinoma from Middle Eastern region. Cancer Cell International, 2019, 19, 334.	1.8	12
3538	The activating transcription factor 2: an influencer of cancer progression. Mutagenesis, 2019, 34, 375-389.	1.0	39
3540	Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression. Journal of Experimental and Clinical Cancer Research, 2019, 38, 492.	3.5	28
3541	The landscape of somatic mutation in normal colorectal epithelial cells. Nature, 2019, 574, 532-537.	13.7	468
3542	Genomewide Expression Profiling Identifies a Novel miRNA-based Signature for the Detection of Peritoneal Metastasis in Patients With Gastric Cancer. Annals of Surgery, 2021, 274, e425-e434.	2.1	25
3543	A probabilistic method for leveraging functional annotations to enhance estimation of the temporal order of pathway mutations during carcinogenesis. BMC Bioinformatics, 2019, 20, 620.	1.2	0
3544	Highly sensitive MLH1 methylation analysis in blood identifies a cancer patient with low-level mosaic MLH1 epimutation. Clinical Epigenetics, 2019, 11, 171.	1.8	7
3545	Discovery, Validation, and Application of Novel Methylated DNA Markers for Detection of Esophageal Cancer in Plasma. Clinical Cancer Research, 2019, 25, 7396-7404.	3.2	33
3546	Controlling Nutritional Status (CONUT) Score Is A Predictor Of Post-Operative Outcomes In Elderly Gastric Cancer Patients Undergoing Curative Gastrectomy: A Prospective Study . Cancer Management and Research, 2019, Volume 11, 9793-9800.	0.9	14
3547	Extracellular vesicles containing oncogenic mutant Î²â€catenin activate Wnt signalling pathway in the recipient cells. Journal of Extracellular Vesicles, 2019, 8, 1690217.	5.5	66

#	Article	IF	Citations
3548	The Chalcone Lonchocarpin Inhibits Wnt/Î²-Catenin Signaling and Suppresses Colorectal Cancer Proliferation. Cancers, 2019, 11, 1968.	1.7	37
3549	Gastrointestinal transcription factors drive lineage-specific developmental programs in organ specification and cancer. Science Advances, 2019, 5, eaax8898.	4.7	26
3550	Computational assessment of SKA1 as a potential cancer biomarker. Biyokimya Dergisi, 2019, 44, 752-760.	0.1	1
3551	Current and Emerging Biomarkers in Metastatic Colorectal Cancer. Current Oncology, 2019, 26, 7-15.	0.9	31
3552	Stat3 is indispensable for damageâ€induced crypt regeneration but not for Wntâ€driven intestinal tumorigenesis. FASEB Journal, 2019, 33, 1873-1886.	0.2	12
3553	An immunohistochemical approach to detect oncogenic CTNNB1 mutations in primary neoplastic tissues. Laboratory Investigation, 2019, 99, 128-137.	1.7	18
3554	Pancan-meQTL: a database to systematically evaluate the effects of genetic variants on methylation in human cancer. Nucleic Acids Research, 2019, 47, D1066-D1072.	6.5	45
3555	PDEÎ´ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas. International Journal of Cancer, 2019, 144, 767-776.	2.3	24
3556	Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. Journal of Hepatology, 2019, 70, 58-65.	1.8	219
3557	DNA methylation changes and somatic mutations as tumorigenic events in Lynch syndrome-associated adenomas retaining mismatch repair protein expression. EBioMedicine, 2019, 39, 280-291.	2.7	21
3558	Gene expression analysis of heat-shock proteins and redox regulators reveals combinatorial prognostic markers in carcinomas of the gastrointestinal tract. Redox Biology, 2019, 25, 101060.	3.9	12
3559	Integrative molecular analysis of colorectal cancer and gastric cancer: What have we learnt?. Cancer Treatment Reviews, 2019, 73, 31-40.	3.4	15
3560	Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine. Journal of Pathology, 2019, 247, 574-588.	2.1	131
3561	Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer. Cancer Medicine, 2019, 8, 408-417.	1.3	63
3562	Epidemiological, clinical and molecular characterization of Lynchâ€like syndrome: A populationâ€based study. International Journal of Cancer, 2019, 145, 87-98.	2.3	28
3563	Therapeutic potential of targeting the Wnt/Î²-catenin signaling pathway in colorectal cancer. Biomedicine and Pharmacotherapy, 2019, 110, 473-481.	2.5	287
3564	FH535 inhibits proliferation and migration of colorectal cancer cells by regulating CyclinA2 and Claudin1 gene expression. Gene, 2019, 690, 48-56.	1.0	19
3565	JAK2 regulates mismatch repair proteinâ€mediated epigenetic alterations in response to oxidative damage. Environmental and Molecular Mutagenesis, 2019, 60, 308-319.	0.9	14

#	Article	IF	Citations
3566	Pharmacogenomics: Success and Challenges. , 2019, , 595-606.		0
3567	(Pro)renin receptor promotes colorectal cancer through the Wnt/beta-catenin signalling pathway despite constitutive pathway component mutations. British Journal of Cancer, 2019, 120, 229-237.	2.9	35
3568	Epithelial RNase H2 Maintains Genome Integrity and Prevents Intestinal Tumorigenesis in Mice. Gastroenterology, 2019, 156, 145-159.e19.	0.6	46
3569	Epigenetic Regulation of <i>Dlg1</i>, via <i>Kaiso</i>, Alters Mitotic Spindle Polarity and Promotes Intestinal Tumorigenesis. Molecular Cancer Research, 2019, 17, 686-696.	1.5	6
3570	Cellular Plasticity in Intestinal Homeostasis and Disease. Cell Stem Cell, 2019, 24, 54-64.	5.2	118
3571	Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the â€˜Uâ€™ out of â€˜CUPâ€™. British Journal of Cancer, 2019, 120, 141-153.	2.9	71
3572	Modeling Human Digestive Diseases With CRISPR-Cas9â€"Modified Organoids. Gastroenterology, 2019, 156, 562-576.	0.6	104
3573	Current synthetic pharmacotherapy for treatment-resistant colorectal cancer: when urgent action is required. Expert Opinion on Pharmacotherapy, 2019, 20, 523-534.	0.9	3
3574	CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors. European Journal of Medicinal Chemistry, 2019, 164, 77-91.	2.6	49
3575	Deciphering molecular properties of hypermutated gastrointestinal cancer. Journal of Cellular and Molecular Medicine, 2019, 23, 370-379.	1.6	10
3576	Role of adenomatous polyposis coli (APC) gene mutations in the pathogenesis of colorectal cancer; current status and perspectives. Biochimie, 2019, 157, 64-71.	1.3	85
3577	Immunological differences between colorectal cancer and normal mucosa uncover a prognostically relevant immune cell profile. OncoImmunology, 2019, 8, e1537693.	2.1	38
3578	Long noncoding RNA <i>MIR31HG</i> is a <i>bona fide</i> prognostic marker with colorectal cancer cellâ€intrinsic properties. International Journal of Cancer, 2019, 144, 2843-2853.	2.3	33
3579	Tales from the crypt: new insights into intestinal stem cells. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 19-34.	8.2	597
3580	miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis. Translational Oncology, 2019, 12, 282-291.	1.7	14
3581	HMGB1â€RAGE signaling facilitates Rasâ€dependent Yap1 expression to drive colorectal cancer stemness and development. Molecular Carcinogenesis, 2019, 58, 500-510.	1.3	36
3582	Identification of novel triazole inhibitors of Wnt/Î²-catenin signaling based on the Niclosamide chemotype. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 317-321.	1.0	7
3583	The c-MYC/NAMPT/SIRT1 feedback loop is activated in early classical and serrated route colorectal cancer and represents a therapeutic target. Medical Oncology, 2019, 36, 5.	1.2	19

#	Article	IF	Citations
3584	<i><scp>SMAD</scp>4</i> alteration associates with invasiveâ€front pathological markers and poor prognosis in colorectal cancer. Histopathology, 2019, 74, 873-882.	1.6	37
3585	Loss of BCAA Catabolism during Carcinogenesis Enhances mTORC1 Activity and Promotes Tumor Development and Progression. Cell Metabolism, 2019, 29, 1151-1165.e6.	7.2	144
3586	Distinct shed microvesicle and exosome microRNA signatures reveal diagnostic markers for colorectal cancer. PLoS ONE, 2019, 14, e0210003.	1.1	67
3587	Orange is the new black: Kinases are the new master regulators of tumor suppression. IUBMB Life, 2019, 71, 738-748.	1.5	9
3588	Multiregion Genomic Analysis of Serially Transplanted Patient-derived Xenograft Tumors. Cancer Genomics and Proteomics, 2019, 16, 21-27.	1.0	13
3589	Overview of the oncogenic signaling pathways in colorectal cancer: Mechanistic insights. Seminars in Cancer Biology, 2019, 58, 65-79.	4.3	94
3590	<i>Growth Factorâ€"Independent 1</i> Is a Tumor Suppressor Gene in Colorectal Cancer. Molecular Cancer Research, 2019, 17, 697-708.	1.5	34
3591	Histo-genomics: digital pathology at the forefront of precision medicine. Diagnosis, 2019, 6, 203-212.	1.2	23
3592	A Strategy to Optimize the Generation of Stable Chromobody Cell Lines for Visualization and Quantification of Endogenous Proteins in Living Cells. Antibodies, 2019, 8, 10.	1.2	20
3593	The phosphoinositide hydrolase phospholipase C delta1 inhibits epithelialâ€mesenchymal transition and is silenced in colorectal cancer. Journal of Cellular Physiology, 2019, 234, 13906-13916.	2.0	14
3594	The Roles of Initiating Truncal Mutations in Human Cancers: The Order of Mutations and Tumor Cell Type Matters. Cancer Cell, 2019, 35, 10-15.	7.7	114
3595	NGS-based oncogenic mutations analysis in advanced colorectal cancer patients improves targeted therapy prediction. Pathology Research and Practice, 2019, 215, 483-489.	1.0	8
3596	Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy. Biochemical Journal, 2019, 476, 535-546.	1.7	44
3597	Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial. Clinical Colorectal Cancer, 2019, 18, 141-148.	1.0	19
3598	MiRâ€30aâ€5p suppresses cell chemoresistance and stemness in colorectal cancer through <scp>USP</scp>22/Wnt/Î²â€catenin signaling axis. Journal of Cellular and Molecular Medicine, 2019, 23, 630-640.	1.6	62
3599	Human UTP14a promotes colorectal cancer progression by forming a positive regulation loop with c-Myc. Cancer Letters, 2019, 440-441, 106-115.	3.2	38
3600	Quantitative analysis of somatically acquired and constitutive uniparental disomy in gastrointestinal cancers. International Journal of Cancer, 2019, 144, 513-524.	2.3	6
3601	DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway. Clinical Cancer Research, 2019, 25, 641-651.	3.2	21

#	Article	IF	Citations
3602	Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. Oncogene, 2019, 38, 1717-1733.	2.6	29
3603	DNA mismatch repair deficiency but not ARID1A loss is associated with prognosis in small intestinal adenocarcinoma. Human Pathology, 2019, 85, 18-26.	1.1	14
3604	Prognostic Effect of Tumor Sidedness in Colorectal Cancer: A SEER-Based Analysis. Clinical Colorectal Cancer, 2019, 18, e104-e116.	1.0	34
3605	Serum- and Glucocorticoid-induced Kinase Sgk1 Directly Promotes the Differentiation of Colorectal Cancer Cells and Restrains Metastasis. Clinical Cancer Research, 2019, 25, 629-640.	3.2	28
3606	Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?. Bulletin Du Cancer, 2019, 106, 105-113.	0.6	35
3607	Earlyâ€onset colorectal cancer in young individuals. Molecular Oncology, 2019, 13, 109-131.	2.1	365
3608	Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations. International Journal of Cancer, 2019, 144, 3023-3030.	2.3	16
3609	Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors. International Journal of Clinical Oncology, 2019, 24, 115-122.	1.0	35
3610	Intracellular Activation of Complement C3 Leads to PD-L1 Antibody Treatment Resistance by Modulating Tumor-Associated Macrophages. Cancer Immunology Research, 2019, 7, 193-207.	1.6	64
3611	HER2-targeted therapy: an emerging strategy in advanced colorectal cancer. Expert Opinion on Investigational Drugs, 2019, 28, 29-38.	1.9	32
3612	Next generation sequencingâ€based gene panel tests for the management of solid tumors. Cancer Science, 2019, 110, 6-15.	1.7	107
3613	Immune checkpoint blockade resistance-related B2M hotspot mutations in microsatellite-unstable colorectal carcinoma. Pathology Research and Practice, 2019, 215, 209-214.	1.0	28
3614	Mutant p53 in colon cancer. Journal of Molecular Cell Biology, 2019, 11, 267-276.	1.5	170
3615	Validation of epigenetic markers to identify colitis associated cancer: Results of module 1 of the ENDCAP-C study. EBioMedicine, 2019, 39, 265-271.	2.7	8
3616	Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repairâ€"Deficient Colon Cancers: Implications for Prognosis. Clinical Cancer Research, 2019, 25, 125-133.	3.2	57
3617	Failure to Rescue in Postoperative Patients With Colon Cancer: Time to Rethink Where You Get Surgery. Journal of Surgical Research, 2019, 234, 1-6.	0.8	13
3618	Loss of expression of Î¼-protocadherin and protocadherin-24 in sporadic and hereditary nonpolyposis colorectal cancers. Human Pathology, 2019, 84, 299-308.	1.1	2
3619	Epigenetic regulation of Amphiregulin and Epiregulin in colorectal cancer. International Journal of Cancer, 2019, 144, 569-581.	2.3	19

#	Article	IF	Citations
3620	Fusion Kinases Identified by Genomic Analyses of Sporadic Microsatellite Instabilityâ€“High Colorectal Cancers. Clinical Cancer Research, 2019, 25, 378-389.	3.2	49
3621	Implications of Epigenetic Drift in Colorectal Neoplasia. Cancer Research, 2019, 79, 495-504.	0.4	26
3622	Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases. Annals of Surgery, 2019, 269, 917-923.	2.1	121
3623	Identifying mutual exclusivity across cancer genomes: computational approaches to discover genetic interaction and reveal tumor vulnerability. Briefings in Bioinformatics, 2019, 20, 254-266.	3.2	46
3624	Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients. Pathology and Oncology Research, 2019, 25, 269-278.	0.9	3
3625	Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications. Seminars in Cancer Biology, 2019, 54, 14-28.	4.3	51
3626	<i>Ferula pseudalliacea</i> induces apoptosis in human colorectal cancer HCT-116 cells via mitochondria-dependent pathway. Archives of Physiology and Biochemistry, 2019, 125, 284-291.	1.0	11
3627	Genome sequencing analysis of liver cancer for precision medicine. Seminars in Cancer Biology, 2019, 55, 120-127.	4.3	56
3628	Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes. Gut, 2019, 68, 465-474.	6.1	52
3629	Semi-supervised identification of cancer subgroups using survival outcomes and overlapping grouping information. Statistical Methods in Medical Research, 2019, 28, 2137-2149.	0.7	5
3630	Systematic Inspection of the Clinical Relevance of <i>TP53</i> Missense Mutations in Gastric Cancer. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2019, 16, 1693-1701.	1.9	12
3631	A survey and evaluation of Web-based tools/databases for variant analysis of TCGA data. Briefings in Bioinformatics, 2019, 20, 1524-1541.	3.2	48
3632	Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis. Gut, 2019, 68, 684-692.	6.1	84
3633	Epigenomic biomarkers for prognostication and diagnosis of gastrointestinal cancers. Seminars in Cancer Biology, 2019, 55, 90-105.	4.3	19
3634	Analysis of <i>KRAS</i>, <i>NRAS</i>, <i>BRAF</i>, <i>PIK3CA</i> and <i>TP53</i> mutations in a large prospective series of locally advanced rectal cancer patients. International Journal of Cancer, 2020, 146, 94-102.	2.3	34
3635	miRâ€330 suppresses EMT and induces apoptosis by downregulating HMGA2 in human colorectal cancer. Journal of Cellular Physiology, 2020, 235, 920-931.	2.0	51
3636	GMSimpute: a generalized two-step Lasso approach to impute missing values in label-free mass spectrum analysis. Bioinformatics, 2020, 36, 257-263.	1.8	13
3637	DC-SIGNâ€“LEF1/TCF1â€“miR-185 feedback loop promotes colorectal cancer invasion and metastasis. Cell Death and Differentiation, 2020, 27, 379-395.	5.0	34

#	Article	IF	Citations
3638	Metabolic pathways regulating colorectal cancer initiation and progression. Seminars in Cell and Developmental Biology, 2020, 98, 63-70.	2.3	203
3639	ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics. Oncogene, 2020, 39, 487-502.	2.6	72
3640	Mutated CEACAMs Disrupt Transforming Growth Factor Beta Signaling and Alter the Intestinal Microbiome to Promote Colorectal Carcinogenesis. Gastroenterology, 2020, 158, 238-252.	0.6	46
3641	Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer. Clinical and Translational Oncology, 2020, 22, 813-822.	1.2	24
3642	Pre-analytics and tumor heterogeneity. New Biotechnology, 2020, 55, 30-35.	2.4	16
3643	Molecular and Genetic Markers in Appendiceal Mucinous Tumors: A Systematic Review. Annals of Surgical Oncology, 2020, 27, 85-97.	0.7	22
3644	Exploiting differential Wnt target gene expression to generate a molecular biomarker for colorectal cancer stratification. Gut, 2020, 69, 1092-1103.	6.1	52
3645	The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models. Cancer Letters, 2020, 473, 186-197.	3.2	80
3646	Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer. Pharmacogenomics Journal, 2020, 20, 136-158.	0.9	15
3647	Comprehensive analysis of the long noncoding RNA expression profile and construction of the lncRNA-mRNA co-expression network in colorectal cancer. Cancer Biology and Therapy, 2020, 21, 157-169.	1.5	20
3648	Pathways of Colorectal Carcinogenesis. Gastroenterology, 2020, 158, 291-302.	0.6	241
3649	Chromosome Engineering of Human Colon-Derived Organoids to Develop a Model of Traditional Serrated Adenoma. Gastroenterology, 2020, 158, 638-651.e8.	0.6	55
3650	RNAIndel: discovering somatic coding indels from tumor RNA-Seq data. Bioinformatics, 2020, 36, 1382-1390.	1.8	12
3651	Pathology, Biomarkers, and Molecular Diagnostics. , 2020, , 225-253.e8.		4
3652	NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer. Advances in Biological Regulation, 2020, 75, 100653.	1.4	25
3653	Immune Activation in Mismatch Repairâ€"Deficient Carcinogenesis: More Than Just Mutational Rate. Clinical Cancer Research, 2020, 26, 11-17.	3.2	61
3654	Pathological Diagnosis of Submucosal Invasive Colorectal Carcinoma (pT1 Colorectal Cancer): Overview of Histopathological and Molecular Markers to Predict Lymph Node Metastasis of Submucosal Invasive Colorectal Cancer. , 2020, , 95-106.		0
3655	IBD-Associated Dysplastic Lesions Show More Chromosomal Instability Than Sporadic Adenomas. Inflammatory Bowel Diseases, 2020, 26, 167-180.	0.9	29

#	Article	IF	Citations
3656	High-dimensional cytometric analysis of colorectal cancer reveals novel mediators of antitumour immunity. Gut, 2020, 69, 691-703.	6.1	92
3657	DNA Damage Response Pathways and Cancer. , 2020, , 154-164.e4.		7
3658	Resorting the function of the colorectal cancer gatekeeper adenomatous polyposis coli. International Journal of Cancer, 2020, 146, 1064-1074.	2.3	23
3659	Biomarker-guided therapy for colorectal cancer: strength in complexity. Nature Reviews Clinical Oncology, 2020, 17, 11-32.	12.5	195
3660	Associations among dietary seaweed intake, c-MYC rs6983267 polymorphism, and risk of colorectal cancer in a Korean population: a caseâ€"control study. European Journal of Nutrition, 2020, 59, 1963-1974.	1.8	11
3661	Role and molecular mechanism of stem cells in colorectal cancer initiation. Journal of Drug Targeting, 2020, 28, 1-10.	2.1	13
3662	Endoscopic Management of Colorectal T1(SM) Carcinoma. , 2020, , .		0
3663	APC mutational patterns in gastric adenocarcinoma are enriched for missense variants with associated decreased survival. Genes Chromosomes and Cancer, 2020, 59, 64-68.	1.5	4
3664	Defining the â€œMetastasomeâ€: Perspectives from the genome and molecular landscape in colorectal cancer for metastasis evolution and clinical consequences. Seminars in Cancer Biology, 2020, 60, 1-13.	4.3	20
3665	Fecal DNA Testing for Colorectal Cancer Screening. Annual Review of Medicine, 2020, 71, 59-69.	5.0	54
3666	CDCP1 enhances Wnt signaling in colorectal cancer promoting nuclear localization of Î²-catenin and E-cadherin. Oncogene, 2020, 39, 219-233.	2.6	39
3667	SOX4: The unappreciated oncogene. Seminars in Cancer Biology, 2020, 67, 57-64.	4.3	114
3668	Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer. Modern Pathology, 2020, 33, 483-495.	2.9	9
3669	Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers. Journal of Gastroenterology, 2020, 55, 15-26.	2.3	115
3670	Proteome analysis of formalinâ€fixed paraffinâ€embedded colorectal adenomas reveals the heterogeneous nature of traditional serrated adenomas compared to other colorectal adenomas. Journal of Pathology, 2020, 250, 251-261.	2.1	6
3671	Elevated Microsatellite Alterations at Selected Tetranucleotides (EMAST) in Colorectal Cancer is Associated with an Elderly, Frail Phenotype and Improved Recurrence-Free Survival. Annals of Surgical Oncology, 2020, 27, 1058-1067.	0.7	14
3672	miRâ€144 suppresses cell proliferation and migration in colorectal cancer by targeting NRAS. Journal of Cellular Biochemistry, 2020, 121, 3871-3881.	1.2	8
3673	Causes of Socioeconomic Disparities in Colorectal Cancer and Intervention Framework and Strategies. Gastroenterology, 2020, 158, 354-367.	0.6	152

#	Article	IF	Citations
3674	Two types of primary mucinous ovarian tumors can be distinguished based on their origin. Modern Pathology, 2020, 33, 722-733.	2.9	25
3675	Wnt Signaling in 3D: Recent Advances in the Applications of Intestinal Organoids. Trends in Cell Biology, 2020, 30, 60-73.	3.6	64
3676	The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Discovery, 2020, 10, 54-71.	7.7	820
3677	Highâ€risk Stage III colon cancer patients identified by a novel fiveâ€gene mutational signature are characterized by upregulation of ILâ€23A and gut bacterial translocation of the tumor microenvironment. International Journal of Cancer, 2020, 146, 2027-2035.	2.3	43
3678	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repairâ€“Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. Journal of Clinical Oncology, 2020, 38, 1-10.	0.8	1,740
3679	Long noncoding RNA PiHL regulates p53 protein stability through GRWD1/RPL11/MDM2 axis in colorectal cancer. Theranostics, 2020, 10, 265-280.	4.6	44
3680	Antiâ€tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on <i>KRAS</i>â€mutated human colorectal cancer cells. Cancer Medicine, 2020, 9, 302-312.	1.3	25
3681	LINC00365 promotes colorectal cancer cell progression through the Wnt/Î²â€catenin signaling pathway. Journal of Cellular Biochemistry, 2020, 121, 1260-1272.	1.2	19
3682	The anaphaseâ€promoting complex: A key mitotic regulator associated with somatic mutations occurring in cancer. Genes Chromosomes and Cancer, 2020, 59, 189-202.	1.5	12
3683	Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase Îµ (<scp><i>POLE</i></scp>). Histopathology, 2020, 76, 366-374.	1.6	15
3684	Epidemiology and Mechanisms of the Increasing Incidence of Colon and Rectal Cancers in Young Adults. Gastroenterology, 2020, 158, 341-353.	0.6	295
3685	Therapeutic Targeting of the Colorectal Tumor Stroma. Gastroenterology, 2020, 158, 303-321.	0.6	51
3686	PP2A Deficiency Enhances Carcinogenesis of Lgr5+ Intestinal Stem Cells Both in Organoids and In Vivo. Cells, 2020, 9, 90.	1.8	3
3687	Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis. Acta OncolÃ³gica, 2020, 59, 417-426.	0.8	22
3688	Microsatellite instability in Japanese female patients with triple-negative breast cancer. Breast Cancer, 2020, 27, 490-498.	1.3	28
3689	Application of Advanced Bioinformatics to Understand and Predict Burnout Among Surgical Trainees. Journal of Surgical Education, 2020, 77, 499-507.	1.2	12
3690	Diffuse capillary malformation with overgrowth contains somatic <i>PIK3CA</i> variants. Clinical Genetics, 2020, 97, 736-740.	1.0	22
3691	Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. Oncologist, 2020, 25, 404-413.	1.9	25

#	Article	IF	Citations
3692	Revisiting the tumorigenesis timeline with a data-driven generative model. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 857-864.	3.3	44
3693	Lysine-Specific Demethylase 1 Mediates AKT Activity and Promotes Epithelial-to-Mesenchymal Transition in <i>PIK3CA</i>-Mutant Colorectal Cancer. Molecular Cancer Research, 2020, 18, 264-277.	1.5	29
3694	Structure and regulation of human epithelial cell transforming 2 protein. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 1027-1035.	3.3	37
3695	Identification of altered biological processes in heterogeneous RNA-sequencing data by discretization of expression profiles. Nucleic Acids Research, 2020, 48, 1730-1747.	6.5	8
3696	The emerging role of mediator complex subunit 12 in tumorigenesis and response to chemotherapeutics. Cancer, 2020, 126, 939-948.	2.0	25
3697	Wholeâ€genome analysis uncovers recurrent <i>IKZF1</i> inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm. Genes Chromosomes and Cancer, 2020, 59, 295-308.	1.5	14
3698	Reliable Clinical MLH1 Promoter Hypermethylation Assessment Using a High-Throughput Genome-Wide Methylation Array Platform. Journal of Molecular Diagnostics, 2020, 22, 368-375.	1.2	25
3699	High mutational burden in colorectal carcinomas with monoallelic POLE mutations: absence of allelic loss and gene promoter methylation. Modern Pathology, 2020, 33, 1220-1231.	2.9	6
3700	Oncogenic Mutations in Armadillo Repeats 5 and 6 of Î²-Catenin Reduce Binding to APC, Increasing Signaling and Transcription of Target Genes. Gastroenterology, 2020, 158, 1029-1043.e10.	0.6	20
3701	NEDD4 and NEDD4L regulate Wnt signalling and intestinal stem cell priming by degrading LGR5 receptor. EMBO Journal, 2020, 39, e102771.	3.5	58
3702	circCCT3 Modulates Vascular Endothelial Growth Factor A and Wnt Signaling to Enhance Colorectal Cancer Metastasis Through Sponging miR-613. DNA and Cell Biology, 2020, 39, 118-125.	0.9	34
3703	Sample Tracking Using Unique Sequence Controls. Journal of Molecular Diagnostics, 2020, 22, 141-146.	1.2	10
3704	Genetic alterations related to endoscopic treatment of colorectal tumors. JGH Open, 2020, 4, 75-82.	0.7	1
3705	Mevalonate Pathway Provides Ubiquinone to Maintain Pyrimidine Synthesis and Survival in p53-Deficient Cancer Cells Exposed to Metabolic Stress. Cancer Research, 2020, 80, 189-203.	0.4	53
3706	The double-edged sword of cancer mutations: exploiting neoepitopes for the fight against cancer. Mutagenesis, 2020, 35, 69-78.	1.0	1
3707	MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer. Clinical Cancer Research, 2020, 26, 183-192.	3.2	79
3708	Aberrant AFP expression characterizes a subset of hepatocellular carcinoma with distinct gene expression patterns and inferior prognosis. Journal of Cancer, 2020, 11, 403-413.	1.2	18
3709	Sequencing artifacts derived from a library preparation method using enzymatic fragmentation. PLoS ONE, 2020, 15, e0227427.	1.1	24

#	Article	IF	Citations
3710	Cas9 Mediated Correction of Î²-catenin Mutation and Restoring the Expression of Protein Phosphorylation in Colon Cancer HCT-116 Cells Decrease Cell Proliferation in vitro and Hamper Tumor Growth in Mice in vivo . OncoTargets and Therapy, 2020, Volume 13, 17-29.	1.0	11
3711	WNT and Î²-Catenin in Cancer: Genes and Therapy. Annual Review of Cancer Biology, 2020, 4, 177-196.	2.3	39
3712	Tissue and Cell-Free DNA-Based Epigenomic Approaches for Cancer Detection. Clinical Chemistry, 2020, 66, 105-116.	1.5	26
3713	Infection-induced signals generated at the plasma membrane epigenetically regulate Wnt signaling in vitro and in vivo. Journal of Biological Chemistry, 2020, 295, 1021-1035.	1.6	4
3714	Neutrophils suppress tumorâ€infiltrating T cells in colon cancer via matrix metalloproteinaseâ€mediated activation of <scp>TGF</scp> Î². EMBO Molecular Medicine, 2020, 12, e10681.	3.3	100
3715	TKP, a serine protease extracted fromTrichosanthes kirilowii, inhibits the migration and invasion of colorectal adenocarcinoma cells by targeting Wnt/Î²â€catenin and Hedgehog/Gli1 signalings. Phytotherapy Research, 2020, 34, 867-878.	2.8	5
3716	Development and Analytical Validation of a DNA Dual-Strand Approach for the US Food and Drug Administrationâ€"Approved Next-Generation Sequencingâ€"Based Praxis Extended RAS Panel for Metastatic Colorectal Cancer Samples. Journal of Molecular Diagnostics, 2020, 22, 159-178.	1.2	3
3717	Molecular Pathology of Colorectal Cancer. Advances in Anatomic Pathology, 2020, 27, 20-26.	2.4	68
3718	Analysis of Colorectal Cancer-Associated Alternative Splicing Based on Transcriptome. DNA and Cell Biology, 2020, 39, 16-24.	0.9	9
3719	Exploring Microsatellite Instability (MSI) in Colorectal Cancer at Elevated Microsatellite Alterations at Selected Tetranucleotides (EMAST). Annals of Surgical Oncology, 2020, 27, 973-974.	0.7	1
3720	Tectal glioma harbors high rates of KRAS G12R and concomitant KRAS and BRAF alterations. Acta Neuropathologica, 2020, 139, 601-602.	3.9	13
3721	Adjuvant chemotherapy for rectal cancer: Current evidence and recommendations for clinical practice. Cancer Treatment Reviews, 2020, 83, 101948.	3.4	51
3722	PRDM14 promotes malignant phenotype and correlates with poor prognosis in colorectal cancer. Clinical and Translational Oncology, 2020, 22, 1126-1137.	1.2	8
3723	KRT17 as a prognostic biomarker for stage II colorectal cancer. Carcinogenesis, 2020, 41, 591-599.	1.3	24
3724	Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer. Cell Stem Cell, 2020, 26, 17-26.e6.	5.2	404
3725	MLH1 promoter hypermethylation: are you absolutely sure about the absence of MLH1 germline mutation? About a new case. Familial Cancer, 2020, 19, 11-14.	0.9	5
3726	A comparative study of multi-omics integration tools for cancer driver gene identification and tumour subtyping. Briefings in Bioinformatics, 2020, 21, 1920-1936.	3.2	51
3727	Gene mutation profiling in Chinese colorectal cancer patients and its association with clinicopathological characteristics and prognosis. Cancer Medicine, 2020, 9, 745-756.	1.3	23

#	Article	IF	Citations
3728	Genetic ablation of tumor necrosis factor-alpha attenuates the promoted colonic Wnt signaling in high fat diet-induced obese mice. Journal of Nutritional Biochemistry, 2020, 77, 108302.	1.9	8
3729	Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer. Cancer Treatment Reviews, 2020, 82, 101935.	3.4	17
3730	Dishevelled family proteins in serous ovarian carcinomas: a clinicopathologic and molecular study. Apmis, 2020, 128, 201-210.	0.9	4
3731	Genomic and transcriptomic profiling of carcinogenesis in patients with familial adenomatous polyposis. Gut, 2020, 69, 1283-1293.	6.1	36
3732	Upregulation of DKK3 by miRâ€483â€3p plays an important role in the chemoprevention of colorectal cancer mediated by black raspberry anthocyanins. Molecular Carcinogenesis, 2020, 59, 168-178.	1.3	20
3733	Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. Targeted Oncology, 2020, 15, 11-24.	1.7	65
3734	Development of a validated LC-MS/MS method for quantification of phosphoinositide 3 kinase inhibitor GSK2636771: Application to a pharmacokinetic study in rat plasma. Journal of Pharmaceutical and Biomedical Analysis, 2020, 179, 112950.	1.4	0
3735	Oncogenic K-ras Induces Mitochondrial OPA3 Expression to Promote Energy Metabolism in Pancreatic Cancer Cells. Cancers, 2020, 12, 65.	1.7	18
3736	Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC). Diagnostics, 2020, 10, 9.	1.3	24
3737	Macroscopic somatic clonal expansion in morphologically normal human urothelium. Science, 2020, 370, 82-89.	6.0	115
3738	Highly multiplexed quantifications of 299 somatic mutations in colorectal cancer patients by automated MALDI-TOF mass spectrometry. BMC Medical Genomics, 2020, 13, 143.	0.7	4
3739	SETD2 as a regulator of N6-methyladenosine RNA methylation and modifiers in cancer. European Journal of Cancer Prevention, 2020, 29, 556-564.	0.6	7
3740	Curcumin Modifies Epithelialâ€"Mesenchymal Transition in Colorectal Cancer Through Regulation of miR-200c/EPM5 . Cancer Management and Research, 2020, Volume 12, 9405-9415.	0.9	16
3741	Tumors driven by <i>RAS</i> signaling harbor a natural vulnerability to oncolytic virus M1. Molecular Oncology, 2020, 14, 3153-3168.	2.1	7
3742	Suppression of CLC-3 reduces the proliferation, invasion and migration of colorectal cancer through Wnt/Î²-catenin signaling pathway. Biochemical and Biophysical Research Communications, 2020, 533, 1240-1246.	1.0	12
3743	Clinical, Pathology, Genetic, and Molecular Features of Colorectal Tumors in Adolescents and Adults 25 Years or Younger. Clinical Gastroenterology and Hepatology, 2021, 19, 1642-1651.e8.	2.4	8
3744	Pan-cancer analysis reveals TAp63-regulated oncogenic lncRNAs that promote cancer progression through AKT activation. Nature Communications, 2020, 11, 5156.	5.8	12
3745	Epigenetic Inactivation of Î±-Internexin Accelerates Microtubule Polymerization in Colorectal Cancer. Cancer Research, 2020, 80, 5203-5215.	0.4	14

#	Article	IF	Citations
3746	Clinical Features and Genomic Characterization of Post-Colonoscopy Colorectal Cancer. Clinical and Translational Gastroenterology, 2020, 11, e00246.	1.3	3
3747	Genetic Alterations of Metastatic Colorectal Cancer. Biomedicines, 2020, 8, 414.	1.4	27
3748	Landscape of Genome-Wide DNA Methylation of Colorectal Cancer Metastasis. Cancers, 2020, 12, 2710.	1.7	18
3749	Molecular Insights Into Colorectal Carcinoma. Archives of Medical Research, 2020, 51, 839-844.	1.5	13
3750	MicroRNA: Another Pharmacological Avenue for Colorectal Cancer?. Frontiers in Cell and Developmental Biology, 2020, 8, 812.	1.8	14
3751	SFPQ Depletion Is Synthetically Lethal with BRAFV600E in Colorectal Cancer Cells. Cell Reports, 2020, 32, 108184.	2.9	19
3752	Repeat expansions confer WRN dependence in microsatellite-unstable cancers. Nature, 2020, 586, 292-298.	13.7	95
3753	Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Targeted Oncology, 2020, 15, 743-750.	1.7	25
3754	Comprehensive analysis of the expression and prognostic value of CXC chemokines in colorectal cancer. International Immunopharmacology, 2020, 89, 107077.	1.7	20
3755	STX2 drives colorectal cancer proliferation via upregulation of EXOSC4. Life Sciences, 2020, 263, 118597.	2.0	3
3756	Establishment of prognostic nomogram for elderly colorectal cancer patients: a SEER database analysis. BMC Gastroenterology, 2020, 20, 347.	0.8	32
3757	Clonal Evolution and Timing of Metastatic Colorectal Cancer. Cancers, 2020, 12, 2938.	1.7	9
3758	Metformin elicits antitumour effect by modulation of the gut microbiota and rescues Fusobacterium nucleatum-induced colorectal tumourigenesis. EBioMedicine, 2020, 61, 103037.	2.7	34
3759	Microsatellite Instability Testing and Therapy Implications. Advances in Molecular Pathology, 2020, 3, 169-188.	0.2	4
3760	Modeling and analysis of site-specific mutations in cancer identifies known plus putative novel hotspots and bias due to contextual sequences. Computational and Structural Biotechnology Journal, 2020, 18, 1664-1675.	1.9	5
3761	Target Enrichment Enables the Discovery of lncRNAs with Somatic Mutations or Altered Expression in Paraffin-Embedded Colorectal Cancer Samples. Cancers, 2020, 12, 2844.	1.7	7
3762	Comprehensive characterization of functional eRNAs in lung adenocarcinoma reveals novel regulators and a prognosis-related molecular subtype. Theranostics, 2020, 10, 11264-11277.	4.6	20
3763	CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence. EBioMedicine, 2020, 61, 103030.	2.7	67

#	Article	IF	Citations
3764	Evaluation of 3 molecular-based assays for microsatellite instability detection in formalin-fixed tissues of patients with endometrial and colorectal cancers. Scientific Reports, 2020, 10, 16386.	1.6	35
3765	Representative cancer-associated U2AF2 mutations alter RNA interactions and splicing. Journal of Biological Chemistry, 2020, 295, 17148-17157.	1.6	29
3766	EGF Relays Signals to COP1 and Facilitates FOXO4 Degradation to Promote Tumorigenesis. Advanced Science, 2020, 7, 2000681.	5.6	25
3767	Discordant DNA mismatch repair protein status between synchronous or metachronous gastrointestinal carcinomas: frequency, patterns, and molecular etiologies. Familial Cancer, 2020, 20, 201-213.	0.9	8
3768	PTPN18 promotes colorectal cancer progression by regulating the c-MYC-CDK4 axis. Genes and Diseases, 2021, 8, 838-848.	1.5	11
3769	Dynamics of genomic and immune responses during primary immunotherapy resistance in mismatch repairâ€“deficient tumors. Journal of Physical Education and Sports Management, 2020, 6, a005678.	0.5	3
3770	A Wnt-Induced Phenotypic Switch in Cancer-Associated Fibroblasts Inhibits EMT in Colorectal Cancer. Cancer Research, 2020, 80, 5569-5582.	0.4	64
3771	Dysregulated Phosphorylation of p53, Autophagy and Stemness Attributes the Mutant p53 Harboring Colon Cancer Cells Impaired Sensitivity to Oxaliplatin. Frontiers in Oncology, 2020, 10, 1744.	1.3	14
3772	The overexpression of AUF1 in colorectal cancer predicts a poor prognosis and promotes cancer progression by activating ERK and AKT pathways. Cancer Medicine, 2020, 9, 8612-8623.	1.3	18
3773	Cleistanthin A induces apoptosis and suppresses motility of colorectal cancer cells. European Journal of Pharmacology, 2020, 889, 173604.	1.7	8
3774	Targeting hypoxia-inducible factor-1, for cancer treatment: Recent advances in developing small-molecule inhibitors from natural compounds. Seminars in Cancer Biology, 2022, 80, 379-390.	4.3	87
3775	Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nature Medicine, 2020, 26, 1859-1864.	15.2	209
3776	Methanolic Extract of Muntingia Calabura L. Mitigates 1,2-Dimethyl Hydrazine Induced Colon Carcinogenesis in Wistar Rats. Nutrition and Cancer, 2020, , 1-13.	0.9	6
3777	Ectodysplasin A receptor (EDAR) promotes colorectal cancer cell proliferation via regulation of the Wnt/Î²-catenin signaling pathway. Experimental Cell Research, 2020, 395, 112170.	1.2	16
3778	Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival. Nature Communications, 2020, 11, 3644.	5.8	55
3779	A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability. Cancer Research, 2020, 80, 3972-3982.	0.4	51
3780	RNAi Screening Identifies that TEX10 Promotes the Proliferation of Colorectal Cancer Cells by Increasing NFâ€<i>Îº</i>B Activation. Advanced Science, 2020, 7, 2000593.	5.6	13
3781	Exploring and modelling colon cancer inter-tumour heterogeneity: opportunities and challenges. Oncogenesis, 2020, 9, 66.	2.1	52

#	Article	IF	Citations
3782	The Interaction of Genomics, Molecular Imaging, and Therapy in Gastrointestinal Tumors. Seminars in Nuclear Medicine, 2020, 50, 471-483.	2.5	2
3783	Tumor organoids to study gastroesophageal cancer: a primer. Journal of Molecular Cell Biology, 2020, 12, 593-606.	1.5	7
3784	SOX9 Is Essential for Triple-Negative Breast Cancer Cell Survival and Metastasis. Molecular Cancer Research, 2020, 18, 1825-1838.	1.5	38
3785	Harnessing Omics Approaches on Advanced Preclinical Models to Discovery Novel Therapeutic Targets for the Treatment of Metastatic Colorectal Cancer. Cancers, 2020, 12, 1830.	1.7	2
3786	Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. Gastroenterology Report, 2020, 8, 179-191.	0.6	60
3787	Comprehensive Constitutional Genetic and Epigenetic Characterization of Lynch-Like Individuals. Cancers, 2020, 12, 1799.	1.7	15
3788	Combinatorial Immunotherapies for Metastatic Colorectal Cancer. Cancers, 2020, 12, 1875.	1.7	19
3789	<i>Jasminum azoricum</i> L. leaves: HPLC-PDA/MS/MS profiling and <i>in-vitro</i> cytotoxicity supported by molecular docking. Natural Product Research, 2021, 35, 5518-5520.	1.0	11
3790	BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. Gastroenterology Report, 2020, 8, 192-205.	0.6	59
3791	Intestinal organoids as tools for enriching and studying specific and rare cell types: advances and future directions. Journal of Molecular Cell Biology, 2020, 12, 562-568.	1.5	33
3792	Piperine suppresses the Wnt/Î²-catenin pathway and has anti-cancer effects on colorectal cancer cells. Scientific Reports, 2020, 10, 11681.	1.6	42
3793	Effect of preoperative chemoradiotherapy on the immunological status of rectal cancer patients. Journal of Radiation Research, 2020, 61, 766-775.	0.8	17
3794	The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer. Annals of Oncology, 2020, 31, 1135-1147.	0.6	58
3795	Medullary Pancreatic Carcinoma Due to Somatic POLE Mutation. Pancreas, 2020, 49, 999-1003.	0.5	20
3796	An amino-terminal BRAF deletion accounting for acquired resistance to RAF/EGFR inhibition in colorectal cancer. Journal of Physical Education and Sports Management, 2020, 6, a005140.	0.5	1
3797	Network-based identification of biomarkers for colon adenocarcinoma. BMC Cancer, 2020, 20, 668.	1.1	5
3798	Spontaneous Polyploids and Antimutators Compete During the Evolution of <i>Saccharomyces cerevisiae</i> Mutator Cells. Genetics, 2020, 215, 959-974.	1.2	10
3799	<i>KRAS</i> and <i>BRAF</i> Concomitant Mutations in a Patient with Metastatic Colon Adenocarcinoma: An Interesting Case Report. Case Reports in Oncology, 2020, 13, 595-600.	0.3	5

#	Article	IF	Citations
3800	Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer . Journal of Experimental Pharmacology, 2020, Volume 12, 475-485.	1.5	7
3801	PAXX, Not NHEJ1 Is an Independent Prognosticator in Colon Cancer. Frontiers in Molecular Biosciences, 2020, 7, 584053.	1.6	10
3802	Hist-Immune signature: a prognostic factor in colorectal cancer using immunohistochemical slide image analysis. OncoImmunology, 2020, 9, 1841935.	2.1	4
3803	Not All Wnt Activation Is Equal: Ligand-Dependent versus Ligand-Independent Wnt Activation in Colorectal Cancer. Cancers, 2020, 12, 3355.	1.7	29
3804	RNA-binding protein RALY reprogrammes mitochondrial metabolism via mediating miRNA processing in colorectal cancer. Gut, 2021, 70, 1698-1712.	6.1	63
3805	Candidate Gene Discovery in Hereditary Colorectal Cancer and Polyposis Syndromesâ€"Considerations for Future Studies. International Journal of Molecular Sciences, 2020, 21, 8757.	1.8	7
3806	Clinicopathological and Molecular Profiles of Sporadic Microsatellite Unstable Colorectal Cancer with or without the CpG Island Methylator Phenotype (CIMP). Cancers, 2020, 12, 3487.	1.7	7
3807	FI-Net: Identification of Cancer Driver Genes by Using Functional Impact Prediction Neural Network. Frontiers in Genetics, 2020, 11, 564839.	1.1	8
3808	The Role of BRAF in Metastatic Colorectal Carcinomaâ€"Past, Present, and Future. International Journal of Molecular Sciences, 2020, 21, 9001.	1.8	8
3809	Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant. Cell Death and Disease, 2020, 11, 1020.	2.7	15
3810	Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clinical Colorectal Cancer, 2021, 20, 137-147.e1.	1.0	17
3811	Wnt and Vitamin D at the Crossroads in Solid Cancer. Cancers, 2020, 12, 3434.	1.7	21
3812	The Crosstalk between FAK and Wnt Signaling Pathways in Cancer and Its Therapeutic Implication. International Journal of Molecular Sciences, 2020, 21, 9107.	1.8	28
3813	NRF2 and the Ambiguous Consequences of Its Activation during Initiation and the Subsequent Stages of Tumourigenesis. Cancers, 2020, 12, 3609.	1.7	44
3814	Genetic profiling for diffuse type and genomically stable subtypes in gastric cancer. Computational and Structural Biotechnology Journal, 2020, 18, 3301-3308.	1.9	12
3815	Gastrointestinal adenocarcinoma analysis identifies promoter methylation-based cancer subtypes and signatures. Scientific Reports, 2020, 10, 21234.	1.6	10
3816	Tn Antigen Expression Defines an Immune Cold Subset of Mismatch-Repair Deficient Colorectal Cancer. International Journal of Molecular Sciences, 2020, 21, 9081.	1.8	4
3817	Prediction of driver variants in the cancer genome via machine learning methodologies. Briefings in Bioinformatics, 2021, 22, .	3.2	13

#	Article	IF	Citations
3818	Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab. Scientific Reports, 2020, 10, 19815.	1.6	7
3819	Site-Specific DNA Demethylation as a Potential Target for Cancer Epigenetic Therapy. Epigenetics Insights, 2020, 13, 251686572096480.	0.6	9
3820	Oncogenic Serine 45-Deleted Î²-Catenin Remains Susceptible to Wnt Stimulation and APC Regulation in Human Colonocytes. Cancers, 2020, 12, 2114.	1.7	7
3821	The human transcriptome: implications for understanding, diagnosing, and treating human disease. , 2020, , 113-138.		0
3822	Molecular basis of diseases of the gastrointestinal tract. , 2020, , 323-344.		0
3823	Characterization of tumors with ultralow tumor mutational burden in Japanese cancer patients. Cancer Science, 2020, 111, 3893-3901.	1.7	15
3824	Integrated genetic and epigenetic analysis of cancerâ€related genes in nonâ€ampullary duodenal adenomas and intramucosal adenocarcinomas. Journal of Pathology, 2020, 252, 330-342.	2.1	16
3825	Zinc-finger antiviral protein acts as a tumor suppressor in colorectal cancer. Oncogene, 2020, 39, 5995-6008.	2.6	12
3826	Clinical Impact of PD-L1 Expression for Survival in Curatively Resected Colon Cancer. Cancer Investigation, 2020, 38, 406-414.	0.6	11
3827	Mathematical model of colorectal cancer initiation. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 20681-20688.	3.3	47
3828	Using genetics to decipher the link between type 2 diabetes and cancer: shared aetiology or downstream consequence?. Diabetologia, 2020, 63, 1706-1717.	2.9	20
3829	Unique genomic and neoepitope landscapes across tumors: a study across time, tissues, and space within a single lynch syndrome patient. Scientific Reports, 2020, 10, 12190.	1.6	3
3830	ColoType: a forty gene signature for consensus molecular subtyping of colorectal cancer tumors using whole-genome assay or targeted RNA-sequencing. Scientific Reports, 2020, 10, 12123.	1.6	22
3831	Steroid receptorâ€associated and regulated protein is a biomarker in predicting the clinical outcome and treatment response in malignancies. Cancer Reports, 2020, 3, e1267.	0.6	2
3833	Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer and Metastasis Reviews, 2020, 39, 1029-1038.	2.7	149
3834	Pan-cancer image-based detection of clinically actionable genetic alterations. Nature Cancer, 2020, 1, 789-799.	5.7	343
3835	Immunotherapy for Early Stage Colorectal Cancer: A Glance into the Future. Cancers, 2020, 12, 1990.	1.7	12
3836	Src Family Tyrosine Kinases in Intestinal Homeostasis, Regeneration and Tumorigenesis. Cancers, 2020, 12, 2014.	1.7	16

#	Article	IF	Citations
3837	Distant Metastasis in Colorectal Cancer Patientsâ€"Do We Have New Predicting Clinicopathological and Molecular Biomarkers? A Comprehensive Review. International Journal of Molecular Sciences, 2020, 21, 5255.	1.8	38
3838	MiRâ€1224â€5p acts as a tumor suppressor via inhibiting the malignancy of rectal cancer through targeting SLC29A3. IUBMB Life, 2020, 72, 2204-2213.	1.5	9
3839	Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093608.	1.4	37
3840	A deep learning model to predict RNA-Seq expression of tumours from whole slide images. Nature Communications, 2020, 11, 3877.	5.8	247
3841	Recurrent Neoantigens in Colorectal Cancer as Potential Immunotherapy Targets. BioMed Research International, 2020, 2020, 1-8.	0.9	9
3842	Prevalence of APC and PTEN Alterations in Urachal Cancer. Pathology and Oncology Research, 2020, 26, 2773-2781.	0.9	10
3843	Cancer-Associated Mutations in Normal Colorectal Mucosa Adjacent to Sporadic Neoplasia. Clinical and Translational Gastroenterology, 2020, 11, e00212.	1.3	3
3844	Genomic alterations in Turcot syndrome: Insights from whole exome sequencing. Journal of the Neurological Sciences, 2020, 417, 117056.	0.3	1
3845	The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. Gastroenterology, 2020, 159, 2146-2162.e33.	0.6	75
3846	Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell. World Journal of Surgical Oncology, 2020, 18, 196.	0.8	7
3847	The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy. Immunotherapy, 2020, 12, 1083-1100.	1.0	27
3848	Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial. European Journal of Cancer, 2020, 137, 250-259.	1.3	15
3849	Role of POLE and POLD1 in familial cancer. Genetics in Medicine, 2020, 22, 2089-2100.	1.1	76
3850	Morphological landscape of endothelial cell networks reveals a functional role of glutamate receptors in angiogenesis. Scientific Reports, 2020, 10, 13829.	1.6	10
3851	Delivery of Personalized Care for Locally Advanced Rectal Cancer: Incorporating Pathological, Molecular Genetic, and Immunological Biomarkers Into the Multimodal Paradigm. Frontiers in Oncology, 2020, 10, 1369.	1.3	13
3852	Neurosurgery for brain metastasis from breast cancer. Translational Cancer Research, 2020, 9, 5063-5076.	0.4	3
3853	The Role of EBV-Induced Hypermethylation in Gastric Cancer Tumorigenesis. Viruses, 2020, 12, 1222.	1.5	33
3854	Identification of Prognostic Markers in Cholangiocarcinoma Using Altered DNA Methylation and Gene Expression Profiles. Frontiers in Genetics, 2020, 11, 522125.	1.1	11

#	Article	IF	Citations
3855	A Middle-Out Modeling Strategy to Extend a Colon Cancer Logical Model Improves Drug Synergy Predictions in Epithelial-Derived Cancer Cell Lines. Frontiers in Molecular Biosciences, 2020, 7, 502573.	1.6	13
3856	Germline Profiling and Molecular Characterization of Early Onset Metastatic Colorectal Cancer. Frontiers in Oncology, 2020, 10, 568911.	1.3	17
3857	Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer. Cancers, 2020, 12, 3073.	1.7	28
3858	Integrative immunogenomic analysis of gastric cancer dictates novel immunological classification and the functional status of tumorâ€infiltrating cells. Clinical and Translational Immunology, 2020, 9, e1194.	1.7	11
3859	Do TRIB1 and IL-9 Gene Polymorphisms Impact the Development and Manifestation of Pituitary Adenoma?. In Vivo, 2020, 34, 2499-2505.	0.6	4
3860	Comprehensive Analysis of DNA Methylation and Prediction of Response to NeoadjuvantTherapy in Locally Advanced Rectal Cancer. Cancers, 2020, 12, 3079.	1.7	13
3861	Best practices for variant calling in clinical sequencing. Genome Medicine, 2020, 12, 91.	3.6	178
3862	Wnt-Independent and Wnt-Dependent Effects of APC Loss on the Chemotherapeutic Response. International Journal of Molecular Sciences, 2020, 21, 7844.	1.8	19
3863	Single-Cell Multiomics Sequencing Reveals Prevalent Genomic Alterations in Tumor Stromal Cells of Human Colorectal Cancer. Cancer Cell, 2020, 38, 818-828.e5.	7.7	146
3864	Synergistic antitumor activity of DHA and JQ1 in colorectal carcinoma. European Journal of Pharmacology, 2020, 885, 173500.	1.7	7
3865	Beyond bevacizumab: a review of targeted agents in metastatic small bowel adenocarcinoma. Medical Oncology, 2020, 37, 106.	1.2	4
3866	Newly established gastrointestinal cancer cell lines retain the genomic and immunophenotypic landscape of their parental cancers. Scientific Reports, 2020, 10, 17895.	1.6	5
3867	NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer. Cancer Genetics, 2020, 248-249, 1-10.	0.2	7
3868	Mechanisms of autoregulation of C3G, activator of the GTPase Rap1, and its catalytic deregulation in lymphomas. Science Signaling, 2020, 13, .	1.6	11
3869	Metastatic colon cancer of the small intestine diagnosed using genetic analysis: a case report. Diagnostic Pathology, 2020, 15, 106.	0.9	1
3870	Somatic mutations in colorectal cancer are associated with the epigenetic modifications. Journal of Cellular and Molecular Medicine, 2020, 24, 11828-11836.	1.6	5
3871	Evaluating genomic biomarkers associated with resistance or sensitivity to chemotherapy in patients with advanced breast and colorectal cancer. Journal of Oncology Pharmacy Practice, 2020, 27, 107815522095184.	0.5	2
3872	Cellular and molecular architecture of the intestinal stem cell niche. Nature Cell Biology, 2020, 22, 1033-1041.	4.6	126

#	Article	IF	Citations
3873	The DNA Glycosylase NEIL2 Suppresses Fusobacterium-Infection-Induced Inflammation and DNA Damage in Colonic Epithelial Cells. Cells, 2020, 9, 1980.	1.8	28
3874	Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy. Radiotherapy and Oncology, 2020, 151, 280-286.	0.3	11
3875	Revisiting the Concept of Stress in the Prognosis of Solid Tumors: A Role for Stress Granules Proteins?. Cancers, 2020, 12, 2470.	1.7	14
3876	Î²-Catenin inhibition shapes tumor immunity and synergizes with immunotherapy in colorectal cancer. OncoImmunology, 2020, 9, 1809947.	2.1	23
3877	Long nonâ€coding RNA ADAMTS9â€AS1 suppresses colorectal cancer by inhibiting the Wnt/Î²â€catenin signalling pathway and is a potential diagnostic biomarker. Journal of Cellular and Molecular Medicine, 2020, 24, 11318-11329.	1.6	43
3878	Classification of Muscle-Invasive Bladder Cancer Based on Immunogenomic Profiling. Frontiers in Oncology, 2020, 10, 1429.	1.3	16
3879	The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution. Nature Communications, 2020, 11, 4740.	5.8	78
3880	Integrated Omics of Metastatic Colorectal Cancer. Cancer Cell, 2020, 38, 734-747.e9.	7.7	144
3881	Large-Scale Topological Changes Restrain Malignant Progression in Colorectal Cancer. Cell, 2020, 182, 1474-1489.e23.	13.5	126
3882	Inferring clonal composition from multiple tumor biopsies. Npj Systems Biology and Applications, 2020, 6, 27.	1.4	5
3883	An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer. Expert Review of Clinical Pharmacology, 2020, 13, 1125-1137.	1.3	7
3884	Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer. Carcinogenesis, 2020, 41, 1507-1517.	1.3	11
3886	Germline RAD54L with somatic POLE defect implicated in Hypermutation phenotype: case report. BMC Gastroenterology, 2020, 20, 255.	0.8	3
3887	Mutant POLQ and POLZ/REV3L DNA polymerases may contribute to the favorable survival of patients with tumors with POLE mutations outside the exonuclease domain. BMC Medical Genetics, 2020, 21, 167.	2.1	2
3888	Treatment With Medicinal Mushroom Extract Mixture Inhibits Translation and Reprograms Metabolism in Advanced Colorectal Cancer Animal Model as Evidenced by Tandem Mass Tags Proteomics Analysis. Frontiers in Pharmacology, 2020, 11, 1202.	1.6	7
3889	Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate. Nature Communications, 2020, 11, 4225.	5.8	47
3890	Adjuvant Chemotherapy in Elderly Colorectal Cancer Patients. Cancers, 2020, 12, 2289.	1.7	14
3891	A Biobank of Colorectal Cancer Patient-Derived Xenografts. Cancers, 2020, 12, 2340.	1.7	13

#	Article	IF	Citations
3892	Mismatch repair and DNA polymeraseÎ´proofreading prevent catastrophic accumulation of leading strand errors in cells expressing a cancer-associated DNA polymeraseÏµvariant. Nucleic Acids Research, 2020, 48, 9124-9134.	6.5	11
3893	MicroRNAâ€191 modulates cisplatinâ€induced DNA damage response by targeting RCC2. FASEB Journal, 2020, 34, 13573-13585.	0.2	8
3894	NAP1L1: A Novel Human Colorectal Cancer Biomarker Derived From Animal Models of Apc Inactivation. Frontiers in Oncology, 2020, 10, 1565.	1.3	17
3895	Somatic POLE exonuclease domain mutations elicit enhanced intratumoral immune responses in stage II colorectal cancer. , 2020, 8, e000881.		22
3896	Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Nonâ€"Small Cell Lung Carcinoma. Molecular Cancer Research, 2020, 18, 1777-1788.	1.5	24
3897	Analyzing and validating the prognostic value and mechanism of colon cancer immune microenvironment. Journal of Translational Medicine, 2020, 18, 324.	1.8	48
3898	Vitamin D Effects on Cell Differentiation and Stemness in Cancer. Cancers, 2020, 12, 2413.	1.7	41
3899	Integrative Analysis of the IQ Motif-Containing GTPase-Activating Protein Family Indicates That the IQGAP3-PIK3C2B Axis Promotes Invasion in Colon Cancer . OncoTargets and Therapy, 2020, Volume 13, 8299-8311.	1.0	10
3900	Evolutionary dynamics of neoantigens in growing tumors. Nature Genetics, 2020, 52, 1057-1066.	9.4	68
3901	Current Status and Perspectives of Patient-Derived Models for Ewingâ€™s Sarcoma. Cancers, 2020, 12, 2520.	1.7	3
3902	An algorithm to quantify intratumor heterogeneity based on alterations of gene expression profiles. Communications Biology, 2020, 3, 505.	2.0	50
3903	Reply to Zhao et al.: NOMO1 is a potential target gene of MRTFB. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 7570-7571.	3.3	1
3904	Bacteria-related changes in host DNA methylation and the risk for CRC. Gut Microbes, 2020, 12, 1800898.	4.3	9
3905	Targeted inhibition of KDM6 histone demethylases eradicates tumor-initiating cells via enhancer reprogramming in colorectal cancer. Theranostics, 2020, 10, 10016-10030.	4.6	21
3906	Cancers from Novel <i>Pole</i>-Mutant Mouse Models Provide Insights into Polymerase-Mediated Hypermutagenesis and Immune Checkpoint Blockade. Cancer Research, 2020, 80, 5606-5618.	0.4	14
3907	Differences in the Drosha and Dicer Cleavage Profiles in Colorectal Cancer and Normal Colon Tissue Samples. Doklady Biochemistry and Biophysics, 2020, 493, 208-210.	0.3	3
3908	Ion Channels in Cancer: Orchestrators of Electrical Signaling and Cellular Crosstalk. Reviews of Physiology, Biochemistry and Pharmacology, 2020, , 103-133.	0.9	9
3909	Downregulation of ORP3 Correlates with Reduced Survival of Colon Cancer Patients with Advanced Nodal Metastasis and of Female Patients with Grade 3 Colon Cancer. International Journal of Molecular Sciences, 2020, 21, 5894.	1.8	10

#	Article	IF	Citations
3910	Human transcription factor and protein kinase gene fusions in human cancer. Scientific Reports, 2020, 10, 14169.	1.6	9
3911	3D imaging of colorectal cancer organoids identifies responses to Tankyrase inhibitors. PLoS ONE, 2020, 15, e0235319.	1.1	21
3912	Analysis of genetic alterations identifies the frequent mutation of GNAS in colorectal laterally spreading tumors. Cancer Communications, 2020, 40, 636-640.	3.7	2
3913	Emerging Roles of Wnt Ligands in Human Colorectal Cancer. Frontiers in Oncology, 2020, 10, 1341.	1.3	85
3914	Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. EBioMedicine, 2020, 59, 102923.	2.7	22
3915	TMPRSS13 promotes cell survival, invasion, and resistance to drug-induced apoptosis in colorectal cancer. Scientific Reports, 2020, 10, 13896.	1.6	11
3916	FAM46C/TENT5C functions as a tumor suppressor through inhibition of Plk4 activity. Communications Biology, 2020, 3, 448.	2.0	20
3917	The Landmark Series: Randomized Control Trials Examining Perioperative Chemotherapy and Postoperative Adjuvant Chemotherapy for Resectable Colorectal Liver Metastasis. Annals of Surgical Oncology, 2020, 27, 4263-4270.	0.7	24
3918	A Global Gene Body Methylation Measure Correlates Independently with Overall Survival in Solid Cancer Types. Cancers, 2020, 12, 2257.	1.7	1
3919	Multifaceted Roles of DNA Methylation in Neoplastic Transformation, from Tumor Suppressors to EMT and Metastasis. Genes, 2020, 11, 922.	1.0	46
3920	A Practical Guide for Structural Variation Detection in the Human Genome. Current Protocols in Human Genetics, 2020, 107, e103.	3.5	12
3921	Comparative Study of Organoids from Patient-Derived Normal and Tumor Colon and Rectal Tissue. Cancers, 2020, 12, 2302.	1.7	37
3922	Molecular Targets for the Treatment of Metastatic Colorectal Cancer. Cancers, 2020, 12, 2350.	1.7	30
3923	Chemoprevention of DMH-Induced Early Colon Carcinogenesis in Male BALB/c Mice by Administration of Lactobacillus Paracasei DTA81. Microorganisms, 2020, 8, 1994.	1.6	13
3924	A meta-learning approach for genomic survival analysis. Nature Communications, 2020, 11, 6350.	5.8	38
3925	The transition from primary colorectal cancer to isolated peritoneal malignancy is associated with an increased tumour mutational burden. Scientific Reports, 2020, 10, 18900.	1.6	9
3926	DEAD-box RNA helicase protein DDX21 as a prognosis marker for early stage colorectal cancer with microsatellite instability. Scientific Reports, 2020, 10, 22085.	1.6	12
3927	Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota. Frontiers in Immunology, 2020, 11, 600886.	2.2	43

#	Article	IF	Citations
3928	Sexual Dimorphism in Colon Cancer. Frontiers in Oncology, 2020, 10, 607909.	1.3	86
3929	Mutation Spectra of the MRN (MRE11, RAD50, NBS1/NBN) Break Sensor in Cancer Cells. Cancers, 2020, 12, 3794.	1.7	10
3930	Prognostic and Predictive Cross-Roads of Microsatellite Instability and Immune Response to Colon Cancer. International Journal of Molecular Sciences, 2020, 21, 9680.	1.8	17
3931	BRAFV600E mutation impinges on gut microbial markers defining novel biomarkers for serrated colorectal cancer effective therapies. Journal of Experimental and Clinical Cancer Research, 2020, 39, 285.	3.5	14
3932	Colorectal Cancer Screening Methods and Molecular Markers for Early Detection. Technology in Cancer Research and Treatment, 2020, 19, 153303382098042.	0.8	17
3933	Emerging Role and Therapeutic Potential of lncRNAs in Colorectal Cancer. Cancers, 2020, 12, 3843.	1.7	29
3934	Computational methods for detecting cancer hotspots. Computational and Structural Biotechnology Journal, 2020, 18, 3567-3576.	1.9	12
3935	Blockade of EIF5A hypusination limits colorectal cancer growth by inhibiting MYC elongation. Cell Death and Disease, 2020, 11, 1045.	2.7	39
3936	Decreased concentrations of intracellular signaling proteins in colon cancer patients with BRAF mutations. Scientific Reports, 2020, 10, 20113.	1.6	5
3937	The majority of Î²-catenin mutations in colorectal cancer is homozygous. BMC Cancer, 2020, 20, 1038.	1.1	25
3938	Intestinal region-specific Wnt signalling profiles reveal interrelation between cell identity and oncogenic pathway activity in cancer development. Cancer Cell International, 2020, 20, 578.	1.8	8
3939	Extended transcriptome analysis reveals genome-wide lncRNA-mediated epigenetic dysregulation in colorectal cancer. Computational and Structural Biotechnology Journal, 2020, 18, 3507-3517.	1.9	2
3940	Targeting Wnt Signaling for Gastrointestinal Cancer Therapy: Present and Evolving Views. Cancers, 2020, 12, 3638.	1.7	25
3941	Role of Oncogenes and Tumor-suppressor Genes in Carcinogenesis: A Review. Anticancer Research, 2020, 40, 6009-6015.	0.5	148
3942	Therapeutic Potential of Apatinib Against Colorectal Cancer by Inhibiting VEGFR2-Mediated Angiogenesis and Î²-Catenin Signaling . OncoTargets and Therapy, 2020, Volume 13, 11031-11044.	1.0	9
3943	PWD/Ph-Encoded Genetic Variants Modulate the Cellular Wnt/Î²-Catenin Response to Suppress <i>Apc</i>Min-Triggered Intestinal Tumor Formation. Cancer Research, 2021, 81, 38-49.	0.4	0
3944	HGF/c-Met Axis: The Advanced Development in Digestive System Cancer. Frontiers in Cell and Developmental Biology, 2020, 8, 801.	1.8	10
3945	BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. Cancers, 2020, 12, 3236.	1.7	23

#	Article	IF	Citations
3946	A Gene Expression High-Throughput Screen (GE-HTS) for Coordinated Detection of Functionally Similar Effectors in Cancer. Cancers, 2020, 12, 3143.	1.7	6
3947	Revealing Prognosis-Related Pathways at the Individual Level by a Comprehensive Analysis of Different Cancer Transcription Data. Genes, 2020, 11, 1281.	1.0	5
3948	Omics technologies for improved diagnosis and treatment of colorectal cancer: Technical advancement and major perspectives. Biomedicine and Pharmacotherapy, 2020, 131, 110648.	2.5	42
3949	Elevated adenomatous polyposis coli in goblet cells is associated with inflammation in mouse and human colon. Experimental Physiology, 2020, 105, 2154-2167.	0.9	1
3950	Single-cell genomic profile-based analysis of tissue differentiation in colorectal cancer. Science China Life Sciences, 2021, 64, 1311-1325.	2.3	4
3951	Molecular Profilingâ€"Based Precision Medicine in Cancer: A Review of Current Evidence and Challenges. Frontiers in Oncology, 2020, 10, 532403.	1.3	20
3952	Germline <i>CDKN1B</i> Loss-of-Function Variants Cause Pediatric Cushingâ€™s Disease With or Without an MEN4 Phenotype. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1983-2005.	1.8	31
3953	Clinical significance of the combined measurement of serum B7-H1 and interleukin-10 in colorectal cancer patients. Medicine (United States), 2020, 99, e20044.	0.4	3
3954	Combination of Inositol Hexaphosphate and Inositol Inhibits Liver Metastasis of Colorectal Cancer in Mice Through the Wnt/Î²-Catenin Pathway . OncoTargets and Therapy, 2020, Volume 13, 3223-3235.	1.0	12
3955	Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants. Cells, 2020, 9, 1116.	1.8	6
3956	Identification of Human Secretome and Membrane Proteome-Based Cancer Biomarkers Utilizing Bioinformatics. Journal of Membrane Biology, 2020, 253, 257-270.	1.0	4
3957	Small Bowel Neuroendocrine Tumors. Current Problems in Surgery, 2020, 57, 100823.	0.6	12
3958	Novel Gene Fusions in Glioblastoma Tumor Tissue and Matched Patient Plasma. Cancers, 2020, 12, 1219.	1.7	11
3959	Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clinical and Translational Oncology, 2020, 22, 1976-1991.	1.2	13
3960	Genetic, structural, and functional characterization of POLE polymerase proofreading variants allows cancer risk prediction. Genetics in Medicine, 2020, 22, 1533-1541.	1.1	17
3961	Prognostic significance of immune landscape in tumour microenvironment of endometrial cancer. Journal of Cellular and Molecular Medicine, 2020, 24, 7767-7777.	1.6	65
3962	Homer1 is a Potential Biomarker for Prognosis in Human Colorectal Carcinoma, Possibly in Association with G3BP1 Signaling . Cancer Management and Research, 2020, Volume 12, 2899-2909.	0.9	9
3963	The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer. Clinical Cancer Research, 2020, 26, 4313-4325.	3.2	22

#	Article	IF	Citations
3964	Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter â€œSLAVEâ€• Study. Cancers, 2020, 12, 1259.	1.7	19
3965	Outcomes of Adjuvant Oral versus Intravenous Fluoropyrimidines for High-Risk Stage II or Stage III Colon Adenocarcinoma: A Propensity Score-Matched, Nationwide, Population-Based Cohort Study. Journal of Cancer, 2020, 11, 4157-4165.	1.2	1
3966	UHRF2 promotes intestinal tumorigenesis through stabilization of TCF4 mediated Wnt/Î²â€catenin signaling. International Journal of Cancer, 2020, 147, 2239-2252.	2.3	20
3967	Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy. Clinical Cancer Research, 2020, 26, 3662-3670.	3.2	107
3968	Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC. Biomedicine and Pharmacotherapy, 2020, 127, 109996.	2.5	35
3969	APC Mutation Marks an Aggressive Subtype of BRAF Mutant Colorectal Cancers. Cancers, 2020, 12, 1171.	1.7	28
3970	Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties. Nature Communications, 2020, 11, 2333.	5.8	33
3971	p53: 800 million years of evolution and 40 years of discovery. Nature Reviews Cancer, 2020, 20, 471-480.	12.8	421
3972	RAS internal tandem duplication disrupts GTPase-activating protein (GAP) binding to activate oncogenic signaling. Journal of Biological Chemistry, 2020, 295, 9335-9348.	1.6	8
3973	Strategies for Functional Interrogation of Big Cancer Data Using Drosophila Cancer Models. International Journal of Molecular Sciences, 2020, 21, 3754.	1.8	5
3974	Functional Hypermethylation of ALDH1L1, PLCL2, and PPP2R3A in Colon Cancer. Molecular Biology, 2020, 54, 178-184.	0.4	2
3975	Integrated multiâ€omics data analyses for exploring the coâ€occurring and mutually exclusive gene alteration events in colorectal cancer. Human Mutation, 2020, 41, 1588-1599.	1.1	13
3976	Stratification and prediction of drug synergy based on target functional similarity. Npj Systems Biology and Applications, 2020, 6, 16.	1.4	37
3977	Harnessing stemness and PD-L1 expression by AT-rich interaction domain-containing protein 3B in colorectal cancer. Theranostics, 2020, 10, 6095-6112.	4.6	18
3978	Reduction of Liver Metastasis Stiffness Improves Response to Bevacizumab in Metastatic Colorectal Cancer. Cancer Cell, 2020, 37, 800-817.e7.	7.7	179
3979	POLE Mutation Spectra Are Shaped by the Mutant Allele Identity, Its Abundance, and Mismatch Repair Status. Molecular Cell, 2020, 78, 1166-1177.e6.	4.5	39
3980	Mechanisms Underlying Recurrent Genomic Amplification in Human Cancers. Trends in Cancer, 2020, 6, 462-477.	3.8	43
3981	Genome-Wide Open Chromatin Methylome Profiles in Colorectal Cancer. Biomolecules, 2020, 10, 719.	1.8	12

#	Article	IF	Citations
3982	Histone Acetyltransferase (HAT) P300/CBP Inhibitors Induce Synthetic Lethality in PTEN-Deficient Colorectal Cancer Cells through Destabilizing AKT. International Journal of Biological Sciences, 2020, 16, 1774-1784.	2.6	17
3983	Diverse LEF/TCF Expression in Human Colorectal Cancer Correlates with Altered Wnt-Regulated Transcriptome in a Meta-Analysis of Patient Biopsies. Genes, 2020, 11, 538.	1.0	12
3984	MSI and EBV Positive Gastric Cancerâ€™s Subgroups and Their Link with Novel Immunotherapy. Journal of Clinical Medicine, 2020, 9, 1427.	1.0	55
3985	Toosendanin-induced apoptosis in colorectal cancer cells is associated with the Îº-opioid receptor/Î²-catenin signaling axis. Biochemical Pharmacology, 2020, 177, 114014.	2.0	21
3986	20,000 picometers under the <scp>OMM</scp>: diving into the vastness of mitochondrial metabolite transport. EMBO Reports, 2020, 21, e50071.	2.0	29
3987	Identification of EMT-related high-risk stage II colorectal cancer and characterisation of metastasis-related genes. British Journal of Cancer, 2020, 123, 410-417.	2.9	20
3988	Identification of common and dissimilar biomarkers for different cancer types from gene expressions of RNA-sequencing data. Gene Reports, 2020, 19, 100654.	0.4	2
3989	Opposite Roles of the JMJD1A Interaction Partners MDFI and MDFIC in Colorectal Cancer. Scientific Reports, 2020, 10, 8710.	1.6	21
3990	Copy number variation of ubiquitin- specific proteases genes in blood leukocytes and colorectal cancer. Cancer Biology and Therapy, 2020, 21, 637-646.	1.5	2
3991	Enhanced Performance of DNA Methylation Markers by Simultaneous Measurement of Sense and Antisense DNA Strands after Cytosine Conversion. Clinical Chemistry, 2020, 66, 925-933.	1.5	12
3992	Patient-derived xenografts as compatible models for precision oncology. Laboratory Animal Research, 2020, 36, 14.	1.1	34
3993	Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer. Frontiers in Oncology, 2020, 10, 560.	1.3	12
3994	Targeting Protein Synthesis in Colorectal Cancer. Cancers, 2020, 12, 1298.	1.7	32
3995	RAS-targeted therapies: is the undruggable drugged?. Nature Reviews Drug Discovery, 2020, 19, 533-552.	21.5	569
3996	The clonal evolution of metastatic colorectal cancer. Science Advances, 2020, 6, eaay9691.	4.7	41
3997	A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases. Journal of Translational Medicine, 2020, 18, 234.	1.8	14
3998	A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial. Clinical Cancer Research, 2020, 26, 4503-4510.	3.2	81
3999	Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence. British Journal of Cancer, 2020, 123, 803-810.	2.9	55

#	Article	IF	Citations
4000	Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Nature Reviews Clinical Oncology, 2020, 17, 595-610.	12.5	124
4001	Profiling DNA mutation patterns by SERS fingerprinting for supervised cancer classification. Biosensors and Bioelectronics, 2020, 165, 112392.	5.3	32
4002	Label-free, automated classification of microsatellite status in colorectal cancer by infrared imaging. Scientific Reports, 2020, 10, 10161.	1.6	13
4003	Population-based Screening for <i>BRAF</i>V600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis. Clinical Cancer Research, 2020, 26, 4599-4605.	3.2	26
4004	Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives. Cancer Treatment Reviews, 2020, 88, 102030.	3.4	44
4005	The Hepatitis B Virus Pre-Core Protein p22 Activates Wnt Signaling. Cancers, 2020, 12, 1435.	1.7	10
4006	Prevalence of <i>PRKDC</i> mutations and association with response to immune checkpoint inhibitors in solid tumors. Molecular Oncology, 2020, 14, 2096-2110.	2.1	21
4007	A mouse model for peritoneal metastases of colorectal origin recapitulates patient heterogeneity. Laboratory Investigation, 2020, 100, 1465-1474.	1.7	17
4008	First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer. Molecular Cancer Therapeutics, 2020, 19, 1598-1612.	1.9	19
4009	Oxygen battle in the gut: Hypoxia and hypoxia-inducible factors in metabolic and inflammatory responses in the intestine. Journal of Biological Chemistry, 2020, 295, 10493-10505.	1.6	170
4010	A TGFÎ²-Dependent Stromal Subset Underlies Immune Checkpoint Inhibitor Efficacy in DNA Mismatch Repairâ€"Deficient/Microsatellite Instability-High Colorectal Cancer. Molecular Cancer Research, 2020, 18, 1402-1413.	1.5	20
4011	Lineage Reversion Drives WNT Independence in Intestinal Cancer. Cancer Discovery, 2020, 10, 1590-1609.	7.7	52
4012	Left-sided location is a risk factor for lymph node metastasis of T1 colorectal cancer: a single-center retrospective study. International Journal of Colorectal Disease, 2020, 35, 1911-1919.	1.0	20
4013	The Relevance of Transcription Factors in Gastric and Colorectal Cancer Stem Cells Identification and Eradication. Frontiers in Cell and Developmental Biology, 2020, 8, 442.	1.8	29
4014	RNF8 induces Î²-catenin-mediated c-Myc expression and promotes colon cancer proliferation. International Journal of Biological Sciences, 2020, 16, 2051-2062.	2.6	22
4015	Adjuvant chemotherapy in rectal cancer: state of the art and future perspectives. Current Opinion in Oncology, 2020, 32, 377-383.	1.1	12
4016	Current status and perspectives of patient-derived rare cancer models. Human Cell, 2020, 33, 919-929.	1.2	15
4017	Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion. Clinical Colorectal Cancer, 2020, 19, 165-177.	1.0	15

#	Article	IF	Citations
4018	Metformin as an Alternative Radiosensitizing Agent to 5-Fluorouracil During Neoadjuvant Treatment for Rectal Cancer. Diseases of the Colon and Rectum, 2020, 63, 918-926.	0.7	23
4019	Circulating Tumor DNA as a Preoperative Marker of Recurrence in Patients with Peritoneal Metastases of Colorectal Cancer: A Clinical Feasibility Study. Journal of Clinical Medicine, 2020, 9, 1738.	1.0	15
4020	Discovery of 3-Quinazolin-4(3<i>H</i>)-on-3-yl-2,<i>N</i>-dimethylpropanamides as Orally Active and Selective PI3KÎ± Inhibitors. ACS Medicinal Chemistry Letters, 2020, 11, 1463-1469.	1.3	4
4021	CUX1, A Controversial Player in Tumor Development. Frontiers in Oncology, 2020, 10, 738.	1.3	16
4022	Clinical-Grade Detection of Microsatellite Instability in Colorectal Tumors by Deep Learning. Gastroenterology, 2020, 159, 1406-1416.e11.	0.6	209
4023	Development and validation of an individualized gene expression-based signature to predict overall survival in metastatic colorectal cancer. Annals of Translational Medicine, 2020, 8, 96-96.	0.7	6
4024	Single Cell Transcriptome in Colorectal Cancerâ€"Current Updates on Its Application in Metastasis, Chemoresistance and the Roles of Circulating Tumor Cells. Frontiers in Pharmacology, 2020, 11, 135.	1.6	33
4025	Germline Mutations in FAF1 Are Associated With Hereditary Colorectal Cancer. Gastroenterology, 2020, 159, 227-240.e7.	0.6	18
4026	12â€Chemokine signature, a predictor of tumor recurrence in colorectal cancer. International Journal of Cancer, 2020, 147, 532-541.	2.3	39
4027	ecTMB: a robust method to estimate and classify tumor mutational burden. Scientific Reports, 2020, 10, 4983.	1.6	17
4028	MCL1 Is Required for Maintenance of Intestinal Homeostasis and Prevention of Carcinogenesis in Mice. Gastroenterology, 2020, 159, 183-199.	0.6	22
4029	The (pro)renin receptor: a novel biomarker and potential therapeutic target for various cancers. Cell Communication and Signaling, 2020, 18, 39.	2.7	27
4030	<scp>KCML</scp> : a machineâ€learning framework for inference of multiâ€scale gene functions from genetic perturbation screens. Molecular Systems Biology, 2020, 16, e9083.	3.2	11
4031	Feedback analysis identifies a combination target for overcoming adaptive resistance to targeted cancer therapy. Oncogene, 2020, 39, 3803-3820.	2.6	14
4032	APC/C ubiquitin ligase: Functions and mechanisms in tumorigenesis. Seminars in Cancer Biology, 2020, 67, 80-91.	4.3	57
4033	Metabolic and immunologic control of intestinal cell function by mTOR. International Immunology, 2020, 32, 455-465.	1.8	10
4034	Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment. Antioxidants, 2020, 9, 207.	2.2	12
4035	Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer. Radiotherapy and Oncology, 2020, 146, 29-36.	0.3	20

#	Article	IF	Citations
4036	Genomic variation as a marker of response to neoadjuvant therapy in locally advanced rectal cancer. Molecular and Cellular Oncology, 2020, 7, 1716618.	0.3	11
4037	Loss of the nuclear Wnt pathway effector TCF7L2 promotes migration and invasion of human colorectal cancer cells. Oncogene, 2020, 39, 3893-3909.	2.6	45
4038	Whole genome analysis identifies the association of TP53 genomic deletions with lower survival in Stage III colorectal cancer. Scientific Reports, 2020, 10, 5009.	1.6	8
4039	Î±-Ketoglutarate attenuates Wnt signaling and drives differentiation in colorectal cancer. Nature Cancer, 2020, 1, 345-358.	5.7	85
4040	Molecular Aspects of Colorectal Adenomas: The Interplay among Microenvironment, Oxidative Stress, and Predisposition. BioMed Research International, 2020, 2020, 1-19.	0.9	34
4041	NGS Evaluation of Colorectal Cancer Reveals Interferon Gamma Dependent Expression of Immune Checkpoint Genes and Identification of Novel IFNÎ³ Induced Genes. Frontiers in Immunology, 2020, 11, 224.	2.2	16
4042	Single Nucleotide Polymorphisms in 25-Hydroxyvitamin D3 1-Alpha-Hydroxylase (CYP27B1) Gene: The Risk of Malignant Tumors and Other Chronic Diseases. Nutrients, 2020, 12, 801.	1.7	16
4043	Targeting P4HA1 with a Small Molecule Inhibitor in a Colorectal Cancer PDX Model. Translational Oncology, 2020, 13, 100754.	1.7	28
4044	Degree and site of chromosomal instability define its oncogenic potential. Nature Communications, 2020, 11, 1501.	5.8	68
4045	Comprehensive bioinformatic analysis of Wnt1 and Wnt1-associated diseases. Intractable and Rare Diseases Research, 2020, 9, 14-22.	0.3	6
4046	Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with <i>KRAS</i>-Mutated Colorectal Cancer. Molecular Cancer Therapeutics, 2020, 19, 1148-1156.	1.9	22
4047	The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer. Oncologist, 2020, 25, 661-668.	1.9	21
4048	Comprehensive review of targeted therapy for colorectal cancer. Signal Transduction and Targeted Therapy, 2020, 5, 22.	7.1	853
4049	Functional informed genomeâ€wide interaction analysis of body mass index, diabetes and colorectal cancer risk. Cancer Medicine, 2020, 9, 3563-3573.	1.3	7
4050	Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer. Journal of Medicinal Chemistry, 2020, 63, 4183-4204.	2.9	25
4051	Potential Influences of RNF6 on Prognosis and Metastasis of Colorectal Cancer: A Clinical Analysis . OncoTargets and Therapy, 2020, Volume 13, 2031-2036.	1.0	2
4052	Inflammatory and mitogenic signals drive interleukin 23 subunit alpha (IL23A) secretion independent of IL12B in intestinal epithelial cells. Journal of Biological Chemistry, 2020, 295, 6387-6400.	1.6	25
4053	Organoid cultures of early-onset colorectal cancers reveal distinct and rare genetic profiles. Gut, 2020, 69, 2165-2179.	6.1	47

#	Article	IF	Citations
4054	Tumor Microenvironment. Cancer Treatment and Research, 2020, , .	0.2	12
4055	Phenotypic Screening of Chemical Libraries Enriched by Molecular Docking to Multiple Targets Selected from Glioblastoma Genomic Data. ACS Chemical Biology, 2020, 15, 1424-1444.	1.6	4
4056	Gene Expression Analysis of Human Papillomavirus-Associated Colorectal Carcinoma. BioMed Research International, 2020, 2020, 1-14.	0.9	10
4057	Di-Ras2 promotes renal cell carcinoma formation by activating the mitogen-activated protein kinase pathway in the absence of von Hippelâ€"Lindau protein. Oncogene, 2020, 39, 3853-3866.	2.6	7
4058	Spontaneous mutations in the single TTN gene represent high tumor mutation burden. Npj Genomic Medicine, 2020, 5, 33.	1.7	71
4059	Comprehensive transcriptome profiling of Taiwanese colorectal cancer implicates an ethnic basis for pathogenesis. Scientific Reports, 2020, 10, 4526.	1.6	9
4060	A dorsal-ventral gradient of Wnt3a/Î²-catenin signals control hindgut extension and colon formation. Development (Cambridge), 2020, 147, .	1.2	6
4061	Mechanistic and Functional Shades of Mucins and Associated Glycans in Colon Cancer. Cancers, 2020, 12, 649.	1.7	37
4062	Guanylate-Binding Protein 1: An Emerging Target in Inflammation and Cancer. Frontiers in Immunology, 2019, 10, 3139.	2.2	57
4063	Biphasic Mathematical Model of Cellâ€"Drug Interaction That Separates Target-Specific and Off-Target Inhibition and Suggests Potent Targeted Drug Combinations for Multi-Driver Colorectal Cancer Cells. Cancers, 2020, 12, 436.	1.7	13
4064	Mutations in the coat complex II component SEC23B promote colorectal cancer metastasis. Cell Death and Disease, 2020, 11, 157.	2.7	7
4065	MIR22HG acts as a tumor suppressor via TGFÎ²/SMAD signaling and facilitates immunotherapy in colorectal cancer. Molecular Cancer, 2020, 19, 51.	7.9	83
4066	CDK1 and CDC20 overexpression in patients with colorectal cancer are associated with poor prognosis: evidence from integrated bioinformatics analysis. World Journal of Surgical Oncology, 2020, 18, 50.	0.8	59
4067	Genome-Scale CRISPR Screening in Human Intestinal Organoids Identifies Drivers of TGF-Î² Resistance. Cell Stem Cell, 2020, 26, 431-440.e8.	5.2	103
4068	Predicted Drosophila Interactome Resource and web tool for functional interpretation of differentially expressed genes. Database: the Journal of Biological Databases and Curation, 2020, 2020, .	1.4	8
4069	The Impact of KRAS Mutation on the Presentation and Prognosis of Non-Metastatic Colon Cancer: an Analysis from the National Cancer Database. Journal of Gastrointestinal Surgery, 2020, 24, 1402-1410.	0.9	19
4070	The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer. Oncogene, 2020, 39, 3571-3587.	2.6	34
4071	Functionally Enigmatic Genes in Cancer: Using TCGA Data to Map the Limitations of Annotations. Scientific Reports, 2020, 10, 4106.	1.6	14

#	Article	IF	Citations
4072	Targeting colorectal cancer via nanodrug delivery systems. , 2020, , 199-212.		1
4073	Characterization of Tumor Blood Vasculature Expression of Human Invasive Bladder Cancer by Laser Capture Microdissection and Transcriptional Profiling. American Journal of Pathology, 2020, 190, 1960-1970.	1.9	8
4074	Spermine synthase and MYC cooperate to maintain colorectal cancer cell survival by repressing Bim expression. Nature Communications, 2020, 11, 3243.	5.8	55
4075	Assessment of anti-cancer effects of koenimbine on colon cancer cells. Human Antibodies, 2020, 28, 185-190.	0.6	3
4076	Molecular analysis of Chinese oesophageal squamous cell carcinoma identifies novel subtypes associated with distinct clinical outcomes. EBioMedicine, 2020, 57, 102831.	2.7	11
4077	Single-cell analysis of clonal maintenance of transcriptional and epigenetic states in cancer cells. Nature Genetics, 2020, 52, 709-718.	9.4	66
4078	Dysregulation of microRNA expression during the progression of colorectal tumors. Pathology International, 2020, 70, 633-643.	0.6	4
4079	Effect of PIERCE1 on colorectal cancer. Experimental Animals, 2020, 69, 414-422.	0.7	0
4080	Silencing the intestinal GUCY2C tumor suppressor axis requires <i>APC</i> loss of heterozygosity. Cancer Biology and Therapy, 2020, 21, 799-805.	1.5	13
4081	Genetic Markers in Lung Cancer Diagnosis: A Review. International Journal of Molecular Sciences, 2020, 21, 4569.	1.8	112
4082	Molecular dissection of CRC primary tumors and their matched liver metastases reveals critical role of immune microenvironment, EMT and angiogenesis in cancer metastasis. Scientific Reports, 2020, 10, 10725.	1.6	21
4083	Targeting Altered Energy Metabolism in Colorectal Cancer: Oncogenic Reprogramming, the Central Role of the TCA Cycle and Therapeutic Opportunities. Cancers, 2020, 12, 1731.	1.7	37
4084	miRNA Clusters with Down-Regulated Expression in Human Colorectal Cancer and Their Regulation. International Journal of Molecular Sciences, 2020, 21, 4633.	1.8	46
4085	Dysregulation of cancer genes by recurrent intergenic fusions. Genome Biology, 2020, 21, 166.	3.8	22
4086	High Expression of FAP in Colorectal Cancer Is Associated With Angiogenesis and Immunoregulation Processes. Frontiers in Oncology, 2020, 10, 979.	1.3	50
4087	Genomic and Transcriptomic Characterisation of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. Cancers, 2020, 12, 1808.	1.7	13
4088	Patient-derived tumor-like cell clusters for drug testing in cancer therapy. Science Translational Medicine, 2020, 12, .	5.8	39
4089	Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance. Drug Resistance Updates, 2020, 52, 100712.	6.5	78

#	Article	IF	Citations
4090	Wnt-driven LARGE2 mediates laminin-adhesive O-glycosylation in human colonic epithelial cells and colorectal cancer. Cell Communication and Signaling, 2020, 18, 102.	2.7	10
4091	Novel Proteome Extraction Method Illustrates a Conserved Immunological Signature of MSI-H Colorectal Tumors. Molecular and Cellular Proteomics, 2020, 19, 1619-1631.	2.5	0
4092	Intestinal stem cells and intestinal organoids. Journal of Genetics and Genomics, 2020, 47, 289-299.	1.7	7
4093	HER2 in Colorectal Carcinoma. Surgical Pathology Clinics, 2020, 13, 485-502.	0.7	24
4094	Genomic profiling of microRNA target genes in colorectal cancer. Tumor Biology, 2020, 42, 101042832093351.	0.8	4
4095	Next-generation sequencing reveals heterogeneous genetic alterations in key signaling pathways of mismatch repair deficient colorectal carcinomas. Modern Pathology, 2020, 33, 2591-2601.	2.9	17
4096	Genomic profiling of colorectal cancer with isolated lung metastasis. Cancer Cell International, 2020, 20, 281.	1.8	7
4097	Genomic Alterations of <i>NTRK</i>, <i>POLE</i>, <i>ERBB2</i>, and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer. Oncologist, 2020, 25, e1671-e1680.	1.9	17
4098	Identification of Genes Related to Clinicopathological Characteristics and Prognosis of Patients with Colorectal Cancer. DNA and Cell Biology, 2020, 39, 690-699.	0.9	21
4099	Improving prediction performance of colon cancer prognosis based on the integration of clinical and multi-omics data. BMC Medical Informatics and Decision Making, 2020, 20, 22.	1.5	20
4100	Mutational processes of distinct POLE exonuclease domain mutants drive an enrichment of a specific TP53 mutation in colorectal cancer. PLoS Genetics, 2020, 16, e1008572.	1.5	27
4101	Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples. Journal of Translational Medicine, 2020, 18, 99.	1.8	12
4102	Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer. Genome Medicine, 2020, 12, 20.	3.6	25
4103	Organoid models of gastrointestinal cancers in basic and translational research. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 203-222.	8.2	108
4104	Significance of gene mutations in the Wnt signaling pathway in traditional serrated adenomas of the colon and rectum. PLoS ONE, 2020, 15, e0229262.	1.1	8
4105	CCBE1 promotes tumor lymphangiogenesis and is negatively regulated by TGFÎ² signaling in colorectal cancer. Theranostics, 2020, 10, 2327-2341.	4.6	37
4106	Impact of mutations in DNA methylation modification genes on genome-wide methylation landscapes and downstream gene activations in pan-cancer. BMC Medical Genomics, 2020, 13, 27.	0.7	17
4107	Cytokine-Induced Guanylate Binding Protein 1 (GBP1) Release from Human Ovarian Cancer Cells. Cancers, 2020, 12, 488.	1.7	14

#	Article	IF	Citations
4108	Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. Cancer Cell, 2020, 37, 371-386.e12.	7.7	68
4109	Chemical Standardization and Anti-Proliferative Activity of Ardisia elliptica Fruit against the HCT116 Human Colon Cancer Cell Line. Molecules, 2020, 25, 1023.	1.7	7
4110	Cell-type-specific signaling networks in heterocellular organoids. Nature Methods, 2020, 17, 335-342.	9.0	75
4111	Identification of potential hub genes via bioinformatics analysis combined with experimental verification in colorectal cancer. Molecular Carcinogenesis, 2020, 59, 425-438.	1.3	12
4112	Machine Learning and Bioinformatics Models to Identify Pathways that Mediate Influences of Welding Fumes on Cancer Progression. Scientific Reports, 2020, 10, 2795.	1.6	23
4113	Spectrum of EGFR aberrations and potential clinical implications: insights from integrative panâ€cancer analysis. Cancer Communications, 2020, 40, 43-59.	3.7	45
4114	APC controls Wnt-induced Î²-catenin destruction complex recruitment in human colonocytes. Scientific Reports, 2020, 10, 2957.	1.6	53
4116	BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors. BMC Cancer, 2020, 20, 129.	1.1	9
4117	Distinct Mesenchymal Cell Populations Generate the Essential Intestinal BMP Signaling Gradient. Cell Stem Cell, 2020, 26, 391-402.e5.	5.2	211
4118	RBP EIF2S2 Promotes Tumorigenesis and Progression by Regulating MYC-Mediated Inhibition via FHIT-Related Enhancers. Molecular Therapy, 2020, 28, 1105-1118.	3.7	37
4119	Yogurt consumption and colorectal polyps. British Journal of Nutrition, 2020, 124, 80-91.	1.2	14
4120	Early-onset colorectal cancer: initial clues and current views. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 352-364.	8.2	220
4121	Autocatalytic Tissue Polymerization Reaction Mechanism in Colorectal Cancer Development and Growth. Cancers, 2020, 12, 460.	1.7	3
4122	Commonly observed RNF43 mutations retain functionality in attenuating Wnt/Î²-catenin signaling and unlikely confer Wnt-dependency onto colorectal cancers. Oncogene, 2020, 39, 3458-3472.	2.6	31
4123	Investigation of sirtuin 1 polymorphisms in relation to the risk of colorectal cancer by molecular subtype. Scientific Reports, 2020, 10, 3359.	1.6	3
4124	Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?. Gastroenterology Report, 2020, 8, 11-24.	0.6	68
4125	Norepinephrineâ€CREB1â€miRâ€373 axis promotes progression of colon cancer. Molecular Oncology, 2020, 14, 1059-1073.	2.1	16
4126	Tumors of theÂGastrointestinal System Including the Pancreas. , 2020, , 691-870.		0

#	Article	IF	Citations
4127	Next generation sequencing of cervical high grade dysplasia and invasive squamous cell carcinoma: A case study. Pathology Research and Practice, 2020, 216, 152863.	1.0	1
4128	Recent insight into the role of FBXW7 as a tumor suppressor. Seminars in Cancer Biology, 2020, 67, 1-15.	4.3	74
4129	HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer. Clinical Colorectal Cancer, 2020, 19, 65-72.	1.0	35
4130	Human endogenous retroviruses env gene expression and long terminal repeat methylation in colorectal cancer patients. Medical Microbiology and Immunology, 2020, 209, 189-199.	2.6	10
4131	Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. British Journal of Cancer, 2020, 122, 1014-1022.	2.9	9
4132	APC-Î²-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis. Cancer Biology and Therapy, 2020, 21, 441-451.	1.5	10
4133	Clinicopathological and molecular correlations in traditional serrated adenoma. Journal of Gastroenterology, 2020, 55, 418-427.	2.3	15
4134	DNMT3B Oncogenic Activity in Human Intestinal Cancer Is Not Linked to CIMP or BRAFV600E Mutation. IScience, 2020, 23, 100838.	1.9	4
4135	Insights regarding novel biomarkers and the pathogenesis of primary colorectal carcinoma based on bioinformatic analysis. Computational Biology and Chemistry, 2020, 85, 107229.	1.1	14
4136	Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutantâ€“driven tumor growth. Science Advances, 2020, 6, eaay2174.	4.7	51
4137	Targeting RICTOR Sensitizes SMAD4-Negative Colon Cancer to Irinotecan. Molecular Cancer Research, 2020, 18, 414-423.	1.5	12
4138	Quantitative Proteomics of the Cancer Cell Line Encyclopedia. Cell, 2020, 180, 387-402.e16.	13.5	596
4139	Pembrolizumab for the treatment of colorectal cancer. Expert Opinion on Biological Therapy, 2020, 20, 219-226.	1.4	21
4140	Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants. Trends in Cancer, 2020, 6, 111-129.	3.8	9
4141	Extensive rewiring of the EGFR network in colorectal cancer cells expressing transforming levels of KRASG13D. Nature Communications, 2020, 11, 499.	5.8	42
4142	FGF14 Functions as a Tumor Suppressor through Inhibiting PI3K/AKT/mTOR Pathway in Colorectal Cancer. Journal of Cancer, 2020, 11, 819-825.	1.2	13
4143	Singleâ€molecule detection of cancer mutations using a novel PCRâ€LDRâ€qPCR assay. Human Mutation, 2020, 41, 1051-1068.	1.1	8
4144	A Multi-Omics Analysis of Bone Morphogenetic Protein 5 (BMP5) mRNA Expression and Clinical Prognostic Outcomes in Different Cancers Using Bioinformatics Approaches. Biomedicines, 2020, 8, 19.	1.4	23

#	Article	IF	Citations
4145	Cancer Stem Cell Marker DCLK1 Correlates with Tumorigenic Immune Infiltrates in the Colon and Gastric Adenocarcinoma Microenvironments. Cancers, 2020, 12, 274.	1.7	53
4146	Modeling rectal cancer to advance neoadjuvant precision therapy. International Journal of Cancer, 2020, 147, 1405-1418.	2.3	25
4147	MicroRNAâ€876â€5p represses the cell proliferation and invasion of colorectal cancer through suppressing YAP signalling via targeting RASAL2. Clinical and Experimental Pharmacology and Physiology, 2020, 47, 867-876.	0.9	11
4148	An Exon Signature to Estimate the Tumor Mutational Burden of Right-sided Colon Cancer Patients. Journal of Cancer, 2020, 11, 883-892.	1.2	5
4149	The somatic mutation landscape of Chinese Colorectal Cancer. Journal of Cancer, 2020, 11, 1038-1046.	1.2	16
4150	Rational application of targeted therapeutics in mucinous colon/appendix cancers with positive predictive factors. Cancer Medicine, 2020, 9, 1753-1767.	1.3	9
4151	ERCC1, PARP-1, and AQP1 as predictive biomarkers in colon cancer patients receiving adjuvant chemotherapy. Cancer Biomarkers, 2020, 27, 251-264.	0.8	9
4152	Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. BioMed Research International, 2020, 2020, 1-24.	0.9	38
4153	Evidence-Based Network Approach to Recommending Targeted Cancer Therapies. JCO Clinical Cancer Informatics, 2020, 4, 71-88.	1.0	8
4154	Mutation Analysis of Colorectal and Gastric Carcinomas Originating from Adenomas: Insights into Genomic Evolution Associated with Malignant Progression. Cancers, 2020, 12, 325.	1.7	5
4155	Revelation of Proteomic Indicators for Colorectal Cancer in Initial Stages of Development. Molecules, 2020, 25, 619.	1.7	31
4156	ADAMTS8 is frequently down-regulated in colorectal cancer and functions as a tumor suppressor. Biochemical and Biophysical Research Communications, 2020, 524, 663-671.	1.0	14
4157	Coaltered <i>Ras/B-raf</i> and <i>TP53</i> Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2020, 26, 1077-1085.	3.2	62
4158	Gene expression network analysis of lymph node involvement in colon cancer identifies AHSA2, CDK10, and CWC22 as possible prognostic markers. Scientific Reports, 2020, 10, 7170.	1.6	6
4159	The Prognostic Value of the Detection of Microbial Translocation in the Blood of Colorectal Cancer Patients. Cancers, 2020, 12, 1058.	1.7	19
4160	Application of trastuzumab emtansine in HERâ€2â€"positive and KRAS/BRAFâ€mutated colon cancer cells. European Journal of Clinical Investigation, 2020, 50, e13255.	1.7	5
4161	Homologous Recombination Repair Truncations Predict Hypermutation in Microsatellite Stable Colorectal and Endometrial Tumors. Clinical and Translational Gastroenterology, 2020, 11, e00149.	1.3	8
4163	Pooled InÂVitro and InÂVivo CRISPR-Cas9 Screening Identifies Tumor Suppressors in Human Colon Organoids. Cell Stem Cell, 2020, 26, 782-792.e7.	5.2	131

#	Article	IF	Citations
4164	Identification of novel biomarkers affecting the metastasis of colorectal cancer through bioinformatics analysis and validation through qRT-PCR. Cancer Cell International, 2020, 20, 105.	1.8	10
4165	Actionable Potentials of Less Frequently Mutated Genes in Colorectal Cancer and Their Roles in Precision Medicine. Biomolecules, 2020, 10, 476.	1.8	8
4166	Emerging links between endosomal pH and cancer. Cancer and Metastasis Reviews, 2020, 39, 519-534.	2.7	49
4167	Switch/sucrose nonfermenting nucleosome complexâ€“deficient colorectal carcinomas have distinct clinicopathologic features. Human Pathology, 2020, 99, 53-61.	1.1	7
4168	Nanobody-based therapeutics against colorectal cancer: Precision therapies based on the personal mutanome profile and tumor neoantigens. Pharmacological Research, 2020, 156, 104790.	3.1	25
4169	Targeting the Î²-catenin signaling for cancer therapy. Pharmacological Research, 2020, 160, 104794.	3.1	54
4170	Interference with ERK-dimerization at the nucleocytosolic interface targets pathological ERK1/2 signaling without cardiotoxic side-effects. Nature Communications, 2020, 11, 1733.	5.8	38
4171	Curcumin Î²â€Dâ€glucuronide exhibits antiâ€“tumor effects on oxaliplatinâ€resistant colon cancer with less toxicity in vivo. Cancer Science, 2020, 111, 1785-1793.	1.7	21
4172	<i>PRKDC</i>: new biomarker and drug target for checkpoint blockade immunotherapy. , 2020, 8, e000485.		32
4173	Analysis of the Circadian Regulation of Cancer Hallmarks by a Cross-Platform Study of Colorectal Cancer Time-Series Data Reveals an Association with Genes Involved in Huntingtonâ€™s Disease. Cancers, 2020, 12, 963.	1.7	15
4174	Mapping the spreading routes of lymphatic metastases in human colorectal cancer. Nature Communications, 2020, 11, 1993.	5.8	68
4175	Control of Angiogenesis via a VHL/miR-212/132 Axis. Cells, 2020, 9, 1017.	1.8	12
4176	Lineage-Specific Epigenomic and Genomic Activation of Oncogene HNF4A Promotes Gastrointestinal Adenocarcinomas. Cancer Research, 2020, 80, 2722-2736.	0.4	37
4177	Canonical BMP Signaling Executes Epithelial-Mesenchymal Transition Downstream of SNAIL1. Cancers, 2020, 12, 1019.	1.7	17
4178	The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis. Cancers, 2020, 12, 1022.	1.7	16
4179	Human Papillomaviruses and Epsteinâ€“Barr Virus Interactions in Colorectal Cancer: A Brief Review. Pathogens, 2020, 9, 300.	1.2	17
4180	Prevalence and characteristics of <i>PIK3CA</i> mutation in mismatch repair-deficient colorectal cancer. Journal of Cancer, 2020, 11, 3827-3833.	1.2	12
4181	Sequencing Strategies for Fusion Gene Detection. BioEssays, 2020, 42, 2000016.	1.2	18

#	Article	IF	Citations
4182	Tumourâ€suppressive effect of oestrogen receptor Î² in colorectal cancer patients, colon cancer cells, and a zebrafish model. Journal of Pathology, 2020, 251, 297-309.	2.1	19
4183	Altered ARID1A expression in colorectal cancer. BMC Cancer, 2020, 20, 350.	1.1	14
4184	Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2020, 26, 4010-4017.	3.2	22
4185	Gastrointestinal tissueâ€based molecular biomarkers: a practical categorisation based on the 2019 World Health Organization classification of epithelial digestive tumours. Histopathology, 2020, 77, 340-350.	1.6	26
4186	<i>KLF4</i> p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer. Molecular Cancer Therapeutics, 2020, 19, 956-965.	1.9	5
4187	Decreased copyâ€neutral loss of heterozygosity in African American colorectal cancers. Genes Chromosomes and Cancer, 2020, 59, 454-464.	1.5	1
4188	Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study. ESMO Open, 2020, 5, e000638.	2.0	47
4189	Comparative genomic profiling of glandular bladder tumours. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 445-454.	1.4	22
4190	How does intestinal-type intraductal papillary mucinous neoplasm emerge? CDX2 plays a critical role in the process of intestinal differentiation and progression. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 21-31.	1.4	17
4191	Promoter Hypomethylation and Increased Expression of the Long Non-coding RNA LINC00152 Support Colorectal Carcinogenesis. Pathology and Oncology Research, 2020, 26, 2209-2223.	0.9	11
4192	Pan-cancer analysis and applications. , 2020, , 307-316.		0
4193	Characterization of a p53/miR-34a/CSF1R/STAT3 Feedback Loop in Colorectal Cancer. Cellular and Molecular Gastroenterology and Hepatology, 2020, 10, 391-418.	2.3	64
4194	Comparative lipidomics of 5-Fluorouracilâ€"sensitive and â€"resistant colorectal cancer cells reveals altered sphingomyelin and ceramide controlled by acid sphingomyelinase (SMPD1). Scientific Reports, 2020, 10, 6124.	1.6	26
4195	Rational design of peptides for identification of linear epitopes and generation of neutralizing monoclonal antibodies against DKK2 for cancer therapy. Antibody Therapeutics, 2020, 3, 63-70.	1.2	5
4196	The Human DNA Mismatch Repair Protein MSH3 Contains Nuclear Localization and Export Signals That Enable Nuclear-Cytosolic Shuttling in Response to Inflammation. Molecular and Cellular Biology, 2020, 40, .	1.1	17
4197	Right and left-sided colon cancers - specificity of molecular mechanisms in tumorigenesis and progression. BMC Cancer, 2020, 20, 317.	1.1	51
4198	Long Non-Coding RNA LEF1-AS1 Promotes Migration, Invasion and Metastasis of Colon Cancer Cells Through miR-30-5p/SOX9 Axis . OncoTargets and Therapy, 2020, Volume 13, 2957-2972.	1.0	19
4199	Role of Wnt/<i>Î²</i>-Catenin Signaling in the Chemoresistance Modulation of Colorectal Cancer. BioMed Research International, 2020, 2020, 1-9.	0.9	69

#	Article	IF	Citations
4200	Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. Clinical Cancer Research, 2020, 26, 3117-3125.	3.2	13
4201	STAT1 as a potential prognosis marker for poor outcomes of early stage colorectal cancer with microsatellite instability. PLoS ONE, 2020, 15, e0229252.	1.1	22
4202	Precision in cancer pharmacogenomics. Pharmacogenomics, 2020, 21, 311-316.	0.6	1
4203	ZMYND8 expression combined with pN and pM classification as a novel prognostic prediction model for colorectal cancer: Based on TCGA and GEO database analysis. Cancer Biomarkers, 2020, 28, 201-211.	0.8	14
4204	Investigation of miRNA and mRNA Co-expression Network in Ependymoma. Frontiers in Bioengineering and Biotechnology, 2020, 8, 177.	2.0	13
4205	Evolutionary Action Score of TP53 Enhances the Prognostic Prediction for Stage I Lung Adenocarcinoma. Seminars in Thoracic and Cardiovascular Surgery, 2021, 33, 221-229.	0.4	2
4206	Upregulation of TIGIT and PD-1 in Colorectal Cancer with Mismatch-repair Deficiency. Immunological Investigations, 2021, 50, 338-355.	1.0	18
4207	Biologically based models of cancer risk in radiation research. International Journal of Radiation Biology, 2021, 97, 2-11.	1.0	11
4208	Stereotactic ablative radiotherapy for colorectal cancer liver metastasis. Seminars in Cancer Biology, 2021, 71, 21-32.	4.3	14
4209	Therapeutics Targeting Mutant KRAS. Annual Review of Medicine, 2021, 72, 349-364.	5.0	41
4210	Characterization of genomic alterations in Chinese colorectal cancer patients. Japanese Journal of Clinical Oncology, 2021, 51, 120-129.	0.6	10
4211	Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling. Redox Biology, 2021, 38, 101780.	3.9	42
4212	Artesunate inhibits intestinal tumorigenesis through inhibiting wnt signaling. Carcinogenesis, 2021, 42, 148-158.	1.3	4
4213	Recent Advances in Digestive Tract Tumors: Updates From the 5th Edition of the World Health Organization â€œBlue Bookâ€. Archives of Pathology and Laboratory Medicine, 2021, 145, 607-626.	1.2	17
4214	Genomic profile and immune contexture in colorectal cancerâ€”relevance for prognosis and immunotherapy. Clinical and Experimental Medicine, 2021, 21, 195-204.	1.9	5
4215	In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer. Clinical Cancer Research, 2021, 27, 288-300.	3.2	13
4216	Analysis of genomic pathogenesis according to the revised Bethesda guidelines and additional criteria. Journal of Cancer Research and Clinical Oncology, 2021, 147, 117-128.	1.2	7
4217	Tumor Sidedness, Recurrence, and Survival After Curative Resection of Localized Colon Cancer. Clinical Colorectal Cancer, 2021, 20, e53-e60.	1.0	24

#	Article	IF	Citations
4218	Curcumin: A therapeutic strategy for colorectal cancer?. Seminars in Cancer Biology, 2021, 73, 321-330.	4.3	31
4219	Major driver mutations are shared between sinonasal intestinal-type adenocarcinoma and the morphologically identical colorectal adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1019-1027.	1.2	14
4220	Technologies for targeting DNA methylation modifications: Basic mechanism and potential application in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188454.	3.3	23
4221	Mutations and mechanisms of WNT pathway tumour suppressors in cancer. Nature Reviews Cancer, 2021, 21, 5-21.	12.8	235
4222	Targeting cancer-cell mitochondria and metabolism to improve radiotherapy response. Translational Oncology, 2021, 14, 100905.	1.7	44
4223	Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. Gastroenterology, 2021, 160, 1164-1178.e6.	0.6	36
4224	IOX1 Suppresses Wnt Target Gene Transcription and Colorectal Cancer Tumorigenesis through Inhibition of KDM3 Histone Demethylases. Molecular Cancer Therapeutics, 2021, 20, 191-202.	1.9	13
4225	Characterization and Clinical Outcomes of DNA Mismatch Repairâ€“deficient Small Bowel Adenocarcinoma. Clinical Cancer Research, 2021, 27, 1429-1437.	3.2	23
4226	Tumor-derived mutations in postoperative plasma of colorectal cancer with microsatellite instability. Translational Oncology, 2021, 14, 100945.	1.7	1
4227	A genomeâ€wide study of the relationship between chromosomal abnormalities and gene expression in colorectal tumors. Genes Chromosomes and Cancer, 2021, 60, 250-262.	1.5	13
4228	Early Adaptation of Colorectal Cancer Cells to the Peritoneal Cavity Is Associated with Activation of â€œStemnessâ€• Programs and Local Inflammation. Clinical Cancer Research, 2021, 27, 1119-1130.	3.2	8
4229	Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. Cancer Treatment Reviews, 2021, 92, 102135.	3.4	2
4230	Oestrogen regulates SOX9 bioavailability by rapidly activating ERK1/2 and stabilising microtubules in a human testis-derived cell line. Experimental Cell Research, 2021, 398, 112405.	1.2	3
4231	Clinical Validation of a Machine-learningâ€“derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. Clinical Cancer Research, 2021, 27, 1174-1183.	3.2	28
4232	The p53/p73 - p21CIP1 tumor suppressor axis guards against chromosomal instability by restraining CDK1 in human cancer cells. Oncogene, 2021, 40, 436-451.	2.6	21
4233	The Balance of Stromal BMP Signaling Mediated by GREM1 and ISLR Drives Colorectal Carcinogenesis. Gastroenterology, 2021, 160, 1224-1239.e30.	0.6	76
4234	A multiplex and fast detection platform for microRNAs based on a self-priming microfluidic chip and duplex-specific nuclease. Analyst, The, 2021, 146, 628-635.	1.7	4
4235	RNA N6-Methyladenosine Methyltransferase METTL3 Facilitates Colorectal Cancer by Activating the m6A-GLUT1-mTORC1 Axis and Is a Therapeutic Target. Gastroenterology, 2021, 160, 1284-1300.e16.	0.6	161

#	Article	IF	Citations
4236	Histological Classification and Immunohistochemical Study of Feline Colorectal Epithelial Tumors. Veterinary Pathology, 2021, 58, 305-314.	0.8	8
4237	Revealing the anticancer potential of candidate drugs in vivo using Caenorhabditis elegans mutant strains. Translational Oncology, 2021, 14, 100940.	1.7	7
4238	Identification and Validation of Six Autophagy-related Long Non-coding RNAs as Prognostic Signature in Colorectal Cancer. International Journal of Medical Sciences, 2021, 18, 88-98.	1.1	23
4239	Multidisciplinary Treatment of Colorectal Cancer. , 2021, , .		2
4240	Alteration of FBXW7 is Associated with Worse Survival in Patients Undergoing Resection of Colorectal Liver Metastases. Journal of Gastrointestinal Surgery, 2021, 25, 186-194.	0.9	17
4241	Genetic heterogeneity and predictive biomarker for pulmonary sarcomatoid carcinomas. Cancer Genetics, 2021, 250-251, 12-19.	0.2	7
4242	Genotype-phenotype associations in colorectal adenocarcinomas and their matched metastases. Human Pathology, 2021, 107, 104-116.	1.1	6
4243	Peptides that immunoactivate the tumor microenvironment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188486.	3.3	20
4244	Exome sequencing identifies ARID2 as a novel tumor suppressor in early-onset sporadic rectal cancer. Oncogene, 2021, 40, 863-874.	2.6	25
4245	Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site. British Journal of Cancer, 2021, 124, 777-785.	2.9	44
4246	Acquired somatic MMR deficiency is a major cause of MSI tumor in patients suspected for â€œLynch-like syndromeâ€•including young patients. European Journal of Human Genetics, 2021, 29, 482-488.	1.4	16
4247	Novel Genetic and Epigenetic Biomarkers of Prognostic and Predictive Significance in Stage II/III Colorectal Cancer. Molecular Therapy, 2021, 29, 587-596.	3.7	52
4248	Role of Tumor Mutation Burden Analysis in Detecting Lynch Syndrome in Precision Medicine: Analysis of 2,501 Japanese Cancer Patients. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 166-174.	1.1	8
4249	A GRN Autocrine-Dependent FAM135B/AKT/mTOR Feedforward Loop Promotes Esophageal Squamous Cell Carcinoma Progression. Cancer Research, 2021, 81, 910-922.	0.4	19
4250	The atypical cadherin MUCDHL antagonizes colon cancer formation and inhibits oncogenic signaling through multiple mechanisms. Oncogene, 2021, 40, 522-535.	2.6	7
4251	<i>Boswellia sacra</i>essential oil manages colon cancer stem cells proliferation and apoptosis: a new perspective for cure. Journal of Essential Oil Research, 2021, 33, 53-62.	1.3	11
4252	Molecular characterization of ulcerative colitis-associated colorectal carcinomas. Modern Pathology, 2021, 34, 1153-1166.	2.9	7
4253	The role of miRNAs in colorectal cancer progression and chemoradiotherapy. Biomedicine and Pharmacotherapy, 2021, 134, 111099.	2.5	76

#	Article	IF	Citations
4254	Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity. Journal of Pathology: Clinical Research, 2021, 7, 75-85.	1.3	4
4255	FMSâ€like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer. Cancer Science, 2021, 112, 314-322.	1.7	8
4256	Genomic destabilization and its associated mutagenesis increase with senescenceâ€associated phenotype expression. Cancer Science, 2021, 112, 515-522.	1.7	14
4257	CIP2A regulates MYC translation (via its 5â€²UTR) in colorectal cancer. International Journal of Colorectal Disease, 2021, 36, 911-918.	1.0	6
4258	Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. Clinical Cancer Research, 2021, 27, 120-130.	3.2	21
4259	Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-XL inhibitor ABT-263 in KRAS-mutant colorectal cancers. Cancer Letters, 2021, 497, 123-136.	3.2	8
4260	Genomic Landscape of Early-stage Colorectal Neoplasia Developing From the Ulcerative Colitis Mucosa in the Japanese Population. Inflammatory Bowel Diseases, 2021, 27, 686-696.	0.9	5
4261	Frequency and coexistence of <i>KRAS</i>, <i>NRAS</i>, <i>BRAF</i> and <i>PIK3CA</i> mutations and occurrence of MMR deficiency in Danish colorectal cancer patients. Apmis, 2021, 129, 61-69.	0.9	10
4262	Transmembrane and Immunoglobulin Domain Containing 1, a Putative Tumor Suppressor, Induces G2/M Cell Cycle Checkpoint Arrest in Colon Cancer Cells. American Journal of Pathology, 2021, 191, 157-167.	1.9	13
4263	Stromal reaction inhibitor and immune-checkpoint inhibitor combination therapy attenuates excluded-type colorectal cancer in a mouse model. Cancer Letters, 2021, 498, 111-120.	3.2	5
4264	Epithelial cell dysfunction in coeliac disease. International Review of Cell and Molecular Biology, 2021, 358, 133-164.	1.6	8
4265	Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). Clinical Cancer Research, 2021, 27, 267-275.	3.2	13
4266	Alteration of fecal microbiota by fucoxanthin results in prevention of colorectal cancer in AOM/DSS mice. Carcinogenesis, 2021, 42, 210-219.	1.3	33
4267	A-CaMP: a tool for anti-cancer and antimicrobial peptide generation. Journal of Biomolecular Structure and Dynamics, 2021, 39, 285-293.	2.0	10
4269	The Infiltration Pattern of Microenvironmental Cells and Different Immune Escape Mechanisms in Colorectal Cancer. SSRN Electronic Journal, 0, , .	0.4	0
4270	CÃ¡ncer colorrectal. Medicine, 2021, 13, 1335-1344.	0.0	1
4271	Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator. Seminars in Cancer Biology, 2022, 83, 335-352.	4.3	28
4272	Unraveling the genomic landscape of colorectal cancer through mutational signatures. Advances in Cancer Research, 2021, 151, 385-424.	1.9	14

#	Article	IF	Citations
4273	Fusobacterium nucleatum Promotes the Progression of Colorectal Cancer Through Cdk5-Activated Wnt/Î²-Catenin Signaling. Frontiers in Microbiology, 2020, 11, 545251.	1.5	22
4274	Integrated molecular characterisation of the MAPK pathways in human cancers reveals pharmacologically vulnerable mutations and gene dependencies. Communications Biology, 2021, 4, 9.	2.0	32
4275	Role and potential clinical utility of ARID1A in gastrointestinal malignancy. Mutation Research - Reviews in Mutation Research, 2021, 787, 108360.	2.4	9
4276	The 2019 World Health Organization Classification of appendiceal, colorectal and anal canal tumours: an update and critical assessment. Pathology, 2021, 53, 454-461.	0.3	55
4277	Integration of gene expression data identifies key genes and pathways in colorectal cancer. Medical Oncology, 2021, 38, 7.	1.2	17
4278	Do clinical trials change practice? A longitudinal, international assessment of colorectal cancer prescribing practices. Cancer Treatment and Research Communications, 2021, 28, 100445.	0.7	1
4279	Characterization of metabolic responses, genetic variations, and microsatellite instability in ammonia-stressed CHO cells grown in fed-batch cultures. BMC Biotechnology, 2021, 21, 4.	1.7	10
4280	Adenylosuccinate lyase is oncogenic in colorectal cancer by causing mitochondrial dysfunction and independent activation of NRF2 and mTOR-MYC-axis. Theranostics, 2021, 11, 4011-4029.	4.6	19
4281	Examining the Role of the MACC1 Gene in Colorectal Cancer Metastasis. , 2021, , 327-352.		0
4282	Racial and ethnic disparities in colorectal cancer incidence and mortality. Advances in Cancer Research, 2021, 151, 197-229.	1.9	37
4283	Multiple microarray analyses identify key genes associated with the development of Non-Small Cell Lung Cancer from Chronic Obstructive Pulmonary Disease. Journal of Cancer, 2021, 12, 996-1010.	1.2	11
4284	Rho GTPases as Key Molecular Players within Intestinal Mucosa and GI Diseases. Cells, 2021, 10, 66.	1.8	14
4285	Molecular Heterogeneity of High Grade Colorectal Adenocarcinoma. Cancers, 2021, 13, 233.	1.7	4
4287	Rate volatility and asymmetric segregation diversify mutation burden in cells with mutator alleles. Communications Biology, 2021, 4, 21.	2.0	1
4288	NOTCH Activation via gp130/STAT3 Signaling Confers Resistance to Chemoradiotherapy. Cancers, 2021, 13, 455.	1.7	8
4289	Features of colorectal cancer in China stratified by anatomic sites: A hospital-based study conducted in university-affiliated hospitals from 2014 to 2018. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 500-511.	0.7	11
4290	Liquid Biopsy Cell-free DNA Biomarkers in Patients With Oligometastatic Colorectal Cancer Treated by Ablative Radiotherapy. Anticancer Research, 2021, 41, 829-834.	0.5	9
4291	Learning Domain-Agnostic Visual Representation for Computational Pathology Using Medically-Irrelevant Style Transfer Augmentation. IEEE Transactions on Medical Imaging, 2021, 40, 3945-3954.	5.4	34

#	Article	IF	Citations
4292	Deep Learning in Multi-Omics Data Integration in Cancer Diagnostic. , 2021, , 255-271.		3
4293	Treatment-induced evolutionary dynamics in nonmetastatic locally advanced rectal adenocarcinoma. Advances in Cancer Research, 2021, 151, 39-67.	1.9	2
4294	Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy. Advances in Cancer Research, 2021, 151, 231-304.	1.9	8
4295	Regulation of Wnt Signaling Pathways at the Plasma Membrane and Their Misregulation in Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 631623.	1.8	44
4296	Spindle and kinetochoreâ€'associated complex subunit 3 accelerates breast cancer cell proliferation and invasion through the regulation of Akt/Wnt/Î²-catenin signaling. Breast Cancer Research and Treatment, 2021, 186, 247-258.	1.1	6
4297	Expression and Role of Dickkopf-1 (Dkk1) in Tumors: From the Cells to the Patients. Cancer Management and Research, 2021, Volume 13, 659-675.	0.9	34
4298	Hedgehog Signaling in Colorectal Cancer: All in the Stroma?. International Journal of Molecular Sciences, 2021, 22, 1025.	1.8	17
4299	Evaluating the utility of tumour mutational signatures for identifying hereditary colorectal cancer and polyposis syndrome carriers. Gut, 2021, 70, 2138-2149.	6.1	27
4300	Deep learning model for the prediction of microsatellite instability in colorectal cancer: a diagnostic study. Lancet Oncology, The, 2021, 22, 132-141.	5.1	198
4301	Immunohistochemical Loss of DPC4 in Tumors With Mucinous Differentiation Arising in or Involving the Gynecologic Tract. International Journal of Gynecological Pathology, 2021, 40, 523-532.	0.9	3
4302	The Pharmacology of WNT Signaling. , 2021, , .		0
4303	Role of CRISPR/Cas9 and other gene editing/engineering technology in intestine diseases. , 2021, , 75-86.		0
4304	Long intergenic non-coding RNA LINC00485 exerts tumor-suppressive activity by regulating miR-581/EDEM1 axis in colorectal cancer. Aging, 2021, 13, 3866-3885.	1.4	5
4305	Regulator of Chromosome Condensation 2 Modulates Cell Cycle Progression, Tumorigenesis, and Therapeutic Resistance. Frontiers in Molecular Biosciences, 2020, 7, 620973.	1.6	7
4306	Functional Common and Rare <i>ERBB2</i> Germline Variants Cooperate in Familial and Sporadic Cancer Susceptibility. Cancer Prevention Research, 2021, 14, 441-454.	0.7	0
4307	ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin. Nature Biotechnology, 2021, 39, 586-598.	9.4	81
4308	Colon cancer and immunotherapyâ€"can we go beyond microsatellite instability?. Translational Gastroenterology and Hepatology, 2021, 6, 12-12.	1.5	19
4309	Molecular correlates of immune cytolytic subgroups in colorectal cancer by integrated genomics analysis. NAR Cancer, 2021, 3, zcab005.	1.6	9

#	Article	IF	Citations
4310	Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin. PLoS ONE, 2021, 16, e0245581.	1.1	8
4311	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature Genetics, 2021, 53, 86-99.	9.4	118
4312	Rationalizing heptadecaphobia: T_H17 cells and associated cytokines in cancer and metastasis. FEBS Journal, 2021, 288, 6942-6971.	2.2	7
4313	E7386, a Selective Inhibitor of the Interaction between Î²-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling. Cancer Research, 2021, 81, 1052-1062.	0.4	30
4314	Diagnosis and prognostic value of C-X-C motif chemokine ligand 1 in colon adenocarcinoma based on The Cancer Genome Atlas and Guangxi cohort. Journal of Cancer, 2021, 12, 5506-5518.	1.2	5
4315	Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. Clinical Cancer Research, 2021, 27, 1695-1705.	3.2	19
4316	Multi-omics analysis to identify susceptibility genes for colorectal cancer. Human Molecular Genetics, 2021, 30, 321-330.	1.4	13
4317	Mapping of colorectal carcinoma diseases with activation of Wnt/beta-catenin signalling pathway using hierarchical clustering approach. Journal of Clinical Pathology, 2022, 75, 168-175.	1.0	1
4318	Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer. Cancers, 2021, 13, 300.	1.7	32
4319	Circular RNA circRHOBTB3 represses metastasis by regulating the HuR-mediated mRNA stability of PTBP1 in colorectal cancer. Theranostics, 2021, 11, 7507-7526.	4.6	87
4320	Intraductal Tumors of the Biliary Tract: Precursor Lesions and Variants. , 2021, , 27-67.		0
4321	Re-expression of REG family and DUOXs genes in CRC organoids by co-culturing with CAFs. Scientific Reports, 2021, 11, 2077.	1.6	12
4322	PHLPPing the balance: restoration of protein kinase C in cancer. Biochemical Journal, 2021, 478, 341-355.	1.7	19
4323	Emerging role of SWI/SNF complex deficiency as a target of immune checkpoint blockade in human cancers. Oncogenesis, 2021, 10, 3.	2.1	25
4324	Chromosome 20q11.21 Amplifications in Colorectal Cancer. Cancer Genomics and Proteomics, 2021, 18, 487-496.	1.0	11
4325	HER2 and APC Mutations Promote Altered Crypt-Villus Morphology and Marked Hyperplasia in the Intestinal Epithelium. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 1105-1120.	2.3	4
4326	S100P Expression via DNA Hypomethylation Promotes Cell Growth in the Sessile Serrated Adenoma/Polyp-Cancer Sequence. Digestion, 2021, 102, 789-802.	1.2	2
4327	Bcl9 Depletion Modulates Endothelial Cell in Tumor Immune Microenvironment in Colorectal Cancer Tumor. Frontiers in Oncology, 2020, 10, 603702.	1.3	3

#	Article	IF	Citations
4328	Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitor. Annals of Translational Medicine, 2021, 9, 129-129.	0.7	24
4329	Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy. Cell, 2021, 184, 226-242.e21.	13.5	258
4330	Mathematical Modeling to Study KRAS Mutant-Specific Responses to Pathway Inhibition. Methods in Molecular Biology, 2021, 2262, 311-321.	0.4	2
4331	Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers. Biomedicines, 2021, 9, 39.	1.4	18
4332	Antioxidants Promote Intestinal Tumor Progression in Mice. Antioxidants, 2021, 10, 241.	2.2	15
4333	Colorectal cancer of the young displays distinct features of aggressive tumor biology: A single-center cohort study. World Journal of Gastrointestinal Surgery, 2021, 13, 164-175.	0.8	9
4335	A greedy approach for mutual exclusivity analysis in cancer study. Biostatistics, 2021, , .	0.9	0
4336	Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years. Toxins, 2021, 13, 149.	1.5	6
4337	A universal molecular prognostic score for gastrointestinal tumors. Npj Genomic Medicine, 2021, 6, 6.	1.7	6
4338	Somatic mutation profiles as molecular classifiers of ulcerative colitisâ€associated colorectal cancer. International Journal of Cancer, 2021, 148, 2997-3007.	2.3	10
4339	Gene mutations of esophageal squamous cell carcinoma based on next-generation sequencing. Chinese Medical Journal, 2021, 134, 708-715.	0.9	5
4340	Downregulation of PAICS due to loss of chromosome 4q is associated with poor survival in stage III colorectal cancer. PLoS ONE, 2021, 16, e0247169.	1.1	4
4341	Genotyping data of routinely processed matched primary/metastatic tumor samples. Data in Brief, 2021, 34, 106646.	0.5	2
4342	Pancreatic ductal adenocarcinoma in the era of precision medicine. Seminars in Oncology, 2021, 48, 19-33.	0.8	8
4344	Potential Mechanism of Immune Evasion Associated with the Master Regulator ASCL2 in Microsatellite Stability in Colorectal Cancer. Journal of Immunology Research, 2021, 2021, 1-12.	0.9	9
4345	Implications for the colorectal surgeon following the 100Â000 Genomes Project. Colorectal Disease, 2021, 23, 1049-1058.	0.7	4
4346	Fibrotic Phenotype of Peritumour Mesenteric Adipose Tissue in Human Colon Cancer: A Potential Hallmark of Metastatic Properties. International Journal of Molecular Sciences, 2021, 22, 2430.	1.8	7
4348	CUT Domains Stimulate Pol Î² Enzymatic Activities to Accelerate Completion of Base Excision Repair. Journal of Molecular Biology, 2021, 433, 166806.	2.0	6

#	Article	IF	Citations
4349	Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. Seminars in Cancer Biology, 2022, 84, 89-102.	4.3	21
4350	Immunotherapy for the treatment of colorectal cancer. Journal of Surgical Oncology, 2021, 123, 760-774.	0.8	18
4351	Genome-wide analysis identifies critical DNA methylations within NTRKs genes in colorectal cancer. Journal of Translational Medicine, 2021, 19, 73.	1.8	15
4352	Uncertainty quantification in the radiogenomics modeling of EGFR amplification in glioblastoma. Scientific Reports, 2021, 11, 3932.	1.6	14
4353	Comprehensive analysis of prognostic immune-related genes in the tumor microenvironment of colorectal cancer. Aging, 2021, 13, 5506-5524.	1.4	3
4354	Colorectal Cancer Stem Cell States Uncovered by Simultaneous Singleâ€Cell Analysis of Transcriptome and Telomeres. Advanced Science, 2021, 8, 2004320.	5.6	36
4355	USP39 mediates p21â€dependent proliferation and neoplasia of colon cancer cells by regulating the p53/p21/CDC2/cyclin B1 axis. Molecular Carcinogenesis, 2021, 60, 265-278.	1.3	11
4358	FBXL6 degrades phosphorylated p53 to promote tumor growth. Cell Death and Differentiation, 2021, 28, 2112-2125.	5.0	17
4360	MicroRNAâ€'124 suppresses the invasion and proliferation of breast cancer cells by targeting TFAP4. Oncology Letters, 2021, 21, 271.	0.8	6
4361	Wnt/Î²-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma. Cancers, 2021, 13, 889.	1.7	24
4362	ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine. JCO Precision Oncology, 2021, 5, 378-388.	1.5	26
4363	Colorectal Cancer-Associated Smad4 R361 Hotspot Mutations Boost Wnt/Î²-Catenin Signaling through Enhanced Smad4â€"LEF1 Binding. Molecular Cancer Research, 2021, 19, 823-833.	1.5	4
4365	MicroRNA-142-3p Inhibits Tumorigenesis of Colorectal Cancer via Suppressing the Activation of Wnt Signaling by Directly Targeting to Î²-Catenin. Frontiers in Oncology, 2020, 10, 552944.	1.3	5
4366	Visualization and Analysis in the Field of Pan-Cancer Studies and Its Application in Breast Cancer Treatment. Frontiers in Medicine, 2021, 8, 635035.	1.2	8
4367	The Prospective Dutch Colorectal Cancer (PLCRC) cohort: real-world data facilitating research and clinical care. Scientific Reports, 2021, 11, 3923.	1.6	13
4368	Fusion Genes and RNAs in Cancer Development. Non-coding RNA, 2021, 7, 10.	1.3	24
4370	Portrait of Cancer Stem Cells on Colorectal Cancer: Molecular Biomarkers, Signaling Pathways and miRNAome. International Journal of Molecular Sciences, 2021, 22, 1603.	1.8	14
4371	Genomic aberrations after short-term exposure to colibactin-producing E. coli transform primary colon epithelial cells. Nature Communications, 2021, 12, 1003.	5.8	84

#	Article	IF	Citations
4372	Differential Effects of Trp53 Alterations in Murine Colorectal Cancer. Cancers, 2021, 13, 808.	1.7	5
4373	Germline and Somatic Whole-Exome Sequencing Identifies New Candidate Genes Involved in Familial Predisposition to Serrated Polyposis Syndrome. Cancers, 2021, 13, 929.	1.7	12
4374	No evidence of EMAST in whole genome sequencing data from 248 colorectal cancers. Genes Chromosomes and Cancer, 2021, 60, 463-473.	1.5	5
4375	Type 2 Innate Lymphoid Cells Protect against Colorectal Cancer Progression and Predict Improved Patient Survival. Cancers, 2021, 13, 559.	1.7	31
4376	Therapeutic targeting of the oncogenic Wnt signaling pathway for treating colorectal cancer and other colonic disorders. Advanced Drug Delivery Reviews, 2021, 169, 118-136.	6.6	58
4377	Low immunogenicity of common cancer hot spot mutations resulting in false immunogenic selection signals. PLoS Genetics, 2021, 17, e1009368.	1.5	19
4378	Malignant subclone drives metastasis of genetically and phenotypically heterogenous cell clusters through fibrotic niche generation. Nature Communications, 2021, 12, 863.	5.8	27
4379	Mutational landscape and potential therapeutic targets for sporadic pancreatic neuroendocrine tumors based on target nextâ€‘generation sequencing. Experimental and Therapeutic Medicine, 2021, 21, 415.	0.8	1
4380	Identification of Tumor Tissue of Origin with RNA-Seq Data and Using Gradient Boosting Strategy. BioMed Research International, 2021, 2021, 1-14.	0.9	8
4381	Ultra-Low DNA Input into Whole Genome Methylation Assays and Detection of Oncogenic Methylation and Copy Number Variants in Circulating Tumour DNA. Epigenomes, 2021, 5, 6.	0.8	10
4382	Selective killing of cancer cells harboring mutant RAS by concomitant inhibition of NADPH oxidase and glutathione biosynthesis. Cell Death and Disease, 2021, 12, 189.	2.7	6
4383	Rare Variants in the DNA Repair Pathway and the Risk of Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 895-903.	1.1	3
4384	B7-H4 induces epithelialâ€“mesenchymal transition and promotes colorectal cancer stemness. Pathology Research and Practice, 2021, 218, 153323.	1.0	11
4385	<i>TRIM58</i> is a prognostic biomarker remodeling the tumor microenvironment in <i>KRAS</i>-driven lung adenocarcinoma. Future Oncology, 2021, 17, 565-579.	1.1	9
4386	Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies. Biomarkers in Medicine, 2021, 15, 201-217.	0.6	1
4387	Uniform genomic data analysis in the NCI Genomic Data Commons. Nature Communications, 2021, 12, 1226.	5.8	61
4388	Differential immune signatures in the tumor microenvironment are associated with colon cancer racial disparities. Cancer Medicine, 2021, 10, 1805-1814.	1.3	17
4389	METTL16, Methyltransferase-Like Protein 16: Current Insights into Structure and Function. International Journal of Molecular Sciences, 2021, 22, 2176.	1.8	46

#	Article	IF	Citations
4390	Effects of the Novel PFKFB3 Inhibitor KAN0438757 on Colorectal Cancer Cells and Its Systemic Toxicity Evaluation In Vivo. Cancers, 2021, 13, 1011.	1.7	22
4392	Differential Outcomes in Codon 12/13 and Codon 61<i>NRAS</i>-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with<i>NRAS</i>-Mutated Tumors. Clinical Cancer Research, 2021, 27, 2996-3004.	3.2	23
4393	KHDRBS3 promotes multiâ€drug resistance and anchorageâ€independent growth in colorectal cancer. Cancer Science, 2021, 112, 1196-1208.	1.7	17
4394	AKT3 Expression in Mesenchymal Colorectal Cancer Cells Drives Growth and Is Associated with Epithelial-Mesenchymal Transition. Cancers, 2021, 13, 801.	1.7	16
4395	Clinical benefit for clinical sequencing using cancer panel testing. PLoS ONE, 2021, 16, e0247090.	1.1	3
4396	Clinical-grade whole-genome sequencing and 3â€² transcriptome analysis of colorectal cancer patients. Genome Medicine, 2021, 13, 33.	3.6	5
4397	A perspective analysis: microRNAs, glucose metabolism, and drug resistance in colon cancer stem cells. Cancer Gene Therapy, 2021, , .	2.2	6
4398	A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients. Npj Precision Oncology, 2021, 5, 7.	2.3	29
4399	Epigenetic Regulatory Enzymes: mutation Prevalence and Coexistence in Cancers. Cancer Investigation, 2021, 39, 257-273.	0.6	15
4400	Emerging Trends for Radio-Immunotherapy in Rectal Cancer. Cancers, 2021, 13, 1374.	1.7	18
4401	Deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer. BMC Genomics, 2021, 22, 214.	1.2	39
4402	Deciphering the Role of Intestinal Crypt Cell Populations in Resistance to Chemotherapy. Cancer Research, 2021, 81, 2730-2744.	0.4	4
4403	Gene expression profile association with poor prognosis in epithelial ovarian cancer patients. Scientific Reports, 2021, 11, 5438.	1.6	11
4404	Fucoxanthin Prevents Colorectal Cancer Development in Dextran Sodium Sulfate-treated ApcMin/+ Mice. Anticancer Research, 2021, 41, 1299-1305.	0.5	9
4405	Comprehensive functional genomic analyses link APC somatic mutation and mRNA-miRNA networks to the clinical outcome of stage-III colorectal cancer patients. Biomedical Journal, 2021, , .	1.4	2
4406	Nestin and CD34 expression in colorectal cancer predicts improved overall survival. Acta OncolÃ³gica, 2021, 60, 727-734.	0.8	5
4407	Expression of cyclin-dependent kinases and their clinical significance with immune infiltrates could predict prognosis in colorectal cancer. Biotechnology Reports (Amsterdam, Netherlands), 2021, 29, e00602.	2.1	10
4408	ZFAS1 Promotes Colorectal Cancer Metastasis Through Modulating miR-34b/SOX4 Targeting. Cell Biochemistry and Biophysics, 2021, 79, 387-396.	0.9	13

#	Article	IF	Citations
4409	Clinicopathological and Molecular Analysis of 45 Cases of Pure Mucinous Breast Cancer. Frontiers in Oncology, 2020, 10, 558760.	1.3	9
4411	CXCL11 Correlates With Antitumor Immunity and an Improved Prognosis in Colon Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 646252.	1.8	78
4412	Integration of comprehensive genomic profiling, tumor mutational burden, and PDâ€L1 expression to identify novel biomarkers of immunotherapy in nonâ€small cell lung cancer. Cancer Medicine, 2021, 10, 2216-2231.	1.3	48
4413	Serrated Lesion Detection in a Population-based Colon Screening Program. Journal of Clinical Gastroenterology, 2021, Publish Ahead of Print, .	1.1	0
4414	MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway. Clinical Colorectal Cancer, 2021, 20, 72-78.	1.0	10
4415	A Triptolide Loaded HER2-Targeted Nano-Drug Delivery System Significantly Suppressed the Proliferation of HER2-Positive and BRAF Mutant Colon Cancer. International Journal of Nanomedicine, 2021, Volume 16, 2323-2335.	3.3	8
4416	Hypermethylation of heparanase 2 promotes colorectal cancer proliferation and is associated with poor prognosis. Journal of Translational Medicine, 2021, 19, 98.	1.8	12
4417	CD4 T Cellâ€"Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repairâ€"Deficient Tumors. Cancer Discovery, 2021, 11, 1844-1859.	7.7	37
4418	Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 307-318.	2.3	17
4421	AIM2 Inhibits BRAF-Mutant Colorectal Cancer Growth in a Caspase-1-Dependent Manner. Frontiers in Cell and Developmental Biology, 2021, 9, 588278.	1.8	6
4422	DNA mechanics and its biological impact. Journal of Molecular Biology, 2021, 433, 166861.	2.0	31
4423	Immune Checkpoint Inhibition as a Strategy in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer. Journal of Immunotherapy and Precision Oncology, 2021, 4, 86-104.	0.6	0
4425	WNT5a in Colorectal Cancer: Research Progress and Challenges. Cancer Management and Research, 2021, Volume 13, 2483-2498.	0.9	6
4426	Long non-coding RNA ZFAS1 is a major regulator of epithelial-mesenchymal transition through miR-200/ZEB1/E-cadherin, vimentin signaling in colon adenocarcinoma. Cell Death Discovery, 2021, 7, 61.	2.0	23
4427	Cancer-Associated Fibroblast-Induced Resistance to Chemotherapy and Radiotherapy in Gastrointestinal Cancers. Cancers, 2021, 13, 1172.	1.7	31
4428	The origins and genetic interactions of KRAS mutations are allele- and tissue-specific. Nature Communications, 2021, 12, 1808.	5.8	90
4429	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. Clinical Cancer Research, 2021, 27, 3234-3242.	3.2	24
4430	Functional States in Tumor-Initiating Cell Differentiation in Human Colorectal Cancer. Cancers, 2021, 13, 1097.	1.7	11

#	Article	IF	Citations
4431	CSK-homologous kinase (CHK/MATK) is a potential colorectal cancer tumour suppressor gene epigenetically silenced by promoter methylation. Oncogene, 2021, 40, 3015-3029.	2.6	13
4432	KRAS G12C inhibition and innate immune targeting. Expert Opinion on Therapeutic Targets, 2021, 25, 1-8.	1.5	6
4434	Microsatellite Instability in Colorectal Cancer Liquid Biopsyâ€"Current Updates on Its Potential in Non-Invasive Detection, Prognosis and as a Predictive Marker. Diagnostics, 2021, 11, 544.	1.3	15
4435	USP42 protects ZNRF3/RNF43 from Râ€spondinâ€dependent clearance and inhibits Wnt signalling. EMBO Reports, 2021, 22, e51415.	2.0	28
4436	Mechanisms of Resistance to KRASG12C-Targeted Therapy. Cancer Discovery, 2021, 11, 1345-1352.	7.7	60
4437	A selective p53 activator and anticancer agent to improve colorectal cancer therapy. Cell Reports, 2021, 35, 108982.	2.9	20
4438	Identification of ZBTB18 as a novel colorectal tumor suppressor gene through genome-wide promoter hypermethylation analysis. Clinical Epigenetics, 2021, 13, 88.	1.8	5
4439	SOX9 is associated with advanced T-stages of clinical stage II colon cancer in young Mexican patients. Oncology Letters, 2021, 22, 497.	0.8	3
4440	Clinicopathological and Molecular Features of Patients with Early and Late Recurrence after Curative Surgery for Colorectal Cancer. Cancers, 2021, 13, 1883.	1.7	10
4441	The Role of p53 Signaling in Colorectal Cancer. Cancers, 2021, 13, 2125.	1.7	106
4442	Microsatellite instability in Gastric Cancer: Between lights and shadows. Cancer Treatment Reviews, 2021, 95, 102175.	3.4	88
4443	Current and Prospective Methods for Assessing Anti-Tumor Immunity in Colorectal Cancer. International Journal of Molecular Sciences, 2021, 22, 4802.	1.8	6
4444	Identification of a ferroptosis-related gene signature predictive model in colon cancer. World Journal of Surgical Oncology, 2021, 19, 135.	0.8	17
4445	CRISPR screens identify a novel combination treatment targeting BCL-XL and WNT signaling for KRAS/BRAF-mutated colorectal cancers. Oncogene, 2021, 40, 3287-3302.	2.6	18
4446	SEMMs: Somatically Engineered Mouse Models. A New Tool for In Vivo Disease Modeling for Basic and Translational Research. Frontiers in Oncology, 2021, 11, 667189.	1.3	14
4447	The Roles of Transmembrane Mucins Located on Chromosome 7q22.1 in Colorectal Cancer. Cancer Management and Research, 2021, Volume 13, 3271-3280.	0.9	6
4448	The Enigmatic Emerging Role of the C-Maf Inducing Protein in Cancer. Diagnostics, 2021, 11, 666.	1.3	3
4450	A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype. Clinical and Translational Science, 2021, 14, 954-963.	1.5	5

#	Article	IF	Citations
4451	Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ. Nature Communications, 2021, 12, 2340.	5.8	43
4452	<scp>Genomeâ€wide</scp> estrogen receptor Î² chromatin binding in human colon cancer cells reveals its tumor suppressor activity. International Journal of Cancer, 2021, 149, 692-706.	2.3	10
4454	Frontiers of CRISPR-Cas9 for Cancer Research and Therapy. Journal of Exploratory Research in Pharmacology, 2021, 000, 000-000.	0.2	1
4455	RGL2 Drives the Metastatic Progression of Colorectal Cancer via Preventing the Protein Degradation of Î²-Catenin and KRAS. Cancers, 2021, 13, 1763.	1.7	6
4456	Rhein Suppresses Colorectal Cancer Cell Growth by Inhibiting the mTOR Pathway In Vitro and In Vivo. Cancers, 2021, 13, 2176.	1.7	12
4457	MED12-Related (Neuro)Developmental Disorders: A Question of Causality. Genes, 2021, 12, 663.	1.0	9
4458	SOX9: An emerging driving factor from cancer progression to drug resistance. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188517.	3.3	42
4459	Discovering the Mutational Profile of Early Colorectal Lesions: A Translational Impact. Cancers, 2021, 13, 2081.	1.7	2
4460	Widespread Alternative Splicing Changes in Metastatic Breast Cancer Cells. Cells, 2021, 10, 858.	1.8	10
4461	Insight Into Chromatin-Enriched RNA: A Key Chromatin Regulator in Tumors. Frontiers in Cell and Developmental Biology, 2021, 9, 649605.	1.8	5
4462	Distinguishing Rectal Cancer from Colon Cancer Based on the Support Vector Machine Method and RNA-sequencing Data. Current Medical Science, 2021, 41, 368-374.	0.7	8
4464	Recommendations for Specimen and Therapy Selection in Colorectal Cancer. Oncology and Therapy, 2021, 9, 451-469.	1.0	0
4465	Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer. Clinical and Translational Medicine, 2021, 11, e401.	1.7	6
4466	Outcomes of young patients diagnosed with locally advanced rectal cancer. Journal of Gastrointestinal Oncology, 2021, 12, 592-601.	0.6	2
4467	A prognostic predictive model constituted with gene mutations of APC, BRCA2, CDH1, SMO, and TSC2 in colorectal cancer. Annals of Translational Medicine, 2021, 9, 680-680.	0.7	2
4468	Increasing prediction accuracy of pathogenic staging by sample augmentation with a GAN. PLoS ONE, 2021, 16, e0250458.	1.1	10
4469	NMD inhibition by 5-azacytidine augments presentation of immunogenic frameshift-derived neoepitopes. IScience, 2021, 24, 102389.	1.9	22
4470	Enhancing the landscape of colorectal cancer using targeted deep sequencing. Scientific Reports, 2021, 11, 8154.	1.6	26

#	Article	IF	Citations
4471	Eps15 Homology Domain-Containing Protein 3 Hypermethylation as a Prognostic and Predictive Marker for Colorectal Cancer. Biomedicines, 2021, 9, 453.	1.4	1
4472	Integrated approaches for precision oncology in colorectal cancer: The more you know, the better. Seminars in Cancer Biology, 2022, 84, 199-213.	4.3	35
4473	MiR-490-3p Silences CDK1 and Inhibits the Proliferation of Colon Cancer Through an LLPS-Dependent miRISC System. Frontiers in Molecular Biosciences, 2021, 8, 561678.	1.6	3
4474	Control Analysis of Protein-Protein Interaction Network Reveals Potential Regulatory Targets for MYCN. Frontiers in Oncology, 2021, 11, 633579.	1.3	3
4475	Ampullary carcinoma of the duodenum: current clinical issues and genomic overview. Surgery Today, 2022, 52, 189-197.	0.7	8
4476	Hybrid Capture-based Genomic Profiling of Circulating Tumor DNA From Patients With Advanced Ovarian Cancer. Pathology and Oncology Research, 2021, 27, 581534.	0.9	4
4477	A Meta-Analysis of Proteomic Blood Markers of Colorectal Cancer. Current Medicinal Chemistry, 2021, 28, 1176-1196.	1.2	6
4478	Clinicopathological, molecular features and prognosis of colorectal cancer with mucinous component. Future Oncology, 2021, 17, 1351-1362.	1.1	7
4479	Rational Treatment of Metastatic Colorectal Cancer: A Reverse Tale of Men, Mice, and Culture Dishes. Cancer Discovery, 2021, 11, 1644-1660.	7.7	11
4481	Genomic Alteration Characterization in Colorectal Cancer Identifies a Prognostic and Metastasis Biomarker: FAM83A|IDO1. Frontiers in Oncology, 2021, 11, 632430.	1.3	32
4482	Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker. Journal of the National Cancer Institute, 2021, 113, 1634-1647.	3.0	28
4483	Controlling for cellular heterogeneity using single-cell deconvolution of gene expression reveals novel markers of colorectal tumors exhibiting microsatellite instability. Oncotarget, 2021, 12, 767-782.	0.8	5
4484	A case report of multiple bilateral breast metastases after colorectal cancer. International Journal of Surgery Case Reports, 2021, 81, 105759.	0.2	5
4485	Toxicity of Combinations of Kinase Pathway Inhibitors to Normal Human Cells in a Three-Dimensional Culture. SLAS Technology, 2021, 26, 255-264.	1.0	5
4487	Decoding Cancer Biology One Cell at a Time. Cancer Discovery, 2021, 11, 960-970.	7.7	37
4488	Histopathological characteristics and artificial intelligence for predicting tumor mutational burden-high colorectal cancer. Journal of Gastroenterology, 2021, 56, 547-559.	2.3	23
4489	<i>IDH1</i> and <i>IDH2</i> Mutations in Colorectal Cancers. American Journal of Clinical Pathology, 2021, 156, 777-786.	0.4	12
4490	Precision oncology in metastatic colorectal cancer â€" from biology to medicine. Nature Reviews Clinical Oncology, 2021, 18, 506-525.	12.5	113

#	Article	IF	Citations
4491	Evaluating the transcriptional fidelity of cancer models. Genome Medicine, 2021, 13, 73.	3.6	26
4492	Pals1 prevents Rac1-dependent colorectal cancer cell metastasis by inhibiting Arf6. Molecular Cancer, 2021, 20, 74.	7.9	8
4494	Fucoxanthin and Colorectal Cancer Prevention. Cancers, 2021, 13, 2379.	1.7	26
4495	Molecular Pathways Associated with Kallikrein 6 Overexpression in Colorectal Cancer. Genes, 2021, 12, 749.	1.0	3
4496	Exome sequencing of early-onset patients supports genetic heterogeneity in colorectal cancer. Scientific Reports, 2021, 11, 11135.	1.6	5
4497	Challenges of Neoantigen Targeting in Lynch Syndrome and Constitutional Mismatch Repair Deficiency Syndrome. Cancers, 2021, 13, 2345.	1.7	3
4498	Intra-Tumoral Genomic Heterogeneity in Rectal Cancer: Mutational Status Is Dependent on Preoperative Biopsy Depth and Location. Cancers, 2021, 13, 2271.	1.7	4
4499	Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer. JCI Insight, 2021, 6, .	2.3	17
4501	The effects of <scp>ARID1A</scp> mutations on colorectal cancer and associations with <scp>PDâ€Ł1</scp> expression by stromal cells. Cancer Reports, 2022, 5, e1420.	0.6	6
4502	Hypoxia-Induced miR-148a Downregulation Contributes to Poor Survival in Colorectal Cancer. Frontiers in Genetics, 2021, 12, 662468.	1.1	16
4503	A comprehensive review of m6A/m6Am RNA methyltransferase structures. Nucleic Acids Research, 2021, 49, 7239-7255.	6.5	190
4504	MLH1 Deficiency Down-Regulates TLR4 Expression in Sporadic Colorectal Cancer. Frontiers in Molecular Biosciences, 2021, 8, 624873.	1.6	1
4505	Mechanisms of breast cancer metastasis. Clinical and Experimental Metastasis, 2022, 39, 117-137.	1.7	27
4506	Antitumor Activity of Nitazoxanide against Colon Cancers: Molecular Docking and Experimental Studies Based on Wnt/Î²-Catenin Signaling Inhibition. International Journal of Molecular Sciences, 2021, 22, 5213.	1.8	10
4507	The Intestinal Epithelium â€" Fluid Fate and Rigid Structure From Crypt Bottom to Villus Tip. Frontiers in Cell and Developmental Biology, 2021, 9, 661931.	1.8	27
4508	High FRMD3 expression is prognostic for worse survival in rectal cancer patients treated with CCRT. International Journal of Clinical Oncology, 2021, 26, 1689-1697.	1.0	9
4509	De Novo Mutation Rate Variation and Its Determinants in<i>Chlamydomonas</i>. Molecular Biology and Evolution, 2021, 38, 3709-3723.	3.5	19
4510	Decreased Tumoral Expression of Colon-Specific Water Channel Aquaporin 8 Is Associated With Reduced Overall Survival in Colon Adenocarcinoma. Diseases of the Colon and Rectum, 2021, 64, 1083-1095.	0.7	5

#	Article	IF	Citations
4511	Identification of cancer driver genes using <i>Sleeping Beauty</i> transposon mutagenesis. Cancer Science, 2021, 112, 2089-2096.	1.7	8
4512	LSD1 and Aberrant DNA Methylation Mediate Persistence of Enteroendocrine Progenitors That Support <i>BRAF</i>-Mutant Colorectal Cancer. Cancer Research, 2021, 81, 3791-3805.	0.4	39
4513	Construction of an immune-related signature with prognostic value for colon cancer. PeerJ, 2021, 9, e10812.	0.9	2
4515	Potential role for the tumor suppressor CYLD in brain and notochord development. Thoracic Cancer, 2021, 12, 1900-1908.	0.8	4
4516	Identification of PI3K-AKT signaling as the dominant altered pathway in intestinal type ampullary cancers through whole-exome sequencing. Journal of Pathology and Translational Medicine, 2021, 55, 192-201.	0.4	3
4518	Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations. Clinical Epigenetics, 2021, 13, 117.	1.8	8
4519	The loss of SHMT2 mediates 5-fluorouracil chemoresistance in colorectal cancer by upregulating autophagy. Oncogene, 2021, 40, 3974-3988.	2.6	25
4520	A Comprehensive Overview of Colon Cancer- A Grim Reaper of the 21st Century. Current Medicinal Chemistry, 2021, 28, 2657-2696.	1.2	19
4521	Captopril, a Renin-Angiotensin System Inhibitor, Attenuates Features of Tumor Invasion and Down-Regulates C-Myc Expression in a Mouse Model of Colorectal Cancer Liver Metastasis. Cancers, 2021, 13, 2734.	1.7	12
4522	Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer. Gut, 2022, 71, 938-949.	6.1	25
4523	Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma. Oncologist, 2021, 26, e1161-e1170.	1.9	8
4524	BMAL1 Knockdown Leans Epithelialâ€"Mesenchymal Balance toward Epithelial Properties and Decreases the Chemoresistance of Colon Carcinoma Cells. International Journal of Molecular Sciences, 2021, 22, 5247.	1.8	19
4525	Identification of Hub Genes in Different Stages of Colorectal Cancer through an Integrated Bioinformatics Approach. International Journal of Environmental Research and Public Health, 2021, 18, 5564.	1.2	3
4526	High Concordance of Genomic Profiles between Primary and Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2021, 22, 5561.	1.8	4
4527	ACBP suppresses the proliferation, migration, and invasion of colorectal cancer via targeting Wnt/beta-catenin signaling pathway. Biomedicine and Pharmacotherapy, 2021, 137, 111209.	2.5	9
4528	Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?. Expert Opinion on Biological Therapy, 2021, 21, 1347-1357.	1.4	14
4529	Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. Cancers, 2021, 13, 2638.	1.7	32
4530	Organoids and Colorectal Cancer. Cancers, 2021, 13, 2657.	1.7	26

#	Article	IF	Citations
4532	Organoid models of the tumor microenvironment and their applications. Journal of Cellular and Molecular Medicine, 2021, 25, 5829-5841.	1.6	27
4533	Identification of KIF4A as a pan-cancer diagnostic and prognostic biomarker via bioinformatics analysis and validation in osteosarcoma cell lines. PeerJ, 2021, 9, e11455.	0.9	4
4535	Anti-proliferative and apoptotic effect of gemini curcumin in p53-wild type and p53-mutant colorectal cancer cell lines. International Journal of Pharmaceutics, 2021, 601, 120592.	2.6	14
4536	Minireview: Novel Micropeptide Discovery by Proteomics and Deep Sequencing Methods. Frontiers in Genetics, 2021, 12, 651485.	1.1	13
4537	Comprehensive analysis of Syk gene methylation in colorectal cancer. Immunity, Inflammation and Disease, 2021, 9, 923-931.	1.3	4
4538	Clinical Implications of Colorectal Cancer Stem Cells in the Age of Single-Cell Omics and Targeted Therapies. Gastroenterology, 2021, 160, 1947-1960.	0.6	42
4539	Acrolein contributes to human colorectal tumorigenesis through the activation of RAS-MAPK pathway. Scientific Reports, 2021, 11, 12590.	1.6	5
4541	Exploring polyps to colon carcinoma voyage: can blocking the crossroad halt the sequence?. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2199-2207.	1.2	5
4542	Analysis of <scp><i>KRAS</i> G12</scp>/<scp>G13</scp> in colorectal cancer using an economical digital <scp>PCR</scp> assay that unequivocally differentiates missense and synonymous alleles. Canadian Journal of Chemical Engineering, 2021, 99, 2554-2569.	0.9	1
4543	Machine learning-based prediction of survival prognosis in cervical cancer. BMC Bioinformatics, 2021, 22, 331.	1.2	18
4546	An integrated magneto-electrochemical device for the rapid profiling of tumour extracellular vesicles from blood plasma. Nature Biomedical Engineering, 2021, 5, 678-689.	11.6	90
4547	LncRNA signature in colorectal cancer. Pathology Research and Practice, 2021, 222, 153432.	1.0	39
4548	Analyzing the Opportunities to Target DNA Double-Strand Breaks Repair and Replicative Stress Responses to Improve Therapeutic Index of Colorectal Cancer. Cancers, 2021, 13, 3130.	1.7	13
4549	A Platform for Validating Colorectal Cancer Driver Genes Using Mouse Organoids. Frontiers in Genetics, 2021, 12, 698771.	1.1	3
4552	Clinical and Functional Characterization of Atypical <i>KRAS</i>/<i>NRAS</i> Mutations in Metastatic Colorectal Cancer. Clinical Cancer Research, 2021, 27, 4587-4598.	3.2	14
4553	Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	62
4554	miRNA Clusters with Up-Regulated Expression in Colorectal Cancer. Cancers, 2021, 13, 2979.	1.7	22
4555	Tracing oncogene-driven remodelling of the intestinal stem cell niche. Nature, 2021, 594, 442-447.	13.7	56

#	Article	IF	Citations
4556	Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies. Cancers, 2021, 13, 3063.	1.7	29
4557	Oncogenic BRAF, unrestrained by TGFÎ²-receptor signalling, drives right-sided colonic tumorigenesis. Nature Communications, 2021, 12, 3464.	5.8	33
4558	Enhanced triacylglycerol catabolism by carboxylesterase 1 promotes aggressive colorectal carcinoma. Journal of Clinical Investigation, 2021, 131, .	3.9	25
4559	Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell, 2021, 39, 845-865.e7.	7.7	503
4560	The Clinical Assessment of MicroRNA Diagnostic, Prognostic, and Theranostic Value in Colorectal Cancer. Cancers, 2021, 13, 2916.	1.7	9
4562	Targeting HER2 genomic alterations in non-small cell lung cancer. Journal of the National Cancer Center, 2021, 1, 58-73.	3.0	13
4563	Targeted next-generation sequencing supports serrated epithelial change as an early precursor to inflammatory bowel diseaseâ€"associated colorectal neoplasia. Human Pathology, 2021, 112, 9-19.	1.1	8
4564	RIP140 Represses Intestinal Paneth Cell Differentiation and Interplays with SOX9 Signaling in Colorectal Cancer. Cancers, 2021, 13, 3192.	1.7	4
4565	Integrated multi-omics analyses on patient-derived CRC organoids highlight altered molecular pathways in colorectal cancer progression involving PTEN. Journal of Experimental and Clinical Cancer Research, 2021, 40, 198.	3.5	27
4566	Organoid Technology and Clinical Applications in Digestive System Cancer. Engineering, 2022, 9, 123-130.	3.2	0
4567	CHK1 inhibitor sensitizes resistant colorectal cancer stem cells to nortopsentin. IScience, 2021, 24, 102664.	1.9	31
4568	Multilevel regulation of Wnt signaling by Zic2 in colon cancer due to mutation of Î²-catenin. Cell Death and Disease, 2021, 12, 584.	2.7	6
4569	Whole-exome sequencing of alpha-fetoprotein producing gastric carcinoma reveals genomic profile and therapeutic targets. Nature Communications, 2021, 12, 3946.	5.8	21
4570	Colorectal cancer cells utilize autophagy to maintain mitochondrial metabolism for cell proliferation under nutrient stress. JCI Insight, 2021, 6, .	2.3	17
4571	Genetic and biological hallmarks of colorectal cancer. Genes and Development, 2021, 35, 787-820.	2.7	159
4572	Bacterial Toxins Are a Never-Ending Source of Surprises: From Natural Born Killers to Negotiators. Toxins, 2021, 13, 426.	1.5	6
4573	PLOD3 Is Associated with Immune Cell Infiltration and Genomic Instability in Colon Adenocarcinoma. BioMed Research International, 2021, 2021, 1-10.	0.9	5
4574	METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF binding. Nature Communications, 2021, 12, 3803.	5.8	74

#	Article	IF	Citations
4575	Perspectives for circulating tumor DNA in clinical management of colorectal cancer. International Journal of Clinical Oncology, 2021, 26, 1420-1430.	1.0	3
4576	MicroRNAâ€'142â€'3p suppresses cell proliferation, invasion and epithelialâ€'toâ€'mesenchymal transition via RAC1â€'ERK1/2 signaling in colorectal cancer. Molecular Medicine Reports, 2021, 24, .	1.1	10
4577	Apc-mutant cells act as supercompetitors in intestinal tumour initiation. Nature, 2021, 594, 436-441.	13.7	108
4578	Tribbles Pseudokinases in Colorectal Cancer. Cancers, 2021, 13, 2825.	1.7	8
4580	Detecting copy number alterations in RNA-Seq using SuperFreq. Bioinformatics, 2021, 37, 4023-4032.	1.8	8
4581	Vignettes to Illustrate the Value of Tumor Biobanks in Cancer Research in Canada. Biopreservation and Biobanking, 2022, 20, 75-83.	0.5	3
4582	Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer. International Journal of Molecular Sciences, 2021, 22, 6813.	1.8	20
4583	DCBLD1 is associated with the integrin signaling pathway and has prognostic value in non-small cell lung and invasive breast carcinoma. Scientific Reports, 2021, 11, 12753.	1.6	6
4584	KRAS mutant rectal cancer cells interact with surrounding fibroblasts to deplete the extracellular matrix. Molecular Oncology, 2021, 15, 2766-2781.	2.1	7
4585	Frequent POLE-driven hypermutation in ovarian endometrioid cancer revealed by mutational signatures in RNA sequencing. BMC Medical Genomics, 2021, 14, 165.	0.7	10
4586	Aminocellulose-Grafted Polymeric Nanoparticles for Selective Targeting of CHEK2-Deficient Colorectal Cancer. ACS Applied Bio Materials, 2021, 4, 5324-5335.	2.3	15
4587	Immune Checkpoint Inhibitor Therapy in Colorectal Cancerâ€"The Role of Cellular Pathology. International Journal of Surgical Pathology, 2021, 29, 584-591.	0.4	3
4588	Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing. Human Pathology, 2021, 112, 20-34.	1.1	19
4589	PROGNOSTIC ROLE OF MOLECULAR SUBTYPES OF COLON CANCER. A CURRENT VIEW ON THE PROBLEM. Siberian Journal of Oncology, 2021, 20, 107-114.	0.1	2
4590	From Genetics to Histomolecular Characterization: An Insight into Colorectal Carcinogenesis in Lynch Syndrome. International Journal of Molecular Sciences, 2021, 22, 6767.	1.8	12
4591	Beta-1 syntrophin (SNTB1) regulates colorectal cancer progression and stemness via regulation of the Wnt/Î²-catenin signaling pathway. Annals of Translational Medicine, 2021, 9, 1016-1016.	0.7	6
4592	Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity. Nature Communications, 2021, 12, 4019.	5.8	13
4593	Epigenetic Regulation of Intestinal Stem Cells and Disease: A Balancing Act of DNA and Histone Methylation. Gastroenterology, 2021, 160, 2267-2282.	0.6	15

#	Article	IF	Citations
4594	Prospective experimental treatment of colorectal cancer patients based on organoid drug responses. ESMO Open, 2021, 6, 100103.	2.0	62
4595	Discovery of a Novel Triazolopyridine Derivative as a Tankyrase Inhibitor. International Journal of Molecular Sciences, 2021, 22, 7330.	1.8	7
4596	Molecular Characterization of Advanced Colorectal Cancer Using Serum Proteomics and Metabolomics. Frontiers in Molecular Biosciences, 2021, 8, 687229.	1.6	13
4597	Metabolic changes in colorectal carcinomas are key factors for the early detection of neoplastic change. Annals of Clinical and Biomedical Research, 2021, 2, .	0.0	0
4601	Integrative Multi-Omics Approaches in Cancer Research: From Biological Networks to Clinical Subtypes. Molecules and Cells, 2021, 44, 433-443.	1.0	57
4602	KRAS-targeted therapies in advanced solid cancers: drug the undruggable?. Pharmacogenomics, 2021, 22, 587-590.	0.6	5
4603	The Promising Effect of Peucedanum chenur Chloroformic Extract on Prevention of Human Colorectal Cancer Progression by Modulating miR-135b, miR-21, and APC Genes. Journal of Gastrointestinal Cancer, 2021, , 1.	0.6	1
4604	Osteopontin as a Regulator of Colorectal Cancer Progression and Its Clinical Applications. Cancers, 2021, 13, 3793.	1.7	19
4605	Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era. International Journal of Molecular Sciences, 2021, 22, 7717.	1.8	7
4606	DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 676922.	2.2	15
4607	Expression of the cancer-associated DNA polymerase Îµ P286R in fission yeast leads to translesion synthesis polymerase dependent hypermutation and defective DNA replication. PLoS Genetics, 2021, 17, e1009526.	1.5	8
4608	An investigation on the <i>câ€MYC, AXIN1</i>, and <i>COL11A1</i> gene expression in colorectal cancer. Biotechnology and Applied Biochemistry, 2022, 69, 1576-1586.	1.4	3
4609	Colorectal Cancer: From Genetic Landscape to Targeted Therapy. Journal of Oncology, 2021, 2021, 1-17.	0.6	28
4610	SPTAN1 Expression Predicts Treatment and Survival Outcomes in Colorectal Cancer. Cancers, 2021, 13, 3638.	1.7	2
4611	Comparative analysis of clonal evolution among patients with right- and left-sided colon and rectal cancer. IScience, 2021, 24, 102718.	1.9	9
4612	Regulation of Wnt Signaling by FOX Transcription Factors in Cancer. Cancers, 2021, 13, 3446.	1.7	18
4613	Clinicopathological and Molecular Characteristics of Colorectal Signet Ring Cell Carcinoma: A Review. Pathology and Oncology Research, 2021, 27, 1609859.	0.9	26
4615	Prevalence of cancer susceptibility variants in patients with multiple Lynch syndrome related cancers. Scientific Reports, 2021, 11, 14807.	1.6	8

#	Article	IF	Citations
4616	Cancer Genomic Profiling in Colorectal Cancer: Current Challenges in Subtyping Colorectal Cancers Based on Somatic and Germline Variants. Journal of the Anus, Rectum and Colon, 2021, 5, 213-228.	0.4	2
4618	The Pivotal Player: Components of NF-Î°B Pathway as Promising Biomarkers in Colorectal Cancer. International Journal of Molecular Sciences, 2021, 22, 7429.	1.8	16
4619	Expression of TCF7L2 in Glioma and Its Relationship With Clinicopathological Characteristics and Patient Overall Survival. Frontiers in Neurology, 2021, 12, 627431.	1.1	2
4620	Potential Role of Traditional Chinese Medicines by Wnt/Î²-Catenin Pathway Compared With Targeted Small Molecules in Colorectal Cancer Therapy. Frontiers in Pharmacology, 2021, 12, 690501.	1.6	8
4621	Predicting Agents That Can Overcome 5-FU Resistance in Colorectal Cancers via Pharmacogenomic Analysis. Biomedicines, 2021, 9, 882.	1.4	5
4622	Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. Gastroenterology, 2021, 161, 196-210.	0.6	23
4623	Machine learning analysis of TCGA cancer data. PeerJ Computer Science, 2021, 7, e584.	2.7	13
4624	Cell Biology of Canonical Wnt Signaling. Annual Review of Cell and Developmental Biology, 2021, 37, 369-389.	4.0	83
4625	Weighted Gene Co-expression Network Analysis Identified a Novel Thirteen-Gene Signature Associated With Progression, Prognosis, and Immune Microenvironment of Colon Adenocarcinoma Patients. Frontiers in Genetics, 2021, 12, 657658.	1.1	4
4626	Immuno-genomic classification of colorectal cancer organoids reveals cancer cells with intrinsic immunogenic properties associated with patient survival. Journal of Experimental and Clinical Cancer Research, 2021, 40, 230.	3.5	18
4627	Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer. Cell Reports, 2021, 36, 109394.	2.9	41
4628	Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i>. Clinical Cancer Research, 2021, 27, 5236-5247.	3.2	74
4629	Ras Family of Small GTPases in CRC: New Perspectives for Overcoming Drug Resistance. Cancers, 2021, 13, 3757.	1.7	3
4630	mtDNA Haplogroup M5 Associated with Risk of Colorectal Cancer in South India Population. Iraqi Journal of Science, 0, , 1863-1872.	0.3	0
4631	Proteomics provides individualized options of precision medicine for patients with gastric cancer. Science China Life Sciences, 2021, 64, 1199-1211.	2.3	8
4632	BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options. Der Pathologe, 2021, 42, 98-109.	0.7	5
4633	An autophagy-related long non-coding RNA signature for patients with colorectal cancer. Physiology International, 2021, 108, 202-220.	0.8	2
4634	A methylationâ€driven gene panel predicts survival in patients with colon cancer. FEBS Open Bio, 2021, 11, 2490-2506.	1.0	6

#	Article	IF	Citations
4635	A pan-cancer organoid platform for precision medicine. Cell Reports, 2021, 36, 109429.	2.9	45
4636	Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis. Cancer Prevention Research, 2021, 14, 851-862.	0.7	8
4637	Prognostic role and clinicopathological features of SMAD4 gene mutation in colorectal cancer: a systematic review and meta-analysis. BMC Gastroenterology, 2021, 21, 297.	0.8	22
4638	Construction of a DLBCL Prognostic Signature Based on Tumor Microenvironment. Expert Review of Hematology, 2021, 14, 679-686.	1.0	6
4639	MIR21-induced loss of junctional adhesion molecule A promotes activation of oncogenic pathways, progression and metastasis in colorectal cancer. Cell Death and Differentiation, 2021, 28, 2970-2982.	5.0	13
4640	CoronaPep: An Anti-Coronavirus Peptide Generation Tool. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2021, 18, 1299-1304.	1.9	5
4641	Anti-tumour effect of neo-antigen-reactive T cells induced by RNA mutanome vaccine in mouse lung cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3255-3268.	1.2	8
4642	Screening and identification of HLA-A2-restricted neoepitopes for immunotherapy of non-microsatellite instability-high colorectal cancer. Science China Life Sciences, 2022, 65, 572-587.	2.3	9
4643	A genomeâ€wide analysis of the molecular alterations occurring in the adenomatous and carcinomatous components of the same tumor based on the adenomaâ€“carcinoma sequence. Pathology International, 2021, 71, 582-593.	0.6	5
4644	Performance Comparisons of AlexNet and GoogLeNet in Cell Growth Inhibition IC50 Prediction. International Journal of Molecular Sciences, 2021, 22, 7721.	1.8	9
4645	Biomarkers and cell-based models to predict the outcome of neoadjuvant therapy for rectal cancer patients. Biomarker Research, 2021, 9, 60.	2.8	12
4646	Trapping Colorectal Cancer Into a Dead-end. Gastroenterology, 2021, 161, 33-35.	0.6	0
4647	Antigen presentation capability and AP-1 activation accompany methotrexate-induced colon cancer cell senescence in the context of aberrant Î²-catenin signaling. Mechanisms of Ageing and Development, 2021, 197, 111517.	2.2	3
4648	Targeting KRAS4A splicing through the RBM39/DCAF15 pathway inhibits cancer stem cells. Nature Communications, 2021, 12, 4288.	5.8	24
4649	Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFNâ€“driven CCL5 and CXCL10. Journal of Experimental Medicine, 2021, 218, .	4.2	61
4650	The impact of site-specific digital histology signatures on deep learning model accuracy and bias. Nature Communications, 2021, 12, 4423.	5.8	111
4651	Tumor Infiltrating Lymphocytes Target HLA-I Phosphopeptides Derived From Cancer Signaling in Colorectal Cancer. Frontiers in Immunology, 2021, 12, 723566.	2.2	14
4652	Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level. Cancer Discovery, 2022, 12, 134-153.	7.7	286

#	Article	IF	Citations
4653	SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis. Oncogene, 2021, 40, 6034-6048.	2.6	9
4654	Identification of Distinct Molecular Patterns and a Four-Gene Signature in Colon Cancer Based on Invasion-Related Genes. Frontiers in Genetics, 2021, 12, 685371.	1.1	3
4655	A ligand-insensitive UNC5B splicing isoform regulates angiogenesis by promoting apoptosis. Nature Communications, 2021, 12, 4872.	5.8	17
4656	Tumor-on-chip modeling of organ-specific cancer and metastasis. Advanced Drug Delivery Reviews, 2021, 175, 113798.	6.6	57
4657	Cell Models for Chromosome 20q11.21 Amplification and Drug Sensitivities in Colorectal Cancer. Medicina (Lithuania), 2021, 57, 860.	0.8	2
4658	Tumor BRCA testing can reveal a high tumor mutational burden related to POLE pathogenic variants. Gynecologic Oncology Reports, 2021, 37, 100855.	0.3	0
4659	Circular RNA ubiquitin-associated protein 2 enhances autophagy and promotes colorectal cancer progression and metastasis via miR-582-5p/FOXO1 signaling. Journal of Genetics and Genomics, 2021, 48, 1091-1103.	1.7	16
4660	Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers. Biomedicines, 2021, 9, 1024.	1.4	9
4661	Novel somatic variants involved in biochemical activity of pure growth hormone-secreting pituitary adenoma without GNAS variant. Scientific Reports, 2021, 11, 16530.	1.6	4
4662	SPARCL1 exhibits different expressions in left- and right-sided colon cancer and is downregulated via DNA methylation. Epigenomics, 2021, 13, 1269-1282.	1.0	2
4663	A body map of somatic mutagenesis in morphologically normal human tissues. Nature, 2021, 597, 398-403.	13.7	107
4664	Multi-Epitope-Based Vaccines for Colon Cancer Treatment and Prevention. Frontiers in Immunology, 2021, 12, 729809.	2.2	14
4665	Momordin Ic induces G0/1 phase arrest and apoptosis in colon cancer cells by suppressing SENP1/c-MYC signaling pathway. Journal of Pharmacological Sciences, 2021, 146, 249-258.	1.1	9
4666	Identification of hub genes and functional modules in colon adenocarcinoma based on public databases by bioinformatics analysis. Journal of Gastrointestinal Oncology, 2021, 12, 1613-1624.	0.6	2
4667	Wnt/Î²-catenin signaling in cancers and targeted therapies. Signal Transduction and Targeted Therapy, 2021, 6, 307.	7.1	186
4669	Employing bioinformatics analysis to identify hub genes and microRNAs involved in colorectal cancer. Medical Oncology, 2021, 38, 114.	1.2	11
4671	ARID1A regulates E-cadherin expression in colorectal cancer cells: a promising candidate therapeutic target. Molecular Biology Reports, 2021, 48, 6749-6756.	1.0	4
4672	The Multifaceted Role of TGF-Î² in Gastrointestinal Tumors. Cancers, 2021, 13, 3960.	1.7	18

#	Article	IF	Citations
4673	Comparison of the multigene panel test and OncoScanâ„¢ for the determination of HER2 amplification in breast cancer. Oncology Reports, 2021, 46, .	1.2	0
4674	Investigating the Mechanism of Scutellariae barbata Herba in the Treatment of Colorectal Cancer by Network Pharmacology and Molecular Docking. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-18.	0.5	8
4675	Current Trends and Research Topics Regarding Intestinal Organoids: An Overview Based on Bibliometrics. Frontiers in Cell and Developmental Biology, 2021, 9, 609452.	1.8	3
4676	Perturbed BMP signaling and denervation promote muscle wasting in cancer cachexia. Science Translational Medicine, 2021, 13, .	5.8	58
4677	CUX1 Facilitates the Development of Oncogenic Properties Via Activating Wnt/Î²-Catenin Signaling Pathway in Glioma. Frontiers in Molecular Biosciences, 2021, 8, 705008.	1.6	5
4678	Genomic Analysis Reveals Heterogeneity Between Lesions in Synchronous Primary Right-Sided and Left-Sided Colon Cancer. Frontiers in Molecular Biosciences, 2021, 8, 689466.	1.6	5
4679	Colorectal Cancer Risk in Patients with Hemorrhoids: A 10-Year Population-Based Retrospective Cohort Study. International Journal of Environmental Research and Public Health, 2021, 18, 8655.	1.2	4
4680	Regulation Network of Colorectal-Cancer-Specific Enhancers in the Progression of Colorectal Cancer. International Journal of Molecular Sciences, 2021, 22, 8337.	1.8	4
4681	Repurposing RNA sequencing for discovery of RNA modifications in clinical cohorts. Science Advances, 2021, 7, .	4.7	12
4682	Insights Into Systemic Sclerosis from Gene Expression Profiling. Current Treatment Options in Rheumatology, 2021, 7, 208-221.	0.6	0
4683	Advances in colorectal cancer genomics and transcriptomics drive early detection and prevention. International Journal of Biochemistry and Cell Biology, 2021, 137, 106032.	1.2	5
4685	Protein Complex Organization Imposes Constraints on Proteome Dysregulation in Cancer. Frontiers in Bioinformatics, 2021, 1, .	1.0	3
4686	The multidimensional role of the Wnt/Î²â€catenin signaling pathway in human malignancies. Journal of Cellular Physiology, 2022, 237, 199-238.	2.0	53
4687	The Mutational Landscape of Myeloid Leukaemia in Down Syndrome. Cancers, 2021, 13, 4144.	1.7	7
4688	Adipose stem cell niche reprograms the colorectal cancer stem cell metastatic machinery. Nature Communications, 2021, 12, 5006.	5.8	38
4689	The recurring features of molecular subtypes in distinct gastrointestinal malignanciesâ€"A systematic review. Critical Reviews in Oncology/Hematology, 2021, 164, 103428.	2.0	6
4690	Identification of prognostic immune-related gene signature associated with tumor microenvironment of colorectal cancer. BMC Cancer, 2021, 21, 905.	1.1	10
4691	Metabolism-associated genes in occurrence and development of gastrointestinal cancer: Latest progress and future prospect. World Journal of Gastrointestinal Oncology, 2021, 13, 758-771.	0.8	3

#	Article	IF	Citations
4692	Learning the structure of Bayesian Networks via the bootstrap. Neurocomputing, 2021, 448, 48-59.	3.5	6
4693	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nature Communications, 2021, 12, 5086.	5.8	58
4694	Role of Ezrin/Radixin/Moesin in the Surface Localization of Programmed Cell Death Ligand-1 in Human Colon Adenocarcinoma LS180 Cells. Pharmaceuticals, 2021, 14, 864.	1.7	13
4695	miR-582-5p inhibits migration and chemo-resistant capabilities of colorectal cancer cells by targeting TNKS2. Genes and Genomics, 2022, 44, 747-756.	0.5	5
4696	Identification and Validation of a Novel Inflammatory Response-Related Gene Signature for the Prognosis of Colon Cancer. Journal of Inflammation Research, 2021, Volume 14, 3809-3821.	1.6	13
4697	Cell-based immunotherapy approaches for colorectal cancer: main achievements and challenges. Future Oncology, 2021, 17, 3253-3270.	1.1	3
4698	Ruthenium Complexes: An Alternative to Platinum Drugs in Colorectal Cancer Treatment. Pharmaceutics, 2021, 13, 1295.	2.0	34
4699	Transcriptomic Analyses of the Adenoma-Carcinoma Sequence Identify Hallmarks Associated With the Onset of Colorectal Cancer. Frontiers in Oncology, 2021, 11, 704531.	1.3	12
4700	A merged microarray meta-dataset for transcriptionally profiling colorectal neoplasm formation and progression. Scientific Data, 2021, 8, 214.	2.4	4
4701	Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer. Journal of the American College of Surgeons, 2021, 233, 272-284e13.	0.2	18
4702	Activated macrophages promote invasion by early colorectal cancer via an interleukin 1Î²â€serum amyloid A1 axis. Cancer Science, 2021, 112, 4151-4165.	1.7	9
4704	The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell, 2021, 39, 1342-1360.e14.	7.7	119
4705	RNF141 interacts with KRAS to promote colorectal cancer progression. Oncogene, 2021, 40, 5829-5842.	2.6	4
4706	An 11-gene signature for the prediction of systemic recurrences in colon adenocarcinoma. Gastroenterology Report, 2021, 9, 451-460.	0.6	3
4708	Characterization of <i>in vitro</i> 3D cultures. Apmis, 2021, 129, 1-30.	0.9	3
4709	NRF2 Mediates Therapeutic Resistance to Chemoradiation in Colorectal Cancer through a Metabolic Switch. Antioxidants, 2021, 10, 1380.	2.2	7
4710	Ginkgolide C promotes apoptosis and abrogates metastasis of colorectal carcinoma cells by targeting Wnt/Î²â€catenin signaling pathway. IUBMB Life, 2021, 73, 1222-1234.	1.5	12
4711	Virusâ€"host interactions in carcinogenesis of Epstein-Barr virus-associated gastric carcinoma: Potential roles of lost ARID1A expression in its early stage. PLoS ONE, 2021, 16, e0256440.	1.1	7

#	Article	IF	Citations
4712	Gastrointestinal cancer classification and prognostication from histology using deep learning: Systematic review. European Journal of Cancer, 2021, 155, 200-215.	1.3	70
4714	MIER3 induces epithelial-mesenchymal transition and promotes breast cancer cell aggressiveness via forming a co-repressor complex with HDAC1/HDAC2/Snail. Experimental Cell Research, 2021, 406, 112722.	1.2	11
4715	Single-cell exome sequencing reveals multiple subclones in metastatic colorectal carcinoma. Genome Medicine, 2021, 13, 148.	3.6	14
4716	Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us. Trends in Cancer, 2021, 7, 823-836.	3.8	32
4717	STARD3: A Prospective Target for Cancer Therapy. Cancers, 2021, 13, 4693.	1.7	11
4718	Integrative Analysis Reveals Potentially Functional N6-Methylandenosine-Related Long Noncoding RNAs in Colon Adenocarcinoma. Frontiers in Genetics, 2021, 12, 739344.	1.1	4
4719	A primary thymic adenocarcinoma with two components that traced distinct evolutionary trajectories. Pathology International, 2021, , .	0.6	1
4720	Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. Nature Cancer, 2021, 2, 1071-1085.	5.7	57
4721	Using Immune-Related Long Non-coding Ribonucleic Acids to Develop a Novel Prognosis Signature and Predict the Immune Landscape of Colon Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 750709.	1.8	1
4724	Predicting the Survival and Immune Landscape of Colorectal Cancer Patients Using an Immune-Related lncRNA Pair Model. Frontiers in Genetics, 2021, 12, 690530.	1.1	3
4725	Advance in Human Epithelial-Derived Organoids Research. Molecular Pharmaceutics, 2021, 18, 3931-3950.	2.3	3
4726	Utility of exome sequencing in routine care for metastatic colorectal cancer. Molecular and Clinical Oncology, 2021, 15, 229.	0.4	1
4727	Stromal Galectin-1 Promotes Colorectal Cancer Cancer-Initiating Cell Features and Disease Dissemination Through SOX9 and Î²-Catenin: Development of Niche-Based Biomarkers. Frontiers in Oncology, 2021, 11, 716055.	1.3	4
4728	Evolution and progression of Barrettâ€™s oesophagus to oesophageal cancer. Nature Reviews Cancer, 2021, 21, 731-741.	12.8	32
4729	Combined histopathological risk score using TP53 protein expression, CD8⁺ T cell density and intratumoral budding is an independent predictor of neoadjuvant therapy response in rectal adenocarcinoma. Histopathology, 2021, 79, 826-835.	1.6	6
4730	MYC Hyperactivates Wnt Signaling in <i>APC</i>/<i>CTNNB1</i>-Mutated Colorectal Cancer Cells through miR-92aâ€"Dependent Repression of <i>DKK3</i>. Molecular Cancer Research, 2021, 19, 2003-2014.	1.5	9
4731	The Expression of Immune Checkpoint Receptors and Ligands in the Colorectal Cancer Tumor Microenvironment. Anticancer Research, 2021, 41, 4895-4905.	0.5	6
4732	Increased somatic mutation burdens in normal human cells due to defective DNA polymerases. Nature Genetics, 2021, 53, 1434-1442.	9.4	85

#	Article	IF	Citations
4733	A Truncated NRIP1 Mutant Amplifies Microsatellite Instability of Colorectal Cancer by Regulating MSH2/MSH6 Expression, and Is a Prognostic Marker of Stage III Tumors. Cancers, 2021, 13, 4449.	1.7	5
4734	Racial Disparities and Sex Differences in Early- and Late-Onset Colorectal Cancer Incidence, 2001â€“2018. Frontiers in Oncology, 2021, 11, 734998.	1.3	28
4735	High-throughput proteomics and AI for cancer biomarker discovery. Advanced Drug Delivery Reviews, 2021, 176, 113844.	6.6	54
4736	Characterization and clinical evaluation of microsatellite instability and loss of heterozygosity within tumor-related genes in colorectal cancer. BMC Medical Genomics, 2021, 14, 235.	0.7	0
4737	An Enhancer-Driven Stem Cellâ€“Like Program Mediated by SOX9 Blocks Intestinal Differentiation in Colorectal Cancer. Gastroenterology, 2022, 162, 209-222.	0.6	27
4738	Moving pan-cancer studies from basic research toward the clinic. Nature Cancer, 2021, 2, 879-890.	5.7	40
4739	DOCâ€2/DAB2 interactive protein destabilizes câ€Myc to impair the growth and selfâ€renewal of colon tumorâ€repopulating cells. Cancer Science, 2021, 112, 4593-4603.	1.7	5
4740	WNT as a Driver and Dependency in Cancer. Cancer Discovery, 2021, 11, 2413-2429.	7.7	108
4741	Implications of Intratumor Heterogeneity on Consensus Molecular Subtype (CMS) in Colorectal Cancer. Cancers, 2021, 13, 4923.	1.7	19
4742	Combining repurposed drugs to treat colorectal cancer. Drug Discovery Today, 2022, 27, 165-184.	3.2	10
4743	Epithelial X-Box Binding Protein 1 Coordinates Tumor Protein p53-Driven DNA Damage Responses and Suppression of Intestinal Carcinogenesis. Gastroenterology, 2022, 162, 223-237.e11.	0.6	15
4746	Exosomes: Emerging modulators of signal transduction in colorectal cancer from molecular understanding to clinical application. Biomedicine and Pharmacotherapy, 2021, 141, 111882.	2.5	18
4747	Multimetric feature selection for analyzing multicategory outcomes of colorectal cancer: random forest and multinomial logistic regression models. Laboratory Investigation, 2022, 102, 236-244.	1.7	9
4748	Image-based assessment of extracellular mucin-to-tumor area predicts consensus molecular subtypes (CMS) in colorectal cancer. Modern Pathology, 2022, 35, 240-248.	2.9	9
4749	Exosome Released FZD10 Increases Ki-67 Expression via Phospho-ERK1/2 in Colorectal and Gastric Cancer. Frontiers in Oncology, 2021, 11, 730093.	1.3	9
4750	APC mutations are common in adenomas but infrequent in adenocarcinomas of the non-ampullary duodenum. Journal of Gastroenterology, 2021, 56, 988-998.	2.3	6
4751	Molecular profiling and identification of prognostic factors in Chinese patients with small bowel adenocarcinoma. Cancer Science, 2021, 112, 4758-4771.	1.7	7
4752	RNA-Sequencing Based microRNA Expression Signature of Colorectal Cancer: The Impact of Oncogenic Targets Regulated by miR-490-3p. International Journal of Molecular Sciences, 2021, 22, 9876.	1.8	6

#	Article	IF	Citations
4753	Spatially organized multicellular immune hubs in human colorectal cancer. Cell, 2021, 184, 4734-4752.e20.	13.5	256
4754	Novel diagnostic and prognostic biomarkers of colorectal cancer: Capable to overcome the heterogeneity-specific barrier and valid for global applications. PLoS ONE, 2021, 16, e0256020.	1.1	7
4755	MSI-WES: aÂsimple approach for microsatellite instability testing using whole exome sequencing. Future Oncology, 2021, 17, 3595-3606.	1.1	4
4756	Distinguishing colorectal adenoma from hyperplastic polyp by WNT2 expression. Journal of Clinical Laboratory Analysis, 2021, 35, e23961.	0.9	14
4757	Personalised Medicine for Colorectal Cancer Using Mechanism-Based Machine Learning Models. International Journal of Molecular Sciences, 2021, 22, 9970.	1.8	7
4758	The expressed mutational landscape of microsatellite stable colorectal cancers. Genome Medicine, 2021, 13, 142.	3.6	4
4759	The Landscape of PIK3CA Mutations in Colorectal Cancer. Clinical Colorectal Cancer, 2021, 20, 201-215.	1.0	24
4760	A 41-Gene Pair Signature for Predicting the Pathological Response of Locally Advanced Rectal Cancer to Neoadjuvant Chemoradiation. Frontiers in Medicine, 2021, 8, 744295.	1.2	2
4761	Genomic Profiling Reveals the Molecular Landscape of Gastrointestinal Tract Cancers in Chinese Patients. Frontiers in Genetics, 2021, 12, 608742.	1.1	5
4762	Tumor models to assess immune response and tumor-microbiome interactions in colorectal cancer. , 2021, 231, 107981.		9
4763	Therapeutic Effects of Polyphenols on the Treatment of Colorectal Cancer by Regulating Wnt Î²-Catenin Signaling Pathway. Journal of Oncology, 2021, 2021, 1-12.	0.6	8
4764	Medullary Carcinoma of the Gastrointestinal Tract: Report on Two Cases with Immunohistochemical and Molecular Features. Diagnostics, 2021, 11, 1775.	1.3	2
4765	Evaluation of a Targeted Next-Generation Sequencing Panel for the Non-Invasive Detection of Variants in Circulating DNA of Colorectal Cancer. Journal of Clinical Medicine, 2021, 10, 4487.	1.0	8
4766	RNAscope compatibility with image analysis platforms for the quantification of tissue-based colorectal cancer biomarkers in archival formalin-fixed paraffin-embedded tissue. Acta Histochemica, 2021, 123, 151765.	0.9	4
4767	Single-cell DNA and RNA sequencing reveals the dynamics of intra-tumor heterogeneity in a colorectal cancer model. BMC Biology, 2021, 19, 207.	1.7	18
4768	MSI testing. Der Pathologe, 2021, 42, 110-118.	0.7	9
4769	Profiling diverse sequence tandem repeats in colorectal cancer reveals co-occurrence of microsatellite and chromosomal instability involving Chromosome 8. Genome Medicine, 2021, 13, 145.	3.6	6
4770	Low-viscosity matrix suspension culture enables scalable analysis of patient-derived organoids and tumoroids from the large intestine. Communications Biology, 2021, 4, 1067.	2.0	15

#	Article	IF	Citations
4772	Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications. Journal of Hematology and Oncology, 2021, 14, 141.	6.9	36
4773	MicroRNA expression in inflammatory bowel disease-associated colorectal cancer. World Journal of Gastrointestinal Oncology, 2021, 13, 995-1016.	0.8	8
4774	UCTD and SLE patients show increased levels of oxidative and DNA damage together with an altered kinetics of DSB repair. Mutagenesis, 2021, 36, 429-436.	1.0	2
4775	Genomics of Black American colon cancer disparities: An RNA sequencing (RNA-Seq) study from an academic, tertiary referral center. Surgery, 2021, 170, 1160-1167.	1.0	2
4776	Strategic enhancement of immune checkpoint inhibition in refractory Colorectal Cancer: Trends and future prospective. International Immunopharmacology, 2021, 99, 108017.	1.7	5
4777	Immunogenomics of Colorectal Cancer Response to CheckpointÂBlockade: Analysis of the KEYNOTE 177 Trial andÂValidation Cohorts. Gastroenterology, 2021, 161, 1179-1193.	0.6	62
4778	Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies. , 2021, 9, e003001.		8
4779	The upregulation of PYCR2 is associated with aggressive colon cancer progression and a poor prognosis. Biochemical and Biophysical Research Communications, 2021, 572, 20-26.	1.0	8
4780	INTS6 promotes colorectal cancer progression by activating of AKT and ERK signaling. Experimental Cell Research, 2021, 407, 112826.	1.2	1
4781	Mice with dysfunctional TGF-Î² signaling develop altered intestinal microbiome and colorectal cancer resistant to 5FU. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166179.	1.8	8
4782	Reducing variability of breast cancer subtype predictors by grounding deep learning models in prior knowledge. Computers in Biology and Medicine, 2021, 138, 104850.	3.9	4
4783	TSHZ3 functions as a tumor suppressor by DNA methylation in colorectal cancer. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101725.	0.7	5
4784	Adenoma to carcinoma: A portrait of molecular and immunological profiles of colorectal sporadic tumors. International Immunopharmacology, 2021, 100, 108168.	1.7	1
4785	Current status and future perspective of immune checkpoint inhibitors in colorectal cancer. Cancer Letters, 2021, 521, 119-129.	3.2	16
4786	Combination of Compound Kushen Injection and cisplatin shows synergistic antitumor activity in p53-R273H/P309S mutant colorectal cancer cells through inducing apoptosis. Journal of Ethnopharmacology, 2022, 283, 114690.	2.0	15
4787	Increased Expression of Long Non-coding RNA H19 is Associated With Colon Cancer Recurrence. Journal of Surgical Research, 2022, 269, 59-68.	0.8	5
4788	Aberrant KIF23 expression is associated with adverse clinical outcome and promotes cellular malignant behavior through the Wnt/Î²-catenin signaling pathway in Colorectal Cancer. Journal of Cancer, 2021, 12, 2030-2040.	1.2	14
4789	Clinical significance of genetic alterations in endoscopically obtained pancreatic cancer specimens. Cancer Medicine, 2021, 10, 1264-1274.	1.3	11

#	Article	IF	Citations
4790	A sensitive HPLC-FLD method for the quantification of alpelisib, a novel phosphatidylinositol 3-kinase inhibitor, in rat plasma: Drug metabolism and pharmacokinetic evaluation in vitro and in vivo. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1163, 122508.	1.2	11
4791	Translation initiation and its relevance in colorectal cancer. FEBS Journal, 2021, 288, 6635-6651.	2.2	10
4792	Molecular Features of the Serrated Pathway to Colorectal Cancer: Current Knowledge and Future Directions. Gut and Liver, 2021, 15, 31-43.	1.4	11
4793	CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration. Cancer Immunology, Immunotherapy, 2021, 70, 1831-1840.	2.0	32
4794	Current state of chemotherapy and immunotherapy regimens in gastric cancer. , 2021, , 289-316.		0
4795	The role of inflammation in gastric tumorigenesis. , 2021, , 25-42.		0
4796	DNA mismatch repair in mammals. , 2021, , 323-347.		1
4797	An integrated multi-omics approach to identify regulatory mechanisms in cancer metastatic processes. Genome Biology, 2021, 22, 19.	3.8	13
4798	ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. Clinical Cancer Research, 2021, 27, 1663-1670.	3.2	30
4799	The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer. Nature Genetics, 2021, 53, 16-26.	9.4	114
4800	Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair. Nucleic Acids Research, 2021, 49, 11067-11082.	6.5	26
4801	Somatic data usage for classification of germ line variants. , 2021, , 169-192.		0
4802	Biomarkers as Putative Therapeutic Targets in Colorectal Cancer. , 2021, , 123-177.		0
4803	Colorectal Cancer: A Model for the Study of Cancer Immunology. , 2021, , 15-30.		0
4804	Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial. Genome Medicine, 2021, 13, 11.	3.6	17
4805	De novo DNA methyltransferase activity in colorectal cancer is directed towards H3K36me3 marked CpG islands. Nature Communications, 2021, 12, 694.	5.8	24
4806	A RAC-GEF network critical for early intestinal tumourigenesis. Nature Communications, 2021, 12, 56.	5.8	11
4807	Pattern Recognition Algorithms for Multi-Omics Data Analysis. , 2021, , 141-158.		3

#	Article	IF	Citations
4808	Bromamine T (BAT) Exerts Stronger Anti-Cancer Properties than Taurine (Tau). Cancers, 2021, 13, 182.	1.7	7
4809	Enhanced neoplasia detection in chronic ulcerative colitis: the ENDCaP-C diagnostic accuracy study. Efficacy and Mechanism Evaluation, 2021, 8, 1-88.	0.9	0
4810	Exploiting KRAS-mediated metabolic reprogramming as a therapeutic target. Nature Genetics, 2021, 53, 9-10.	9.4	6
4811	PDGFRÎ² is an essential therapeutic target for BRCA1-deficient mammary tumors. Breast Cancer Research, 2021, 23, 10.	2.2	9
4813	A Negative Feedback Loop Between NAMPT and TGF-Î² Signaling Pathway in Colorectal Cancer Cells. OncoTargets and Therapy, 2021, Volume 14, 187-198.	1.0	9
4814	A portable pen-sized instrumentation to measure stiffness of soft tissues in vivo. Scientific Reports, 2021, 11, 378.	1.6	6
4815	Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening?. Cancer Treatment and Research Communications, 2021, 28, 100442.	0.7	14
4816	PI3KCA Mutations in Uterine Cervix Carcinoma. Journal of Clinical Medicine, 2021, 10, 220.	1.0	11
4817	<i>BRAF, MEK</i> and <i>EGFR</i> inhibition as treatment strategies in <i>BRAF</i> V600E metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199297.	1.4	38
4818	Immunotherapy in Colorectal Cancer: Current and Future Strategies. Journal of the Anus, Rectum and Colon, 2021, 5, 11-24.	0.4	59
4819	Lithium and Therapeutic Targeting of GSK-3. Cells, 2021, 10, 255.	1.8	49
4820	Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project. Cancer Research and Treatment, 2021, 53, 123-130.	1.3	12
4821	Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer. Annual Review of Medicine, 2021, 72, 399-413.	5.0	12
4822	Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features. Nature Communications, 2021, 12, 574.	5.8	39
4823	Endothelial protein C receptor is overexpressed in colorectal cancer as a result of amplification and hypomethylation of chromosome 20q. Journal of Pathology: Clinical Research, 2017, 3, 155-170.	1.3	7
4824	EPIC: A Tool to Estimate the Proportions of Different Cell Types from Bulk Gene Expression Data. Methods in Molecular Biology, 2020, 2120, 233-248.	0.4	248
4825	Omic Data, Information Derivable and Computational Needs. , 2014, , 41-63.		1
4826	Beyond the Island: Epigenetic Biomarkers of Colorectal and Prostate Cancer. Methods in Molecular Biology, 2015, 1238, 103-124.	0.4	3

#	Article	IF	Citations
4827	Genetic Instability Markers in Cancer. Methods in Molecular Biology, 2020, 2055, 133-154.	0.4	2
4828	Mechanisms of Environmental and Occupational Carcinogenesis. , 2020, , 39-55.		1
4829	The Intestinal Tumour Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1226, 1-22.	0.8	10
4830	The Role of the Immune Infiltrate in Distinct Cancer Types and Its Clinical Implications. Cancer Treatment and Research, 2020, 180, 197-211.	0.2	4
4831	3D Radiation Biology for Identifying Radiosensitizers. Cancer Drug Discovery and Development, 2020, , 115-135.	0.2	2
4833	HITâ€™nDRIVE: Multi-driver Gene Prioritization Based on Hitting Time. Lecture Notes in Computer Science, 2014, , 293-306.	1.0	35
4834	Using Analysis Algorithms and Image Processing for Quantitative Description of Colon Cancer Cells. Advances in Intelligent Systems and Computing, 2014, , 385-395.	0.5	2
4836	The Biology of AYA Cancers. Pediatric Oncology, 2017, , 43-67.	0.5	3
4837	Title is missing!. , 2017, , .		56
4839	The Molecular Pathology of Lung Cancer: Pre-analytic Considerations. Molecular Pathology Library, 2018, , 79-92.	0.1	1
4840	MYC Regulation of Metabolism and Cancer. , 2015, , 101-122.		1
4841	TGF-Î² as Tumor Suppressor: Lessons from Mouse Models. , 2013, , 139-168.		2
4842	Wnt Pathway at a Glance: From the Deep of the Crypts to the Current Ways of Targeting. , 2014, , 85-106.		1
4843	Targeting SCF E3 Ligases for Cancer Therapies. Advances in Experimental Medicine and Biology, 2020, 1217, 123-146.	0.8	34
4844	Systems Biology and Integrated Computational Methods for Cancer-Associated Mutation Analysis. , 2020, , 335-362.		3
4845	Biomarkers in the Management of Peritoneal Metastases. , 2020, , 251-279.		2
4846	Immunotherapy for Lynch Syndrome Patients. , 2020, , 117-122.		1
4847	The structure and regulation of the E3 ubiquitin ligase HUWE1 and its biological functions in cancer. Investigational New Drugs, 2020, 38, 515-524.	1.2	32

#	Article	IF	Citations
4848	Frequent RNF43 mutation contributes to moderate activation of Wnt signaling in colorectal signet-ring cell carcinoma. Protein and Cell, 2020, 11, 292-298.	4.8	11
4849	Necroptosis, ADAM proteases and intestinal (dys)function. International Review of Cell and Molecular Biology, 2020, 353, 83-152.	1.6	5
4850	KAP1 Is a Chromatin Reader that Couples Steps of RNA Polymerase II Transcription to Sustain Oncogenic Programs. Molecular Cell, 2020, 78, 1133-1151.e14.	4.5	26
4851	Picking Winners and Losers: Cell Competition in Tissue Development and Homeostasis. Trends in Genetics, 2020, 36, 490-498.	2.9	16
4852	Infection-induced signals generated at the plasma membrane epigenetically regulate Wnt signaling in vitro and in vivo. Journal of Biological Chemistry, 2020, 295, 1021-1035.	1.6	4
4853	Mechanisms of inactivation of the tumour suppressor gene RHOA in colorectal cancer. British Journal of Cancer, 2018, 118, 106-116.	2.9	24
4854	WNT signalling pathways as therapeutic targets in cancer. , 0, .		1
4855	A novel UBE2T inhibitor suppresses Wnt/Î²-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination. Oncogene, 2021, 40, 1027-1042.	2.6	55
4856	H3K4 methylation at active genes mitigates transcription-replication conflicts during replication stress. Nature Communications, 2020, 11, 809.	5.8	41
4857	Comprehensive molecular characterization of mitochondrial genomes in human cancers. Nature Genetics, 2020, 52, 342-352.	9.4	256
4858	KRT18 is correlated with the malignant status and acts as an oncogene in colorectal cancer. Bioscience Reports, 2019, 39, .	1.1	47
4859	Epigenetic plasticity, selection, and tumorigenesis. Biochemical Society Transactions, 2020, 48, 1609-1621.	1.6	11
4860	Upregulation of polycistronic microRNA-143 and microRNA-145 in colonocytes suppresses colitis and inflammation-associated colon cancer. Epigenetics, 2021, 16, 1317-1334.	1.3	10
4861	Serrated neoplasia in the colorectum: gut microbiota and molecular pathways. Gut Microbes, 2021, 13, 1-12.	4.3	12
4862	IPO11 mediates Î²catenin nuclear import in a subset of colorectal cancers. Journal of Cell Biology, 2020, 219, .	2.3	27
4863	Racial Disparities in Epigenetic Aging of the Right vs Left Colon. Journal of the National Cancer Institute, 2021, 113, 1779-1782.	3.0	23
4864	MAP2K1-Mutated Melanocytic Neoplasms With a SPARK-Like Morphology. American Journal of Dermatopathology, 2021, 43, 412-417.	0.3	14
4865	Immunohistochemical Examination is Highly Sensitive and Specific for Detection of the V600E BRAF Mutation in Colorectal Serrated Lesions. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 446-453.	0.6	1

#	Article	IF	Citations
4866	Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features. American Journal of Surgical Pathology, 2021, 45, 421-429.	2.1	31
4867	Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2022, 275, e229-e237.	2.1	14
4868	Aligner optimization increases accuracy and decreases compute times in multi-species sequence data. Microbial Genomics, 2017, 3, e000122.	1.0	13
4938	<i>GTF2IRD1</i> on chromosome 7 is a novel oncogene regulating the tumorâ€suppressor gene <i>TGFÎ²R2</i> in colorectal cancer. Cancer Science, 2020, 111, 343-355.	1.7	15
4939	Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials. ESMO Open, 2020, 5, e000605.	2.0	18
4940	Identification of 6 Hub Proteins and Protein Risk Signature of Colorectal Cancer. BioMed Research International, 2020, 2020, 1-17.	0.9	3
4941	Gene Alterations of N6-Methyladenosine (m6A) Regulators in Colorectal Cancer: A TCGA Database Study. BioMed Research International, 2020, 2020, 1-13.	0.9	13
4942	Prognostic Significance of Immune Cell Populations Identified by Machine Learning in Colorectal Cancer Using Routine Hematoxylin and Eosinâ€"Stained Sections. Clinical Cancer Research, 2020, 26, 4326-4338.	3.2	35
4943	Inactivation of mTORC2 in macrophages is a signature of colorectal cancer that promotes tumorigenesis. JCI Insight, 2019, 4, .	2.3	19
4944	Nardilysin controls intestinal tumorigenesis through HDAC1/p53â€"dependent transcriptional regulation. JCI Insight, 2018, 3, .	2.3	10
4945	RIP140 increases APC expression and controls intestinal homeostasis and tumorigenesis. Journal of Clinical Investigation, 2014, 124, 1899-1913.	3.9	45
4946	The genomic landscape of small intestine neuroendocrine tumors. Journal of Clinical Investigation, 2013, 123, 2502-2508.	3.9	254
4947	IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. Journal of Clinical Investigation, 2014, 124, 1853-1867.	3.9	613
4948	The deubiquitinase USP28 controls intestinal homeostasis and promotes colorectal cancer. Journal of Clinical Investigation, 2014, 124, 3407-3418.	3.9	124
4949	Matricellular protein SPARCL1 regulates tumor microenvironmentâ€"dependent endothelial cell heterogeneity in colorectal carcinoma. Journal of Clinical Investigation, 2016, 126, 4187-4204.	3.9	68
4950	The deubiquitinase USP9X regulates FBW7 stability and suppresses colorectal cancer. Journal of Clinical Investigation, 2018, 128, 1326-1337.	3.9	77
4953	Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway. Molecular Medicine, 2020, 26, 14.	1.9	23
4954	Targeting the NAD+ salvage pathway suppresses APC mutation-driven colorectal cancer growth and Wnt/Î²-catenin signaling via increasing Axin level. Cell Communication and Signaling, 2020, 18, 16.	2.7	23

#	Article	IF	Citations
4955	KRAS and GNAS Co-Mutation in Metastatic Low-Grade Appendiceal Mucinous Neoplasm (LAMN) to the Ovaries: A Practical Role for Next-Generation Sequencing. American Journal of Case Reports, 2017, 18, 558-562.	0.3	11
4956	Elevated G-Protein Receptor 125 (GPR125) Expression Predicts Good Outcomes in Colorectal Cancer and Inhibits Wnt/Î²-Catenin Signaling Pathway. Medical Science Monitor, 2018, 24, 6608-6616.	0.5	20
4957	Integrative Gene Expression Profiling Analysis to Investigate Potential Prognostic Biomarkers for Colorectal Cancer. Medical Science Monitor, 2020, 26, e918906.	0.5	20
4958	Linking patient outcome to high throughput protein expression data identifies novel regulators of colorectal adenocarcinoma aggressiveness. F1000Research, 2015, 4, 99.	0.8	9
4959	TCGA Workflow: Analyze cancer genomics and epigenomics data using Bioconductor packages. F1000Research, 0, 5, 1542.	0.8	155
4960	TCGA Workflow: Analyze cancer genomics and epigenomics data using Bioconductor packages. F1000Research, 2016, 5, 1542.	0.8	140
4961	DNA methylation detection methods used in colorectal cancer. World Journal of Clinical Cases, 2019, 7, 2916-2929.	0.3	10
4962	Mathematical Modelling of Molecular Pathways Enabling Tumour Cell Invasion and Migration. PLoS Computational Biology, 2015, 11, e1004571.	1.5	130
4963	Quantifying Clonal and Subclonal Passenger Mutations in Cancer Evolution. PLoS Computational Biology, 2016, 12, e1004731.	1.5	95
4964	BeWith: A Between-Within method to discover relationships between cancer modules via integrated analysis of mutual exclusivity, co-occurrence and functional interactions. PLoS Computational Biology, 2017, 13, e1005695.	1.5	38
4965	Integrated Multiregional Analysis Proposing a New Model of Colorectal Cancer Evolution. PLoS Genetics, 2016, 12, e1005778.	1.5	134
4966	P1 Ref Endonuclease: A Molecular Mechanism for Phage-Enhanced Antibiotic Lethality. PLoS Genetics, 2016, 12, e1005797.	1.5	24
4967	Identification of Novel Candidate Genes for Early-Onset Colorectal Cancer Susceptibility. PLoS Genetics, 2016, 12, e1005880.	1.5	52
4968	Intestinal stem cell overproliferation resulting from inactivation of the APC tumor suppressor requires the transcription cofactors Earthbound and Erect wing. PLoS Genetics, 2017, 13, e1006870.	1.5	20
4969	Exome-wide somatic mutation characterization of small bowel adenocarcinoma. PLoS Genetics, 2018, 14, e1007200.	1.5	62
4970	The INO80 chromatin remodeler sustains metabolic stability by promoting TOR signaling and regulating histone acetylation. PLoS Genetics, 2018, 14, e1007216.	1.5	23
4971	Colorectal cancer mutational profiles correlate with defined microbial communities in the tumor microenvironment. PLoS Genetics, 2018, 14, e1007376.	1.5	65
4972	Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study. PLoS Medicine, 2016, 13, e1002162.	3.9	148

#	Article	IF	Citations
4973	Genome-Scale Discovery of DNA-Methylation Biomarkers for Blood-Based Detection of Colorectal Cancer. PLoS ONE, 2012, 7, e50266.	1.1	103
4974	Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells. PLoS ONE, 2012, 7, e51449.	1.1	39
4975	Promoter Hypermethylation of ARID1A Gene Is Responsible for Its Low mRNA Expression in Many Invasive Breast Cancers. PLoS ONE, 2013, 8, e53931.	1.1	46
4976	MSH3 Mismatch Repair Protein Regulates Sensitivity to Cytotoxic Drugs and a Histone Deacetylase Inhibitor in Human Colon Carcinoma Cells. PLoS ONE, 2013, 8, e65369.	1.1	41
4977	Mutational Analysis of Hedgehog Signaling Pathway Genes in Human Malignant Mesothelioma. PLoS ONE, 2013, 8, e66685.	1.1	29
4978	Functional Comparison of Human Adenomatous Polyposis Coli (APC) and APC-Like in Targeting Beta-Catenin for Degradation. PLoS ONE, 2013, 8, e68072.	1.1	26
4979	Large Scale Comparison of Gene Expression Levels by Microarrays and RNAseq Using TCGA Data. PLoS ONE, 2013, 8, e71462.	1.1	189
4980	Distinct Gene Expression Signatures in Lynch Syndrome and Familial Colorectal Cancer Type X. PLoS ONE, 2013, 8, e71755.	1.1	28
4981	Functional Comparison between Genes Dysregulated in Ulcerative Colitis and Colorectal Carcinoma. PLoS ONE, 2013, 8, e71989.	1.1	6
4982	Identification and Characterization of Cancer Mutations in Japanese Lung Adenocarcinoma without Sequencing of Normal Tissue Counterparts. PLoS ONE, 2013, 8, e73484.	1.1	41
4983	Specific Extracellular Matrix Remodeling Signature of Colon Hepatic Metastases. PLoS ONE, 2013, 8, e74599.	1.1	46
4984	Simultaneous Activation of Kras and Inactivation of p53 Induces Soft Tissue Sarcoma and Bladder Urothelial Hyperplasia. PLoS ONE, 2013, 8, e74809.	1.1	14
4985	Novel Genes Associated with Colorectal Cancer Are Revealed by High Resolution Cytogenetic Analysis in a Patient Specific Manner. PLoS ONE, 2013, 8, e76251.	1.1	52
4986	Massively Parallel Sequencing Reveals an Accumulation of De Novo Mutations and an Activating Mutation of LPAR1 in a Patient with Metastatic Neuroblastoma. PLoS ONE, 2013, 8, e77731.	1.1	24
4987	Experimental Design-Based Functional Mining and Characterization of High-Throughput Sequencing Data in the Sequence Read Archive. PLoS ONE, 2013, 8, e77910.	1.1	32
4988	CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features. PLoS ONE, 2013, 8, e77945.	1.1	104
4989	Proliferation of Colorectal Cancer Is Promoted by Two Signaling Transduction Expression Patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK. PLoS ONE, 2013, 8, e78086.	1.1	22
4990	The Genome of Polymorphonuclear Neutrophils Maintains Normal Coding Sequences. PLoS ONE, 2013, 8, e78685.	1.1	1

#	Article	IF	Citations
4991	Differences in Survival between Colon and Rectal Cancer from SEER Data. PLoS ONE, 2013, 8, e78709.	1.1	120
4992	Deciphering Genomic Alterations in Colorectal Cancer through Transcriptional Subtype-Based Network Analysis. PLoS ONE, 2013, 8, e79282.	1.1	15
4993	Correlation of Chromosomal Instability, Telomere Length and Telomere Maintenance in Microsatellite Stable Rectal Cancer: A Molecular Subclass of Rectal Cancer. PLoS ONE, 2013, 8, e80015.	1.1	37
4994	Assessment of Whole Genome Amplification for Sequence Capture and Massively Parallel Sequencing. PLoS ONE, 2014, 9, e84785.	1.1	10
4995	Clustering Gene Expression Regulators: New Approach to Disease Subtyping. PLoS ONE, 2014, 9, e84955.	1.1	32
4996	Identification of Two Wnt-Responsive Elements in the Intron of RING Finger Protein 43 (RNF43) Gene. PLoS ONE, 2014, 9, e86582.	1.1	23
4997	On the Reproducibility of TCGA Ovarian Cancer MicroRNA Profiles. PLoS ONE, 2014, 9, e87782.	1.1	26
4998	Different Roles for the Axin Interactions with the SAMP versus the Second Twenty Amino Acid Repeat of Adenomatous Polyposis Coli. PLoS ONE, 2014, 9, e94413.	1.1	5
4999	Integrated Multidimensional Analysis Is Required for Accurate Prognostic Biomarkers in Colorectal Cancer. PLoS ONE, 2014, 9, e101065.	1.1	12
5000	Mining TCGA Data Using Boolean Implications. PLoS ONE, 2014, 9, e102119.	1.1	11
5001	Spontaneous Genomic Alterations in a Chimeric Model of Colorectal Cancer Enable Metastasis and Guide Effective Combinatorial Therapy. PLoS ONE, 2014, 9, e105886.	1.1	12
5002	Anomalies in Network Bridges Involved in Bile Acid Metabolism Predict Outcomes of Colorectal Cancer Patients. PLoS ONE, 2014, 9, e107925.	1.1	4
5003	A Pathway-Centric Survey of Somatic Mutations in Chinese Patients with Colorectal Carcinomas. PLoS ONE, 2015, 10, e0116753.	1.1	12
5004	Personalized Oncogenomics: Clinical Experience with Malignant Peritoneal Mesothelioma Using Whole Genome Sequencing. PLoS ONE, 2015, 10, e0119689.	1.1	36
5005	The Identification of Specific Methylation Patterns across Different Cancers. PLoS ONE, 2015, 10, e0120361.	1.1	48
5006	ALDH1B1 Is Crucial for Colon Tumorigenesis by Modulating Wnt/Î²-Catenin, Notch and PI3K/Akt Signaling Pathways. PLoS ONE, 2015, 10, e0121648.	1.1	61
5007	Co-Evolution of Somatic Variation in Primary and Metastatic Colorectal Cancer May Expand Biopsy Indications in the Molecular Era. PLoS ONE, 2015, 10, e0126670.	1.1	36
5008	Amplicon Sequencing of Colorectal Cancer: Variant Calling in Frozen and Formalin-Fixed Samples. PLoS ONE, 2015, 10, e0127146.	1.1	34

#	Article	IF	Citations
5009	A Transition Zone Showing Highly Discontinuous or Alternating Levels of Stem Cell and Proliferation Markers Characterizes the Development of PTEN-Haploinsufficient Colorectal Cancer. PLoS ONE, 2015, 10, e0131108.	1.1	3
5010	Focus on 16p13.3 Locus in Colon Cancer. PLoS ONE, 2015, 10, e0131421.	1.1	11
5011	Increasing Nucleosome Occupancy Is Correlated with an Increasing Mutation Rate so Long as DNA Repair Machinery Is Intact. PLoS ONE, 2015, 10, e0136574.	1.1	29
5012	High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer. PLoS ONE, 2015, 10, e0138141.	1.1	24
5013	c-MYC Copy-Number Gain Is an Independent Prognostic Factor in Patients with Colorectal Cancer. PLoS ONE, 2015, 10, e0139727.	1.1	49
5014	Precritical State Transition Dynamics in the Attractor Landscape of a Molecular Interaction Network Underlying Colorectal Tumorigenesis. PLoS ONE, 2015, 10, e0140172.	1.1	12
5015	1,25(OH)2D3 Deficiency Induces Colon Inflammation via Secretion of Senescence-Associated Inflammatory Cytokines. PLoS ONE, 2016, 11, e0146426.	1.1	21
5016	Colorectal Cancer Genetic Heterogeneity Delineated by Multi-Region Sequencing. PLoS ONE, 2016, 11, e0152673.	1.1	25
5017	Biobanking of Fresh-Frozen Human Adenocarcinomatous and Normal Colon Tissues: Which Parameters Influence RNA Quality?. PLoS ONE, 2016, 11, e0154326.	1.1	17
5018	Refining Pathways: A Model Comparison Approach. PLoS ONE, 2016, 11, e0155999.	1.1	5
5019	Computational Identification of Novel Stage-Specific Biomarkers in Colorectal Cancer Progression. PLoS ONE, 2016, 11, e0156665.	1.1	60
5020	Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer. PLoS ONE, 2016, 11, e0159954.	1.1	25
5021	Methylation of Breast Cancer Predisposition Genes in Early-Onset Breast Cancer: Australian Breast Cancer Family Registry. PLoS ONE, 2016, 11, e0165436.	1.1	12
5022	Differential Roles of AXIN1 and AXIN2 in Tankyrase Inhibitor-Induced Formation of Degradasomes and Î²-Catenin Degradation. PLoS ONE, 2017, 12, e0170508.	1.1	24
5023	Cudraflavone C Induces Tumor-Specific Apoptosis in Colorectal Cancer Cells through Inhibition of the Phosphoinositide 3-Kinase (PI3K)-AKT Pathway. PLoS ONE, 2017, 12, e0170551.	1.1	50
5024	An integrative study on the impact of highly differentially methylated genes on expression and cancer etiology. PLoS ONE, 2017, 12, e0171694.	1.1	1
5025	Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS ONE, 2017, 12, e0173345.	1.1	65
5026	Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA. PLoS ONE, 2017, 12, e0174308.	1.1	40

#	Article	IF	Citations
5027	Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability. PLoS ONE, 2017, 12, e0174863.	1.1	23
5028	Multiple components of PKA and TGF-Î² pathways are mutated in pseudomyxoma peritonei. PLoS ONE, 2017, 12, e0174898.	1.1	15
5029	Tumor location as a novel high risk parameter for stage II colorectal cancers. PLoS ONE, 2017, 12, e0179910.	1.1	18
5030	Actionable mutations in canine hemangiosarcoma. PLoS ONE, 2017, 12, e0188667.	1.1	56
5031	Active BRAF-V600E is the key player in generation of a sessile serrated polyp-specific DNA methylation profile. PLoS ONE, 2018, 13, e0192499.	1.1	18
5032	Novel putative drivers revealed by targeted exome sequencing of advanced solid tumors. PLoS ONE, 2018, 13, e0194790.	1.1	3
5033	Transcriptomic and proteomic intra-tumor heterogeneity of colorectal cancer varies depending on tumor location within the colorectum. PLoS ONE, 2020, 15, e0241148.	1.1	13
5034	Microbial Biomarkers for Colorectal Cancer Identified with Random Forest Model. Exploratory Research and Hypothesis in Medicine, 2020, 000, 1-000.	0.1	2
5035	Depressed Colorectal Cancer: A New Paradigm in Early Colorectal Cancer. Clinical and Translational Gastroenterology, 2020, 11, e00269.	1.3	7
5036	Mutation Hotspots in the Î²-Catenin Gene: Lessons from the Human Cancer Genome Databases. Molecules and Cells, 2019, 42, 8-16.	1.0	83
5037	Complex Interplay between the RUNX Transcription Factors and Wnt/Î²-Catenin Pathway in Cancer: A Tango in the Night. Molecules and Cells, 2020, 43, 188-197.	1.0	15
5038	The Role of Nuclear Receptor Subfamily 1 Group H Member 4 (NR1H4) in Colon Cancer Cell Survival through the Regulation of c-Myc Stability. Molecules and Cells, 2020, 43, 459-468.	1.0	13
5039	Knowing the tumour microenvironment to optimise immunotherapy. Acta Otorhinolaryngologica Italica, 2019, 39, 2-8.	0.7	16
5040	Cadherins down-regulation: towards a better understanding of their relevance in colorectal cancer. Histology and Histopathology, 2020, 35, 1391-1402.	0.5	2
5041	New insights into 4E-BP1-regulated translation in cancer progression and metastasis. Cancer Cell & Microenvironment, 2014, 1, .	0.8	12
5042	Nucleotide depletion reveals the impaired ribosome biogenesis checkpoint as a barrier against <scp>DNA</scp> damage. EMBO Journal, 2020, 39, e103838.	3.5	24
5043	The actin modulator <scp>hMENA</scp> regulates <scp>GAS</scp> 6â€•<scp>AXL</scp> axis and proâ€tumor cancer/stromal cell cooperation. EMBO Reports, 2020, 21, e50078.	2.0	20
5044	Metronomic chemotherapy offsets HIFÎ± induction upon maximumâ€tolerated dose in metastatic cancers. EMBO Molecular Medicine, 2020, 12, e11416.	3.3	20

#	Article	IF	Citations
5045	Cancer of Unknown Primary (<scp>CUP</scp>): genetic evidence for a novel nosological entity? A case report. EMBO Molecular Medicine, 2020, 12, e11756.	3.3	10
5046	Hormone receptor expression of colorectal cancer diagnosed during the peri-partum period. Endocrine Connections, 2019, 8, 1149-1158.	0.8	5
5047	First description of ultramutated endometrial cancer caused by germline loss-of-function and somatic exonuclease domain mutations in POLE gene. Genetics and Molecular Biology, 2020, 43, e20200100.	0.6	2
5048	Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal Cancer. Oncologist, 2019, 24, 1534-1542.	1.9	15
5049	Inflammation Driven Activation of Wnt Pathway: A Potential Mechanism Responsible for Obesity-associated Colorectal Cancer. Obesity Research - Open Journal, 2015, 1, 10-15.	0.4	3
5050	Microsatellite instability in colorectal cancer. EXCLI Journal, 2018, 17, 159-168.	0.5	100
5051	Evaluation of microsatellite instability in tumor and tumor marginal samples of sporadic colorectal cancer using mononucleotide markers. EXCLI Journal, 2018, 17, 945-951.	0.5	3
5052	Integrated analysis of colorectal cancer microRNA datasets: identification of microRNAs associated with tumor development. Aging, 2018, 10, 1000-1014.	1.4	135
5053	Systematic profiling of alternative splicing events and splicing factors in left- and right-sided colon cancer. Aging, 2019, 11, 8270-8293.	1.4	25
5054	Colon cancer-specific diagnostic and prognostic biomarkers based on genome-wide abnormal DNA methylation. Aging, 2020, 12, 22626-22655.	1.4	4
5055	Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project. Genes and Cancer, 2016, 7, 301-308.	0.6	15
5056	In colonic Ï0 (rho0) cells reduced mitochondrial function mediates transcriptomic alterations associated with cancer. Oncoscience, 2017, 4, 189-198.	0.9	11
5057	ZC3H12A Expression in Different Stages of Colorectal Cancer. Oncoscience, 2019, 6, 301-311.	0.9	10
5058	Epigenetic and genetic dispositions of ovarian carcinomas. Oncoscience, 2014, 1, 574-579.	0.9	13
5059	Critical function of the necroptosis adaptor RIPK3 in protecting from intestinal tumorigenesis. Oncotarget, 2016, 7, 46384-46400.	0.8	62
5060	Integrated <i>in vivo</i> genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer. Oncotarget, 2016, 7, 42859-42872.	0.8	10
5061	Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival. Oncotarget, 2016, 7, 55098-55109.	0.8	31
5062	Myotubularin-related protein 7 inhibits insulin signaling in colorectal cancer. Oncotarget, 2016, 7, 50490-50506.	0.8	21

#	Article	IF	Citations
5063	SOX9 is an atypical intestinal tumor suppressor controlling the oncogenic Wnt/ÃŸ-catenin signaling. Oncotarget, 2016, 7, 82228-82243.	0.8	42
5064	Association mining of mutated cancer genes in different clinical stages across 11 cancer types. Oncotarget, 2016, 7, 68270-68277.	0.8	9
5065	Epithelial-mesenchymal transition and nuclear Î²-catenin induced by conditional intestinal disruption of<i>Cdh1</i>with<i>Apc</i>is E-cadherin EC1 domain dependent. Oncotarget, 2016, 7, 69883-69902.	0.8	6
5066	Mutational burdens and evolutionary ages of thyroid follicular adenoma are comparable to those of follicular carcinoma. Oncotarget, 2016, 7, 69638-69648.	0.8	70
5067	Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget, 2013, 4, 1399-1415.	0.8	133
5068	Epithelial splicing regulatory protein 1 and 2 paralogues correlate with splice signatures and favorable outcome in human colorectal cancer. Oncotarget, 2016, 7, 73800-73816.	0.8	32
5069	<i>RNF43</i> and <i>ZNRF3</i> are commonly altered in serrated pathway colorectal tumorigenesis. Oncotarget, 2016, 7, 70589-70600.	0.8	83
5070	High-throughput proteomics integrated with gene microarray for discovery of colorectal cancer potential biomarkers. Oncotarget, 2016, 7, 75279-75292.	0.8	29
5071	Heparan sulfate hexasaccharide selectively inhibits cancer stem cells self-renewal by activating p38 MAP kinase. Oncotarget, 2016, 7, 84608-84622.	0.8	34
5072	<i>LDB1</i>overexpression is a negative prognostic factor in colorectal cancer. Oncotarget, 2016, 7, 84258-84270.	0.8	14
5073	Genomic profiling of stage II and III colon cancers reveals <i>APC</i> mutations to be associated with survival in stage III colon cancer patients. Oncotarget, 2016, 7, 73876-73887.	0.8	9
5074	Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. Oncotarget, 2016, 7, 82504-82510.	0.8	64
5075	MiR-384 inhibits human colorectal cancer metastasis by targeting KRAS and CDC42. Oncotarget, 2016, 7, 84826-84838.	0.8	40
5076	Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer. Oncotarget, 2016, 7, 78932-78945.	0.8	36
5077	CREB1 directly activates the transcription of ribonucleotide reductase small subunit M2 and promotes the aggressiveness of human colorectal cancer. Oncotarget, 2016, 7, 78055-78068.	0.8	28
5078	Multiple mutations of lung squamous cell carcinoma shared common mechanisms. Oncotarget, 2016, 7, 79629-79636.	0.8	14
5079	Loss of ZG16 is regulated by miR-196a and contributes to stemness and progression of colorectal cancer. Oncotarget, 2016, 7, 86695-86703.	0.8	24
5080	The miR-196b miRNA inhibits the GATA6 intestinal transcription factor and is upregulated in colon cancer patients. Oncotarget, 2017, 8, 4747-4759.	0.8	23

#	Article	IF	Citations
5081	The synthetic lethal killing of RAD54B-deficient colorectal cancer cells by PARP1 inhibition is enhanced with SOD1 inhibition. Oncotarget, 2016, 7, 87417-87430.	0.8	21
5082	The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors. Oncotarget, 2017, 8, 3237-3245.	0.8	20
5083	Targeted exome sequencing reveals distinct pathogenic variants in Iranians with colorectal cancer. Oncotarget, 2017, 8, 7852-7866.	0.8	24
5084	High throughput estimation of functional cell activities reveals disease mechanisms and predicts relevant clinical outcomes. Oncotarget, 2017, 8, 5160-5178.	0.8	66
5085	Whole-exome sequencing identified mutational profiles of high-grade colon adenomas. Oncotarget, 2017, 8, 6579-6588.	0.8	27
5086	KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis. Oncotarget, 2017, 8, 22175-22186.	0.8	44
5087	KRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents. Oncotarget, 2017, 8, 17995-18009.	0.8	11
5088	Detection of <i>COPB2</i> as a <i>KRAS</i> synthetic lethal partner through integration of functional genomics screens. Oncotarget, 2017, 8, 34283-34297.	0.8	6
5089	WNT signaling and distant metastasis in colon cancer through transcriptional activity of nuclear Î²-Catenin depend on active PI3K signaling. Oncotarget, 2014, 5, 2999-3011.	0.8	51
5090	A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. Oncotarget, 2017, 8, 32918-32929.	0.8	46
5091	A loss-of-function mutation in PTCH1 suggests a role for autocrine hedgehog signaling in colorectal tumorigenesis. Oncotarget, 2013, 4, 2208-2211.	0.8	28
5092	<i>FBXW7</i> missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget, 2017, 8, 39268-39279.	0.8	69
5093	Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment. Oncotarget, 2017, 8, 64999-65008.	0.8	14
5094	TrkC promotes colorectal cancer growth and metastasis. Oncotarget, 2017, 8, 41319-41333.	0.8	11
5095	Inhibition of colorectal cancer genomic copy number alterations and chromosomal fragile site tumor suppressor FHIT and WWOX deletions by DNA mismatch repair. Oncotarget, 2017, 8, 71574-71586.	0.8	6
5096	Frequent L1 retrotranspositions originating from<i>TTC28</i>in colorectal cancer. Oncotarget, 2014, 5, 853-859.	0.8	60
5097	mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer. Oncotarget, 2017, 8, 47902-47915.	0.8	20
5098	TRIB1 promotes colorectal cancer cell migration and invasion through activation MMP-2 via FAK/Src and ERK pathways. Oncotarget, 2017, 8, 47931-47942.	0.8	45

#	Article	IF	Citations
5099	Assessment of concordance between fresh-frozen and formalin-fixed paraffin embedded tumor DNA methylation using a targeted sequencing approach. Oncotarget, 2017, 8, 48126-48137.	0.8	12
5100	Exosome-encapsulated microRNAs as circulating biomarkers for colorectal cancer. Oncotarget, 2017, 8, 60149-60158.	0.8	110
5101	Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer. Oncotarget, 2017, 8, 63140-63154.	0.8	19
5102	Molecular characterization of circulating colorectal tumor cells defines genetic signatures for individualized cancer care. Oncotarget, 2017, 8, 68026-68037.	0.8	18
5103	Application of <i>in vivo</i> imaging techniques to monitor therapeutic efficiency of PLX4720 in an experimental model of microsatellite instable colorectal cancer. Oncotarget, 2017, 8, 69756-69767.	0.8	10
5104	Concurrent somatic mutations in driver genes were significantly correlated with lymph node metastasis and pathological types in solid tumors. Oncotarget, 2017, 8, 68746-68757.	0.8	6
5105	Comprehensive bioinformatics analysis of the characterization and determination underlying mechanisms of over-expression and co-expression of genes residing on 20q in colorectal cancer. Oncotarget, 2017, 8, 78642-78659.	0.8	17
5106	Acquired somatic <i>TP53</i> or <i>PIK3CA</i> mutations are potential predictors of when polyps evolve into colorectal cancer. Oncotarget, 2017, 8, 72352-72362.	0.8	17
5107	Investigation of IL-23 (p19, p40) and IL-23R identifies nuclear expression of IL-23 p19 as a favorable prognostic factor in colorectal cancer: a retrospective multicenter study of 675 patients. Oncotarget, 2014, 5, 4671-4682.	0.8	10
5108	RRS1 silencing suppresses colorectal cancer cell proliferation and tumorigenesis by inhibiting G2/M progression and angiogenesis. Oncotarget, 2017, 8, 82968-82980.	0.8	32
5109	Epigenetic silencing of tumor suppressor candidate 3 confers adverse prognosis in early colorectal cancer. Oncotarget, 2017, 8, 84714-84728.	0.8	5
5110	Deletion of<i>Ptprd</i>and<i>Cdkn2a</i>cooperate to accelerate tumorigenesis. Oncotarget, 2014, 5, 6976-6982.	0.8	22
5111	Loss of 4E-BP1 function induces EMT and promotes cancer cell migration and invasion via cap-dependent translational activation of snail. Oncotarget, 2014, 5, 6015-6027.	0.8	43
5112	<i>Thymine DNA Glycosylase (TDG)</i> is involved in the pathogenesis of intestinal tumors with reduced <i>APC</i> expression. Oncotarget, 2017, 8, 89988-89997.	0.8	18
5113	Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer. Oncotarget, 2017, 8, 87837-87847.	0.8	49
5114	Interferon-inducible CXC-chemokines are crucial immune modulators and survival predictors in colorectal cancer. Oncotarget, 2017, 8, 89998-90012.	0.8	57
5115	Oncogenic dependency on Î²-catenin in liver cancer cell lines correlates with pathway activation. Oncotarget, 2017, 8, 114526-114539.	0.8	16
5116	Somatic <i>PRDM2</i> c.4467delA mutations in colorectal cancers control histone methylation and tumor growth. Oncotarget, 2017, 8, 98646-98659.	0.8	13

#	Article	IF	Citations
5117	The <i>NF1</i> gene revisited - from bench to bedside. Oncotarget, 2014, 5, 5873-5892.	0.8	139
5118	Decreased expression of interferon-induced protein 2 (IFIT2) by Wnt/Î²-catenin signaling confers anti-apoptotic properties to colorectal cancer cells. Oncotarget, 2017, 8, 100176-100186.	0.8	18
5119	Immunological landscape of consensus clusters in colorectal cancer. Oncotarget, 2017, 8, 105299-105311.	0.8	55
5120	Loss of p53-inducible long non-coding RNA LINC01021 increases chemosensitivity. Oncotarget, 2017, 8, 102783-102800.	0.8	13
5121	Hypermethylation of <i>BEND5</i> contributes to cell proliferation and is a prognostic marker of colorectal cancer. Oncotarget, 2017, 8, 113431-113443.	0.8	12
5122	Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression. Oncotarget, 2014, 5, 6611-6619.	0.8	53
5123	Targeting G-protein coupled receptor-related signaling pathway in a murine xenograft model of appendiceal pseudomyxoma peritonei. Oncotarget, 2017, 8, 106888-106900.	0.8	19
5124	Genomic landscape of colitis-associated cancer indicates the impact of chronic inflammation and its stratification by mutations in the Wnt signaling. Oncotarget, 2018, 9, 969-981.	0.8	34
5125	Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma. Oncotarget, 2018, 9, 464-476.	0.8	23
5126	EGFR expression in patients with stage III colorectal cancer after adjuvant chemotherapy and on cancer cell function. Oncotarget, 2017, 8, 114663-114676.	0.8	27
5127	Cooperation between ZEB2 and Sp1 promotes cancer cell survival and angiogenesis during metastasis through induction of survivin and VEGF. Oncotarget, 2018, 9, 726-742.	0.8	16
5128	Copy number profiles of paired primary and metastatic colorectal cancers. Oncotarget, 2018, 9, 3394-3405.	0.8	14
5129	Spinophilin expression determines cellular growth, cancer stemness and 5-flourouracil resistance in colorectal cancer. Oncotarget, 2014, 5, 8492-8502.	0.8	18
5130	Significance of intratissue estrogen concentration coupled with estrogen receptors levels in colorectal cancer prognosis. Oncotarget, 2017, 8, 115546-115560.	0.8	12
5131	Modified miR-15a has therapeutic potential for improving treatment of advanced stage colorectal cancer through inhibition of BCL2, BMI1, YAP1 and DCLK1. Oncotarget, 2018, 9, 2367-2383.	0.8	47
5132	Impact of LMP7 (rs2071543) gene polymorphism in increasing cancer risk: evidence from a meta-analysis and trial sequential analysis. Oncotarget, 2018, 9, 6572-6585.	0.8	7
5133	The transcriptional and mutational landscapes of lipid metabolism-related genes in colon cancer. Oncotarget, 2018, 9, 5919-5930.	0.8	28
5134	Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy. Oncotarget, 2014, 5, 9199-9213.	0.8	31

#	Article	IF	Citations
5135	MicroRNA-873 inhibits colorectal cancer metastasis by targeting ELK1 and STRN4. Oncotarget, 2019, 10, 4192-4204.	0.8	15
5136	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. Oncotarget, 2018, 9, 9741-9750.	0.8	12
5137	LRP1 expression in colon cancer predicts clinical outcome. Oncotarget, 2018, 9, 8849-8869.	0.8	28
5138	The benefit of tumor molecular profiling on predicting treatments for colorectal adenocarcinomas. Oncotarget, 2018, 9, 11371-11376.	0.8	2
5139	Affinity-purified DNA-based mutation profiles of endometriosis-related ovarian neoplasms in Japanese patients. Oncotarget, 2018, 9, 14754-14763.	0.8	19
5140	Potential therapeutic targets of <i>TP53</i> gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer. Oncotarget, 2018, 9, 16234-16247.	0.8	24
5141	Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor. Oncotarget, 2018, 9, 17756-17769.	0.8	34
5142	Clinical application of targeted next-generation sequencing for colorectal cancer patients: a multicentric Belgian experience. Oncotarget, 2018, 9, 20761-20768.	0.8	21
5143	Comprehensive molecular analysis based on somatic copy number alterations in intramucosal colorectal neoplasias and early invasive colorectal cancers. Oncotarget, 2018, 9, 22895-22906.	0.8	6
5144	An improved method for culturing patient-derived colorectal cancer spheroids. Oncotarget, 2018, 9, 21950-21964.	0.8	29
5145	Comprehensive identification of long noncoding RNAs in colorectal cancer. Oncotarget, 2018, 9, 27605-27629.	0.8	16
5146	Identification of different mutational profiles in cancers arising in specific colon segments by next generation sequencing. Oncotarget, 2018, 9, 23960-23974.	0.8	13
5147	Melanoma-associated mutants within the serine-rich domain of PAK5 direct kinase activity to mitogenic pathways. Oncotarget, 2018, 9, 25386-25401.	0.8	3
5148	Epigenetic dysregulation of<i>TET2</i>in human glioblastoma. Oncotarget, 2018, 9, 25922-25934.	0.8	29
5149	Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content. Oncotarget, 2018, 9, 31502-31515.	0.8	21
5150	A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors. Oncotarget, 2018, 9, 31709-31718.	0.8	32
5151	FGFR3 mRNA overexpression defines a subset of oligometastatic colorectal cancers with worse prognosis. Oncotarget, 2018, 9, 32204-32218.	0.8	19
5152	The frequency of promoter DNA hypermethylation is decreased in colorectal neoplasms of familial adenomatous polyposis. Oncotarget, 2018, 9, 32653-32666.	0.8	4

#	Article	IF	Citations
5153	Intestinal epithelial Notch-1 protects from colorectal mucinous adenocarcinoma. Oncotarget, 2018, 9, 33536-33548.	0.8	7
5154	Genomic mechanisms of immune evasion in colorectal cancer: from discovery to clinical practice. Oncotarget, 2018, 9, 33743-33744.	0.8	3
5155	Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer. Oncotarget, 2018, 9, 35623-35638.	0.8	15
5156	Heterogeneity in the lymphocytic infiltration of deficient DNA mismatch repair colon cancers. Oncotarget, 2018, 9, 36722-36723.	0.8	1
5157	Accurate diagnosis of mismatch repair deficiency in colorectal cancer using high-quality DNA samples from cultured stem cells. Oncotarget, 2018, 9, 37534-37548.	0.8	3
5158	Assessment of intra-tumoural colorectal cancer prognostic biomarkers using RNA in situ hybridisation. Oncotarget, 2019, 10, 1425-1439.	0.8	9
5159	Driver genes exome sequencing reveals distinct variants in African Americans with colorectal neoplasia. Oncotarget, 2019, 10, 2607-2624.	0.8	8
5160	A global immune gene expression signature for human cancers. Oncotarget, 2019, 10, 1993-2005.	0.8	9
5161	PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC. Oncotarget, 2019, 10, 6768-6780.	0.8	9
5162	<i>FOXL2</i> homozygous genotype and chromosome instability are associated with recurrence in adult granulosa cell tumors of the ovary. Oncotarget, 2020, 11, 419-428.	0.8	7
5163	Prolyl 4-hydroxylase alpha 1 protein expression risk-stratifies early stage colorectal cancer. Oncotarget, 2020, 11, 813-824.	0.8	7
5164	Methylation of<i>MGMT</i>and<i>ADAMTS14</i>in normal colon mucosa: biomarkers of a field defect for cancerization preferentially targeting elder African-Americans. Oncotarget, 2015, 6, 3420-3431.	0.8	29
5165	Hypoxia induces a lipogenic cancer cell phenotype via HIF1Î±-dependent and -independent pathways. Oncotarget, 2015, 6, 1920-1941.	0.8	72
5166	Advances in dynamic modeling of colorectal cancer signaling-network regions, a path toward targeted therapies. Oncotarget, 2015, 6, 5041-5058.	0.8	24
5167	Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. Oncotarget, 2015, 6, 6029-6039.	0.8	29
5168	Vasohibin-1 suppresses colon cancer. Oncotarget, 2015, 6, 7880-7898.	0.8	24
5169	Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo. Oncotarget, 2015, 6, 15332-15347.	0.8	25
5170	RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers. Oncotarget, 2015, 6, 15681-15689.	0.8	12

#	Article	IF	Citations
5171	Chronic chemotherapeutic stress promotes evolution of stemness and WNT/beta-catenin signaling in colorectal cancer cells: implications for clinical use of WNT-signaling inhibitors. Oncotarget, 2015, 6, 18518-18533.	0.8	25
5172	Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development. Oncotarget, 2015, 6, 20160-20176.	0.8	66
5173	Genome-wide mutation profiles of colorectal tumors and associated liver metastases at the exome and transcriptome levels. Oncotarget, 2015, 6, 22179-22190.	0.8	44
5174	Identification and characterization of <i>RET</i> fusions in advanced colorectal cancer. Oncotarget, 2015, 6, 28929-28937.	0.8	94
5175	miRNA-99b-5p suppresses liver metastasis of colorectal cancer by down-regulating mTOR. Oncotarget, 2015, 6, 24448-24462.	0.8	76
5176	LINE-1 hypomethylation in normal colon mucosa is associated with poor survival in Chinese patients with sporadic colon cancer. Oncotarget, 2015, 6, 23820-23836.	0.8	7
5177	MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients. Oncotarget, 2015, 6, 26278-26290.	0.8	39
5178	Identification of GALNT14 as a novel neuroblastoma predisposition gene. Oncotarget, 2015, 6, 26335-26346.	0.8	43
5179	Clonal origins and parallel evolution of regionally synchronous colorectal adenoma and carcinoma. Oncotarget, 2015, 6, 27725-27735.	0.8	31
5180	Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer. Oncotarget, 2015, 6, 28312-28326.	0.8	79
5181	Prostaglandins induce early growth response 1 transcription factor mediated microsomal prostaglandin E2 synthase up-regulation for colorectal cancer progression. Oncotarget, 2015, 6, 39941-39959.	0.8	23
5182	Molecular pathological epidemiology of colorectal cancer in Chinese patients with <i>KRAS</i> and <i>BRAF</i> mutations. Oncotarget, 2015, 6, 39607-39613.	0.8	34
5183	Correlation of clinical features and genetic profiles of stromal interaction molecule 1 (<i>STIM1</i>) in colorectal cancers. Oncotarget, 2015, 6, 42169-42182.	0.8	20
5184	Remarkable similarities of chromosomal rearrangements between primary human breast cancers and matched distant metastases as revealed by whole-genome sequencing. Oncotarget, 2015, 6, 37169-37184.	0.8	25
5185	Mutational profiling of colorectal cancers with microsatellite instability. Oncotarget, 2015, 6, 42334-42344.	0.8	69
5186	RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action. Oncotarget, 2016, 7, 38892-38907.	0.8	116
5187	Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer. Oncotarget, 2016, 7, 3068-3083.	0.8	19
5188	Genome-wide profiling of DNA methylation and gene expression in esophageal squamous cell carcinoma. Oncotarget, 2016, 7, 4507-4521.	0.8	24

#	Article	IF	Citations
5189	<i>NTRK1</i> fusions for the therapeutic intervention of Korean patients with colon cancer. Oncotarget, 2016, 7, 8399-8412.	0.8	24
5190	Double-strand break repair and colorectal cancer: gene variants within 3â€² UTRs and microRNAs binding as modulators of cancer risk and clinical outcome. Oncotarget, 2016, 7, 23156-23169.	0.8	40
5191	Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome. Oncotarget, 2016, 7, 11165-11193.	0.8	76
5192	Bisleuconothine A, a bisindole alkaloid, inhibits colorectal cancer cell <i>in vitro</i> and <i>in vivo</i> targeting Wnt signaling. Oncotarget, 2016, 7, 10203-10214.	0.8	18
5193	Mutanome and expression of immune response genes in microsatellite stable colon cancer. Oncotarget, 2016, 7, 17711-17725.	0.8	6
5194	Distinct features between<i>MLH1</i>-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway. Oncotarget, 2016, 7, 14095-14111.	0.8	35
5195	Clinicopathologic distribution of <i>KRAS</i> and <i>BRAF</i> mutations in a Chinese population with colorectal cancer precursor lesions. Oncotarget, 2016, 7, 17265-17274.	0.8	16
5196	Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment. Oncotarget, 2016, 7, 19610-19619.	0.8	12
5197	Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. Oncotarget, 2016, 7, 22543-22555.	0.8	11
5198	Genomic markers of panitumumab resistance including ERBB2/HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC). Oncotarget, 2016, 7, 18953-18964.	0.8	11
5199	Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations. Oncotarget, 2016, 7, 23825-23836.	0.8	10
5200	Integrated analysis of long non-coding RNAs in human colorectal cancer. Oncotarget, 2016, 7, 23897-23908.	0.8	33
5201	Sciellin mediates mesenchymal-to-epithelial transition in colorectal cancer hepatic metastasis. Oncotarget, 2016, 7, 25742-25754.	0.8	20
5202	Tumor suppressor PRSS8 targets Sphk1/S1P/Stat3/Akt signaling in colorectal cancer. Oncotarget, 2016, 7, 26780-26792.	0.8	34
5203	Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response. Oncotarget, 2016, 7, 28356-28368.	0.8	16
5204	The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance. Oncotarget, 2016, 7, 28273-28285.	0.8	34
5205	Altered oncomodules underlie chromatin regulatory factors driver mutations. Oncotarget, 2016, 7, 30748-30759.	0.8	3
5206	Colorectal cancer cells display chaperone dependency for the unconventional prefoldin URI1. Oncotarget, 2016, 7, 29635-29647.	0.8	16

#	Article	IF	Citations
5207	<i>NRAS</i> germline variant G138R and multiple rare somatic mutations on <i>APC</i> in colorectal cancer patients in Taiwan by next generation sequencing. Oncotarget, 2016, 7, 37566-37580.	0.8	5
5208	CYB5R1 links epithelial-mesenchymal transition and poor prognosis in colorectal cancer. Oncotarget, 2016, 7, 31350-31360.	0.8	20
5209	Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer. Oncotarget, 2016, 7, 36632-36644.	0.8	15
5210	Efficacy of the combination of MEK and CDK4/6 inhibitors<i>in vitro</i>and<i>in vivo</i>in KRAS mutant colorectal cancer models. Oncotarget, 2016, 7, 39595-39608.	0.8	101
5211	The chronological sequence of somatic mutations in early gastric carcinogenesis inferred from multiregion sequencing of gastric adenomas. Oncotarget, 2016, 7, 39758-39767.	0.8	20
5212	PTRF suppresses the progression of colorectal cancers. Oncotarget, 2017, 8, 48650-48659.	0.8	23
5213	Quantitative proteomics reveals that distant recurrence-associated protein R-Ras and Transgelin predict post-surgical survival in patients with Stage III colorectal cancer. Oncotarget, 2016, 7, 43868-43893.	0.8	13
5214	MicroRNA-375 suppresses human colorectal cancer metastasis by targeting Frizzled 8. Oncotarget, 2016, 7, 40644-40656.	0.8	46
5215	Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance. Oncotarget, 2016, 7, 39293-39301.	0.8	45
5216	UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response. Oncotarget, 2016, 7, 44113-44128.	0.8	17
5217	A 4-miRNA signature predicts the therapeutic outcome of glioblastoma. Oncotarget, 2016, 7, 45764-45775.	0.8	35
5218	Over-expression of <i>AURKA</i>, <i>SKA3</i> and <i>DSN1</i> contributes to colorectal adenoma to carcinoma progression. Oncotarget, 2016, 7, 45803-45818.	0.8	63
5219	Alterations of DNA damage repair in cancer: from mechanisms to applications. Annals of Translational Medicine, 2020, 8, 1685-1685.	0.7	44
5220	Increasing incidence of colon cancer in patients <50 years old: a new entity?. Annals of Translational Medicine, 2016, 4, 164-164.	0.7	11
5221	Towards tumor immunodiagnostics. Annals of Translational Medicine, 2016, 4, 263-263.	0.7	11
5222	Colorectal cancer genomics and designing rational trials. Annals of Translational Medicine, 2018, 6, 159-159.	0.7	19
5223	Review: KRAS mutations are influential in driving hepatic metastases and predicting outcome in colorectal cancer. Chinese Clinical Oncology, 2019, 8, 53-53.	0.4	8
5224	Progress in Understanding the IL-6/STAT3 Pathway in Colorectal Cancer . OncoTargets and Therapy, 2020, Volume 13, 13023-13032.	1.0	66

#	Article	IF	Citations
5225	Targeting BRD9 for Cancer Treatment: A New Strategy. OncoTargets and Therapy, 2020, Volume 13, 13191-13200.	1.0	24
5226	CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review. Protein and Peptide Letters, 2020, 27, 931-944.	0.4	20
5227	Chemical Disruption of Wnt-dependent Cell Fate Decision-making Mechanisms in Cancer and Regenerative Medicine. Current Medicinal Chemistry, 2015, 22, 4091-4103.	1.2	14
5228	Therapeutic Targeting of Cancers with Loss of PTEN Function. Current Drug Targets, 2014, 15, 65-79.	1.0	194
5229	Inulin as a Delivery Vehicle for Targeting Colon-Specific Cancer. Current Drug Delivery, 2020, 17, 651-674.	0.8	8
5230	Synergistic Effect of Epigenetic Inhibitors Decitabine and Suberoylanilide Hydroxamic Acid on Colorectal Cancer In vitro. Current Molecular Pharmacology, 2019, 12, 281-300.	0.7	18
5231	Prognostic Role of BRAF Mutations in Colorectal Cancer Liver Metastases. Anticancer Research, 2016, 36, 4805-4812.	0.5	22
5232	Cancer Immunology and Immunotherapy. Anticancer Research, 2016, 36, 5593-5606.	0.5	69
5233	Up-regulation of SLC9A9 Promotes Cancer Progression and Is Involved in Poor Prognosis in Colorectal Cancer. Anticancer Research, 2017, 37, 2255-2263.	0.5	18
5234	Clinicopathological and Prognostic Significance of Epithelial Gremlin1 Expression in Gastric Cancer. Anticancer Research, 2018, 38, 1419-1425.	0.5	8
5235	K-ras Mutations as the Earliest Driving Force in a Subset of Colorectal Carcinomas. In Vivo, 2017, 31, 527-542.	0.6	18
5236	The Impact of Long-term Exposure to Low Levels of Inorganic Arsenic on the Hypomethylation of SEPT9 Promoter in Epithelial-Mesenchymal Transformed Colorectal Cancer Cell Lines. International Journal of Molecular and Cellular Medicine, 2019, 8, 130-138.	1.1	4
5237	Evaluation of colorectal cancer subtypes and cell lines using deep learning. Life Science Alliance, 2019, 2, e201900517.	1.3	65
5238	Â¿Existen ventajas clÃnicas al evaluar el estado de los genes KRAS, NRAS, BRAF, PIK3CA, PTEN y HER2 en pacientes con cÃ¡ncer colorrectal?. Revista Colombiana De Cirugia, 2017, 32, 45-55.	0.2	2
5239	Mediator kinase module and human tumorigenesis. Critical Reviews in Biochemistry and Molecular Biology, 2015, 50, 393-426.	2.3	88
5240	High Frequency of KRAS Codon 146 and FBXW7 Mutations in Thai Patients with Stage II-III Colon Cancer. Asian Pacific Journal of Cancer Prevention, 2019, 20, 2319-2326.	0.5	10
5241	The mutational landscape of hepatocellular carcinoma. Clinical and Molecular Hepatology, 2015, 21, 220.	4.5	108
5242	Innate Lymphoid Cells in Colorectal Cancers: A Double-Edged Sword. Frontiers in Immunology, 2019, 10, 3080.	2.2	14

#	Article	IF	Citations
5243	PVT1 Long Non-coding RNA in Gastrointestinal Cancer. Frontiers in Oncology, 2020, 10, 38.	1.3	43
5244	Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us?. Cancers, 2015, 7, 1925-1958.	1.7	51
5245	Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer. Genes, 2021, 12, 33.	1.0	23
5246	Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements. International Journal of Molecular Sciences, 2021, 22, 130.	1.8	160
5247	Differences Regarding the Molecular Features and Gut Microbiota Between Right and Left Colon Cancer. Annals of Coloproctology, 2018, 34, 280-285.	0.5	44
5248	miR-330 Regulates Colorectal Cancer Oncogenesis by Targeting BACH1. Advanced Pharmaceutical Bulletin, 2020, 10, 444-451.	0.6	18
5249	Whole exome sequencing identifies genomic alterations in proximal and distal colorectal cancer. Bulletin of the Geological Society of Malaysia, 2019, 2, .	0.5	1
5250	Frizzled Receptors in Tumors, Focusing on Signaling, Roles, Modulation Mechanisms, and Targeted Therapies. Oncology Research, 2020, 28, 661-674.	0.6	14
5251	<i>PNN</i>and<i>KCNQ1OT1</i>Can Predict the Efficacy of Adjuvant Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer Patients. Oncology Research, 2020, 28, 631-644.	0.6	10
5252	Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma. , 2020, 1, 53-70.		5
5253	Clinical applications of next-generation sequencing in colorectal cancers. World Journal of Gastroenterology, 2013, 19, 6784.	1.4	29
5254	Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients. World Journal of Gastroenterology, 2013, 19, 8474.	1.4	9
5255	Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. World Journal of Gastroenterology, 2014, 20, 4230.	1.4	79
5256	Emerging role of the Î²-catenin-PPARÎ³ axis in the pathogenesis of colorectal cancer. World Journal of Gastroenterology, 2014, 20, 7137.	1.4	43
5257	Colorectal cancer with liver metastases: Neoadjuvant chemotherapy, surgical resection first or palliation alone?. World Journal of Gastroenterology, 2014, 20, 12391.	1.4	48
5258	Accumulation of aberrant DNA methylation during colorectal cancer development. World Journal of Gastroenterology, 2014, 20, 978.	1.4	55
5259	Recent applications of chemosensitivity tests for colorectal cancer treatment. World Journal of Gastroenterology, 2014, 20, 16398.	1.4	16
5260	Early-onset colorectal cancer: A separate subset of colorectal cancer. World Journal of Gastroenterology, 2014, 20, 17288.	1.4	97

#	Article	IF	Citations
5261	Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer. World Journal of Gastroenterology, 2014, 20, 18404.	1.4	38
5262	Annexin A10 expression in colorectal cancers with emphasis on the serrated neoplasia pathway. World Journal of Gastroenterology, 2015, 21, 9749.	1.4	24
5263	Integration of genome scale data for identifying new players in colorectal cancer. World Journal of Gastroenterology, 2016, 22, 534.	1.4	3
5264	Genomic diversity of colorectal cancer: Changing landscape and emerging targets. World Journal of Gastroenterology, 2016, 22, 5668.	1.4	14
5265	Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World Journal of Gastroenterology, 2016, 22, 6345.	1.4	94
5266	<i>HER2</i>aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists. World Journal of Gastroenterology, 2016, 22, 7926.	1.4	43
5267	Involvement of methylation-associated silencing of formin 2 in colorectal carcinogenesis. World Journal of Gastroenterology, 2018, 24, 5013-5024.	1.4	10
5268	Landscape of BRIP1 molecular lesions in gastrointestinal cancers from published genomic studies. World Journal of Gastroenterology, 2020, 26, 1197-1207.	1.4	8
5269	Mouse models of colorectal cancer: Past, present and future perspectives. World Journal of Gastroenterology, 2020, 26, 1394-1426.	1.4	89
5271	DNAâ€'methylated gene markers for colorectal cancer in TCGA database. Experimental and Therapeutic Medicine, 2020, 19, 3042-3050.	0.8	10
5272	High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer. International Journal of Oncology, 2020, 57, 237-248.	1.4	47
5273	Butyrate enhances the efficacy of radiotherapy via FOXO3A in colorectal cancer patientâ€'derived organoids. International Journal of Oncology, 2020, 57, 1307-1318.	1.4	44
5274	MicroRNAâ€'195 suppresses rectal cancer growth and metastasis via regulation of the PI3K/AKT signaling pathway. Molecular Medicine Reports, 2019, 20, 4449-4458.	1.1	10
5275	A subset of patients with MSS/MSIâ€'lowâ€'colorectal cancer showed increased CD8(+) TILs together with upâ€'regulated IFNâ€'Î³. Oncology Letters, 2019, 18, 5977-5985.	0.8	33
5276	Upregulation of microRNAâ€'31 is associated with poor prognosis in patients with advanced colorectal cancer. Oncology Letters, 2020, 19, 2685-2694.	0.8	6
5277	Intratumoral heterogeneity of glutaminase and lactate dehydrogenase A protein expression in colorectal cancer. Oncology Letters, 2020, 19, 2934-2942.	0.8	4
5278	Overexpression of LBX2 associated with tumor progression and poor prognosis in colorectal cancer. Oncology Letters, 2020, 19, 3751-3760.	0.8	6
5279	Effects and mechanism of the bile acid (farnesoid X) receptor on the Wnt/Î²â€'catenin signaling pathway in colon cancer. Oncology Letters, 2020, 20, 337-345.	0.8	11

#	Article	IF	Citations
5280	Downregulation of CLCA4 expression is associated with the development and progression of colorectal cancer. Oncology Letters, 2020, 20, 631-638.	0.8	9
5281	PDâ€'L1 expression increased by IFNâ€Î³ via JAK2â€'STAT1 signaling and predicts a poor survival in colorectal cancer. Oncology Letters, 2020, 20, 1127-1134.	0.8	50
5282	Effect of KRAS and NRAS mutations on the prognosis of patients with synchronous metastatic colorectal cancer presenting with liverâ€'only and lungâ€'only metastases. Oncology Letters, 2020, 20, 2119-2130.	0.8	10
5283	MUC1â€'induced immunosuppression in colon cancer can be reversed by blocking the PD1/PDL1 signaling pathway. Oncology Letters, 2020, 20, 1-1.	0.8	11
5284	RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer. Oncology Reports, 2020, 43, 1853-1862.	1.2	15
5285	The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study. Korean Journal of Internal Medicine, 2019, 34, 165-177.	0.7	20
5286	Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer. Korean Journal of Internal Medicine, 2019, 34, 1188-1196.	0.7	3
5287	Genomic-Glycosylation Aberrations in Tumor Initiation, Progression and Management. AIMS Medical Science, 2016, 3, 386-416.	0.2	3
5288	Impact of somatic mutations on patterns of metastasis in colorectal cancer. Journal of Gastrointestinal Oncology, 2015, 6, 645-9.	0.6	66
5289	New therapeutic strategies for BRAF mutant colorectal cancers. Journal of Gastrointestinal Oncology, 2015, 6, 650-9.	0.6	21
5290	Tumor evolution and intratumor heterogeneity in colorectal carcinoma: insights from comparative genomic profiling of primary tumors and matched metastases. Journal of Gastrointestinal Oncology, 2015, 6, 668-75.	0.6	22
5291	Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. Translational Lung Cancer Research, 2015, 4, 721-7.	1.3	26
5292	Personalized Disease Phenotypes from Massive OMICs Data. Advances in Bioinformatics and Biomedical Engineering Book Series, 2015, , 359-378.	0.2	8
5293	Prognostic Role of KRAS mRNA Expression in Breast Cancer. Journal of Breast Cancer, 2019, 22, 548.	0.8	20
5294	Implications of Circadian Rhythm Regulation by microRNAs in Colorectal Cancer. Cancer Translational Medicine, 2016, 2, 1.	0.2	18
5295	Unique characteristics of ARID1A mutation and protein level in gastric and colorectal cancer: A meta-analysis. Saudi Journal of Gastroenterology, 2017, 23, 268.	0.5	30
5296	Immune landscape and biomarkers for immuno-oncology in colorectal cancers. Journal of Pathology and Translational Medicine, 2020, 54, 351-360.	0.4	9
5297	Identification of Diverse Adenosine-to-Inosine RNA Editing Subtypes in Colorectal Cancer. Cancer Research and Treatment, 2017, 49, 1077-1087.	1.3	22

#	Article	IF	Citations
5298	Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. Cancer Research and Treatment, 2019, 51, 211-222.	1.3	12
5299	Fibroblast Growth Factor Receptor 1 (FGFR1) Amplification Detected by Droplet Digital Polymerase Chain Reaction (ddPCR) Is a Prognostic Factor in Colorectal Cancers. Cancer Research and Treatment, 2020, 52, 74-84.	1.3	16
5300	Histones: Controlling Tumor Signaling Circuitry. Journal of Carcinogenesis & Mutagenesis, 2013, 1, 1-12.	0.3	18
5301	Inflammation-associated microsatellite alterations: Mechanisms and significance in the prognosis of patients with colorectal cancer. World Journal of Gastrointestinal Oncology, 2018, 10, 1-14.	0.8	39
5302	Precision medicine for gastrointestinal cancer: Recent progress and future perspective. World Journal of Gastrointestinal Oncology, 2019, 12, 1-20.	0.8	31
5303	Epigenetic field defects in progression to cancer. World Journal of Gastrointestinal Oncology, 2013, 5, 43.	0.8	45
5304	Role of microRNA-7 in digestive system malignancy. World Journal of Gastrointestinal Oncology, 2016, 8, 121.	0.8	18
5305	Molecular predictive markers in tumors of the gastrointestinal tract. World Journal of Gastrointestinal Oncology, 2016, 8, 772.	0.8	6
5306	CpG island methylator phenotype in adenocarcinomas from the digestive tract: Methods, conclusions, and controversies. World Journal of Gastrointestinal Oncology, 2017, 9, 105.	0.8	9
5307	Molecular classifications of gastric cancers: Novel insights and possible future applications. World Journal of Gastrointestinal Oncology, 2017, 9, 194.	0.8	46
5308	Development of cancer-initiating cells and immortalized cells with genomic instability. World Journal of Stem Cells, 2015, 7, 483.	1.3	17
5309	Regulation of<i>MYC</i>gene expression by aberrant Wnt/Î²-catenin signaling in colorectal cancer. World Journal of Biological Chemistry, 2015, 6, 290.	1.7	113
5310	Holistic cancer genome profiling for every patient. Swiss Medical Weekly, 2020, 150, w20158.	0.8	5
5311	Increasing the Î± 2, 6 Sialylation of Glycoproteins May Contribute to Metastatic Spread and Therapeutic Resistance in Colorectal Cancer. Gut and Liver, 2013, 7, 629-641.	1.4	98
5312	Impact of primary tumour location on colorectal liver metastases: A systematic review. World Journal of Clinical Oncology, 2020, 11, 294-307.	0.9	9
5313	Genomic era diagnosis and management of hereditary and sporadic colon cancer. World Journal of Clinical Oncology, 2014, 5, 1036.	0.9	11
5314	Adjuvant chemotherapy for rectal cancer: Is it needed?. World Journal of Clinical Oncology, 2015, 6, 225.	0.9	18
5315	Genomic Profiling of Liver Cancer. Genomics and Informatics, 2013, 11, 180.	0.4	8

#	Article	IF	Citations
5316	Mechanism of Chemoprevention against Colon Cancer Cells Using Combined Gelam Honey and Ginger Extract via mTOR and Wnt/Î²-catenin Pathways. Asian Pacific Journal of Cancer Prevention, 2015, 16, 6549-6556.	0.5	42
5317	Research progress in the radioprotective effect of the canonical Wnt pathway. Cancer Biology and Medicine, 2013, 10, 61-71.	1.4	17
5318	Structural basis for activation and non-canonical catalysis of the Rap GTPase activating protein domain of plexin. ELife, 2013, 2, e01279.	2.8	66
5319	Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks. ELife, 2014, 3, e02725.	2.8	71
5320	Opposing roles of nuclear receptor HNF4Î± isoforms in colitis and colitis-associated colon cancer. ELife, 2016, 5, .	2.8	63
5321	Blockade of the LRP16-PKR-NF-ÎºB signaling axis sensitizes colorectal carcinoma cells to DNA-damaging cytotoxic therapy. ELife, 2017, 6, .	2.8	19
5322	Explosive mutation accumulation triggered by heterozygous human Pol Îµ proofreading-deficiency is driven by suppression of mismatch repair. ELife, 2018, 7, .	2.8	33
5323	Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. ELife, 2018, 7, .	2.8	217
5324	Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells. ELife, 2019, 8, .	2.8	80
5325	Cell-autonomous regulation of epithelial cell quiescence by calcium channel Trpv6. ELife, 2019, 8, .	2.8	20
5326	A regulatory microRNA network controls endothelial cell phenotypic switch during sprouting angiogenesis. ELife, 2020, 9, .	2.8	35
5327	CNApp, a tool for the quantification of copy number alterations and integrative analysis revealing clinical implications. ELife, 2020, 9, .	2.8	48
5328	Torsin ATPases influence chromatin interaction of the Torsin regulator LAP1. ELife, 2020, 9, .	2.8	17
5329	A pan-cancer analysis of prognostic genes. PeerJ, 2015, 3, e1499.	0.9	32
5330	Cancer driver genes: a guilty by resemblance doctrine. PeerJ, 2019, 7, e6979.	0.9	2
5331	Characterization of bidirectional gene pairs in The Cancer Genome Atlas (TCGA) dataset. PeerJ, 2019, 7, e7107.	0.9	8
5332	A transcriptional co-expression network-based approach to identify prognostic biomarkers in gastric carcinoma. PeerJ, 2020, 8, e8504.	0.9	6
5333	The â€œImmunoscoreâ€• in rectal cancer: could we search quality beyond quantity of life?. Oncotarget, 2022, 13, 18-31.	0.8	3

#	Article	IF	Citations
5334	Detection of Cells Displaying High Expression of CLIC4 in Tumor Tissue of Patients With Colorectal Cancer. In Vivo, 2021, 35, 3165-3173.	0.6	1
5335	A novel amplification gene PCI domain containing 2 (PCID2) promotes colorectal cancer through directly degrading a tumor suppressor promyelocytic leukemia (PML). Oncogene, 2021, 40, 6641-6652.	2.6	4
5336	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. Npj Precision Oncology, 2021, 5, 95.	2.3	9
5337	Gastrointestinal cancer organoidsâ€"applications in basic and translational cancer research. Experimental and Molecular Medicine, 2021, 53, 1459-1470.	3.2	15
5338	Organ Specificity and Heterogeneity of Cancer-Associated Fibroblasts in Colorectal Cancer. International Journal of Molecular Sciences, 2021, 22, 10973.	1.8	12
5339	The Genomic Landscape of Serrated Lesion of the Colorectum: Similarities and Differences With Tubular and Tubulovillous Adenomas. Frontiers in Oncology, 2021, 11, 668466.	1.3	4
5340	rPAC: Route based pathway analysis for cohorts of gene expression data sets. Methods, 2022, 198, 76-87.	1.9	10
5341	Statin use is associated with a reduced incidence of colorectal cancer expressing SMAD4. British Journal of Cancer, 2022, 126, 297-301.	2.9	5
5342	The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?. Frontiers in Oncology, 2021, 11, 745187.	1.3	33
5343	Association between Fusobacterium nucleatum and patient prognosis in metastatic colon cancer. Scientific Reports, 2021, 11, 20263.	1.6	11
5344	Pilot Nanostring PanCancer pathway analysis of colon adenocarcinoma in a tertiary healthcare centre in Kerala, India. Ecancermedicalscience, 2021, 15, 1302.	0.6	3
5345	Downregulation of microRNAâ€6125 promotes colorectal cancer growth through YTHDF2â€dependent recognition of N6â€methyladenosineâ€modified GSK3Î². Clinical and Translational Medicine, 2021, 11, e602.	1.7	36
5347	Concordance analysis of microsatellite instability status between polymerase chain reaction based testing and next generation sequencing for solid tumors. Scientific Reports, 2021, 11, 20003.	1.6	23
5348	Evolutionary patterns of chromosomal instability and mismatch repair deficiency in proximal and distal colorectal cancer. Colorectal Disease, 2022, 24, 157-176.	0.7	9
5349	A novel xenonucleic acid-mediated molecular clamping technology for early colorectal cancer screening. PLoS ONE, 2021, 16, e0244332.	1.1	6
5350	Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers. Genes, 2021, 12, 1593.	1.0	2
5351	Isoformâ€specific effects of transcription factor TCFL5 on the pluripotencyâ€related genes SOX2 and KLF4 in colorectal cancer development. Molecular Oncology, 2022, 16, 1876-1890.	2.1	1
5352	A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic Colorectal Cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI â€" Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPAK II Trial with Early Results. Oncology, 2021, , 1-11.	0.9	1

#	Article	IF	Citations
5353	EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC. Clinical Lung Cancer, 2022, 23, 60-71.	1.1	5
5354	TRPC1 promotes the genesis and progression of colorectal cancer via activating CaM-mediated PI3K/AKT signaling axis. Oncogenesis, 2021, 10, 67.	2.1	19
5355	The Frequency of DNA Mismatch Repair Deficiency Is Very Low in Surgically Resected Lung Carcinoma. Frontiers in Oncology, 2021, 11, 752005.	1.3	9
5357	Metastatic Rectal Carcinoma with Long-Term Remission due to Modern Multimodality Treatment. Case Reports in Oncology, 2021, 14, 1475-1482.	0.3	1
5358	Disease Modeling on Tumor Organoids Implicates AURKA as a Therapeutic Target in Liver Metastatic Colorectal Cancer. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 517-540.	2.3	11
5359	Low expression of CD24 is associated with poor survival in colorectal cancer. Biochimie, 2022, 192, 91-101.	1.3	3
5360	Transcriptomic Analysis Identifies Complement Component 3 as a Potential Predictive Biomarker for Chemotherapy Resistance in Colorectal Cancer. Frontiers in Molecular Biosciences, 2021, 8, 763652.	1.6	4
5361	SMRT: Randomized Data Transformation for Cancer Subtyping and Big Data Analysis. Frontiers in Oncology, 2021, 11, 725133.	1.3	7
5362	A Microsatellite in the Coding Sequence of HLA-A/B Is a Mutation Hotspot in Colon Cancer With Microsatellite Instability. Gastroenterology, 2022, 162, 960-963.e3.	0.6	0
5365	The role of PDGFRA as a therapeutic target in young colorectal cancer patients. Journal of Translational Medicine, 2021, 19, 446.	1.8	11
5366	Systematic review of tumour budding and association with common mutations in patients with colorectal cancer. Critical Reviews in Oncology/Hematology, 2021, 167, 103490.	2.0	3
5367	Deep learning can predict lymph node status directly from histology in colorectal cancer. European Journal of Cancer, 2021, 157, 464-473.	1.3	32
5368	Inferring Transcriptional Modules from Microarray and ChIP-Chip Data Using Penalized Matrix Decomposition. Lecture Notes in Computer Science, 2013, , 252-259.	1.0	0
5369	Genetic and Epigenetic Interaction in the Development of Colorectal Cancers. , 2013, 03, .		0
5370	Mutational Activation of KRAS and BRAF in Colorectal Cancer. , 2013, , 121-156.		1
5371	Potential Applications of Tanshinones in Gastrointestinal and Hepatic Diseases. Journal of Biomolecular Research & Therapeutics, 0, , .	0.2	2
5372	Colorectal Cancer Genome and Its Implications. , 2013, , 247-265.		0
5373	Copy-Number Alterations in the Colorectal Cancer Genome. , 2013, , 267-287.		0

#	Article	IF	Citations
5374	The Clinical Significance of Mutations in Colorectal Cancer. , 2013, , 231-245.		0
5375	Computational Tools and Resources for Integrative Modeling in Systems Biology. , 2013, , 399-428.		0
5377	Role of Next-Generation Sequencing Technologies. , 2013, , 1-16.		0
5379	EXTRACTING SIGNIFICANT SAMPLE-SPECIFIC CANCER MUTATIONS USING THEIR PROTEIN INTERACTIONS. , 2013, , .		0
5380	Microarray-Based Investigations in Cancer. , 2014, , 87-106.		0
5381	Pathology, Biomarkers, and Molecular Diagnostics. , 2014, , 226-252.e6.		1
5382	Medical Oncology. , 2014, , 71-82.		0
5383	DNA Damage Response Pathways and Cancer. , 2014, , 142-153.e3.		2
5384	Statistical Methods for the Analysis of Next Generation Sequencing Data from Paired Tumor-Normal Samples. , 2014, , 379-404.		0
5386	Discovery and Characterization of Cancer Genetic Susceptibility Alleles. , 2014, , 309-321.e3.		0
5387	RAS Genes and Cancer. , 2014, , 157-171.		0
5388	OMICS for Tumor Biomarker Research. , 2014, , 1-22.		0
5390	Next Generation Sequencing in Cancer Research and Clinical Application. , 2014, , 71-94.		1
5391	Rare Cancers. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 109-130.	0.6	0
5392	Genomic Applications in Colorectal and Pancreatic Tumors. , 2015, , 415-434.		0
5393	Genetics, Screening, and Chemoprevention. , 2015, , 57-80.		0
5394	Analysis of the role of RAS Family Mutations in Metastatic Colorectal Cancer (mCRC): Current Treatment Practice. Forum of Clinical Oncology, 2014, 5, 12-15.	0.1	0
5395	Biomarkers in Metastatic Colorectal Cancer. Biomarkers in Disease, 2015, , 601-629.	0.0	1

#	Article	IF	Citations
5396	Targeted Therapy and Novel Agents for the Treatment of Gastric Cancer: A View Toward the Future. , 2015, , 317-330.		0
5397	Colon and Ovarian Translocations. , 2015, , 417-426.		0
5398	Targeted Therapies For Intestinal Tumorigenesis. , 2015, , 391-440.		0
5399	Hereditary CRC Syndromes. , 2015, , 1-28.		0
5400	AXL. , 2015, , 1-11.		0
5401	Dosing â€“ When Less is More. RSC Drug Discovery Series, 2015, , 249-266.	0.2	0
5405	El paradigma neurogenÃ³mico: La libertad y las dimensiones antropolÃ³gicas del paciente. Scientia Et Fides, 2015, 3, 193.	0.3	0
5406	HER3 over-expression and overall survival in gastrointestinal cancers. Oncotarget, 2015, 6, 42868-42878.	0.8	6
5409	Personalized Disease Phenotypes from Massive OMICs Data. , 2016, , 2316-2337.		0
5411	A Bioinformatic Approach to MSI Cancer Research. Bioengineering and Bioscience, 2016, 4, 7-10.	0.2	0
5412	Genomic Analysis. , 2016, , 83-106.		0
5413	Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 27-107.	0.1	0
5415	Biomedical Applications of Gut Stem Cells: Gaining First-Hand Insights for Developing Therapy for the Future. Journal of Stem Cell Research & Therapeutics, 2016, 1, .	0.1	0
5417	The Intersection of Epidemiology and Pathology. , 2017, , 3-9.		0
5418	Pathology and Molecular Pathology of Colorectal Cancer. , 2017, , 409-446.		2
5421	A Systems Biology Comparison of Ovarian Cancers Implicates Putative Somatic Driver Mutations through Protein-Protein Interaction Models. PLoS ONE, 2016, 11, e0163353.	1.1	5
5426	Analysis of the frequency of NRAS and c-Kit gene mutations in patients with BRAF-negative melanoma. Russian Journal of Skin and Venereal Diseases, 2016, 19, 324-327.	0.0	0
5427	Molecular stratification of sporadic and hereditary colorectal cancer â€“ mini review. Rad Hrvatske Akademije Znanosti I Umjetnosti Medicinske Znanosti, 2017, 530, 73-80.	0.1	0

#	Article	IF	Citations
5428	Grundprinzipien der Tumorstehung. , 2017, , 1-16.		0
5431	Personalised Genomics and Molecular Profiles in Colorectal Cancer: Towards Precision Cancer Care. , 2017, , 261-285.		0
5432	Malignant Tumors Arising in Inflammatory Bowel Disease. , 2017, , 669-683.		0
5451	The macro-evolutionary events in esophageal squamous cell carcinoma. Oncotarget, 2017, 8, 112770-112782.	0.8	0
5452	Precision Medicine Based on Next Generation Sequencing and Master Controllers. , 2018, , 1-35.		0
5454	Future Therapies in Medical Oncology. , 2018, , 111-124.		0
5457	Medical Oncology Management of Hereditary Colorectal Cancer. , 2018, , 401-413.		0
5458	Annexin A1 is upregulated in p53-positive gastric cancer. Annals of Cancer Research and Therapy, 2018, 26, 26-30.	0.1	1
5460	Pathology of Tumor Angiogenesis. , 2018, , 1-22.		1
5461	Stellenwert der systemischen Chemotherapie bei fortgeschrittener peritonealer Metastasierung. , 2018, , 245-260.		0
5463	Drug Resistance Against Tyrosine Kinase Inhibitor in Gastrointestinal Malignancies. , 2018, , 191-224.		0
5466	Pathologic Assessment and Specimen Quality After Total Mesorectal Excision of Rectal Cancer. , 2018, , 99-106.		0
5468	A novel isolation method for cancer prognostic factors via the p53 pathway by a combination of in vitro and in silico analyses. Oncoscience, 2018, 5, 88-98.	0.9	0
5478	EARLY PREDICTABILITY FACTORS IN PROGNOSTICATION OF COLORECTAL CARCINOMAS- A STUDY. Journal of Evolution of Medical and Dental Sciences, 2018, 7, 3883-3887.	0.1	1
5483	Tankyrase: Function and Tankyrase Inhibitor in Cancer. Biomedical Science Letters, 2018, 24, 150-156.	0.0	0
5485	Calcium and vitamin D in the serrated neoplastic pathway: Friends or foes?. World Journal of Gastrointestinal Pathophysiology, 2018, 9, 59-62.	0.5	1
5494	Pathology of Tumor Angiogenesis. , 2019, , 253-274.		0
5495	Circulating Tumor DNA in Colorectal Cancerâ€"From Concept to Clinic. Oncology & Hematology Review, 2019, 15, 33.	0.2	1

#	Article	IF	Citations
5498	Targeting HER2 in Lung Cancer. Current Cancer Research, 2019, , 125-136.	0.2	0
5499	Molecular Diagnostics and Genomic Profiling in Individualized Therapies of Gastrointestinal Cancers. , 2019, , 613-631.		0
5500	Stromal Barriers Within the Tumor Microenvironment and Obstacles to Nanomedicine. , 2019, , 57-89.		3
5501	Prognostic Factors in Geriatric Patients with Metastatic Colon Cancer. Journal of Cancer Therapy, 2019, 10, 779-788.	0.1	0
5502	Simultaneous Quadruple Advanced Colorectal Cancer Synchronously Associated with Esophageal Cancerâ€"Report of a Caseâ€". Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2019, 80, 1764-1769.	0.0	0
5503	Chemotherapy and Biologic Therapy in Rectal Cancer: An Update. , 2019, , 407-444.		0
5504	Colorectal Cancer Prevention. , 2019, , 473-509.		1
5516	Eicosapentaenoic acid and/or aspirin for preventing colorectal adenomas during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: the seAFOod RCT. Efficacy and Mechanism Evaluation, 2019, 6, 1-154.	0.9	7
5527	miRâ€'5191 functions as a tumor suppressor by targeting RPS6KB1 in colorectal cancer. International Journal of Oncology, 2019, , .	1.4	3
5534	Network Entropy Reveals that Cancer Resistance to MEK Inhibitors Is Driven by the Resilience of Proliferative Signaling. Studies in Computational Intelligence, 2020, , 751-761.	0.7	0
5535	Integrated Cancer Subtyping using Heterogeneous Genome-Scale Molecular Datasets. , 2019, , .		4
5536	Resistance of the stableâ€"towards more precise prediction of response to immune checkpoint blockade in microsatellite-unstable cancer patients. Annals of Translational Medicine, 2019, 7, 603-603.	0.7	0
5537	Norepinephrine transporter promotes the invasion of human colon cancer cells. Oncology Letters, 2020, 19, 824-832.	0.8	2
5539	The Biology of Colorectal Liver Metastases. , 2020, , 7-20.		0
5540	Molecular Biomarkers for the Management of Colorectal Cancer Liver Metastases. , 2020, , 21-34.		0
5541	Targeted molecular proï¬ling of genetic alterations in colorectal cancer using nextâ€'generation sequencing. Oncology Letters, 2020, 19, 1137-1144.	0.8	0
5543	Current status of the genetic susceptibility in attenuated adenomatous polyposis. World Journal of Gastrointestinal Oncology, 2019, 11, 1101-1114.	0.8	5
5546	Colorectal Cancer Disparities in Latinos: Genes vs. Environment. , 2020, , 35-41.		3

#	Article	IF	Citations
5547	MappingÂthe Radiogenome of Human Cancers. Cancer Drug Discovery and Development, 2020, , 35-61.	0.2	0
5548	Cancer Stem Cells in Patient Survival and Therapies in Cancer. , 2020, , 339-369.		0
5555	Clinicopathological and mutational differences between tumors with multiple metastases and single lung metastasis in colorectal cancer. Oncology Letters, 2020, 20, 541-550.	0.8	3
5559	Systemic inflammation markers in blood samples of colorectal cancer patients. Progress in Health Sciences, 2020, 10, 92-101.	0.1	0
5564	Î³â€'H2AX as a potential indicator of radiosensitivity in colorectal cancer cells. Oncology Letters, 2020, 20, 2331-2337.	0.8	14
5568	Molecular characteristics of colorectal hyperplastic polyp subgroups. Turkish Journal of Gastroenterology, 2020, 31, 573-580.	0.4	7
5569	Introduction to Digital Pathology from Historical Perspectives to Emerging Pathomics. , 2022, , 1-22.		2
5570	Combined Assessment of the Tumorâ€"Stroma Ratio and Tumor Immune Cell Infiltrate for Immune Checkpoint Inhibitor Therapy Response Prediction in Colon Cancer. Cells, 2021, 10, 2935.	1.8	12
5571	Cyclomodulins and Hemolysis in E. coli as Potential Low-Cost Non-Invasive Biomarkers for Colorectal Cancer Screening. Life, 2021, 11, 1165.	1.1	1
5572	Epithelial Wnt secretion drives the progression of inflammation-induced colon carcinoma in murine model. IScience, 2021, 24, 103369.	1.9	4
5573	Drug Repositioning Based on the Reversal of Gene Expression Signatures Identifies TOP2A as a Therapeutic Target for Rectal Cancer. Cancers, 2021, 13, 5492.	1.7	17
5574	Therapeutic strategies targeting Wnt/Î²â€'catenin signaling for colorectal cancer (Review). International Journal of Molecular Medicine, 2021, 49, .	1.8	24
5575	APC and TP53 Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes. Cancers, 2021, 13, 5394.	1.7	7
5577	Disruption of Tumor Suppressors HNF4Î±/HNF1Î± Causes Tumorigenesis in Liver. Cancers, 2021, 13, 5357.	1.7	4
5578	Clinicopathologic Characteristics of FBXW7-Mutated Colorectal Adenocarcinoma and Association with Aberrant Beta-catenin Localization. Human Pathology, 2021, 119, 51-58.	1.1	1
5579	miR-34a-5p suppresses colorectal cancer cell proliferation through silencing Microtubule Actin Crosslinking Factor 1 (MACF1) gene. Gene Reports, 2021, 25, 101416.	0.4	1
5580	Therapeutic Suppression of FAK-AKT Signaling Overcomes Resistance to SHP2 Inhibition in Colorectal Carcinoma. Frontiers in Pharmacology, 2021, 12, 739501.	1.6	3
5581	USH2A Mutation is Associated With Tumor Mutation Burden and Antitumor Immunity in Patients With Colon Adenocarcinoma. Frontiers in Genetics, 2021, 12, 762160.	1.1	9

#	Article	IF	Citations
5582	Sclonal architectures predict clinical outcome in colon adenocarcinoma. Journal of Cellular and Molecular Medicine, 2021, 25, 1796-1800.	1.6	3
5583	Personalized Management of Cancers of Various Organs/Systems. , 2021, , 509-602.		0
5584	Multicohort and crossâ€platform validation of a prognostic Wnt signature in colorectal cancer. Clinical and Translational Medicine, 2020, 10, e199.	1.7	1
5589	Interrelation between miRNA and mRNA expression in HT-29 line cells under hypoxia. Bulletin of Russian State Medical University, 2020, , .	0.3	0
5590	Preclinical and Clinical Advances of Targeted Protein Degradation as a Novel Cancer Therapeutic Strategy: An Oncologist Perspective. Targeted Oncology, 2021, 16, 1-12.	1.7	4
5591	Assaying circulating-tumor DNA to predict recurrence of localized colon cancer. Digestive Medicine Research, 2020, 3, 112-112.	0.2	0
5592	FAM83F regulates canonical Wnt signalling through an interaction with CK1Î±. Life Science Alliance, 2021, 4, e202000805.	1.3	6
5593	Genetic and stochastic influences upon tumor formation and tumor types in Li-Fraumeni mouse models. Life Science Alliance, 2021, 4, e202000952.	1.3	4
5594	IMiDs induce FAM83F degradation via an interaction with CK1Î± to attenuate Wnt signalling. Life Science Alliance, 2021, 4, e202000804.	1.3	3
5597	GAPDH and PUM1: Optimal Housekeeping Genes for Quantitative Polymerase Chain Reaction-Based Analysis of Cancer Stem Cells and Epithelial-Mesenchymal Transition Gene Expression in Rectal Tumors. Cureus, 2020, 12, e12020.	0.2	6
5599	MsrB1 Promotes Proliferation and Invasion of Colorectal Cancer Cells via GSK-3Î²/Î²-catenin Signaling Axis. Cell Transplantation, 2021, 30, 096368972110532.	1.2	7
5600	Mutational Characterization of Colorectal Cancer from Korean Patients with Targeted Sequencing. Journal of Cancer, 2021, 12, 7300-7310.	1.2	2
5601	Omics-based biomarkers for CRC. , 2022, , 249-263.		2
5602	Diagnostic, prognostic, predictive and therapeutic molecular biomarkers in CRC: Understanding the present and foreseeing the future. , 2022, , 207-230.		0
5603	Bioinformatic tools for research in CRC. , 2022, , 231-247.		0
5604	IS THERE A CLINICAL PATHOLOGICAL CORRELATION OF COLORECTAL ADENOCARCINOMA WITH THE IMMUNOHISTOCHEMICAL EXPRESSION OF OPN AND ABCB5?. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2020, 33, e1569.	0.5	2
5605	GALNT6 Knockdown Inhibits the Proliferation and Migration of Colorectal Cancer Cells and Increases the Sensitivity of Cancer Cells to 5-FU. Journal of Cancer, 2021, 12, 7413-7421.	1.2	3
5606	The Detection of Dynamical Organization in Cancer Evolution Models. Communications in Computer and Information Science, 2020, , 49-61.	0.4	1

#	Article	IF	Citations
5608	Selection of the Most Informative Genes in the Task of Cancer Tumors Recognition Based on the Gene Expression Profile. Advances in Intelligent Systems and Computing, 2020, , 895-909.	0.5	0
5610	Colorectal Cancer Genetics: An Overview of the Actionable Building Blocks. , 2020, , 29-71.		1
5611	Standards der pathologischen PrÃparatebearbeitung und Befunderhebung beim Rektumkarzinom. , 2020, , 29-35.		1
5612	Immune Targets in Colorectal Cancer. Diagnostics and Therapeutic Advances in GI Malignancies, 2020, , 205-230.	0.2	0
5614	MIER3 suppresses the progression of non-small cell lung cancer by inhibiting Wnt/Î²-Catenin pathway and histone acetyltransferase activity. Translational Cancer Research, 2020, 9, 346-357.	0.4	2
5616	KRAS. Encyclopedia of Pathology, 2020, , 1-2.	0.0	0
5617	ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER?. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2020, 33, e1568.	0.5	4
5618	The neuron navigator 2 gene and Alzheimer's disease. , 2020, , 3-24.		0
5622	Role of ACE2/TMPRSS2 genes regulation by intestinal microRNA isoforms in the COVID-19 pathogenesis. Bulletin of Russian State Medical University, 2020, , .	0.3	3
5623	Effects of electrical stimulation on cell activity, cell cycle, cell apoptosis and Î²â€'catenin pathway in the injured dorsal root ganglion cell. Molecular Medicine Reports, 2020, 21, 2385-2394.	1.1	7
5624	DNA Methylation Profiling: An Emerging Paradigm for Cancer Diagnosis. Annual Review of Pathology: Mechanisms of Disease, 2022, 17, 295-321.	9.6	83
5625	Virulent Bacteria as Inflammatory and Immune Co-Factor in Colon Carcinogenesis: Evidence From Two Monozygotic Patients and Validation in CRC Patient and Healthy Cohorts. Frontiers in Cellular and Infection Microbiology, 2021, 11, 749750.	1.8	1
5626	Mechanistic dissection unmasks colibactin as a prevalent mutagenic driver of cancer. Cancer Cell, 2021, 39, 1439-1441.	7.7	5
5627	More than FOLFOX and FOLFIRI: The Management of Metastatic Colorectal Cancer in the Era of Precision Oncology. European Medical Journal Oncology, 0, , 43-52.	0.0	1
5628	Molecular and Pathology Features of Colorectal Tumors and Patient Outcomes Are Associated with <i>Fusobacterium nucleatum</i> and Its Subspecies <i>animalis</i>. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 210-220.	1.1	19
5629	High PGD2 receptor 2 levels are associated with poor prognosis in colorectal cancer patients and induce VEGF expression in colon cancer cells and migration in a zebrafish xenograft model. British Journal of Cancer, 2022, 126, 586-597.	2.9	7
5630	Comprehensive Analysis of the Expression and Prognosis for MMPs in Human Colorectal Cancer. Frontiers in Oncology, 2021, 11, 771099.	1.3	17
5631	Human mucosal tissue-resident memory T cells in health and disease. Mucosal Immunology, 2022, 15, 389-397.	2.7	30

#	Article	IF	Citations
5632	Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?. International Journal of Molecular Sciences, 2021, 22, 11941.	1.8	27
5633	The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer. Current Treatment Options in Oncology, 2021, 22, 113.	1.3	9
5635	Earlyâ€'onset colorectal cancer: A distinct entity with unique genetic features. Oncology Letters, 2020, 20, 33.	0.8	0
5636	Concurrent Wnt pathway component expression in breast and colorectal cancer. Pathology Research and Practice, 2020, 216, 153005.	1.0	4
5637	Multi-omics integrative analysis and survival risk model construction of non-small cell lung cancer based on The Cancer Genome Atlas datasets. Oncology Letters, 2020, 20, 58.	0.8	2
5644	Incidental Pulmonary Metastases Revealing Subcentimeter Papillary Thyroid Carcinoma. AACE Clinical Case Reports, 2020, 6, e273-e278.	0.4	0
5645	Space-log: a novel approach to inferring gene-gene net-works using SPACE model with log penalty. F1000Research, 0, 9, 1159.	0.8	0
5646	Pathologic Features of Colorectal Carcinomas. , 2021, , 455-480.		2
5647	APC mutations in human colon lead to decreased neuroendocrine maturation of ALDH+ stem cells that alters GLP-2 and SST feedback signaling: Clue to a link between WNT and retinoic acid signalling in colon cancer development. PLoS ONE, 2020, 15, e0239601.	1.1	14
5652	Commentary: Pulmonary metastasectomy efficacy: A game of clones?. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, 503-510.	0.4	0
5653	KRAS mutations are negatively correlated with immunity in colon cancer. Aging, 2021, 13, 750-768.	1.4	10
5654	Single Nucleotide Polymorphisms in Colitis-Associated Colorectal Cancer: A Current Overview with Emphasis on the Role of the Associated Genes Products. Current Drug Targets, 2020, 21, 1456-1462.	1.0	1
5655	Rightward shift in colorectal cancer: experience in 1101 patients. Minerva Surgery, 2020, 75, 225-233.	0.1	3
5656	Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia. International Journal of Molecular Epidemiology and Genetics, 2013, 4, 140-9.	0.4	14
5657	Detecting statistical interaction between somatic mutational events and germline variation from next-generation sequence data. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2014, , 51-62.	0.7	4
5658	Molecular genetics of colorectal cancer. Annals of Gastroenterology, 2014, 27, 9-14.	0.4	126
5659	Current and Future Role of the Gastroenterologist in GI Cancer Management. Journal of Digestive Cancer Reports, 2013, 1, 78-81.	0.0	3
5660	A mathematical model for short-term vs. long-term survival in patients with glioma. American Journal of Cancer Research, 2014, 4, 862-73.	1.4	8

#	Article	IF	Citations
5662	Advanced colorectal adenoma related gene expression signature may predict prognostic for colorectal cancer patients with adenoma-carcinoma sequence. International Journal of Clinical and Experimental Medicine, 2015, 8, 4883-98.	1.3	4
5663	Biomarker-directed Targeted Therapy in Colorectal Cancer. Journal of Digestive Cancer Reports, 2015, 3, 5-10.	0.0	5
5666	Novel Therapies in Development for Metastatic Colorectal Cancer. Gastrointestinal Cancer Research: GCR, 2014, 7, S2-7.	0.8	2
5667	MiR-182 promotes proliferation and invasion and elevates the HIF-1Î±-VEGF-A axis in breast cancer cells by targeting FBXW7. American Journal of Cancer Research, 2016, 6, 1785-98.	1.4	29
5668	HEREDITARY, SPORADIC AND METASTATIC COLORECTAL CANCER ARE COMMONLY DRIVEN BY SPECIFIC SPECTRUMS OF DEFECTIVE DNA MISMATCH REPAIR COMPONENTS. Transactions of the American Clinical and Climatological Association, 2016, 127, 81-97.	0.9	15
5669	Tumor suppressor genes in familial adenomatous polyposis. Gastroenterology and Hepatology From Bed To Bench, 2017, 10, 3-13.	0.6	35
5670	Interrogating Patient-level Genomics and Mouse Phenomics towards Understanding Cytokines in Colorectal Cancer Metastasis. AMIA Summits on Translational Science Proceedings, 2017, 2017, 227-236.	0.4	0
5672	Consensus Molecular Subtypes of Colorectal Cancer and their Clinical Implications. International Biological and Biomedical Journal, 2017, 3, 105-111.	7.0	54
5673	BANCR: a cancer-related long non-coding RNA. American Journal of Cancer Research, 2017, 7, 1779-1787.	1.4	16
5674	mutation status is highly homogeneous between areas of the primary tumor and the corresponding metastasis of colorectal adenocarcinomas: one less problem in patient care. American Journal of Cancer Research, 2017, 7, 1978-1989.	1.4	9
5675	Synergistic anticancer activity of a novel oral chemotherapeutic agent containing trifluridine and tipiracil in combination with anti-PD-1 blockade in microsatellite stable-type murine colorectal cancer cells. American Journal of Cancer Research, 2017, 7, 2032-2040.	1.4	7
5676	LncRNA SUMO1P3 drives colon cancer growth, metastasis and angiogenesis. American Journal of Translational Research (discontinued), 2017, 9, 5461-5472.	0.0	31
5677	Genomics of adult and pediatric solid tumors. American Journal of Cancer Research, 2018, 8, 1356-1386.	1.4	14
5678	Species-specific function of microRNA-7702 in human colorectal cancer cells via targeting TADA1. American Journal of Translational Research (discontinued), 2018, 10, 2579-2589.	0.0	4
5679	Mismatch repair-based stratification for immune checkpoint blockade therapy. American Journal of Cancer Research, 2018, 8, 1977-1988.	1.4	8
5680	Hypermethylated and its clinical significance in colorectal cancer. American Journal of Translational Research (discontinued), 2018, 10, 4290-4301.	0.0	3
5681	SRC and TP53 play critical role in low-grade dysplasia colorectal mucosa transformation into cancer. Gastroenterology and Hepatology From Bed To Bench, 2018, 11, S104-S110.	0.6	2
5682	Gene expression profile analysis of colon cancer grade II into grade III transition by using system biology. Gastroenterology and Hepatology From Bed To Bench, 2019, 12, 60-66.	0.6	5

#	Article	IF	Citations
5683	A review on role of ATM gene in hereditary transfer of colorectal cancer. Acta Biomedica, 2019, 89, 463-469.	0.2	7
5686	Fibroblast growth factor-10 and epithelial-mesenchymal transition in colorectal cancer. EXCLI Journal, 2019, 18, 530-539.	0.5	4
5687	Integrated Cancer Subtyping using Heterogeneous Genome-Scale Molecular Datasets. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2020, 25, 551-562.	0.7	2
5688	Expression status of four mismatch repair proteins in patients with colorectal cancer: clinical significance in 1238 cases. International Journal of Clinical and Experimental Pathology, 2019, 12, 3685-3699.	0.5	6
5689	Combined effects of EGFR and hedgehog signaling blockade on inhibition of head and neck squamous cell carcinoma. International Journal of Clinical and Experimental Pathology, 2017, 10, 9816-9828.	0.5	0
5690	N6-methyladenosine methyltransferase METTL3 promotes colorectal cancer cell proliferation through enhancing MYC expression. American Journal of Translational Research (discontinued), 2020, 12, 1789-1806.	0.0	9
5691	Overexpressed gene signature of EPH receptor A/B family in cancer patients-comprehensive analyses from the public high-throughput database. International Journal of Clinical and Experimental Pathology, 2020, 13, 1220-1242.	0.5	11
5692	Prognostic impact of cancer stem cell markers and in colorectal cancer. American Journal of Translational Research (discontinued), 2020, 12, 5797-5807.	0.0	1
5693	Cooperation between ETS transcription factor ETV1 and histone demethylase JMJD1A in colorectal cancer. International Journal of Oncology, 2020, 57, 1319-1332.	3.9	3
5694	Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancer. American Journal of Cancer Research, 2021, 11, 530-545.	1.4	2
5695	Clinicopathological and molecular features between synchronous and metachronous metastases in colorectal cancer. American Journal of Cancer Research, 2021, 11, 1646-1658.	1.4	0
5696	Hippo-YAP signaling in digestive system tumors. American Journal of Cancer Research, 2021, 11, 2495-2507.	1.4	3
5697	Integrative multiplatform-based molecular profiling of human colorectal cancer reveals proteogenomic alterations underlying mitochondrial inactivation. American Journal of Cancer Research, 2021, 11, 2893-2910.	1.4	1
5698	Stomach-specific c-Myc overexpression drives gastric adenoma in mice through AKT/mammalian target of rapamycin signaling. Bosnian Journal of Basic Medical Sciences, 2021, 21, 434-446.	0.6	1
5699	ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER?. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2021, 34, e1585.	0.5	0
5700	A Text-Based Computational Framework for Patient-Specific Modeling for Classification of Cancers. SSRN Electronic Journal, 0, , .	0.4	0
5701	Differential Expression of miR-20a and miR-145 in Colorectal Tumors as Potential Location-specific miRNAs. MicroRNA (Shariqah, United Arab Emirates), 2021, 10, 66-73.	0.6	2
5702	Methylated circulating tumor DNA biomarkers for the blood-based detection of cancer signals. , 2022, , 471-512.		0

#	Article	IF	Citations
5703	Systems biology and big data analytics. , 2022, , 425-442.		0
5704	Evaluation of Classic, Attenuated, and Oligopolyposis of the Colon. Gastrointestinal Endoscopy Clinics of North America, 2022, 32, 95-112.	0.6	1
5705	Tribbles Gene Expression Profiles in Colorectal Cancer. Gastrointestinal Disorders, 2021, 3, 218-236.	0.4	0
5706	Expression of nonâ€'homologous end joining factor, Ku80, is negatively correlated with PDâ€'L1 expression in cancer cells after Xâ€'ray irradiation. Oncology Letters, 2021, 23, 29.	0.8	7
5707	Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights. Nature Communications, 2021, 12, 6821.	5.8	15
5708	Novel Methylation Biomarkers for Colorectal Cancer Prognosis. Biomolecules, 2021, 11, 1722.	1.8	21
5709	STOML2 interacts with PHB through activating MAPK signaling pathway to promote colorectal Cancer proliferation. Journal of Experimental and Clinical Cancer Research, 2021, 40, 359.	3.5	7
5710	Elevated Sodium Pump Î±3 Subunit Expression Promotes Colorectal Liver Metastasis via the p53-PTEN/IGFBP3-AKT-mTOR Axis. Frontiers in Oncology, 2021, 11, 743824.	1.3	3
5711	A Portrait of Intratumoral Genomic and Transcriptomic Heterogeneity at Single-Cell Level in Colorectal Cancer. Medicina (Lithuania), 2021, 57, 1257.	0.8	5
5712	Stromal Cells Promote Matrix Deposition, Remodelling and an Immunosuppressive Tumour Microenvironment in a 3D Model of Colon Cancer. Cancers, 2021, 13, 5998.	1.7	8
5713	Comprehensive Analysis of Subtype-Specific Molecular Characteristics of Colon Cancer: Specific Genes, Driver Genes, Signaling Pathways, and Immunotherapy Responses. Frontiers in Cell and Developmental Biology, 2021, 9, 758776.	1.8	10
5714	Sporadic and Inherited Colorectal Cancer: How Epidemiology and Molecular Biology Guide Screening and Treatment. , 2022, , 397-412.		0
5715	Oxidative Distress Induces Wnt/Î²-Catenin Pathway Modulation in Colorectal Cancer Cells: Perspectives on APC Retained Functions. Cancers, 2021, 13, 6045.	1.7	9
5716	Rare germline variants in the AXIN2 gene in families with colonic polyposis and colorectal cancer. Familial Cancer, 2021, , 1.	0.9	5
5717	Correlation between circulating tumor DNA and carcinoembryonic antigen levels in patients with metastatic colorectal cancer. Cancer Medicine, 2021, 10, 8820-8828.	1.3	10
5718	Clinicopathological and molecular analyses of hyperplastic lesions including microvesicular variant and goblet cell rich variant hyperplastic polyps and hyperplastic nodulesâ€"Hyperplastic nodule is an independent histological entity. Pathology International, 2021, , .	0.6	2
5719	Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?. Frontiers in Oncology, 2021, 11, 769305.	1.3	13
5720	Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer. Frontiers in Oncology, 2021, 11, 764618.	1.3	17

#	Article	IF	Citations
5721	HIF-Dependent NFATC1 Activation Upregulates ITGA5 and PLAUR in Intestinal Epithelium in Inflammatory Bowel Disease. Frontiers in Genetics, 2021, 12, 791640.	1.1	14
5722	Comprehensive analyses of microRNA and mRNA expression in colorectal serrated lesions and colorectal cancer with a MSI phenotype. Genes Chromosomes and Cancer, 2021, , .	1.5	3
5723	Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance. Oncology Reports, 2021, 47, .	1.2	3
5724	<i>TP53</i> Gain-of-Function and Nonâ€"Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2022, 40, 171-179.	0.8	33
5725	Bridging the Species Gap: Morphological and Molecular Comparison of Feline and Human Intestinal Carcinomas. Cancers, 2021, 13, 5941.	1.7	5
5727	Drug discovery efforts toward inhibitors of canonical Wnt/Î²-catenin signaling pathway in the treatment of cancer: A composition-of-matter review (2010â€"2020). Drug Discovery Today, 2022, 27, 1115-1127.	3.2	13
5728	Machine learning of genomic features in organotropic metastases stratifies progression risk of primary tumors. Nature Communications, 2021, 12, 6692.	5.8	16
5729	DNM1: A Prognostic Biomarker Associated with Immune Infiltration in Colon Cancerâ€"A Study Based on TCGA Database. BioMed Research International, 2021, 2021, 1-9.	0.9	4
5730	Dvl2 facilitates the coordination of NFâ€Î°B and Wnt signaling to promote colitisâ€associated colorectal progression. Cancer Science, 2022, 113, 565-575.	1.7	8
5731	Nano-scale physical properties characteristic to metastatic intestinal cancer cells identified by high-speed scanning ion conductance microscope. Biomaterials, 2022, 280, 121256.	5.7	13
5733	Age-dependent prognostic value of <i>KRAS</i> mutation in metastatic colorectal cancer. Future Oncology, 2021, 17, 4883-4893.	1.1	5
5734	Identifying Diagnostic MicroRNAs and Investigating Their Biological Implications in Rectal Cancer. JAMA Network Open, 2021, 4, e2136913.	2.8	3
5735	The correlation between intestinal microbiota and colorectal cancer. Klinicheskaia Meditsina, 2021, 99, 339-341.	0.2	0
5736	<i>Fusobacterium nucleatum</i> drives a pro-inflammatory intestinal microenvironment through metabolite receptor-dependent modulation of IL-17 expression. Gut Microbes, 2021, 13, 1987780.	4.3	54
5737	ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER?. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2021, 34, e1585.	0.5	0
5738	Prognostic value of LINC02560 in colorectal cancer correlates with tumor microenvironment immunity. Journal of Cancer, 2021, 12, 7507-7517.	1.2	2
5739	Targeted deep sequencing reveals APC mutations as predictors of overall survival in Chinese colorectal patients receiving adjuvant chemotherapy. Scandinavian Journal of Gastroenterology, 2022, , 1-8.	0.6	0
5740	Non-coding RNAs as liquid biopsy biomarkers in cancer. British Journal of Cancer, 2022, 126, 351-360.	2.9	44

#	Article	IF	Citations
5741	Targeting the undruggable oncogenic KRAS: the dawn of hope. JCI Insight, 2022, 7, .	2.3	27
5742	A Pan-Cancer Study of KMT2 Family as Therapeutic Targets in Cancer. Journal of Oncology, 2022, 2022, 1-10.	0.6	5
5743	Prognostic Impact of An Integrative Landscape of Clinical, Immune, and Molecular Features in Non-Metastatic Rectal Cancer. Frontiers in Oncology, 2021, 11, 801880.	1.3	5
5745	Economic assessment of molecular imaging in the oncology treatment process. European Journal of Radiology, 2022, 146, 110105.	1.2	1
5746	The gut microbiota can orchestrate the signaling pathways in colorectal cancer. Apmis, 2022, 130, 121-139.	0.9	12
5747	Allele-specific endogenous tagging and quantitative analysis of Î²-catenin in colorectal cancer cells. ELife, 2022, 11, .	2.8	3
5748	Suppression of colorectal carcinogenesis by naringin. Phytomedicine, 2022, 96, 153897.	2.3	14
5749	Granatin B and punicalagin from Chinese herbal medicine pomegranate peels elicit reactive oxygen species-mediated apoptosis and cell cycle arrest in colorectal cancer cells. Phytomedicine, 2022, 97, 153923.	2.3	5
5750	Iron-mediated epigenetic activation of NRF2 targets. Journal of Nutritional Biochemistry, 2022, 101, 108929.	1.9	13
5751	Bolbostemma paniculatum (Maxim.) Franquet extract suppresses the development of colorectal cancer through downregulation of PI3K/Akt pathway. Journal of Ethnopharmacology, 2022, 287, 114937.	2.0	2
5753	Comparision Of BRAF V600E, COXâ€“2 and p53 As Biomarkers For The Early Detection Of Colorectal Cancer. The Journal of Bahria University Medical and Dental College, 2019, 09, 147-150.	0.0	2
5754	Cooperation between ETS transcription factor ETV1 and histone demethylase JMJD1A in colorectal cancer. International Journal of Oncology, 2020, 57, 1319-1332.	1.4	9
5755	Stomach-specific c-Myc overexpression drives gastric adenoma in mice via AKT/mTOR signaling. Bosnian Journal of Basic Medical Sciences, 2021, 21, 434-446.	0.6	7
5756	Biomarkers for Immunotherapy in Gastrointestinal Cancers. , 2021, , 273-296.		0
5757	Controlling Wnt Signaling Specificity and Implications for Targeting WNTs Pharmacologically. Handbook of Experimental Pharmacology, 2021, 269, 3-28.	0.9	3
5758	RNA signaling pathway <i>via</i> exosomes in cellular population. Drug Delivery System, 2021, 36, 241-247.	0.0	0
5759	Characterization of the consensus mucosal microbiome of colorectal cancer. NAR Cancer, 2021, 3, zcab049.	1.6	9
5760	Tumour genotypes account for survival differences in rightâ€•and leftâ€sided colon cancers. Colorectal Disease, 2022, 24, 601-610.	0.7	6

#	Article	IF	Citations
5761	LncRNAs, the Molecules Involved in Communications With Colorectal Cancer Stem Cells. Frontiers in Oncology, 2022, 12, 811374.	1.3	4
5762	Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy. Frontiers in Immunology, 2021, 12, 808964.	2.2	53
5763	Comprehensive Approach to Distinguish Patients with Solid Tumors from Healthy Controls by Combining Androgen Receptor Mutation p.H875Y with Cell-Free DNA Methylation and Circulating miRNAs. Cancers, 2022, 14, 462.	1.7	16
5764	Genomic studies controvert the existence of the CUX1 p75 isoform. Scientific Reports, 2022, 12, 151.	1.6	1
5765	Predictive and Therapeutic Implications of a Novel PLCÎ³1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer. Clinical Cancer Research, 2022, 28, 1203-1216.	3.2	7
5766	Computerâ€extracted features of nuclear morphology in hematoxylin and eosin images distinguish <scp>s</scp>tage <scp>II</scp> and <scp>IV</scp> colon tumors. Journal of Pathology, 2022, 257, 17-28.	2.1	4
5767	A framework for mutational signature analysis based on DNA shape parameters. PLoS ONE, 2022, 17, e0262495.	1.1	4
5768	Hydrophobic Tagging-Induced Degradation of PDEÎ´ in Colon Cancer Cells. ACS Medicinal Chemistry Letters, 2022, 13, 298-303.	1.3	10
5769	Identification of an at-risk subpopulation with high immune infiltration based on the peroxisome pathway and TIM3 in colorectal cancer. BMC Cancer, 2022, 22, 44.	1.1	8
5770	Transcriptomic-Assisted Immune and Neoantigen Profiling in Premalignancy. Methods in Molecular Biology, 2022, 2435, 95-105.	0.4	1
5771	In-silico characterization of phytochemicals identified from Vitex negundo (L) extract as potential therapy for Wnt-signaling proteins. Egyptian Journal of Medical Human Genetics, 2022, 23, .	0.5	4
5772	Therapeutic Potential of Naturally Occurring Small Molecules to Target the Wnt/Î²-Catenin Signaling Pathway in Colorectal Cancer. Cancers, 2022, 14, 403.	1.7	16
5773	CpG Island Methylator Phenotypeâ€"A Hope for the Future or a Road to Nowhere?. International Journal of Molecular Sciences, 2022, 23, 830.	1.8	8
5774	Epigenome-Wide DNA Methylation Profiling in Colorectal Cancer and Normal Adjacent Colon Using Infinium Human Methylation 450K. Diagnostics, 2022, 12, 198.	1.3	10
5775	Comprehensive clinicopathologic, molecular, and immunologic characterization of colorectal carcinomas with loss of three intestinal markers, CDX2, SATB2, and KRT20. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 543-555.	1.4	5
5776	Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets. Cancers, 2022, 14, 664.	1.7	7
5777	Identification of differentially distributed gene expression and distinct sets of cancer-related genes identified by changes in mean and variability. NAR Genomics and Bioinformatics, 2022, 4, lqab124.	1.5	6
5778	Performance of prognostic models incorporating KRAS mutation status to predict survival after resection of colorectal liver metastases. Hpb, 2022, , .	0.1	2

#	Article	IF	Citations
5779	Copyâ€number intratumor heterogeneity increases the risk of relapse in chemotherapyâ€naive stage <scp>II</scp> colon cancer. Journal of Pathology, 2022, 257, 68-81.	2.1	6
5780	Characterization of <scp><i>RNF43</i></scp> frameshift mutations that drive <scp>Wnt</scp> ligandâ€• and <scp>R</scp>â€spondinâ€dependent colon cancer. Journal of Pathology, 2022, 257, 39-52.	2.1	17
5781	Neurofibromin and suppression of tumorigenesis: beyond the GAP. Oncogene, 2022, 41, 1235-1251.	2.6	13
5782	Space-log: a novel approach to inferring gene-gene net-works using SPACE model with log penalty. F1000Research, 2020, 9, 1159.	0.8	0
5783	Ezrin and Radixin Differentially Modulate Cell Surface Expression of Programmed Death Ligand-1 in Human Pancreatic Ductal Adenocarcinoma KP-2 Cells. Immuno, 2022, 2, 68-84.	0.6	7
5784	Microsatellite instability is biased in Amsterdam II-defined Lynch-related cancer cases with family history but is rare in other cancers: a summary of 1000 analyses. BMC Cancer, 2022, 22, 73.	1.1	5
5785	DANSR: A Tool for the Detection of Annotated and Novel Small RNAs. Non-coding RNA, 2022, 8, 9.	1.3	0
5786	Emerging actionable targets to treat therapy-resistant colorectal cancers. Cancer Drug Resistance (Alhambra, Calif), 2022, 5, 36-63.	0.9	6
5787	Deconvolving Clinically Relevant Cellular Immune Cross-talk from Bulk Gene Expression Using CODEFACS and LIRICS Stratifies Patients with Melanoma to Antiâ€"PD-1 Therapy. Cancer Discovery, 2022, 12, 1088-1105.	7.7	28
5788	Molecular characteristics of youngâ€onset colorectal cancer in Vietnamese patients. Asia-Pacific Journal of Clinical Oncology, 2022, , .	0.7	3
5789	Targeting Post-Translational Regulation of p53 in Colorectal Cancer by Exploiting Vulnerabilities in the p53-MDM2 Axis. Cancers, 2022, 14, 219.	1.7	3
5790	Validation of Urinary Charged Metabolite Profiles in Colorectal Cancer Using Capillary Electrophoresis-Mass Spectrometry. Metabolites, 2022, 12, 59.	1.3	6
5791	Precision medicine for metastatic colorectal cancer in clinical practice. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110727.	1.4	23
5792	Dual Inhibition of Myc Transcription and PI3K Activity Effectively Targets Colorectal Cancer Stem Cells. Cancers, 2022, 14, 673.	1.7	4
5793	KLF3 and PAX6 are candidate driver genes in late-stage, MSI-hypermutated endometrioid endometrial carcinomas. PLoS ONE, 2022, 17, e0251286.	1.1	2
5794	Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors. Cancers, 2022, 14, 695.	1.7	3
5795	MethReg: estimating the regulatory potential of DNA methylation in gene transcription. Nucleic Acids Research, 2022, 50, e51-e51.	6.5	8
5796	Association Between Tumor Mutation Profile and Clinical Outcomes Among Hispanic-Latino Patients With Metastatic Colorectal Cancer. Frontiers in Oncology, 2021, 11, 772225.	1.3	5

#	Article	IF	Citations
5797	Immune translational control by CPEB4 regulates intestinal inflammation resolution and colorectal cancer development. IScience, 2022, 25, 103790.	1.9	4
5798	Fluctuating methylation clocks for cell lineage tracing at high temporal resolution in human tissues. Nature Biotechnology, 2022, 40, 720-730.	9.4	22
5799	NSAIDs Overcome PIK3CA Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models. Cancers, 2022, 14, 506.	1.7	4
5800	Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data. Journal of Personalized Medicine, 2022, 12, 128.	1.1	6
5801	Predictive â€œomicâ€• biomarkers of drug response: Colorectal cancer as a model. , 2022, , 199-240.		2
5802	Discovery of 3,4-Dihydrobenzo[<i>f</i>][1,4]oxazepin-5(2<i>H</i>)-one Derivatives as a New Class of Selective TNIK Inhibitors and Evaluation of Their Anti-Colorectal Cancer Effects. Journal of Medicinal Chemistry, 2022, 65, 1786-1807.	2.9	10
5803	Canonical TGFÎ² signaling induces collective invasion in colorectal carcinogenesis through a Snail1- and Zeb1-independent partial EMT. Oncogene, 2022, 41, 1492-1506.	2.6	10
5804	Metabolic Reprogramming in Gastric Cancer: Trojan Horse Effect. Frontiers in Oncology, 2021, 11, 745209.	1.3	9
5805	TEAD4 nuclear localization and regulation by miR-4269 and miR-1343-3p in colorectal carcinoma. Pathology Research and Practice, 2022, 231, 153791.	1.0	3
5806	N6-Methylandenosine-Related Gene Expression Signatures for Predicting the Overall Survival and Immune Responses of Patients With Colorectal Cancer. SSRN Electronic Journal, 0, , .	0.4	0
5807	Probing the mechanisms of two exonuclease domain mutators of DNA polymerase Ïµ. Nucleic Acids Research, 2022, 50, 962-974.	6.5	7
5808	Mutational Landscape and Actionable Target Rates on Advanced Stage Refractory Cancer Patients: A Multicenter Chilean Experience. Journal of Personalized Medicine, 2022, 12, 195.	1.1	1
5809	Non-Coding RNAs in Colorectal Cancer: Their Functions and Mechanisms. Frontiers in Oncology, 2022, 12, 783079.	1.3	17
5810	A glycolysis-related two-gene risk model that can effectively predict the prognosis of patients with rectal cancer. Human Genomics, 2022, 16, 5.	1.4	7
5811	Immune subtypes and neoantigen-related immune evasion in advanced colorectal cancer. IScience, 2022, 25, 103740.	1.9	4
5812	Colorectal cancer inhibition by BET inhibitor JQ1 is MYC-independent and not improved by nanoencapsulation. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 171, 39-49.	2.0	3
5813	Metformin bicarbonate-mediated efficient RNAi for precise targeting of TP53 deficiency in colon and rectal cancers. Nano Today, 2022, 43, 101406.	6.2	8
5814	PLHPP2 inhibits the stemness of colorectal cancer by inactivating the Nrf2 signaling pathway. Journal of Cancer, 2022, 13, 1313-1323.	1.2	0

#	Article	IF	Citations
5815	Ferroptosis-associated molecular classification characterized by distinct tumor microenvironment profiles in colorectal cancer. International Journal of Biological Sciences, 2022, 18, 1773-1794.	2.6	12
5816	Emerging drug targets for colon cancer: A preclinical assessment. Expert Opinion on Therapeutic Targets, 2022, 26, 207-216.	1.5	4
5817	GÎ±i2-induced conductin/axin2 condensates inhibit Wnt/Î²-catenin signaling and suppress cancer growth. Nature Communications, 2022, 13, 674.	5.8	15
5818	The eternal quest for self-improvement of somatic cells. Cell Genomics, 2022, 2, 100094.	3.0	0
5819	Increased mitochondrial proline metabolism sustains proliferation and survival of colorectal cancer cells. PLoS ONE, 2022, 17, e0262364.	1.1	12
5820	Biallelic mutations in cancer genomes reveal local mutational determinants. Nature Genetics, 2022, 54, 128-133.	9.4	16
5821	Shifting the Focus of Signaling Abnormalities in Colon Cancer. Cancers, 2022, 14, 784.	1.7	3
5822	Is precision medicine for colorectal liver metastases still a utopia? New perspectives by modern biomarkers, radiomics, and artificial intelligence. World Journal of Gastroenterology, 2022, 28, 608-623.	1.4	9
5823	ILâ€36 Î³ and ILâ€36Ra Reciprocally Regulate Colon Inflammation and Tumorigenesis by Modulating the Cellâ€"Matrix Adhesion Network and Wnt Signaling. Advanced Science, 2022, , 2103035.	5.6	12
5824	Overexpression of aldolase, fructoseâ€bisphosphate C and its association with spheroid formation in colorectal cancer. Pathology International, 2022, 72, 176-186.	0.6	5
5825	Association between Altered Oncogenic Signaling Pathways and Overall Survival of Patients with Metastatic Colorectal Cancer. Diagnostics, 2021, 11, 2308.	1.3	4
5826	Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps. Cell, 2021, 184, 6262-6280.e26.	13.5	125
5827	Characterizing and exploiting the many roles of aberrant H2B monoubiquitination in cancer pathogenesis. Seminars in Cancer Biology, 2022, 86, 782-798.	4.3	8
5828	Cancer gene mutation frequencies for the U.S. population. Nature Communications, 2021, 12, 5961.	5.8	78
5829	Spatial genomics enables multi-modal study of clonal heterogeneity in tissues. Nature, 2022, 601, 85-91.	13.7	117
5830	Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis. Clinical Cancer Research, 2022, 28, 928-938.	3.2	29
5831	Deciphering functional tumor states at singleâ€cell resolution. EMBO Journal, 2022, 41, e109221.	3.5	23
5835	Exploration of Combinational Therapeutic Strategies for HCC Based on TCGA HCC Database. Oncologie, 2022, 24, 101-111.	0.2	5

#	Article	IF	Citations
5836	Development of RNA-Based Medicine for Colorectal Cancer: Current Scenario. , 2022, , 339-360.		1
5837	MDICC: novel method for multi-omics data integration and cancer subtype identification. Briefings in Bioinformatics, 2022, 23, .	3.2	15
5838	Master Transcription Regulators and Transcription Factors Regulate Immune-Associated Differences Between Patients of African and European Ancestry With Colorectal Cancer. , 2022, 1, 328-341.		2
5839	A Î²-Catenin-TCF-Sensitive Locus Control Region Mediates GUCY2C Ligand Loss in Colorectal Cancer. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 1276-1296.	2.3	6
5841	Pathophysiology roles and translational opportunities of miRNAs in colorectal cancer. , 2022, , 203-244.		1
5842	REIA: A database for cancer A-to-I RNA editing with interactive analysis. International Journal of Biological Sciences, 2022, 18, 2472-2483.	2.6	7
5843	Molecular Classifications of Gastrointestinal Tract Tumors. , 2022, , 943-977.		0
5844	Mechanisms of lymphatic spread in colon cancer: insights from molecular and genetic studies. , 2022, , 43-55.		0
5845	Predicting response to neoadjuvant chemoradiotherapy in rectal cancer: from biomarkers to tumor models. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210779.	1.4	21
5846	Mapping Proteome Changes in Microsatellite Stable, Recurrent Colon Cancer Reveals a Significant Immune System Signature. Cancer Genomics and Proteomics, 2022, 19, 130-144.	1.0	0
5847	Chirurgische Onkologie. , 2022, , 369-381.		0
5848	Target therapy in cancer treatment. , 2022, , .		0
5849	miRNome Profiling and Functional Analysis Reveal Involvement of hsa-miR-1246 in Colon Adenoma-Carcinoma Transition by Targeting AXIN2 and CFTR. International Journal of Molecular Sciences, 2022, 23, 2107.	1.8	7
5850	Tumor RNA transfected DCs derived from iPS cells elicit cytotoxicity against cancer cells induced from colorectal cancer patients in vitro. Scientific Reports, 2022, 12, 3295.	1.6	7
5851	CCT5 induces epithelial-mesenchymal transition to promote gastric cancer lymph node metastasis by activating the Wnt/Î²-catenin signalling pathway. British Journal of Cancer, 2022, 126, 1684-1694.	2.9	27
5852	Lynch-like Syndrome: Potential Mechanisms and Management. Cancers, 2022, 14, 1115.	1.7	8
5853	Early Breast Cancer Evolution by Autosomal Broad Copy Number Alterations. International Journal of Genomics, 2022, 2022, 1-17.	0.8	1
5854	Prognostic value of the combination of primary tumor location and RAS mutational status on patients with colorectal liver metastasis undergoing hepatectomy. Journal of Surgical Oncology, 2022, 125, 1002-1012.	0.8	4

#	Article	IF	Citations
5855	Molecular Patterns Based on Immunogenomic Signatures Stratify the Prognosis of Colon Cancer. Frontiers in Bioengineering and Biotechnology, 2022, 10, 820092.	2.0	3
5856	Single-cell transcriptomic profiling unravels the adenoma-initiation role of protein tyrosine kinases during colorectal tumorigenesis. Signal Transduction and Targeted Therapy, 2022, 7, 60.	7.1	31
5857	Predicting Mutational Status of Driver and Suppressor Genes Directly from Histopathology With Deep Learning: A Systematic Study Across 23 Solid Tumor Types. Frontiers in Genetics, 2021, 12, 806386.	1.1	14
5858	Global and context-specific transcriptional consequences of oncogenic Fbw7 mutations. ELife, 2022, 11, .	2.8	6
5859	First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced <i>KRAS</i>^{<i>G12C</i>} Solid Tumors (KRYSTAL-1). Journal of Clinical Oncology, 2022, 40, 2530-2538.	0.8	130
5860	Global analysis of RNA-binding proteins identifies a positive feedback loop between LARP1 and MYC that promotes tumorigenesis. Cellular and Molecular Life Sciences, 2022, 79, 147.	2.4	4
5861	Delineating the intra-patient heterogeneity of molecular alterations in treatment-naÃ¯ve colorectal cancer with peritoneal carcinomatosis. Modern Pathology, 2022, , .	2.9	4
5862	The Bright and the Dark Side of TGF-Î² Signaling in Hepatocellular Carcinoma: Mechanisms, Dysregulation, and Therapeutic Implications. Cancers, 2022, 14, 940.	1.7	16
5863	Cell-type heterogeneity: Why we should adjust for it in epigenome and biomarker studies. Clinical Epigenetics, 2022, 14, 31.	1.8	18
5864	Stage-differentiated ensemble modeling of DNA methylation landscapes uncovers salient biomarkers and prognostic signatures in colorectal cancer progression. PLoS ONE, 2022, 17, e0249151.	1.1	9
5866	Bacterial Involvement in Progression and Metastasis of Colorectal Neoplasia. Cancers, 2022, 14, 1019.	1.7	15
5867	Frequency and Clinicopathological Characteristics of Patients With KRAS/BRAF Double-Mutant Colorectal Cancer: An In Silico Study. Pathology and Oncology Research, 2022, 28, 1610206.	0.9	3
5868	Tumor stromal nicotinamide N-methyltransferase overexpression as a prognostic biomarker for poor clinical outcome in early-stage colorectal cancer. Scientific Reports, 2022, 12, 2767.	1.6	10
5869	Based on Molecular Subtypes, Immune Characteristics and Genomic Variation to Constructing and Verifying Multi-Gene Prognostic Characteristics of Colorectal Cancer. Frontiers in Cell and Developmental Biology, 2022, 10, 828415.	1.8	1
5870	Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential. British Journal of Cancer, 2022, , .	2.9	2
5871	A retrospective analysis using deep-learning models for prediction of survival outcome and benefit of adjuvant chemotherapy in stage II/III colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1955-1963.	1.2	8
5872	Development of a miRNAâ€based classifier for detection of colorectal cancer molecular subtypes. Molecular Oncology, 2022, 16, 2693-2709.	2.1	6
5873	Ras Pathway Activation and MEKi Resistance Scores Predict the Efficiency of MEKi and SRCi Combination to Induce Apoptosis in Colorectal Cancer. Cancers, 2022, 14, 1451.	1.7	3

#	Article	IF	Citations
5874	A text-based computational framework for patient -specific modeling for classification of cancers. IScience, 2022, 25, 103944.	1.9	7
5875	Genomeâ€wide analysis of <scp>mRNA</scp> and <scp>microRNA</scp> expression in colorectal cancer and adjacent normal mucosa. Journal of Pathology: Clinical Research, 2022, , .	1.3	0
5876	Vitamin D and Cancer: An Historical Overview of the Epidemiology and Mechanisms. Nutrients, 2022, 14, 1448.	1.7	85
5877	Natural History of Human Epidermal Growth Factor Receptor 2â€"Amplified and Human Epidermal Growth Factor Receptor 2 Wild-Type Refractory Metastatic Colorectal Cancer in US Clinical Practice. JCO Clinical Cancer Informatics, 2022, 6, e2100133.	1.0	0
5878	Genetic Alterations and Microenvironment that Drive Malignant Progression of Colorectal Cancer: Lessons from Mouse and Organoid Models. Journal of Cancer Prevention, 2022, 27, 1-6.	0.8	2
5879	Exploration of predictive biomarkers for postoperative recurrence of stage <scp>II</scp> / <scp>III</scp> colorectal cancer using genomic sequencing. Cancer Medicine, 2022, , .	1.3	2
5880	Systemic therapy for gastric cancer: Perioperative strategies and beyond. Journal of Surgical Oncology, 2022, 125, 1151-1160.	0.8	10
5881	Identification of CT Imaging Phenotypes of Colorectal Liver Metastases from Radiomics Signaturesâ€"Towards Assessment of Interlesional Tumor Heterogeneity. Cancers, 2022, 14, 1646.	1.7	13
5882	The Wnt Pathway: From Signaling Mechanisms to Synthetic Modulators. Annual Review of Biochemistry, 2022, 91, 571-598.	5.0	138
5883	Multigene Panel Sequencing Reveals Cancer-Specific and Common Somatic Mutations in Colorectal Cancer Patients: An Egyptian Experience. Current Issues in Molecular Biology, 2022, 44, 1332-1352.	1.0	4
5884	Colorectal cancer carcinogenesis: From bench to bedside. World Journal of Gastrointestinal Oncology, 2022, 14, 654-663.	0.8	19
5885	PUMILIO proteins promote colorectal cancer growth via suppressing p21. Nature Communications, 2022, 13, 1627.	5.8	14
5886	Disruption of the crypt niche promotes outgrowth of mutated colorectal tumor stem cells. JCI Insight, 2022, 7, .	2.3	4
5887	Interactive Analysis, Exploration, and Visualization of RNA-Seq Data with SeqCVIBE. Methods and Protocols, 2022, 5, 27.	0.9	1
5889	Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer. JAMA Oncology, 2022, 8, 760.	3.4	35
5890	Mechanistic Clues Provided by Concurrent Changes in the Expression of Genes Encoding the M1 Muscarinic Receptor, Î²-Catenin Signaling Proteins, and Downstream Targets in Adenocarcinomas of the Colon. Frontiers in Physiology, 2022, 13, 857563.	1.3	3
5891	Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer. Cancers, 2022, 14, 1388.	1.7	22
5892	Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies. Cancers, 2022, 14, 1732.	1.7	185

#	Article	IF	Citations
5893	Small-Molecule Inhibitors of Tankyrases as Prospective Therapeutics for Cancer. Journal of Medicinal Chemistry, 2022, 65, 5244-5273.	2.9	16
5894	Four-Year Disease-Free Remission in a Patient With POLE Mutationâ€"Associated Colorectal Cancer Treated Using Antiâ€"PD-1 Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 218-223.	2.3	4
5896	ExhauFS: exhaustive search-based feature selection for classification and survival regression. PeerJ, 2022, 10, e13200.	0.9	7
5897	Translational advances in pancreatic ductal adenocarcinoma therapy. Nature Cancer, 2022, 3, 272-286.	5.7	90
5898	Aberrant SKP1 Expression: Diverse Mechanisms Impacting Genome and Chromosome Stability. Frontiers in Cell and Developmental Biology, 2022, 10, 859582.	1.8	7
5899	Smad4 and p53 synergize in suppressing autochthonous intestinal cancer. Cancer Medicine, 2022, , .	1.3	9
5900	Cribriform type adenocarcinoma of the colorectum: comprehensive molecular analyses of a distinctive histologic subtype of colorectal cancer. Carcinogenesis, 2022, , .	1.3	2
5901	Early age of onset and broad cancer spectrum persist in MSH6- and PMS2-associated Lynch syndrome. Genetics in Medicine, 2022, 24, 1187-1195.	1.1	7
5902	Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies. International Journal of Molecular Sciences, 2022, 23, 3706.	1.8	5
5903	Phase <scp>II</scp> study of durvalumab monotherapy in patients with previously treated microsatellite instabilityâ€high/mismatch repairâ€deficient or <scp><i>POLE</i></scp>â€mutated metastatic or unresectable colorectal cancer. International Journal of Cancer, 2022, 150, 2038-2045.	2.3	19
5904	Loss of function of BRCA1 promotes EMT in mammary tumors through activation of TGFÎ²R2 signaling pathway. Cell Death and Disease, 2022, 13, 195.	2.7	12
5905	Mismatch repair deficiency and clinical implications in prostate cancer. Prostate, 2022, 82, .	1.2	9
5906	Quantifying the contribution of transcription factor activity, mutations and microRNAs to CD274 expression in cancer patients. Scientific Reports, 2022, 12, 4374.	1.6	6
5907	Polymerase Epsilon-Associated Ultramutagenesis in Cancer. Cancers, 2022, 14, 1467.	1.7	9
5908	Development of Low-Molecular-Weight Compounds Targeting the Cancer-Associated KLF5 Transcription Factor. ACS Medicinal Chemistry Letters, 2022, 13, 687-694.	1.3	3
5909	Landscape of <i>KRAS</i>^{G12C}, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in <i>KRAS</i>-Mutated Cancers. JCO Precision Oncology, 2022, 6, e2100245.	1.5	31
5910	Review article: Lynch Syndromeâ€"a mechanistic and clinical management update. Alimentary Pharmacology and Therapeutics, 2022, 55, 960-977.	1.9	8
5911	Molecular Biomarker of Drug Resistance Developed From Patient-Derived Organoids Predicts Survival of Colorectal Cancer Patients. Frontiers in Oncology, 2022, 12, 855674.	1.3	1

#	Article	IF	Citations
5912	TBX20 inhibits colorectal cancer tumorigenesis by impairing NHEJâ€mediated DNA repair. Cancer Science, 2022, 113, 2008-2021.	1.7	6
5913	Exome and Tissue-Associated Microbiota as Predictive Markers of Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer. Frontiers in Oncology, 2022, 12, 809441.	1.3	2
5914	DNA Methylation Malleability and Dysregulation in Cancer Progression: Understanding the Role of PARP1. Biomolecules, 2022, 12, 417.	1.8	6
5915	Anatomic position determines oncogenic specificity in melanoma. Nature, 2022, 604, 354-361.	13.7	44
5916	The impact of KRAS mutation, microsatellite instability, and tumor laterality on the prognosis of nonmetastatic colon cancer. Surgery, 2022, 171, 657-665.	1.0	6
5917	Microbiota-dependent activation of the myeloid calcineurin-NFAT pathway inhibits B7H3- and B7H4-dependent anti-tumor immunity in colorectal cancer. Immunity, 2022, 55, 701-717.e7.	6.6	16
5918	Interactions between miRNAs and Double-Strand Breaks DNA Repair Genes, Pursuing a Fine-Tuning of Repair. International Journal of Molecular Sciences, 2022, 23, 3231.	1.8	7
5919	Multi-Region Genomic Landscape Analysis for the Preoperative Prediction of Lymph Node Metastasis in Esophageal Carcinoma. Frontiers in Genetics, 2022, 13, 830601.	1.1	1
5920	Pyrimethamine inhibits cell growth by inducing cell senescence and boosting CD8+ T-cell mediated cytotoxicity in colorectal cancer. Molecular Biology Reports, 2022, 49, 4281-4292.	1.0	7
5921	An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy. BMC Cancer, 2022, 22, 256.	1.1	4
5923	Signaling Pathways Involved in 5-FU Drug Resistance in Cancer. Cancer Investigation, 2022, 40, 516-543.	0.6	3
5925	Precision Oncology in Colorectal Cancers- Therapeutics and Beyond (CME article). International Journal of Cancer Care and Delivery, 2022, 2, .	0.0	0
5926	Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers. Nature Communications, 2022, 13, 1618.	5.8	23
5927	Molecular Landscape of Small Bowel Adenocarcinoma. Cancers, 2022, 14, 1287.	1.7	7
5928	BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications. Critical Reviews in Oncology/Hematology, 2022, 172, 103647.	2.0	10
5929	Comprehensive cancer-oriented biobanking resource of human samples for studies of post-zygotic genetic variation involved in cancer predisposition. PLoS ONE, 2022, 17, e0266111.	1.1	4
5930	3D and organoid culture in research: physiology, hereditary genetic diseases and cancer. Cell and Bioscience, 2022, 12, 39.	2.1	23
5931	Molecular Network of Colorectal Cancer and Current Therapeutic Options. Frontiers in Oncology, 2022, 12, 852927.	1.3	20

#	Article	IF	Citations
5932	Multiplexed single-cell analysis reveals prognostic and nonprognostic T cell types in human colorectal cancer. JCI Insight, 2022, 7, .	2.3	24
5933	KRAS Mutants Upregulate Integrin Î²4 to Promote Invasion and Metastasis in Colorectal Cancer. Molecular Cancer Research, 2022, 20, 1305-1319.	1.5	3
5934	<i>N</i>-Carbamoyl Alanine-Mediated Selective Targeting for CHEK2-Null Colorectal Cancer. ACS Omega, 2022, 7, 13095-13101.	1.6	3
5935	HER2 targeted therapy in colorectal cancer: New horizons. Cancer Treatment Reviews, 2022, 105, 102363.	3.4	12
5936	m6A binding protein YTHDF2 in cancer. Experimental Hematology and Oncology, 2022, 11, 21.	2.0	29
5937	Artificial intelligence for detection of microsatellite instability in colorectal cancerâ€"a multicentric analysis of a pre-screening tool for clinical application. ESMO Open, 2022, 7, 100400.	2.0	47
5938	Histopathological and genetic features of mismatch repairâ€deficient highâ€grade prostate cancer. Histopathology, 2022, 80, 1050-1060.	1.6	6
5939	Cause, Epidemiology, and Histology of Polyps and Pathways to Colorectal Cancer. Gastrointestinal Endoscopy Clinics of North America, 2022, 32, 177-194.	0.6	29
5940	The Prognostic Significance of RIMKLB and Related Immune Infiltrates in Colorectal Cancers. Frontiers in Genetics, 2022, 13, 818994.	1.1	1
5942	Precision medicineâ€based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience. Molecular Oncology, 2022, 16, 2575-2584.	2.1	8
5943	N6-Methyladenosine Reader YTHDF1 Promotes ARHGEF2 Translation and RhoA Signaling in Colorectal Cancer. Gastroenterology, 2022, 162, 1183-1196.	0.6	89
5944	Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape. Journal of Pathology, 2022, 257, 340-351.	2.1	11
5945	The Genomics of Colorectal Cancer in Populations with African and European Ancestry. Cancer Discovery, 2022, 12, 1282-1293.	7.7	28
5946	A suspension technique for efficient large-scale cancer organoid culturing and perturbation screens. Scientific Reports, 2022, 12, 5571.	1.6	11
5947	Bayesian networks elucidate complex genomic landscapes in cancer. Communications Biology, 2022, 5, 306.	2.0	5
5948	Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update. Critical Reviews in Oncology/Hematology, 2022, 173, 103663.	2.0	27
5949	Transcriptome analysis of colorectal cancer liver metastasis: The importance of long non-coding RNAs and fusion transcripts in the disease pathogenesis. Molecular and Cellular Probes, 2022, 63, 101816.	0.9	1
5950	Involvement of TMEM16A/ANO1 upregulation in the oncogenesis of colorectal cancer. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2022, 1868, 166370.	1.8	4

#	Article	IF	Citations
5951	Targeting ligand-dependent wnt pathway dysregulation in gastrointestinal cancers through porcupine inhibition. , 2022, 238, 108179.		11
5952	The application and research advances of organoids in clinical medicine. Scientia Sinica Vitae, 2023, 53, 221-237.	0.1	1
5953	Tumor irradiation may facilitate the detection of tumor-specific mutations in plasma. World Journal of Clinical Oncology, 2021, 12, 1215-1226.	0.9	1
5954	The role of AKR1 family in tamoxifen resistant invasive lobular breast cancer based on data mining. BMC Cancer, 2021, 21, 1321.	1.1	5
5955	Gut Dysbiosis and Intestinal Barrier Dysfunction: Potential Explanation for Early-Onset Colorectal Cancer. Frontiers in Cellular and Infection Microbiology, 2021, 11, 744606.	1.8	28
5956	Analysis of dynamic molecular networks: the progression from colorectal adenoma to cancer. Journal of Gastrointestinal Oncology, 2021, 12, 2823-2837.	0.6	3
5957	Development and Validation of a Targeted â€˜Liquidâ€™ NGS Panel for Treatment Customization in Patients with Metastatic Colorectal Cancer. Diagnostics, 2021, 11, 2375.	1.3	3
5958	The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, nonâ€coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles. Journal of Cellular Physiology, 2022, 237, 1720-1752.	2.0	27
5959	<i>ENTREP/FAM189A2</i> encodes a new ITCH ubiquitin ligase activator that is downregulated in breast cancer. EMBO Reports, 2022, 23, e51182.	2.0	8
5960	ECMâ€"Receptor Regulatory Network and Its Prognostic Role in Colorectal Cancer. Frontiers in Genetics, 2021, 12, 782699.	1.1	29
5961	Promoter methylation-mediated repression of UNC5 receptors and the associated clinical significance in human colorectal cancer. Clinical Epigenetics, 2021, 13, 225.	1.8	3
5962	Molecular pathways in post-colonoscopy versus detected colorectal cancers: results from a nested caseâ€"control study. British Journal of Cancer, 2022, 126, 865-873.	2.9	6
5963	Deep learning for the detection of microsatellite instability from histology images in colorectal cancer: A systematic literature review. ImmunoInformatics, 2021, 3-4, 100008.	1.2	21
5964	Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response. Nature Communications, 2021, 12, 7297.	5.8	25
5965	Genomic evolution during locoregional recurrence in colorectal cancer determined by whole-exome sequencing. Journal of Bio-X Research, 2021, Publish Ahead of Print, .	0.3	0
5966	Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer. Cancers, 2021, 13, 6311.	1.7	30
5967	Multifocal Organoid Capturing of Colon Cancer Reveals Pervasive Intratumoral Heterogenous Drug Responses. Advanced Science, 2022, 9, e2103360.	5.6	14
5968	Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer. Journal of Advanced Research, 2022, 40, 109-124.	4.4	10

#	Article	IF	Citations
5969	Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach. Cell Reports, 2021, 37, 110096.	2.9	7
5970	A Review of Emerging Biomarkers for Immune Checkpoint Inhibitors in Tumors of the Gastrointestinal Tract. Medical Science Monitor, 2022, 28, e935348.	0.5	2
5971	Conditional prediction of consecutive tumor evolution using cancer progression models: What genotype comes next?. PLoS Computational Biology, 2021, 17, e1009055.	1.5	11
5972	STAT3-YAP/TAZ signaling in endothelial cells promotes tumor angiogenesis. Science Signaling, 2021, 14, eabj8393.	1.6	50
5973	Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B. PLoS ONE, 2021, 16, e0262198.	1.1	4
5974	Mucinous adenocarcinoma: A unique clinicopathological subtype in colorectal cancer. World Journal of Gastrointestinal Surgery, 2021, 13, 1567-1583.	0.8	17
5975	Identification of Subtypes and a Prognostic Gene Signature in Colon Cancer Using Cell Differentiation Trajectories. Frontiers in Cell and Developmental Biology, 2021, 9, 705537.	1.8	7
5978	Defects in MMR Genes as a Seminal Example of Personalized Medicine: From Diagnosis to Therapy. Journal of Personalized Medicine, 2021, 11, 1333.	1.1	9
5979	Intra-Tumor Heterogeneity of Colorectal Cancer Necessitates the Multi-Regional Sequencing for Comprehensive Mutational Profiling. Cancer Management and Research, 2021, Volume 13, 9209-9223.	0.9	4
5980	NFâ€ºB signaling in inflammation and cancer. MedComm, 2021, 2, 618-653.	3.1	107
5981	SMAD4 mutations do not preclude epithelialâ€"mesenchymal transition in colorectal cancer. Oncogene, 2022, 41, 824-837.	2.6	12
5982	Artificial intelligence, molecular subtyping, biomarkers, and precision oncology. Emerging Topics in Life Sciences, 2021, 5, 747-756.	1.1	1
5983	A Case of Microsatellite Instabilityâ€"High Colon Cancer in a Young Woman With Familial Adenomatous Polyposis. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1377-1381.	2.3	3
5984	PRUNE2 inhibits progression of colorectal cancer<i> inÂvitro</i> and <i>inÂvivo</i>. Experimental and Therapeutic Medicine, 2021, 23, 169.	0.8	2
5985	SH2D4A downregulation due to loss of chromosome 8p is associated with poor prognosis and low T cell infiltration in colorectal cancer. British Journal of Cancer, 2022, 126, 917-926.	2.9	3
5987	Bufalin Suppresses Colorectal Cancer Cells by the Blockade of Canonical Wnt Signaling Pathway. , 2022, , .		0
5988	Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer. BMC Cancer, 2022, 22, 394.	1.1	7
5989	Dissection of Immune Profiles in Microsatellite Stable and Low Microsatellite Instability Colon Adenocarcinoma by Multiomics Data Analysis. Journal of Oncology, 2022, 2022, 1-20.	0.6	0

#	Article	IF	Citations
5990	Development of Tissue-Agnostic Treatments for Patients with Cancer. Annual Review of Cancer Biology, 2022, 6, 147-165.	2.3	8
5991	Integrative analysis of mutated genes and mutational processes reveals novel mutational biomarkers in colorectal cancer. BMC Bioinformatics, 2022, 23, 138.	1.2	9
5992	Panel Informativity Optimizer. Journal of Molecular Diagnostics, 2022, 24, 697-709.	1.2	2
5993	The number of cycles of adjuvant chemotherapy in stage III and high-risk stage II rectal cancer: a nomogram and recursive partitioning analysis. World Journal of Surgical Oncology, 2022, 20, 119.	0.8	0
5994	Cytospin-A Regulates Colorectal Cancer Cell Division and Migration by Modulating Stability of Microtubules and Actin Filaments. Cancers, 2022, 14, 1977.	1.7	3
5995	Circle RNA circ_0007331 promotes colorectal carcinoma by targeting miR-205-5p/high-mobility group A2 axis. Bioengineered, 2022, 13, 9312-9321.	1.4	3
5997	Comprehensive Molecular Profiling of Colorectal Cancer With Situs Inversus Totalis by Next-Generation Sequencing. Frontiers in Oncology, 2022, 12, 813253.	1.3	1
5998	Gene-Mutation-Based Algorithm for Prediction of Treatment Response in Colorectal Cancer Patients. Cancers, 2022, 14, 2045.	1.7	4
5999	Integrated Analysis of Necroptosis-Related Genes for Prognosis, Immune Microenvironment Infiltration, and Drug Sensitivity in Colon Cancer. Frontiers in Medicine, 2022, 9, 845271.	1.2	12
6000	Serrated Colorectal Lesions: An Up-to-Date Review from Histological Pattern to Molecular Pathogenesis. International Journal of Molecular Sciences, 2022, 23, 4461.	1.8	15
6003	Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer. International Journal of Molecular Sciences, 2022, 23, 4441.	1.8	30
6004	Efficacy and safety of regorafenib in Japanese patients with advanced gastrointestinal stromal tumors. International Journal of Clinical Oncology, 2022, 27, 1164-1172.	1.0	5
6005	Co-expression patterns explain how a basic transcriptional role for MYC modulates <i>Wnt</i> and MAPK pathways in colon and lung adenocarcinomas. Cell Cycle, 2022, 21, 1619-1638.	1.3	1
6006	Roles of ARID1A variations in colorectal cancer: a collaborative review. Molecular Medicine, 2022, 28, 42.	1.9	5
6007	Tumor microenvironment-aware, single-transcriptome prediction of microsatellite instability in colorectal cancer using meta-analysis. Scientific Reports, 2022, 12, 6283.	1.6	5
6008	Molecular mechanisms of tumour budding and its association with microenvironment in colorectal cancer. Clinical Science, 2022, 136, 521-535.	1.8	4
6009	Discovery of benzo[d]oxazol-2(3H)-one derivatives as a new class of TNIK inhibitors for the treatment of colorectal cancer. Bioorganic and Medicinal Chemistry Letters, 2022, 67, 128745.	1.0	3
6102	CRISPR-Based Screening in Three-Dimensional Organoid Cultures to Identify TGF-Î² Pathway Regulators. Methods in Molecular Biology, 2022, 2488, 99-111.	0.4	2

#	Article	IF	Citations
6103	Comprehensive genetic characterization of rectal cancer in a large cohort of Japanese patients: differences according to tumor location. Journal of Gastroenterology, 2022, 57, 476-485.	2.3	2
6104	A stop-gain mutation in GXYLT1 promotes metastasis of colorectal cancer via the MAPK pathway. Cell Death and Disease, 2022, 13, 395.	2.7	5
6105	Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR Ã— LGR5 bispecific antibody with efficacy in epithelial tumors. Nature Cancer, 2022, 3, 418-436.	5.7	46
6106	Bispecific antibodies seek out colon cancer stem cells. Nature Cancer, 2022, 3, 379-380.	5.7	3
6109	Multi-OMICs data analysis identifies molecular features correlating with tumor immunity in colon cancer. Cancer Biomarkers, 2022, 33, 261-271.	0.8	3
6110	Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 116-119.	2.3	4
6111	Personalizing first-line treatment in advanced colorectal cancer: Present status and future perspectives.. Journal of Clinical and Translational Research, 2021, 7, 771-785.	0.3	1
6112	SMAD4 mutations identified in Iranian patients with colorectal cancer and polyp.. Gastroenterology and Hepatology From Bed To Bench, 2021, 14, S32-S40.	0.6	0
6113	Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS. Cancer Treatment and Research Communications, 2022, 32, 100569.	0.7	1
6114	RIP140 regulates POLK gene expression and the response to alkylating drugs in colon cancer cells. Cancer Drug Resistance (Alhambra, Calif), 2022, 5, 401-415.	0.9	2
6115	Deciphering clonal dynamics and metastatic routines in a rare patient of synchronous triple-primary tumors and multiple metastases with MPTevol. Briefings in Bioinformatics, 2022, 23, .	3.2	2
6116	Association of microsatellite instability (MSI) status with the 5-year outcome and genetic ancestry in a large Brazilian cohort of colorectal cancer. European Journal of Human Genetics, 2022, 30, 824-832.	1.4	8
6118	Genetic Characteristics of Resectable Colorectal Cancer with Pulmonary Metastasis. Canadian Journal of Gastroenterology and Hepatology, 2022, 2022, 1-8.	0.8	2
6119	Human Epidermal Growth Factor Receptor 2 Overexpression and Amplification in Patients With Colorectal Cancer: A Large-Scale Retrospective Study in Chinese Population. Frontiers in Oncology, 2022, 12, 842787.	1.3	3
6120	The Patient-Derived Cancer Organoids: Promises and Challenges as Platforms for Cancer Discovery. Cancers, 2022, 14, 2144.	1.7	5
6121	Colorectal Cancer Develops Inherent Radiosensitivity That Can Be Predicted Using Patient-Derived Organoids. Cancer Research, 2022, 82, 2298-2312.	0.4	14
6122	Patient-Derived Organoids of Colorectal Cancer: A Useful Tool for Personalized Medicine. Journal of Personalized Medicine, 2022, 12, 695.	1.1	3
6124	Predictive value of chromosome 18q11.2â€q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase <scp>III</scp>â€trial <scp>AGITGâ€MAX</scp>. International Journal of Cancer, 2022, 151, 1166-1174.	2.3	1

#	Article	IF	Citations
6125	RNF43 R117fs mutant positively regulates Wnt/Î²-catenin signaling by failing to internalize FZD expressed on the cell surface. Scientific Reports, 2022, 12, 7013.	1.6	4
6126	Comprehensive profiling of 1015 patientsâ€™ exomes reveals genomic-clinical associations in colorectal cancer. Nature Communications, 2022, 13, 2342.	5.8	21
6127	Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 279-298.	1.8	11
6128	Systematic molecular analysis of the human secretome and membrane proteome in gastrointestinal adenocarcinomas. Journal of Cellular and Molecular Medicine, 2022, 26, 3329-3342.	1.6	4
6129	Berberine as a Potential Agent for the Treatment of Colorectal Cancer. Frontiers in Medicine, 2022, 9, 886996.	1.2	12
6130	Cancer-Associated Fibroblasts and Squamous Epithelial Cells Constitute a Unique Microenvironment in a Mouse Model of Inflammation-Induced Colon Cancer. Frontiers in Oncology, 2022, 12, .	1.3	6
6131	Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance. Npj Breast Cancer, 2022, 8, 60.	2.3	11
6132	Assimilating Epigenetics and Transcriptomics for the Identification of Prognostic Novel Biomarkers and Imminent Targets in Colorectal Carcinoma with Therapeutic Potential. Current Molecular Medicine, 2023, 23, 784-798.	0.6	2
6133	Refining colorectal cancer classification and clinical stratification through a single-cell atlas. Genome Biology, 2022, 23, 113.	3.8	48
6134	Oligometastatic Rectal Adenocarcinoma Treated With Short-Course Radiation Therapy and Chemotherapy With Nonoperative Intent of the Primary for Locoregional Complete Responders. Practical Radiation Oncology, 2022, 12, e406-e414.	1.1	1
6135	Use of Cabozantinib to Treat MET-amplified Pediatric Colorectal Cancer. Journal of Pediatric Hematology/Oncology, 2022, Publish Ahead of Print, .	0.3	0
6136	Chaotic driven gorilla troops optimizer based NMF approach for integrative analysis of multiple source data. International Journal of Information Technology (Singapore), 0, , .	1.8	0
6137	Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy. Targeted Oncology, 2022, , 1.	1.7	1
6138	Functional genetic screen identifies ITPR3/calcium/RELB axis as a driver of colorectal cancer metastatic liver colonization. Developmental Cell, 2022, 57, 1146-1159.e7.	3.1	6
6139	An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy. Biology Direct, 2022, 17, 10.	1.9	0
6140	Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB. International Journal of Molecular Sciences, 2022, 23, 5097.	1.8	3
6141	Multi-Omic Data Improve Prediction of Personalized Tumor Suppressors and Oncogenes. Frontiers in Genetics, 2022, 13, .	1.1	1
6142	Benchmarking weakly-supervised deep learning pipelines for whole slide classification in computational pathology. Medical Image Analysis, 2022, 79, 102474.	7.0	64

#	Article	IF	Citations
6143	Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. Cancer Discovery, 2022, 12, 1656-1675.	7.7	48
6144	Clinicopathologic and genomic characteristics of mucinous gastric adenocarcinoma. Gastric Cancer, 2022, 25, 697-711.	2.7	7
6145	Inflammatory Bowel Disease Therapy: Beyond the Immunome. Frontiers in Immunology, 2022, 13, .	2.2	3
6146	Genetic Profiling of Colorectal Carcinomas of Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2022, , .	0.9	2
6148	Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells. OncoImmunology, 2022, 11, 2069214.	2.1	4
6149	Discovery of Small-Molecule Inhibitors of the PTK7/Î²-Catenin Interaction Targeting the Wnt Signaling Pathway in Colorectal Cancer. ACS Chemical Biology, 2022, 17, 1061-1072.	1.6	1
6150	Resistance to <scp>DNA</scp> repair inhibitors in cancer. Molecular Oncology, 2022, 16, 3811-3827.	2.1	28
6151	HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 219-232.	1.8	21
6152	Breaking the Immune Complexity of the Tumor Microenvironment Using Single-Cell Technologies. Frontiers in Genetics, 2022, 13, .	1.1	3
6153	Regulation of protein complex partners as a compensatory mechanism in aneuploid tumors. ELife, 2022, 11, .	2.8	7
6154	Mutational landscape of normal epithelial cells in Lynch Syndrome patients. Nature Communications, 2022, 13, 2710.	5.8	19
6155	Identifying tumor antigens and immunoâ€subtyping in colon adenocarcinoma to facilitate the development of <scp>mRNA</scp> vaccine. Cancer Medicine, 2022, , .	1.3	3
6156	Cell line models for drug discovery in PIK3CA-mutated colorectal cancers. Medical Oncology, 2022, 39, 89.	1.2	3
6157	Integration of human inspection and artificial intelligenceâ€based morphological typing of patientâ€derived organoids reveals interpatient heterogeneity of colorectal cancer. Cancer Science, 2022, 113, 2693-2703.	1.7	6
6158	Clustered 8-Oxo-Guanine Mutations and Oncogenic Gene Fusions in Microsatellite-Unstable Colorectal Cancer. JCO Precision Oncology, 2022, 6, e2100477.	1.5	2
6159	Anti-colon cancer activities of green-synthesized <i>Moringa oleifera</i>â€“AgNPs against human colon cancer cells. Green Processing and Synthesis, 2022, 11, 545-554.	1.3	11
6161	AP4 suppresses DNA damage, chromosomal instability and senescence via inducing MDC1/Mediator of DNAÂdamage Checkpoint 1 and repressing MIR22HG/miR-22-3p. Molecular Cancer, 2022, 21, .	7.9	17
6162	Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma. Frontiers in Oncology, 2022, 12, .	1.3	3

#	Article	IF	Citations
6163	Human Epidermal Growth Factor Receptor 2â€"Targeting Approaches for Colorectal Cancer: Clinical Implications of Novel Treatments and Future Therapeutic Avenues. JCO Oncology Practice, 2022, 18, 545-554.	1.4	8
6164	Gene-expression profiles of pretreatment biopsies predict complete response of rectal cancer patients to preoperative chemoradiotherapy. British Journal of Cancer, 2022, 127, 766-775.	2.9	6
6165	Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets. Oncogene, 2022, 41, 3455-3460.	2.6	19
6166	NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN). Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	1
6167	Use of Translational, Genetically Modified Porcine Models to Ultimately Improve Intestinal Disease Treatment. Frontiers in Veterinary Science, 2022, 9, .	0.9	0
6169	FBXW7 and Its Downstream NOTCH Pathway Could be Potential Indicators of Organ-Free Metastasis in Colorectal Cancer. Frontiers in Oncology, 2022, 11, .	1.3	9
6170	Diagnostic Value of Potential MicroRNAs in CRC: A Meta-Analysis. MicroRNA (Shariqah, United Arab) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.6	3
6171	Epithelial to mesenchymal transition influences fibroblast phenotype in colorectal cancer by altering miRâ€200 levels in extracellular vesicles. Journal of Extracellular Vesicles, 2022, 11, .	5.5	18
6172	Zinc finger protein 280C contributes to colorectal tumorigenesis by maintaining epigenetic repression at H3K27me3-marked loci. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	5
6173	Different types of reactions to E7386 among colorectal cancer patientâ€'derived organoids and corresponding CAFs. Oncology Letters, 2022, 24, .	0.8	0
6174	Ring Finger Protein 125 Is an Anti-Proliferative Tumor Suppressor in Hepatocellular Carcinoma. Cancers, 2022, 14, 2589.	1.7	5
6175	Loss of CHGA Protein as a Potential Biomarker for Colon Cancer Diagnosis: A Study on Biomarker Discovery by Machine Learning and Confirmation by Immunohistochemistry in Colorectal Cancer Tissue Microarrays. Cancers, 2022, 14, 2664.	1.7	5
6176	Engineered colorectal cancer tissue recapitulates key attributes of a patient-derived xenograft tumor line. Biofabrication, 2022, 14, 045001.	3.7	8
6177	High prevalence of unusual <i>KRAS</i>, <i>NRAS</i>, and <i>BRAF</i> mutations in <i>POLE</i><scp><i>â€</i></scp>hypermutated colorectal cancers. Molecular Oncology, 2022, 16, 3055-3065.	2.1	0
6178	Hormonal and Genetic Regulatory Events in Breast Cancer and Its Therapeutics: Importance of the Steroidogenic Acute Regulatory Protein. Biomedicines, 2022, 10, 1313.	1.4	9
6179	Identification and Characterization of Human Colorectal Cancer Cluster Predominantly Expressing EP3 Prostanoid Receptor Subtype. Biological and Pharmaceutical Bulletin, 2022, 45, 698-702.	0.6	1
6180	KIAA1363â€"A Multifunctional Enzyme in Xenobiotic Detoxification and Lipid Ester Hydrolysis. Metabolites, 2022, 12, 516.	1.3	2
6181	Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade. Journal of Clinical Oncology, 2022, 40, 2735-2750.	0.8	62

#	Article	IF	Citations
6182	Estimating tumor mutational burden from RNA-sequencing without a matched-normal sample. Nature Communications, 2022, 13, .	5.8	4
6183	Mutation of <scp> <i>KRAS</i> </scp> in colorectal adenocarcinoma in Greenland. Apmis, 0, , .	0.9	1
6186	Armamentarium in drug delivery for colorectal cancer. Critical Reviews in Therapeutic Drug Carrier Systems, 2022, , .	1.2	2
6187	Base excision repair accessory factors in senescence avoidance and resistance to treatments. Cancer Drug Resistance (Alhambra, Calif), 2022, 5, 703-20.	0.9	2
6188	Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211050.	1.4	8
6189	Requirement of CLIC4 Expression in Human Colorectal Cancer Cells for Sensitivity to Growth Inhibition by Fucoxanthinol. Cancer Genomics and Proteomics, 2022, 19, 428-444.	1.0	1
6190	Single-cell analyses define a continuum of cell state and composition changes in the malignant transformation of polyps to colorectal cancer. Nature Genetics, 2022, 54, 985-995.	9.4	77
6191	Tissue-Specific Downregulation of Fatty Acid Synthase Suppresses Intestinal Adenoma Formation via Coordinated Reprograming of Transcriptome and Metabolism in the Mouse Model of Apc-Driven Colorectal Cancer. International Journal of Molecular Sciences, 2022, 23, 6510.	1.8	9
6192	Molecular and clinicopathological analysis revealed an immuno-checkpoint inhibitor as a potential therapeutic target in a subset of high-grade myxofibrosarcoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 1-17.	1.4	3
6193	Application of histology-agnostic treatments in metastatic colorectal cancer. Digestive and Liver Disease, 2022, 54, 1291-1303.	0.4	5
6194	Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors. Frontiers in Oncology, 0, 12, .	1.3	22
6195	Intraoperative opioids are associated with decreased recurrence rates in colon adenocarcinoma: a retrospective observational cohort study. British Journal of Anaesthesia, 2022, 129, 172-181.	1.5	9
6196	Ferroptosis-Associated Molecular Features to Aid Patient Clinical Prognosis and Therapy Across Human Cancers. Frontiers in Immunology, 0, 13, .	2.2	0
6197	Somatic Mutations in Exon 7 of the TP53 Gene in Index Colorectal Lesions Are Associated with the Early Occurrence of Metachronous Adenoma. Cancers, 2022, 14, 2823.	1.7	0
6198	RNF43 G659fs is an oncogenic colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition. Nature Communications, 2022, 13, .	5.8	18
6199	Association between germline variants and somatic mutations in colorectal cancer. Scientific Reports, 2022, 12, .	1.6	1
6200	ARID1A loss derepresses a group of human endogenous retrovirus-H loci to modulate BRD4-dependent transcription. Nature Communications, 2022, 13, .	5.8	7
6201	Deep Sequencing of Early T Stage Colorectal Cancers Reveals Disruption of Homologous Recombination Repair in Microsatellite Stable Tumours with High Mutational Burdens. Cancers, 2022, 14, 2933.	1.7	3

#	Article	IF	Citations
6202	MCC Gene Silencing Is a CpG Island Methylator Phenotype-Associated Factor That Predisposes Colon Cancer Cells to Irinotecan and Olaparib. Cancers, 2022, 14, 2859.	1.7	1
6203	Target-Based Small Molecule Drug Discovery for Colorectal Cancer: A Review of Molecular Pathways and In Silico Studies. Biomolecules, 2022, 12, 878.	1.8	6
6204	Reciprocal regulation of Daxx and PIK3CA promotes colorectal cancer cell growth. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	5
6206	Drug Resistance in Colorectal Cancer: From Mechanism to Clinic. Cancers, 2022, 14, 2928.	1.7	34
6207	PBXIP1 â€" an indicator for poor outcome and metastatic spread in colorectal cancer. Pathology Research and Practice, 2022, , 153993.	1.0	0
6208	Effect of gut microbiota in the colorectal cancer and potential target therapy. Discover Oncology, 2022, 13, .	0.8	5
6209	Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer. British Journal of Cancer, 2022, 127, 1043-1050.	2.9	3
6211	Genes copy number variation in colorectal cancer patients as a marker of the disease clinical outcome and response to therapy. South Russian Journal of Cancer, 2022, 3, 52-64.	0.1	1
6212	Genome-wide analysis of mRNA expression identified the involvement of trefoil factor 1 in the development of sessile serrated lesions. Pathology Research and Practice, 2022, 236, 153987.	1.0	1
6213	Deep Neural Network for the Prediction of KRAS Genotype in Rectal Cancer. Journal of the American College of Surgeons, 2022, 235, 482-493.	0.2	1
6214	MUC1 expressing tumor growth was retarded after human mucin 1 (MUC1) plasmid DNA immunization. International Journal of Immunopathology and Pharmacology, 2022, 36, 039463202211123.	1.0	0
6215	Transcriptomic landscape of sodium butyrate-induced growth inhibition of human colorectal cancer organoids. Molecular Omics, 0, , .	1.4	2
6216	CaracterizaciÃ³n molecular de pacientes con cÃ¡ncer colorrectal. Biomedica, 2022, 42, 154-171.	0.3	1
6217	Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy. Nature Cancer, 2022, 3, 1052-1070.	5.7	36
6218	Somatic targeted mutation profiling of colorectal cancer precursor lesions. BMC Medical Genomics, 2022, 15, .	0.7	3
6219	Comprehensive Analysis of microRNA Expression During the Progression of Colorectal Tumors. Digestive Diseases and Sciences, 2023, 68, 813-823.	1.1	1
6220	A Transcription Factor Signature Can Identify the CMS4 Subtype and Stratify the Prognostic Risk of Colorectal Cancer. Frontiers in Oncology, 0, 12, .	1.3	3
6222	MicroRNA Methylome Signature and Their Functional Roles in Colorectal Cancer Diagnosis, Prognosis, and Chemoresistance. International Journal of Molecular Sciences, 2022, 23, 7281.	1.8	5

#	Article	IF	Citations
6223	Immunotherapy for Colorectal Cancer in the Era of Precision Medicine. , 0, , .		0
6224	Genomic and transcriptomic analysis of Korean colorectal cancer patients. Genes and Genomics, 2022, 44, 967-979.	0.5	2
6225	Evaluating utility and feasibility of mismatch repair testing of colorectal cancer patients in a low-middle-income country. Scientific Reports, 2022, 12, .	1.6	0
6226	Nuclear chromosome locations dictate segregation error frequencies. Nature, 2022, 607, 604-609.	13.7	39
6227	Salivary metabolomics with machine learning for colorectal cancer detection. Cancer Science, 2022, 113, 3234-3243.	1.7	11
6228	Cytokineâ€•and chemokineâ€induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy. Cancer Communications, 2022, 42, 689-715.	3.7	41
6229	Genome-Wide Analysis of microRNA and mRNA Expression in Colorectal Intramucosal Neoplasia and Colorectal Cancer With a Microsatellite-Stable Phenotype Based on Adenoma-Carcinoma Sequences. Frontiers in Oncology, 0, 12, .	1.3	3
6230	Prognostic Value of KRAS Mutations in Colorectal Cancer Patients. Cancers, 2022, 14, 3320.	1.7	18
6231	S-Adenosylmethionine Inhibits Colorectal Cancer Cell Migration through Mirna-Mediated Targeting of Notch Signaling Pathway. International Journal of Molecular Sciences, 2022, 23, 7673.	1.8	3
6232	Metalloprotease ADAM9 cleaves ephrin-B ligands and differentially regulates Wnt and mTOR signaling downstream of Akt kinase in colorectal cancer cells. Journal of Biological Chemistry, 2022, 298, 102225.	1.6	4
6234	Construction and Verification of a Fibroblast-Related Prognostic Signature Model for Colon Cancer. Frontiers in Genetics, 0, 13, .	1.1	6
6235	Relationship between ATOH1 and tumor microenvironment in colon adenocarcinoma patients with different microsatellite instability status. Cancer Cell International, 2022, 22, .	1.8	3
6236	The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer. Nature Communications, 2022, 13, .	5.8	21
6237	Proteomic analysis of low- and high-grade human colon adenocarcinoma tissues and tissue-derived primary cell lines reveals unique biological functions of tumours and new protein biomarker candidates. Clinical Proteomics, 2022, 19, .	1.1	2
6238	Exploring immunotherapy in colorectal cancer. Journal of Hematology and Oncology, 2022, 15, .	6.9	104
6239	Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing. British Journal of Cancer, 2022, 127, 1304-1311.	2.9	8
6240	Enhanced polymerase activity permits efficient synthesis by cancer-associated DNA polymerase Ïµ variants at low dNTP levels. Nucleic Acids Research, 2022, 50, 8023-8040.	6.5	4
6241	POLE/POLD1 mutation and tumor immunotherapy. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	42

#	Article	IF	Citations
6242	Conserved Control Path in Multilayer Networks. Entropy, 2022, 24, 979.	1.1	0
6243	<scp>RNA</scp> polymerase I inhibition induces terminal differentiation, growth arrest, and vulnerability to senolytics in colorectal cancer cells. Molecular Oncology, 2022, 16, 2788-2809.	2.1	0
6244	An international report on bacterial communities in esophageal squamous cell carcinoma. International Journal of Cancer, 2022, 151, 1947-1959.	2.3	7
6245	Real-world application of next-generation sequencing-based test for surgically resectable colorectal cancer in clinical practice. Future Oncology, 2022, 18, 2701-2711.	1.1	0
6246	Single-cell sequencing reveals CD133+CD44â^'-originating evolution and novel stemness related variants in human colorectal cancer. EBioMedicine, 2022, 82, 104125.	2.7	9
6247	Identification of A2BAR as a potential target in colorectal cancer using novel fluorescent GPCR ligands. Biomedicine and Pharmacotherapy, 2022, 153, 113408.	2.5	2
6248	Extrinsic proofreading. DNA Repair, 2022, 117, 103369.	1.3	1
6249	Capturing the latent space of an Autoencoder for multi-omics integration and cancer subtyping. Computers in Biology and Medicine, 2022, 148, 105832.	3.9	7
6250	Colorectal cancer immunotherapy-Recent progress and future directions. Cancer Letters, 2022, 545, 215816.	3.2	32
6251	Serial Analysis of Gene Mutations and Gene Expression during First-Line Chemotherapy against Metastatic Colorectal Cancer: Identification of Potentially Actionable Targets within the Multicenter Prospective Biomarker Study REVEAL. Cancers, 2022, 14, 3631.	1.7	3
6252	Whole-Genome Sequencing Identified KCNJ12 and SLC25A5 Mutations in Port-Wine Stains. Frontiers in Medicine, 0, 9, .	1.2	0
6253	Clinical Validity of Tumor-Informed Circulating Tumor DNA Analysis in Patients Undergoing Surgery of Colorectal Metastases. Diseases of the Colon and Rectum, 0, Publish Ahead of Print, .	0.7	1
6254	A Detailed Overview About the Single-Cell Analyses of Solid Tumors Focusing on Colorectal Cancer. Pathology and Oncology Research, 0, 28, .	0.9	5
6255	Transcriptomic and Cellular Content Analysis of Colorectal Cancer by Combining Multiple Independent Cohorts. Clinical and Translational Gastroenterology, 2023, 14, e00517.	1.3	3
6256	Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring <i>POLE</i> exonuclease domain mutation. , 2022, 10, e004487.		5
6257	Forkhead Box S1 mediates epithelial-mesenchymal transition through the Wnt/Î²-catenin signaling pathway to regulate colorectal cancer progression. Journal of Translational Medicine, 2022, 20, .	1.8	3
6258	Dysregulated expression of suppressor loop of circadian rhythm genes in colorectal cancer pathogenesis. Minerva Medica, 2022, 113, .	0.3	2
6259	E3 ubiquitin ligase MAGI3 degrades c-Myc and acts as a predictor for chemotherapy response in colorectal cancer. Molecular Cancer, 2022, 21, .	7.9	13

#	Article	IF	Citations
6260	Genomic and epigenomic profiles distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer. EBioMedicine, 2022, 82, 104165.	2.7	7
6261	Overexpression of the miR-17-92 cluster in colorectal adenoma organoids causes a carcinoma-like gene expression signature. Neoplasia, 2022, 32, 100820.	2.3	5
6262	Lynch syndrome pre-screening and comprehensive characterization in a multi-center large cohort of Chinese patients with colorectal cancer. Cancer Biology and Medicine, 0, , 1-14.	1.4	0
6263	Poziotinib Inhibits HER2-Mutantâ€"Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer. Cancer Research, 2022, 82, 2928-2939.	0.4	7
6264	Interaction between microbiota and immunity and its implication in colorectal cancer. Frontiers in Immunology, 0, 13, .	2.2	10
6265	Anatomic location of colorectal cancer presents a new paradigm for its prognosis in African American patients. PLoS ONE, 2022, 17, e0271629.	1.1	4
6266	Regulation of the <scp> <i>THRA</i> </scp> gene, encoding the thyroid hormone nuclear receptor TRÎ±1, in intestinal lesions. Molecular Oncology, 0, , .	2.1	0
6267	Classification of colon adenocarcinoma based on immunological characterizations: Implications for prognosis and immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	4
6268	Paladin, overexpressed in colon cancer, is required for actin polymerisation and liver metastasis dissemination. Oncogenesis, 2022, 11, .	2.1	1
6269	New Insights into Bile Acids Related Signaling Pathways in the Onset of Colorectal Cancer. Nutrients, 2022, 14, 2964.	1.7	15
6270	Metabolic balance in colorectal cancer is maintained by optimal Wnt signaling levels. Molecular Systems Biology, 2022, 18, .	3.2	3
6271	Exome sequencing revealed comparable frequencies of RNF43 and BRAF mutations in Middle Eastern colorectal cancer. Scientific Reports, 2022, 12, .	1.6	3
6273	DNA methylation-based epigenetic signatures predict somatic genomic alterations in gliomas. Nature Communications, 2022, 13, .	5.8	5
6274	Identification of Six Genes as Diagnostic Markers for Colorectal Cancer Detection by Integrating Multiple Expression Profiles. Journal of Oncology, 2022, 2022, 1-17.	0.6	1
6275	Polysaccharide immunization and colorectal cancer: A systematic review and network meta-analysis. Frontiers in Nutrition, 0, 9, .	1.6	2
6276	Computational Analysis of Pathological Image Enables Interpretable Prediction for Microsatellite Instability. Frontiers in Oncology, 0, 12, .	1.3	1
6277	Identification of the Antigens Recognised by Colorectal Cancer Patients Using Sera from Patients Who Exhibit a Crohnâ€™s-like Lymphoid Reaction. Biomolecules, 2022, 12, 1058.	1.8	0
6278	Therapeutic Targeting of Cancer Stem Cells Prevents Resistance of Colorectal Cancer Cells to MEK Inhibition. ACS Pharmacology and Translational Science, 2022, 5, 724-734.	2.5	6

#	Article	IF	Citations
6279	Cancer-Associated Stromal Fibroblast-Derived Transcriptomes Predict Poor Clinical Outcomes and Immunosuppression in Colon Cancer. Pathology and Oncology Research, 0, 28, .	0.9	9
6280	Prognostic Impact of TP53 Mutations and Tumor Mutational Load in Colorectal Cancer. Gastrointestinal Disorders, 2022, 4, 165-179.	0.4	3
6281	The Prognostic Roles of PYCR2 and ZBTB18 Expression in Tissues of Colorectal Carcinoma and Non-Neoplastic Tissues: An Immunohistochemical Study. Journal of Coloproctology, 0, , .	0.1	0
6282	The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. International Journal of Molecular Sciences, 2022, 23, 8535.	1.8	9
6283	Biologics in rectal cancer. Expert Opinion on Biological Therapy, 0, , 1-13.	1.4	0
6284	Differential ion mobility mass spectrometry in immunopeptidomics identifies neoantigens carrying colorectal cancer driver mutations. Communications Biology, 2022, 5, .	2.0	8
6286	DEPDC1B promotes colorectal cancer via facilitating cell proliferation and migration while inhibiting apoptosis. Cell Cycle, 2023, 22, 131-143.	1.3	3
6287	Synthetic lethality in personalized cancer therapy. Genome Instability & Disease, 0, , .	0.5	0
6288	Nucleolar protein NOC4L inhibits tumorigenesis and progression by attenuating SIRT1-mediated p53 deacetylation. Oncogene, 2022, 41, 4474-4484.	2.6	4
6289	Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer. Nature Medicine, 2022, 28, 1646-1655.	15.2	42
6290	Genomeâ€wide analysis of colorectal cancer based on geneâ€based somatic copy number alterations during neoplastic progression within the same tumor. Cancer Medicine, 0, , .	1.3	1
6291	DNA methylation analysis of normal colon organoids from familial adenomatous polyposis patients reveals novel insight into colon cancer development. Clinical Epigenetics, 2022, 14, .	1.8	10
6292	HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	3
6293	Utilising Proteomics and Organoid Cultures for Predicting Treatment Response in Colorectal Cancer. , 0, , .		0
6294	GREAP: a comprehensive enrichment analysis software for human genomic regions. Briefings in Bioinformatics, 2022, 23, .	3.2	4
6295	Crosstalk between PI3K/Akt and Wnt/Î²-catenin pathways promote colorectal cancer progression regardless of mutational status. Cancer Biology and Therapy, 2022, 23, 1-13.	1.5	15
6296	Predicting the Prognostic Value of POLI Expression in Different Cancers via a Machine Learning Approach. International Journal of Molecular Sciences, 2022, 23, 8571.	1.8	2
6297	Drosophila as a toolkit to tackle cancer and its metabolism. Frontiers in Oncology, 0, 12, .	1.3	5

#	Article	IF	Citations
6298	Fused inverse-normal method for integrated differential expression analysis of RNA-seq data. BMC Bioinformatics, 2022, 23, .	1.2	0
6299	The immune phenotypes and different immune escape mechanisms in colorectal cancer. Frontiers in Immunology, 0, 13, .	2.2	5
6300	Microsatellite Instability: From the Implementation of the Detection to a Prognostic and Predictive Role in Cancers. International Journal of Molecular Sciences, 2022, 23, 8726.	1.8	18
6301	Game-theoretic link relevance indexing on genome-wide expression dataset identifies putative salient genes with potential etiological and diapeutics role in colorectal cancer. Scientific Reports, 2022, 12, .	1.6	0
6302	Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Molecular Cancer, 2022, 21, .	7.9	55
6303	Single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer tumors. Genome Medicine, 2022, 14, .	3.6	30
6305	Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement. , 2022, 33, 627-663.		0
6306	Recurrent NOMO1 Gene Deletion Is a Potential Clinical Marker in Early-Onset Colorectal Cancer and Is Involved in the Regulation of Cell Migration. Cancers, 2022, 14, 4029.	1.7	3
6307	In the literature: July 2022. ESMO Open, 2022, 7, 100556.	2.0	0
6309	Molecular Profiling of Tumor Tissue in Mexican Patients with Colorectal Cancer. Current Issues in Molecular Biology, 2022, 44, 3770-3778.	1.0	0
6310	Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment. Frontiers in Medicine, 0, 9, .	1.2	5
6311	Clinical and Genomic Characterization of Interval Colorectal Cancer in 3 Prospective Cohorts. Gastroenterology, 2022, 163, 1522-1530.e5.	0.6	4
6312	Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results. Journal of Clinical Oncology, 2023, 41, 233-242.	0.8	13
6313	Molecular characterization of colorectal cancer related peritoneal metastatic disease. Nature Communications, 2022, 13, .	5.8	26
6314	Mechanisms and prospects of circular RNAs and their interacting signaling pathways in colorectal cancer. Frontiers in Oncology, 0, 12, .	1.3	5
6315	Targeting <i>KRAS</i>: Crossroads of Signaling and Immune Inhibition. Journal of Immunotherapy and Precision Oncology, 2022, 5, 68-78.	0.6	6
6317	Molecular Characterization of Adenocarcinomas Arising in the Urinary Bladder Following Augmentation Cystoplasty: A Multi-Institutional Study. Human Pathology, 2022, , .	1.1	0
6318	Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment. European Journal of Cancer, 2022, 175, 136-157.	1.3	76

#	Article	IF	Citations
6319	FOXF2 Regulates PRUNE2 Transcription in the Pathogenesis of Colorectal Cancer. Technology in Cancer Research and Treatment, 2022, 21, 153303382211187.	0.8	2
6320	Hypermutation/Hypermutable. , 2022, , .		0
6321	<i>Csf1r</i> mediates enhancement of intestinal tumorigenesis caused by inactivation of <i>Mir34a</i>. International Journal of Biological Sciences, 2022, 18, 5415-5437.	2.6	3
6322	Genetic and epigenetic dependencies in colorectal cancer development. Gastroenterology Report, 2022, 10, .	0.6	19
6323	A General Overview on Causes, Risk Factors, Diagnosis, Treatment, and Role of Oxidative Stress Biomarkers in Colorectal Cancer. , 2022, , 3877-3895.		0
6324	End-to-End Learning forÂImage-Based Detection ofÂMolecular Alterations inÂDigital Pathology. Lecture Notes in Computer Science, 2022, , 88-98.	1.0	2
6325	Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211117.	1.4	8
6326	The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells. Science Signaling, 2022, 15, .	1.6	24
6327	Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer. BMC Cancer, 2022, 22, .	1.1	16
6328	Insights into Early Onset Colorectal Cancer through Analysis of Normal Colon Organoids of Familial Adenomatous Polyposis Patients. Cancers, 2022, 14, 4138.	1.7	1
6329	Cancer cell histone density links global histone acetylation, mitochondrial proteome and histone acetylase inhibitor sensitivity. Communications Biology, 2022, 5, .	2.0	4
6330	Diagnostic and prognostic potential of the novel biomarker nuclear cap binding protein subunit 2 (NCBP2) in colon adenocarcinoma. Journal of Gastrointestinal Oncology, 2022, 13, 1782-1792.	0.6	4
6331	The Genomic Environment of BRAF Mutated and BRAF/PIK3CA Double Mutated Colorectal Cancers. Journal of Clinical Medicine, 2022, 11, 5132.	1.0	2
6332	Decreased NHE3 expression in colon cancer is associated with DNA damage, increased inflammation and tumor growth. Scientific Reports, 2022, 12, .	1.6	1
6334	Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. Cancer Cell, 2022, 40, 1161-1172.e5.	7.7	44
6336	Pan-cancer analysis of co-occurring mutations in RAD52 and the BRCA1-BRCA2-PALB2 axis in human cancers. PLoS ONE, 2022, 17, e0273736.	1.1	4
6337	Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce TÂcell paralysis. Cell Reports, 2022, 40, 111384.	2.9	8
6338	Effect of TP53 deficiency and KRAS signaling on the bioenergetics of colon cancer cells in response to different substrates: A single cell study. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	2

#	Article	IF	Citations
6339	MAP7D2 reduces CD8+ cytotoxic T lymphocyte infiltration through MYH9-HMGB1 axis in colorectal cancer. Molecular Therapy, 2023, 31, 90-104.	3.7	3
6340	Multifaceted investigation underlies diverse mechanisms contributing to the downregulation of Hedgehog pathway-associated genes INTU and IFT88 in lung adenocarcinoma and uterine corpus endometrial carcinoma. Aging, 0, , .	1.4	0
6341	Utilization of cytologic cell blocks for targeted sequencing of solid tumors. Cancer Medicine, 2023, 12, 4042-4063.	1.3	3
6342	Genomic landscape of colorectal carcinoma in sub-Saharan Africa. Journal of Clinical Pathology, 2023, 76, 5-10.	1.0	2
6346	Pan-cancer analysis of Chromobox (CBX) genes for prognostic significance and cancer classification. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2023, 1869, 166561.	1.8	7
6347	Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapy. , 2022, 10, e004669.		7
6349	Proteogenomic analysis of cancer aneuploidy and normal tissues reveals divergent modes of gene regulation across cellular pathways. ELife, 0, 11, .	2.8	13
6350	Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers. Cancer Research, 2022, 82, 4058-4078.	0.4	4
6351	The immune microenvironment landscape shows treatment-specific differences in rectal cancer patients. Frontiers in Immunology, 0, 13, .	2.2	8
6353	Recursive integration of synergised graph representations of multi-omics data for cancer subtypes identification. Scientific Reports, 2022, 12, .	1.6	0
6354	Associating resistance to immune checkpoint inhibitors with immunological escape in colorectal cancer. Frontiers in Oncology, 0, 12, .	1.3	0
6355	From organoids to bedside: Advances in modeling, decoding and targeting of colorectal cancer. International Journal of Cancer, 2023, 152, 1304-1313.	2.3	4
6356	Experimental reproducibility limits the correlation between mRNA and protein abundances in tumor proteomic profiles. Cell Reports Methods, 2022, 2, 100288.	1.4	11
6357	Dissecting the Kinetic Mechanism of Human Lysine Methyltransferase 2D and Its Interactions with the WRAD2 Complex. Biochemistry, 2022, 61, 1974-1987.	1.2	0
6358	Immune depletion of the methylated phenotype of colon cancer is closely related to resistance to immune checkpoint inhibitors. Frontiers in Immunology, 0, 13, .	2.2	2
6359	Targeted Next-Generation Sequencing-Based Multiple Gene Mutation Profiling of Patients with Rectal Adenocarcinoma Receiving or Not Receiving Neoadjuvant Chemoradiotherapy. International Journal of Molecular Sciences, 2022, 23, 10353.	1.8	0
6360	A-to-I nonsynonymous RNA editing was significantly enriched in the ubiquitination site and correlated with clinical features and immune response. Scientific Reports, 2022, 12, .	1.6	1
6361	Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: A proof-of-concept study. Frontiers in Oncology, 0, 12, .	1.3	10

#	Article	IF	Citations
6362	Patientâ€Derived Organoids from Colorectal Cancer with Paired Liver Metastasis Reveal Tumor Heterogeneity and Predict Response to Chemotherapy. Advanced Science, 2022, 9, .	5.6	41
6363	Secondary bile acids mediate high-fat dietâ€"induced upregulation of R-spondin 3 and intestinal epithelial proliferation. JCI Insight, 2022, 7, .	2.3	7
6364	Circulating Tumor DNA-Based Disease Monitoring of Patients with Locally Advanced Esophageal Cancer. Cancers, 2022, 14, 4417.	1.7	7
6365	Metabolic Pathways Regulating Colorectal Cancer: A Potential Therapeutic Approach. Current Pharmaceutical Design, 2022, 28, 2995-3009.	0.9	10
6366	Mechanism and strategies of immunotherapy resistance in colorectal cancer. Frontiers in Immunology, 0, 13, .	2.2	13
6367	Colorectal cancer: Metabolic interactions reshape the tumor microenvironment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188797.	3.3	24
6368	Interpretation of the role of germline and somatic non-coding mutations in cancer: expression and chromatin conformation informed analysis. Clinical Epigenetics, 2022, 14, .	1.8	3
6369	Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals potential therapeutic strategies. Nature Communications, 2022, 13, .	5.8	18
6370	Mismatch repair deficiency in rectal cancer: an evolving scenario. Annals of Translational Medicine, 2022, 10, 951-951.	0.7	0
6371	Teenage-Onset Colorectal Cancers in a Digenic Cancer Predisposition Syndrome Provide Clues for the Interaction between Mismatch Repair and Polymerase Î´ Proofreading Deficiency in Tumorigenesis. Biomolecules, 2022, 12, 1350.	1.8	9
6372	Identification of the Minimum Combination of Serum microRNAs to Predict the Recurrence of Colorectal Cancer Cases. Annals of Surgical Oncology, 2023, 30, 233-243.	0.7	9
6374	BAT26 Only Microsatellite Instability with High Tumor Mutation Burdenâ€"A Rare Entity Associated with PTEN Protein Loss and High PD-L1 Expression. International Journal of Molecular Sciences, 2022, 23, 10730.	1.8	1
6375	ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer. Nature Communications, 2022, 13, .	5.8	9
6376	Integrated single-cell RNA-seq analysis identifies immune heterogeneity associated with KRAS/TP53 mutation status and tumor-sideness in colorectal cancers. Frontiers in Immunology, 0, 13, .	2.2	9
6377	Genetic and microenvironmental intra-tumor heterogeneity impacts colorectal cancer evolution and metastatic development. Communications Biology, 2022, 5, .	2.0	13
6378	Comprehensive analysis of the differential expression and prognostic value of COL1A2 in colon adenocarcinoma. Aging, 2022, 14, 7390-7407.	1.4	2
6379	Clone wars: From molecules to cell competition in intestinal stem cell homeostasis and disease. Experimental and Molecular Medicine, 2022, 54, 1367-1378.	3.2	6
6380	A prognostic sixâ€gene expression riskâ€score derived from proteomic profiling of the metastatic colorectal cancer secretome. Journal of Pathology: Clinical Research, 2022, 8, 495-508.	1.3	3

#	Article	IF	Citations
6381	Modulation of tumor environment in colorectal cancer â€" could gut microbiota be a key player?. , 0, 1, .		1
6382	Heparanase modulates the prognosis and development of BRAF V600E-mutant colorectal cancer by regulating AKT/p27Kip1/Cyclin E2 pathway. Oncogenesis, 2022, 11, .	2.1	2
6383	Heat selection enables highly scalable methylome profiling in cell-free DNA for noninvasive monitoring of cancer patients. Science Advances, 2022, 8, .	4.7	5
6384	Artificial intelligence in histopathology: enhancing cancer research and clinical oncology. Nature Cancer, 2022, 3, 1026-1038.	5.7	115
6385	Tiny <i>Drosophila</i> intestinal stem cells, big power. Cell Biology International, 0, , .	1.4	0
6386	The cAMP/PKA/CREB and TGFÎ²/SMAD4 Pathways Regulate Stemness and Metastatic Potential in Colorectal Cancer Cells. Cancer Research, 2022, 82, 4179-4190.	0.4	16
6387	The Prognostic Utilities of DNA Mismatch Repair Status and KRAS and BRAF Mutation in Korean Colorectal Cancer Patients: The KASID Multicenter Study. Oncology, 2023, 101, 49-58.	0.9	2
6389	Prevalence of Molecular Alterations in a Swiss Cohort of 512 Colorectal Carcinoma Patients by Targeted Next-Generation Sequencing Analysis in Routine Diagnostics. Pathobiology, 2023, 90, 166-175.	1.9	0
6390	CINSARC signature outperforms gold-standard TNM staging and consensus molecular subtypes for clinical outcome in stage IIâ€"III colorectal carcinoma. Modern Pathology, 2022, 35, 2002-2010.	2.9	4
6391	Role of AI and digital pathology for colorectal immuno-oncology. British Journal of Cancer, 2023, 128, 3-11.	2.9	7
6392	Smoking Is a Risk Factor of Colorectal Advanced Adenomas Compared to Nonadvanced Adenomas. Open Journal of Gastroenterology, 2022, 12, 278-285.	0.1	0
6393	Effects of pectins on colorectal cancer: targeting hallmarks as a support for future clinical trials. Food and Function, 2022, 13, 11438-11454.	2.1	5
6394	Molecular Pathology of Gastric Cancer. Journal of Gastric Cancer, 2022, 22, 264.	0.9	6
6395	Colorectal Cancer Diagnosis in the Era of Genomic Medicine. Nihon Daicho Komonbyo Gakkai Zasshi, 2022, 75, 453-460.	0.1	0
6396	Molecular analyses of peritoneal metastasis from colorectal cancer. Journal of the Korean Medical Association, 2022, 65, 586-593.	0.1	1
6397	GPER Agonist G1 Prevents Wnt-Induced JUN Upregulation in HT29 Colorectal Cancer Cells. International Journal of Molecular Sciences, 2022, 23, 12581.	1.8	4
6398	Predicting immunotherapy outcomes in patients with MSI tumors using NLR and CT global tumor volume. Frontiers in Oncology, 0, 12, .	1.3	3
6399	Targeting KRAS in PDAC: A New Way to Cure It?. Cancers, 2022, 14, 4982.	1.7	15

#	Article	IF	Citations
6400	Kap-Î²2/Transportin mediates Î²-catenin nuclear transport in Wnt signaling. ELife, 0, 11, .	2.8	5
6401	Rewiring glucose metabolism improves 5-FU efficacy in p53-deficient/KRASG12D glycolytic colorectal tumors. Communications Biology, 2022, 5, .	2.0	5
6402	Genomic Microsatellite Signatures Identify Germline Mismatch Repair Deficiency and Risk of Cancer Onset. Journal of Clinical Oncology, 2023, 41, 766-777.	0.8	10
6403	A simple approach for detecting <i>HLAâ€A</i> *02 alleles in archival formalinâ€fixed paraffinâ€embedded tissue samples and an application example for studying cancer immunoediting. Hla, 0, , .	0.4	2
6404	Low-dose immunogenic chemotherapeutics promotes immune checkpoint blockade in microsatellite stability colon cancer. Frontiers in Immunology, 0, 13, .	2.2	6
6405	Differential Expression in the Tumor Microenvironment of mRNAs Closely Associated with Colorectal Cancer Metastasis. Annals of Surgical Oncology, 0, , .	0.7	0
6406	Clinicopathological features and prognosis of colonic and rectal gastrointestinal stromal tumors: A propensity score matching analysis. Frontiers in Surgery, 0, 9, .	0.6	1
6407	Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer: Signaling Pathways to Therapeutic Strategies. Cancers, 2022, 14, 5160.	1.7	7
6409	Risk of cancer in individuals with Lynch-like syndrome and their families: a systematic review. Journal of Cancer Research and Clinical Oncology, 2023, 149, 25-46.	1.2	6
6410	Sensitization of Patient-Derived Colorectal Cancer Organoids to Photon and Proton Radiation by Targeting DNA Damage Response Mechanisms. Cancers, 2022, 14, 4984.	1.7	0
6411	Amino acid metabolism-based molecular classification of colon adenocarcinomavia in silico analysis. Frontiers in Immunology, 0, 13, .	2.2	1
6412	Three-target treatment combined with surgery for BRAF V600E-mutant colon cancer with peritoneal metastasis: a case report. Journal of Gastrointestinal Oncology, 2022, 13, 2647-2653.	0.6	1
6413	Impact of clinical data veracity on cancer genomic research. JNCI Cancer Spectrum, 0, , .	1.4	0
6415	The pivotal application of patient-derived organoid biobanks for personalized treatment of gastrointestinal cancers. Biomarker Research, 2022, 10, .	2.8	5
6416	Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective. Cancers, 2022, 14, 4828.	1.7	11
6417	Computational study on new natural compound inhibitors of Traf2 and Nck-interacting kinase (TNIK). Aging, 0, , .	1.4	0
6418	Sensitivities and Dependencies of BRAF Mutant Colorectal Cancer Cell Lines with or without PIK3CA Mutations for Discovery of Vulnerabilities with Therapeutic Potential. Medicina (Lithuania), 2022, 58, 1498.	0.8	3
6419	SMAD4 Loss Induces c-MYCâ€“Mediated NLE1 Upregulation to Support Protein Biosynthesis, Colorectal Cancer Growth, and Metastasis. Cancer Research, 2022, 82, 4604-4623.	0.4	5

#	Article	IF	Citations
6420	Blockade of Nuclear <i>Î²</i>â€Catenin Signaling via Direct Targeting of RanBP3 with NU2058 Induces Cell Senescence to Suppress Colorectal Tumorigenesis. Advanced Science, 2022, 9, .	5.6	7
6421	Clinical strategy of conversion therapy and surgical treatment for liver metastases from colorectal cancer. World Chinese Journal of Digestology, 2022, 30, 897-913.	0.0	0
6422	Use of Personalized Biomarkers in Metastatic Colorectal Cancer and the Impact of AI. Cancers, 2022, 14, 4834.	1.7	0
6423	Endoscopic polypectomy for malignant polyps: Should tumor location (right versus left side) guide clinical decisions?. Surgery, 2023, 173, 674-680.	1.0	0
6424	Molecular Pathogenesis of Colorectal Cancer: Impact of Oncogenic Targets Regulated by Tumor Suppressive miR-139-3p. International Journal of Molecular Sciences, 2022, 23, 11616.	1.8	8
6425	Wnt Signaling in the Phenotype and Function of Tumor-Associated Macrophages. Cancer Research, 2023, 83, 3-11.	0.4	4
6426	A local tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma. Nature Communications, 2022, 13, .	5.8	9
6427	Clinicopathological characteristics and prognosis of colon cancer with lung metastasis without liver metastasis: A large population-based analysis. Medicine (United States), 2022, 101, e31333.	0.4	1
6428	Germline Testing for Individuals with Pancreatic Adenocarcinoma and Novel Genetic Risk Factors. Hematology/Oncology Clinics of North America, 2022, 36, 943-960.	0.9	0
6429	CancÃ©rogenÃ¨se et variants faux sens pathogÃ¨nes duÂdomaine exonuclÃ©asique des ADN polymÃ©rases Îµ et Î´. Medecine/Sciences, 2022, 38, 763-765.	0.0	0
6430	Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer. Cancers, 2022, 14, 4874.	1.7	11
6432	Molecular Analyses in Peritoneal Metastasis from Colorectal Cancer: A Review-An English Version. Journal of the Anus, Rectum and Colon, 2022, 6, 197-202.	0.4	3
6433	Targeting RAS mutants in malignancies: successes, failures, and reasons for hope. Cancer Communications, 2023, 43, 42-74.	3.7	9
6435	The co-evolution of the genome and epigenome in colorectal cancer. Nature, 2022, 611, 733-743.	13.7	39
6437	Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial. British Journal of Cancer, 2022, 127, 2241-2248.	2.9	9
6438	Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nature Medicine, 2022, 28, 2171-2182.	15.2	131
6439	Somatic mutations in FAT cadherin family members constitute an underrecognized subtype of colorectal adenocarcinoma with unique clinicopathologic features. World Journal of Clinical Oncology, 0, 13, 779-788.	0.9	0
6440	Loss of bone morphogenetic protein signaling in fibroblasts results in CXCL12-driven serrated polyp development. Journal of Gastroenterology, 2023, 58, 25-43.	2.3	3

#	Article	IF	Citations
6442	Organoids for Modeling (Colorectal) Cancer in a Dish. Cancers, 2022, 14, 5416.	1.7	4
6443	Local recurrence after endoscopic resection of sessile serrated lesions: A multicenter prospective study by the Osaka Gut Forum. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 2306-2312.	1.4	3
6444	Myosin Vb as a tumor suppressor gene in intestinal cancer. Oncogene, 0, , .	2.6	0
6445	<scp>MIST</scp>: multiple instance learning network based on Swin Transformer for whole slide image classification of colorectal adenomas. Journal of Pathology, 2023, 259, 125-135.	2.1	11
6446	Intestinal <i>Apc</i>â€inactivation induces HSP25 dependency. EMBO Molecular Medicine, 2022, 14, .	3.3	2
6447	Multiregional Sequencing Analysis Reveals Extensive Genetic Heterogeneity in Gastric Tumors from Latinos. Cancer Research Communications, 2022, 2, 1487-1496.	0.7	2
6448	Targeted exome-based predictors of patterns of progression of colorectal liver metastasis after percutaneous thermal ablation. British Journal of Cancer, 0, , .	2.9	1
6449	Advances in immunotherapy for MMR proficient colorectal cancer. Cancer Treatment Reviews, 2022, 111, 102480.	3.4	11
6450	Tumour break load is a biologically relevant feature of genomic instability with prognostic value in colorectal cancer. European Journal of Cancer, 2022, 177, 94-102.	1.3	2
6451	RAS: Circuitry and therapeutic targeting. Cellular Signalling, 2023, 101, 110505.	1.7	1
6452	The Role of DNA Methylation and DNA Methyltransferases in Cancer. Advances in Experimental Medicine and Biology, 2022, , 317-348.	0.8	7
6453	Cancer-cell-intrinsic mechanisms regulate MDSCs through cytokine networks. International Review of Cell and Molecular Biology, 2023, , 1-31.	1.6	0
6454	Early detection and prognosis prediction for colorectal cancer by circulating tumour DNA methylation haplotypes: a multicentre cohort study. EClinicalMedicine, 2023, 55, 101717.	3.2	23
6455	Machine learning with in silico analysis markedly improves survival prediction modeling in colon cancer patients. Cancer Medicine, 2023, 12, 7603-7615.	1.3	4
6456	Roles of transducin-like enhancer of split (TLE) family proteins in tumorigenesis and immune regulation. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	4
6457	Chromosome Inequality: Causes and Consequences of Non-Random Segregation Errors in Mitosis and Meiosis. Cells, 2022, 11, 3564.	1.8	11
6458	MiR-17-3p Facilitates Aggressive Cell Phenotypes in Colon Cancer by Targeting PLCD1 Through Affecting KIF14. Applied Biochemistry and Biotechnology, 2023, 195, 1723-1735.	1.4	5
6459	Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death. Molecular Cancer Therapeutics, 2023, 22, 52-62.	1.9	5

#	Article	IF	Citations
6460	A rare case of unresectable, microsatellite instability-high hepatocellular carcinoma and an examination of the tumor microenvironment. International Cancer Conference Journal, 0, , .	0.2	1
6462	Cancerâ€associated fibroblasts potentiate colorectal cancer progression by crosstalk of the <scp>IGF2</scp>â€"<scp>IGF1R</scp> and <scp>Hippoâ€"YAP1</scp> signaling pathways. Journal of Pathology, 2023, 259, 205-219.	2.1	9
6463	Evaluating Multiple Next-Generation Sequencingâ€"Derived Tumor Features to Accurately Predict DNA Mismatch Repair Status. Journal of Molecular Diagnostics, 2023, 25, 94-109.	1.2	5
6464	Axin1 Protects Colon Carcinogenesis by an Immune-Mediated Effect. Cellular and Molecular Gastroenterology and Hepatology, 2023, 15, 689-715.	2.3	8
6465	Distinct Molecular Profiles of Sporadic Early-Onset Colorectal Cancer: A Population-Based Cohort and Systematic Review. , 2023, 2, 347-359.		4
6466	Gene interaction perturbation network deciphers a high-resolution taxonomy in colorectal cancer. ELife, 0, 11, .	2.8	10
6468	Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges. International Journal of Molecular Sciences, 2022, 23, 13696.	1.8	0
6469	Upregulation of YKL-40 Promotes Metastatic Phenotype and Correlates with Poor Prognosis and Therapy Response in Patients with Colorectal Cancer. Cells, 2022, 11, 3568.	1.8	8
6471	Systematic discovery and functional dissection of enhancers needed for cancer cell fitness and proliferation. Cell Reports, 2022, 41, 111630.	2.9	10
6472	Missed colorectal cancers in a fecal immunochemical test-based screening program: Molecular profiling of interval carcinomas. World Journal of Gastrointestinal Oncology, 0, 14, 2195-2207.	0.8	2
6474	The Association of R-Loop Binding Proteins Subtypes with CIN Implicates Therapeutic Strategies in Colorectal Cancer. Cancers, 2022, 14, 5607.	1.7	0
6475	PRMT6 functionally associates with PRMT5 to promote colorectal cancer progression through epigenetically repressing the expression of CDKN2B and CCNG1. Experimental Cell Research, 2023, 422, 113413.	1.2	6
6476	Metastatic recurrence in colorectal cancer arises from residual EMP1+ cells. Nature, 2022, 611, 603-613.	13.7	50
6477	Effects of Polyunsaturated Fatty Acids on Colorectal Cancer Patients: A Meta-Analysis of Randomized Controlled Trials. Nutrition and Cancer, 0, , 1-13.	0.9	0
6478	N-glycosylation Regulates Intrinsic IFN-Î³ Resistance in Colorectal Cancer: Implications for Immunotherapy. Gastroenterology, 2023, 164, 392-406.e5.	0.6	10
6479	Emerging evidence of immunotherapy for colorectal cancer. Annals of Gastroenterological Surgery, 2023, 7, 216-224.	1.2	4
6480	Multi-omics Data Fusion using Adaptive GTO guided Non-negative Matrix Factorization for Cancer Subtype Discovery. Computer Methods and Programs in Biomedicine, 2022, , 107246.	2.6	0
6481	The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review. Cancer Treatment Reviews, 2023, 112, 102488.	3.4	6

#	Article	IF	Citations
6483	The genetic alterations of rectal neuroendocrine tumor and indications for therapy and prognosis: a systematic review. Endocrine Journal, 2022, , .	0.7	0
6484	KRAS. Encyclopedia of Pathology, 2022, , 462-463.	0.0	0
6485	Circulating Tumour DNA and Risk-Stratified Surveillance Strategies for Patients with Colorectal Liver Metastases. , 2022, , 557-562.		0
6486	Cancer-Related Signaling Pathway and Prognosis. , 2022, , 475-481.		0
6487	Artificial intelligence in gastric cancer: applications and challenges. Gastroenterology Report, 2022, 10, .	0.6	9
6488	Cancer-associated fibroblast-derived exosome miR-181b-3p promotes the occurrence and development of colorectal cancer by regulating SNX2 expression. Biochemical and Biophysical Research Communications, 2023, 641, 177-185.	1.0	12
6489	PathIN: an integrated tool for the visualization of pathway interaction networks. Computational and Structural Biotechnology Journal, 2023, 21, 378-387.	1.9	2
6490	Immune Checkpoint Inhibitor Combination Therapy for Stage IV Pancreatic Cancer in 1 Case and Literature Review. Advances in Clinical Medicine, 2022, 12, 10299-10303.	0.0	0
6491	Improved Survival After CLM Resection over 20ÂYears. , 2022, , 537-548.		0
6492	Microsatellite instability in gastric cancer is a predictor of a favorable prognosis. Arkhiv Patologii, 2022, 84, 5.	0.0	2
6493	IS SURVIVIN LEVEL IDENTICAL BETWEEN ADENOMAS OF PROXIMAL AND DISTAL COLON?. Revista Argentina De AnatomÃa ClÃnica, 2022, 14, 58-64.	0.1	0
6494	Comprehensive Review of Biomarkers for the Treatment of Locally Advanced Colon Cancer. Cells, 2022, 11, 3744.	1.8	9
6495	Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53â€"Mutated Metastatic Colorectal Cancer. Cancers, 2022, 14, 5921.	1.7	1
6496	Extrinsic cell death pathway plasticity: a driver of clonal evolution in cancer?. Cell Death Discovery, 2022, 8, .	2.0	1
6498	API-2-Induced Cell Migration Is Overcome by Small Molecular Approaches Inhibiting Î²-Catenin. Current Issues in Molecular Biology, 2022, 44, 6006-6014.	1.0	1
6499	The HIF-prolyl hydroxylases have distinct and nonredundant roles in colitis-associated cancer. JCI Insight, 2022, 7, .	2.3	4
6500	The Somatic Mutation Landscape of UDP-Glycosyltransferase (UGT) Genes in Human Cancers. Cancers, 2022, 14, 5708.	1.7	1
6501	TGF-Î² Signaling in Metastatic Colorectal Cancer (mCRC): From Underlying Mechanism to Potential Applications in Clinical Development. International Journal of Molecular Sciences, 2022, 23, 14436.	1.8	13

#	Article	IF	Citations
6502	Transcriptomic and immunophenotypic profiling reveals molecular and immunological hallmarks of colorectal cancer tumourigenesis. Gut, 2023, 72, 1326-1339.	6.1	15
6503	Proteotranscriptomics Analysis Reveals Signature Pathways Associated with Colorectal Cancer Progression: a Pilot Study. , 2022, , .		0
6504	Distinct clinical pattern of colorectal cancer patients with POLE mutations: A retrospective study on real-world data. Frontiers in Genetics, 0, 13, .	1.1	5
6505	Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer. Frontiers in Immunology, 0, 13, .	2.2	1
6506	Comprehensive microRNA analysis across genome-edited colorectal cancer organoid models reveals miR-24 as a candidate regulator of cell survival. BMC Genomics, 2022, 23, .	1.2	2
6507	Activated PyK2 and Its Associated Molecules Transduce Cellular Signaling from the Cancerous Milieu for Cancer Metastasis. International Journal of Molecular Sciences, 2022, 23, 15475.	1.8	5
6508	Letâ€7bâ€5p inhibits colon cancer progression by prohibiting <scp>APC</scp> ubiquitination degradation and the Wnt pathway by targeting <scp>NKD1</scp>. Cancer Science, 2023, 114, 1882-1897.	1.7	5
6510	The Molecular Genetics of Colorectal Cancer, Hereditary Colorectal Cancer Syndromes, and Early-Onset Colorectal Cancer. Digestive Disease Interventions, 0, , .	0.3	0
6511	The sodium channel subunit SCNN1B suppresses colorectal cancer via suppression of active c-Raf and MAPK signaling cascade. Oncogene, 2023, 42, 601-612.	2.6	1
6512	Development and validation of a new stage-specific nomogram model for predicting cancer-specific survival in patients in different stages of colon cancer: A SEER population-based study and external validation. Frontiers in Oncology, 0, 12, .	1.3	4
6513	Integrated analysis of necroptosis-related genes for evaluating immune infiltration and colon cancer prognosis. Frontiers in Immunology, 0, 13, .	2.2	6
6514	CRAC and SK Channels: Their Molecular Mechanisms Associated with Cancer Cell Development. Cancers, 2023, 15, 101.	1.7	5
6515	Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice. , 2022, 10, e005345.		12
6518	Trastuzumab Combined with Irinotecan in Patients with HER2-Positive Metastatic Colorectal Cancer: A Phase II Single-Arm Study and Exploratory Biomarker Analysis. Cancer Research and Treatment, 2023, 55, 626-635.	1.3	5
6519	A Race-Specific, DNA Methylation Analysis of Aging in Normal Rectum: Implications for the Biology of Aging and Its Relationship to Rectal Cancer. Cancers, 2023, 15, 45.	1.7	6
6520	Microbiome Profiling from Fecal Immunochemical Test Reveals Microbial Signatures with Potential for Colorectal Cancer Screening. Cancers, 2023, 15, 120.	1.7	3
6521	MicroRNA-378a-3p prevents initiation and growth of colorectal cancer by fine tuning polyamine synthesis. Cell and Bioscience, 2022, 12, .	2.1	3
6522	Identification of DDX60 as a Regulator of MHC-I Class Molecules in Colorectal Cancer. Biomedicines, 2022, 10, 3092.	1.4	5

#	Article	IF	Citations
6523	Loss of Dok-3 in Non-tumor Cells Induces Malignant Transformation of Benign Epithelial Tumor Cells of the Intestine. Cancer Research Communications, 2022, 2, 1590-1600.	0.7	0
6524	Multiparametric and accurate functional analysis of genetic sequence variants using CRISPR-Select. Nature Genetics, 2022, 54, 1983-1993.	9.4	7
6525	Strong Hereditary Predispositions to Colorectal Cancer. Genes, 2022, 13, 2326.	1.0	6
6526	Recent Progress in Immunotherapy for Metastatic Colorectal Cancer. Journal of Digestive Cancer Reports, 2022, 10, 65-73.	0.0	0
6527	Tumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients. Frontiers in Oncology, 0, 12, .	1.3	2
6529	Tissue microarrey: a potential cost-effective approach for mismatch repair testing in colorectal cancer. BMC Gastroenterology, 2022, 22, .	0.8	1
6530	Epithelial TGFÎ² engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features. Nature Communications, 2022, 13, .	5.8	2
6532	Multimodal Learning for Multi-omics: A Survey. , 2023, 01, .		1
6533	Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT. Efficacy and Mechanism Evaluation, 2022, 9, 1-92.	0.9	1
6534	A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy. International Journal of Molecular Sciences, 2023, 24, 118.	1.8	2
6535	Emerging Tests for Noninvasive Colorectal Cancer Screening. Clinical Gastroenterology and Hepatology, 2023, 21, 604-616.	2.4	9
6536	Shallow Whole-Genome Sequencing of Cell-Free DNA (cfDNA) Detects Epithelial Ovarian Cancer and Predicts Patient Prognosis. Cancers, 2023, 15, 530.	1.7	0
6537	Transcriptional activity mediated by Î²-CATENIN and TCF/LEF family members is completely dispensable for survival and propagation of multiple human colorectal cancer cell lines. Scientific Reports, 2023, 13, .	1.6	4
6538	Dietary fiber as a wide pillar of colorectal cancer prevention and adjuvant therapy. Critical Reviews in Food Science and Nutrition, 0, , 1-21.	5.4	3
6539	Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers. Nature Communications, 2023, 14, .	5.8	9
6541	Oncotherapeutic Strategies in Early Onset Colorectal Cancer. Cancers, 2023, 15, 552.	1.7	4
6542	Multiomics Study of a Novel Naturally Derived Small Molecule, NSC772864, as a Potential Inhibitor of Proto-Oncogenes Regulating Cell Cycle Progression in Colorectal Cancer. Cells, 2023, 12, 340.	1.8	1
6543	Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation. International Journal of Molecular Sciences, 2023, 24, 1727.	1.8	6

#	Article	IF	Citations
6544	Nonâ€coding RNAs are correlated to TGFâ€Î² receptor type 2 in patients with colorectal cancer. Journal of Gene Medicine, 2023, 25, .	1.4	6
6545	Peritoneal metastases from primary appendiceal and colorectal carcinomas demonstrate distinct molecular identities on comprehensive tumor analysis. Journal of Surgical Oncology, 0, , .	0.8	0
6546	DNA methylation-based patterns for early diagnostic prediction and prognostic evaluation in colorectal cancer patients with high tumor mutation burden. Frontiers in Oncology, 0, 12, .	1.3	2
6547	Liquid biopsy approaches and immunotherapy in colorectal cancer for precision medicine: Are we there yet?. Frontiers in Oncology, 0, 12, .	1.3	3
6549	LncRNA LIMp27 Regulates the DNA Damage Response through p27 in p53â€Defective Cancer Cells. Advanced Science, 2023, 10, .	5.6	4
6550	Fast, accurate, and racially unbiased pan-cancer tumor-only variant calling with tabular machine learning. Npj Precision Oncology, 2023, 7, .	2.3	2
6551	Matrine restrains the development of colorectal cancer through regulating the <scp>AGRN</scp>/Wnt/Î²â€catenin pathway. Environmental Toxicology, 2023, 38, 809-819.	2.1	4
6552	Comprehensive analysis of the prognosis and immune infiltrates for the BET protein family reveals the significance of BRD4 in glioblastoma multiforme. Frontiers in Cell and Developmental Biology, 0, 11, .	1.8	2
6553	Impact of cytotoxic T lymphocytes immunotherapy on prognosis of colorectal cancer patients. Frontiers in Oncology, 0, 13, .	1.3	0
6555	The complex network of transcription factors, immune checkpoint inhibitors and stemness features in colorectal cancer: A recent update. Seminars in Cancer Biology, 2023, 89, 1-17.	4.3	6
6556	Alteraciones genÃ©ticas en la vÃa canÃ³nica Wnt/Î²-catenina en cÃ¡ncer colorrectal. Horizonte MÃ©dico, 2022, 22, e1945.	0.1	0
6557	Medicinal Chemistry Strategies for the Development of Inhibitors Disrupting Î²-Cateninâ€™s Interactions with Its Nuclear Partners. Journal of Medicinal Chemistry, 2023, 66, 1-31.	2.9	6
6558	Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer. Cancers, 2023, 15, 183.	1.7	5
6559	Targeting <i>KRAS G12C</i> mutations in colorectal cancer. Gastroenterology Report, 2022, 11, .	0.6	1
6560	Recent Advancement of Colorectal Cancer and Their Herbal Essential Oil Treatment. , 2022, 1, 133-144.		9
6561	Single-cell profiling reveals differences between human classical adenocarcinoma and mucinous adenocarcinoma. Communications Biology, 2023, 6, .	2.0	4
6562	The Evolutionary Landscape of Colorectal Tumorigenesis: Recent Paradigms, Models, and Hypotheses. Gastroenterology, 2023, 164, 841-846.	0.6	2
6564	Microsatellite instability assessment is instrumental for Predictive, Preventive and Personalised Medicine: status quo and outlook. EPMA Journal, 2023, 14, 143-165.	3.3	6

#	Article	IF	Citations
6565	SWEET: a single-sample network inference method for deciphering individual features in disease. Briefings in Bioinformatics, 2023, 24, .	3.2	3
6566	Driver and targetable alterations in Chinese patients with small bowel carcinoma. Journal of Cancer Research and Clinical Oncology, 2023, 149, 6139-6150.	1.2	0
6567	Case report: A unique presentation of a high-grade neuroepithelial tumor with EWSR1::PATZ1 fusion with diagnostic, molecular, and therapeutic insights. Frontiers in Oncology, 0, 13, .	1.3	3
6568	Regulation and functions of cell division in the intestinal tissue. Seminars in Cell and Developmental Biology, 2023, 150-151, 3-14.	2.3	3
6569	Patterns of Somatic Variants in Colorectal Adenoma and Carcinoma Tissue and Matched Plasma Samples from the Hungarian Oncogenome Program. Cancers, 2023, 15, 907.	1.7	3
6570	Tumor immunology. , 2023, , 245-452.		0
6571	USP7 inactivation suppresses APC-mutant intestinal hyperproliferation andÂtumor development. Stem Cell Reports, 2023, 18, 570-584.	2.3	5
6572	What is precision medicine in oncology?. , 2023, , 1-30.		0
6573	New developments in targeted therapy for metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592211485.	1.4	8
6574	Panâ€Cancer landscape of protein activities identifies drivers of signalling dysregulation and patient survival. Molecular Systems Biology, 2023, 19, .	3.2	10
6575	Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. Nature Medicine, 2023, 29, 458-466.	15.2	28
6576	Wnt3a is a promising target in colorectal cancer. , 2023, 40, .		2
6577	Comprehensive Study of Microsatellite Instability Testing and Its Comparison With Immunohistochemistry in Gastric Cancers. Journal of Gastric Cancer, 0, 23, .	0.9	0
6578	Pancancer survival prediction using a deep learning architecture with multimodal representation and integration. Bioinformatics Advances, 2023, 3, .	0.9	4
6580	Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma. Cancers, 2023, 15, 863.	1.7	6
6581	<scp>MIMT1</scp> and <scp>LINC01550</scp> are uncharted <scp>lncRNAs</scp> downâ€regulated in colorectal cancer. International Journal of Experimental Pathology, 0, , .	0.6	1
6582	The Role of TP53 in Adaptation and Evolution. Cells, 2023, 12, 512.	1.8	13
6583	Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer. Frontiers in Oncology, 0, 13, .	1.3	13

#	Article	IF	Citations
6585	Molecular Characteristics of Early-Onset Colorectal Cancer According to Detailed Anatomical Locations: Comparison With Later-Onset Cases. American Journal of Gastroenterology, 2023, 118, 712-726.	0.2	10
6586	Colitis-Associated Cancers. , 2023, , 773-788.		0
6587	A Novel Molecular Analysis Approach in Colorectal Cancer Suggests New Treatment Opportunities. Cancers, 2023, 15, 1104.	1.7	1
6588	Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer. Cancer Communications, 2023, 43, 435-454.	3.7	13
6589	Determinants of Lymph Node Yield and Involvement in Resectable Colon Cancer: A Study of Anatomical, Pathological, and Fresh, Nonfixed Specimen Dissection. Indian Journal of Surgery, 2023, 85, 1177-1183.	0.2	1
6590	Lower Expression of CFTR Is Associated with Higher Mortality in a Meta-Analysis of Individuals with Colorectal Cancer. Cancers, 2023, 15, 989.	1.7	1
6591	Phenolic Phytochemicals for Prevention and Treatment of Colorectal Cancer: A Critical Evaluation of In Vivo Studies. Cancers, 2023, 15, 993.	1.7	10
6592	Bile salt hydrolase in non-enterotoxigenic Bacteroides potentiates colorectal cancer. Nature Communications, 2023, 14, .	5.8	15
6593	Wnt Signaling Inhibitors and Their Promising Role in Tumor Treatment. International Journal of Molecular Sciences, 2023, 24, 6733.	1.8	6
6594	Rectal Cancer after Prostate Radiation: A Complex and Controversial Disease. Cancers, 2023, 15, 2214.	1.7	2
6596	An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer. Clinical Cancer Research, 2023, 29, 2291-2298.	3.2	3
6597	Immune Checkpoint Inhibitors in pMMR/MSS Colorectal Cancer. Journal of Gastrointestinal Cancer, 2023, 54, 1017-1030.	0.6	3
6598	Targeting Rat Sarcoma Viral Oncogene Homolog for Treatment of Gastrointestinal Cancers. Advances in Oncology, 2023, 3, 161-177.	0.1	0
6599	Metabolic codependencies in the tumor microenvironment and gastric cancer: Difficulties and opportunities. Biomedicine and Pharmacotherapy, 2023, 162, 114601.	2.5	2
6600	Oncomicrobial Community Profiling Identifies Clinicomolecular and Prognostic Subtypes of Colorectal Cancer. Gastroenterology, 2023, 165, 104-120.	0.6	15
6601	Molecular profiling of colorectal cancer in a genetically admixed Hispanic population. Cancer Medicine, 2023, 12, 11686-11702.	1.3	0
6602	Microsatellite Instability: A Review of Molecular Epidemiology and Implications for Immune Checkpoint Inhibitor Therapy. Cancers, 2023, 15, 2288.	1.7	2
6603	Organ Preservation in MSS Rectal Cancer. Clinics in Colon and Rectal Surgery, 0, , .	0.5	0

#	Article	IF	Citations
6604	Inflammatory fibroid polyp: A series of 29 cases and a systematic review of the literature. Human Pathology Reports, 2023, 32, 300703.	0.1	1
6605	KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics. Critical Reviews in Oncology/Hematology, 2023, 186, 103987.	2.0	3
6607	<scp>DNMT3b</scp> affects colorectal cancer development by regulating <scp>FLI1</scp> through <scp>DNA</scp> hypermethylation. Kaohsiung Journal of Medical Sciences, 2023, 39, 364-376.	0.8	0
6608	Cancer stem cells in colorectal cancer: Signaling pathways involved in stemness and therapy resistance. Critical Reviews in Oncology/Hematology, 2023, 182, 103920.	2.0	18
6609	The genetic profile and molecular subtypes of human pseudomyxoma peritonei and appendiceal mucinous neoplasms: a systematic review. Cancer and Metastasis Reviews, 2023, 42, 335-359.	2.7	1
6610	Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice. Cancers, 2023, 15, 900.	1.7	3
6611	Validity of pathological diagnosis for early colorectal cancer in genetic background. Cancer Medicine, 2023, 12, 8490-8498.	1.3	2
6612	MSIMEP: Predicting microsatellite instability from microarray DNA methylation tumor profiles. IScience, 2023, 26, 106127.	1.9	1
6613	Spindle function and Wnt pathway inhibition by PBX1 to suppress tumor progression via downregulating DCDC2 in colorectal cancer. Oncogenesis, 2023, 12, .	2.1	1
6614	Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape. Cancers, 2023, 15, 1022.	1.7	6
6615	The diagnostic significance of CDH17-positive circulating tumor cells in patients with colorectal cancer. Expert Review of Molecular Diagnostics, 2023, 23, 171-179.	1.5	2
6617	RRP15 deficiency induces ribosome stress to inhibit colorectal cancer proliferation and metastasis via LZTS2-mediated Î²-catenin suppression. Cell Death and Disease, 2023, 14, .	2.7	7
6618	Mapping Spatiotemporal Heterogeneity in Tumor Profiles by Integrating High-Throughput Imaging and Omics Analysis. ACS Omega, 2023, 8, 6126-6138.	1.6	9
6619	TET1 and TDG Suppress Inflammatory Response in Intestinal Tumorigenesis: Implications for Colorectal Tumors With the CpG Island Methylator Phenotype. Gastroenterology, 2023, 164, 921-936.e1.	0.6	4
6620	Delayed Cardiac Metastasis from Renal Cell Carcinoma Caused by VHL Mutation. Journal of Kidney Cancer and VHL, 2023, 10, 15-18.	0.2	2
6621	Wnt Signaling in the Gastrointestinal Tract in Health and Disease. Physiologia, 2023, 3, 86-97.	0.6	1
6622	An antibodyâ€"drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer. British Journal of Cancer, 2023, 128, 1592-1602.	2.9	4
6623	The role of Evi/Wntless in exporting Wnt proteins. Development (Cambridge), 2023, 150, .	1.2	1

#	Article	IF	Citations
6624	A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors. Nature Cancer, 2023, 4, 240-256.	5.7	13
6625	Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma. EMBO Molecular Medicine, 2023, 15, .	3.3	5
6626	Whole genome sequencing of Malaysian colorectal cancer patients reveals specific druggable somatic mutations. Frontiers in Molecular Biosciences, 0, 9, .	1.6	1
6627	TCF7L1 Regulates LGR5 Expression in Colorectal Cancer Cells. Genes, 2023, 14, 481.	1.0	1
6628	Relation between mismatch repair status, chemoresponse, survival and anatomic location in gastroesophageal adenocarcinoma. Canadian Journal of Surgery, 2023, 66, E79-E87.	0.5	1
6629	Increased expression of GIPC2 in colon adenocarcinoma is associated with a favorable prognosis and high levels of immune cell infiltration. Oncology Reports, 2023, 49, .	1.2	0
6631	Reactive Oxygen Species and Ferroptosis at the Nexus of Inflammation and Colon Cancer. Antioxidants and Redox Signaling, 0, , .	2.5	3
6632	The intestine: A highly dynamic microenvironment for IgA plasma cells. Frontiers in Immunology, 0, 14, .	2.2	9
6633	TCF7L2, CASC8, and GREM1 polymorphism and colorectal cancer in south-eastern Romanian population. Medicine (United States), 2023, 102, e33056.	0.4	0
6634	Colorectal adenosquamous carcinoma: genomic profiling of a rare histotype of colorectal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2023, 482, 879-885.	1.4	3
6635	Urachal carcinoma: The journey so far and the road ahead. Pathology Research and Practice, 2023, 243, 154379.	1.0	2
6636	Promotion of colorectal cancer by transcription factor BHLHE40 involves upregulation of ADAM19 and KLF7. Frontiers in Oncology, 0, 13, .	1.3	4
6638	Cancer Research in Adenocarcinoma, Adenoma, Adenomatous Polyposis Coli, and Colitis-Associated Neoplasia: A Special Issue. Cancers, 2023, 15, 1328.	1.7	0
6639	Transcription factor B-MYB activates lncRNA CCAT1 and upregulates SOCS3 to promote chemoresistance in colorectal cancer. Chemico-Biological Interactions, 2023, 374, 110412.	1.7	2
6640	A compilation of bioinformatic approaches to identify novel downstream targets for the detection and prophylaxis of cancer. Advances in Protein Chemistry and Structural Biology, 2023, , 75-113.	1.0	0
6641	Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical developmentâ€"a narrative review. Translational Lung Cancer Research, 2023, 12, 346-368.	1.3	5
6642	Mapping Immune Correlates and Surfaceome Genes in BRAF Mutated Colorectal Cancers. Current Oncology, 2023, 30, 2569-2581.	0.9	1
6643	Organoids and organs-on-chips: insights into predicting the efficacy of systemic treatment in colorectal cancer. Cell Death Discovery, 2023, 9, .	2.0	12

#	Article	IF	Citations
6644	A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF<i>V600E</i>-Mutant<i>KRAS</i>Wild-Type Metastatic Colorectal Cancer. Oncologist, 2023, 28, 230-238.	1.9	9
6645	Association Between Survival and Metastatic Site in Mismatch Repairâ€"Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab. JAMA Network Open, 2023, 6, e230400.	2.8	15
6646	Long-read sequencing identifies novel structural variations in colorectal cancer. PLoS Genetics, 2023, 19, e1010514.	1.5	7
6648	Synergistic anticancer effects of crocin combined with deuterium-depleted water on HT-29 cells. Anti-Cancer Drugs, 2023, 34, 1162-1170.	0.7	1
6649	Circulating Tumor DNA: The Dawn of a New Era in the Optimization of Chemotherapeutic Strategies for Metastatic Colo-Rectal Cancer Focusing on RAS Mutation. Cancers, 2023, 15, 1473.	1.7	1
6650	Biochemical Studies of Systemic Lupus Erythematosus-Associated Mutations in Nonreceptor Tyrosine Kinases Ack1 and Brk. Biochemistry, 2023, 62, 1124-1137.	1.2	0
6651	Characterization of POLE c.1373Aâ€‰>â€‰T p.(Tyr458Phe), causing high cancer risk. Molecular Genetics and Genomics, 0, , .	1.0	0
6653	<scp>MicroRNA</scp> 483â€3p overexpression unleashes invasive growth of metastatic colorectal cancer via <scp><i>NDRG1</i></scp> downregulation and ensuing activation of the <scp>ERBB3</scp>/<scp>AKT</scp> axis. Molecular Oncology, 2023, 17, 1280-1301.	2.1	1
6654	Ginsenoside Rh2 suppresses colon cancer growth by targeting the miR-150-3p/SRCIN1/Wnt axis. Acta Biochimica Et Biophysica Sinica, 2023, 55, 633-648.	0.9	1
6655	Genotypeâ€"Phenotype Correlations in Autosomal Dominant and Recessive APC Mutation-Negative Colorectal Adenomatous Polyposis. Digestive Diseases and Sciences, 0, , .	1.1	2
6656	Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach. Clinical Cancer Research, 2023, 29, 2445-2455.	3.2	1
6657	N6-methyladenosine related gene expression signatures for predicting the overall survival and immune responses of patients with colorectal cancer. Frontiers in Genetics, 0, 14, .	1.1	1
6658	Subtype-specific kinase dependency regulates growth and metastasis of poor-prognosis mesenchymal colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2023, 42, .	3.5	0
6659	Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours. BMC Cancer, 2023, 23, .	1.1	3
6660	Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer. Cancer Research and Treatment, 2023, 55, 927-938.	1.3	4
6661	Fusobacterium nucleatum induces a tumor microenvironment with diminished adaptive immunity against colorectal cancers. Frontiers in Cellular and Infection Microbiology, 0, 13, .	1.8	5
6662	A targeted genetic modifier screen in <i>Drosophila</i> uncovers vulnerabilities in a genetically complex model of colon cancer. G3: Genes, Genomes, Genetics, 2023, 13, .	0.8	3
6663	Reprogramming of palmitic acid induced by dephosphorylation of ACOX1 promotes Î²-catenin palmitoylation to drive colorectal cancer progression. Cell Discovery, 2023, 9, .	3.1	16

#	Article	IF	Citations
6664	Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Oncology, 2023, 14, 1175-1177.	0.6	1
6665	Combined inhibition of polyamine metabolism and eIF5A hypusination suppresses colorectal cancer growth through a converging effect on MYC translation. Cancer Letters, 2023, 559, 216120.	3.2	7
6666	Are High Levels of Microsatellite Instability and Microsatellite Stability Identical in DNA Mismatch Repair-Deficient Colorectal Cancer Patients?. Canadian Journal of Gastroenterology and Hepatology, 2023, 2023, 1-6.	0.8	1
6667	Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies. Cancers, 2023, 15, 1679.	1.7	6
6668	Differential Spatial Gene and Protein Expression Associated with Recurrence Following Chemoradiation for Localized Anal Squamous Cell Cancer. Cancers, 2023, 15, 1701.	1.7	4
6671	Aberrant HMGA2 Expression Sustains Genome Instability That Promotes Metastasis and Therapeutic Resistance in Colorectal Cancer. Cancers, 2023, 15, 1735.	1.7	1
6673	Genetic heterogeneity of colorectal cancer and the microbiome. World Journal of Gastrointestinal Oncology, 0, 15, 443-463.	0.8	1
6674	Integrated multi-omics approach to distinct molecular characterization and classification of early-onset colorectal cancer. Cell Reports Medicine, 2023, 4, 100974.	3.3	5
6675	Carbon-Based Nanomaterials as Drug Delivery Agents for Colorectal Cancer: Clinical Preface to Colorectal Cancer Citing Their Markers and Existing Theranostic Approaches. ACS Omega, 2023, 8, 10656-10668.	1.6	5
6676	The SMARCA4R1157W mutation facilitates chromatin remodeling and confers PRMT1/SMARCA4 inhibitors sensitivity in colorectal cancer. Npj Precision Oncology, 2023, 7, .	2.3	3
6678	Serrated colonic lesions. Current review. , 2023, 3, 30-37.		0
6679	Rectum adenocarcinoma metabolic subtypes analysis and a risk prognostic model construction based on fatty acid metabolism genes. Medicine (United States), 2023, 102, e33186.	0.4	0
6680	Pipeline for characterizing alternative mechanisms (PCAM) based on bi-clustering to study colorectal cancer heterogeneity. Computational and Structural Biotechnology Journal, 2023, 21, 2160-2171.	1.9	0
6681	Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients. Breast Cancer, 0, , .	1.3	1
6682	Phenotypic Heterogeneity Analysis of APC-Mutant Colon Cancer by Proteomics and Phosphoproteomics Identifies RAI14 as a Key Prognostic Determinant in East Asians and Westerners. Molecular and Cellular Proteomics, 2023, 22, 100532.	2.5	7
6683	Immune Activation following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study. International Journal of Molecular Sciences, 2023, 24, 5869.	1.8	1
6684	The Gut Microbiome, Microsatellite Status and the Response to Immunotherapy in Colorectal Cancer. International Journal of Molecular Sciences, 2023, 24, 5767.	1.8	4
6686	Clinical presentation and outcome of patients with enteric-type adenocarcinoma of the lung: A pooled analysis of published cases. Lung Cancer, 2023, 179, 107176.	0.9	4

#	Article	IF	Citations
6687	Primate protein-ligand interfaces exhibit significant conservation and unveil human-specific evolutionary drivers. PLoS Computational Biology, 2023, 19, e1010966.	1.5	0
6688	Chemoproteomics Reveals That Quaternary Protoberberine Alkaloids Inhibit Telomerase Activity Oncologically by Binding to PES1. Chemistry and Biodiversity, 2023, 20, .	1.0	0
6689	Oleic Acid Dissolves cGASâ€"DNA Phase Separation to Inhibit Immune Surveillance. Advanced Science, 0, , 2206820.	5.6	2
6690	Clonal and â€œIntrinsicâ€• Heterogeneity of Somatic Variants in Microsatellite-Stable Colorectal Carcinomas and Their Metastases. Laboratory Investigation, 2023, 103, 100132.	1.7	1
6691	Spectrum of BRCA1 interacting helicase 1 aberrations and potential prognostic and therapeutic implication: a pan cancer analysis. Scientific Reports, 2023, 13, .	1.6	0
6692	The Complex Role of HBeAg and Its Precursors in the Pathway to Hepatocellular Carcinoma. Viruses, 2023, 15, 857.	1.5	0
6693	APC mutation correlated with poor response of immunotherapy in colon cancer. BMC Gastroenterology, 2023, 23, .	0.8	1
6694	Case Report: Identification of a rare nonsense mutation in the POC1A gene by NGS in a diabetes mellitus patient. Frontiers in Genetics, 0, 14, .	1.1	1
6696	Landscape of KRAS, BRAF, and PIK3CA Mutations and Clinical Features of EBV-Associated and Microsatellite Unstable Gastric Cancer. Molecular Biology, 2023, 57, 61-73.	0.4	1
6697	Molecular genetic positioning of small intestine and papilla of Vater carcinomas including clinicopathological classification. Cancer Medicine, 2023, 12, 11491-11502.	1.3	0
6698	The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent. Cancer Chemotherapy and Pharmacology, 2023, 91, 401-412.	1.1	2
6700	Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer. Oncogene, 2023, 42, 1620-1633.	2.6	7
6701	Oncogenic signaling is coupled to colorectal cancer cell differentiation state. Journal of Cell Biology, 2023, 222, .	2.3	2
6702	Metastatic colorectal adenocarcinoma tumor purity assessment from whole exome sequencing data. PLoS ONE, 2023, 18, e0271354.	1.1	0
6704	A New Wave of Targeting â€˜Undruggableâ€™ Wnt Signaling for Cancer Therapy: Challenges and Opportunities. Cells, 2023, 12, 1110.	1.8	8
6705	The role of LIN28B in tumor progression and metastasis in solid tumor entities. Oncology Research, 2023, 31, 101-115.	0.6	2
6706	Multi-omic molecular profiling and network biology for precision anaesthesiology: a narrative review. British Journal of Anaesthesia, 2023, 131, 26-36.	1.5	2
6707	TGFÎ² and the Tumor Microenvironment in Colorectal Cancer. Cells, 2023, 12, 1139.	1.8	1

#	Article	IF	Citations
6710	Histopathology images predict multi-omics aberrations and prognoses in colorectal cancer patients. Nature Communications, 2023, 14, .	5.8	23
6711	Dickkopf 4 Alone and in Combination with Leucyl-tRNA Synthetase as a Good Prognostic Biomarker for Human Colorectal Cancer. BioMed Research International, 2023, 2023, 1-10.	0.9	0
6712	Proliferation Inhibitory Activity of Quinones from Blaps rynchopetera Defense Secretion on Colorectal Tumor Cells. Chinese Journal of Integrative Medicine, 0, , .	0.7	0
6713	KaryoCreate: A CRISPR-based technology to study chromosome-specific aneuploidy by targeting human centromeres. Cell, 2023, 186, 1985-2001.e19.	13.5	16
6714	Molecular subtyping in colorectal cancer: A bridge to personalized therapy (Review). Oncology Letters, 2023, 25, .	0.8	3
6715	Correlation of preclinical and clinical biomarkers with efficacy and toxicity of cancer immunotherapy. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592311638.	1.4	0
6716	RSPO2 as Wnt signaling enabler: Important roles in cancer development and therapeutic opportunities. Genes and Diseases, 2024, 11, 788-806.	1.5	2
6718	Tumor necrosis factor-Î± knockout mitigates intestinal inflammation and tumorigenesis in obese Apc1638N mice. Journal of Nutritional Biochemistry, 2023, 117, 109355.	1.9	1
6719	Information about immune cell proportions and tumor stage improves the prediction of recurrence in patients with colorectal cancer. Patterns, 2023, , 100736.	3.1	0
6720	Single-cell multi-omics sequencing and its application in tumor heterogeneity. Briefings in Functional Genomics, 2023, 22, 313-328.	1.3	2
6721	<scp><i>TP53</i></scp> mutations predict poor response to immunotherapy in patients with metastatic solid tumors. Cancer Medicine, 2023, 12, 12438-12451.	1.3	2
6723	Impact of Primary Tumor Location and Genomic Alterations on Survival Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Colorectal Peritoneal Metastases. Annals of Surgical Oncology, 2023, 30, 4459-4470.	0.7	3
6724	Metastatic sites and lesion numbers cooperated to predict efficacy of <scp>PD</scp> â€1 inhibitorâ€based combination therapy for patients with metastatic colorectal cancer. Cancer Medicine, 0, , .	1.3	0
6725	Identification of KRAS mutation and HER2 expression in Indonesian colorectal cancer population: a cross-sectional study. Annals of Medicine and Surgery, 2023, 85, 1761-1768.	0.5	1
6726	Late-stage MC38 tumours recapitulate features of human colorectal cancer â€" implications for appropriate timepoint selection in preclinical studies. Frontiers in Immunology, 0, 14, .	2.2	0
6732	A review on emerging targeted therapies for the management of metastatic colorectal cancers. , 2023, 40, .		6
6774	Cancers digestifs. , 2023, , 199-205.		0
6776	The current status and prospect of immunotherapy in colorectal cancer. Clinical and Translational Oncology, 2024, 26, 39-51.	1.2	4

#	Article	IF	Citations
6812	Molecular pathology of colorectal cancer. Memo - Magazine of European Medical Oncology, 2023, 16, 116-121.	0.3	0
6840	Case Report: Longitudinal monitoring of clonal evolution by circulating tumor DNA for resistance to anti-EGFR antibody in a case of metastatic colorectal cancer. Frontiers in Oncology, 0, 13, .	1.3	0
6844	Bioinformatics and Biostatistics in Precision Medicine. , 2023, , 189-235.		1
6846	Omics in Precision Medicine. , 2023, , 237-263.		1
6850	Prognostic value of primary tumor location in colorectal cancer: an updated meta-analysis. Clinical and Experimental Medicine, 2023, 23, 4369-4383.	1.9	3
6880	Pathology of Digestive System Malignancies. , 2023, , 259-273.		0
6884	Applications of Nanotechnology in Converging the Biomarker Science for Advancement in Cancer Detection and Treatment. , 2023, , 1-31.		0
6892	Editorial: The impact of genetics on CRC therapy: from adaptive mutability to drug resistance. Frontiers in Oncology, 0, 13, .	1.3	0
6899	Applications of Nanotechnology in Converging the Biomarker Science for Advancement in Cancer Detection and Treatment. , 2023, , 1-30.		0
6913	The (pro)renin receptor as a pharmacological target in cardiorenal diseases. Hypertension Research, 2023, 46, 2527-2534.	1.5	1
6932	Metabolic profiling stratifies colorectal cancer and reveals adenosylhomocysteinase as a therapeutic target. Nature Metabolism, 2023, 5, 1303-1318.	5.1	5
6934	The circadian clock circuitry deconvolutes colorectal cancer and lung adenocarcinoma heterogeneity in a dynamic time-related framework. Cancer Gene Therapy, 2023, 30, 1323-1329.	2.2	0
6941	Hyperactivation of oncogenic driver pathways as a precision therapeutic strategy. Nature Genetics, 2023, 55, 1613-1614.	9.4	0
6951	Systems biology approaches to unveiling the expression of phospholipases in various types of cancerâ€"Transcriptomics and protein-protein interaction networks. , 2023, , 271-307.		0
6974	Prompt-MIL: Boosting Multi-instance Learning Schemes via Task-Specific Prompt Tuning. Lecture Notes in Computer Science, 2023, , 624-634.	1.0	4
6993	Genetic alterations shape innate immune cells to foster immunosuppression and cancer immunotherapy resistance. Clinical and Experimental Medicine, 2023, 23, 4289-4296.	1.9	1
7010	Vitamin D and colorectal cancer. , 2024, , 859-899.		0
7032	A Context Aware Lung Cancer Survival Prediction Network byÂUsing Whole Slide Images. Communications in Computer and Information Science, 2024, , 374-386.	0.4	0

#	Article	IF	Citations
7050	Signification and Application of Mutator and Antimutator Phenotype-Induced Genetic Variations in Evolutionary Adaptation and Cancer Therapeutics. Journal of Microbiology, 2023, 61, 1013-1024.	1.3	0
7054	Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies. Drugs, 0, , .	4.9	0
7061	Decoding the basis of histological variation in human cancer. Nature Reviews Cancer, 0, , .	12.8	1
7068	Emerging trends in gastrointestinal cancers: Targeting developmental pathways in carcinogenesis and tumor progression. International Review of Cell and Molecular Biology, 2024, , .	1.6	0
7069	Novel targeting strategies on signaling pathways of colorectal cancer. , 2024, , 489-531.		0
7103	Case report: Efficacy of immunotherapy as conversion therapy in dMMR/MSI-H colorectal cancer: a case series and review of the literature. Frontiers in Immunology, 0, 15, .	2.2	0
7108	Molecular pathological classification of colorectal cancerâ€"an update. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2024, 484, 273-285.	1.4	1
7168	Generation, Expansion, and Biobanking of Gastrointestinal Patient-Derived Organoids from Tumor and Normal Tissues. Methods in Molecular Biology, 2024, , 123-133.	0.4	0